The Vaccine Ontology (VO) is a community-based biomedical ontology in the domain of vaccine and vaccination. VO aims to standardize vaccine types and annotations, integrate various vaccine data, and support computer-assisted reasoning. The VO supports basic vaccine R&D and clinical vaccine usage. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities.
OWL-DL
An ontology in the domain of vaccine and vaccination
Vaccine Ontology
Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification.
Really of interest to developers only
BFO OWL specification label
Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2
BFO CLIF specification label
editor preferred term
The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English)
PERSON:Daniel Schober
example of usage
A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold.
in branch
An annotation property indicating which module the terms belong to. This is currently experimental and not implemented yet.
has curation status
PERSON:Alan Ruttenberg
PERSON:Bill Bug
PERSON:Melanie Courtot
definition
The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions.
2012-04-05: Barry Smith The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. Can you fix to something like: A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. Alan Ruttenberg Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. On the specifics of the proposed definition: We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with.
editor note
An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology.
term editor
Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people
20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115.
alternative label
A label for a class or property that can be used to refer to the class or property instead of the preferred rdfs:label. Alternative labels should be used to indicate community- or context-specific labels, abbreviations, shorthand forms and the like.
Consider re-defing to: An alternative name for a class or property which can mean the same thing as the preferred name (semantically equivalent, narrow, broad or related).
definition source
Formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007
Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w
has obsolescence reason
Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification.
curator note
An administrative note of use for a curator but of no use for a user
term tracker item
the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/
An IRI or similar locator for a request or discussion of an ontology term.
Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg
The 'tracker item' can associate a tracker with a specific ontology term.
ontology term requester
The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition.
The 'term requester' can credit the person, organization or project who request the ontology term.
is denotator type
Relates an class defined in an ontology, to the type of it's denotator
In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type')
Alan Ruttenberg
imported from
For external terms/classes, the ontology from which the term was imported
expand expression to
ObjectProperty: RO_0002104 Label: has plasma membrane part Annotations: IAO_0000424 "http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.org/obo/owl/GO#GO_0005886 and http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)"
A macro expansion tag applied to an object property (or possibly a data property) which can be used by a macro-expansion engine to generate more complex expressions from simpler ones
Chris Mungall
expand assertion to
ObjectProperty: RO??? Label: spatially disjoint from Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary.org/obo/BFO_0000051 some ?X) (http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)"
A macro expansion tag applied to an annotation property which can be expanded into a more detailed axiom.
first order logic expression
antisymmetric property
part_of antisymmetric property xsd:true
Use boolean value xsd:true to indicate that the property is an antisymmetric property
OBO foundry unique label
An alternative name for a class or property which is unique across the OBO Foundry.
The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools .
PERSON:Bjoern Peters
PERSON:Chris Mungall
GROUP:OBO Foundry <http://obofoundry.org/>
has ID digit count
Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" 'has ID digit count' : 7, rdfs:label "RO id policy" 'has ID policy for': "RO"
Relates an ontology used to record id policy to the number of digits in the URI. The URI is: the 'has ID prefix" annotation property value concatenated with an integer in the id range (left padded with "0"s to make this many digits)
Person:Alan Ruttenberg
has ID range allocated
Datatype: idrange:1 Annotations: 'has ID range allocated to': "Chris Mungall" EquivalentTo: xsd:integer[> 2151 , <= 2300]
Relates a datatype that encodes a range of integers to the name of the person or organization who can use those ids constructed in that range to define new terms
has ID range allocated to
has ID policy for
Relating an ontology used to record id policy to the ontology namespace whose policy it manages
has ID prefix
Relates an ontology used to record id policy to a prefix concatenated with an integer in the id range (left padded with "0"s to make this many digits) to construct an ID for a term being created.
elucidation
person:Alan Ruttenberg
Person:Barry Smith
Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms
has associated axiom(nl)
An axiom associated with a term expressed using natural language
has associated axiom(fol)
An axiom expressed in first order logic using CLIF syntax
is allocated id range
Relates an ontology IRI to an (inclusive) range of IRIs in an OBO name space. The range is give as, e.g. "IAO_0020000-IAO_0020999"
Add as annotation triples in the granting ontology
has ontology root term
Ontology annotation property. Relates an ontology to a term that is a designated root term of the ontology. Display tools like OLS can use terms annotated with this property as the starting point for rendering the ontology class hierarchy. There can be more than one root.
Nicolas Matentzoglu
may be identical to
A annotation relationship between two terms in an ontology that may refer to the same (natural) type but where more evidence is required before terms are merged.
David Osumi-Sutherland
VFB
Edges asserting this should be annotated with to record evidence supporting the assertion and its provenance.
scheduled for obsoletion on or after
Used when the class or object is scheduled for obsoletion/deprecation on or after a particular date.
Chris Mungall, Jie Zheng
GO ontology
has axiom id
A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI
has axiom label
term replaced by
Use on obsolete terms, relating the term to another term that can be used as a substitute
ISA alternative term
An alternative term used by the ISA tools project (http://isa-tools.org).
Requested by Alejandra Gonzalez-Beltran https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178
ISA tools project (http://isa-tools.org)
An alternative term used by the IEDB.
PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters
NCBI GeneID
NCBI LocusTag
modification date
The NCBITaxon ontology ID of an organism.
organism NCBITaxon ID
A chromosome ID where a gene is located.
chromosome ID of gene
an annotation property that specifies the type of a gene
type of gene
an annotation property that specifies a nomenclature status
nomenclature status
An annotation property that represents a gene's association with PubMed publication(s).
has PubMed association
This is an annotation used on an object property to indicate a logical characterstic beyond what is possible in OWL.
logical characteristic of object property
'part disjoint with' 'defined by construct' """ PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX : <http://example.org/ CONSTRUCT { [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?a ; owl:disjointWith [ a owl:Restriction ; owl:onProperty :part_of ; owl:someValuesFrom ?b ] ] } WHERE { ?a :part_disjoint_with ?b . }
Links an annotation property to a SPARQL CONSTRUCT query which is meant to provide semantics for a shortcut relation.
The property is intended to be used exclusively on synonym assertions, to express that the synonym in question is the preference of a specific community. For example, one community may prefer to say call a disease "A" and another one "B" (but they are the same thing).
A provenance property that denotes a synonym to be the preferred one for a specific community.
CHEBI:26523 (reactive oxygen species) has an exact synonym (ROS), which is of type OMO:0003000 (abbreviation)
A synonym type for describing abbreviations or initalisms
A synonym type for describing ambiguous synonyms
A synonym type for describing dubious synonyms
EFO:0006346 (severe cutaneous adverse reaction) has an exact synonym (scar), which is of the type OMO:0003003 (layperson synonym)
A synonym type for describing layperson or colloquial synonyms
CHEBI:23367 (molecular entity) has an exact synonym (molecular entities), which is of the type OMO:0003004 (plural form)
A synonym type for describing pluralization synonyms
CHEBI:16189 (sulfate) has an exact synonym (sulphate), which is of the type OMO:0003005 (UK spelling synonym)
A synonym type for describing UK spelling variants
A synonym type for misnomers, i.e., a synonym that is not technically correct but is commonly used anyway
MAPT, the gene that encodes the Tau protein, has a previous name DDPAC. Note: in this case, the name type is more specifically the gene symbol.
A synonym type for names that have been used as primary labels in the past.
The legal name for Harvard University (https://ror.org/03vek6s52) is President and Fellows of Harvard College
A synonym type for the legal entity name
CHEBI:46195 has been assigned the english International Nonproproprietary Name (INN) "paracetamol". In some cases such as this one, the INN might be the same as the ontology's primary label
The International Nonproprietary Name (INN) is a standardize name for a pharmaceutical drug or active ingredient issued by the World Health Organization (WHO) meant to address the issues with country- or language-specific brand names. These are issued in several languages, including English, Latin, French, Russian, Spanish, Arabic, and Chinese.
nasopharynx (UBERON:0001728) has the latin name "pars nasalis pharyngis
A synonym type for describing Latin term synonyms.
NASA is an word acronym for the US National Aeronautics and Space Administration because the acronym is pronounced. FBI is an initialism (also known as alphabetism) for the US Federal Bureau of Investigation since the letters are pronounced one at a time. JPEG is an acronym for Joint Photographic Experts Group but does not count as a word acronym nor an initialism since it is mixed how it is pronounced.
A synonym type for describing abbreviations that are a part of the full name's words, such as initialisms or alphabetisms.
A serial number such as "12324X"; a stop sign; a written proper name such as "OBI
An information content entity that is a mark(s) or character(s) used as a conventional representation of another entity.
An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context.
tooth SubClassOf 'never in taxon' value 'Aves'
x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL.
Class: ?X DisjointWith: RO_0002162 some ?Y
PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX never_in_taxon: <http://purl.obolibrary.org/obo/RO_0002161> CONSTRUCT { in_taxon: a owl:ObjectProperty . a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . ?x rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom [ a owl:Class ; owl:complementOf ?taxon ] ] . } WHERE { ?x never_in_taxon: ?taxon . }
A is mutually_spatially_disjoint_with B if both A and B are classes, and there exists no p such that p is part_of some A and p is part_of some B.
Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y)
PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX part_of: <http://purl.obolibrary.org/obo/BFO_0000050> PREFIX mutually_spatially_disjoint_with: <http://purl.obolibrary.org/obo/RO_0002171> CONSTRUCT { part_of: a owl:ObjectProperty . [ a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?x ; a owl:Restriction ; owl:onProperty part_of: ; owl:someValuesFrom ?y ] ] } WHERE { ?x mutually_spatially_disjoint_with: ?y . }
mutually spatially disjoint with
An assertion that holds between an ontology class and an organism taxon class, which is intepreted to yield some relationship between instances of the ontology class and the taxon.
taxonomic class assertion
S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S
PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#> PREFIX owl: <http://www.w3.org/2002/07/owl#> PREFIX in_taxon: <http://purl.obolibrary.org/obo/RO_0002162> PREFIX present_in_taxon: <http://purl.obolibrary.org/obo/RO_0002175> CONSTRUCT { in_taxon: a owl:ObjectProperty . ?witness rdfs:label ?label . ?witness rdfs:subClassOf ?x . ?witness rdfs:subClassOf [ a owl:Restriction ; owl:onProperty in_taxon: ; owl:someValuesFrom ?taxon ] . } WHERE { ?x present_in_taxon: ?taxon . BIND(IRI(CONCAT( "http://purl.obolibrary.org/obo/RO_0002175#", MD5(STR(?x)), "-", MD5(STR(?taxon)) )) as ?witness) BIND(CONCAT(STR(?x), " in taxon ", STR(?taxon)) AS ?label) }
The SPARQL expansion for this relation introduces new named classes into the ontology. For this reason it is likely that the expansion should only be performed during a QC pipeline; the expanded output should usually not be included in a published version of the ontology.
present in taxon
An assertion that involves at least one OWL object that is intended to be expanded into one or more logical axioms. The logical expansion can yield axioms expressed using any formal logical system, including, but not limited to OWL2-DL.
logical macro assertion
A logical macro assertion whose domain is an IRI for a class
The domain for this class can be considered to be owl:Class, but we cannot assert this in OWL2-DL
logical macro assertion on a class
A logical macro assertion whose domain is an IRI for a property
logical macro assertion on a property
Used to annotate object properties to describe a logical meta-property or characteristic of the object property.
logical macro assertion on an object property
A shortcut relationship that holds between two entities based on their identity criteria
logical macro assertion involving identity
A shortcut relationship between two entities x and y1, such that the intent is that the relationship is functional and inverse function, but there is no guarantee that this property holds.
in approximate one to one relationship with
'anterior end of organism' is-opposite-of 'posterior end of organism'
'increase in temperature' is-opposite-of 'decrease in temperature'
x is the opposite of y if there exists some distance metric M, and there exists no z such as M(x,z) <= M(x,y) or M(y,z) <= M(y,x).
An annotation property that represents a matched vaccine identifier used in the VIOLIN database.
An annotation property that represents the trade name of a product.
An annotation property that represents the active ingredient of a vaccine.
An annotation property that represents the vaccine ingredient of a vaccine. Such an ingredient may not be active.
An annotation property that describes the dose information of a vaccine
The vaccine Prevnar (trade name) has a FDA-defined proper name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein). Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm
An annotation property that represents the proper name of a vaccine, which is defined in an official way such as one defined by FDA.
The vaccine Prevnar has the manufacturer: Wyeth Pharmaceuticals Inc. Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm
An annotation property that represents the manufacturer of a vaccine
The vaccine Prevnar has the indications: - Immunization of infants 2, 4, 6 and 12-15 months of age to prevent invasive pneumococcal disease. - Immunization of infants and toddlers against otitis media caused by vaccine serotypes. Reference: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm180017.htm
An annotation property that represents the indications of a vaccine defined by the USA FDA.
Prevnar has the package insert PDF URL: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM137038.pdf . Recorded on 11/26/2018.
An annotation property that represents a URL of the package insert PDF document of a licensed vaccine
An annotation property that indicate the number that is generated by FDA based on a request from an applicant of a product licensing.
As seen: http://purl.bioontology.org/ontology/RXNORM/901644, the RxNORM vaccine term "Prevnar 13 vaccine 0.5 ML Prefilled Syringe" has Preferred Name of: 0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Prefilled Syringe [Prevnar 13]". In this case, the whole preferred name is annotated under the annotation property "RxNORM Preferred Name".
An identifier assigned by the Vaccine Adjuvant Compendium (VAC: https://vac.niaid.nih.gov/)
An annotation property that represents the annotated information about the antigens used for a specific vaccine.
An annotation property that refers to a specific CVX ID.
An annotation property that shows the status of vaccine developmeint including: clinical trial, research, licensed, or Emergency Use Authorization (EUA).
An annotation property that represents an identifier of RxNorm or RxNorm extension concept assigned by OMOP.
An annotation property that represents an identifier of RxNorm extension term assigned by OMOP.
An annotation property that refers to full vaccine name in CVX code set.
An annotation property that refers to short description in CVX code set.
An alternative label for a class or property which has a more general meaning than the preferred name/primary label.
has broad synonym
disease characteristic (MONDO:0021125) has cross-reference (http://www.geneontology.org/formats/oboInOwl#hasDbXref) "NCIT:C41009"^^xsd:string
An annotation property that links an ontology entity or a statement to a prefixed identifier or URI.
An alternative label for a class or property which has the exact same meaning than the preferred name/primary label.
has exact synonym
An alternative label for a class or property which has a more specific meaning than the preferred name/primary label.
has narrow synonym
An alternative label for a class or property that has been used synonymously with the primary term name, but the usage is not strictly correct.
has related synonym
is part of
my brain is part of my body (continuant parthood, two material entities)
my stomach cavity is part of my stomach (continuant parthood, immaterial entity is part of material entity)
this day is part of this year (occurrent parthood)
a core relation that holds between a part and its whole
Everything is part of itself. Any part of any part of a thing is itself part of that thing. Two distinct things cannot be part of each other.
Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/
Parthood requires the part and the whole to have compatible classes: only an occurrent can be part of an occurrent; only a process can be part of a process; only a continuant can be part of a continuant; only an independent continuant can be part of an independent continuant; only an immaterial entity can be part of an immaterial entity; only a specifically dependent continuant can be part of a specifically dependent continuant; only a generically dependent continuant can be part of a generically dependent continuant. (This list is not exhaustive.) A continuant cannot be part of an occurrent: use 'participates in'. An occurrent cannot be part of a continuant: use 'has participant'. A material entity cannot be part of an immaterial entity: use 'has location'. A specifically dependent continuant cannot be part of an independent continuant: use 'inheres in'. An independent continuant cannot be part of a specifically dependent continuant: use 'bearer of'.
part_of
part of
has part
my body has part my brain (continuant parthood, two material entities)
my stomach has part my stomach cavity (continuant parthood, material entity has part immaterial entity)
this year has part this day (occurrent parthood)
a core relation that holds between a whole and its part
Everything has itself as a part. Any part of any part of a thing is itself part of that thing. Two distinct things cannot have each other as a part.
Parthood requires the part and the whole to have compatible classes: only an occurrent have an occurrent as part; only a process can have a process as part; only a continuant can have a continuant as part; only an independent continuant can have an independent continuant as part; only a specifically dependent continuant can have a specifically dependent continuant as part; only a generically dependent continuant can have a generically dependent continuant as part. (This list is not exhaustive.) A continuant cannot have an occurrent as part: use 'participates in'. An occurrent cannot have a continuant as part: use 'has participant'. An immaterial entity cannot have a material entity as part: use 'location of'. An independent continuant cannot have a specifically dependent continuant as part: use 'bearer of'. A specifically dependent continuant cannot have an independent continuant as part: use 'inheres in'.
has_part
realized in
this disease is realized in this disease course
this fragility is realized in this shattering
this investigator role is realized in this investigation
is realized by
realized_in
[copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003])
Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process
realizes
this disease course realizes this disease
this investigation realizes this investigator role
this shattering realizes this fragility
to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003])
Paraphrase of elucidation: a relation between a process and a realizable entity, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process
preceded by
x is preceded by y if and only if the time point at which y ends is before or equivalent to the time point at which x starts. Formally: x preceded by y iff ω(y) <= α(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point.
An example is: translation preceded_by transcription; aging preceded_by development (not however death preceded_by aging). Where derives_from links classes of continuants, preceded_by links classes of processes. Clearly, however, these two relations are not independent of each other. Thus if cells of type C1 derive_from cells of type C, then any cell division involving an instance of C1 in a given lineage is preceded_by cellular processes involving an instance of C. The assertion P preceded_by P1 tells us something about Ps in general: that is, it tells us something about what happened earlier, given what we know about what happened later. Thus it does not provide information pointing in the opposite direction, concerning instances of P1 in general; that is, that each is such as to be succeeded by some instance of P. Note that an assertion to the effect that P preceded_by P1 is rather weak; it tells us little about the relations between the underlying instances in virtue of which the preceded_by relation obtains. Typically we will be interested in stronger relations, for example in the relation immediately_preceded_by, or in relations which combine preceded_by with a condition to the effect that the corresponding instances of P and P1 share participants, or that their participants are connected by relations of derivation, or (as a first step along the road to a treatment of causality) that the one process in some way affects (for example, initiates or regulates) the other.
is preceded by
preceded_by
precedes
x precedes y if and only if the time point at which x ends is before or equivalent to the time point at which y starts. Formally: x precedes y iff ω(x) <= α(y), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point.
occurs in
b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t
occurs_in
unfolds in
unfolds_in
Paraphrase of definition: a relation between a process and an independent continuant, in which the process takes place entirely within the independent continuant
site of
[copied from inverse property 'occurs in'] b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t
Paraphrase of definition: a relation between an independent continuant and a process, in which the process takes place entirely within the independent continuant
contains process
process profile of
This document is about information artifacts and their representations
A (currently) primitive relation that relates an information artifact to an entity.
7/6/2009 Alan Ruttenberg. Following discussion with Jonathan Rees, and introduction of "mentions" relation. Weaken the is_about relationship to be primitive. We will try to build it back up by elaborating the various subproperties that are more precisely defined. Some currently missing phenomena that should be considered "about" are predications - "The only person who knows the answer is sitting beside me" , Allegory, Satire, and other literary forms that can be topical without explicitly mentioning the topic.
Smith, Ceusters, Ruttenberg, 2000 years of philosophy
is about
An information artifact IA mentions an entity E exactly when it has a component/part that denotes E
7/6/2009 Alan Ruttenberg. P4 RC1 munges our GCI so remove it for now: mentions some entity equivalentTo has_part some ('generically denotes' some entity)
7/6/2009 Alan Ruttenberg: Add this relation following conversation with Jonathan Rees that N&S GCI for is_about was too strong. Really it was simply sufficient. To effect this change we introduce this relation, which is subproperty of is_about, and have previous GCI use this relation "mentions" in it's (logical) definition
PERSON: Jonathan Rees
Person: Alan Ruttenberg
mentions
see is_input_of example_of_usage
The inverse property of is_specified_input_of
8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works.
PERSON: Alan Ruttenberg
has_specified_input
some Autologous EBV(Epstein-Barr virus)-transformed B-LCL (B lymphocyte cell line) is_input_for instance of Chromum Release Assay described at https://wiki.cbil.upenn.edu/obiwiki/index.php/Chromium_Release_assay
A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of.
is_specified_input_of
The inverse property of is_specified_output_of
has_specified_output
is_manufactured_by
http://www.affymetrix.com/products/arrays/specific/hgu133.affx is_manufactered_by http://www.affymetrix.com/ (if we decide to use these URIs for the actual entities)
c is_manufactured_by o means that there was a process p in which c was built in which a person, or set of people or machines did the work(bore the "Manufacturer Role", and those people/and or machines were members or of directed by the organization to do this.
Liju Fan
has_make
has_manufacturer
A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of.
is_specified_output_of
A cell sorting process achieves the objective specification 'material separation objective'
This relation obtains between a planned process and a objective specification when the criteria specified in the objective specification are met at the end of the planned process.
modified according to email thread from 1/23/09 in accordince with DT and PPPB branch
the relation of the cells in the finger of the skin to the finger, in which an indeterminate number of grains are parts of the whole by virtue of being grains in a collective that is part of the whole, and in which removing one granular part does not nec- essarily damage or diminish the whole. Ontological Whether there is a fixed, or nearly fixed number of parts - e.g. fingers of the hand, chambers of the heart, or wheels of a car - such that there can be a notion of a single one being missing, or whether, by contrast, the number of parts is indeterminate - e.g., cells in the skin of the hand, red cells in blood, or rubber molecules in the tread of the tire of the wheel of the car.
Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. Definition take from the definition of granular parthood in the cited paper. Needs work to put into standard form
PAPER: Granularity, scale and collectivity: When size does and does not matter, Alan Rector, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349
This relation obtains between an objective specification and a planned process when the criteria specified in the objective specification are met at the end of the planned process.
A relation between an information content entity and a value specification that specifies its value.
inheres in
this fragility is a characteristic of this vase
this red color is a characteristic of this apple
a relation between a specifically dependent continuant (the characteristic) and any other entity (the bearer), in which the characteristic depends on the bearer for its existence.
inheres_in
Note that this relation was previously called "inheres in", but was changed to be called "characteristic of" because BFO2 uses "inheres in" in a more restricted fashion. This relation differs from BFO2:inheres_in in two respects: (1) it does not impose a range constraint, and thus it allows qualities of processes, as well as of information entities, whereas BFO2 restricts inheres_in to only apply to independent continuants (2) it is declared functional, i.e. something can only be a characteristic of one thing.
characteristic of
bearer of
this apple is bearer of this red color
this vase is bearer of this fragility
Inverse of characteristic_of
A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist.
bearer_of
is bearer of
has characteristic
participates in
this blood clot participates in this blood coagulation
this input material (or this output material) participates in this process
this investigator participates in this investigation
a relation between a continuant and a process, in which the continuant is somehow involved in the process
participates_in
has participant
this blood coagulation has participant this blood clot
this investigation has participant this investigator
this process has participant this input material (or this output material)
a relation between a process and a continuant, in which the continuant is somehow involved in the process
Has_participant is a primitive instance-level relation between a process, a continuant, and a time at which the continuant participates in some way in the process. The relation obtains, for example, when this particular process of oxygen exchange across this particular alveolar membrane has_participant this particular sample of hemoglobin at this particular time.
has_participant
A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The journal article (a generically dependent continuant) is concretized as the quality (a specifically dependent continuant), and both depend on that copy of the printed journal (an independent continuant).
An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process).
A relationship between a generically dependent continuant and a specifically dependent continuant or process, in which the generically dependent continuant depends on some independent continuant or process in virtue of the fact that the specifically dependent continuant or process also depends on that same independent continuant. A generically dependent continuant may be concretized as multiple specifically dependent continuants or processes.
is concretized as
A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The quality (a specifically dependent continuant) concretizes the journal article (a generically dependent continuant), and both depend on that copy of the printed journal (an independent continuant).
A relationship between a specifically dependent continuant or process and a generically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant or process also depends on that same independent continuant. Multiple specifically dependent continuants or processes can concretize the same generically dependent continuant.
concretizes
this catalysis function is a function of this enzyme
a relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence
A function inheres in its bearer at all times for which the function exists, however the function need not be realized at all the times that the function exists.
function_of
is function of
This relation is modeled after the BFO relation of the same name which was in BFO2, but is used in a more restricted sense - specifically, we model this relation as functional (inherited from characteristic-of). Note that this relation is now removed from BFO2020.
function of
this red color is a quality of this apple
a relation between a quality and an independent continuant (the bearer), in which the quality specifically depends on the bearer for its existence
A quality inheres in its bearer at all times for which the quality exists.
is quality of
quality_of
quality of
this investigator role is a role of this person
a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence
A role inheres in its bearer at all times for which the role exists, however the role need not be realized at all the times that the role exists.
is role of
role_of
role of
this enzyme has function this catalysis function (more colloquially: this enzyme has this catalysis function)
a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence
A bearer can have many functions, and its functions can exist for different periods of time, but none of its functions can exist when the bearer does not exist. A function need not be realized at all the times that the function exists.
has_function
has function
this apple has quality this red color
a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence
A bearer can have many qualities, and its qualities can exist for different periods of time, but none of its qualities can exist when the bearer does not exist.
has_quality
has quality
this person has role this investigator role (more colloquially: this person has this role of investigator)
a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence
A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists.
has_role
has role
a relation between an independent continuant (the bearer) and a disposition, in which the disposition specifically depends on the bearer for its existence
has disposition
disposition of
this cell derives from this parent cell (cell division)
this nucleus derives from this parent nucleus (nuclear division)
a relation between two distinct material entities, the new entity and the old entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity
This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops from'.
derives_from
derives from
this parent cell derives into this cell (cell division)
this parent nucleus derives into this nucleus (nuclear division)
a relation between two distinct material entities, the old entity and the new entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity
This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops into'. To avoid making statements about a future that may not come to pass, it is often better to use the backward-looking 'derives from' rather than the forward-looking 'derives into'.
derives_into
derives into
is location of
my head is the location of my brain
this cage is the location of this rat
a relation between two independent continuants, the location and the target, in which the target is entirely within the location
Most location relations will only hold at certain times, but this is difficult to specify in OWL. See http://purl.obolibrary.org/obo/ro/docs/temporal-semantics/
location_of
location of
located in
my brain is located in my head
this rat is located in this cage
a relation between two independent continuants, the target and the location, in which the target is entirely within the location
Location as a relation between instances: The primitive instance-level relation c located_in r at t reflects the fact that each continuant is at any given time associated with exactly one spatial region, namely its exact location. Following we can use this relation to define a further instance-level location relation - not between a continuant and the region which it exactly occupies, but rather between one continuant and another. c is located in c1, in this sense, whenever the spatial region occupied by c is part_of the spatial region occupied by c1. Note that this relation comprehends both the relation of exact location between one continuant and another which obtains when r and r1 are identical (for example, when a portion of fluid exactly fills a cavity), as well as those sorts of inexact location relations which obtain, for example, between brain and head or between ovum and uterus
located_in
This is redundant with the more specific 'independent and not spatial region' constraint. We leave in the redundant axiom for use with reasoners that do not use negation.
the surface of my skin is a 2D boundary of my body
a relation between a 2D immaterial entity (the boundary) and a material entity, in which the boundary delimits the material entity
A 2D boundary may have holes and gaps, but it must be a single connected entity, not an aggregate of several disconnected parts.
Although the boundary is two-dimensional, it exists in three-dimensional space and thus has a 3D shape.
2D_boundary_of
boundary of
is 2D boundary of
is boundary of
2D boundary of
my body has 2D boundary the surface of my skin
a relation between a material entity and a 2D immaterial entity (the boundary), in which the boundary delimits the material entity
has boundary
has_2D_boundary
has 2D boundary
A relation that applies between a cell(c) and a gene(g) , where the process of 'transcription, DNA templated (GO_0006351)' is occuring in in cell c and that process has input gene g.
x 'cell expresses' y iff: cell(x) AND gene(y) AND exists some 'transcription, DNA templated (GO_0006351)'(t) AND t occurs_in x AND t has_input y
X ends_after Y iff: end(Y) before_or_simultaneous_with end(X)
ends after
X starts_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (start(X) before_or_simultaneous_with end(Y))
starts during
X happens_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (end(X) before_or_simultaneous_with end(Y))
happens during
X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y).
ends during
x is in taxon y if an only if y is an organism, and the relationship between x and y is one of: part of (reflexive), developmentally preceded by, derives from, secreted by, expressed.
Connects a biological entity to its taxon of origin.
w 'has component' p if w 'has part' p and w is such that it can be directly disassembled into into n parts p, p2, p3, ..., pn, where these parts are of similar type.
The definition of 'has component' is still under discussion. The challenge is in providing a definition that does not imply transitivity.
For use in recording has_part with a cardinality constraint, because OWL does not permit cardinality constraints to be used in combination with transitive object properties. In situations where you would want to say something like 'has part exactly 5 digit, you would instead use has_component exactly 5 digit.
has component
definition "x has gene product of y if and only if y is a gene (SO:0000704) that participates in some gene expression process (GO:0010467) where the output of that process is either y or something that is ribosomally translated from x"
We would like to be able to express the rule: if t transcribed from g, and t is a noncoding RNA and has an evolved function, then t has gene product g.
gene product of
every HOTAIR lncRNA is the gene product of some HOXC gene
every sonic hedgehog protein (PR:000014841) is the gene product of some sonic hedgehog gene
x has gene product y if and only if x is a gene (SO:0000704) that participates in some gene expression process (GO:0010467) where the output of that process is either y or something that is ribosomally translated from y
has gene product
'neural crest cell' SubClassOf expresses some 'Wnt1 gene'
x expressed in y if and only if there is a gene expression process (GO:0010467) that occurs in y, and one of the following holds: (i) x is a gene, and x is transcribed into a transcript as part of the gene expression process (ii) x is a transcript, and the transcription of x is part of the gene expression process (iii) x is a mature gene product such as a protein, and x was translated or otherwise processes from a transcript that was transcribed as part of this gene expression process
expressed in
Do not use this relation directly. It is ended as a grouping for relations between occurrents involving the relative timing of their starts and ends.
A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations.
temporally related to
g is over-expressed in t iff g is expressed in t, and the expression level of g is increased relative to some background.
g is under-expressed in t iff g is expressed in t, and the expression level of g is decreased relative to some background.
c has-biological-role r iff c has-role r and r is a biological role (CHEBI:24432)
c has-application-role r iff c has-role r and r is an application role (CHEBI:33232)
c has-chemical-role r iff c has-role r and r is a chemical role (CHEBI:51086)
x is ubiquitously expressed in y if and only if x is expressed in y, and the majority of cells in y express x
Revisit this term after coordinating with SO/SOM. The domain of this relation should be a sequence, as an instance of a DNA molecule is only expressed in the cell of which it is a part.
ubiquitously expressed in
y expresses x if and only if there is a gene expression process (GO:0010467) that occurs in y, and one of the following holds: (i) x is a gene, and x is transcribed into a transcript as part of the gene expression process (ii) x is a transcript, and x was transcribed from a gene as part of the gene expression process (iii) x is a mature gene product (protein or RNA), and x was translated or otherwise processed from a transcript that was transcribed as part of the gene expression process.
expresses
ubiquitously expresses
q characteristic of part of w if and only if there exists some p such that q inheres in p and p part of w.
Because part_of is transitive, inheres in is a sub-relation of characteristic of part of
characteristic of part of
A relationship that holds via some environmental process
Do not use this relation directly. It is ended as a grouping for a diverse set of relations, all involving the process of evolution.
evolutionarily related to
holds between two entities when some genome-level process such as gene expression is involved. This includes transcriptional, spliceosomal events. These relations can be used between either macromolecule entities (such as regions of nucleic acid) or between their abstract informational counterparts.
Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving the genome of an organism
genomically related to
An organism that is a member of a population of organisms
is member of is a mereological relation between a item and a collection.
member of
has member is a mereological relation between a collection and an item.
has member
relation that links two events, processes, states, or objects such that one event, process, state, or object (a cause) contributes to the production of another event, process, state, or object (an effect) where the cause is partly or wholly responsible for the effect, and the effect is partly or wholly dependent on the cause.
This branch of the ontology deals with causal relations between entities. It is divided into two branches: causal relations between occurrents/processes, and causal relations between material entities. We take an 'activity flow-centric approach', with the former as primary, and define causal relations between material entities in terms of causal relations between occurrents. To define causal relations in an activity-flow type network, we make use of 3 primitives: * Temporal: how do the intervals of the two occurrents relate? * Is the causal relation regulatory? * Is the influence positive or negative? The first of these can be formalized in terms of the Allen Interval Algebra. Informally, the 3 bins we care about are 'direct', 'indirect' or overlapping. Note that all causal relations should be classified under a RO temporal relation (see the branch under 'temporally related to'). Note that all causal relations are temporal, but not all temporal relations are causal. Two occurrents can be related in time without being causally connected. We take causal influence to be primitive, elucidated as being such that has the upstream changed, some qualities of the donwstream would necessarily be modified. For the second, we consider a relationship to be regulatory if the system in which the activities occur is capable of altering the relationship to achieve some objective. This could include changing the rate of production of a molecule. For the third, we consider the effect of the upstream process on the output(s) of the downstream process. If the level of output is increased, or the rate of production of the output is increased, then the direction is increased. Direction can be positive, negative or neutral or capable of either direction. Two positives in succession yield a positive, two negatives in succession yield a positive, otherwise the default assumption is that the net effect is canceled and the influence is neutral. Each of these 3 primitives can be composed to yield a cross-product of different relation types.
Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving cause and effect.
causally related to
q towards e2 if and only if q is a relational quality such that q inheres-in some e, and e != e2 and q is dependent on e2
This relation is provided in order to support the use of relational qualities such as 'concentration of'; for example, the concentration of C in V is a quality that inheres in V, but pertains to C.
x is transcribed from y if and only if x is synthesized from template y
x is the ribosomal translation of y if and only if a ribosome reads x through a series of triplet codon-amino acid adaptor activities (GO:0030533) and produces y
Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all of which have a disease as the subject.
causal relationship with disease as subject
DEPRECATED This relation is similar to but different in important respects to the characteristic-of relation. See comments on that relation for more information.
DEPRECATED inheres in
DEPRECATED bearer of
This relation groups relations between diseases and any other kind of entity.
Do not use this relation directly. It is intended as a grouping for a diverse set of relations, in which the subject or object is a disease.
A type of 'has vaccine component' relation that specifies a vaccine conjugate protein for a specific vaccine
A type of 'has vaccine vector' relation that specifies a bacterial vaccine vector
A relation that specifies contraindication of a vaccine.
This relation may be replaced by has_vaccine_allergen. We need to determine if any vaccine contraindicator is not a vaccine allergen.
A type of 'has vaccine vector' that is specifically for viral vaccine vector
A 'has vaccine component' relation that specifies the plasmid used for development of a particular DNA vaccine.
A relation between a disorder and an infectious pathogen.
The relation 'infection_of' is introduced to represent an infection caused by an infectious pathogen. A pathogen infection is a disorder. Since the number of pathogens is large, there are numerous infections. To make the description of a specific infection simple, the shortcut term 'infection_of' is defined: infection_of X = infection and has_part some (organism X and has_disposition some infectious disposition)
An object property that specifies a process that is induced by vaccination of a vaccine
A 'has vaccine component' relation that specifies a gene inserted to DNA vaccine plasmid for development of a particular DNA vaccine, and this gene encodes for a protein antigen.
An object property that defines a relation between a vaccine and its component
An object property that specifies a vaccine antigen
This relation only works for those vaccine antigen that is physically part of a vaccine preparation. It does not include those antigens that are not part of vaccine. For example, a protein antigen expressed in a DNA vaccine is not a part of vaccine pe ser. In this case, the vaccine expresses the protein, but the gene is part of the vaccine, not the protein. For the case, we can use the relation 'DNA vaccine expresses protein antigen' under the relation 'expresses'.
A type of 'has vaccine antigen' relation that is specifically for vaccine protective protein antigen used in subunit vaccine development
A type of 'has vaccine antigen' relation that is specifically for vaccine protective antigen component
A type of 'has vaccine component' relation that is specifically for vaccine adjuvant component
A type of 'has vaccine component' relation that is specifically for vaccine vector component
An object property that specifies a relation between a vaccine and a vaccine allergen
An object property that indicates a secretion of a material (e.g., protein) from a vaccine organism.
A 'has vaccine component' relation that is specifically used for vaccine preservative
An object property that specifies a relation between a vaccine and a vaccinate route
An object property that specifies a relation between a vaccine and its vaccinee
An 'expresses' relation that specifies a relation between a DNA vaccine and a protein antigen to be expressed by the DNA vaccine.
"A vaccinates B" means that the vaccine A is used for vaccinating the host B (e.g., human).
A relation between a vaccine instance and an organism type such that if the vaccine instance is given to an instance of the organism by the process vaccination, then it changes the organism's disposition to have an immune response against a disease.
has_vaccine_allegen is a relation that specifies an allegen to a vaccine.
An object property that represents a mutational relation between a vaccine organism and another material (e.g., gene or protein). the mutated material initially exists in the original wildtype organism.
An object property that specifies a relation between a vaccine and a vaccine virmugen.
This is a shortcut relation. Domain: vaccine Range: a gene Shortcut: is_specified_output_of some ('preparation of gene mutant vaccine' and (has_specified_input some gene))
A 'has subunit vaccine antigen' relation that indicates the antigen is protective.
A relation that specifies a company that distributes a product (e.g., vaccine). The company is very likely not the manufacturer of the product.
A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism' and has_disposition some disease)))))))). The domain of this relation is a vaccine. The range of this relation is a disease.
An object property that represents an organism has a mutation of a specific gene from the organism genome.
A shortcut relation that is equivalent to: 'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine recipient role' and (role_of some 'organism')))))))). The domain of this relation is a vaccine. The range of this relation is a organism.
An object property that represents a relation between a vaccine with a prime-boost schedule and a vaccine used for priming.
An object property that represents a relation between a vaccine with a prime-boost schedule and a vaccine used for boost.
A shortcut relation that is equivalent to: processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'pathogen')))))))) The domain of this relation is a vaccine. The range of this relation is a pathogen (a bacterium, a virus, a fungus, and a parasite) Ranges: organism and 'has role' some 'pathogen role'
A shortcut relation that is equivalent to: ('vaccine' and 'has function' some ('vaccine function' and ('is realized by' some ('vaccine immunization' and 'has participant' some ('organism' and 'has role' some 'laboratory animal model role'))))). The domain of this relation is a vaccine. The range of this relation is a organism.
A shortcut object property that represents a relation between a vaccine and a disease process where the vaccine immunizes a host against a disease process.
obsolete immunizes against disease process
An object property that represents a relation between a material entity and biological process
An object property that represents a relation between a material entity (such as vaccine or vaccine adjuvant) and an immune profile where the material entity can induce the immune profile in a host.
The vaccine adjuvant T-vant targets the molecular receptor TLR4. Reference: https://vac.niaid.nih.gov/view?id=61.
An object property that represents a relation in which a material entity specifically interacts with or targets a molecular entity acting as a receptor.
A relation between a material entity and a parasite where the material entity causes some process against some parasite such that transmitting to additional hosts or vectors.
capable of blocking transmission (of life cycle)
A relation between a vaccine and a parasite where the vaccine immunizes against some parasite such that the parasite is blocked transmitting to additional hosts or vectors.
blocks transmission of pathogen via vaccine
A relation between a vaccine X and organism Y where the vaccine X generates an immune response in a vaccinated organism and the immune product (e.g., antibody) can be transferred to the organism Y
vaccine immunity response transferrable to organism
Julius Caesar
Verdi’s Requiem
the Second World War
your body mass index
BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81
Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf
An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])
entity
An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts.
BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240
Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants
A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])
if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])
if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])
if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])
(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002]
(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001]
(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002]
(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002]
continuant
An entity that has temporal parts and that happens, unfolds or develops through time.
BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region
BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players.
Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process.
Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame.
An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])
Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])
b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])
(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001]
(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001]
occurrent
a chair
a heart
a leg
a molecule
a spatial region
an atom
an orchestra.
an organism
the bottom right portion of a human torso
the interior of your mouth
b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])
For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])
For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])
(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001]
(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002]
(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002]
A continuant that is a bearer of quality and realizable entity entities, in which other entities inhere and which itself cannot inhere in anything.
independent continuant
BFO 2 Reference: Spatial regions do not participate in processes.
Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional.
A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])
All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])
(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001]
(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001]
spatial region
Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional
A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])
All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])
Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])
(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002]
(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001]
(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001]
temporal region
an infinitely thin plane in space.
the surface of a sphere-shaped part of space
A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])
(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001]
two-dimensional spatial region
the spatiotemporal region occupied by a human life
the spatiotemporal region occupied by a process of cellular meiosis.
the spatiotemporal region occupied by the development of a cancer tumor
A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])
All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])
Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])
Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])
Every spatiotemporal region occupies_spatiotemporal_region itself.
Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])
(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002]
(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001]
(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001]
(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001]
(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001]
spatiotemporal region
a process of cell-division, \ a beating of the heart
a process of meiosis
a process of sleeping
the course of a disease
the flight of a bird
the life of an organism
your process of aging.
p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])
BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)
(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003]
An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t.
process
an atom of element X has the disposition to decay to an atom of element Y
certain people have a predisposition to colon cancer
children are innately disposed to categorize objects in certain ways.
the cell wall is disposed to filter chemicals in endocytosis and exocytosis
BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type.
b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])
If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])
(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002]
(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002]
disposition
the disposition of this piece of metal to conduct electricity.
the disposition of your blood to coagulate
the function of your reproductive organs
the role of being a doctor
the role of this boundary to delineate where Utah and Colorado meet
A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances.
To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])
All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])
(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002]
(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002]
realizable entity
A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])
(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001]
zero-dimensional spatial region
the ambient temperature of this portion of air
the color of a tomato
the length of the circumference of your waist
the mass of this piece of gold.
the shape of your nose
the shape of your nostril
a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])
If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])
(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001]
(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001]
quality
Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key
of one-sided specifically dependent continuants: the mass of this tomato
of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates.
the disposition of this fish to decay
the function of this heart: to pump blood
the mutual dependence of proton donors and acceptors in chemical reactions [79
the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction
the pink color of a medium rare piece of grilled filet mignon at its center
the shape of this hole.
the smell of this portion of mozzarella
b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])
Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc.
(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003]
A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same.
specifically dependent continuant
John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married.
the priest role
the role of a boundary to demarcate two neighboring administrative territories
the role of a building in serving as a military target
the role of a stone in marking a property boundary
the role of subject in a clinical trial
the student role
A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts.
BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives.
b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])
(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001]
role
or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29
the FMA:regional parts of an intact human body.
the Western hemisphere of the Earth
the division of the brain into regions
the division of the planet into hemispheres
the dorsal and ventral surfaces of the body
the upper and lower lobes of the left lung
BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions
b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])
(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004]
fiat object part
an edge of a cube-shaped portion of space.
A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])
(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001]
one-dimensional spatial region
a collection of cells in a blood biobank.
a swarm of bees is an aggregate of members who are linked together through natural bonds
a symphony orchestra
an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)
defined by fiat: the aggregate of members of an organization
defined through physical attachment: the aggregate of atoms in a lump of granite
defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container
defined via attributive delimitations such as: the patients in this hospital
the aggregate of bearings in a constant velocity axle joint
the aggregate of blood cells in your body
the nitrogen atoms in the atmosphere
the restaurants in Palo Alto
your collection of Meissen ceramic plates.
An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects
BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee).
ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158.
b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])
(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004]
object aggregate
a cube-shaped region of space
a sphere-shaped region of space,
A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])
(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001]
three-dimensional spatial region
Manhattan Canyon)
a hole in the interior of a portion of cheese
a rabbit hole
an air traffic control region defined in the airspace above an airport
the Grand Canyon
the Piazza San Marco
the cockpit of an aircraft
the hold of a ship
the interior of a kangaroo pouch
the interior of the trunk of your car
the interior of your bedroom
the interior of your office
the interior of your refrigerator
the lumen of your gut
your left nostril (a fiat part – the opening – of your left nasal cavity)
b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])
(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002]
site
atom
cell
cells and organisms
engineered artifacts
grain of sand
molecule
organelle
organism
planet
solid portions of matter
star
BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting.
BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below).
BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47
BFO 2 Reference: an object is a maximal causally unified material entity
BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74
b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])
object
The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity.
the pdf file on your laptop, the pdf file that is a copy thereof on my laptop
the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule.
b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])
(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001]
A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time.
generically dependent continuant
the function of a hammer to drive in nails
the function of a heart pacemaker to regulate the beating of a heart through electricity
the function of amylase in saliva to break down starch into sugar
BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc.
A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])
(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001]
function
the boundary between the 2nd and 3rd year of your life.
p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])
Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])
(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002]
(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001]
process boundary
the temporal region during which a process occurs.
BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks).
A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])
(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001]
one-dimensional temporal region
a flame
a forest fire
a human being
a hurricane
a photon
a puff of smoke
a sea wave
a tornado
an aggregate of human beings.
an energy wave
an epidemic
the undetached arm of a human being
An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time.
BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60
BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity.
BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here.
A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])
Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])
every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])
(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002]
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002]
(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002]
material entity
b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])
BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions.
BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29
Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions.
Every continuant fiat boundary is located at some spatial region at every time at which it exists
(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001]
continuant fiat boundary
BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10
immaterial entity
The Equator
all geopolitical boundaries
all lines of latitude and longitude
the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin.
the median sulcus of your tongue
a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])
(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001]
one-dimensional continuant fiat boundary
On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels
One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance.
The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on.
b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])
b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])
(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005]
(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002]
process profile
a marriage bond, an instance of requited love, an obligation between one person and another.
b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])
(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001]
relational quality
a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])
(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001]
two-dimensional continuant fiat boundary
the geographic North Pole
the point of origin of some spatial coordinate system.
the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet
zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona.
a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])
(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001]
zero-dimensional continuant fiat boundary
a temporal region that is occupied by a process boundary
right now
the moment at which a child is born
the moment at which a finger is detached in an industrial accident
the moment of death.
temporal instant.
A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])
(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001]
zero-dimensional temporal region
A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])
history
An organic hydroxy compound that consists of benzene bearing a single hydroxy substituent. The parent of the class of phenols.
A carbonyl group with two C-bound amine groups. The commercially available fertilizer has an analysis of 46-0-0 (N-P2O5-K2O).
Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria).
Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
An aldehyde resulting from the formal oxidation of methanol.
A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class
2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside
A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.
Any of a group of aminoglycoside antibiotics produced by fermentation of some Micromonospora spp.
4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)pentopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside
A glycosyl glycoside formed by glucose and fructose units joined by an acetal oxygen bridge from hemiacetal of glucose to the hemiketal of the fructose.
beta-D-fructofuranosyl alpha-D-glucopyranoside
Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.
A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances.
An inorganic chloride salt having sodium(1+) as the counterion.
A dipeptide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of methyl L-phenylalaninate. Commonly used as an artificial sweetener.
methyl L-alpha-aspartyl-L-phenylalaninate
1-methyl N-L-alpha-aspartyl-L-phenylalanate
3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester
3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid
A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.
1,2-benzisothiazol-3(2H)-one 1,1-dioxide
A (1->6)-alpha-D-glucan which has extra branching consisting of (1->2), (1->3) or (1->4) linkages.
A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 (w + x + y + z = 20) and a single terminal is capped by a dodecanoyl group.
Polyoxyethylene (20) sorbitan monolaurate
A polymer composed of PEG-ylated sorbitan, where the total number of poly(ethylene glycol) units is 20 (w + x + y + z = 20) and a single terminal is capped by an oleoyl group.
Polyoxyethylene (20) sorbitan monooleate
An organic sodium salt that is the monosodium salt of glutamic acid.
A broad-spectrum highly toxic antibiotic or mixture of antibiotics produced by a streptomyces (Streptomyces fradiae) and used medically especially to treat local infections.
An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.
sodium [(2-carboxylatophenyl)sulfanyl](ethyl)mercurate(1-)
sodium ethyl[2-(sulfanyl-kappaS)benzoato(2-)]mercurate(1-)
[(o-carboxyphenyl)thio]ethylmercury sodium salt
ethyl(2-mercaptobenzoato-S)mercury sodium salt
ethylmercurithiosalicylic acid sodium salt
o-(ethylmercurithio)benzoic acid sodium salt
A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane.
The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one).
A vertebrate phagocyte with a single nucleus.
This extended description was generated by ChatGPT and reviewed by the CellGuide team, who added references, and by the CL editors, who approved it for inclusion in CL. It may contain information that applies to only to some subtypes and species, and so should not be considered definitional. Mononuclear phagocytes are immune cells that form a critical part of the body's innate immune system, the body's first line of defense against infections. Mononuclear phagocytes are characterized by the presence of a single, large nucleus. The ‘Mononuclear Phagocyte System’ nomenclature was introduced to distinguish mononuclear monocytes and macrophages from other cells with multiple nuclei. However, the cells within the mononuclear phagocyte system represent a highly heterogeneous group, all of which are able to perform highly efficient phagocytosis - engulfing and digesting microbes and cellular debris to fight infections and to maintain normal tissue homeostasis. In addition to phagocytosis, mononuclear phagocytes also secrete chemical compounds to recruit other immune cells to a site of infection. These cells produce different types of signaling molecules, including cytokines, chemokines, and reactive oxygen species, triggering a cascade of responses to ensure rapid and efficient containment and neutralization of invading pathogens. These cells are also involved in antigen presentation, a process essential for stimulating an adaptive immune response. They can process and present antigens to T cells, thereby linking the innate and adaptive immune responses. Mononuclear phagocytes play key roles in tissue repair and remodeling. After infection or injury, these cells help in the clearance of dead cells and debris, a crucial step in the initiation of tissue remodeling and the resolution of inflammation. Overall, mononuclear phagocytes are versatile cells that have tailored their functions to meet the unique challenges of different tissues within the body. They are pivotal in homeostasis, immunity, and inflammation, making them important aspects in a range of human diseases including infection, autoimmunity, and cancer.
The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated.
This extended description was generated by ChatGPT and reviewed by the CellGuide team, who added references, and by the CL editors, who approved it for inclusion in CL. It may contain information that applies to only to some subtypes and species, and so should not be considered definitional. Hepatocytes are the major cell type constituting 70-80% of the liver's cytoplasmic mass, playing crucial roles in maintaining the body's metabolic homeostasis. Dimensions of mature hepatocytes typically range from 20 to 30 μm in humans, but size may vary depending on their location within the liver lobule. Hepatocytes are characterized by high biosynthetic, enzymatic, and endocytic activity. They contain abundant mitochondria, smooth and rough endoplasmic reticulum, peroxisomes, lysosomes, and a large nucleus that is often binucleate. The liver consists of three zones - the periportal Zone 1, midzone 2, and pericentral Zone 3 - which have differential nutrient and oxygen status, and damage susceptibility; hepatocytes in the different zones show signifcant functional heterogeneity ('hepatocyte functional zonation'). Hepatocytes are involved in a multitude of critical functions including the metabolism of lipids, carbohydrates, and proteins, the synthesis of serum proteins (e.g., albumin, transferrin, and lipoproteins), the detoxification and excretion of endogenous and exogenous substances, the storage of vitamins and minerals, and the production and secretion of bile. Heterocytes demonstrate a remarkable regenerative capacity, which enables the liver to recover from injury and loss of tissue mass. Notably, hepatocytes perform biotransformation with both phase I and phase II enzymes, which modify drugs, xenobiotics, and various substances for elimination from the body. Phase I enzymes, such as cytochrome P450, catalyze both oxidative and reductive reactions of many xenobiotics; many of the products of phase I enzymes are substrates for the phase II enzymes, which catalyze conjugation reactions. Alterations in hepatocyte function have significant implications for overall human health and disease. Certain conditions, such as hepatitis, cirrhosis, and liver cancer, can profoundly affect hepatocyte structure and function, thereby disrupting the liver's ability to perform its vital roles within the body. As the primary site for drug metabolism, changes in hepatocyte function can also impact the effectiveness and toxicity of pharmaceuticals. The regenerative ability of hepatocytes makes them valuable cells for liver regenerative medicine and bioartificial liver support systems, and their study has provided significant insights into liver biology and disease.
Hepatocytes are reportedly MHC Class I-positive and MHC Class II-positive.
A cell that moves by its own activities.
A red blood cell. In mammals, mature erythrocytes are biconcave disks containing hemoglobin whose function is to transport oxygen.
Any cell capable of ingesting particulate matter via phagocytosis.
A mononuclear phagocyte present in variety of tissues, typically differentiated from monocytes, capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells.
Morphology: Diameter 30_M-80 _M, abundant cytoplasm, low N/C ratio, eccentric nucleus. Irregular shape with pseudopods, highly adhesive. Contain vacuoles and phagosomes, may contain azurophilic granules; markers: Mouse & Human: CD68, in most cases CD11b. Mouse: in most cases F4/80+; role or process: immune, antigen presentation, & tissue remodelling; lineage: hematopoietic, myeloid.
A phagocyte in vertebrates that is able to phagocytosis.
An achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.
A cell of the monocyte, granulocyte, mast cell, megakaryocyte, or erythroid lineage.
A cell of the monocyte, granulocyte, or mast cell lineage.
A leukocyte with a single non-segmented nucleus in the mature form.
A bacterial pneumonia has_material_basis_in Streptococcus pneumoniae.
Streptococcus pneumonia
A viral infectious disease that results_in infection located_in joint, has_material_basis_in Chikungunya virus (Alphavirus chikungunya), which is transmitted_by Aedes mosquito bite. The infection has_symptom fever, has_symptom arthralgia, and has_symptom maculopapular rash.
Chikungunya fever
chikungunya
A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions.
infectious disease
disease by infectious agent
A viral infectious disease that results_in inflammation located_in brain, has_material_basis_in Tick-borne encephalitis virus (Orthoflavivirus encephalitidis), which is transmitted_by Ixodes ticks. The infection has_symptom drowsiness, has_symptom confusion, has_symptom sensory disturbances, and has_symptom paralysis.
Central European encephalitis
Far Eastern TBE
Russian spring-summer encephalitis
Siberian tick-borne encephalitis
Taiga encephalitis
Western European tick-borne encephalitis
west-Siberian encephalitis
tick-borne encephalitis
A bacterial infectious disease that results_in infection by bacteria as a result of their presence or activity within the normal, healthy host, and their intrinsic virulence is, in part, a necessary consequence of their need to reproduce and spread.
primary bacterial infectious disease
An organ system cancer located_in the respiratory system that is characterized by uncontrolled cellular proliferation in the respiratory tract.
respiratory system cancer
A cancer that is classified based on the organ it starts in.
organ system cancer
A cancer that is classified by the type of cell from which it is derived.
cell type cancer
A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.
mantle cell lymphoma
A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.
lymphoid cancer
lymphoma
An immune system cancer that is located_in the lymphatic system and is characterized by uncontrolled cellular proliferation of lymphoid tissue.
lymphatic system cancer
An organ system cancer located_in the immune system that is characterized by uncontrolled cellular proliferation in organs of the immune system.
immune system cancer
An organ system benign neoplam that is located_in the thoracic cavity.
thoracic benign neoplasm
An organ system cancer located_in the muscular and skeletal organs and characterized by uncontrolled cellular proliferation of the musculoskeletal organs.
skeletal system cancer
musculoskeletal system cancer
A gastrointestinal system cancer that is located_in the pharynx.
pharyngeal neoplasm
pharynx neoplasm
pharyngeal cancer
pharynx cancer
A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.
skeletal disease
bone disease
A bacterial meningitis that has_material_basis_in Neisseria meningitidis infection.
meningococcal meningitis
A bacterial meningitis that has_material_basis_in Haemophilus influenzae infection.
haemophilus meningitis
A gastrointestinal system cancer that is located_in the hepatobiliary system.
hepatobiliary system cancer
A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2, a subtype of Betacoronavirus pandemicum.
2019 Novel Coronavirus (2019-nCoV)
2019-nCoV infection
COVID19
SARS-CoV-2 infection
Wuhan coronavirus infection
Wuhan seafood market pneumonia virus infection
COVID-19
An immune system disease that is characterized by recognition by mature donor T cells, that contaminate the allogeneic bone marrow, of the recipient's tissue as foreign, causing a severe inflammatory disease characterized by rashes, diarrhea, and liver disease, and that has_material_basis_in an associated with variation in the interleukin-10 gene (IL10) on chromosome 1q32.
GvHD
graft versus host disease
graft-versus-host disease
An intestinal cancer that is located_in the small intestine.
small intestine cancer
A gastrointestinal system cancer that is located_in the intestine.
malignant intestinal tumors
malignant neoplasm of intestine
intestinal cancer
A viral infectious disease that results in inflammation located in salivary gland, has_material_basis_in Mumps rubulavirus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.
mumps
A male reproductive organ cancer that is located_in the prostate.
NGP - new growth of prostate
hereditary prostate cancer
malignant tumor of the prostate
prostate cancer, familial
prostate neoplasm
prostatic cancer
prostatic neoplasm
tumor of the prostate
Xref MGI. OMIM mapping confirmed by DO. [SN].
prostate cancer
A disease by infectious agent that results_in infection, has_material_basis_in Bacteria.
bacterial infectious disease
A gastrointestinal system cancer that is located_in the stomach.
gastric cancer
gastric neoplasm
OMIM mapping confirmed by DO. [SN].
stomach cancer
A tauopathy that is characterized by memory lapses, confusion, emotional instability and progressive loss of mental ability and results in progressive memory loss, impaired thinking, disorientation, and changes in personality and mood starting and leads in advanced cases to a profound decline in cognitive and physical functioning and is marked histologically by the degeneration of brain neurons especially in the cerebral cortex and by the presence of neurofibrillary tangles and plaques containing beta-amyloid.
Alzheimer disease
Alzheimers dementia
Alzheimer's disease
A viral infectious disease that results_in infection located_in brain, has_material_basis_in Japanese encephalitis virus (Orthoflavivirus japonicum), which is transmitted_by Culex tritaeniorhynchus mosquito bite. The infection has_symptom headache, has_symptom high fever, has_symptom neck stiffness, has_symptom stupor, has_symptom disorientation, has_symptom coma, has_symptom tremors, has_symptom convulsions, and has_symptom spastic paralysis.
Japanese B encephalitis
Japanese encephalitis
A female reproductive system disease that is located_in the ovary.
ovarian disease
An urinary system cancer that results_in malignant growth located_in the urinary bladder.
bladder cancer
tumor of the bladder
urinary bladder cancer
A brucellosis that involves an infection caused by Brucella suis [NCBITaxon:29461] in swine and humans. The disease has_symptom fever, has_symptom chills, has_symptom malaise, has_symptom diaphoresis, has_symptom arthralgia, has_symptom myalgia, has_symptom headache, has_symptom anorexia, and has_symptom fatigue.
Brucella suis brucellosis
A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has_symptom fever, has_symptom sweat, has_symptom headache, has_symptom back pain, has_symptom physical weakness, has_symptom joint pain and has_symptom fatigue.
Maltese fever
undulant fever
Bang's disease
Gibraltar fever
Malta fever
Mediterranean fever
brucellosis
A primary bacterial infectious disease that is a zoonotic infectious disease affecting multiple organs, has_material_basis_in Coxiella burnetii, which is transmitted_by inhalation of air contaminated by barnyard dust containing dried placental material, birth fluids, or excreta of infected herd animals, transmitted_by ingestion of contaminated milk, transmitted_by tick bites and transmitted_by contact with infected person. The infection has_symptom fever, has_symptom headache, has_symptom cough, has_symptom pleuritic chest pain, has_symptom myalgia and has_symptom arthralgia.
Infection due to Coxiella burnetii
Q fever
A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm.
connective and soft tissue neoplasm
tumor of soft tissue and skeleton
sarcoma
A commensal bacterial infectious disease that results_in inflammation located_in respiratory tract, has_material_basis_in Bordetella pertussis, or has_material_basis_in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).
WC - Whooping cough
bordetella infection
whooping cough
pertussis
A viral infectious disease that has_material_basis_in human papillomaviruses, which establish productive infections only in the stratified epithelium of the skin or mucous membranes. These viruses cause warts and sometimes tumors. They are transmitted_by sexual contact.
HPV
Human papillomavirus infectious disease
A viral infectious disease that results in inflammation located in brain or located in spinal cord, has_material_basis_in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.
Lyssa
rabies
A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has_material_basis_in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.
Infection due to Clostridium tetani
clostridial tetanus
tetanus
A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.
corynebacterium infection
diphtheria
A primary bacterial infectious disease that results_in infection, has_material_basis_in Borrelia burgdorferi, which is transmitted_by blacklegged tick (Ixodes scapularis) or transmitted_by western blacklegged tick (Ixodes pacificus). The infection has_symptom fever, has_symptom headache, has_symptom fatigue, and has_symptom skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system.
Bannwarth syndrome
Bannworth's syndrome
Lyme borreliosis
Neurological Lyme disease
lyme neuroboInOwlrreliosis
neuroboInOwlrreliosis
Lyme disease
A nervous system cancer that is located in the peripheral nervous system.
neoplasm of peripheral nerve
nerve sheath neoplasm
tumor of PNS
peripheral nervous system neoplasm
An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
head and neck neoplasm
head and neck tumours
head/neck neoplasm
tumor of head and neck
head and neck cancer
A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva.
female reproductive cancer
malignant Gynecologic tumor
malignant neoplasm of female genital organ
female reproductive organ cancer
An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.
allergic hypersensitivity disease
hypersensitivity
hypersensitivity reaction type I disease
allergic disease
A viral infectious disease that results in infection, has_material_basis_in Dengue virus (Orthoflavivirus denguei), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.
Dengue Fever
breakbone fever
classic dengue
classical dengue
dengue disease
A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.
induced malaria
Xref MGI.
malaria
A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.
leukemia
A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis A virus (Hepatovirus ahepa), which is transmitted_by ingestion of contaminated food or water, or transmitted_by direct contact with an infected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice.
Viral hepatitis, type A
Viral hepatitis A
hepatitis A
A viral infectious disease that results_in infection located_in upper respiratory tract or located_in lower respiratory tract, has_material_basis_in Human respiratory syncytial virus, which is transmitted_by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted_by contaminated fomites. The infection has_symptom runny nose, has_symptom fever, has_symptom cough, has_symptom wheezing, and has_symptom respiratory distress.
RSV
respiratory syncytial virus
respiratory syncytial virus infectious disease
A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.
BT - Brain tumour
adult brain tumor
adult malignant brain neoplasm
brain neoplasm
brain neoplasm, adult
malignant brain tumour
malignant primary brain neoplasm
malignant primary brain tumor
malignant tumor of Brain
malignant tumor of adult brain
neoplasm of brain
primary brain neoplasm
primary brain tumor
primary malignant neoplasm of brain
tumor of the Brain
brain cancer
A respiratory system cancer that is located_in the lung.
lung neoplasm
lung cancer
A primary bacterial infectious disease that is a communicable systemic illness, has_material_basis_in Salmonella enterica subsp enterica serovar Typhi, which is transmitted_by ingestion of food or water contaminated with the feces of an infected person. The infection has_symptom fever, has_symptom diarrhea, has_symptom prostration, has_symptom headache, has_symptom splenomegaly, has_symptom liver enlargement, has_symptom eruption of rose-colored spots, and has_symptom leukopenia.
Typhoid
typhoid fever
A disease by infectious agent that is carried out by a parasite which by definition is a pathogen that simultaneously injures and derives sustenance from its host.
Ectoparasitic disease
parasitemia
parasitic infectious disease
A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.
Malaria fever, subtertian
falciparum malaria
malignant tertian fever
Plasmodium falciparum malaria
A brucellosis that involves an infection caused by Brucella melitensis [NCBITaxon:29459] in cattle, goats, sheep and humans. The disease has_symptom fever, has_symptom malaise, has_symptom anorexia, has_symptom limb pain and has_symptom back pain.
Brucella melitensis brucellosis
A brucellosis that involves an infection caused by Brucella abortus [NCBITaxon:235] in cattle and humans. The disease has_symptom fever, has_symptom chills, has_symptom sweats, has_symptom weight loss, has_symptom malaise, has_symptom headaches, has_symptom myalgia, and has_symptom arthralgia.
Brucella abortus brucellosis
A disease that is characterized by abnormally rapid cell division.
cell process disease
neoplasm
disease of cellular proliferation
A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.
Cholera - Vibrio cholerae
Cholera due to Vibrio cholerae
Vibrio cholerae
cholera
A disease of anatomical entity that is located_in reproductive system organs.
genital system disease
reproductive system disease
A head and neck cancer that has_material_basis_in epithelial cells and is located in the upper aerodigestive tract, including the lip, oral cavity (mouth), nasal cavity, paranasal sinuses, pharynx, and larynx.
carcinoma of the neck
carcinoma of neck
head and neck carcinoma
A disease of anatomical entity that located_in the respiratory system which extends from the nasal sinuses to the diaphragm.
respiratory system disease
A connective tissue disease that develops from an antecedent Group A Streptococcal pharyngeal infection and has_symptom carditis, has_symptom polyarthritis, has_symptom chorea, has_symptom erythema marginatum, has_symptom subcutaneous nodules, has_symptom arthralgia, has_symptom prolonged PR interval, and/or has_symptom fever.
ACUTE RHEUMATIC FEVER
RhF - Rheumatic fever
rheumatic fever
An organ system cancer that originates in the mammary gland.
breast tumor
malignant neoplasm of breast
malignant tumor of the breast
mammary cancer
mammary tumor
primary breast cancer
mammary neoplasm
breast cancer
A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.
malignant neoplasm
malignant tumor
primary cancer
Updating out dated UMLS CUI.
cancer
A disease of anatomical entity that occurs in the muscular and/or skeletal system.
musculoskeletal system disease
An organ system cancer located_in endocrine system that is characterized by uncontrolled cellular proliferation of the hormone producing glands of the endocrine system.
Endocrine tumor
endocrine neoplasm
malignant Endocrine tumor
malignant neoplasm of endocrine gland
malignant tumour of endocrine gland
neoplasm of endocrine gland
neoplasm of endocrine system
endocrine gland cancer
Mesothelioma of Peritoneum
benign peritoneal mesothelioma
An endocrine gland cancer located_in the pancreas.
Ca body of pancreas
Ca head of pancreas
Ca tail of pancreas
malignant neoplasm of body of pancreas
malignant neoplasm of head of pancreas
malignant neoplasm of tail of pancreas
pancreas neoplasm
pancreatic neoplasm
pancreatic tumor
pancreatic cancer
A disease of anatomical entity that is located_in kidney, ureter, bladder and urethra.
Non-neoplastic urinary tract disease
urinary tract disease
urinary system disease
A connective tissue cancer that is located_in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.
CA - bone cancer
bone neoplasm
bone tumour
malignant bone neoplasm
malignant bone tumour
malignant neoplasm of bone
malignant osseous tumor
neoplasm of bone
osseous tumor
bone cancer
A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye.
Naevocarcinoma
malignant melanoma
melanoma
An organ system cancer that is manifested in the reproductive organs.
Reproductive tumor
malignant reproductive system neoplasm
cancer of reproductive system
reproductive organ cancer
atherosclerosis
A female reproductive organ cancer that is located_in fallopian tube.
fallopian tube neoplasm
malignant neoplasm of uterine tube
malignant tumor of fallopian tube
malignant tumour of fallopian tube
neoplasm of fallopian tube
tumor of the fallopian tube
tumor, fallopian tube, malignant
fallopian tube cancer
A colorectal cancer that is located_in the rectum.
carcinoma of rectum
carcinoma of the rectum
malignant Rectal tumor
malignant neoplasm of rectum
malignant rectum tumor
malignant tumor of rectum
rectal cancer
cancer of rectum
rectum cancer
A musculoskeletal system cancer that is located_in connective tissue.
Tumour of connective tissue
connective tissue neoplasm
mesenchymal tissue malignant neoplasm
neoplasm of connective tissues
connective tissue cancer
A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis B virus (Orthohepadnavirus hominoidei), which is transmitted_by sexual contact, blood transfusions, or fomites like needles or syringes. The infection has_symptom fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, clay-colored bowel movements, joint pain, and jaundice.
chronic hepatitis B
hepatitis B infection
Serum hepatitis
hepatitis B
A primary bacterial infectious disease that has_material_basis_in Francisella tularensis, which is transmitted by dog tick bite (Dermacentor variabilis), transmitted by deer flies (Chrysops sp) or transmitted by contact with infected animal tissues.
tularemia
A colorectal cancer that is located_in the colon.
colon cancer
A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.
female reproductive system disease
A female reproductive organ cancer that is located_in the ovary.
malignant Ovarian tumor
malignant tumour of ovary
ovarian neoplasm
ovary neoplasm
primary ovarian cancer
tumor of the Ovary
ovarian cancer
An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.
Hematologic malignancy
Hematologic neoplasm
Hematological tumors
blood cancer
hematopoietic and lymphoid system tumor
hematopoietic cancer
hematopoietic neoplasm
hematopoietic tumors
malignant hematopoietic neoplasm
hematologic cancer
A urinary system cancer that is located_in the kidney.
malignant neoplasm of kidney except pelvis
malignant tumour of kidney
renal cancer
kidney cancer
A disease of anatomical entity that is located_in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body.
endocrine system disease
A disease of anatomical entity that is located_in the immune system.
immune system disease
A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue.
adenocarcinoma
A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
epithelial cancer
epithelioma
malignant Epithelioma
carcinoma
A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.
GBM
adult glioblastoma multiforme
glioblastoma multiforme
grade IV adult Astrocytic tumor
primary glioblastoma multiforme
spongioblastoma multiforme
glioblastoma
A malignant glioma that is has_material_basis_in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.
Astrocytic tumor
astrocytoma of Cerebrum
astrocytoma of brain
astroglioma
cerebral astrocytoma
malignant astrocytoma
An organ system cancer located_in the nervous system that affects the central or peripheral nervous system.
malignant neoplasm of nervous system
neoplasm of nervous system
nervous system neoplasm
neural neoplasm
neural tumor
tumor of the nervous system
nervous system cancer
A gastrointestinal system disease that is located_in the liver and/or biliary tract.
liver and biliary tract disease
hepatobiliary disease
An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system.
GI tumor
digestive system cancer
gastrointestinal tract cancer
gastrointestinal system cancer
A viral infectious disease that results in infection of primates, rodents and humans, located in skin, has_material_basis_in Monkeypox virus (Orthopoxvirus monkeypox), which is transmitted by contact with the animal's blood, body fluids, rash, or with the body fluids of a sick person, transmitted by fomites, and transmitted by respiratory droplets. The infection has symptom fever, has symptom muscle ache, has symptom headache, and has symptom lymphadenopathy.
monkeypox
November 2022 WHO name update.
mpox
A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.
central nervous system disease
A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus).
Osteogenic sarcoma
Skeletal sarcoma
bone tissue neoplasm
osteoid sarcoma
osteosarcoma
A connective tissue cancer that has_material_basis_in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm.
Ewing's family localized tumor
Ewing's sarcoma/peripheral primitive neuroectodermal tumor
Ewing's tumor
Ewings sarcoma
Ewings sarcoma-primitive neuroectodermal tumor
PNET of Thoracopulmonary Region
localized Ewing sarcoma
localized Ewing's sarcoma
localized Ewing's sarcoma/peripheral primitive neuroectodermal tumor
localized Ewing's tumor
localized peripheral primitive neuroectodermal tumor
peripheral primitive neuroectodermal tumor
Ewing sarcoma
A female reproductive system disease that is located_in the uterus.
uterine disease
A hepatobiliary system cancer that is located_in the liver.
Ca liver - primary
Resectable malignant neoplasm of Liver
hepatic cancer
hepatic neoplasm
malignant hepato-biliary neoplasm
malignant neoplasm of liver
malignant neoplasm of liver, not specified as primary or secondary
malignant neoplasm of liver, primary
malignant tumor of liver
neoplasm of liver
non-resectable primary hepatic malignant neoplasm
primary liver cancer
primary malignant neoplasm of liver
resectable malignant neoplasm of the liver
liver cancer
A nervous system cancer that is located_in the central nervous system.
CNS neoplasm
central nervous system tumor
central nervous system tumors
malignant neoplasm of central nervous system
malignant tumor of CNS
neoplasm of central nervous system
central nervous system cancer
A female reproductive organ cancer that is located_in the uterus.
CA - cancer of uterus
Tumour of uterus
malignant neoplasm of uterus
malignant uterine tumor
neoplasm of uterus
uterine tumor
uterus neoplasm
uterine cancer
A stomach carcinoma that derives_from epithelial cells of glandular origin.
adenocarcinoma of stomach
stomach adenocarcinoma
gastric adenocarcinoma
A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.
male genital cancer
male reproductive system neoplasm
malignant neoplasm of male genital organ
malignant neoplasm of male genital organ or tract
malignant neoplasm of male genital organs
malignant tumor of male Reproductive system
malignant tumor of male genital organ
neoplasm of male genital organ
tumor of male Reproductive system
male genital neoplasm
male reproductive organ cancer
A lung cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells and is located_in the lungs and has_symptom cough and has_symptom chest discomfort or pain and has_symptom weight loss and has_symptom hemoptysis.
cancer of lung
carcinoma of lung
lung carcinoma
A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.
NSCLC
Non-small cell lung cancer
non-small cell lung carcinoma
lung non-small cell carcinoma
A primary bacterial infectious disease that is located_in lungs, located_in lymph nodes, located_in pericardium, located_in brain, located_in pleura or located_in gastrointestinal tract, has_material_basis_in Mycobacterium tuberculosis, which is transmitted_by droplets released into the air when an infected person coughs or sneezes.
tuberculosis
An organ system cancer that is located_in the kidneys, ureteres, bladder or urethra.
urinary system cancer
A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism.
disease
An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.
autoimmune hypersensitivity disease
hypersensitivity reaction type II disease
autoimmune disease
A viral infectious disease that is a hemorrhagic fever, has_material_basis_in Bundibugyo virus (Orthoebolavirus bundibugyoense), Sudan ebolavirus (Orthoebolavirus sudanense), Tai Forest ebolavirus (Orthoebolavirus taiense), or Zaire ebolavirus (Orthoebolavirus zairense), which are transmitted_by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has_symptom fever, has_symptom headache, has_symptom joint pain, has_symptom muscle aches, has_symptom sore throat, has_symptom weakness, has_symptom diarrhea, has_symptom vomiting, has_symptom stomach pain, has_symptom rash, has_symptom red eyes, has_symptom hiccups, and has_symptom internal and external bleeding.
Ebola
Ebola disease
Ebola hemorrhagic fever
Ebola virus disease
A female reproductive organ cancer that is located_in the cervix.
cervical neoplasm
cervix cancer
cervix uteri cancer
neoplasm of uterine cervix
tumor of the Cervix Uteri
uterine cervical neoplasm
cervical cancer
A biliary tract cancer that is located_in the bile duct.
Ca extrahepatic bile ducts
bile duct tumor
malignant neoplasm of the extrahepatic bile duct
bile duct cancer
A reproductive system disease that affects male reproductive organs.
male reproductive system disease
A bile duct carcinoma that derives_from epithelial cells of glandular origin.
bile duct adenocarcinoma
A bile duct cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
bile duct carcinoma
A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells.
adult primary Cholangiocarcinoma
adult primary cholangiocellular carcinoma
cholangiosarcoma
cholangiocarcinoma
A viral infectious disease that results in destruction located in motor neurons, has_material_basis_in Human poliovirus 1, has_material_basis_in Human poliovirus 2, or has_material_basis_in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.
poliomyelitis
A hematopoietic cancer that derives_from the blood-forming stem cells of the bone marrow.
bone Marrow tumor
bone marrow neoplasm
malignant bone Marrow tumor
malignant neoplasm of bone marrow
bone marrow cancer
A gastrointestinal system cancer that is located_in the esophagus.
Ca lower third oesophagus
Ca middle third oesophagus
esophagus cancer
malignant neoplasm of distal third of esophagus
malignant neoplasm of lower third of oesophagus
malignant neoplasm of middle third of oesophagus
malignant neoplasm of proximal third of esophagus
malignant neoplasm of upper third esophagus
malignant tumor of Distal Third of esophagus
malignant tumor of Proximal Third of esophagus
malignant tumor of abdominal esophagus
malignant tumor of the middle Third of the esophagus
esophageal cancer
A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.
HIV infection
human immunodeficiency virus infectious disease
A gastrointestinal system disease that is located_in the intestine.
intestinal disease
A lung carcinoma that has_material_basis_in primitive-appearing cells that are smaller than normal cells and is located_in the lung.
lung small cell carcinoma
A stomach cancer that is located_in the stomach.
cancer of the stomach
carcinoma of stomach
gastric carcinoma
stomach carcinoma
A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck.
carcinoma of the head and neck
squamous cell carcinoma of the head and neck
squamous cell carcinomas of head and neck
head and neck squamous cell carcinoma
A nervous system disease that affects the peripheral nervous system.
peripheral nerve disease
peripheral neuropathy
peripheral nervous system disease
A Human immunodeficiency virus infectious disease that results_in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has_material_basis_in Human immunodeficiency virus 1 or has_material_basis_in Human immunodeficiency virus 2, which are transmitted_by sexual contact, transmitted_by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted_by congenital method, and transmitted_by contaminated needles. Opportunistic infections are common in people with AIDS.
AIDS
acquired Immune deficiency
acquired immune deficiency syndrome
acquired immunodeficiency syndrome
A musculoskeletal system disease that affects tissues such as skin, tendons, and cartilage.
connective tissue disorder
disorder of connective tissue
connective tissue disease
A mature B-cell neoplasm that is composed of plasma cells.
Plasma cell dyscrasia
Plasma cell tumour
Plasmacytic tumor
plasma cell neoplasm
A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver.
Hepatoma
hepatocellular carcinoma
A liver cancer that has_material_basis_in epithelial cells.
Liver and Intrahepatic bile duct carcinoma
liver carcinoma
A disease that manifests in a defined anatomical structure.
disease of anatomical entity
A non-Hodgkin lymphoma that has_material_basis_in B cells.
B-cell lymphocytic neoplasm
B-cell lymphoma
A disease of anatomical entity that has_material_basis_in hematopoietic cells.
Blood disease
Blood dyscrasia
DISEASE OF THE BLOOD AND BLOOD-FORMING ORGANS
Hematological disease
blood disorder
disease of haematopoietic system
disease of hematopoietic system
haematopoietic system disease
hematopoietic system disease
A primary bacterial infectious disease that results_in infection located_in skin, located_in lung lymph nodes or located_in gastrointestinal tract, has_material_basis_in Bacillus anthracis, transmitted_by contact with infected animals or animal products, transmitted_by airborne spores or transmitted_by ingestion of undercooked meat from infected animals and has_symptom skin ulcer, has_symptom nausea, has_symptom poor appetite, has_symptom bloody diarrhea, has_symptom fever or has_symptom shortness of breath.
anthrax disease
An autonomic nervous system neoplasm that derives_from immature nerve cells.
neuroblastoma
A disease of anatomical entity that is located_in the gastrointestinal tract.
GIT disease
Gastroenteropathy
alimentary system disease
digestive system disorder
gastrointestinal disease
gastrointestinal disorder
gastrointestinal system disease
A viral infectious disease that results in infection, located in respiratory tract, has_material_basis_in Influenzavirus A (Alphainfluenzavirus), has_material_basis_in Influenzavirus B (Betainfluenzavirus), or has_material_basis_in Influenzavirus C (Gammainfluenzavirus), which are transmitted_by droplet spread of oronasal secretions during coughing, sneezing, or talking from an infected person. It is a highly contagious disease that affects birds and mammals and has_symptom chills, has_symptom fever, has_symptom sore throat, has_symptom runny nose, has_symptom muscle pains, has_symptom severe headache, has_symptom cough, and has_symptom weakness.
Influenza with other manifestations
flu
influenza with non-respiratory manifestation
influenza
A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located_in joint.
Inflammatory disorder of joint
arthritis
A lower respiratory tract disease in which the function of the lungs is adversely affected by narrowing or blockage of the airways resulting in poor air flow, a loss of elasticity in the lungs that produces a decrease in the total volume of air that the lungs are able to hold, and clotting, scarring, or inflammation of the blood vessels that affect the ability of the lungs to take up oxygen and to release carbon dioxide.
Updating out dated CUI and removing lung abscess as a synonym.
lung disease
A viral infectious disease that results_in infection located_in nerve fiber, has_material_basis_in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted_by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has_symptom rash which is followed by blisters, has_symptom headache, has_symptom fever, has_symptom malaise, has_symptom itching, has_symptom burning pain, and has_symptom paresthesia.
Shingles
herpes zona
herpes zoster
A pharynx cancer that is located_in the oropharynx.
Oropharyngeal carcinoma
malignant Oropharyngeal tumor
malignant tumor of oropharynx
malignant tumour of mesopharynx
oropharyngeal cancer
oropharynx cancer
A viral infectious disease that results_in infection located_in skin, has_material_basis_in Measles virus, which is transmitted_by contact with oronasal secretions, or semen of an infected person. The infection has_symptom fever, has_symptom cough, has_symptom coryza, has_symptom conjunctivitis, and has_symptom maculopapular, erythematous rash.
morbilli
measles
A disease of anatomical entity that is located_in the central nervous system or located_in the peripheral nervous system.
nervous system disease
A viral infectious disease that results_in infection located_in skin, has_material_basis_in Human herpesvirus 3, which is transmitted_by direct contact with secretions from the rash, or transmitted_by droplet spread of respiratory secretions. The infection has_symptom anorexia, has_symptom myalgia, has_symptom nausea, has_symptom fever, has_symptom headache, has_symptom sore throat, and has_symptom blisters.
varicella
chickenpox
A viral infectious disease that results in infection located in skin, has_material_basis_in Variola virus (Orthopoxvirus variola), which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk.
Ordinary smallpox
smallpox
A pneumonia involving inflammation of the lungs caused by bacteria.
Pneumonia due to other gram-negative bacteria
gram-negative pneumonia
bacterial pneumonia
A viral infectious disease that results_in infection located_in skin, has_material_basis_in Rubella virus (Rubivirus rubellae), which is transmitted_by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted_by congenital method. The infection has_symptom rash on the face which spreads to the trunk and limbs, has_symptom fever, has_symptom lymphadenopathy, has_symptom joint pains, has_symptom headache, and has_symptom conjunctivitis.
german measles
rubella
A viral infectious disease that results_in inflammation located_in facial nerve, which leads to paralysis of one side of the face, has_material_basis_in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The infection has_symptom vesicular rash of the ear or mouth, has_symptom tinnitus, has_symptom vertigo, has_symptom otalgia, and has_symptom headache.
Geniculate herpes zoster
Herpes zoster auricularis
Herpetic geniculate ganglionitis
Ramsay Hunt syndrome type 2
Ramsay Hunt syndrome type II
Ramsey Hunt syndrome
geniculate neuralgia
nervus intermedius neuralgia
herpes zoster oticus
A large intestine cancer that is located_in the colon and/or located_in the rectum.
colorectal cancer
A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or throat, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.
Nasopharyngeal carcinoma
malignant Nasopharyngeal tumor
malignant neoplasm of nasopharynx
nasopharynx cancer
carcinoma of nasopharynx
nasopharynx carcinoma
A disease by infectious agent that results in infection, has_material_basis_in Viruses.
Viral Infection
Viral disease
virus infection
viral infectious disease
A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.
diabetes
diabetes mellitus
A meningitis that has_material_basis_in a bacterial infection.
bacterial meningitis
A myeloid neoplasm that is located_in the plasma cells in bone marrow.
myeloma
multiple myeloma
A viral infectious disease that results in infection, has_material_basis_in Yellow fever virus (Orthoflavivirus flavi), which is transmitted by Aedes, transmitted by Haemagogus, or transmitted by Sabethes species of mosquitoes. The infection has symptom fever, has symptom muscle pain, has symptom backache, has symptom headache, has symptom shivers, has symptom loss of appetite, has symptom jaundice, and has symptom bleeding from the mouth, nose, eyes or stomach leading to vomitus containing blood.
Sylvatic yellow fever
Yellow fever, sylvan
jungle yellow fever
urban yellow fever
yellow fever
An immune response mediated by cells expressing specific receptors for antigens produced through a somatic diversification process, and allowing for an enhanced secondary response to subsequent exposures to the same antigen (immunological memory).
An immune response taking place in mucosal tissues, including those of the intestinal tract, nasal and upper respiratory tract, and genital tract.
immune response in mucosal-associated lymphoid tissue
Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.
A biological process is the execution of a genetically-encoded biological module or program. It consists of all the steps required to achieve the specific biological objective of the module. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence.
Note that, in addition to forming the root of the biological process ontology, this term is recommended for the annotation of gene products whose biological process is unknown. When this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code 'no data' (ND), is used to indicate this.
A protein complex that in its canonical form is composed of two identical immunoglobulin heavy chains and two identical immunoglobulin light chains, held together by disulfide bonds and sometimes complexed with additional proteins. An immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together.
A protein complex in this context is meant as a stable set of interacting proteins which can be co-purified by an acceptable method, and where the complex has been shown to exist as an isolated, functional unit in vivo. Acceptable experimental methods include stringent protein purification followed by detection of protein interaction. The following methods should be considered non-acceptable: simple immunoprecipitation, pull-down experiments from cell extracts without further purification, colocalization and 2-hybrid screening. Interactions that should not be captured as protein complexes include: 1) enzyme/substrate, receptor/ligand or any similar transient interactions, unless these are a critical part of the complex assembly or are required e.g. for the receptor to be functional; 2) proteins associated in a pull-down/co-immunoprecipitation assay with no functional link or any evidence that this is a defined biological entity rather than a loose-affinity complex; 3) any complex where the only evidence is based on genetic interaction data; 4) partial complexes, where some subunits (e.g. transmembrane ones) cannot be expressed as recombinant proteins and are excluded from experiments (in this case, independent evidence is necessary to find out the composition of the full complex, if known). Interactions that may be captured as protein complexes include: 1) enzyme/substrate or receptor/ligand if the complex can only assemble and become functional in the presence of both classes of subunits; 2) complexes where one of the members has not been shown to be physically linked to the other(s), but is a homologue of, and has the same functionality as, a protein that has been experimentally demonstrated to form a complex with the other member(s); 3) complexes whose existence is accepted based on localization and pharmacological studies, but for which experimental evidence is not yet available for the complex as a whole.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism.
Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC.
A protein complex composed of two identical immunoglobulin heavy chains of an IgG isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgG immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an IgG immunoglobulin complex has the function of antigen binding if a suitable antigen is available. Also, IgG isotypes vary by species.
A protein complex composed of two identical immunoglobulin heavy chains of the IgD isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgD immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an IgD immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
A protein complex composed of two identical immunoglobulin heavy chains of the IgE isotype and two identical immunoglobulin light chains, held together by disulfide bonds. An IgE immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an IgE immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
A protein complex composed of two identical immunoglobulin heavy chains of the IgA isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and sometimes complexed with J chain or J chain and secretory component. An IgA immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an IgA immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
A protein complex composed of two identical immunoglobulin heavy chains of the IgM isotype and two identical immunoglobulin light chains, held together by disulfide bonds, and in its circulating form complexed with J chain in polymeric forms. An IgM immunoglobulin complex may be embedded in the plasma membrane or present in the extracellular space, in mucosal areas or other tissues, or circulating in the blood or lymph.
Note that an IgM immunoglobulin complex has the function of antigen binding if a suitable antigen is available.
conditional specification
A directive information entity that specifies what should happen if the trigger condition is fulfilled.
PlanAndPlannedProcess Branch
OBI branch derived
measurement unit label
Examples of measurement unit labels are liters, inches, weight per volume.
A measurement unit label is as a label that is part of a scalar measurement datum and denotes a unit of measure.
2009-03-16: provenance: a term measurement unit was proposed for OBI (OBI_0000176) , edited by Chris Stoeckert and Cristian Cocos, and subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definition of this, different, term.
2009-03-16: review of this term done during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI.
PERSON: Melanie Courtot
objective specification
In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction.
A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved.
2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed."
2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that.
Answers the question, why did you do this experiment?
PERSON: Barry Smith
PERSON: Bjoern Peters
PERSON: Jennifer Fostel
goal specification
OBI Plan and Planned Process/Roles Branch
Pour the contents of flask 1 into flask 2
A directive information entity that describes an action the bearer will take.
OBI Plan and Planned Process branch
action specification
datum label
A label is a symbol that is part of some other datum and is used to either partially define the denotation of that datum or to provide a means for identifying the datum as a member of the set of data with the same label
GROUP: IAO
9/22/11 BP: changed the rdfs:label for this class from 'label' to 'datum label' to convey that this class is not intended to cover all kinds of labels (stickers, radiolabels, etc.), and not even all kind of textual labels, but rather the kind of labels occuring in a datum.
journal article
Examples are articles published in the journals, Nature and Science. The content can often be cited by reference to a paper based encoding, e.g. Authors, Title of article, Journal name, date or year of publication, volume and page number.
A report that is published in a journal.
PERSON: Chris Stoeckert
data item
Data items include counts of things, analyte concentrations, and statistical summaries.
An information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements.
2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers.
2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum.
2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym.
2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/
JAR: datum -- well, this will be very tricky to define, but maybe some information-like stuff that might be put into a computer and that is meant, by someone, to denote and/or to be interpreted by some process... I would include lists, tables, sentences... I think I might defer to Barry, or to Brian Cantwell Smith JAR: A data item is an approximately justified approximately true approximate belief
data
information content entity
Examples of information content entites include journal articles, data, graphical layouts, and graphs.
A generically dependent continuant that is about some thing.
2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ).
information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity.
10 feet. 3 ml.
A scalar measurement datum is a measurement datum that is composed of two parts, numerals and a unit label.
2009-03-16: we decided to keep datum singular in scalar measurement datum, as in this case we explicitly refer to the singular form
Would write this as: has_part some 'measurement unit label' and has_part some numeral and has_part exactly 2, except for the fact that this won't let us take advantage of OWL reasoning over the numbers. Instead use has measurment value property to represent the same. Use has measurement unit label (subproperty of has_part) so we can easily say that there is only one of them.
scalar measurement datum
An information content entity whose concretizations indicate to their bearer how to realize them in a process.
2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.
2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it.
8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO
Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan
directive information entity
algorithm
PMID: 18378114.Genomics. 2008 Mar 28. LINKGEN: A new algorithm to process data in genetic linkage studies.
A plan specification which describes the inputs and output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata.
Philippe Rocca-Serra
adapted from discussion on OBI list (Matthew Pocock, Christian Cocos, Alan Ruttenberg)
curation status specification
The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.
Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting)
report
Examples of reports are gene lists and investigation reports. These are not published (journal) articles but may be included in a journal article.
A document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. Examples of reports are journal article, patent application, grant progress report, case report (not patient record).
2009-03-16: comment from Darren Natale: I am slightly uneasy with the sentence "Topic of the report is on something that has completed." Should it be restricted to those things that are completed? For example, a progress report is (usually) about something that definitely has *not* been completed, or may include (only) projections. I think the definition would not suffer if the whole sentence is deleted.
2009-03-16: this was report of results with definition: A report is a narrative object that is a formal statement of the results of an investigation, or of any matter on which definite information is required, made by some person or body instructed or required to do so.
2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI.
2009-08-10 Alan Ruttenberg: Larry Hunter suggests that this be obsoleted and replaced by 'document'. Alan restored as there are OBI dependencies and this merits further discussion
disagreement about where reports go. alan: only some gene lists are reports. Is a report all the content of some document? The example of usage suggests that a report may be part of some article. Term needs clarification
GROUP: OBI
data set
Intensity values in a CEL file or from multiple CEL files comprise a data set (as opposed to the CEL files themselves).
A data item that is an aggregate of other data items of the same type that have something in common. Averages and distributions can be determined for data sets.
2009/10/23 Alan Ruttenberg. The intention is that this term represent collections of like data. So this isn't for, e.g. the whole contents of a cel file, which includes parameters, metadata etc. This is more like java arrays of a certain rather specific type
2014-05-05: Data sets are aggregates and thus must include two or more data items. We have chosen not to add logical axioms to make this restriction.
person:Allyson Lister
person:Chris Stoeckert
data about an ontology part
Data about an ontology part is a data item about a part of an ontology, for example a term
plan specification
PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice.
A directive information entity with action specifications and objective specifications as parts, and that may be concretized as a realizable entity that, if realized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified.
2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term.
2014-03-31: A plan specification can have other parts, such as conditional specifications.
2022-01-16 Updated definition to that proposed by Clint Dowloand, IAO Issue 231.
Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved
Clint Dowland
2/3/2009 Comment from OBI review. Action specification not well enough specified. Conditional specification not well enough specified. Question whether all plan specifications have objective specifications. Request that IAO either clarify these or change definitions not to use them
measurement datum
Examples of measurement data are the recoding of the weight of a mouse as {40,mass,"grams"}, the recording of an observation of the behavior of the mouse {,process,"agitated"}, the recording of the expression level of a gene as measured through the process of microarray experiment {3.4,luminosity,}.
A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device.
2/2/2009 is_specified_output of some assay?
obsolescence reason specification
The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value.
The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology.
document
A journal article, patent application, laboratory notebook, or a book
A collection of information content entities intended to be understood together as a whole
PERSON: Lawrence Hunter
publication
journal article, newspaper story, book, etc.
A document that is the output of a publishing process.
PERSON: Jie Zheng
published document
Revisit the term in Octorber 2020. Improve the defintion.
denotator type
The Basic Formal Ontology ontology makes a distinction between Universals and defined classes, where the formal are "natural kinds" and the latter arbitrary collections of entities.
A denotator type indicates how a term should be interpreted from an ontological perspective.
Barry Smith, Werner Ceusters
identifier
An information content entity that is the outcome of a dubbing process and is used to refer to one instance of entity shared by a group of people to refer to that individual entity.
Justin Whorton
Mathias Brochhausen
proper name
Sep 29, 2016: The current definition has been amended from the previous version: "A proper name is an information content entity that is the outcome of a dubbing process and is used to refer to one instance of entity shared by a group of people to refer to that individual entity." to more accuratly reflect the necessary and sufficient condition on the class. (MB)
ontology module
I have placed this under 'data about an ontology part', but this can be discussed. I think this is OK if 'part' is interpreted reflexively, as an ontology module is the whole ontology rather than part of it.
ontology file
This class and it's subclasses are applied to OWL ontologies. Using an rdf:type triple will result in problems with OWL-DL. I propose that dcterms:type is instead used to connect an ontology URI with a class from this hierarchy. The class hierarchy is not disjoint, so multiple assertions can be made about a single ontology.
base ontology module
An ontology module that comprises only of asserted axioms local to the ontology, excludes import directives, and excludes axioms or declarations from external ontologies.
editors ontology module
An ontology module that is intended to be directly edited, typically managed in source control, and typically not intended for direct consumption by end-users.
source ontology module
main release ontology module
An ontology module that is intended to be the primary release product and the one consumed by the majority of tools.
TODO: Add logical axioms that state that a main release ontology module is derived from (directly or indirectly) an editors module
bridge ontology module
An ontology module that consists entirely of axioms that connect or bridge two distinct ontology modules. For example, the Uberon-to-ZFA bridge module.
import ontology module
A subset ontology module that is intended to be imported from another ontology.
TODO: add axioms that indicate this is the output of a module extraction process.
import file
subset ontology module
An ontology module that is extracted from a main ontology module and includes only a subset of entities or axioms.
ontology slim
subset ontology
curation subset ontology module
A subset ontology that is intended as a whitelist for curators using the ontology. Such a subset will exclude classes that curators should not use for curation.
analysis ontology module
An ontology module that is intended for usage in analysis or discovery applications.
analysis subset ontology module
single layer ontology module
A subset ontology that is largely comprised of a single layer or strata in an ontology class hierarchy. The purpose is typically for rolling up for visualization. The classes in the layer need not be disjoint.
ribbon subset
single layer subset ontology module
exclusion subset ontology module
A subset of an ontology that is intended to be excluded for some purpose. For example, a blacklist of classes.
antislim
external import ontology module
An imported ontology module that is derived from an external ontology. Derivation methods include the OWLAPI SLME approach.
external import
species subset ontology module
A subset ontology that is crafted to either include or exclude a taxonomic grouping of species.
taxon subset
reasoned ontology module
An ontology module that contains axioms generated by a reasoner. The generated axioms are typically direct SubClassOf axioms, but other possibilities are available.
generated ontology module
An ontology module that is automatically generated, for example via a SPARQL query or via template and a CSV.
TODO: Add axioms (using PROV-O?) that indicate this is the output-of some reasoning process
template generated ontology module
An ontology module that is automatically generated from a template specification and fillers for slots in that template.
taxonomic bridge ontology module
ontology module subsetted by expressivity
obo basic subset ontology module
A subset ontology that is designed for basic applications to continue to make certain simplifying assumptions; many of these simplifying assumptions were based on the initial version of the Gene Ontology, and have become enshrined in many popular and useful tools such as term enrichment tools. Examples of such assumptions include: traversing the ontology graph ignoring relationship types using a naive algorithm will not lead to cycles (i.e. the ontology is a DAG); every referenced term is declared in the ontology (i.e. there are no dangling clauses). An ontology is OBO Basic if and only if it has the following characteristics: DAG Unidirectional No Dangling Clauses Fully Asserted Fully Labeled No equivalence axioms Singly labeled edges No qualifier lists No disjointness axioms No owl-axioms header No imports
ontology module subsetted by OWL profile
EL++ ontology module
A symbiont role borne by an organism in virtue of the fact that it derives a growth, survival, or fitness advantage from symbiosis while the other symbiont's growth, survival, or fitness is reduced.
In the medical community, the term 'parasite' is used with the narrower meaning of eukaryotic pathogen.
The role is realized in processes that result in the parasite's growth, survival, or fitness advantage or in the other organism's growth, survival, or fitness reduction.
parasite role
A symbiont host role borne by an organism in virtue of the fact that its partner in symbiosis reaches developmental maturity or reproduces sexually in the host.
primary host role
The role is realized in developmental and reproduction processes of the host's partner in symbiosis.
definitive host role
An infectious agent transporter role that is borne by an organism active in the transfer of an infectious agent to an organism of another Species and in which the agent is infectious.
The role is realized in a transmission process. A bearer of a vector role is also a bearer of a host role.
infectious agent vector role
An infectious agent vector role borne by an organism in virtue of the fact that the infectious agent multiplies in the vector.
biological vector of infectious agent role
A disposition to initiate processes that result in a disorder.
pathogenicity
A pathogenic disposition is realized in processes that create a disorder.
The use of 'initiates' is intended to convey that a pathogenic disposition is realized when processes resulting in a disorder begin because of some action on the part of the bearer of the disposition. By this interpretation of 'initiates', disorder-causing entities such as glass, UV light, and toxins do not have a pathogenic disposition.
pathogenic disposition
A material entity with a pathogenic disposition.
pathogen
A biological macromolecule produced by a pathogen and that has a virulence factor disposition.
virulence factor
A part of an extended organism that itself has as part a population of one or more infectious agents and that (1) exists as a result of processes initiated by members of the infectious agent population and is (2) clinically abnormal in virtue of the presence of this infectious agent population, or (3) has a disposition to bring clinical abnormality to immunocompetent organisms of the same Species as the host (the organism corresponding to the extended organism) through transmission of a member or offspring of a member of the infectious agent population.
The organism corresponding to the extended organism is host to the infectious agents. By this definition, parts of the host can be considered part of the infection.
infection
A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas.
infectious bovine rhinotracheitis virus BHV-1
Avian infectious laryngotracheitis virus
Infectious bursal disease virus of chickens
infectious pancreatic necrosis virus IPNV
eastern equine encephalomyelitis virus EEEV
Venezuelan equine encephalitis virus VEE
Venezuelan equine encephalomyelitis virus
avian infectious bronchitis coronavirus IBV
Porcine transmissable gastroenteritis coronavirus
Porcine transmissible gastroenteritis coronavirus
porcine transmissible gastroenteritis virus
transmissible gastroenteritis coronavirus
transmissible gastroenteritis virus TGEV
negative-sense genome single-stranded RNA viruses
Cell-associated subacute sclerosing panencephalitis
Subacute sclerosing panencephalitis virus
subacute sclerosing panencephalitis virus, SSPEV
viral haemorrhagic scepticaemia virus VHS
viral haemorrhagic septicaemia virus VHSV
Chimpanzee immunodeficiency virus (SIV(CPZ))
purple photosynthetic bacteria and relatives
"Alphaproteobacteriota" Whitman et al. 2018
Bacillota corrig. Gibbons and Murray 2021
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Middle East respiratory syndrome coronavirus
Middle East respiratory syndrome-related coronavirus
Salmonella enterica subsp. enterica serovar Enteritidis
Yersinia enterocolitica subsp. enterocolitica
Clostridium perfringens (Veillon and Zuber 1898) Hauduroy et al. 1937 (Approved Lists 1980)
Mycobacterium Lehmann and Neumann 1896 (Approved Lists 1980)
Mycobacterium tuberculosis typus gallinaceus
Mycobacterium tuberculosis typus bovinus
Mycobacterium tuberculosis variant bovis
Mycobacterium tuberculosis (Zopf 1883) Lehmann and Neumann 1896 (Approved Lists 1980)
Mycobacterium tuberculosis typus humanus
Firmicutes corrig. Gibbons and Murray 1978 (Approved Lists 1980)
Infectious laryngo-tracheitis-like viruses
Infectious laryngotracheitis-like viruses
Budgerigar fledgling disease polyomavirus
Brucella melitensis biovar Suis str. 1330
Severe acute respiratory syndrome coronavirus 2
Bacteroides melaninogenicus subsp. macacae
Porcine reproductive and respiratory syndrome virus (PRRSV)
Porcine respiratory and reproductive syndrome virus
porcine reproductive and respiratory syndrome virus PRRSV
porcine reproductive and respiratory syndrome virus, PRRSV
Porcine reproductive and respiratory syndrome virus
"Chlorobacterium" Guillebeau 1890, nom. rejic. Opin. 6 (not "Chlorobacterium" Lauterborn 1916)
Pseudomonas Migula 1894 (Approved Lists 1980)
Serpens Hespell 1977 (Approved Lists 1980)
Pseudomonas aeruginosa (Schroeter 1872) Migula 1900 (Approved Lists 1980)
probable synonym or variety: "Pseudomonas polycolor" Clara 1930
Severe acute respiratory syndrome coronavirus
post-transfusion hepatitis non A non B virus
Lymphocytic choriomeningitis mammarenavirus
Crimean-Congo hemorrhagic fever nairovirus
Crimean-Congo hemorrhagic fever orthonairovirus
Mycobacterium tuberculosis variant bovis BCG
Leptospira kirschneri serovar Grippotyphosa
Yersinia enterocolitica subsp. enterocolitica str. 8081
Yersinia enterocolitica subsp. enterocolitica strain 8081
Yersinia enterocolitica subsp. enterocolitica 8081
Moraxella (subgen. Moraxella Lwoff 1939) bovis
Diplokokkus intracellularis meningitidis
Micrococcus meningitidis cerebrospinalis
Haemamoeba vivax Grassi and Feletti, 1890
Salmonella cholerae-suis subsp. cholerae-suis
Salmonella choleraesuis subsp. choleraesuis
Salmonella enterica subsp. enterica serovar Gallinarum
Yersinia pseudotuberculosis subsp. pestis
Aeromonas hydrophila (Chester 1901) Stanier 1943 (Approved Lists 1980)
Severe acute respiratory syndrome-related coronavirus
Pasteurella haemolytica Newsom and Cross 1932 (Approved Lists 1980)
Burkholderia/Oxalobacter/Ralstonia group
Chlamydia psittaci (Lillie 1930) Page 1968
Corynebacteriales Goodfellow and Jones 2015
Corynebacteriineae corrig. Stackebrandt et al. 1997
Mycobacteriales Janke 1924 (Approved Lists 1980)
Leptospira interrogans serovar Icterohaemorrhagiae
Salmonella enterica subsp. enterica serovar Typhi
Salmonella choleraesuis serotype typhimurium
Salmonella enterica serotype Typhimurium
Salmonella enterica subsp. enterica serovar 1,4,[5],12:i:1,2
Salmonella enterica subsp. enterica serovar Typhimurium
Bacillus/Lactobacillus/Streptococcus group
Enterobacteriaceae and related endosymbionts
Cytophaga-Flexibacter-Bacteroides phylum
Flavobacterium columnare (Bernardet and Grimont 1989) Bernardet et al. 1996
Flexibacter columnaris (ex Davis 1922) Bernardet and Grimont 1989
A test to determine if a subject has ever had a tuberculosis infection. A small amount of purified tuberculosis protein is placed under the skin of the forearm and a positive skin reaction indicates previous exposure to Mycobacterium tuberculosis.
a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event.
Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'.
YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device.
YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention.
YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623.
YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740.
YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events.
YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'.
WEB: http://en.wikipedia.org/wiki/Adverse_event
WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068
The OAE official website is: http://www.oae-ontology.org/.
an adverse event that occurs after a vaccination.
A contraindication is a disposition that increases the risk of harm involved in using a particular drug, carrying out a medical procedure, or engaging in a particular activity such that the risk of harm exceeds a threshold. An contraindication serves as a reason to withhold a certain medical treatment.
Yongqun He, Sirarat Sarntivijai, Mathias Brochhausen, William Hogan, ‎Philip E. Empey
an adverse event that is induced by a vaccination.
Injecting mice with a vaccine in order to test its efficacy
A process that realizes a plan which is the concretization of a plan specification.
'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.)
We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some objectives is a planned process.
6/11/9: Edited at workshop. Used to include: is initiated by an agent
This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call)
planned process
Fact sheet - Regulating the companies The role of the regulator. Ofwat is the economic regulator of the water and sewerage industry in England and Wales. http://www.ofwat.gov.uk/aptrix/ofwat/publish.nsf/Content/roleofregulator_factsheet170805
a regulatory role involved with making and/or enforcing relevant legislation and governmental orders
Person:Jennifer Fostel
OBI
regulator role
regulation-assigned role
Approval letter
Regulation-assigned role is a regulatory role defined by legislation or governmental orders
Person: Jennifer Fostel
regulatory role
Regulatory agency, Ethics committee, Approval letter; example: Browse these EPA Regulatory Role subtopics http://www.epa.gov/ebtpages/enviregulatoryrole.html Feb 29, 2008
a role which inheres in material entities and is realized in the processes of making, enforcing or being defined by legislation or orders issued by a governmental body.
GROUP: Role branch
OBI, CDISC
govt agents responsible for creating regulations; proxies for enforcing regulations. CDISC definition: regulatory authorities. Bodies having the power to regulate. NOTE: In the ICH GCP guideline the term includes the authorities that review submitted clinical data and those that conduct inspections. These bodies are sometimes referred to as competent
processed material
Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples
Is a material entity that is created or changed during material processing.
evaluant role
When a specimen of blood is assayed for glucose concentration, the blood has the evaluant role. When measuring the mass of a mouse, the evaluant is the mouse. When measuring the time of DNA replication, the evaluant is the DNA. When measuring the intensity of light on a surface, the evaluant is the light source.
a role that inheres in a material entity that is realized in an assay in which data is generated about the bearer of the evaluant role
Role call - 17nov-08: JF and MC think an evaluant role is always specified input of a process. Even in the case where we have an assay taking blood as evaluant and outputting blood, the blood is not the specified output at the end of the assay (the concentration of glucose in the blood is)
examples of features that could be described in an evaluant: quality.... e.g. "contains 10 pg/ml IL2", or "no glucose detected")
Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term.
assay
Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house.
A planned process that has the objective to produce information about a material entity (the evaluant) by examining it.
12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation.
Discussion on OBI call 2023-05-01 resulted in an agreement to revise the textual definition of 'assay'. https://github.com/obi-ontology/obi/issues/1683.
measuring
scientific observation
Buffer, dye, a catalyst, a solvating agent.
A role inhering in a biological or chemical entity that is intended to be applied in a scientific technique to participate (or have molecular components that participate) in a chemical reaction that facilitates the generation of data about some entity distinct from the bearer, or the generation of some specified material output distinct from the bearer.
PERSON:Matthew Brush
Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term. May 28 2013. Updated definition taken from ReO based on discussions initiated in Philly 2011 workshop. Former defnition described a narrower view of reagents in chemistry that restricts bearers of the role to be chemical entities ("a role played by a molecular entity used to produce a chemical reaction to detect, measure, or produce other substances"). Updated definition allows for broader view of reagents in the domain of biomedical research to include larger materials that have parts that participate chemically in a molecular reaction or interaction.
(copied from ReO) Reagents are distinguished from instruments or devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in or have parts that participate in some chemical interaction or reaction during their intended participation in some technique. By contrast, instruments do not participate in a chemical reaction/interaction during the technique. Reagents are distinguished from study subjects/evaluants in that study subjects and evaluants are that about which conclusions are drawn and knowledge is sought in an investigation - while reagents, by definition, are not. It should be noted, however, that reagent and study subject/evaluant roles can be borne by instances of the same type of material entity - but a given instance will realize only one of these roles in the execution of a given assay or technique. For example, taq polymerase can bear a reagent role or an evaluant role. In a DNA sequencing assay aimed at generating sequence data about some plasmid, the reagent role of the taq polymerase is realized. In an assay to evaluate the quality of the taq polymerase itself, the evaluant/study subject role of the taq is realized, but not the reagent role since the taq is the subject about which data is generated. In regard to the statement that reagents are 'distinct' from the specified outputs of a technique, note that a reagent may be incorporated into a material output of a technique, as long as the IDENTITY of this output is distinct from that of the bearer of the reagent role. For example, dNTPs input into a PCR are reagents that become part of the material output of this technique, but this output has a new identity (ie that of a 'nucleic acid molecule') that is distinct from the identity of the dNTPs that comprise it. Similarly, a biotin molecule input into a cell labeling technique are reagents that become part of the specified output, but the identity of the output is that of some modified cell specimen which shares identity with the input unmodified cell specimen, and not with the biotin label. Thus, we see that an important criteria of 'reagent-ness' is that it is a facilitator, and not the primary focus of an investigation or material processing technique (ie not the specified subject/evaluant about which knowledge is sought, or the specified output material of the technique).
reagent role
A cell lysis, production of a cloning vector, creating a buffer.
A planned process which results in physical changes in a specified input material
material transformation
material processing
population
PMID12564891. Environ Sci Technol. 2003 Jan 15;37(2):223-8. Effects of historic PCB exposures on the reproductive success of the Hudson River striped bass population.
a population is a collection of individuals from the same taxonomic class living, counted or sampled at a particular site or in a particular area
1/28/2013, BP, on the call it was raised that we may want to switch to an external ontology for all populatin terms: http://code.google.com/p/popcomm-ontology/
PERSON: Philippe Rocca-Serra
adapted from Oxford English Dictionnary
rem1: collection somehow always involve a selection process
A role of a material entity that is being recognized in whole or in part by receptors of the immune system such as antibodies or T cell receptors.
An antigen is a substance that prompts the generation of antibodies and can cause an immune response. Wikipedia http://en.wikipedia.org/wiki/Antigen. In the strict sense, immunogens are those substances that elicit a response from the immune system, whereas antigens are defined as substances that bind to specific antibodies. Not all antigens produce an immunogenic response, but all immunogens are antigens
Role Branch
9Mar09 waiting for discussion with immunology terms
antigen role
organization
PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods.
An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members.
BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based: 1) there are organization_member_roles (president, treasurer, branch editor), with individual persons as bearers 2) there are organization_roles (employer, owner, vendor, patent holder) 3) an organization has a charter / rules / bylaws, which specify what roles there are, how they should be realized, and how to modify the charter/rules/bylaws themselves. It is debatable what the organization itself is (some kind of dependent continuant or an aggregate of people). This also determines who/what the bearer of organization_roles' are. My personal favorite is still to define organization as a kind of 'legal entity', but thinking it through leads to all kinds of questions that are clearly outside the scope of OBI. Interestingly enough, it does not seem to matter much where we place organization itself, as long as we can subclass it (University, Corporation, Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO, W3C, University of Oklahoma), and have it play roles. This leads to my proposal: We define organization through the statements 1 - 3 above, but without an 'is a' statement for now. We can leave it in its current place in the is_a hierarchy (material entity) or move it up to 'continuant'. We leave further clarifications to BFO, and close this issue for now.
protocol
PCR protocol, has objective specification, amplify DNA fragment of interest, and has action specification describes the amounts of experimental reagents used (e..g. buffers, dNTPS, enzyme), and the temperature and cycle time settings for running the PCR.
A plan specification which has sufficient level of detail and quantitative information to communicate it between investigation agents, so that different investigation agents will reliably be able to independently reproduce the process.
OBI branch derived + wikipedia (http://en.wikipedia.org/wiki/Protocol_%28natural_sciences%29)
Injecting a drug into a mouse. Adding IL-2 to a cell culture. Adding NaCl into water.
is a process with the objective to place a material entity bearing the 'material to be added role' into a material bearing the 'target of material addition role'.
Class was renamed from 'administering substance', as this is commonly used only for additions into organisms.
adding a material entity into a target
is the injection of a material entity (bearing the administered substance role) into the peritoneum (bearing the target role) of an organism using a syringe
drug added to a buffer contained in a tube; substance injected into an animal;
A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role is added into another material entity (the target).
9 March 09 from discussion with PA branch
material to be added role
transfer function
A transfer function is a function to displace a material from one location to another.
Accuracy of oral liquid measuring devices: comparison of dosing cup and oral dosing syringe.Ann Pharmacother. 2008 Jan;42(1):46-52. Epub 2007 Dec 4. PMID: 18056832
A processed material which is used to introduce or draw fluids from a material entity. A syringe is made of a piston and body. the movement of the piston in the body determines the amount/volume of fluid to inject or draw
Multiple Small-Dose Injections Can Reduce the Passage of Sclerosant Foam into Deep Veins During Foam Sclerotherapy for Varicose Veins. Eur J Vasc Endovasc Surg. 2008 Oct 13. PMID: 18922712
injection is process which aims at introducing a compound or a mixture into a material entity (either biological entity or instrument) by relying on devices such as syringe or injector connection, attached or forced into a vascular system (veins of an organism or tubes of a machine) or in a tissue.
injection
Rats were injected intraperitoneally with either rrIL-6 (250 ng/0.5 ml) or equal-volume sterile saline twice within an interval of 24 h
The administration of a substance into the peritoneum of an organism
creating a mouse infected with LCM virus
is the specification of an objective to add a material into a target material. The adding is asymmetric in the sense that the target material largely retains its identity
adding material objective
the objective to determine the weight of a mouse.
an objective specification to determine a specified type of information about an evaluated entity (the material entity bearing evaluant role)
assay objective
peritoneum of an animal receiving an interperitoneal injection; solution in a tube receiving additional material; location of absorbed material following a dermal application.
A role of a material entity that is realized in an "adding a material entity into a target" process where the bearer of the role (the target) receives the addition of another material entity.
From Branch discussion with BP, AR, MC -- there is a need for the recipient to interact with the administered material. for example, a tooth receiving a filling was not considered to be a target role.
target of material addition role
regulatory agency
A regulatory agency is a organization that has responsibility over or for the legislation (acts and regulations) for a given sector of the government.
The objective to create a mouse infected with LCM virus. The objective to create a defined solution of PBS.
an objective specifiction that creates an specific output object from input materials.
artifact creation objective
material transformation objective
A planned process with the objective to produce a processed material which will have a function for future use.
A person or organization (having manufacturer role) is a participant in this process
Manufacturing implies reproducibility and responsibility AR
This includes a single scientist making a processed material for personal use.
manufacturing
is the objective to manufacture a material of a certain function (device)
manufacturing objective
With respect to The Accuri C6 Flow Cytometer System, the organization Accuri bears the role manufacturer role. With respect to a transformed line of tissue culture cells derived by a specific lab, the lab whose personnel isolated the cll line bears the role manufacturer role. With respect to a specific antibody produced by an individual scientist, the scientist who purifies, characterizes and distributes the anitbody bears the role manufacturer role.
Manufacturer role is a role which inheres in a person or organization and which is realized by a manufacturing process.
the sodium and chloride ions in a glass of salt water
a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates
Collective
Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349
scattered molecular aggregate
Mixing two fluids. Adding salt into water. Injecting a mouse with PBS.
is a material processing with the objective to combine two or more material entities as input into a single material entity as output.
created at workshop as parent class for 'adding material into target', which is asymmetric, while combination encompasses all addition processes.
statistical hypothesis test
A statistical hypothesis test data transformation is a data transformation that has objective statistical hypothesis test.
PERSON: James Malone
statistical hypothesis test objective
is a data transformation objective where the aim is to estimate statistical significance with the aim of proving or disproving a hypothesis by means of some data transformation.
James Malone
WEB: http://en.wikipedia.org/wiki/Statistical_hypothesis_testing
creating a mixture of molecules in solution
is a process with the objective to prepare a liquid solution of one or more chemicals at desired concentrations.
is an objective to obtain an output material that contains several input materials.
The administration of a live pathogenic organism to a host.
Pathogen: An agent of disease. A disease producer. The term pathogen most commonly is used to refer to infectious organisms. These include bacteria (such as staph), viruses (such as HIV), and fungi (such as yeast). Less commonly, pathogen refers to a noninfectious agent of disease such as a chemical. http://www.medterms.com/script/main/art.asp?articlekey=6383
pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role
6 April 2009: from the Vaccine Community
In biology, a host is an organism that harbors a virus or parasite, or a mutual or commensal symbiont, typically providing nourishment and shelter. http://en.wikipedia.org/wiki/Host_(biology) 30 March 09
host role is a role played by an organism and realized by providing nourishment, shelter or a means of reproduction to another organism within the organism playing the host role
30Mar09 virus reproducing inside a cell; bacteria causing a disease, host can be harmed or not. we want to avoid a cat sitting on my lap and an animal care technician; these are not examples or hosts; dental cares = on tooth, but part of outer layer of tooth, so covered by "within" in the definition
In a study in which gene expression is measured in patients between 8 month to 4 years old that have mild or severe malaria and in which the hypothesis is that gene expression in that age group is a function of disease status, disease status is the independent variable.
a directive information entity that is part of a study design. Independent variables are entities whose values are selected to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled
2/2/2009 Original definition - In the design of experiments, independent variables are those whose values are controlled or selected by the person experimenting (experimenter) to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled.
In the Philly 2013 workshop the label was chosen to distinguish it from "dependent variable" as used in statistical modelling. See: http://en.wikipedia.org/wiki/Statistical_modeling
Web: http://en.wikipedia.org/wiki/Dependent_and_independent_variables
2009-03-16: work has been done on this term during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify thisdefinition please notify OBI.
study design independent variable
In a study in which gene expression is measured in patients between 8 month to 4 years old that have mild or severe malaria and in which the hypothesis is that gene expression in that age group is a function of disease status, the gene expression is the dependent variable.
dependent variable specification is part of a study design. The dependent variable is the event studied and expected to change when the independent variable varies.
2/2/2009 In the design of experiments, independent variables are those whose values are controlled or selected by the person experimenting (experimenter) to determine its relationship to an observed phenomenon (the dependent variable). In such an experiment, an attempt is made to find evidence that the values of the independent variable determine the values of the dependent variable (that which is being measured). The independent variable can be changed as required, and its values do not represent a problem requiring explanation in an analysis, but are taken simply as given. The dependent variable on the other hand, usually cannot be directly controlled.
study design dependent variable
An objective specification maintains some or all of the qualities of a material over time.
A person or organization that has a manufacturer role.
A planned process with the objective to maintain some or all of the characteristics of an input material over time.
A statement in a journal article indicating that the age of a patient at the onset of disease is not known. A statement indicating that the weight of a mouse was not measured.
An information content entity created to indicate that information about something is not available to the person recording it.
This class should probably end up in IAO. It could be further breaken down to indicate different kinds of lack of knowledge, e.g. inability to determine something vs. no attempt made to determine something vs. no informatino available if it was even attempted to determine something. The design pattern should be generalizable. 'unknown sex' is the first example, and needed immediately.
A measurement datum that is reported on a categorical scale.
A voltmeter is a measurement device which is intended to perform some measure function.
An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure.
A material entity that is designed to perform a function in a scientific investigation, but is not a reagent.
2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of "device", and are enumerating the types of roles that a reagent can perform. 2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions. Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear. For example: (1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component. This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part. (2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay. (3) A gel running box is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it. This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel. In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent role is not transitive across the part_of relation). In this way, the asserted disjointness between a reagent and device holds, as both roles are never realized in the same bearer during execution of an assay.
a protocol specifying to administer 1 ml of vaccine to a mouse
a directive information entity that describes the dose that will be administered to a target
An organism has been injected 1ml of vaccine
A measurement datum that measures the quantity of something that may be administered to an organism or that an organism may be exposed to. Quantities of nutrients, drugs, vaccines and toxins are referred to as doses.
A value specification that is specifies one category out of a fixed number of nominal categories
The value of 'positive' in a classification scheme of "positive or negative"; the value of '20g' on the quantitative scale of mass.
An information content entity that specifies a value within a classification scheme or on a quantitative scale.
This term is currently a descendant of 'information content entity', which requires that it 'is about' something. A value specification of '20g' for a measurement data item of the mass of a particular mouse 'is about' the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change 'value specification' to remove the 'is about' requirement.
The administration of a challenge to a live host.
reactant role
A role borne by a biological or chemical entity that participates or has molecular components that participate in a chemical reaction.
animal
fungus
plant
virus
A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs.
10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms')
13-02-2009: OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. This issue is outside the scope of OBI.
WEB: http://en.wikipedia.org/wiki/Organism
phosphate buffered saline solution
PMID: 16279733.Dent Mater J. 2005 Sep;24(3):414-21.PBS buffer solutions with different pH values can change porosity of DNA-chitosan complexes.
Phosphate buffered saline (abbreviated PBS) is a buffer solution commonly used in biochemistry. It is a salty solution containing sodium chloride, sodium phosphate and in some preparations potassium chloride and potassium phosphate. The buffer helps to maintain a constant pH. The concentration usually matches the human body (isotonic).
PERSON: Tina Boussard
PBS buffer
WEB: http://en.wikipedia.org/wiki/Phosphate_buffered_saline
data transformation
The application of a clustering protocol to microarray data or the application of a statistical testing method on a primary data set to determine a p-value.
A planned process that produces output data from input data.
Elisabetta Manduchi
Helen Parkinson
Melanie Courtot
Richard Scheuermann
Ryan Brinkman
Tina Hernandez-Boussard
data analysis
data processing
Branch editors
data transformation objective
normalize objective
An objective specification to transformation input data into output data
Modified definition in 2013 Philly OBI workshop
A statistical hypothesis test in which the means of several groups are all equal.
chemical solution
PMID: 18289311.Anesth Analg. 2008 Apr;106(4):1078-86.Less impairment of hemostasis and reduced blood loss in pigs after resuscitation from hemorrhagic shock using the small-volume concept with hypertonic saline/hydroxyethyl starch as compared to administration of 4% gelatin or 6% hydroxyethyl starch solution.
A material entity that is made up of at least 2 scattered molecular aggregates, one playing the role of solvent and the other one playing the role of solute.
liquid chemical solution
A buffer of carbonic acid (H2CO3) and bicarbonate (HCO3-) is present in blood plasma, to maintain a pH between 7.35 and 7.45. http://en.wikipedia.org/wiki/Buffer_solution
a role which inheres in some molecular entity realized during the process of buffering
buffer role
PMID: 18373502.Transfusion. 2008 Mar 25. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors.
solvent role is a role which inheres in a molecular entity capable of ensuring the dissolution of another chemical entity and realized by the process of solvation
The class CHEBI:solvent is logically equivalent to this class, iff it is properly subsumed under the BFO:role branch. The label and textual definition of this CHEBI class are however misleadingly denoting the material entity that bears this role and not the role itself. The OBI modeling was needed as what is considered a solvent in a mixture can depend on the intent of the person creating the mixture. It would be great if this could be dealt with in CHEBI itself. See also https://github.com/obi-ontology/obi/issues/1771.
adpated from wikipedia (http://en.wikipedia.org/wiki/Solvatation)
solvent role
PMID: 18380397.Pharmazie. 2008 Feb;63(2):113-21.Deviations of drug solubility in water-cosolvent mixtures from the Jouyban-Acree model--effect of solute structure.
solute role is a role played by a chemical entity which is dissolved by another chemical entity (the solvent) when creating a solution
adapted from wikipedia (http://en.wikipedia.org/wiki/Solute)
solute role
PMID: 18550121.Total Prostate Specific Antigen Stability Confirmed After Long-Term Storage of Serum at -80C. J Urol. 2008 Jun 10.
A planned process with the objective to preserve and protect material entities by placing them in an identified location which may have a controlled environment.
storage
study design
a matched pairs study design describes criteria by which subjects are identified as pairs which then undergo the same protocols, and the data generated is analyzed by comparing the differences between the paired subjects, which constitute the results of the executed study design.
A plan specification comprised of protocols (which may specify how and what kinds of data will be gathered) that are executed as part of an investigation and is realized during a study design execution.
Editor note: there is at least an implicit restriction on the kind of data transformations that can be done based on the measured data available.
experimental design
rediscussed at length (MC/JF/BP). 12/9/08). The definition was clarified to differentiate it from protocol.
administering substance in vivo
Balb/c mice received an intracameral or subconjunctival injection of trinitrophenylated spleen cells
injecting mice with 10 ug morphine intranasally, a patient taking two pills of 1 mg aspirin orally
A process by which a substance is intentionally given to an organism resulting in exposure of the organism to that substance.
2009-11-10. Tracker: https://sourceforge.net/tracker/?func=detail&aid=2893050&group_id=177891&atid=886178
Different routes and means of administration should go as children underneath this
Update the definition based on the discussion. Details see the tracker: https://sourceforge.net/p/obi/obi-terms/738/
needs roles such as perturber and perturbee (children of input role). Perturb is too strong. Host might be the name for one role. Others considered: Doner, Donated, Acceptor.
Bjoern Peters
IEDB
A material entity that has the antigen role.
antigen
A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule.
WEB: http://www.ncbi.nlm.nih.gov/books/NBK21640/
gene
A gene of an organism of Mycobacterium tuberculosis H37Rv
gene of Mycobacterium tuberculosis H37Rv
A gene of an organism of Brucella melitensis bv. 1 str. 16M
gene of Brucella melitensis bv. 1 str. 16M
A gene of Mycobacterium tuberculosis H37Rv that has a protein-coding gene disposition
protein-coding gene of Mycobacterium tuberculosis H37Rv
A gene of Brucella melitensis bv. 1 str. 16M that has a protein-coding gene disposition
protein-coding gene of Brucella melitensis bv. 1 str. 16M
Pantoate--beta-alanine ligase PanC (pantothenate synthetase) (pantoate activating enzyme)
Possible preprotein translocase ATPase SecA2
Probable aspartate 1-decarboxylase precursor PanD (aspartate alpha-decarboxylase)
Diaminopimelate decarboxylase LysA (DAP decarboxylase)
Fatty-acid-AMP ligase FadD26 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase)
Probable anthranilate phosphoribosyltransferase TrpD
Probable 3-isopropylmalate dehydratase (small subunit) LeuD (isopropylmalate isomerase) (alpha-IPM isomerase) (IPMI)
Probable daunorubicin-dim-transport integral membrane protein ABC transporter DrrC
Alternative RNA polymerase sigma factor SigE
Possible two component system response transcriptional positive regulator PhoP
A bodily process that is clinically abnormal.
The totality of all processes through which a given disease instance is realized.
A hindgut that is a part of or originated from a Triatominae bug.
An exflagellated microgametocyte stage in the lifecycle of Plasmodium falciparum that occurs in the midgut of a mosquito vector.
P. falciparum exflagellated microgametocyte stage
Plasmodium falciparum exflagellated microgametocyte stage
A microgametocyte stage in the Plasmodium falciparum lifecycle that occurs either in the bloodstream of a human host or the midgut of a mosquito vector.
Plasmodium falciparum microgametocyte stage
A gamete stage in apicomplexan parasites when exflagellated microgametocyte divides into microgamete.
A gametocyte stage where a cell differentiates into a female sexual form called macrogametocyte.
A midgut that is a part of or originated from an Anopheles mosquito.
A parasite lifecycle stage of trypanosomes. In trypomastigote stage, the kinetoplast is near the posterior end of the body, and the flagellum lies attached to the cell body for most of its length by an undulating membrane.
An erythrocytic schizont stage in the Plasmodium falciparum lifecycle that occurs in the infected erythrocytes of a human host.
updated according to OPL terms Plasmodium final excel file from C. Janse, S. Khan
P. falciparum erythorcytic schizont stage
Plasmodium falciparum erythrocytic schizont stage
A parasite lifecycle stage of apicomplexan species where a daughter cell, called merozoite is produced from schizont through schizogony.
A hepatocyte that is a part of or originated from a human (Homo sapiens).
An erythrocytic ring trophozoite stage in the Plasmodium falciparum life cycle that occurs in erythrocytes of a human host. During this stage some Plasmodium falciparum merozoites undergo asexual reproduction cycle in erythrocytes and form young trophozoites that are referred to as "ring form" due to their morphology.
P. falciparum erythrocytic ring trophozoite stage
Wikipedia: Plasmodium falciparum biology
Plasmodium falciparum erythrocytic ring trophozoite stage
A lifecycle stage of Trypanosoma brucei.
A Plasmodium falciparum gametocyte that is a male gametocyte and found in either bloodstream of a human host or midgut of a mosquito vector. The microgametocyte is a precursor cell of the microgamete.
A parasite lifecycle stage of some protozoan parasites that is a non-reproductive, feeding and growing stage.
A schizont stage that occurs in hepatocyte where sporozoites mature into a schizont.
A Plasmodium falciparum divides through schizogony. Depending on its location, it is either called hepatic or erythrocytic schizont. The schizont is a dividing stage with 2 or more nuclei.
A macrogametocyte stage in the Plasmodium falciparum lifecycle that occurs either in the bloodstream of a human host or the midgut of a mosquito vector.
gametocytes are mainly found in the blood
Plasmodium falciparum macrogametocyte stage
A parasite lifecycle stage of sporozoa consisting of a zygote enclosed by cyst wall.
Mosby's Medical Dictionary, 8th edition. � 2009, Elsevier. (http://medical-dictionary.thefreedictionary.com/oocyst)
A macrogamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector.
A schizont stage that occurs in erythrocytes where trophozoites mature into a schizont and schizont produces daughter trophozoites or merozoites.
A parasite lifecycle stage that is the multinucleate stage in the development of some members of the Sarcodina and some sporozoans during schizogony.
A gamete stage in parasites when macrogametocytes produce macrogametes through the process known as gametogenesis.
A Plasmodium falciparum that is a 'banana-shaped' form and originates from the round zygote. The ookinete is found in the midgut of a mosquito vector and traverses the midgut wall of a mosquito vector.
A hepatic schizont stage in the lifecycle of Plasmodium falciparum that occurs in the infected hepatocytes of a human host.
Plasmodium falciparum hepatic schizont stage
An erythrocyte that is a part of or originated from a human (Homo sapiens).
A merozoite stage in the Plasmodium falciparum lifecycle that occurs in the bloodstream or hepatocytes of a human host.
A Plasmodium falciparum schizont that is found in infected erythrocytes of a human host.
Plasmodium falciparum erythrocytic schizont
An oocyst stage in the Plasmodium falciparum lifecycle that occurs on the hemocoel side of the midgut of a mosquito vector. During this stage Plasmodium falciparum ookinete invades and escapes midgut wall of mosquito and embed itself onto the exterior of the gut membrane and develop encysted zygote, called oocyst.
A sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the human host.
Blood that is part of or originated from a human (Homo sapiens).
A microgametocyte stage in some apicomplexan parasites where microgametocyte gets matured and form microgamete through the process known as exflagellation.
A salivary gland that is a part of or originated from an Anopheles mosquito.
A Plasmodium falciparum that is produced in a schizont, found in the bloodstream of a human host and invades erythrocytes.
A Plasmodium falciparum is formed in the oocyst. It migrates to and resides in the salivary glands of the mosquito vector. A distinction is made between oocyst-derived and salivary gland-derived sporozoites. Sporozoites invade hepatocytes in the vertebrate host.
A Plasmodium falciparum that oocyst is formed, after traversal of the midgut wall by the ookinete stage, on the hemocoel side of the midgut wall of the mosquito vector.
An early trophozoite stage of Plasmodium sp. where a large central vacuole and peripheral nucleus give an appearance of a signet ring.
A gametocyte stage where a cell differentiates into a male sexual form called microgametocyte.
A Plasmodium falciparum is a feeding form. The trophozoite stage has only 1 nucleus. Depending on its location, it is either called hepatic or erythrocytic trophozoite.
A life cycle stage where a cell differentiates into male or female sexual forms.
A parasite lifecycle stage of some sporozoans where cells divide through sporogony producing daughter cells called sporozoites that infect new hosts.
A parasite lifecycle stage of some sporozoans where motile and elongated zygote is formed by the fertilization of the macrogamete during the sexual reproductive phase of the sporozoan life cycle, specifically the malarial parasite Plasmodium.
Mosby's Medical Dictionary, 8th edition. � 2009, Elsevier. (http://medical-dictionary.thefreedictionary.com/ookinete)
A schizont stage in the Plasmodium falciparum lifecycle that occurs in erythrocytes or in hepatocytes.
A Plasmodium falciparum zygote is formed after fertilisation of the macrogamete by a microgamete in the midgut of the mosquito vector. This round form is the only diploid stage in the Plasmodium falciparum life cycle.
A Plasmodium falciparum microgametocyte that is matured with flagellated motile microgametes still attached to its central body. Exflagellated microgametocyte of Plasmodium falciparum is found in the midgut of a mosquito vector.
P. falciparum exflagellated microgametocyte
Plasmodium falciparum exflagellated microgametocyte
A Trypanosoma cruzi that is found in the bloodstream of infected mammals. It is a non-dividing form that is infectious for its insect vector.
A lifecycle stage of Plasmodium falciparum.
A Plasmodium falciparum gamete that is a matured form of the macrogametocyte and is found in the midgut of a mosquito vector. The macrogamete is fertilized by the microgamete, forming the zygote
A trypomastigote stage in the Trypanosoma cruzi lifecycle that occurs either in the vertebrate host or an insect vector.
A microgamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector.
A parasite role which is realized only during parasitic infection of a human.
A Plasmodium falciparum gamete that is a matured form of exflagellated microgametocyte and found in the midgut of a mosquito vector. The microgamete fertilizes the macrogamete, forming the zygote.
A trypomastigote stage in the Trypanosoma brucei lifecycle that occurs in the vertebrate host.
A Trypanosoma brucei that is a Trypomastigote form of Trypanosoma brucei. In this form the large kinetoplast is postnuclear and is at the most posterior part of the body and the flagellum emerges from the flagellar pocket, and runs along the entire length of the body as an undulating membrane.
An ookinete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector and on the outside of the midgut.
A Plasmodium falciparum schizont that is found in infected hepatocytes (i.e., liver cells) of a human host.
A gametocyte stage in the lifecycle of Plasmodium falciparum.
A zygote stage in the Plasmodium falciparum lifecycle that occurs in the midgut of the mosquito vector where a microgamete and a macrogamete fertilizes each other to produce a diploid cell.
A Plasmodium falciparum gametocyte that is a female gametocyte and found either in bloodstream of a human host or midgut of mosquito vector. The macrogametocyte is a precursor of the macrogamete.
An erythrocytic trophozoite stage in the Plasmodium falciparum life cycle that occurs in erythrocytes of a human host.
P. falciparum erythrocytic trophozoite stage
Plasmodium falciparum erythrocytic trophozoite stage
A Plasmodium falciparum erythrocytic trophozoite that is found in erythrocytes. It is a young trophozoite stage that has a typical 'ring-like' appearance. Ring-form trophozoites of Plasmodium falciparum are often thin and delicate, measuring on average 1/5 the diameter of the red blood cell.
P. falciparum erythrocytic ring trophozoite
Plasmodium falciparum erythrocytic ring trophozoite
An organism living in, with, or on another organism in parasitism. Individual members of parasite species, such as Leishmania, Plasmodium, Trypanosoma, etc. are members of this class.
A Plasmodium falciparum merozoite that is produced in a hepatic schizont and released into the bloodstream of a human host. These forms invade erythrocytes.
A Plasmodium falciparum merozoite that is produced in an erythrocytic schizont and released into the bloodstream of a human host. These forms invade erythrocytes.
Plasmodium falciparum erythrocytic merozoite
A trophozoite stage in some protozoan parasite life cycle that occurs in erythrocytes.
definition adapted from that for P. falciparum erythrocytic trophozoite stage and parent trophozoite stage
A Plasmodium falciparum trophozoite that is found in erythrocytes. It is a feeding stage with a single nucleus.
Plasmodium falciparum erythrocytic trophozoite
An erythrocytic merozoite stage in the Plasmodium falciparum lifecycle that occurs in the bloodstream of a human host.
P. falciparum erythrocytic merozoite stage
Plasmodium falciparum erythrocytic merozoite stage
A hepatic merozoite stage in the Plasmodium falciparum lifecycle that occurs in the hepatocyte of a human host.
Plasmodium falciparum hepatic merozoite stage
A merozoite stage in the Plasmodium lifecycle that occurs in the hepatocyte of a vertebrate host.
definition adapted from that for P. falciparum hepatic merozoite stage
A merozoite stage in the apicomplexan lifecycle that occurrs in the bloodstream of a vertebrate host.
definition adapted from that for P. falciparum salivary erythrocytic merozoite stage and from the general merozoite definition
A Plasmodium falciparum that is located either in the bloodstream of the human host or midgut of mosquito vector. Gametocytes are the precursor cells of the macro- or micro-gametes.
A hepatic trophozoite stage in the Plasmodium falciparum life cycle that occurs in hepatocytes of a human host.
Plasmodium falciparum hepatic trophozoite stage
A trophozoite stage in the Plasmodium falciparum lifecycle that occurs in a human host.
A sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the human host.
Plasmodium falciparum oocyst-derived sporozoite stage
A sporozoite stage in the Plasmodium lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the vertebrate host.
definition adapted from that for P. falciparum salivary gland derived sporozoite stage
A salivary gland-derived sporozoite stage in the Plasmodium falciparum lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the human host.
Plasmodium falciparum salivary gland-derived sporozoite stage
A Plasmodium falciparum sporozoite that is formed in the oocyst. It migrates to and resides in the salivary glands of the mosquito vector. Sporozoites invade hepatocytes in a human host.
P. falciparum salivary gland-derived sporozoite
Plasmodium falciparum salivary gland-derived sporozoite
A sporozoite stage in some parasite lifecycle that occurs in the hemocoel and the salivary glands of the mosquito. Sporozoites invade hepatocytes in the vertebrate host.
definition adapted from that for P. falciparum oocyte derived sporozoite stage
A Plasmodium falciparum trophozoite that is found in hepatocytes of a human host. It is a feeding stage with a single nucleus
Plasmodium falciparum hepatic trophozoite
A Plasmodium falciparum that is found in midgut of mosquito vector. There are two forms of gametes: micro- and macrogametocytes.
A Plasmodium falciparum sporozoite that is found in the infected hepatocytes of a human host.
Plasmodium falciparum oocyst-derived sporozoite
A life cycle stage of some parasites that develop into mature sexual cells.
A trophozoite stage in some protozoan parasite life cycle that occurs in hepatocytes.
definition adapted from that for P. falciparum hepatic trophozoite stage and from parent trophozoite stage
A gamete stage in the Plasmodium falciparum lifecycle that occurs in the midgut of a mosquito vector.
A Plasmodium that is found in the midgut of a mosquito vector during gamete lifecycle stage. There are two forms of gametes: micro- and macrogametocytes.
A Plasmodium gamete that is in a matured form of the macrogametocyte and found in the midgut of a mosquito vector. The macrogamete is fertilized by the microgamete, forming the zygote.
A Plasmodium gamete that is in a matured form of exflagellated microgametocyte and found in the midgut of a mosquito vector. The microgamete fertilises the macrogamete, forming the zygote.
A Plasmodium that is located either in the bloodstream of the vertebrate host or midgut of mosquito vector during gametocyte stage. Gametocytes are the precursor cells of the macro- or microgametes
A Plasmodium gametocyte that is a female gametocyte of Plasmodium and found either in the bloodstream of the vertebrate host or midgut of mosquito vector. The macrogametocyte is a precursor of the macrogamete.
A Plasmodium gametocyte that is a male gametocyte of Plasmodium and found either in the bloodstream of a vertebrate host or midgut of a mosquito vector. The microgametocyte is a precursor cell of the microgamete
A Plasmodium that is during merozoite lifecycle stage, occurs in the bloodstream of a vertebrate host.
A Plasmodium merozoite that is produced in an erythrocytic schizont and released into the bloodstream of a vertebrate host. These forms invade erythrocytes.
A Plasmodium merozoite that is produced in a hepatic schizont and released into the bloodstream of a vertebrate host. These forms invade erythrocytes.
A Plasmodium that is formed after traversal of the midgut wall by the ookinete stage, on the hemocoel side of the midgut wall of the mosquito vector.
A Plasmodium that is a 'banana-shaped' form originates from the round zygote. The ookinete is found in the midgut of a mosquito vector and traverses the midgut wall of a mosquito vector.
A Plasmodium that is a form divides through schizogony. Depending on its location, it is either called hepatic or erythrocytic schizont. The schizont is a dividing stage with 2 or more nuclei.
A Plasmodium schizont that is found in infected erythrocytes of a vertebrate host.
A Plasmodium schizont that is found in infected hepatocytes (i.e. liver cells) of a vertebrate host.
A Plasmodium that is formed in the oocyst and migrates to and reside in the salivary glands of the mosquito vector. A distinction is made between oocyst-derived and salivary gland-derived sporozoites. Sporozoites invade hepatocytes in the vertebrate host.
A Plasmodium sporozoite that is found in the infected hepatocytes of a vertebrate host.
A Plasmodium sporozoite that is found in the salivary glands of the mosquito vector.
Plasmodium salivary gland-derived sporozoite
A Plasmodium that is a feeding form which has a single nucleus during the trophozoite stage. Depending on its location, it is either called hepatic or erythrocytic trophozoite.
A Plasmodium trophozoite that is found in erythrocytes of a vertebrate host.
A Plasmodium erythrocytic trophozoite that has a typical 'ring-like' appearance. Ring-form trophozoites of Plasmodium are often thin and delicate, measuring on average 1/5 the diameter of the red blood cell.
Plasmodium erythrocytic ring trophozoite
A Plasmodium trophozoite that is found in hepatocytes.
A Plasmodium that is formed after fertilization of the macrogamete by a microgamete in the midgut of the mosquito vector. This round form is the only diploid stage in the Plasmodium life cycle.
A gamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector.
A macrogamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector.
A microgamete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector.
A gametocyte stage in the lifecycle of Plasmodium.
A macrogametocyte stage in the Plasmodium lifecycle that occurs either in the bloodstream of a vertebrate host or the midgut of a mosquito vector.
A microgametocyte stage in the Plasmodium lifecycle that occurs either in the bloodstream of a vertebrate host or the midgut of a mosquito vector.
A merozoite stage in the Plasmodium lifecycle that occurs in the bloodstream or hepatocytes of a vertebrate host.
An erythrocytic merozoite stage in the Plasmodium lifecycle that occurs in the bloodstream of a vertebrate host.
A hepatic merozoite stage in the Plasmodium lifecycle that occurs in the hepatocyte of a vertebrate host.
An oocyst stage in the Plasmodium lifecycle that occurs on the hemocoel side of the midgut of a mosquito vector. During this stage Plasmodium ookinete invades and escapes midgut wall of mosquito and embed itself onto the exterior of the gut membrane and develop encysted zygote, called oocyst.
An ookinete stage in the Plasmodium lifecycle that occurs in the midgut of a mosquito vector and on the outside of the midgut.
A schizont stage in the Plasmodium lifecycle that occurs in erythrocytes or in hepatocytes.
An erythrocytic schizont stage in the Plasmodium lifecycle that occurs in the infected erythrocytes of a vertebrate host.
A hepatic schizont stage in the Plasmodium lifecycle that occurs in the infected hepatocytes of a vertebrate host.
A sporozoite stage in the Plasmodium lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the vertebrate host.
A sporozoite stage in the Plasmodium lifecycle that develops in oocyst of the mosquito midgut.
Plasmodium oocyst-derived sporozoite stage
A salivary gland-derived sporozoite stage in the Plasmodium lifecycle that occurs in the salivary glands of the mosquito and invades hepatocytes in the vertebrate host.
Plasmodium salivary gland-derived sporozoite stage
A trophozoite stage in the Plasmodium lifecycle that occurs in a vertebrate host.
An erythrocytic trophozoite stage in the Plasmodium life cycle that occurs in erythrocytes of a vertebrate host.
Plasmodium erythrocytic trophozoite stage
An erythrocytic ring trophozoite stage in the Plasmodium life cycle that occurs in erythrocytes of a vertebrate host. During this stage some Plasmodium merozoites undergo asexual reproduction cycle in erythrocytes and form young trophozoites that are referred to as "ring form" due to their morphology.
Plasmodium erythrocytic ring trophozoite stage
A hepatic trophozoite stage in the Plasmodium life cycle that occurs in hepatocytes of a vertebrate host.
A zygote stage in the Plasmodium lifecycle that occurs in the midgut of the mosquito vector where a microgamete and a macrogamete fertilizes each other to produce a diploid cell.
Blood that is part of or originated from a vertebrate.
An erythrocyte that is a part of or originated from a vertebrate.
A hepatocyte that is a part of or originated from a vertebrate.
Cerebrospinal fluid that is a part of or originated from a mammal.
Blood that is part of or originated from a mammalia.
A macrophage that is a part of or originated from a mammalia.
A parasite lifecycle stage that parasite replicates rapidly within the host cell.
A Plasmodium vivax is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector.
A Plasmodium vivax that is found in the bloodstream of the human host and invades erythrocytes.
A Plasmodium berghei is formed in the oocyst. It migrates to and resides in the gut of the mosquito vector.
A Neospora caninum that is found intracellular in the intermediate hosts in which asexual replication takes place.
A Sarcocystis neurona that is found in the bloodstream of the human host and invades erythrocytes.
A Toxoplasma gondii that is formed in tissue in a host and replicates quickly. This replaces the previous term as .
A sporozoite stage in Plasmodium vivax life cycle.
A merozoite stage in the Plasmodium vivax life cycle.
A sporozoite stage in the Plasmodium berghei life cycle.
A tachyzoite stage in the Neospora caninum life cycle.
A merozoite stage in the Sarcocystis neurona life cycle.
A tachyzoite stage in the Toxoplasma gondii life cycle.
Tachyzoites can be found in various organs and tissues during the acute phase of Toxoplasma gondii infection, including lymph nodes, spleen, liver, lungs, and the central nervous system.
An erythrocyte that is a part of or originated from a Canis lupus familiaris.
A lifecycle stage of Plasmodium berghei.
A lifecycle stage of Sarcocystis neurona.
A Plasmodium yoelii in sporozoite stage.
A Plasmodium yoelii in gametocyte stage.
A Plasmodium chabaudi in sporozoite stage.
A Plasmodium knowlesi in sporozoite stage.
A Plasmodium knowlesi in merozoite stage.
A sporozoite stage in the Plasmodium yoelii.
A merozoite stage in the Plasmodium yoelii.
A gametocyte stage in the Plasmodium yoelii.
A sporozoite stage in the Plasmodium chabaudi.
A sporozoite stage in the Plasmodium knowlesi.
A merozoite stage in the Plasmodium knowlesi.
An erythrocyte that is a part of or originated from a primate.
A lifecycle stage of Plasmodium chabaudi.
A lifecycle stage of Plasmodium knowlesi.
Yingtong Liu, Anthony Huffman, Oliver He
biomarker role
Material entity that has a measurable quality, or that participates in a measurement process profile, which can be used as an indicator of an underlying biological state or identity.
The NIH Biomarkers and Surrogate Endpoint Working Group defined a biomarker as “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” (https://pubmed.ncbi.nlm.nih.gov/11240971/). However, the definition of 'characteriistc' is unclear, so we do not use the exact definintion in the ontology.
biomarker
Biomarker that has a measurable quality or process profile(s), that can be used as an indicator of an underlying immune state or identity.
A biomarker that is indicative of an immune response
immune biomarker
A dependent entity that inheres in a bearer by virtue of how the bearer is related to other entities
A time quality inhering in a bearer by virtue of how long the bearer has existed.
A physical quality which inheres in a bearer by virtue of the number of the bearer's repetitive actions in a particular time.
An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.
A quality in which events occur in sequence.
An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population.
A viability quality inhering in a bearer or a population by virtue of the bearer's ability to survive or the long term survival ability of a given population.
A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies.
A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities.
A physical quality inhering in a bearer by virtue of ratio of the bearer's output to the bearer's input.
A quality which inheres in a continuant.
multiply inhering quality of a physical entity
Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles.
A viability quality inhering in a bearer by virtue of the cessation of the bearer's life.
An efficiency quality inhering in a bearer by virtue of the bearer's lacking efficiency.
An efficiency quality inhering in a bearer by virtue of the bearer's having efficiency.
A quality that inheres in an entire organism or part of an organism.
A quality inhering in a bearer by virtue of the severity of infectious disease caused by the bearer in a target organism.
A quality of an object that has a value that is decreased compared to normal or average.
An amino acid chain that is canonically produced de novo by ribosome-mediated translation of a genetically-encoded mRNA, and any derivatives thereof.
Note that the definition allows for experimentally-manipulated genes, and allows for artifically-produced derivatives that mimic those found naturally. Note also that the definition excludes protein complexes, which some also consider a protein. Those who wish to refer to a class representing both senses of the word are directed to PR:000064867 ("protein-containing molecular entity"). Proteins (in the sense defined here) that descended from a common ancestor can be classified into families and superfamilies composed of products of evolutionarily-related genes. The domain architecture of a protein is described by the order of its constituent domains. Proteins with the same domains in the same order are defined as homeomorphic [PRO:WCB).
A protein that has a core domain composition consisting of a signal peptide, an extracellular domain with multiple Leucine rich repeat (Pfam:PF13855) domain (LRR), a cysteine-rich region, a single-pass transmembrane domain and a C-terminal cytoplasmic tail containing a TIR domain (Pfam:PF01582).
A Toll-like receptor that is a translation product of the human TLR1 gene or a 1:1 ortholog thereof.
Toll/interleukin-1 receptor-like protein
A Toll-like receptor that is a translation product of the human TLR2 gene or a 1:1 ortholog thereof.
Toll/interleukin-1 receptor-like protein 4
A Toll-like receptor that is a translation product of the human TLR3 gene or a 1:1 ortholog thereof.
A Toll-like receptor that is a translation product of the human TLR4 gene or a 1:1 ortholog thereof.
A Toll-like receptor that is a translation product of the human TLR5 gene or a 1:1 ortholog thereof.
Toll/interleukin-1 receptor-like protein 3
A Toll-like receptor that is a translation product of the human TLR6 gene or a 1:1 ortholog thereof.
A Toll-like receptor that is a translation product of the human TLR7 gene or a 1:1 ortholog thereof.
A Toll-like receptor that is a translation product of the human TLR8 gene or a 1:1 ortholog thereof.
A Toll-like receptor that is a translation product of the human TLR9 gene or a 1:1 ortholog thereof. Non-methylated CpG motifs, present in viral and bacterial DNA, are one of many pathogen-associated molecular patterns (PAMP) recognized by the mammalian innate immune system. Recognition of this PAMP occurs through a specific interaction with Toll-like receptor 9 and this interaction can induce cytokine responses that influence both innate and adaptive immune responses.
A protein that is a translation product of the human CLEC6A gene or a 1:1 ortholog thereof.
dendritic cell-associated C-type lectin 2
A protein that is a translation product of the human CLEC7A gene or a 1:1 ortholog thereof.
dendritic cell-associated C-type lectin 1
A protein that is a translation product of the human AIM2 gene or a 1:1 ortholog thereof.
A protein that is a translation product of the human CLEC4E gene or a 1:1 ortholog thereof.
A protein that is a translation product of the human IFIH1 gene or a 1:1 ortholog thereof.
interferon induced with helicase C domain protein 1
interferon-induced with helicase C domain protein 1
melanoma differentiation-associated protein 5
interferon-induced helicase C domain-containing protein 1
A protein that is a translation product of the human NLRP3 gene or a 1:1 ortholog thereof.
angiotensin/vasopressin receptor AII/AVP-like
cold autoinflammatory syndrome 1 protein
cold autoinflammatory syndrome 1 protein homolog
mast cell maturation-associated-inducible protein 1
NACHT, LRR and PYD domains-containing protein 3
A protein that is a translation product of the human NOD1 gene or a 1:1 ortholog thereof.
caspase recruitment domain-containing protein 4
nucleotide-binding oligomerization domain-containing protein 1
A protein that is a translation product of the human NOD2 gene or a 1:1 ortholog thereof.
caspase recruitment domain-containing protein 15
nucleotide-binding oligomerization domain-containing protein 2
A SODC domain protein that is a translation product of the human SOD1 gene or a 1:1 ortholog thereof.
A protein that is a translation product of the human CLEC9A gene or a 1:1 ortholog thereof.
A protein that is a translation product of the human RIGI gene or a 1:1 ortholog thereof.
probable ATP-dependent RNA helicase DDX58
antiviral innate immune response receptor RIG-I
A protein that is a translation product of the human CGAS gene or a 1:1 ortholog thereof.
OBSOLETE. A material entity that minimally consists of a protein.
Note: Made obsolete since the term definition was much broader than intended. Originally meant to include only single proteins (and derivatives thereof; PR:000000001), protein-containing complexes (GO:0032991), and protein aggregates (PR:000050566), it instead also included cells defined as having certain protein attachments.
obsolete protein-containing material entity
A protein that is a translation product of the S gene in SARS-CoV-2.
Category=organism-gene. Note: 1273 aa protein. Undergoes additional processing by proteolytic cleavage.
Category=organism-gene. Note: 75 aa protein. A protein that is a translation product of the E gene in SARS-CoV-2.
envelope small membrane protein (SARS-CoV-2)
The olfactory organ of vertebrates, consisting of nares, olfactory epithelia and the structures and skeletal framework of the nasal cavity.
Organ that is the specialized structure of the face that contains olfactory neurons. The peripheral olfactory organ is paired[ZFA:0000047].
a protuberance in vertebrates that houses the nostrils, or nares, which admit and expel air for respiration in conjunction with the mouth. Behind the nose are the olfactory mucosa and the sinuses. Behind the nasal cavity, air next passes through the pharynx, shared with the digestive system, and then into the rest of the respiratory system. In humans, the nose is located centrally on the face; on most other mammals, it is on the upper tip of the snout[WP]. GO: The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity)[Wikipedia:Nose].
the organ that is specialized for smell and is part of the respiratory system
the structure of the nose varies across vertebrates. In tetrapods the nose is part of the respiratory system.[PMID:25312359]
Multi-tissue structure that is comprised of a secretory epithelial layer (mesothelium) and a connective tissue layer.
A multi-tissue structure that is comprised of a secretory epithelial layer and a connective tissue layer.[TAO]
a smooth membrane consisting of a thin layer of cells which excrete serous fluid. Serous membranes line and enclose several body cavities, known as serous cavities, where they secrete a lubricating fluid which reduces friction from muscle movement. Serosa is not to be confused with adventitia, a connective tissue layer which binds together structures rather than reducing friction between them. Each serous membrane is composed of a secretory epithelial layer and a connective tissue layer underneath. The epithelial layer, known as mesothelium, consists of a single layer of avascular flat nucleated cells (cuboidal epithelium) which produce the lubricating serous fluid. This fluid has a consistency similar to thin mucus. These cells are bound tightly to the underlying connective tissue. The connective tissue layer provides the blood vessels and nerves for the overlying secretory cells, and also serves as the binding layer which allows the whole serous membrane to adhere to organs and other structures.[WP]
in FMA, SM = mesothelium + connective tissue. It excludes the cavity. Serous sac = SM + cavity. Note that the SM is a subtype of wall in FMA.
Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome.
Anatomical structure that performs a specific function or group of functions [WP].
Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
CARO v1 does not include a generic 'organ' class, only simple and compound organ. CARO v2 may include organ, see https://github.com/obophenotype/caro/issues/4
A multicellular structure that is a part of an organ.
currently defined in a very broad sense, may be replaced by more specific classes in the future
A spatiotemporal region encompassing some part of the life cycle of an organism.
this class represents a proper part of the life cycle of an organism. The class 'life cycle' should not be placed here
the WBls class 'all stages' belongs here as it is the superclass of other WBls stages
we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage
A stage at which the organism is a single cell produced by means of sexual reproduction.
As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG]
The proximal portion of the digestive tract, containing the oral cavity and bounded by the oral opening. In vertebrates, this extends to the pharynx and includes gums, lips, tongue and parts of the palate. Typically also includes the teeth, except where these occur elsewhere (e.g. pharyngeal jaws) or protrude from the mouth (tusks).
Cavity in which food is initially ingested and generally contains teeth, tongue and glands.[AAO]
Molecular and developmental cell lineage data suggest that the acoel mouth opening is homologous to the mouth of protostomes and deuterostomes and that the last common ancestor of the Bilateria (the 'urbilaterian') had only this single digestive opening.[well established][VHOG]
some AOs place this as developing from the stomodeum but we weaken this to developmental contribution, as the mouth includes non-ectodermal derivatives
in FMA, the tongue, palate etc are part of the mouth which is itself a subdivision of the face. ZFA includes a separate class 'oral region' which is part of the mouth, but excludes tongue and lips
A fluid that is composed of blood plasma and erythrocytes.
This class excludes blood analogues, such as the insect analog of blood. See UBERON:0000179 haemolymphatic fluid.
A complex mixture of cells suspended in a liquid matrix that delivers nutrients to cells and removes wastes. (Source: BioGlossary, www.Biology-Text.com)[TAO]
Highly specialized circulating tissue consisting of several types of cells suspended in a fluid medium known as plasma.[AAO]
relationship loss: subclass specialized connective tissue (AAO:0000571)[AAO]
Recent findings strongly suggest that the molecular pathways involved in the development and function of blood cells are highly conserved among vertebrates and various invertebrates phyla. (...) There is now good reason to believe that, in vertebrates and invertebrates alike, blood cell lineages diverge from a common type of progenitor cell, the hemocytoblast.[well established][VHOG]
An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium.
Portion of alimentary canal with increased circular and longitudinal smooth muscle. Bounded posteriorly by the pyloric sphincter. Mucosal lining has increased folding.[AAO]
It appears that the stomach has an ancient origin. The stomach first appears in the fish lineage. The prevertebrate chordates do not have a true stomach, whereas the cartilaginous and bony fish do. Although most fish do have a true stomach, some fish species appear to have lost the stomach secondarily. The remaining vertebrate lineages do have a true stomach (at least in the adult animal), although there is great variation in the size and shape of the stomach.[well established][VHOG]
We restrict this to the vertebrate specific structure - see the grouping class 'food storage organ' for analogous structures in other species. Teleosts: Zebrafish is functionally stomach-less, but may retain ontogenic footprint. Although the precise shape and size of the stomach varies widely among different vertebrates, the relative positions of the oesophageal and duodenal openings remain relatively constant. As a result, the organ always curves somewhat to the left before curving back to meet the pyloric sphincter. However, lampreys, hagfishes, chimaeras, lungfishes, and some teleost fish have no stomach at all, with the oesophagus opening directly into the intestine. The gastric lining is usually divided into two regions, an anterior portion lined by fundic glands, and a posterior with pyloric glands. Cardiac glands are unique to mammals, and even then are absent in a number of species. The distributions of these glands vary between species, and do not always correspond with the same regions as in man. Furthermore, in many non-human mammals, a portion of the stomach anterior to the cardiac glands is lined with epithelium essentially identical to that of the oesophagus. Ruminants, in particular, have a complex stomach, the first three chambers of which are all lined with oesophageal mucosa
Saliva-secreting exocrine glands of the oral cavity[GO].
currently we define saliva and salivary glands very generally in functional terms but it may be more appropriate to split this class. From WP: In most vertebrates, saliva does not contain any enzymes, consisting of mucus and water only, and its primary function is to moisten food while eating. As a result, true salivary glands are rarely found in fish or aquatic tetrapods, although there are often individual mucus-secreting cells. Amphibians have a single salivary gland, the intermaxillary gland, located in the forward part of the palate. Reptiles and birds normally have only very small glands on the lips, palate, and base of the mouth, although there are some birds with large glands, which produce a sticky saliva that helps in nest-building. The distinct parotid, submandibular, and sublingual glands are only developed in mammals.
A gland that produces the saliva. [Bemis_WE, Functional_Anatomy_of_the_Vertebrates:_An_Evolutionary_Perspective, Glossary_G-25, Grande_L, Liem_KF, Third_Edition_(2001)_Orlando_Fla.:_Harcourt_College_Publishers, Walker_WF][VHOG]
In air-feeding animals, the lack of water column to lubricate the food has been compensated for by the evolution of the salivary glands. These glands are present only in amniotes and are controlled by the parasympathetic system.[well established][VHOG]
The salivary glands in mammals are exocrine glands, glands with ducts, that produce saliva. They also secrete amylase, an enzyme that breaks down starch into maltose. In other organisms such as insects, salivary glands are often used to produce biologically important proteins like silk or glues, and fly salivary glands contain polytene chromosomes that have been useful in genetic research. The salivary glands of some species are modified to produce enzymes; salivary amylase is found in many, but by no means all, bird and mammal species (including humans, as noted above). Furthermore, the venom glands of poisonous snakes, Gila monsters, and some shrews, are modified salivary glands
Middle subdivision of a digestive tract[CJM]. In vertebrates: The middle part of the alimentary canal from the stomach, or entrance of the bile duct, to, or including, the large intestine[GO].
Note we define this generically to include invertebrates (partly for consistency with GO), but the class may be split in future. We may explicitly make this a developmental class
The bilaterian gut is typically a complete tube that opens to the exterior at both ends. It consists of mouth, foregut, midgut, hindgut, and anus (reference 1); Although all vertebrates have a digestive tract and accessory glands, various parts of this system are not necessarily homologous, analogous, or even present in all species. Therefore, broad comparisons can be best made under the listings of headgut, foregut, midgut, pancreas and biliary system, hindgut (reference 2).[well established][VHOG]
In humans: originates from the foregut at the opening of the bile duct into the duodenum and continues through the small intestine and much of the large intestine until the transition to the hindgut about two-thirds of the way through the transverse colon
in FMA this represents an embryonic region.
The caudalmost subdivision of a digestive tract.
Note we define this generically to include invertebrates (partly for consistency with GO), but the class may be split in future (vertebrates have some contribution from NC - https://github.com/obophenotype/uberon/wiki/The-neural-crest). We may explicitly make this a developmental class
the caudal portion of the primitive digestive tube of the embryo
in FMA this class has no children. In MA it has a single child hindgut epithelium
Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species.
Muscle tissue that consists primarily of skeletal muscle fibers.
TODO - add skeletal muscle organ? See GO:0060538 skeletal muscle organ development. Todo - group FBbt:00005073 - somatic muscle.
Muscle, composed of long cylindrical, multinucleated cells that attaches to the skeleton via tendons.[TAO]
Tissue which consists of skeletal muscle fibers surrounded by endomysium. Examples: Skeletal muscle tissue of biceps, Skeletal muscle tissue of diaphragm[FMA]
This result implies the following views in terms of evolutionary differentiation: (1) Arthropod striated muscle and vertebrate skeletal and cardiac muscles share a common ancestor. In other words, they did not evolve independently (...) (5) The divergence of vertebrate skeletal and cardiac muscles/vertebrate smooth muscle and nonmuscle is at least before that of vertebrates/arthropods. In other words, emergence of skeletal and cardiac musle type tissues preceded the vertebrate/arthropod divergence (ca. 700 MYA).[well established][VHOG]
Distensible musculomembranous organ situated in the anterior part of the pelvic cavity in which urine collects before excretion[MP].
A saccular organ in which urine accumulates before discharge from the body. [Bemis_WE, Functional_Anatomy_of_the_Vertebrates:_An_Evolutionary_Perspective, Glossary_G-29, Grande_L, Liem_KF, Third_Edition_(2001)_Orlando_Fla.:_Harcourt_College_Publishers, Walker_WF][VHOG]
Anatomical structure which consists of a membranous sac used to temporarily store urine until it is excreted from the body.[AAO]
In tetrapods, the urinary bladder arises as an outpocketing of the cloaca. (...) The tetrapod urinary bladder appears first among amphibians and is present in Sphenodon, turtles, most lizards, ostriches among birds, and all mammals.[well established][VHOG]
The urinary bladder evolved in tetrapods. Birds to not possess a true urinary bladder, although Palaeognathae have an undifferentiated cloacal outpocketing that serves a similar function[https://github.com/obophenotype/uberon/issues/454]
A clear, colorless, bodily fluid, that occupies the subarachnoid space and the ventricular system around and inside the brain and spinal cord.
many sources state the CP as sole producer of CSF, but this is disputed [DOI:10.1007/s11064-015-1581-6]
Portion of organism substance that is a clear fluid that occupies the subarachnoid space and the ventricular system around and inside the brain.[TAO]
In vertebrates, at early stages of Central Nervous System (CNS) development, the architecture of the brain primordium reveals the presence of the cavity of brain vesicles, which is filled by Embryonic Cerebro-Spinal Fluid (E-CSF). (...) Rat and chick E-CSF proteomes are similar, although rat is more complex in certain groups of proteins, e.g., apolipoproteins, which may be involved in the control of neural diversity, and has soluble enzymes present, just like adult human CSF, but unlike chick E-CSF, revealing phylogenetic brain differences between these groups of vertebrates.[uncertain][VHOG]
EHDAA2 models this as developing from CP, which is wrong
the FMA def states that this is subarachnoid spaces only. ZFA def states subarachnoid spaces and brain ventricles, but not SC (and has part_of to brain). Circulation: It circulates from the lateral ventricles to the foramen of Monro (Interventricular foramen), third ventricle, aqueduct of Sylvius (Cerebral aqueduct), fourth ventricle, foramen of Magendie (Median aperture) and foramina of Luschka (Lateral apertures), subarachnoid space over brain and spinal cord. It should be noted that the CSF moves in a pulsatile manner throughout the CSF system with nearly zero net flow. CSF is reabsorbed into venous sinus blood via arachnoid granulations.
Any of the tubular branching vessels that carry blood from the capillaries toward the heart.
TODO - check with MA - vein vs venous blood vessel
Part of the circulatory system composed of blood vessels which carry blood from other organs, tissues, and cells to the heart.[AAO]
The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG]
A vessel through which blood circulates in the body.
consider adopting the EMAPA superclass 'vascular element', which includes microvasculature (e.g. capillaries), vascular plexus
Any of the vessels through which blood circulates in the body. [XAO:0001011_][VHOG]
Any of the vessels through which blood circulates in the body.[AAO]
annelids have blood vessels, but this class is not applicable to annelids.
FMA:63183 Blood vessel is categorized as 'general anatomical term'. Suggestion to map to region of vascular tree from Terry H at JAX
Lowermost layer of the integumentary system in vertebrates. Types of cells that are found in the hypodermis are fibroblasts, adipose cells, and macrophages. It is derived from the mesoderm, but unlike the dermis, it is not derived from the dermatome region of the mesoderm. The hypodermis is used mainly for fat storage[WP].
A layer separating the inner face of the dermis from the subjacent muscle cells. It is covered on both sides by a basement membrane. It contains pigment cells. Le Guellec et al, 2004.[TAO]
A layer separating the inner face of the dermis from the subjacent muscle cells. It is covered on both sides by a basement membrane. It contains pigment cells[FMA:70544].
BTO has 'subcutis', as part of dermis. We follow FMA in having distinct classes for hypodermis and superficial fascia, and including these as part of the non-skin intgeument.
The organ covering the body that consists of the dermis and epidermis.
consider 'integumentary system' for invertebrates
MA uses the term skin to refer to what is called here: zone of skin
A serous membrane that lines the peritoneal cavity[VHOG,modified].
An epithelium that lines the peritoneal cavity.[TAO]
Serous membrane that forms the lining of the abdominal cavity or the coelom. It covers most of the intra-abdominal organs, supports the abdominal organs, and serves as a conduit for their blood and lymph vessels and nerves. It is composed of a layer of mesothelium.[AAO]
Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO].
One of the four types of tissue in traditional classifications. Tissue that contains cells with contractile filaments that move past each other and change the size of the cell. Muscle tissue also is separated into three distinct categories.[AAO]
Vertebrate muscle is categorized into three major muscle types defined by their structural and functional properties: skeletal, cardiac and smooth. In Dmel the counterparts are somatic, heart/cardiac and visceral. Here we take a cell type based approach.
An organ that functions as a secretory or excretory organ.
A gland that is part of a digestive tract [Automatically generated definition].
An anatomical structure that develops (entirely or partially) from the mesoderm.
An anatomical structure that develops (entirely or partially) from the ectoderm.
A proximal-distal subdivision of the digestive tract.
intended to denote both embryonic and adult structures. Note the FMA grouping here is not quite correct.
Liquid components of living organisms. includes fluids that are excreted or secreted from the body as well as body water that normally is not.
An anatomical structure that has more than one cell as a part.
Gland of the epithelium lining the oral cavity. The most common are the salivary glands.
Note that Kardong classifies lacrimal glands here. EHDAA2 includes pituitary primordium, as this develops from oral mucosa
Any of the organs or elements that are part of the digestive system. Examples: tongue, esophagus, spleen, crop, lunge feeding organ, tooth elements.
A membranous sac in animals that serves as the receptacle of a liquid or contains gas.
A pathogen component in vaccine that contains only a part of the pathogen organism instead of the whole organism.
Material entity that is manufactured to realize the vaccine function.
Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases.
Process of administering a vaccine in vivo to a recipient (e.g., a human), with the intent to invoke a protective or therapeutic adaptive immune response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=96
Active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
Preparation: The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer prepared from the Haemophilus influenzae type b (HiB) strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. The tetanus toxoid is prepared by extraction, ammonium sulfate purification, and formalin inactivation of the toxin from cultures of Clostridium tetani (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. When ActHIB vaccine is reconstituted with saline diluent, each single dose of 0.5 mL is formulated to contain 10 mu g of purified capsular polysaccharide conjugated to 24 mu g of inactivated tetanus toxoid, and 8.5% of sucrose (ActHIB 2005). Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157&keywords=
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157
ActHIB vaccine is indicated for the active immunization of infants and children 2 months through 5 years of age for the prevention of invasive disease caused by H influenzae type b.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=371
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=383
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=774
Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 through 64 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=325
WEB: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf
For active immunization of persons ages 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
Product Name: Measles Virus Vaccine, Live
vaccine-induced B cell antigen processing and presentation
vaccine-induced B cell cytokine production
vaccine-induced B cell mediated immunity
A vaccine that protects against Bacillus anthrax that causes anthrax.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=15
For the active immunization for the prevention of disease caused by Bacillus anthracis in persons between 18 and 65 years of age at high risk of exposure.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=372
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=385
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=772
Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 years of age and older.
whole organism vaccine that uses killed pathogen organism as its component.
A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=138
A bacterial vaccine vector that uses B. abortus vaccine strain RB51 as the vector.
Brucella abortus strain RB51 vaccine vector
Brucella abortus vaccine RB51 is a Brucella abortus vaccine that is licensed in the USA since 1992.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=10
A live attenuated Brucella abortus vaccine that is licensed and used in many countries.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=109
A vaccine that protects against Brucella that causes brucellosis in animals and humans.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3180
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=368
Product Name: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) & Hepatitis B Vaccine (Recombinant)
Vaccine components see http://www.vaccinesafety.edu/components-DTaP.htm
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=356
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=363
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=775
Indicated for active immunization against diphtheria, tetanus and pertussis as a five dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=369
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=386
Product Name: Tetanus & Diphtheria Toxoids Adsorbed for Adult Use
A vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. MENHIBRIX is approved for use in children 6 weeks of age through 18 months of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3832
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3833
Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b for children 6 weeks of age through 18 months of age.
A vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins.
Diphtheria and Tetanus Toxoids Adsorbed USP by Sanofi Pasteur Inc
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=313
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=353
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=362
Product Name: Diphtheria & Tetanus Toxoids Adsorbed
Diphtheria and Tetanus Toxoids Adsorbed USP vaccine by Sanofi Pasteur Inc
This term is obsolete since there is another term with the same meaning.
obsolete Diphtheria and Tetanus Toxoids Adsorbed by Sanofi Pasteur Ltd
A vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph.
Dryvax is a freeze-dried calf lymph smallpox vaccine. It is the world's oldest smallpox vaccine, created in the late 19th century by American Home Products, a predecessor of Wyeth. By the 1940s, Wyeth was the leading US manufacturer of the vaccine and the only manufacturer by the 1960s. After world health authorities declared smallpox had been eradicated from nature in 1980, Wyeth stopped making the vaccine.
Product Name: Smallpox Vaccine, Dried, Calf Lymph Type
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=116
A viral vaccine that protects against infection of an adenovirus.
An assay that measures the persistent survival of live vaccine in a host in vivo.
A bacterial vaccine that prevents against Escherichia coli infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=327
Active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine. FLULAVAL is approved for use in persons 6 months of age and older.
Product Name: Influenza Virus Vaccine, Trivalent, Types A and B
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=328
For the active immunization of individuals 2-49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=326
For active immunization of persons 3 years of age and older for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=329
For active immunization of persons 4 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=330
Fluzone is indicated for active immunization of persons 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
A gene that once deleted, would make an attenuated microbe that can be used as a live attenuated vaccine against virulent pathogen.
Quadrivalent vaccine meaning it protects against 4 strains of virus (types 6, 11, 16, and 18). The vaccine was made using genetic engineering techniques. The genes that encode a specific protein from each of these strains are expressed in yeast in large-scale fermentation cultures. Protein purification methods are then used to isolate the proteins and make the vaccine. Cited from: http://biotech.about.com/b/2008/09/03/gardasil-safety-of-genetically-engineered-hpv-vaccine-still-in-question.htm
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=337
- Prevention of vulvar and vaginal cancer - Vaccination in females 9 through 26 years of age for prevention of the following diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18: - Cervical Cancer - Genital warts (condyloma acuminata) and the following precancerous or dysplastic lesions: - Cervical adenocarcinoma in situ (AIS)cancer - Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3 - Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 - Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 - Cervical intraepithelial neoplasia (CIN) grade 1 - Vaccination in boys and men 9 through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11 - Vaccination in people ages 9 through 26 years for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18
a lentivirus vaccine vector that uses a HIV strain as the vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=320
HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.
Vaccine that protects against Neisseria meningitidis infection.
IPOL, Poliovirus Vaccine Inactivated is a sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). IPOL vaccine is a highly purified, inactivated poliovirus vaccine with enhanced potency.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=338
IPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3.
A jourmal article that mentions a vaccine, which was retrieved from PubMed and annotated using VO-SciMinner.
The Imovax(R) 9 Rabies Vaccine is a sterile, stable, freeze-dried 10 suspension of rabies virus prepared from strain PM-1503-3M.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=341
Vaccine for use in all age groups for pre-exposure and post-exposure prophylaxis against rabies.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=355
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=361
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=776
For active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=324
WEB: http://atomicnewsreview.org/2009/10/22/approval-for-the-arepanrix%E2%84%A2-gsk-vaccine-in-canada/
Product Name: Influenza Virus Vaccine, H5N1 (for National Stockpile)
influenza virus vaccine H5N1 (Sanofi Pasteur Inc)
JE-VAX is a sterile, lyophilized vaccine for subcutaneous use, prepared by inoculating mice intracerebrally with Japanese encephalitis (JE) virus, "Nakayama-NIH" strain.
Indicated for Active Immunization against JE for persons one year age and older.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=358
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=365
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5551
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5581
Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX(R) and/or PEDIARIX(R) for the first three doses and INFANRIX(R) for the fourth dose.
Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
a bacterial vaccine vector that uses L. moncytogenes as the vector.
A Measles-Mumps-Rubella vaccine that is live attenuated and manufactured by Merck & Co, Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=374
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=375
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=601
M-M-R II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.For active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135. Menomune – A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older.
A Measles-Mumps vaccine that is manufactured by Merck and used for human.
Product Name: Measles and Mumps Virus Vaccine, Live
Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=381
WEB: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm
Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=316
For active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135. Menomune - A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older.
Product Name: Rubella Virus Vaccine Live
A Mycobacterium vaccine that protects against Mycobacterium tuberculosis.
Mycobax is a BCG vaccine that is made by Sanofi Pasteur, Ltd. Ref: http://www.biopharma.com/cgi/full6.lasso?Key=412.65916
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=315
an influenza vaccine that is similar to Fluzone but has high dose.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=754
WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM305079.pdf
Fluzone High-Dose is indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=453
Active immunization of persons 4 years of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.
influenza A (H1N1) 2009 Monovalent Vaccine (Novartis)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=357
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=364
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=610
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=611
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=760
For active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
PedvaxHIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=161
Liquid PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=359
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=367
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=613
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=614
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=765
For active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease caused by Haemophilus influenzae type b when administered to infants and children 6 weeks through 4 years of age (prior to fifth birthday).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=319
Plague vaccine by Greer Laboratories Inc
a malaria vaccine that protects against malaria caused by Plasmodium falciparum.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=317
PNEUMOVAX 23 is indicated for active immunization against pneumococcal disease caused by those pneumococcal types included in the vaccine in persons 50 years of age or older and persons greater than or equal to 2 years of age who are at increased risk for pneumococcal disease.
Product Name: Pneumococcal Vaccine, Polyvalent
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=339
Product Name: Poliovirus Vaccine Inactivated (Human Diploid Cell)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=318
- Immunization of infants 2, 4, 6 and 12-15 months of age to prevent invasive pneumococcal disease. - Immunization of infants and toddlers against otitis media caused by vaccine serotypes.
Product Name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
A Measles-Mumps-Rubella-Vericella vaccine that is live and manufactured by Merck & Co, Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=376
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=377
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=378
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=379
WEB: http://www.merck.com/product/usa/pi_circulars/p/proquad/proquad_pi.pdf
For vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5567
WEB: https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112854.htm
Fluzone Intradermal Quadrivalent indicated for active immunization for use in adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
A vaccine adjuvant that is formed as a mineral salt.
RabAvert Rabies Vaccine is a sterile, freeze-dried vaccine obtained by growing the fixed-virus strain Flury Low Egg Passage (LEP) in primary cultures of chicken fibroblasts.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6181
Pre-exposure and post-exposure immunization of children and adults
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=340
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3116
Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7.
Adenovirus, type 4 and type 7, live, oral
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=344
For prevention of rotavirus gastroenteritis in infants 6 weeks to 32 weeks of age caused by types G1, G2, G3, G4, and G9.
a lentivirus vaccine vector that uses a SIV strain as the vector
T helper type 1 (Th1) lymphocytes secrete secrete interleukin (IL)-2, interferon-γ, and lymphotoxin-α and stimulate type 1 immunity, which is characterized by intense phagocytic activity. https://academic.oup.com/cid/article/32/1/76/311106
vaccine-induced T-helper 1 type immune response
Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. https://academic.oup.com/cid/article/32/1/76/311106
vaccine-induced T-helper 2 type immune response
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=370
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=384
Indicated for active immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=351
For the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder. For the prophylaxis of primary or recurrent state Ta and/or T1 papillary tumors following transurethral resection (TUR).
Typhim Vi, Typhoid Vi Polysaccharide Vaccine, for intramuscular use, is a sterile solution containing the cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=352
For active immunization against typhoid fever for persons two years of age or older.
vaccine-induced T cell mediated immunity
T cell vaccine antigen processing and presentation
Tetanus Toxoid Adsorbed by Aventis Pasteur Inc
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=631
Tetanus Toxoid Adsorbed by Aventis Pasteur Inc vaccine
E. coli Int280a has been found to be a protective antigen. This subunit vaccine uses E. coli Int280a combined with adjuvant. This antigen can be used for development of type-specific EPEC or EHEC vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=277
Tetanus and Diphtheria Toxoids Adsorbed by MA Biologic Lab
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5574
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5582
Tetanus and Diphtheria Toxoids Adsorbed vaccine by MA Biologic Lab
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=354
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=366
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=777
Product Name: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=349
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=350
Active immunization of persons 18 years of age or older against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus.
A vaccine adjuvant that contains microbial derived material.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=347
Indicated for active immunization for the prevention of varicella in individuals 12 months of age and older
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=248
For immunization of adults and children greater than 6 years of age against disease caused by Salmonella typhi.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=346
For active immunization of persons 9 months of age and older who: - Are living in or traveling to endemic areas; - Travelling internationally to countries that require evidence of vaccination from entering travelers or; - Laboratory Personnel who might be expose to virulent yellow fever virus or to concentrated preparations of the yellow fever vaccine strain by direct or indirect contact or by aerosols should by vaccinated.
a viral vaccine vector that uses Yellow fever vaccine strain 17D as the vector.
A viral vaccine that protects against infection with Yellow fever virus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=348
For prevention of herpes zoster (shingles) in individuals 50 years of age and older.
a vaccine organism that is live and attenuated
An aluminum vaccine adjuvant that contains aluminum hydroxide.
An aluminum vaccine adjuvant that is aluminum phosphate.
Vaccination frequency is a qualitative term that represents how many times vaccination has occurred.
A mineral salt vaccine adjuvant composed of calcium phosphate.
An emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion.
vaccine-induced adaptive immune response
a viral vaccine vector that uses an adenovirus as the vector.
A vaccine role that indicates the vaccine being a combination vaccine.
A Freund's emulsified oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis).
A Freund's emulsified oil adjuvant that does not contain the mycobacterial components.
A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae.
a viral vaccine vector that uses an alphavirus as the vector.
A vaccine vector role that inheres in a recombinant vaccine vector as a vaccine component. The combination of a recombinant vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombinant vector vaccine.
A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium.
Corynebacterium-derived P40 vaccine adjuvant
an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen.
The Latin "adjuvans" means to help, particularly to reach a goal. Adjuvant therapy for cancer is surgery followed by chemotherapy or radiation to help decrease the risk of the cancer recurring (coming back). An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system.
A titer of antibody that shows how much antibody an organism has produced that recognizes a particular epitope, expressed as the greatest dilution ratio (or its reciprocal) that still gives a positive result. ELISA is a common means of determining antibody titers.
WEB: http://en.wikipedia.org/wiki/Antibody_titer
an organismal quality that indicates an organism (e.g., human) is immunized against a disease.
To assign the state of 'immunized', we will need to do some assay to measure indicators of immunity, e.g., antibody titers in serum samples.
a bacterial vaccine against an infection with F. tularensis.
A vaccine preparation that results in the generation of a toxoid vaccine
A Brucella abortus gene that has the name sodC and comes from strain 2308.
IMMUNOGENICITY: The SodC protein induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-alpha but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. This gene has been used for vaccine development [PubMed: 10816475][PubMed: 11953393][PubMed: 12933826]. MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [PubMed: 15845493].
Brucella abortus cattle vaccine RB51 was developed by serial passages of virulent B. abortus strain 2308 in vitro in rifampin agar plates (Reference: PMID: 1908158).
A live attenuated vaccine prepraration process that is performed by serial passages in vitro for pathogen attenuation.
live attenuated vaccine preparation by serial passages in vitro
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=454
Active immunization of persons 6 months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.
influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)
a virulence of vaccine organism that shows an avirulent pheontype of the organism as the major component of a vaccine. The avirulence means that an vaccine organism is not virulent and does not cause pathogenic phenotype in a host organism.
vaccine-induced gene up-regulation controlling intracellular bacterial replication
A vaccine that targets against a bacterial disease.
a vaccine vector that uses a live bacterium as the vector
pcDNA3.1V5HisTOPO/TA DNA vaccine plasmid
a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine.
A vaccine preparation that results in the generation of a inactivated vaccine
a processed material that is output of the vaccine preparation and part of a vaccine.
A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria.
vaccine-induced antibacterial agglutination antibody response
A vaccine that uses RNA(s) derived from a pathogen organism.
Using RNA may eliminate the problem of having to tailor a vaccine for each individual patient with their specific immunity. The advantage of RNA is that it can be used for all immunity types and can be taken from a single cell. DNA vaccines need to produce RNA which then prompts the manufacture of proteins. However, RNA vaccine eliminates the step from DNA to RNA.
A synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA).
A titer measurement of viable bacterial or fungal numbers. Unlike in direct microscopic counts where all cells, dead and living, are counted, CFU measures viable cells. By convenience the results are given as CFU/mL (colony-forming units per milliliter) for water, and CFU/g (colony-forming units per gram) for soil or other porous material.
WEB: http://en.wikipedia.org/wiki/Colony-forming_unit
An emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators.
A synthetic vaccine adjuvant that is an emulsifier called Arlacel A.
A Montanide vaccine adjuvant that is Montanide 103.
A microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines.
Bordetella pertussis component vaccine adjuvant
a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA.
Conjugate vaccine is vaccine that conjugates/links antigens to the molecules that form the outer coat of disease-causing bacteria to promote an immune response.
A conjugate vaccine is created by covalently attaching a poor (polysaccharide organism) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes of the carrier on the attached antigen. --from wikipedia.
A vaccine preparation that results in the generation of a recombinant vector vaccine
influenza A virus A/California/7/2009 (H1N1) antigen
Characteristics: Inactivated baculovirus expressed PCV2 ORF2 protein; adjuvanted
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=387
Characteristics: Inactivated PCD1-2 chimera; adjuvanted
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=388
A vaccine contraindication is a contraindication that increases the risks of a vaccination.
A vaccine role that is not licensed or in clinical trial; instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model.
an immune response detection assay that detects specific antiviral antibodies in a test serum. The serum, usually a twofold dilution series, is mixed with a standard number, usually 4 to 8 HA units, of virus and incubated prior to the addition of a standard suspension of erythrocytes. The highest dilution of serum that inhibits hemagglutination is the HI titer of the serum. For example, influenza (AI) viruses agglutinate erythrocytes through the interaction of the virus surface glycoprotein, the hemagglutinin (HA), with receptors on the surface of the erythrocyte. Inhibition of the agglutination reaction by HA subtype-specific antisera is the basis of the hemagglutination-inhibition (HI) assay.
an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication.
a DNA vaccine plasmid that uses the plasmid labeled pCI.
WEB: http://www.ncbi.nlm.nih.gov/nuccore/5870896
a vaccine component that is used to dissolve vaccine powder into liquid. The vaccine in a powder form has to be reconstituted by mixing vaccine powder with vaccine solvent before administered.
a vaccine component that contains the solid form of all vaccine components. A vaccine can be reconstituted by mixing vaccine powder with vaccine solvent.
A vaccine preparation that results in the generation of a bacterial vaccine
life-threatening reaction to previous vaccination
life-threatening reaction to previous influenza vaccination
vaccine-induced down-regulated gene expression
A vaccine prepraration process that is performed by heat inactivation of virulent pathogen.
inactivated vaccine preparation using heat inactivation
CFU reduction assay is an assay that measures the reduction of the colony forming units of infected pathogens in vaccine-vaccinated animals compared to nonvaccinated animals.
assay of CFU reduction in spleen is a CFU reduction assay that is measured using the extracted spleen as the tissue for isolation of infected pathogens.
Arginine is a conditionally essential amino acid, meaning most of the time it can be manufactured by the human body, and does not need to be obtained directly through the diet. The biosynthetic pathway however does not produce sufficient arginine, and some must still be consumed through diet. Individuals who have poor nutrition or certain physical conditions may be advised to increase their intake of foods containing arginine. Infants are unable to meet their requirements and thus arginine is nutritionally essential for infants.
A physical quality inhering in a bearer by virtue of the bearer being fit to be eaten.
Melanie has submitted this term and its two subclasses to obo: http://sourceforge.net/tracker/?func=detail&aid=2873643&group_id=76834&atid=595654
A quality of edibility that inheres in a bearer by virtue of the bearer being suitable for oral ingestion as food, drug, or vaccine.
Vaccine efficacy is an efficacy of a vaccine in induction of protective immune response in vivo or protection against infection of a virulent pathogen. Specifically, vaccine efficacy (VE) is the percentage reduction in disease incidence attributable to vaccination, calculated by means of the following equation: VE(%) = (U - V)/U x 100 where U = the incidence in unvaccinated people and V = the incidence in vaccinated people. Ref: Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71.
vaccine-induced antiviral neutralizing antibody response
A DNA vaccine plasmid vector that has the plasmid label pgp.LAMP-1. This plasmid has a CMV promoter and contains the human lysosomal-associated membrane protein-1 signal sequence.
A DNA vaccine plasmid vector that has the plasmid label pES. This plasmid has a CMV promoter and contains a kanamycin resistance gene.
vaccine-induced follicular dendritic cell activation
sodBFt is a live vaccine strain mutant of Francisella tularensis with reduced Fe-superoxide dismutase gene expression. Ref: PMID:18692537.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=55
C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice
A vaccine that targets against a fungus infection.
A live attenuated Francisella tularensis vaccine. It is available in American Type Culture Collection with ATCC ID: 29684.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=52
vaccine-induced T cell interferon-gamma production
To induce or modify protective or therapeutic immune response against a disease.
PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term.
a viral vaccine vector that uses a herpesvirus as the vector.
An immune system process that is realized in the calibrated response of the recipient to a vaccine.
The definition of this term is based on the definition of 'immune response (GO:0006955)' . It is a child term of this GO term.
Process that specifies the organism's response to an administered vaccine.
a process that specifies host response to a vaccine adjuvant.
Process that specifies host response to a vaccine component.
a process that specifies host response to a vaccine antigen.
a process that specifies host response to a vaccine vector.
A viral vaccine that protects against infection with human immunodeficiency virus that causes AIDS.
A legal organization that represents an association of people with a specific objective.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=135
Brucella melitensis strain VTRM1 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=136
KKF24 is a recombinant strain of Francisella novicida U112 with iglC mutation (F. novicida delta-iglC::ermC). PMID:14680699.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=60
An iglC mutant is highly attenuated in mice. Inoculated mice were challenged 30 days later with wild type F. tularensis and were highly protected
F. tularensis vaccine LVS lipopolysaccharide
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=58
obsolete vaccine-induced antibody mediated immune response
a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier.
WEB: http://www.ncbi.nlm.nih.gov/pubmed/16337664
Emulsifiers help bind ingredients together and keep them from separating, most commonly with oil and water. An emulsifier is also a surfactant that reduces the surface tension of a liquid and results in an easier, smoother spread. Reference: http://www.wisegeek.org/what-is-polysorbate-80.htm
B. melitensis lipopolysaccharide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=137
Brucella melitensis lipopolysaccharide vaccine
B. melitensis LPS-GBOMP noncovalent complex vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=307
Brucella melitensis LPS-GBOMP noncovalent complex vaccine
A whole organism vaccine that uses an inativated pathogen organism as its component.
B. abortus DNA vaccine expressing BCSP31, SOD and L7/L12
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=211
Brucella abortus DNA vaccine encoding BCSP31, SOD and L7/L12
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=111
Brucella abortus conjugate vaccine using L7/L12
B. melitensis DNA vaccine encoding Omp31
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=293
Brucella melitensis DNA vaccine encoding Omp31
bacterial vaccine that protect against Mycoplasma hyopneumoniae infection
A quality of edibility that inheres in a bearer by virtue of the bearer being not suitable for oral ingestion.
tertiary vaccination is a vaccination that is performed at the third time in a row.
Protozoa are a diverse group of unicellular eukaryotic organisms,[1] many of which are motile. Originally, protozoa had been defined as unicellular protists with animal-like behavior, e.g., movement. Protozoa were regarded as the partner group of protists to protophyta, which have plant-like behaviour, e.g., photosynthesis.(http://en.wikipedia.org/wiki/Protozoa)
A vaccination site that is used for injection of a vaccine.
A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the bp26 deletion. It has similar vaccine efficacy to Rev. 1. Its advantage compared to Rev. 1 is that this feature of bp26 deletion promotes diagnosis. PMID:17070627.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=295
Brucella melitensis bp26 deletion vaccine
A spontaneous mutant of the SCHU S4 strain that protects against virulent F. tularensis infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=57
A route of administration that inject the material(such as vaccines, allergens) directly into a muscle.
A rounte of administration that located in nose.
A route of administration that located in the peritoneum.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=308
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=301
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=452
Active immunization of persons ages 6 months and older against influenza disease caused by pandemic (H1N1) 2009 virus.
influenza A (H1N1) 2009 Monovalent vaccine (CSL Limited)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=456
Active immunization of individuals 2-49 years of age against influenza disease caused by pandemic (H1N1) 2009 virus.
influenza A (H1N1) 2009 Monovalent vaccine (MedImmune LLC)
Vaccine role that is characteristic of a live virulent vaccine.
A synthetic vaccine adjuvant that is PCPP salt.
polyidi (carboxylatophenoxy) lphosphazene
Megan Egg is a Salmonella vaccine that that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is formulated fro immunization of pullets. Megan Egg contains the same Megan Vac1 organism but Megan Vac1 is used for younger birds (broilers).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=752
WEB: http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf
obsolete B. ovis microparticle subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=445
Brucella recombinant SurA protein vaccine
a viral vaccine vector that uses a lentivirus as the vector.
a licensed human vaccine that is licensed in the USA.
A vaccine that is licensed for commercial use.
lipopolysaccharide of pathogen organism as vaccine component
A particulate antigen delivery system vaccine adjuvant that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.
A vaccine that is made from microbes that have been attenuated (weakened) in the laboratory so that they can't cause disease.
Vaccine that uses a live, pathogenic (disease-causing) microorganism to stimulate the immune system.
quaternary vaccination is a vaccination that is performed at the fourth time in a row.
A vaccine that is used to improve conception.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=292
Brucella recombinant DnaK protein vaccine
divalent DNA B. abortus vaccine using L7/L12 and Omp16
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=302
divalent DNA Brucella abortus vaccine using L7/L12 and Omp16
'Mycobacterium avium relA mutant vaccine' includes a gene mutation of relA from virulent Mycobacterium avium.
A live attenuated vaccine prepraration process that is performed by mutation of a gene(s) from a virulent pathogen.
live attenuated vaccine preparation by gene mutant
A route of administration that is through the membrane covering the muscles and nerves at the back of the eyeball
An oral route of administration that is underneath the tongue.
a vaccine-induced T cell interferon-gramm production that results from the addition of a vaccine adjuvant
vaccine-induced, adjuvant boosted T cell interferon-gramm production
B. abortus DNA vaccine encoding L7/L12 and P39
Brucella abortus DNA vaccine encoding L7/L12 and P39
attenuated Brucella abortus with deletion of znuA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=288
attenuated Brucella abortus with deletion of znuA vaccine
A microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT.
E. coli LT toxin derived vaccine adjuvant
viral vaccine that is used to protect against Feline panleukopenia virus infection
Vaccine that protects against Leptospira spp. infection.
a Campylobacter bacterial vaccine that is used to protect against Campylobacter fetus infection
bacterial vaccine that is used to protect against Pseudomonas aeruginosa infection
Bordetella bacterial vaccine that is used to protect against Bordetella bronchiseptica infection
a vaccine organism that is inactived/killed
A live attenuated Brucella melitensis vaccine that is composed of live Brucella melitensis attenuated mutant vjbR::Tn5 (BMEII1116) delivered using a microsphere delivery system.
microencapsulated B. melitensis mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=304
The deletion of vjbR gene in Brucella melitensis strain 16M made a live attenuated vaccine and provided significance protection against mice
microencapsulated Brucella melitensis mutant vaccine
A vaccine-induced adjuvant boosted T cell interferon-gramm production that results from the addition of a IL-15 vaccine adjuvant
vaccine-induced T cell interferon-gramm production boosted by IL-15 vaccine adjuvant
A vaccine that contains one vaccine for priming and at least one other vaccine for boosting.
A prime-boost vaccine that contains one DNA vaccine for priming and at least one other vaccine for boosting.
prime-boost vaccine with DNA vaccine priming
complex of porin and S-LPS from B. abortus strain 2308
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=291
porin-S-LPS from Brucella abortus strain 2308 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=13
The AIDSVAX that is bicovalent vaccine including two kinds of gp120 protein: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (MN and GNE8 are strain names).
link to another well-known study: VAX004
linkto the clinical trail database by : ClinicalTrials.gov Identifier: NCT00002441
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=113
recombinant O. anthropi 49237SOD vaccine
organ or tissue specific immune response to vaccine
Pandemrix is an influenza vaccine for influenza pandemics, such as the H1N1 2009 flu pandemic colloquially called the swine flu. The vaccine was developed by GlaxoSmithKline and patented in September 2006.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3957
As well as the active antigen derived from A/California/7/2009 (H1N1), the vaccine contains an immunologic adjuvant AS03 which consists of DL-alpha-tocopherol (vitamin E), squalene and polysorbate 80. Thiomersal (thimerosal) is added as a preservative. Being manufactured in chicken eggs, it contains trace amounts of egg proteins. Additional important non-medicinal ingredients are formaldehyde, sodium deoxycholate, and sucrose. (http://en.wikipedia.org/wiki/Pandemrix)
B. melitensis Bp26 and Tf protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=300
Brucella melitensis Bp26 and Tf protein vaccine
A Brucella subunit vaccine that uses recombinant Brucella melitensis 16M P39, a putative periplasmic binding protein.
B. melitensis P39 recombinant protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=198
Brucella melitensis P39 recombinant protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=212
Panvax is an H1N1 unadjuvanted monovalent vaccine.
WEB: http://www.infowars.com/h1n1-panvax-training-powerpoint-received-by-health-care-workers-in-australia/
A role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity.
Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008
A route of administration that is located in the vein
A vaccine that protects against some protozoan disease.
Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine injection 0.5mL vial
Product Name: Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine injection 0.5mL vial
a Varicella-zoster virus vaccine that is live attenuated.
a vaccine component that originates from an organism such as a pathogen or a modified organism.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=199
A cancer vaccine that is used against melanoma, a malignant tumor of melanocytes.
WEB: http://en.wikipedia.org/wiki/Melanoma
escheriosome-encapsulated B. abortus L7/L12
escheriosome-mediated delivery of B. abortus L7/L12
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=298
escheriosome-mediated delivery of Brucella abortus L7/L12 vaccine
a pneumococcal vaccine that is formed using polyvalent polysaccharides
WEB: http://www.who.int/vaccines/en/pneumococcus.shtml
The most common form of the polyvalent pneumococcal vaccine is called the protein-polysaccharide combinations which is known as conjugate vaccines and contain 7-11 selected polysaccharides bound to a protein carrier. The protein-polysaccharide combinations are able to induce a T-cell dependent immune response. These vaccines are likely to be protective even in children under two years of age, and may reduce pneumococcal transmission through a herd effect.
WEB: http://www.ncbi.nlm.nih.gov/pubmed/10700309
a Staphyloccoccus vaccine that is made using engineered toxoid.
period of persistence of vaccine induced immune response is a temporal interval during which a vaccine-induced immune response continuously exists. This term is related to the process 'persistence of vaccine induced immune response'.
period of persistence of vaccine induced immune response
A vaccine clinical trial that investigates the safety profile of a vaccine in a small group (10-50) of healthy volunteers.
A vaccine clinical trial that studies vaccine efficacy with a target population (numbering 50-100). Different dosage levels will also be explored at this stage to determine the optimum dose.
A vaccine clinical trial that takes the trial to a large-scale safety and efficacy study in a relevant patient population, usually in excess of 3,000.
The final stage of vaccine clinical evaluation. Phase IV occurs after a vaccine or therapy is licensed and is being used by large numbers of people. These studies are not always required or completed.
Seven F. tularensis proteins including IglC (rLm/iglC) were expressed in recombinant L. monocytogenes (rLm) vaccines. These 7 F. tularensis proteins are: AcpA, Bfr, DnaK, GroEL, IglC, Pld and KatG from SchuS4 strain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=929
Francisella tularensis DNA vaccine rLm/iglC
A subunit nontypeable H. influenzae vaccine that uses Hap protein.
nontypeable H. influenzae Hap protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=170
Nontypeable Haemophilus influenzae Hap protein vaccine
Smallpox virus vaccine that uses vaccinia virus. The vaccine is made from a laboratory strain of the live vaccinia virus that has been attenuated, or weakened, so that it stimulates an immune response without causing the severe disease associated with smallpox.
WEB: http://en.wikipedia.org/wiki/Vaccinia
Vaccinia virus is well known for its role as a vaccine that helped eradicate the smallpox disease, making it the first human disease to be successfully eradicated by science.
Mixed Bacterial Vaccine (MBV, Coley's Toxins) is a historical, vaguely defined preparation of heat-inactivated Streptococcus pyogenes and Serratia marcescens used as non-specific immunotherapy in the treatment of cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6314
Vaccine vector that is a DNA plasmid used to deliver the genetic code into the cells within the body.
B. melitensis DNA vaccine encoding Omp31 boosted with Omp31
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=446
Brucella melitensis DNA vaccine encoding Omp31 boosted with Omp31
Vaccine that protects against Moraxella bovis infection. Moraxella bovis is a Gram-negative, aerobic, oxidase-positive diplococcus that is implicated in infectious bovine keratoconjunctivitis, an eye disease of cattle, also colloquially known as Pink Eye.
WEB: http://en.wikipedia.org/wiki/Moraxella_bovis
a Moraxella bovis vaccine that is prepared using a bacterial bacterin.
a USA licensed vaccine role that indicates the vaccine is for veterinary uses.
WEB: http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-15-2009/0005094621&EDATE @2009/10/06
WEB: http://www.examiner.com/x-7707-Infectious-Disease-Examiner~y2009m9d15-News-Release-H1N1-vaccines-get-FDA-approval-expected-to-be-available-in-4-weeks @2009/10/06. H1N1 vaccines get FDA approval. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. Obtaining FDA licensure of this vaccine for A (H1N1) pandemic response is a key milestone that will enable Sanofi Pasteur to provide a licensed vaccine to the U.S. government to support pandemic immunization efforts
vaccine approval process is a processual entity that involves approval of a vaccine.
WEB: http://energycommerce.house.gov/images/stories/Documents/PDF/publications/109_health.pdf @2009/10/06. This is the US Health Law which includes a section about vaccine.
WEB: http://www.hhs.gov/nvpo/factsheets/fs_tableII_doc2.htm @2009/10/06 #Following the FDA's review of a license application, the sponsor and the FDA may present their findings to the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC). This non-FDA expert committee (scientists, physicians, biostatisticians, and a consumer representative) provides advice to the Agency regarding the safety and efficacy of the vaccine for the proposed indication.
Role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a recipient organism.
This role should be a subclass of 'test substance role', which will be mireoted from OBI by OntoFox.
CFU measurement assay is an assay that measures the colony forming unit (CFU) of a bacterium in a specific location (e.g., spleen of a mouse).
A measurement datum that measues the vaccine effectiveness. It is assessed with respect to prevention of the disease against which the vaccine is given. One simple method to estimate vaccine effectiveness is to use routine data on notifications of disease cases in vaccinated and unvaccinatted children and to compare the porportion of cases vaccinated with the vaccine covervage among the same age group in the general population. If p is the proportion vaccinated in the population and c is the proportion of cases reported to be vaccinated, then VE = (p-c)/p(1-c) x 100%.
Hadler TC, et al. Immunization in developing countries. In: Vaccines. Editors: Plotkin S, et al. 2008. p1542-71.
WEB: http://en.wikipedia.org/wiki/Influenza_vaccine
vaccine licensing is a vaccine approval process that involves in licensing a vaccine.
a viral vaccine vector that uses an poxvirus as the vector.
a Salmonella vaccine against infection with S. paratyphi, which causes paratyphoid fevers. Paratyphoid fevers are a group of enteric illnesses caused by serotypic strains of the Salmonella genus of bacteria, S. Paratyphi.
WED: http://en.wikipedia.org/wiki/Paratyphoid_fever
Moraxella Bovis Bacterin Piliguard Pinkeye-1 Trivalent
WEB: http://www.jefferspet.com/%252332moraxella-bovis-bacterin-piliguard-pinkeye-1-trivalent/camid/liv/cp/16435/
Moraxella Bovis Bacterin Piliguard Pinkeye-1 trivalent vaccine
Brucella vaccine using nonpathogenic alphaproteobacteria
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=275
A viral vaccine that protects against infection with Parainfluenza 3 virus.
A vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to prevent a specific disorder.
Colibacillosis, caused by avian pathogenic Escherichia coli (APEC), is a major problem for the poultry industry in the world.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=134
APEC vaccine using GST-Iss fusion protein
a vaccine that is used for prevention against a disease.
Protection efficacy is an efficiency that is associated with protection by a biological product (e.g., vaccine) against a disease.
An antigen that stimulates protective immunity when used in vivo.
E. coli heat-labile enterotoxin B-subunit (LB-T) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=274
E. coli O157:H7 subunit vaccine expressing Esps and Tir
an influenza virus vaccine against equine influenza viral infection
Bacterial vaccine against infection with Coxiella burnetii which causes Q fever
WEB: http://en.wikipedia.org/wiki/Q_fever
protein of pathogen organism as vaccine component
a S. aureus vaccine that uses bacterin as the protective antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=125
a S. aureus vaccine that uses the bacterial phage lysate as the protective antigen.
Staphylococcus aureus phage lysate vaccine
a Mycoplasma gallisepticum vaccine that uses bacterin as the protective antigen
Mycoplasma gallisepticum bacterin vaccine
a bacterial vaccine that uses bacterin from a bacterial strain isolated from a herd with a purpose to generate hard-specific vaccine.
WEB: http://addisonlabs.com/products/autogenous-bacterins.php
an autogenous bacterin vaccine that is prepared for poultry use.
WEB: http://www.hygieialabs.com/autopoultry.html
Nontypeable Haemophilus influenzae vaccine
Nontypeable Haemophilus influenzae (NTHi) is a nonencapsulated Haemophilus influenzae (a gram-negative bacterium). It is the cause of a number of human respiratory tract diseases, such as otitis media, sinusitis, bronchitis, and pneumonia.
non-typeable H. influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=169
Nontypeable Haemophilus influenzae rLP4/rLP6 and Moraxella catarrhalis UspA2 protein vaccine
killed nontypeable H. influenzae whole-cell vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=163
killed nontypeable Haemophilus influenzae whole-cell vaccine
a Rabies virus vaccine against Rabies in animal
a Rabies virus vaccine against Rabies in human
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=122
E. coli vaccine using intimin polypeptide
nontypeable H. influenzae cell membrane vaccine (CM-Hi)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=194
Nontypeable Haemophilus influenzae cell membrane vaccine (CM-Hi)
Nontypeable H. influenzae lipooligosaccharide-tetanus toxoid conjugate vaccine
nontypeable H. influenzae LOS-TT conjugate vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=164
Nontypeable Haemophilus influenzae LOS-TT conjugate vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=127
A vaccine preparation process that uses recombinant molecular technology to prepare recombinant protein.
A subunit vaccine that is made using a part of whole organism as subunit for vaccine development.
A vaccine that uses a modified virus or bacterium as the vector to deliver vaccine antigen(s) to the cells of the host body.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=128
A chicken egg protein allergen where the protein allergen is ovalbumin, the main protein found in egg write, making up 60-65% of the total protein.
WEB: http://en.wikipedia.org/wiki/Ovalbumin
a S. typhi vaccine that is live and orally administerred
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=126
A licensed vaccine role that is bears in a licensed human vaccine.
Discussed among Barry Smith, Anna Maria Masci, Jie Zheng and Oliver He. The vaccine recipient will be associate with vaccine directly rather than using the role.
Process that results in an adaptive immune response to one or more antigens.
WEB: http://en.wikipedia.org/wiki/Immunization
An immunization that involves the introduction of foreign molecules into a recipient body, in a way which causes the recipient to actively induce adaptive immunity against the immunization target.
An immunization where pre-synthesized elements of the immune system are transferred to an organism so that the body does not need to produce these elements itself.
Currently, antibodies can be used for passive immunization. This method of immunization works very quickly. However, it is short lasting. The antibodies are naturally broken down. If there are no B cells to produce more antibodies, they will disappear.
natural active immunization is an active immunization that occur naturally when a person or animal comes in contact with antigens includeing microbes.
Immunization that is induced by a vaccine via vaccination process.
induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine.
induction of adaptive immune response to antigen
Process that prevents a disorder that is the physical basis of a disease.
Process that leads to treat a disorder that is the physical basis of a disease.
modification of adaptive immune response to antigen is an active immunization process that results in modification of an adaptive immune response to some antigens, for example, in a therapeutic vaccine.
modification of adaptive immune response to antigen
obsolete preventive infectious disease vaccine function
infection disorder prevention is a process that prevents a disorder that is the physical basis of an infectious disease.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=281
E. coli vaccine using verocytotoxin toxoid
Inactivated ETEC expressing CFA/I and CFA/II
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=286
Inactivated ETEC expressing CFA/I and CFA/II vaccine
a vaccine role that indicates the vaccine being a whole organism vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=278
EHEC O157 subunit vaccine using his-tagged N-terminal intimin
an organism that is used as part of a vaccine
A Canada licensed vaccine role that indicates the vaccine is for veterinary uses.
obsolete Canada licensed veterinary vaccine role
a diphtheria vaccine that uses diphtheria toxoid
nontypeable H. influenzae P5 peptide MVF/H3 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=193
Nontypeable Haemophilus influenzae P5 peptide MVF/H3 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=195
Nontypeable Haemophilus influenzae rTbpB vaccine
ACAM2007 is a vaccine candidate expressing CFA/II.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=115
WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095642/
a viral vaccine against a disease caused by a virus belong to Poxviridae.
a Salmonella vaccine against both typhoid caused by S. typhi and paratyphoid caused by S. paratyphi.
ACAM2017 was derived from ACAM2007. Genes aroC, ompC, and ompF were deleted, while CS1 and pStrep were added.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=117
DNA vaccine contains the gene fragment encoding AAs 173-764 of PA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=23
Bacillus anthracis DNA vaccine encoding PA63
GenBank: AC020633; Protein RefSeq: NP_001090
B. anthracis DNA vaccine encoding PA83 and LF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=30
Bacillus anthracis DNA vaccine encoding PA83 and LF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=24
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=309
M. tuberculosis arabinomannan-protein conjugate
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=223
Mycobacterium tuberculosis arabinomannan-protein conjugate vaccine
A route of administration that is loacted in the hypodermis (subcutaneous tissue) region.
A vaccine that is composed of a purified protein(s) or other antigenic determinant(s) from a disease-causing organism. A subunit vaccine does not include the whole organism of a pathogen, so the subunits have less risk of causing adverse reactions.
recombinant S. typhimurium secreting M. tuberculosis ESAT-6
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=176
recombinant Salmonella typhimurium secreting Mycobacterium tuberculosis ESAT-6 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=171
equine EEV, VEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid
time of survival of live vaccine inside host is a temporal interval during which a live vaccine survives inside a host organism. This entity is related to the process survival of live vaccine inside host.
time of survival of live vaccine inside host
equine EEV, VEE & WEV encephalomyelitis-tetanus toxoid
equine EEV, VEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=177
attenuated Mycobacterium bovis strain WAg539 vaccine
a population of human beings who are vaccinated.
a population group that are vaccinated with a specific vaccine
human vaccinee population at age 2-17 years old
A vaccine that is used for treatment for a disease.
A licensed vaccine role that is bears in a licensed veterinary vaccine.
obsolete licensed veterinary vaccine role
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=179
attenuated Mycobacterium bovis strain WAg520 vaccine
A titer (or titre) is a measure of concentration. Titer testing employs serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer corresponds to the highest dilution factor that still yields a positive reading; for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1:256.
a vaccine that is designed to immunize against two or more strains of the same microorganism, or against two or more microorganisms.
WEB: http://coastalcarolinaresearch.com/?p=679
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=180
attenuated Mycobacterium bovis strain WAg522 vaccine
recombinant nontypeable H. influenzae protein P6 with AdDP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=189
recombinant nontypeable Haemophilus influenzae protein P6 vaccine with AdDP adjuvant
A synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP.
adamantylamide dipeptide vaccine adjuvant
A toxin is a poisonous substance produced within living cells or organisms; man-made substances created by artificial processes are thus excluded.
The term was first used by organic chemist Ludwig Brieger (1849-1919).[3] For a toxic substance not produced within living organisms, "toxicant" and "toxics" are also sometimes used.[citation needed]. Toxins can be small molecules, peptides, or proteins that are capable of causing disease on contact with or absorption by body tissues interacting with biological macromolecules such as enzymes or cellular receptors. Toxins vary greatly in their severity, ranging from usually minor and acute (as in a bee sting) to almost immediately deadly (as in botulinum toxin).-- from Wikipedia.
A vaccine containing a toxoid, used to protect against toxins produced by certain bacteria. A toxoid (also called inactivated toxin) is a processed toxin that has been treated by chemical means, heat, or irradiation and is no longer capable of causing disease.
A vaccine function realized the process of vaccination and leading to induction of an adaptive immune response to treat an existing specific disorder.
a combination vaccine that is used against both bacterial and viral infections.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=222
Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Guerin vaccination
Mycobacterium tuberculosis secA2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=236
Vaccine that protects against Vibrio infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=166
A vaccine that protects against Campylobacter bacterial infectioni.
vaccine-induced up-regulated gene expression
a viral vaccine vector that uses an AAV virus as the vector.
vaccination protocol is the protocol of a vaccination procedure.
A vaccine that protects against Chlamydia bacterial infection.
A path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body.
CDISC has a codelist: Rout of Administration. Desription from CDISC: The course by which a substance was administered in order to reach the site of action in the body. CDISC_SDTM_Route_of_Administration_Terminology
vaccine candidate is a processed material that is designed to prevent or ameliorate a disorder in a target organism by modulating adaptive immune responses in that organism by administrating the vaccine.
During our call, we decided not to say vaccine candidate is an output of vaccine preparation, which may be reserved for vaccine alone. -- Aug 4, 2009.
vaccine preservative that has thimerosal as part.
A subunit vaccine that uses small peptide(s) as immunoepitopes.
H1N1 Influenza vaccine is an Influenza virus vaccine that is used to vaccinate against H1N1 Influenza subtype vaccine.
bacterial vaccine that is used to protect against Haemophilus somnus infection
A vaccine component is a chemical substance added to a vaccine to enhance and direct the immune response to a protective antigen. Vaccine adjuvants may cause a range of serious side-effects.
A vaccine regulatory process that is for vaccine producer to apply for vaccine license.
nontypeable H. influenzae gene hel (encoding P4)
An assay that is used to detect the immune response of a host to vaccination of a vaccine.
immunization objective is the specification of an objective to achieve immunization.
a multivalent vaccine that is designed to immunize against at least one bacterial disease and one viral disease.
multivalent vaccine against bacterial and viral diseases
a bacterial vaccine against infection of Bordetella bacterial infection
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=178
Study evaluated immunogenicity and protection against Mycobacterium tuberculosis in rhesus monkeys with an attenuated M. tuberculosis with a disrupted phoP gene (SO2) as a single-dose vaccine. SO2 treatment showed reduced average lung bacterial counts (1.0 and 1.2 log respectively, compared with 0.4 log for BCG) and significant protective effect by reduction in C-reactive protein levels, body weight loss, and decrease of erythrocyte-associated hematologic parameters (MCV, MCH, Hb, Ht) as markers of inflammatory infection, all relative to non-vaccinated controls
Mycobacterium tuberculosis phoP mutant SO2 vaccine
A bacterial vaccine that is used to protect against Aeromonas bacterial infection
vaccine preparation is a manufacturing process to produce a vaccine.
An assay that is used to detect if a vaccine protects a host against infection of virulent pathogen after vaccine immunization.
Vaccine that protects against Mycobacterium bacterial infection.
vaccine specific T cell cytokine production
vaccine specific T cell mediated cytotoxicity
A dose of vaccine specified by the vaccine manufacturer, distributor, or a regulatory agent.
Planned process by which a vaccine is tested clinically for safety and effectiveness. Clinical trials are conducted in phases. Classically, clinical trials unfold in three phases in order to gather data and information about a vaccine and its performance. This will form the basis of a dossier submitted to regulatory authorities by way of an application for licensure. After a vaccine is licensed and is being used by large numbers of people, a Phase IV study may or may not be taken for vaccine clinical evaluation.
Most vaccines against a pathogen (e.g., HIV) are not tested by vaccinating people and then deliberately exposing them to virulent pathogen (e.g., HIV). This strategy is never for a vaccine against a disease as serious as HIV. The best way to determine if a vaccine is effective is to test it in a randomized, controlled, double-blind clinical trial. This type of trial is often referred to as the gold standard in medical research and provides the strongest evidence for the efficacy of a vaccine.
A vaccine that uses whole organism as its component
WEB: http://onlinelibrary.wiley.com/doi/10.1038/npg.els.0000491/full
Vaccine vector that is a genetically engineered virus or bacterium used to deliver genetic code into the cells within the body.
a vaccine component that uses a microbe (e.g., bacterium, virus, and parasitic organism) as a vector that is inserted with the DNA(s) of a heterologous protective antigen(s) to generate a "recombinant vector vaccine". The microorganism used as a vector generally has a stable non or low pathogenic phenotype for the species the vaccine is intended for.
WEB: http://en.wikipedia.org/wiki/Vaccine
WEB: http://www.biosafety.be/GT/Regulatory/Veterinary_vaccines/EMEA_000404en.pdf
WEB: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003856.pdf
an orthopoxvirus vaccine vector that uses vaccinia virus as the vector
Vaccine that protects against Yersinia bacterial infection.
A bacterial vaccine that is used to protect against Edwardsiella bacterial infection
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=173
Vaccine that protects against Mycoplasma bacterial infection.
A Canada licensed vaccine role that indicates the vaccine is used for human
obsolete Canada licensed human vaccine role
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=437
A vaccine that targets against a viral disease.
a vaccine vector that uses a virus as the vector.
bacterial vaccine that is used to protect against Haemophilus parasuis infection
a virulence of vaccine that shows a virulent pheontype of the organism as the major component of a vaccine. The virulent phenotype means that an vaccine organism is virulent and is able to cause a pathogenic phenotype in a host organism.
M' (intended to refer to a male biological sex), 'Male', 'Man', '1' (intended to refer to a male biological sex)
A biological sex datum that represents the biological sex of an animal (including human) as being male.
Nontypeable H. influenzae protein P6 with cholera toxin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=188
Nontypeable Haemophilus influenzae protein P6 with cholera toxin vaccine
Role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection.
Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research.
A role that inheres in a material entity that becomes an ingredient of a vaccine.
Vaccine that protects against Pasteurella multocida infection.
Animal model of vaccine research is a role played by some organism (e.g., mouse) that is used for vaccine research in the laboratory.
laboratory animal model of vaccine research
a vaccine antigen role that inheres in a vaccine antigen which is capable of inducing protective immunity.
A vaccine role that indicates the vaccine being a DNA vaccine.
A vaccine role that indicates the vaccine being a subunit vaccine.
A vaccine role that indicates the vaccine being a conjugate vaccine.
Survival assessment is an assay that measures the occurence of death events in one or more organisms that are monitored over time.
Need to point out more specifically that survival/death is measured.
A vaccine used to prevent infection by Haemophilus influenzae type b (Hib) bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
H. influenzae Type b capsular polysaccharide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=165
Haemophilus influenzae type b capsular polysaccharide vaccine
An E. coli vaccine that uses subunit antigen type.
B. anthracis recombinant vaccine using PA domain 4
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=20
Bacillus anthracis recombinant vaccine using PA domain 4
A licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market.
A vaccine in clinical trial role is a regulation-assigned role that inheres in a vaccine that is currently in clinical trial.
In medical research, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices.
Vaccine induced immue response mediated hrough a body fluid
vaccine-induced antibody mediated immune response
A B. melitensis vaccine that is recombinant B. melitensis Rev. 1 vaccine with the p39 gene deletion.
B. melitensis Rev. 1 P39 deletion mutant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=448
Brucella melitensis Rev. 1 with P39 deletion vaccine
a licensed vaccine with license for human use.
A vaccine role that indicates the vaccine being a recombinant vector vaccine.
bacterial vaccine that is used to protect against Flavobacterium columnare infection
A bacterial vaccine that protects against infection with Clostridium spp.
a Clostridium vaccine that protects against infection with Clostridium tetani that causes tenanus.
Combination vaccine is a vaccine that induces protection against multiple infectious diseases or several different serotypes of the same organism. The anitgens contained in combination vaccines are either formulated together by the manufacturer or physically mixed by a health care provider just prior to administration. Both approaches require licensure. Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1624.
A viral vaccine that protects against infection with influenza virus.
There is no single 'influenza virus' in NCBI_Taxon. We usually use: ('unidentified influenza virus' or 'Influenzavirus A' or 'Influenzavirus B' or 'Influenzavirus C') However, even this may not be comprehensive.
a vaccine with license that is used for cattle.
A viral vaccine that protects against infection with Hepatitis B virus.
A viral vaccine that protects against infection with Hepatitis A virus.
A bacteria vaccine that prevents against Yersinia pestis infection that causes plague.
A viral vaccine that protects against infection with Rabies virus.
A viral vaccine that protects against infection with Smallpox virus.
A viral vaccine that protects against infection with Measles virus.
A viral vaccine that protects against infection with Mumps virus.
A viral vaccine that protects against infection with Rotavirus.
In most cases HibTITER was administered concomitantly with other vaccines including DTP, DTaP, hepatitis B vaccine, IPV, OPV, pneumococcal 7-valent conjugate vaccine, MMR, and/or meningococcal group C conjugate vaccine (not licensed in the US).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=160
Ref: http://www.rxlist.com/prohibit-drug.htm
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=162
Vaccine that protects against Haemophilus infection.
A vaccine that protects against Haemophilus influenzae type b infection.
Haemophilus influenzae serotype b vaccine
A live attenuated Shigella flexneri 2a vaccine that carries deletions of the plasmid-borne virulence gene icsA (mediating intra- and intercellular spread) and the chromosomal locus iuc (encoding aerobactin).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=259
A viral vaccine that protects against infection with Poliovirus.
A viral vaccine that protects against infection with Japanese encephalitis virus.
CVD 1208 is derived from wild type Shigella flexneri 2a strain 2457T and has defined deletions in four genes: (1) the guaBA chromosomal operon that encodes two enzymes (inositol 5'-monophosphate dehydrogenase and guanosine 5'synthase) essential for de novo purine biosynthesis; (2) set, a locus in a chromosomal pathogenicity island that encodes Shigella enterotoxin (ShET); (3) Pic, an autotransporter mucinase encoded on the opposite strand from set; and (4) sen, an invasiveness plasmid gene encoding ShET.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=441
a vaccine against human papillomavirus infection
CVD 1208S is the same thing as CVD 1208, but CVD 1208S was prepared using animal-free media.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=272
a Herpesvirus vaccine that is used against Varicella-zoster virus infection.
A Shigella flexneri vaccine that is an aro-D mutant derivative of EcSf2a-1.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=267
A Salmonella vaccine against typhoid fever (or called typoid), caused by Salmonella enterica enterica, serovar Typhi.
heat-killed virulent Shigella flexneri 2a
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=268
heat-killed virulent Shigella flexneri 2a vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=269
Recombinant SFL124-27 expressing S. dysenteriae type 1 O antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=258
recombinant SFL124-27 expressing Shigella dysenteriae type 1 O antigen vaccine
a Streptococcal vaccine that is used against S. pneumoniae infection, which causes pneumococcal diseases.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=263
An aroA and virG mutant (CVD 1203) is attenuated in guinea pigs, as shown by the Sereny test. Guinea pigs inoculated with CVD 1203 were also protected from challenge with wild type S. flexneri
Shigella dysenteriae 1 strain WRSd1 vaccine
A live attenuated Shigella flexneri 2a vaccine with specific deletion mutations in virG, sen, set, and guaBA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=260
Shigella flexneri 2a strain CVD 1207 vaccine
A stable attenuated Shigella sonnei strain with virG mutation. PMID:9712824.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=264
A virG mutant (WRSS1) is attenuated in guinea pigs and induced significant protection from challenge with wild type Shigella sonnei
S. flexneri 2a LPS vaccine complexed with N. meningitidis proteosomes
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=270
Shigella flexneri 2a LPS vaccine complexed with Neisseria meningitidis proteosomes vaccine
Process that regulates vaccine-related processes, such as vaccine trial, vaccine license application.
Process of transporting vaccine from one place to another place.
A recombinant vector vaccine role that inheres in a bacterium that carries a vaccine antigen for development of a particular vaccine
obsolete recombinant bacterial vector vaccine role
A subunit vaccine role that indicates the vaccine being a peptide vaccine.
A recombinant vector vaccine role that inheres in a virus that carries a vaccine antigen for development of a particular vaccine
obsolete recombinant viral vector vaccine role
a vaccine residual that is from antibiotics used during the manufacture process.
A vaccine regulation process for vaccine clinical trials.
A vaccination process that occurs at the first time to a host organization in a specified period.
A vaccination process that occurs after the primer vaccination with a purpose to boost host immune response to vaccine antigen.
Brucella melitensis Rev. 1B. melitensis strain Rev. 1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=110
Brucella melitensis strain Rev. 1 vaccine
a licensed human vaccine that is licensed in Canada
A vaccine preparation that results in the generation of a DNA vaccine
A vaccine preparation that results in the generation of a conjugate vaccine
A vaccine preparation that results in the generation of a subunit vaccine
A vaccine preparation that results in the generation of a live attenuated vaccine
A vaccine preparation that results in the generation of a RNA vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=11
a Brucella vaccine against infection wtih B. suis
An orally administrable brucellosis vaccine that was was developed in China. It is effective for oral vaccination of sheep, goats, cattle and pigs.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=447
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=123
A viral vaccine that protects against infection with Dengue virus.
A viral vaccine that protects against infection with Ebola virus.
A viral vaccine that protects against infection with Herpesvirus.
A vaccine role that indicates the vaccine being a RNA vaccine.
A Measles-Mumps vaccine that also protects against infection with Rubella virus.
measles, mumps and rubella virus vaccine
A Corynebacterium diphtheriae vaccine that also protect against infection with Clostridium tetani.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=265
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=442
A bacterial vaccine that protects against infection with Corynebacterium diphtheriae that causes Diphtheria.
A Measles virus vaccine that also protects against infection with Mumps virus.
A Measles-Mumps-Rubella vaccine that also protects against Varicella.
measles, mumps, rubella, and varicella virus vaccine
diphtheria, tetanus toxoids and pertussis vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=273
A malaria vaccine that comprises recombinant Plasmodium falciparum (P. falciparum) blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=206
Plasmodium falciparum vaccine combination B
A vaccine that protects against diphtheria, tetanus, pertussis, and poliovirus.
diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine
Diphtheria-Tetanus-Pertussis-Poliovirus vaccine
A vaccine used to prevent infections of diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, and poliovirus.
Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine
A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine
a viral vaccine against Hepatitis B virus and at the same time against bacterial H. influenzae serotype b.
A vaccine that contains DNA and modified vaccinia virus Ankara (MVA) encoding thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP). This vaccine is used with a prime-boost regime by DNA priming and MVA boosting.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=210
A viral vaccine that protects against infection with Papillomavirus.
A viral vaccine that protects against infection with Parainfluenza virus.
A viral vaccine that protects against infection with Pseudorabies virus.
A viral vaccine that prevents against infection with Simian immunodeficiency virus.
A viral vaccine that protects against West Nile virus infection.
A viral vaccine that prevents infection with Respiratory syncytial virus.
A vaccine that is used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. It can be a subunit or a gene-deleted vaccine.
A vaccine that is edible and derived from an edible plant. The transgenic plant is used as recombinant protein production system. The edible plant tissue functions as an oral vaccine.
A subunit vaccine that is produced by using only the antigenic part of the disease causing organism. It often requires a "booster" every few years to maintain their effectiveness.
A particulate antigen delivery system vaccine adjuvant that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.
A vaccine that is used to prevent conception.
A vaccine that prevents or treats Alzheimer disease.
Plasmodium vaccine is a vaccine that prevents against Plasmodium species causing malaria. It is made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
a protozoan vaccine that prevents against infection with Leishmania.
A bacterial vaccine that prevents infection with Vibrio cholera.
Vaccine that protects against Borrelia burgdorferi infection causing Lyme disease.
A bacterial vaccine that prevents against Bordetella pertussis infection that causes pertussis or whooping cough.
Vaccine that protects against Pseudomonas infection.
Vaccine that protects against Rickettsia infection. Typhus is any of several similar diseases caused by Rickettsia bacteria. So Rickettsial vaccine is also called typhus vaccine.
WEB: http://en.wikipedia.org/wiki/Typhus_vaccine
Vaccine that protects against Salmonella species infection.
Vaccine that protects against Shigella species infection.
Vaccine that protects against Staphylococcus infection.
BCG Vaccine is a Mycobacterium tuberculosis vaccine that is a live attenuated strain of Mycobacterium bovis (Bacillus Calmette Guerin; BCG).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=143
For the prevention of tuberculosis in persons not previously infected with M. tuberculosis who are at high risk for exposure.
Vaccine that protects against streptococcal infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=207
MSP3-LSP subunit vaccine with aluminium hydroxide adjuvant
RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=200
Plasmodium falciparum RTS,S/AS02A vaccine
P. falciparum MSP1 from transgenic mice with Freund's adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=234
Plasmodium falciparum MSP1 from transgenic mice vaccine with Freund's adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=208
P. vivax PVS25 vaccine with Montanide ISA-720 adjuvant
A recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. PMID:17442466.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=232
Plasmodium falciparum FMP1/AS02A vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=204
Plasmodium falciparum ABRA protein vaccine
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus NP protein.
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus GP protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=69
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP24 protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=65
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP30 protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=66
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP35 protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=67
An Ebola virus vaccine that is composed of VEE replicon particle (VRP) encoding Ebola virus VP40 protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=68
A DNA vaccine that encodes for a secreted form of Ebola virus GP protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=73
A vaccine combination that includes a DNA vaccine and a recombinant adenovirus Ad5 expressing the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5 vaccine is used for boosting. PMID:11797011.
DNA and adenoviral vector Ad5 expressing SIV gag protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=145
DNA and adenoviral vector Ad5 expressing SIV gag protein vaccine
A gene that is a pathogen gene used for vaccine preparation or a host gene encoding for an immune factor important in induction of protective immunity. a vaccine-associated gene that exists in a pathogen and has been engineered for vaccine develoment. This gene can encode for protective antigen that is overexpressed for vaccine development. This gene can also be a virulence factor that is mutated to attenuate a virulent pathogen with the purpose of making attenuated vaccine.
The term 'gene' has appears in several ontologies, such as Sequence Ontology (SO) and Protein Ontology (PRO). We may choose to use a 'gene' term from other ontologies. The 'gene' term in SO has ID: SO:0000704.
A recombinant adenovirus (Ad5) expressing the codon-optimized SIV gag gene. PMID:11797011.
adenoviral vector Ad5 expressing SIV gag protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=444
adenoviral vector Ad5 expressing SIV gag protein vaccine
A vaccine combination that includes a DNA vaccine and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) that express the same codon-optimized SIV gag gene. The DNA vaccine is used for priming, and the Ad5/35 vaccine is used for boosting. PMID:16079886.
DNA and Ad5/35 vector expressing HIV gp160 protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=146
DNA and Ad5/35 vector expressing HIV gp160 protein vaccine
A Brucella gene that is from B. abortus.
A Brucella abortus gene that has the name wboA and comes from strain 2308.
Brucella abortus gene wboA is interrupted in Brucella abortus cattle vaccine RB51.
Interferon-gamma (IFN-g) is an indicative of Th1 immune response. It is produced in host immunized by vaccines such as Brucella abortus cattle vaccine RB51.
Interferon-gamma (IFN-g) is an indicative of Th1 immune response.
a storage process that is specifically for vaccine.
a vaccine storage that is execuated at room temperature. Room temperature is also referred to as ambient temperature. Room temperature denotes a certain temperature within enclosed space at which humans are accustomed. Room temperature is usually indicated by general human comfort, with the common range of 10 degree C (50 degree F) to 28 degree C (82.4 degree F).
vaccine storage that is executed in refrigerator, usually 0-10^C.
vaccine storage that is executed in freezer under 0^C.
Effectiveness is physical quality that represents the capability of a single physical entity (e.g., vaccine) producing an effect (e.g, protection against a disease).
A vaccine role that indicates the vaccine being a toxoid vaccine.
A vaccination process that is implemented fast.
A measure datum that measures the coverage of vaccination in a specific area during a specific time period.
WEB: http://www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCode=SP_CORP&codeRubrique=19
WEB: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/
A DNA vaccine plasmid vector that has the plasmid label pSCAR . CMV promotor is used.
a licensed vaccine role that indicates the vaccine occurs in USA.
A cattle vaccine with license that is used in USA.
A dose of vaccine that is used in a vaccination. Vaccination dose may be and may be not the same as the vaccine dose.
A HIV vaccine that is composed of a DNA vaccine expressing conserved, multiple HIV epitopes. PMID:16359234.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=149
DNA vaccine expressing multiple HIV epitopes
A HIV vaccine that is made of recombinant HIV gp120 protein adjuvanted with the adjuvant NanoEmulsion. PMID:18260780.
recombinant HIV gp120 with adjuvant NanoEmulsion
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=310
recombinant HIV gp120 with adjuvant NanoEmulsion vaccine
Aeromonas bacterial vaccine that is used to protect against Aeromonas salmonicida infection.
A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). PMID:12120997.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=156
a bacterial vaccine against V. anguillarum infection
A recombinant modified vaccinia Ankara (MVA) expressing HIV Gag, Pol, and Env proteins. PMID:16472543.
MVA expressing HIV Gag, Pol and Env proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=153
MVA expressing HIV Gag, Pol and Env proteins vaccine
A SIV vaccine that is composed of a DNA vaccine and a poxvirus vector expressing the same SIV antigens. PMID:15258286.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=154
DNA and poxvirus priming-boosting SIV vaccine
A B. abortus vaccine that is recombinant B. abortus strain 19 vaccine with the p39 gene deletion.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=449
Brucella abortus S19 with P39 deletion vaccine
A Yersinia pestis vaccine that uses a recombinant Ad5-based vector (E1a, partial E1b, and partial E3 deletion) to express Y. pestis V antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=48
A Yersinia pestis vaccine that is a pigmentation negative mutant of Y. pestis derived from a fully virulent strain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=32
A Yersinia pestis subunit vaccine that uses Y. pestis F1 protein as antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=36
A Y. pestis subunit vaccine that uses recombinant F1 and V antigens. PMID:312163.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=50
A Y. pestis subunit vaccine that uses recombinant Y. pestis V antigen. PMID:7622205.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=44
recombinant Yersinia pestis V antigen vaccine
modified Y. pestis with TLR4-stimulating LPS
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=35
modified Yersinia pestis with TLR4-stimulating LPS vaccine
A Yersinia pestis subunit vaccine that contains staphylococcal protein A-V antigen fusion peptide (PAV). PMID:7622225.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=62
recombinant Y. pestis YopD protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=37
recombinant Yersinia pestis YopD protein vaccine
In vitro-cultured merozoites, chemically inactivated
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=433
A Y. pestis subunit vaccine that uses Y. pestis YscF protein as antigen. PMID:15978133.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=81
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=56
Live temperature-sensitive mutant strain for subcutaneous or intramuscular injection
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=417
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=402
A Y. pestis vaccine that uses the recombinant V10 (rV10), a variant (lacking residues 271 to 300) of Yersinia pestis LcrV. PMID:16861680.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=54
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=413
Live temperature-sensitive mutant strain; spray inhalation or drinking water
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=420
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=47
VSV vector expressing Yersinia pestis lcrV vaccine
A formalin-inactivated preparation that was manufactured by Cutter Biologicals (a division of Miles Laboratories, Inc.). It is now available only from Greer Laboratories, Inc. The killed or inactivated plague vaccine is prepared from Y. pestis organisms grown in artificial media and then inactivated in formaldehyde.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=31
A vaccine that stimulates the pig's own immune system to produce specific antibodies against GnRF. This temporarily inhibits testes function and thus stops the production and accumulation of boar taint-causing compounds.
Peptide-protein conjugate and water-miscible adjuvant; control of boar taint
WEB: http://www.improvac.co.nz/sites/improvac/en-nz/Pages/productoverview.aspx
Vaccine component that is added to the immunogen by the vaccine manufacturer for a specific purpose. Additives include adjuvants, preservatives and stablizers, as well as materials that are added to affect pH and isotonicity.
Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73.
Vaccine additive that is added to a vaccine formulation to prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during use. Ref: Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 73.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=412
Vaccine additive that helps to protect the vaccine from adverse conditions such as the freeze-drying process (for those vaccines that are freeze-dried) or heat.
Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 75.
A vaccine component that remains from the vaccine manufacturing process.
Although no all manufacturing residuals may be identified and quantified, their presence and quantity is assumed to be constant because of the constancy of the manufacturing process.
a vaccine residual that is used to inactivate bacteria and viruses or to detoxify bacterial toxins. For example, formaldehyde is a frequently used inactivation agent in vaccine preparation.
Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78.
a vaccine residual that is generatead from cell culture for vaccine preparation. Examples include: antibiotics, sensitizing substances, bacterial and cellular residuals, and adventitious agents.
Finn TM and Egan W, in Vaccines fifth edition, 2008. Page 78-81.
Measurement process profile determined by the measurement data generated from a measurement process which indicates the degree of immunological protection in the vaccine recipient.
Correlated profile of immune protection that is reflected by serologic antibody levels.
serologic correlated profile of immune protection
Correlated profile of immune protection that is reflected by a cell mediated immune response.
cell mediated immune correlate of protection
cell mediated correlated profile of immune protection
Vaccine effectiveness is an effectiveness associated with a vaccine.
Canada is a country that exists in north America.
In vitro-cultured supernatant antigens, reduce clinical disease
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=434
a licensed status that occurs in Canada.
Vaccine that protects against Porphyromonas gulae infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=571
Influvac is an Influenza virus vaccine that is manufactured by Solvay Pharma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=597
Vaxigrip is an Influenza virus vaccine that is manufactured by 'Sanofi Pasteur Limited.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=642
Babesia bigemina vaccine by local veterinary institutes
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=404
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=430
Babesia bovis vaccine by local veterinary institutes
Anthrax Spore Vaccine is a B. anthracis vaccine that is prepared with a relatively nonpathogenic, noncapsulated variant strain of B. anthracis, originally developed at the Onderstepoort Laboratory, Pretoria, South Africa. Further work was conducted in England, India and in many other countries. Vaccine Strain is Sterne 34F2. The vaccine is a suspension of viable Bacillus anthracis spores in saponin.
B. anthracis Sterne strain spore vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=17
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=451
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=29
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=396
pCLF4 is a Bacillus anthracis vaccine that contains the N-terminal region (amino acids [aa] 10-254) of Bacillus anthracis LF cloned into the pCI expression plasmid.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=28
Equity Oestrus Control Vaccine for Horses is prepared from an analogue of gonadotropin releasing factor (GnRF) linked to a carrier protein. It has an adjuvant that enhances the level and duration of the immune response to GnRF with minimal injection site reactivity. It is used as an aid in the control of oestrus and oestrus-related behaviour in fillies and mares not intended for breeding.
Peptide-protein conjugate and proprietary adjuvant (immunostimulating complex); control of estrus and estrus-related behavior
Equity Oestrus Control Vaccine for Horses
WEB: https://www.pfizeranimalhealth.com.au/products/352/equityreg-oestrus-control-vaccine.aspx
The difference between single-dose and multi-dose Vaxigrip is that multi-dose Vaxigrip contains preservative thimoseral.
We still have not made it defined class since we still need to figure out how to represent multi-dose vs. single dose. The previous method discussed brief needs vetting. --YH
A mineral salt vaccine adjuvant that is composed of some aluminum compound.
a role inhers in a vaccine component that when added into a vccine formmulation, it can prevent the growth of bacteria or fungi that inadvertently may be introduced into the vaccine during administrating process or the manufacturing process.
P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.
The CFR requires that, with certain defined exceptions, preservatives must be added to mulitdose vials of vaccine. (P73 Chapter 6, Vaccine 5th edition by Plotkin, S. et al.)
A route of administration that located in the mouth
A route of administration that inject the material(such as vaccines, allergens) into the skin itself.
Recombinant ApxII, TbpB, CysL, OmlA(1), and OmlA(2) proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=421
Age at vaccination is the age of an experiment animal at the time of vaccination.
Theileria annulata vaccine by local veterinary institutes
Dose is a measurement data that measures the quantity of something that may be eaten by or administered to an organism, or that an organism may be exposed to. Quantities of nutrients, drugs, vaccines and toxins are referred to as doses.
obsolete on 2/1/2020, using the OBI dose term (OBI_0000984) instead.
A dose of a virulent pathogen used for a vaccine challenge process.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=393
Secondary vaccination is a vaccination that is performed immediately after the primary or the first vaccination.
Protozoan vaccine that is used to protect against Eimeria spp. (Eimeria) infection.
surface antigens from the zona pellucida
vaccine allergen is a material entity that is capable of stimulating a type-I hypersensitivity reaction in atopic individuals who has been vaccinated with a vaccine.
passive immunization that Immunity is transferred from mother to fetus through placental transfer of IgG or colostral transfer of IgA.
passive immunization using natural maternal antibody
chicken egg protein allergen is a vaccine allergen that is composed of chicken egg protein.
Egg protein may come from NCIS thesaurus egg - poultry, combination of minimal anatomy terminology and NCBI taxonomy... Eventually, this term chicken egg protein allergen may become a cross product of sevreal ontology terms.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=405
Vaccine component that is used as antigen to produce an immune responce protect against the specific pathogen or disease.
This is a modified or partial form of the virus, bacteria or the toxin that causes the disease against which the vaccine protects. The vaccine antigen is altered from its original form so it no longer causes disease but it can produce an immune response.(Vaccine components FactSheet of NCIRS)
To create this term for cover some other vaccines such as cancer vaccine and so on.
a cell culture residual in vaccine that is bovine albumin.
bovine albumin cell culture residual in vaccine
a cell culture residual in vaccine that is bovine serum.
bovine serum cell culture residual in vaccine
a vaccine stablizer that is based on monosodium glutamate.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=407
Infected blood from splenectomized calves
a cell culture residual in vaccine that is human albumin.
human albumin cell culture residual in vaccine
a cell culture residual in vaccine that is human serum.
human serum cell culture residual in vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=403
a vaccine stabilizer that is a polysorbate 20. It encourages the suspension of one liquid in another and has mild toxicity.
Potential Acute Health Effects: Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Reference: http://www.sciencelab.com/msds.php?msdsId=9926640
a vaccine emulsifier that uses polysorbate 80, also known as polyoxyethylene sorbitan monooleate or Tween(TM) 80.
WEB: http://www.wisegeek.org/what-is-polysorbate-80.htm
Tween 80 is an amber-colored, viscous liquid with a slightly bitter taste. The product is a derivative of sorbitol and oleic acid.
a cell culture residual in vaccine that is residual protein from cell culture.
vaccine residual protein from cell culture
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3095
a vaccine stabilizer that is specifically made by sorbitol.
Sorbitol, also known as glucitol, is a sugar alcohol that the human body metabolizes slowly. It can be obtained by reduction of glucose, changing the aldehyde group to a hydroxyl group. Sorbitol is found in apples, pears, peaches, and prunes. It is synthesized by sorbitol-6-phosphate dehydrogenase, and converted to fructose by succinate dehydrogenase and sorbitol dehydrogenase. Succinate dehydrogenase is an enzyme complex that participates in the citric acid cycle. (wikipedia)
A vaccine that is made of a TK-negative (TK -) and gI/gE-negative (gI/gE -) pseudorabies virus (PRV) mutant to protect pigs against Aujeszky's disease. Aujeszky's disease is also known as pseudorabies. It is a disease primarily of pigs and is caused by porcine herpesvirus 1. This disease is characterized by respiratory, reproductive and nervous signs.
gE- and thymidine kinase-deleted marker vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=389
a cell culture residual in vaccine that is sucrose albumin.
sucrose albumin cell culture residual in vaccine
A synthetic vaccine adjuvant that is derived from Xanthomonas campestris, has a pentasaccharide repeating unit structure, and its terminus contains a mannose moiety which acts as a toll-like receptor 2 agonist.
a cell culture residual in vaccine that is from yeast extract.
yeast extract cell culture residual in vaccine
a cell culture residual in vaccine that is yeast protein.
yeast protein cell culture residual in vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=410
Diphtheria-Tetanus-Pertussis-Haemophilus b vaccine
A Measles virus vaccine that is also used against Rubella virus infection.
A vaccine that protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, Hepatitis B, and Haemophilus influenzae type b.
Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=394
a bacterial vaccine against S. equi infection
a bacterial vaccine against Mycoplasma gallisepticum infection
Baculovirus recombinant E2 protein without emulsion
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=391
Pharyngeal mucosal route is an oral route of administration.
Chimera virus on NDV backbone; field trials in 2007
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=400
host survival to pathogen challenge after vaccination
a B. abortus vaccine that uses a conjugate vaccine format
a B. abortus vaccine that uses a recombinant vector.
Brucella abortus recombinant vector vaccine
A vaccine that protects against Herpes simplex virus type 1.
killed infectious bursal disease virus vaccine
live attenuated infectious bursal disease virus vaccine
An E. coli vaccine that uses a live mutant by knocking out one gene(s) from a wild type E. coli.
an E. coli vaccine that uses toxoid antigen
PMID: http://www.ncbi.nlm.nih.gov/pubmed/9682399
An E. coli vaccine that uses a recombinant vaccine vector to express an E. coli antigen(s)
recombinant vaccine vector E. coli vaccine
A DNA vaccine plasmid vector that has the plasmid label pBLUESCRIPT.
Davidson College - pBLUESCRIPT: Plasmids and Phages Combine For pBluescript [http://www.bio.davidson.edu/Courses/Molbio/MolStudents/spring2003/Keogh/plasmids.html]
Derived from pUC vectors; cross between phages and plasmids and therefore in a special category called "phagemids" (Davidson College - pBLUESCRIPT)
A DNA vaccine plasmid vector that has the plasmid label nkCMVint.
A pUC-18-based plasmid; also contains intron A and an SV40 polyadenylation termination signal sequence. It has a CMV promoter.
An E. coli vaccine against uropathogenic E. coli infections
An E. coli vaccine against extraintestinal pathogenic E. coli infections
extraintestinal pathogenic E. coli vaccine
An E. coli vaccine against enterohemorrhagic E. coli infections
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5555
For active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine. Flublok is approved for use in persons 18 years of age and older.
Live or inactivated gE-deleted marker vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=392
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5560
For active immunization of persons 4 years of age and older for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=390
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5564
For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is approved for use in persons 2 through 49 years of age
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5565
FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.FLUARIX QUADRIVALENT is approved for use in persons aged 6 months and older
a tetanus vaccine manusfactured by Sanofi Pasteur Inc. that is only for booster use (not recommended for primary immunization)
Tetanus Toxoid (for Boost use Only) by Sanofi Pasteur Inc
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=314
WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142732.pdf
Tetanus Toxoid vaccine (for Boost use Only) by Sanofi Pasteur Inc
a viral vaccine that is used to protect against fowl pox virus infection
Viral vaccine that is used to protect against Bovine herpesvirus 1 infection.
Theileria parva vaccine by local veterinary institutes
A DNA vaccine plasmid vector that has the plasmid label pDONR221. The plasmid length is 4762.
Addgene: http://www.addgene.org/vector-database/2394/
Invitrogen: http://tools.invitrogen.com/content/sfs/manuals/gateway_pdonr_vectors.pdf
pDONR221 Sequence: http://tools.invitrogen.com/content/sfs/vectors/pdonr221_seq.txt
A DNA vaccine plasmid vector that has the plasmid label pCN3. The plasmid promoter is CMV.
A DNA vaccine plasmid vector that has the plasmid label V1R.
A DNA vaccine plasmid vector that has the plasmid label pVAC1 3.0. The manufacturer is Invitrogen.
A contraceptive vaccine that has proven highly effective in deer and can be used to control populations.
Crude ZPA preparation; supplied to research groups only
A DNA vaccine plasmid vector that has the plasmid label pSin-CMV-Vac. The promoter is CMV.
A DNA vaccine plasmid vector that has the plasmid label pGACAG. The promoter is CAG and the antibiotics resistance gene is kanamycin.
A DNA vaccine plasmid vector that has the plasmid label pVCL1012. The promoter is HCMV and the manufacturer is Vical Inc.
A DNA vaccine plasmid vector that has the plasmid label pSCA1.
A DNA vaccine plasmid vector that has the plasmid label phCMV1. This plasmid is 4200 base pairs long, has a CMV promoter, contains kanamycin and neomycin antibiotics resistance genes, and is manufactured by Genlantis.
WEB: http://www.genlantis.com/faq-phcmv.html
A DNA vaccine plasmid vector that has the plasmid label pCJ-3. This plasmid has a CMV promoter and a kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His. This plasmid has a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pSecTag2 C. This plasmid is 5167 base pairs long, has a CMV promoter and ampicillin and zeocin resistance genes.
WEB: http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf
A DNA vaccine plasmid vector that has the plasmid label pBC12/CMV/IL-2.
NIH AIDS Reagent Program - pBC12/CMV/IL-2: [https://www.aidsreagent.org/reagentdetail.cfm?t=expression_vectors&id=159]
Derived from plasmid pBC12/CMV; expresses IL-2 (NIH AIDS Reagent Program - pBC12/CMV/IL-2). Its length is: 4732.
Cultured trophozoites, reduces disease and cyst shedding
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=432
The plant-based Newcastle disease virus vaccine is a Newcastle disease virus vaccine that is developed by Dow AgroSciences LLC. It uses technology discovered at Washington University. It is the first plant-made animal vaccine approved for sale in the United States.
HN recombinant produced in plant cell lines (registered but not on market)
plant-based Newcastle disease virus vaccine
A Measles-Mumps-Rubella vaccine that is manufactured by Sanofi Aventis.
A live attenuated quality of a bacterial vaccine strain.
obsolete bacterial vaccine organism live attenuated
A live attenuated quality of a virus vaccine strain.
obsolete viral vaccine organism live attenuated
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=399
A live attenuated vaccine that protects against Marek's disease virus.
live attenuated Marek's disease virus vaccine
A live attenuated viral vaccine that protects aganist Newcastle disease virus infection.
live attenuated Newcastle disease virus vaccine
an avian reovirus vaccine that using live attenauted reovirus.
Sporulated oocysts of several or all of the avian species
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=424
a feline panleukopenia virus vaccine where the virus used is live attenuated.
live attenuated feline panleukopenia virus vaccine
Megan Vac1 is a Salmoneela vaccine that consists of a double gene-deleted S. enterica serovar Typhimurium strain and is designed for protection of broilers to reduce Salmonella contamination.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=423
a bacterial vaccine vector that uses TB vaccine BCG as the vector.
an avian influenza vaccine that uses inactivated viral organism
a viral vaccine vector that uses a vesicular stomatitis virus (VSV) as the vector.
vesicular stomatitis virus vaccine vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=414
a parasite vaccine vector using a live attenuated Leishmania tarentolae strain.
autologous dendritic cell melanoma vaccine
obsolete vaccine-induced mouse immune response
WEB: http://www.ncbi.nlm.nih.gov/pubmed/21907709
a bacterial vaccine vector using a live attenuated Salmonella enterica strain SL3261.
Salmonella typhimurium SL3261 vaccine vector
WEB: http://www.ncbi.nlm.nih.gov/pubmed/21964456
a bacterial vaccine vector using a live attenuated Edwardsiella tarda strain EIB202
Edwardsiella tarda EIB202 vaccine vector
a vaccine vector that uses a parasite as the vector.
a bacterial vaccine against Yersinia ruckeri infection
WEB: http://www.ncbi.nlm.nih.gov/pubmed/23403993
a bacterial vaccine vector using a live attenuated Streptococcus gordonii vaccine vector.
WEB: http://www.ncbi.nlm.nih.gov/pubmed/16823926
a bacterial vaccine vector using a live attenuated Bordetella pertussis BPZE as a vaccine vector.
Bordetella pertussis BPZE vaccine vector
WEB: http://www.ncbi.nlm.nih.gov/pubmed/9767712
a bacterial vaccine vector using the HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae. This mutant lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector.
Actinobacillus pleuropneumoniae HS93Tox vaccine vector
an Avipox virus vaccine vector that uses a fowlpox virus as the vector
A Listeria monocytogenes vaccine vector that uses the highly attenuated LM1-2 strain
an Avipox virus vaccine vector that uses an attenuated canarypox virus strain
Poulet et al. 2007, PubMed PMID: 17227690.
WEB: http://en.wikipedia.org/wiki/Canarypox
a bacterial vaccine vector that uses an attenuated Vibrio cholerae strain
a viral vaccine vector that uses an avian paramyxovirus strain
avian paramyxovirus type 3 vaccine vector
a herpesvirus vaccine vector that uses a herpes simplex virus strain
an adenovirus vaccine vector that uses the simian adenovirus ChAd63 strain.
an orthopoxvirus vaccine vector that uses an attenuated Raccoon poxvirus strain
Live temperature-sensitive mutant strain; eye drop administration
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=418
A herpesevirus vaccine vector that uses an established live-virus vaccine against Aujeszky's disease of swine, pseudorabies virus (PrV) strain Bartha (PrV-Ba), to serve as vector.
Suid herpesvirus 1 strain Bartha vaccine vector
pseudorabies virus strain Bartha vaccine vector
an adenovirus vaccine vector that uses a porcine adenovirus 3 strain
a viral vaccine vector that uses a poliovirus strain
Live submucosal vaccine; deletions in aroA gene
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=416
an adenovirus vaccine vector that uses a chimpanzee adenovirus strain
a viral vaccine vector that uses a measles virus strain
a viral vaccine vector that uses a Coxsackievirus strain
a poxvirus vaccine vector that uses an attenuated Oka varicella virus strain
Human herpesvirus 3 strain Oka vaccine vaccine
a viral vaccine vector that uses a NewCastle virus strain
a viral vaccine vector that uses a myxoma virus strain
a viral vaccine vector that uses a Maraba virus strain
a bacterial vaccine vector that uses an attenuated Mycobacterium smegmatis strain
a bacterial vaccine vector that uses an attenuated Lactobacillus gasseri strain
A Herpes simplex virus vaccine vector that uses a virus type 1 strain
a bacterial vaccine vector that uses an E. coli strain
Reference: http://www.spaquaculture.com/default.aspx?pageid=553
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=415
a viral vaccine vector that uses a duck enteritis virus strain
a herpesvirus vaccine vector that uses a CMV virus strain
a bacterial vaccine vector that uses a Salmonella typhi strain
a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is a natural host for the vector.
a bacterial vaccine against Mycoplasma synoviae infection
a recombinant vector vaccine that uses a homologous vector, i.e., when the target species of the vaccine is not one of the natural hosts for the vector.
an adenovirus vaccine vector that uses an Adenovirus serotype 5 strain.
an adenovirus vaccine vector that contains a deletion of the gp64 gene. As a result of the deletion, this vector is unable to propagate infection from cell to cell, and this defect results from both a severe reduction in the production of budded virions and the absence of GP64 on virions.
protozoan vaccine that is used to protect against Giardia intestinalis infection
a viral vaccine vector that uses a baculovirus as the vector
Chlamydia bacterial vaccine against C. abortus infection
an adenovirus vaccine vector that uses a complex adenovirus as the vector strain.
an adenovirus vaccine vector that uses a human adenovirus as the vector strain.
a viral vaccine vector that uses a murine leukemia virus as the vaccine vector
WEB: http://en.wikipedia.org/wiki/Murine_leukemia_virus
WEB: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr58e0821a1.htm
CDC recommendation of the use of Influenza A (h1N1) 2009 vaccine
A population group that have priority for vaccination when a vaccine is first available.
Chimera H5N3 virus, inactivated in oil-based adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=401
a vaccinia vaccine vector that uses the highly attenuated NYVAC as vector
A highly attenuated vaccinia virus strain, NYVAC (vP866), was derived from a plaque-cloned isolate of the Copenhagen vaccine strain by the precise deletion of 18 open reading frames (ORFs) from the viral genome. Source: http://www.ncbi.nlm.nih.gov/pubmed/1566575
NCBI Taxonomy ID: 10249 (for Vaccinia virus Copenhagen)
passive immunization by injecting a recipient with pre-made antibody, antitoxin, epitope, etc.
passive immunization by injecting pre-made immune element
A vaccine used to increase the fecundity in breeding ewes. Ovastim increases the number of multiple ovulations and therefore the number of multiple births.
WEB: http://www.virbac.co.nz/p-virbacnzpuben/display.aspx?srv=p-virbacnz&typ=pub&lang=en&cmd=view&style=styles/specie.xsl&select=PRODUCT[@ID$eq$PRODUCT_264]&affp=&
Canarypox virus-vectored vaccine (HA and F antigens)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=408
persons living with or providing care for infants aged <6 months
health-care and emergency medical services personnel
persons aged 25--64 years with medical conditions at higher risk for influenza-related complications
a viral vaccine vector that uses a retroviral strain
Inactivation is a processual entity that produces inactive material.
a retroviral vaccine vector where a Rous sarcoma virus (a retrovirus) is used
Vaccine that protects against Lawsonia intracellularis infection.
a poxvirus vaccine vector that uses a swinepox virus as the vector
a vaccinia virus vector that uses the Modified Vaccinia Ankara (MVA) virus.
Modified Vaccinia Ankara (MVA) virus vaccine vector
a poxvirus vaccine vector that uses an ORF virus which is a parapoxvirus.
a vaccinia virus vector that uses the MVTT vaccine strain as the vector. MVTT is an attenuated vaccine strain.
a fertility vaccine that enhance fertility in sheep.
Linked to human serum albumin; increased ovulation/twinning
WEB: http://www.journals.elsevierhealth.com/periodicals/anirep/article/PII0378432093901125/abstract
A poxvirus vaccine vector that uses an attenuated lumpy skin disease virus as the vector.
a viral vaccine vector that uses a bovine parainfluenza virus strain as vector
bovine parainfluenza virus vaccine vector
Gametocyte antigen(s); transmission blocking through maternal antibody transfer
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=436
Bordetella bacterial vaccine against infection of B. avium
a poxvirus vaccine vector that uses an attenuated capripoxvirus strain as the vaccine vector
Survival of live vaccine inside host is a process that represents the survival of a live vaccine inside its host. The time of the survival is often important for the success of the live vaccine.
Persistence of vaccine induced immune response is a processual entity that indicates the persistence of an immune reponse induced by a vaccine in a vaccinated host.
persistence of vaccine induced immune response
a bacterial vaccine vector that uses a Corynebacterium pseudotuberculosis strain as the vaccine vector
Corynebacterium pseudotuberculosis vaccine vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=431
a viral vaccine vector that uses a rhabdovirus-based viral strain as the vaccine vector
a recombinant vaccine vector that uses Saccharomyces cerevisiae as the vaccine vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=406
a viral vaccine vector that uses a Venezuelan equine encephalitis virus strain as the vaccine vector
Venezuelan equine encephalitis virus vaccine vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=753
Active immunization of adults 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella infection.
a canarypox vaccine vector that uses an attenuated canarypox virus strain ALVAC. The ALVAC vector is a canarypox virus clone obtained after four rounds of plaque purification of a strain from a vaccine for canaries.
WEB: http://www.ncbi.nlm.nih.gov/pubmed/17227690
an adenovirus vaccine vector that is not able to replicate.
non-replicating adenovirus accine vector
a bacterial vaccine against A. pleuropneumoniae infection
an adenovirus vaccine vector that is able to replicate.
assay of CFU reduction in liver is a CFU reduction assay that is measured using the extracted liver as the tissue for isolation of infected pathogens.
assay of CFU reduction in lung is a CFU reduction assay that is measured using the extracted lung as the tissue for isolation of infected pathogens.
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella abortus infection.
live attenuated Brucella abortus vaccine
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella melitensis infection.
live attenuated Brucella melitensis vaccine
live attenuated Brucella vaccine is a live attenuated vaccine that protects against a Brucella suis infection.
S48 strain with a lost ability to form cysts after passages in mice
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=429
vaccine viability is a viability of a vaccine organism.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=395
a recombinant vaccine vector that uses a fungus as the vaccine vector
a poxvirus vaccine vector that uses an avipox virus as the vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=139
Brucella DNA vaccine encoding chimera BLSOmp31
vaccine being viable is a vaccine viability that indicates a vaccine uses live organism.
a poxvirus vaccine vector that uses an orthopox virus as the vector
A cytokine vaccine adjuvant that contains IL-12.
Vaccine that protects against Piscirickettsia salmonis infection.
An E. coli vaccine against enterotoxigenic E. coli infections
B. abortus L7/L12 is a B. abortus subunit vaccine using L7/L12 that is formed by recombinant Human Serum Albumin (HAS)-L7/L12 fusion protein.
Brucella abortus Human serum albumin (HAS)-L7/L12
An E. coli vaccine against Shiga toxin-producing E. coli (STEC) infections
WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2238053/
a vaccine against avian pathogenic Escherichia coli (APEC) infection, a major problem for the poultry industry in the world.
an E. coli vaccine against O157 E. coli strain infections
Extracted ApxI, ApxII, ApxIII, and outer membrane proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=422
PUREVAX Ferret Distemper is a lyophilized ferret vaccine of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=409
specification of time interval after vaccination for challenge is a plan specification that specifies the time interval after vacciation for challenge
specification of vaccination-challenge interval
pathogen challenge protocol is a protocol that is used for a pathogen challenge process.
A titer measurement of viable bacterial or fungal numbers. It equals to a reduction of a CFU count from another CFU count. This term is often used as a measurement of a vaccine protection study.
intraperitoneal pathogen challenge is a pathogen challenge process that occurs in the intraperitoneal site of a host.
a vaccination process that occurs in the intraperitoneal route
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4329
KLH-s-FimH1-25 with CFA and then IFA vaccine
an E. coli subunit vaccine that uses E. coli FimH adhesin protein as teh antigen, and uses the complete Freund's adjuvant (CFA) in the first vaccination and the incomplete Freund's adjuvant (IFA) in the boost vaccination.
PMID: http://www.ncbi.nlm.nih.gov/pubmed/9110982
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4330
E. coli FimH with CFA and then IFA vaccine
E. coli DNA vaccine is a DNA vaccine that protects against an E. coli infection.
a vaccine organism that is a specific strain
B. melitensis bp26 and omp31 deletion vaccine is a Brucella melitensis vaccine that has double deletions of bp26 and omp31.
B. melitensis Rev. 1 with bp26 and omp31 deletions
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=779
Brucella melitensis Rev. 1 with bp26 and omp31 deletions vaccine
pCIOmp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pCI plasmid.
pTargeTomp31 is a B. melitensis DNA vaccine expressing Omp31 that uses the pTargeT mammalian expression system vector (Promega, USA).
B. abortus L7/L12 fused to MBP is a B. abortus subunit vaccine using L7/L12 that uses recombinant L7/L12 fused on maltose binding protein MBP.
Brucella abortus L7/L12 fused to MBP vaccine
inactivated influenza vaccine is an inactivated viral vaccine that targets at influenza viral infections.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=426
live attenuated influenza vaccine is a live attenuated vaccine that protects against influenza viral infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=419
a vaccine role that is borne by an organism strain serving as a vaccine
Peptide conjugated to keyhole limpet hemocyanin in mycobacterium-oil adjuvant (AdjuVac); contraceptive vaccine to control wildlife
WEB: http://www.aphis.usda.gov/wildlife_damage/nwrc/research/reproductive_control/gonacon.shtml
a contraceptive vaccine that is used in wildlife population
In ovo delivery using proprietary platform injection system
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=425
A data set that represents a set of data for a list of variables (e.g., vaccination dose) for the data analysis of an vaccine investigation study.
He Y, Xiang Z, Todd T, Courtot M, Brinkman R, Zheng J, Stoeckert CJ, Malone J, Rocca-Serra P, Sansone S, Fostel J, Soldatova LN, Peters B, Rutternberg A. Ontology representation and ANOVA analysis of vaccine protection investigation. Proceeding of Bio-Ontologies 2010: Semantic Applications in Life Sciences, ISMB, July 9-10, 2010. Boston, MA, USA. Full length paper. URL: http://www.hegroup.org/docs/ANOVA_Vaccine_usecase_camera.pdf
Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.
a vaccination that occurs in the intramuscular route.
A measurement datum that represents a vaccine strain. Different strains can be represented using distinct digital numbers.
A measurement datum that represents vaccine viability. 0 = live; 1 = irradiated; 2 = killed.
A measurement datum that indicates the usage of a vaccine adjuvant. Different digital numbers can be used to represent different adjuvants.
A measurement datum that represents a specific protective antigen used in a vaccine. The antigen can be represented by a described digit.
A measurement datum that represents a specific mutated gene from a vaccine strain. The mutated can be represented by a described digit.
A measurement datum that represents a specific mouse strain used for vaccination. Different strains can be represented using discretized digitals. For example, 0 = BALB/c; 1 = CD1; 2 = mixed/outbred; 3 = C57BL/6; 4 = OF1; 5 = 129/Sv; 6 = Swiss albino.
A measurement datum that represents the biological sex of an animal. The result can be represented using a discretized digit, for example, 0 = female; 1 = male.
A measurement datum that represents a specific route (e.g., i.p.) used for vaccination. Different routes can be represented using discretized digitals. 0 = IP; 1 = PO; 2 = SC; 3 = IM; 4 = IN; 6 = IG; 7 = IV; 8 = ID.
A vaccination dose that is used with the unit of colony forming units (CFU).
An age range at vaccination that represents the animal age (unit: day) at the time of vaccination.
A measurement datum that represents a specific pathogen strain used for animal challenge study. Different pathogen strains can be represented using discretized digitals.
A measurement datum that represents a specific pathogen used for animal challenge study. Different pathogens can be represented using discretized digitals.
Native fucose-mannose-ligand antigen complex
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=435
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=411
A challenge dose that is represented with the unit of colony forming units (CFU).
A measurement datum that represents a length of days as the interval between a vaccination and a challenge in a specific vaccine protection study.
A colony forming unit (CFU) from the sample of mouse spleen.
A reduction of colony forming unit that was measured with the unit of colony forming units (CFU) from the sample of mouse spleen.
A measurement datum that represents a type of vaccine protection efficacy as an outcome of a vaccine protection study. The result can be represented as a digit, for example, 0 = no protection, and 1 = protection (determined by a p-value cutoff).
A Chlamydia bacterial vaccine against Chlamydia trachomatis infection
B. abortus BLS-L7/L12 is a B. abortus subunit vaccine using L7/L12 that is made as a recombinant BLS-L7/L12 fusion protein vaccine.
recombinant Brucella BLS-L7/L12 fusion protein vaccine
recombinant Brucella lumazine synthase and L7/L12 fusion protein vaccine
vaccine protection efficacy measurement is an assay that measures the protection efficayc of a vaccine.
a subunit vaccien that uses LPS as protective antigen
viral vaccine that is used to protect against African swine fever virus infection
A viral vaccine that protects against infection with Foot-and-mouth disease virus.
Bacterial vaccine that uses inactivated bacterial organism.
an anti-reproductive vaccine for cattle. The vaccine is based on the established principle that antibodies to the hypothalamic releasing hormone, gonadotrophin releasing hormone (GnRH) block the action of GnRH on pituitary secretion of luteinizing hormone and follicle stimulating hormone, leading to gonadal atrophy in mammals. The vaccine comprises an immunogenic GnRH:ovalbumin conjugate formulated in a novel double adjuvant system and is administered in a two-dose treatment regimen.
LHRH peptide conjugated to ovalbumin; oil emulsion adjuvant
WEB: http://www.ncbi.nlm.nih.gov/pubmed/1370000
A viral vaccine that protects against infection with Lymphocytic choriomeningitis mammarenavirus
obsolete Lymphocytic choriomeningitis mammarenavirus vaccine
Bacterial vaccine that is live and attenuated.
Vaccine that is used for animals (excluding humans), for example, pet, domestic, wildlife, and livestock animals.
a B. abortus vaccine that uses subunit antigen
A viral vaccine that protects aganist Newcastle disease virus infection.
A viral vaccine that protects against infection with Viral hemorrhagic septicemia virus
Viral hemorrhagic septicemia virus vaccine
A viral vaccine that protects against infection with Human herpesvirus 5.
A viral vaccine that protects against infection with Coxsackievirus
A protozoan vaccine that protects against infection with Schistosoma japonicum
Vaccine that protects against Treponema pallidum infection.
A vaccine that protects against Leishmania major.
A vaccine preparation that results in the generation of a viral vaccine
A vaccine preparation that results in the generation of a protozoan vaccine
A vaccine preparation that results in the generation of a fungal vaccine
A microbial derivative vaccine adjuvant compsed of CpG DNA.
An emulsion vaccine adjuvant that is a stable oil-in-water emulsion.
A synthetic vaccine adjuvant named RC529 that is a lipid A mimetic.
An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2).
An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions.
A cholera toxin derived vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae.
cholera toxin B subunit vaccine adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1115
- Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 weeks through 5 years of age (prior to the 6th birthday). - Active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A In children 6 weeks through 5 years of age (prior to the 6th birthday). - Active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children 6 years through 17 years of age (prior to the 18th birthday). - Active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults 18 years of age and older. - Limitations: Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine.
SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and invasive disease caused by these serotypes (including sepsis, meningitis, bacteraemic pneumonia, pleural empyema and bacteraemia).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1114
WEB: http://www.gsk.ca/english/docs-pdf/product-monographs/Synflorix.pdf
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1113
For active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 when administered to individuals 2 months to 55 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1116
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1117
An aqueous formula of the synthetic vaccine adjuvant RC529.
RC529-AF can be obtained from Corixa Corporation (Seattle, WA).
RC529 vaccine adjuvant in an aqueour formulation
A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595.
3-O-deacylated monophosphoryl lipid A vaccine adjuvant
An E. coli LT toxin derived vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant.
LTK63 is an enzymatically inactive mutant of the heat-labile enterotoxin of Escherichia coli. It can be used as a potent mucosal adjuvant.
is a bacterial toxin (usually an exotoxin) whose toxicity has been weakened or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained.
WEB: http://en.wikipedia.org/wiki/Toxoid
capsular polysaccharide of pathogen organism as vaccine component
a subunit vaccine that uses polysaccharide as protective antigen
polysaccharide of pathogen organism as vaccine component
The specification of an objective to prevent a disorder.
The specification of an objective to ameliorate a disorder.
A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum.
killed Corynebacterium parvum vaccine adjuvant
An emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate.
A synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen.
A liposome-based vaccine adjuvant that have a positive surface charge.
A tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina.
A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.
monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.
A combination vaccine adjuvant that is a combination of 50 ug of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 ug of aluminium salt.
An emulsion vaccine adjuvant which is an emulsion plus DDA.
A tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega.
A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria.
WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-720-@/view-1044-seproduit.html?menuid=,979,&lang=en
A Montanide vaccine adjuvant that is a mineral oil adjuvant.
A Montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion.
WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-51-@/view-1042-seproduit.html?menuid=,979,&lang=en
An emulsion vaccine adjuvant developed by Montanide.
An E. coli LT toxin derived vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin.
B subunit of E. coli heat-labile enterotoxin
A synthetic vaccine adjuvant with the tradename Polygen.
URL: http://www.mvp-technologies.com/adjuvants/Polygen%20Final%20Technical%20Bulletin.pdf
Role that inheres in an organism that is the target of a vaccine administration (vaccination process).
A role that represents a target (i.e., some disorder) of immunization.
obsolete immunization target role of pathogen
obsolete immunization target role of bacterial pathogen
obsolete immunization target role of viral pathogen
obsolete immunization target role of parasite pathogen
obsolete immunization target role of fungal pathogen
A carbohydrate vaccine adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models.
A combination vaccine adjuvant that suspension of 1-2um ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens.
A synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino beta-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ).
N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate
A synthetic vaccine adjuvant that is N, N-dioctadecyl-N', N'-bis(2-hydroxyethyl) propanediamine (Avridine).
N, N-dioctadecyl-N', N'-bis( 2-hydroxyethyl) propanediamine
A calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts.
A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein.
cholera toxin A1-subunit-ProteinA D-fragment fusion protein
A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide.
A carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose.
A combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8).
A cytokine vaccine adjuvant that includes GM-CSF.
A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant.
An IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma.
recombinant hIFN-gamma/Interferon-g vaccine adjuvant
A cytokine vaccine adjuvant that includes IL-1b.
A cytokine vaccine adjuvant that includes IL-2.
A cytokine vaccine adjuvant that includes IL-7 and induces Th1/Th2/Th17 mixed immune profile.
A synthetic vaccine adjuvant that includes loxoribine which is a guanosine analog derivatized at position N7 and C8, and activates TLR-7.
An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion.
A liposome-based vaccine adjuvant that consists of liposomes containing the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE).
A synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP.
A synthetic vaccine adjuvant called murapalmitine.
Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl
A synthetic vaccine adjuvant that includes an MDP analog called D-Murapalmitine.
Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl
A synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase.
A synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen.
non-ionic surfactant vesicles vaccine adjuvant
A synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate.
A synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates.
A saponin vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. Specifically, it is an acylated 3, 28-bisdesmodic triterpene glycosides (1,3) or "saponin" with a molecular formula of C92O46H148 and molecular weight of 1990 Da. QS-21 is one of the active fractions of the bark of Chilean tree, Quillaja saponaria, purified using a reverse-phase chromatography (RP-HPLC).
An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation.
An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel.
A cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β.
An emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA).
An emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen.
SPT (Antigen Formulation) vaccine adjuvant
A synthetic vaccine adjuvant stearyl tyrosine is considered an "organic equivelant" of aluminum hydroxide.
A synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP).
A synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE.
An emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA.
An emusion vaccine adjuvant that contains alpha-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion.
An E. coli LT toxin derived vaccine adjuvant that is a mutant form of E.coli heat-labile toxin.
A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin.
E. coli heat-labile toxin vaccine adjuvant
An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants.
amorphous aluminum hydroxyphosphate sulfate adjuvant
recombinant Brucella abortus Bfr protein vaccine
Brucella abortus subunit vaccine using Bfr
Brucella abortus subunit vaccine using Omp16
B. melitensis DNA vaccine encoding Bp26 and Tf
Brucella melitensis DNA vaccine encoding Bp26 and Tf
A synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline.
A synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod.
An emulsion vaccine adjuvant containing 2.5% squalene.
Microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria.
A synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA.
WEB: http://en.wikipedia.org/wiki/Polyinosinic:polycytidylic_acid
A particulate antigen delivery system vaccine adjuvant that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.
ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431.
A saponin vaccine adjuvant that is made from highly purified saponins.
WEB: http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx
A particulate antigen delivery system vaccine adjuvant that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.
albumin-heparin microparticles vaccine adjuvant
A combination vaccine adjuvant and is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion.
A cytokine vaccine adjuvant that includes B7-2.
A synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines.
WEB: http://en.wikipedia.org/wiki/Bupivacaine
A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid.
cationic liposome-DNA complex JVRS-100 vaccin adjuvant
A synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations.
A synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs.
Polyester poly (DL-lactide-co-glycolide)
DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant
A cytokine vaccine adjuvant that uses the adjuvant effect of cytokine IL-15.
A liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs).
Immunoliposomes Containing Antibodies to Costimulatory Molecules
immunoliposomes vaccine adjuvant containing antibodies to costimulatory molecules
An E. coli LT toxin derived vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala -> Arg in position 72 of the A subunit.
A microbial derivative vaccine adjuvant containing MPL and squalene.
a vaccine preservative that contains formaldehyde.
WEB: http://www.mja.com.au/public/issues/184_04_200206/eld10500_fm.pdf
A microbial derived vaccine adjuvant made of E112K mC, a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112.
non-toxic mutant E112K of Cholera Toxin mCT-E112K
non-toxic mutant E112K of Cholera Toxin mCT-E112K vaccine adjuvant
A microbial derivative vaccine adjuvant that is derived from cholera toxin.
A combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic(R) L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)].
A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus.
Sendai Proteoliposomes, Sendai-containing Lipid Matrices
Sendai Proteoliposomes, Sendai-containing Lipid Matrices vaccine adjuvant
A synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP).
N-acetyl muramyl-L-threonyl-D-isoglutamine
threonyl muramyl dipeptide (TMDP) vaccine adjuvant
A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded.
A vaccine adjuvant that contains active cytokine compound.
A vaccine adjuvant that is composed of differnt compounds under more than one category.
A vaccine adjuvant that serves as a particulate antigen delivery system.
particulate antigen delivery system vaccine adjuvant
A vaccine adjuvant that contains synthetic material.
A vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface.
WEB: http://www.citt.ufl.edu/team/sepulveda/html/en_tensioactivos.htm
A vaccine adjuvant that is primarily composed of carbohydrates.
A cytokine vaccine adjuvant that includes IFN-gamma.
a role that is inherenced in a gene that can be mutated in a virulent pathogen, leading to an attenuated strain serving as a live attenuated vaccine strain.
bacterial vaccine that is used to protect against Clostridium perfringens infection
A viral vaccine that protects against infection with CCHF virus
Crimean-Congo Haemorrhagic Fever vaccine
A viral vaccine that protects against infection with Caprine herpesvirus type 1 virus
an inactivation vaccine that is prepared by heat inactivation.
an inactivation vaccine that is prepared by irradiation inactivation.
an inactivation vaccine that is prepared by H2O2 inactivation.
an inactivation vaccine that is prepared by formalin inactivation.
A vaccine prepraration process that is performed by H2O2 inactivation of virulent pathogen.
inactivated vaccine preparation using H2O2 inactivation
an organismal quality that indicates an organism (e.g., human) is not yet immunized against a disease.
an organismal quality that indicates an organism (e.g., human) is immunized against a disease through vaccination with a licensed vaccine.
immunized by vaccination with a licensed vaccine
an organism that is vaccinated with a vaccine
A Streptococcus vaccine against Streptococcus agalactiae infection.
an organismal quality that indicates an organism (e.g., human) is vaccinated with a vaccine.
an organismal quality that indicates an organism (e.g., human) is unvaccinated with any vaccine.
a vaccinated quality that indicates an organism is vaccinated with a licensed vaccine.
a unvaccinated quality that indicates an organism has not been vaccinated with a licensed vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3066
an organism that is immunized for a disease
A viral vaccine that protects against infection with Rabbit hemorrhagic disease virus
rabbit hemorrhagic disease virus vaccine
an organism that is unvaccinated with a vaccine
A bacterial gene from Actinobacillus pleuropneumoniae.
A vaccine that protects against Trypanosoma cruzi.
A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi CRP-10 protein.
Trypanosoma cruzi DNA vaccine encoding CRP-10
A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G2 protein.
Trypanosoma cruzi DNA vaccine encoding G2
A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi G4 protein.
Trypanosoma cruzi DNA vaccine encoding G4
A T. cruzi DNA vaccine that uses a DNA plasmid expressing T. cruzi TSA-1 protein.
Trypanosoma cruzi DNA vaccine encoding TSA-1
A T. cruzi DNA vaccine that uses a DNA plasmid pGFP expressing T. cruzi TSA-1 protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=811
A T. cruzi subunit vaccine that uses T. cruzi PAR1 protein as protective antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=806
A T. cruzi subunit vaccine that uses T. cruzi PAR2 protein as protective antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=810
A T. cruzi vaccine that uses attenuated Salmonella to express T. cruzi Cruzipain protein.
T. cruzi vaccine using attenuated Salmonella expressing T. cruzi Cruzipain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=804
Trypanosoma cruzi vaccine using attenuated Salmonella expressing Trypanosoma cruzi Cruzipain
A T. cruzi vaccine that uses Sendai virus vector to express T. cruzi amastigote surface protein-2.
T. cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=802
Trypanosoma cruzi vaccine using Sendai virus vector expressing amastigote surface protein-2
a vaccine that contains two or more individual vaccines.
a cocktail vaccine that contains both subunit vaccine and inactivated whole organism vaccines.
cocktail vaccine containing subunit vaccine and inactivated whole organism vaccine
a prime-boost vaccine with DNA vaccine priming that contains a subunit vaccine for boosting
vaccine containing DNA vaccine for priming and subunit vaccine for boosting
a prime-boost vaccine with a DNA vaccine priming that contains a Ad vector vaccine for boosting
vaccine containing DNA vaccine for priming and Ad vector vaccine for boosting
a conjugate vaccine that conjugate more than one open reading frames of protective antigens or conjugate a protective antigen to a carrier protein.
An example of fusion protein vaccine is Mtb72f fusion protein vaccine. Reference: PubMed: 15187142.
A Brucella gene that is from B. melitensis.
A bacterial gene that is from Bacillus anthracis.
A bacterial gene that is from Listeria monocytogenes.
A bacterial gene that is from Mycobacterium avium.
A bacterial gene that is from Staphylococcus aureus.
A bacterial gene that is from Aeromonas hydrophila.
A bacterial gene that is from Bordetella bronchiseptica.
A bacterial gene that is from Aeromonas salmonicida.
A bacterial gene that is from Bordetella pertussis.
A bacterial gene that is from Borrelia burgdorferi.
A bacterial gene that is from Burkholderia pseudomallei.
A bacterial gene that is from Edwardsiella ictaluri.
A bacterial gene that is from Edwardsiella tarda.
A bacterial gene that is from Francisella tularensis.
A bacterial gene that is from Mannheimia haemolytica.
A bacterial gene that is from Mycoplasma gallisepticum.
A bacterial gene that is from Neisseria meningitidis.
A bacterial gene that is from Pasteurella multocida.
A bacterial gene that is from Salmonella Typhi.
A bacterial gene that is from Salmonella Gallinarum.
A bacterial gene that is from Salmonella Typhimurium.
A bacterial gene that is from Salmonella Enteritidis.
A bacterial gene that is from Vibrio cholerae.
A viral gene that is from Bovine herpesvirus 1.
A bacterial gene that is from Yersinia enterocolitica.
A bacterial gene that is from Yersinia pestis.
A bacterial gene that is from Yersinia pseudotuberculosis.
A bacterial gene that is from Yersinia ruckeri.
A viral gene that is from Bovine Respiratory Syncytial Virus.
A viral gene that is from Classical swine fever virus.
A viral gene that is from Equid herpesvirus 1.
A viral gene that is from Feline herpesvirus 1.
A viral gene that is from Feline immunodeficiency virus.
A viral gene that is from Feline infectious peritonitis virus.
Feline infectious peritonitis virus gene
A viral gene that is from Gallid herpesvirus 1.
A viral gene that is from Hepatitis B virus.
A viral gene that is from Human herpesvirus 1.
A viral gene that is from Human metapneumovirus.
A viral gene that is from Human Respiratory Syncytial Virus.
A viral gene that is from Infectious Hematopoietic Necrosis Virus.
Infectious Hematopoietic Necrosis Virus gene
A viral gene that is from Porcine respiratory and reproductive syndrome virus.
Porcine respiratory and reproductive syndrome virus gene
A viral gene that is from Pseudorabies virus.
A viral gene that is from Simian Immunodeficiency Virus.
A viral gene that is from Tick-borne Encephalitis Virus.
A viral gene that is from West Nile virus.
A viral gene that is from Western equine encephalomyelitis virus.
Western equine encephalomyelitis virus gene
A protozoan gene that is from Leishmania donovani.
A Plasmodium gene that is from Plasmodium berghei.
A Plasmodium gene that is from Plasmodium yoelii.
A protozoan gene that is from Toxoplasma gondii.
A viral gene that is from Human herpesvirus 2.
A viral vaccine that protects against infection with Rinderpest virus
bacterial vaccine that is used to protect against Erysipelothrix rhusiopathiae infection
protozoan vaccine that is used to protect against Tritrichomonas suis infection
viral vaccine that is used to protect against Orf Virus infection
Vaccine that used for immunizing fishes.
viral vaccine that is used to protect against Fowlpox virus infection
Vaccine that used for immunizing carnivora.
Vaccine that used for immunizing cat (felis catus).
Vaccine that used for immunizing cattle.
Vaccine that used for immunizing dog (Canis familiaris).
Vaccine that used for immunizing chicken.
Vaccine that used for immunizing catfish.
Vaccine that used for immunizing gray wolf.
Vaccine that used for immunizing parrot.
Vaccine that used for immunizing sei whale.
Vaccine that used for immunizing salmoninae (tourts, salmons & chars).
Vaccine that used for immunizing turkey.
The objective that intends to produce vaccine via the vaccine preparation process.
A viral vaccine that protects against infection with African horse sickness virus
viral vaccine that is used to protect against Pigeonpox virus infection
A viral vaccine that protects against infection with Borna disease virus
A viral vaccine that protects against infection with Caprine herpesvirus 1
viral vaccine that is used to protect against Equid herpesvirus 1 infection
viral vaccine that is used to protect against Feline herpesvirus 1 (Felid herpesvirus 1) infection
Viral vaccine that is used to protect against Gallid herpesvirus 1 infection
viral vaccine that is used to protect against Canine adenovirus type 1 (Canine adenovirus 1) infection
viral vaccine that is used to protect against Canine Adenovirus Type 2 (Canine adenovirus 2) infection
viral vaccine that is used to protect against Bovine papillomavirus infection
viral vaccine that is used to protect against Avian Polyomavirus infection
viral vaccine that is used to protect against Mink enteritis virus infection
viral vaccine that is used to protect against Porcine parvovirus infection
viral vaccine that is used to protect against Porcine rotavirus infection
viral vaccine that is used to protect against Equine rotavirus infection
viral vaccine that is used to protect against Infectious Bursal Disease Virus (IBDV) infection
viral vaccine that is used to protect against Eastern Equine Encephalitis Virus infection
Eastern Equine Encephalitis Virus vaccine
viral vaccine that is used to protect against VEE Virus (Venezuelan equine encephalitis virus) infection
viral vaccine that is used to protect against Equine arteritis virus infection
viral vaccine that is used to protect against Bovine viral diarrhea virus 1 infection
viral vaccine that is used to protect against Infectious Bronchitis Virus (IBV) infection
viral vaccine that is used to protect against Bovine coronavirus infection
viral vaccine that is used to protect against Feline infectious peritonitis virus infection
Feline infectious peritonitis virus vaccine
viral vaccine that is used to protect against Transmissible gastroenteritis virus infection
Transmissible gastroenteritis virus vaccine
NCT: https://clinicaltrials.gov/ct2/show/NCT00023647
obsolete Bovine Parainfluenza 3 Virus vaccine
viral vaccine that is used to protect against Bovine Respiratory Syncytial Virus infection
Bovine Respiratory Syncytial Virus vaccine
viral vaccine that is used to protect against Feline immunodeficiency virus infection
viral vaccine that is used to protect against Feline calicivirus infection
viral vaccine that is used to protect against Chicken Anemia Virus infection
viral vaccine that is used to protect against Porcine respiratory and reproductive syndrome virus (Porcine reproductive and respiratory syndrome virus) infection
Porcine respiratory and reproductive syndrome virus vaccine
Vaccine that protects against Riemerella anatipestifer infection.
viral vaccine that is used to protect against Avian Reovirus (Avian orthoreovirus) infection
viral vaccine that is used to protect against avian pneumovirus (avian metapneumovirus) infection
viral vaccine that is used to protect against Bluetongue virus infection
viral vaccine that is used to protect against Turkey hemorrhagic enteritis virus (Turkey adenoirus 3) infection
Turkey hemorrhagic enteritis virus vaccine
viral vaccine that is used to protect against Canarypox virus infection
viral vaccine that is used to protect against Psittacid herpesvirus 1 infection
A vaccine that protects against infection with Mycobacterium bovis
viral vaccine that is used to protect against Infectious salmon anemia virus infection
An Edwardsiella bacterial vaccine that is used to protect against Edwardsiella ictaluri infection
viral vaccine that is used to protect against Avian Encephalomyelitis Virus infection
Vaccine that protects against Mannheimia haemolytica infection.
viral vaccine that is used to protect against Porcine circovirus 2 infection
viral vaccine that is used to protect against Duck enteritis virus (Anatid herpesvirus 1) infection
viral vaccine that is used to protect against Canine parainfluenza virus infection
viral vaccine that is used to protect against Avian Paramyxovirus infection
viral vaccine that is used to protect against Duck hepatitis virus 1 (Duck hepatitis A virus) infection
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1557
Canary Pox Modified Live Virus Vaccine (USDA: 1623.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2092
Pigeon Pox Live Virus Vaccine (USDA: 1881.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2093
Pigeon Pox Live Virus Vaccine (USDA: 1881.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2094
Pigeon Pox Live Virus Vaccine (USDA: 1881.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2111
Quail Pox Live Virus Vaccine (USDA: 18E1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1925
Fox Encephalitis Killed Virus Vaccine (USDA: 1635.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1967
Mink Distemper Modified Live Virus Vaccine (USDA: 1451.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1968
Mink Distemper Modified Live Virus Vaccine (USDA: 1451.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1969
Mink Distemper Modified Live Virus Vaccine (USDA: 1451.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1972
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1766
Feline calicivirus Killed Virus Vaccine (USDA: 15C5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1765
Feline calicivirus Modified Live Virus Vaccine (USDA: 15C1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1767
Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1768
Feline immunodeficiency virus Killed Virus Vaccine (USDA: 15A5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1771
Feline Infectious Peritonitis Modified Live Virus Vaccine (USDA: 15A1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1772
Feline Leukemia Killed Virus Vaccine (USDA: 1555.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1773
Feline Leukemia Killed Virus Vaccine (USDA: 1555.21)
Feline Leukemia Killed Virus Vaccine (USDA: 1555.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1775
Feline Leukemia Killed Virus Vaccine (USDA: 1555.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1776
Feline Leukemia Live Canarypox Vector Vaccine (USDA: 1555.R3)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1819
Feline Panleukopenia Killed Virus Vaccine (USDA: 1565.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1815
Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1816
Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1817
Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1818
Feline Panleukopenia Modified Live Virus Vaccine (USDA: 1561.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1820
Feline Rhinotracheitis Modified Live Virus Vaccine (USDA: 16A1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1714
Edwardsiella ictaluri Avirulent Live Culture Vaccine (USDA: 1531.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1122
Anthrax Spore live culture Vaccine (USDA: 1011.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1179
Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1180
Bovine Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1095.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1178
Bovine Respiratory Syncytial Virus Vaccine Modified Live Virus (USDA: 1091.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1186
Bovine Rhinotracheitis Killed Virus Vaccine (USDA: 1105.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1181
Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1182
Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1183
Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1184
Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1185
Bovine Rhinotracheitis Modified Live Virus Vaccine (USDA: 1101.B0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1354
Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1355
Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1356
Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1357
Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1358
Bovine Virus Diarrhea Killed Virus Vaccine (USDA: 1205.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1351
Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1352
Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1353
Bovine Virus Diarrhea Modified Live Virus Vaccine (USDA: 1201.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1383
Brucella Abortus Strain 19, Live Culture Vaccine (USDA: 1251.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1384
Brucella Abortus Strain 19, Live Culture, Reduced Dose Vaccine (USDA: 1251.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1385
Brucella Abortus Strain RB-51, Live Culture Vaccine (USDA: 1261.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2077
Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2078
Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1841.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2121
Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2122
Salmonella Choleraesuis Avirulent Live Culture Vaccine (USDA: 19A1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2123
Salmonella Dublin Live Culture Vaccine (USDA: 19D1.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2143
Trichomonas Foetus Killed Protozoa Vaccine (USDA: 1859.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2144
Wart Killed Virus Vaccine (USDA: 1985.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1124
Avian Encephalomyelitis Killed Virus Vaccine (USDA: 1015.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1125
Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1126
Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1127
Avian Encephalomyelitis Live Virus Vaccine (USDA: 1051.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1147
avian influenza H10N9 Subtype, Killed Virus Vaccine (USDA: 1057.H0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1149
avian influenza H2N2 Subtype, Killed Virus Vaccine (USDA: 1057.H2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1150
avian influenza H3N4 Subtype, Killed Virus Vaccine (USDA: 1057.H3)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1151
avian influenza H4N6 Subtype, Killed Virus Vaccine (USDA: 1057.H4)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1152
avian influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 1057.H5)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1146
avian influenza H5N9 Subtype, Killed Virus Vaccine (USDA: 1057.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1153
avian influenza H6N8 Subtype, Killed Virus Vaccine (USDA: 1057.H6)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1158
avian influenza H7N2 Subtype, Killed Virus Vaccine (USDA: 10F5.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1154
avian influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 1057.H7)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1159
avian influenza H7N3 Subtype, Killed Virus Vaccine (USDA: 10F5.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1148
avian influenza H1N1 Subtype, Killed Virus Vaccine (USDA: 1057.H1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1157
avian influenza H5N2 Subtype, Killed Virus Vaccine (USDA: 10F5.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1156
avian influenza H5N3 Subtype, Killed Virus Vaccine (USDA: 1057.R3)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1155
avian influenza H9N2 Subtype, Killed Virus Vaccine (USDA: 1057.H9)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1163
Avian Paramyxovirus Type 1, Killed Virus Vaccine (USDA: 10C5.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1162
Avian Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 10C5.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1164
Avian Pneumovirus Modified Live Virus Vaccine (USDA: 1A31.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1166
Avian Reovirus Killed Virus Vaccine (USDA: 1045.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1167
Avian Reovirus Killed Virus Vaccine (USDA: 1045.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1168
Avian Reovirus Killed Virus Vaccine (USDA: 1045.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1169
Avian Reovirus Killed Virus Vaccine (USDA: 1045.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1361
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1373
Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.1M)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1375
Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1376
Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1377
Bronchitis Ark Type, Live Virus Vaccine (USDA: 1231.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1365
Bronchitis Conn Type, Live Virus Vaccine (USDA: 1231.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1368
Bronchitis Delaware Type, Modified Live Virus Vaccine (USDA: 1231.1D)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1371
Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1J)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1372
Bronchitis Georgia Type, Live Virus Vaccine (USDA: 1231.1L)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1382
Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1235.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1363
Bronchitis Mass & Ark Types, Live Virus Vaccine (USDA: 1231.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1364
Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1370
Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA: 1231.1G)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1374
Bronchitis Mass & Conn Types, Live Virus Vaccine (USDA:1231.1N)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1362
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1366
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1367
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1369
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1231.1F)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1378
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1379
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1232.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1380
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1233.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1381
Bronchitis Mass Type, Live Virus Vaccine (USDA: 1235.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1403
Bursal Disease Killed Virus Vaccine (USDA: 1275.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1404
Bursal Disease Killed Virus Vaccine (USDA: 1275.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1405
Bursal Disease Killed Virus Vaccine (USDA: 1275.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1386
Bursal Disease Live Virus Vaccine (USDA: 1271.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1387
Bursal Disease Live Virus Vaccine (USDA: 1271.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1388
Bursal Disease Live Virus Vaccine (USDA: 1271.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1389
Bursal Disease Live Virus Vaccine (USDA: 1271.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1390
Bursal Disease Live Virus Vaccine (USDA: 1271.0A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1391
Bursal Disease Live Virus Vaccine (USDA: 1271.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1392
Bursal Disease Live Virus Vaccine (USDA: 1271.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1393
Bursal Disease Live Virus Vaccine (USDA: 1271.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1394
Bursal Disease Live Virus Vaccine (USDA: 1271.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1396
Bursal Disease Live Virus Vaccine (USDA: 1271.16)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1397
Bursal Disease Live Virus Vaccine (USDA: 1271.17)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1398
Bursal Disease Live Virus Vaccine (USDA: 1271.18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1399
Bursal Disease Live Virus Vaccine (USDA: 1271.19)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1400
Bursal Disease Live Virus Vaccine (USDA: 1271.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1401
Bursal Disease Live Virus Vaccine (USDA: 1271.41)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1402
Bursal Disease Live Virus Vaccine (USDA: 1272.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1395
Bursal Disease Modified Live VirusVaccine (USDA: 1271.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1409
Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1410
Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1411
Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.41)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1412
Bursal Disease Standard & Variant, Killed Virus Vaccine (USDA: 12B5.4A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1407
Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1408
Bursal Disease Standard & Variant, Live Virus Vaccine (USDA: 12B1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1406
Bursal Disease Variant, Killed Virus Vaccine (USDA: 12A5.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1413
Bursal Disease Variant, Live Virus Vaccine (USDA: 12L1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1697
Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1698
Chicken Anemia Virus Live Virus Vaccine (USDA: 10A1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1699
Chicken Anemia Virus Modified Live Virus Vaccine (USDA: 10A1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1702
Coccidiosis Live Oocysts Vaccine (USDA: 1431.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1703
Coccidiosis Live Oocysts Vaccine (USDA: 1431.51)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1705
Coccidiosis Live Oocysts Vaccine (USDA: 1431.56)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1706
Coccidiosis Live Oocysts Vaccine (USDA: 1431.57)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1707
Coccidiosis Live Oocysts Vaccine (USDA: 1431.58)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1708
Coccidiosis Live Oocysts Vaccine (USDA: 1431.59)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1709
Coccidiosis Live Oocysts Vaccine (USDA: 1431.5C)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1704
Coccidiosis Live Oocysts, Chicken Isolates Vaccine (USDA: 1431.55)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1903
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1904
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1905
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1906
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1907
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1908
Fowl Laryngotracheitis Modified Live Virus Vaccine (USDA: 1601.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1913
Fowl Pox Live Virus Vaccine (USDA: 1621.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1914
Fowl Pox Live Virus Vaccine (USDA: 1621.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1915
Fowl Pox Live Virus Vaccine (USDA: 1621.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1916
Fowl Pox Live Virus Vaccine (USDA: 1621.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1917
Fowl Pox Live Virus Vaccine (USDA: 1621.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1918
Fowl Pox Live Virus Vaccine (USDA: 1622.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1945
Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1948
Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1952
Marek's Disease Serotype 1, Live Virus Vaccine (USDA: 16L1.09)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1934
Marek's Disease Serotype 2, Live Virus Vaccine (USDA: 1631.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1936
Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1937
Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1938
Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1641.06)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1949
Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 16L1.06)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1946
Marek's Disease Serotypes 1 & 2 & 3, Live Virus Vaccine (USDA: 16L1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1935
Marek's Disease Serotypes 1 & 3, Live Herpesvirus Chimera Vaccine (USDA: 1631.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1944
Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16G1.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1947
Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1951
Marek's Disease Serotypes 1 & 3, Live Virus Vaccine (USDA: 16L1.08)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1939
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1940
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1941
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1942
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1651.05)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1943
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16G1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1950
Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 16L1.07)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1973
Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1974
Mycoplasma Gallisepticum Live Culture Vaccine (USDA: 1751.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1981
Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1982
Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1983
Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1984
Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 1711.18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1991
Newcastle Disease B1 Type, B1 Strain, Live Virus Vaccine (USDA: 17A2.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1993
Newcastle Disease B1 Type, C2 Strain, Live VirusVaccine (USDA: 17B1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1985
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.0A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1986
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1987
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1988
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1989
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.16)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1990
Newcastle Disease B1 Type, LaSota Strain, Live Virus Vaccine (USDA: 1721.17)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1977
Newcastle Disease Killed Virus Vaccine (USDA: 1705.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1978
Newcastle Disease Killed Virus Vaccine (USDA: 1705.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1979
Newcastle Disease Killed Virus Vaccine (USDA: 1705.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1980
Newcastle Disease Killed Virus Vaccine (USDA: 1705.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1976
Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 1701.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1992
Newcastle Disease VG/GA Strain, Live Virus Vaccine (USDA: 17A2.V1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2087
Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2088
Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2089
Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.03)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2090
Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2091
Pasteurella Multocida Avirulent Live Culture, Avian Isolate Vaccine (USDA: 1871.05)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2124
Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2125
Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2126
Salmonella Typhimurium Live Culture Vaccine (USDA: 19C1.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2139
Tenosynovitis Live Virus Vaccine (USDA: 1951.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2135
Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2136
Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2137
Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.03)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2138
Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2140
Tenosynovitis Modified Live Virus Vaccine (USDA: 1951.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2141
Tenosynovitis Modified Live Virus Vaccine (USDA: 1952.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1712
Duck Virus Enteritis Modified Live Virus Vaccine (USDA: 1461.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1713
Duck Virus Hepatitis Modified Live Virus Vaccine (USDA: 14B1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2120
Riemerella Anatipestifer Avirulent Live Culture Vaccine (USDA: 1811.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1902
Flavobacterium Columnare Avirulent Live Culture Vaccine (USDA: 17F1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1172
Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1173
Bordetella Bronchiseptica Avirulent Live Culture Vaccine (USDA: 1081.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1562
Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1563
Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1561
Canine Coronavirus Modified Live Virus Vaccine (USDA: 14P1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1691
canine influenza H3N8, killed virus vaccine (USDA: 15K5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1692
Canine Parainfluenza Modified Live Virus Vaccine (USDA: 1421.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1711
Distemper Live Canarypox Vector Vaccine (USDA: 1471.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1710
Distemper Modified Live Virus Vaccine (USDA: 1471.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1926
Giardia Lamblia Killed Protozoa Vaccine (USDA: 18G5.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1975
Neospora Caninum Killed Protozoa Vaccine (USDA: 1N11.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2085
Parvovirus Killed Virus Vaccine (USDA: 18P5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2086
Parvovirus Killed Virus Vaccine (USDA: 18P5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2079
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2080
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2081
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2082
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2083
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2084
Parvovirus Modified Live Virus Vaccine (USDA: 18M1.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2115
Rabies Killed Virus Vaccine (USDA: 1905.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2116
Rabies Killed Virus Vaccine (USDA: 1905.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2117
Rabies Killed Virus Vaccine (USDA: 1905.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2118
Rabies Killed Virus Vaccine (USDA: 1905.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2119
Rabies Killed Virus Vaccine (USDA: 1905.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2113
Rabies Live Canarypox Vector Vaccine (USDA: 1901.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2114
Rabies Live Canarypox Vector Vaccine (USDA: 1901.R6)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2112
Rabies Live Vaccinia Vector Vaccine (USDA: 1901.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1731
Equine Arteritis Modified Live Virus Vaccine (USDA: 1531.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1735
equine influenza killed virus vaccine (USDA: 1505.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1736
equine influenza killed virus vaccine (USDA: 1505.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1737
equine influenza killed virus vaccine (USDA: 1505.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1738
equine influenza killed virus vaccine (USDA: 1505.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1739
equine influenza killed virus vaccine (USDA: 1505.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1740
equine influenza killed virus vaccine (USDA: 1505.28)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1734
equine influenza live canarypox vector vaccine (USDA: 1501.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1732
equine influenza modified live virus vaccine (USDA: 1501.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1733
equine influenza modified live virus vaccine (USDA: 1501.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1742
Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1743
Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1744
Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1745
Equine Rhinopneumonitis Killed Virus Vaccine (USDA: 1525.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1741
Equine Rhinopneumonitis Modified Live Virus Vaccine (USDA: 1521.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1756
Equine Rotavirus Killed Virus Vaccine (USDA: 1E15.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2127
Streptococcus Equi Live Culture Vaccine (USDA: 1831.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1165
Avian Polyomavirus Killed Virus Vaccine (USDA: 1A15.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1701
Chlamydia Psittaci Killed Chlamydia Vaccine (USDA: 1585.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1700
Chlamydia Psittaci Modified Live Chlamydia Vaccine (USDA: 1581.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2076
Pacheco's Disease Killed Virus Vaccine (USDA: 18C5.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1757
Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1758
Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1759
Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1760
Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.03)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1761
Erysipelothrix Rhusiopathiae Avirulent Live Culture Vaccine (USDA: 1541.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1927
Haemophilus Parasuis Avirulent Live Culture Vaccine (USDA: 19J1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1929
Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1930
Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1931
Lawsonia Intracellularis Avirulent Live Culture Vaccine (USDA: 10L1.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2095
Porcine Circovirus Type 2, Killed Virus Vaccine (USDA: 19K5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2102
Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2103
Porcine Reproductive & Respiratory Syndrome Reproductive & Respiratory Form, Modified Live Virus Vaccine (USDA: 19T1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2101
Porcine Reproductive & Respiratory Syndrome Reproductive Form, Killed Virus Vaccine (USDA: 19S5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2098
Porcine Reproductive & Respiratory Syndrome Reproductive Form, Modified Live Virus Vaccine (USDA: 19Q1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2099
Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2100
Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine (USDA: 19S1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2104
Porcine Rotavirus Modified Live Virus Vaccine (USDA: 19E1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2107
Pseudorabies Modified Live Virus Vaccine (USDA: 1891.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2108
Pseudorabies Modified Live Virus Vaccine (USDA: 1891.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2109
Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2110
Pseudorabies Modified Live Virus Vaccine (USDA: 1891.R4)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2134
swine influenza pH1N1, killed virus vaccine (USDA: 19A5.2P)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2142
Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 1961.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2147
West Nile Virus Killed Virus Vaccine (USDA: 1995.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2148
West Nile Virus Killed Virus Vaccine (USDA: 1995.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2145
West Nile Virus Live Canarypox Vector Vaccine (USDA: 1991.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2146
West Nile Virus Live Flavivirus Chimera Vaccine (USDA: 1991.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1170
Bluetongue Modified Live Virus Vaccine (USDA: 1061.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5554
WEB: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM518295.pdf
Active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Afluria Quadrivalent is approved for use in persons 6 months of age and older.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1123
Arthrobacter Live Culture Vaccine (USDA: 1K11.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1171
Bordetella Avium Avirulent Live Culture Vaccine (USDA: 1021.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1762
Escherichia coli avirulent live culture vaccine (USDA: 1551.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1764
Escherichia coli avirulent live culture vaccine (USDA: 15R1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1763
Escherichia coli live culture vaccine (USDA: 1551.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1928
Hemorrhagic Enteritis Live Virus Vaccine (USDA: 17E1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2096
Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine (USDA: 19K5.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2128
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2129
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2130
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2131
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2132
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2133
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1970
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1971
Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine (USDA: 1679.31)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2884
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2885
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2886
Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid (USDA: 4929.31)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2887
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2888
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2889
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2890
Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2891
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2892
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2893
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2894
Mink Distemper-Enteritis Modified Live & Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 4949.31)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2881
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2882
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2883
Mink Distemper-Enteritis Modified Live Virus & Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4929.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2895
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2896
Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2897
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2898
Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C Bacterin-Toxoid (USDA: 4955.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2899
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2900
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2901
Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2902
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2903
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2904
Mink Enteritis Killed Virus Vaccine-Clostridium botulinum Type C-Pseudomonas aeruginosa Bacterin-Toxoid (USDA: 49A5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1769
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1770
Feline Immunodeficiency-Leukemia Virus Killed Virus Vaccine (USDA: 15D5.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1777
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1778
Feline Leukemia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1A69.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1779
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1780
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1781
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1782
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1783
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1784
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1785
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1786
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 15B5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1787
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1788
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1789
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1790
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1791
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1792
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1793
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1794
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 15B9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1795
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1796
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1797
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1798
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1799
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1800
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1801
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1802
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1803
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1804
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1810
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1811
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1812
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1813
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1814
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Killed Chlamydia Vaccine (USDA: 1559.2C)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1805
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1806
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1807
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1808
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1809
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1559.2B)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1821
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1822
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1823
Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1824
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1825
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1826
Feline Rhinotracheitis-Calici-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16F1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1839
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1840
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1841
Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1842
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1843
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1844
Feline Rhinotracheitis-Calici-Panleukopenia Killed Virus Vaccine (USDA: 16D5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1851
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1852
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1853
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live & Killed Virus Vaccine (USDA: 16D9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1827
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1828
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1829
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1830
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1831
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1832
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1833
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1834
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1835
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1836
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1837
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1838
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D1.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1845
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1846
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1847
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1848
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1849
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1850
Feline Rhinotracheitis-Calici-Panleukopenia Modified Live Virus Vaccine (USDA: 16D8.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1862
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1863
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1864
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1865
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1866
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1867
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1868
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1869
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Killed Virus, Killed Chlamydia Vaccine (USDA: 16E5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1870
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1871
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1872
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1873
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Killed Chlamydia Vaccine (USDA: 16E6.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1854
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1855
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1856
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1857
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1858
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1859
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1860
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1861
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E1.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1874
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1875
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1876
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1877
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Modified Live Virus, Modified Live Chlamydia Vaccine (USDA: 16E8.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1878
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1879
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1880
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1881
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1882
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live & Killed Virus, Modified Live Chlamydia Vaccine (USDA: 1619.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1883
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1884
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1885
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1886
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1887
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Modified Live Virus and Chlamydia, Canarypox Vector Vaccine (USDA: 1619.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1888
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1889
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1890
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1891
Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live & Killed Virus Vaccine (USDA: 16T9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1892
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1893
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1894
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1895
Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Modified Live Virus, Canarypox Vector Vaccine (USDA: 16T9.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1896
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1897
Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1898
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1899
Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1900
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1901
Feline Rhinotracheitis-Calicivirus Modified Live Virus Vaccine (USDA: 16C1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1174
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1175
Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1176
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1177
Bovine Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1161.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2152
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2153
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2154
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2155
Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2156
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2157
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2158
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2159
Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45H5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2160
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2161
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2162
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2163
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2164
Bovine Rhinotracheitis Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 4109.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2165
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2166
Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4019.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2167
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2168
Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4059.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2169
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2170
Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4069.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2171
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2172
Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2173
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2174
Bovine Rhinotracheitis Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4089.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2187
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2188
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2189
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2190
Bovine Rhinotracheitis-Parainfluenza 3 Killed Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin (USDA: 4265.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1187
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1188
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1189
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1190
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1191
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1192
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1193
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1194
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1195
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1196
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1121.31)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2175
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2176
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2177
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 4139.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2178
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2179
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2180
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4129.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2181
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2182
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2183
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4179.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2184
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2185
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2186
Bovine Rhinotracheitis-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4209.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1197
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1198
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1199
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1200
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1201
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1202
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1203
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1204
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1205
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1206
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1207
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1208
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1209
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1210
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1211
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1071.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1212
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1213
Bovine Rhinotracheitis-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11B5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1224
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1225
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1226
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1227
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine (USDA: 1155.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2195
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2196
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2197
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2198
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2199
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2200
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2201
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2202
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4145.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2203
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2204
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2205
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2206
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2207
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 43S5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2208
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2209
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2210
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2211
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2212
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2213
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid (USDA: 43T5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2214
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2215
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2216
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4335.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2217
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2218
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2219
Bovine Rhinotracheitis-Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4336.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1214
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1215
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1216
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1217
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1218
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1219
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1220
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1221
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1222
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1223
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine (USDA: 1151.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2191
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2192
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2193
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2194
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4141.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2220
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2221
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2222
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4339.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2223
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2224
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2225
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4359.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2226
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2227
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2228
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Hardjo-Pomona Bacterin (USDA: 4399.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2229
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2230
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2231
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2232
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2233
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2234
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2235
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2236
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2237
Bovine Rhinotracheitis-Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4389.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1252
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1253
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1254
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine (USDA: 1175.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2252
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2253
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2254
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2255
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4435.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1228
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1229
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1230
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1231
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1232
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1233
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1234
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1235
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1236
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1237
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1238
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1239
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1240
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1241
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1242
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1243
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1244
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1245
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1246
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1247
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1248
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1249
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1251
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine (USDA: 1171.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2238
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2239
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2240
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2241
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2242
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2243
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2244
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2245
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4560.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2246
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2247
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2248
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2249
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2251
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4489.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2256
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2257
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2258
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2259
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2260
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2261
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2262
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2263
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4439.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2264
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2265
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2266
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2267
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin (USDA: 4479.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2268
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2269
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2270
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2271
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4509.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2486
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2487
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2488
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2489
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Mannheimia Haemolytica Bacterin (USDA: 44A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1255
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1256
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1257
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1258
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1259
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1260
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1261
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1262
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1263
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1264
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1265
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1266
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1267
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1268
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1269
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1270
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1271
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1272
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1273
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1274
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1275
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1276
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1277
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1278
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1279
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1280
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1281
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1282
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1283
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1284
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1285
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1286
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1287
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1288
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1289
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1290
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.28)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1291
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1292
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1293
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1294
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 1181.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1295
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1296
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1297
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1298
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1299
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1300
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1301
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1302
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 1185.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2277
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2278
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2279
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2280
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2281
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2282
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2283
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2284
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2285
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2286
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2287
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2288
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44M5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2313
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2314
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2315
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2316
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2317
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2318
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2319
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2320
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2321
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2322
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2323
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2324
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2325
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2326
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2327
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2328
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2329
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2330
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B6.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2343
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2344
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2345
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2346
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2347
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2348
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2349
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2350
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C7.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2367
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2368
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2369
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2370
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44D5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2375
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2376
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2377
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2378
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2379
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2380
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2381
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2382
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2383
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2384
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D7.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2405
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2406
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2407
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2408
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2409
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica Bacterin (USDA: 4477.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2426
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2427
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2428
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2429
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2430
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2431
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2432
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2433
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2434
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2435
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2436
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2437
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4465.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2438
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2439
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2440
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2441
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2442
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2443
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2444
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2445
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4466.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2482
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2483
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2484
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2485
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin (USDA: 4475.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1303
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1304
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1305
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1306
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1307
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1308
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1309
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1310
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1311
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1312
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1313
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1314
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1315
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1316
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1317
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1318
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1187.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1319
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1320
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1321
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1322
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1323
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1324
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1325
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1326
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1327
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1328
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1329
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1330
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine (USDA: 1189.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2331
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2332
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2333
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2334
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2335
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2336
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2337
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2338
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2339
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2340
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2341
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2342
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B9.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2371
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2372
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2373
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2374
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44F9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2454
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2455
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2456
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2457
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2458
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2459
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2460
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2461
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2470
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2471
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2472
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2473
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2478
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2479
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2480
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2481
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2289
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2290
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2291
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2292
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2293
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2294
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2295
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2296
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2297
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2298
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2299
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2300
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2301
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2302
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2303
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2304
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2305
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2306
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2307
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2308
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2309
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2310
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2311
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2312
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44B1.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2351
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2352
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2353
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2354
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2355
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2356
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2357
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2358
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2359
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2360
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2361
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2362
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2363
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2364
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2365
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2366
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus Bacterin (USDA: 44C9.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2385
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2386
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2387
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2388
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2389
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2390
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2391
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2392
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2393
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2394
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2395
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2396
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2397
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2398
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2399
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2400
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2401
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2402
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2403
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2404
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Haemophilus somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 44D9.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2410
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2411
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2412
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2413
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2414
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2415
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2416
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2417
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2418
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2419
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2420
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2421
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2422
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2423
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2424
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2425
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4461.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2446
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2447
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2448
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2449
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2450
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2451
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2452
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2453
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2462
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2463
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2464
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2465
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2466
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2467
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2468
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2469
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2474
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2475
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2476
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2477
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4469.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2272
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2273
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2274
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2275
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2276
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Hardjo Bacterin (USDA: 4L49.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2490
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2491
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2492
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2493
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2494
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2495
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2496
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2497
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica Toxoid (USDA: 4X49.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2498
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2499
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2500
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2501
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2502
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2503
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2504
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2505
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2506
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2507
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Modified Live Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 45B9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1331
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1332
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1333
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1334
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1335
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1336
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 11A8.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1346
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1347
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1348
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 11A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1337
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1338
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1339
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1340
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1341
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1342
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1343
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1344
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1345
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine (USDA: 11A1.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2508
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2509
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2510
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2511
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2512
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2513
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2514
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2515
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2516
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2517
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2518
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2519
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4367.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1350
Bovine Rotavirus-Coronavirus Modified Killed Virus Vaccine (USDA: 1935.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1349
Bovine Rotavirus-Coronavirus Modified Live Virus Vaccine (USDA: 1931.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2520
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2521
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2522
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2523
Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2524
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2525
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2526
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2527
Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 4570.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2528
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2529
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2530
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2531
Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid (USDA: 4575.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2532
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2533
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2534
Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2535
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2536
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2537
Bovine Rotavirus-Coronavirus Killed Virus Vaccine-Escherichia Coli Bacterin (USDA: 4585.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2538
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2539
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2540
Bovine Virus Diarrhea Killed Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 45B5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2541
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2542
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2543
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2544
Bovine Virus Diarrhea Killed Virus Vaccine-Haemophilus somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid (USDA: 4C95.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2545
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2546
Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2547
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2548
Bovine Virus Diarrhea Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4595.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2549
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2550
Bovine Virus Diarrhea Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4599.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1359
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1360
Bovine Virus Diarrhea-Respiratory Syncytial Virus Killed Virus Vaccine (USDA: 12A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1932
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1933
Mannheimia Haemolytica-Pasteurella Multocida Avirulent Live Culture Vaccine (USDA: 1861.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1143
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1144
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1145
Avian Encephalomyelitis-Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector, Live Virus Vaccine (USDA:1D61.R0)
JZ: it may be same as term VO:0002048, USDA: 12C2.50, current USDA numbers are not correct since manufacturer is not same.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1437
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1438
Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: )
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1160
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1161
avian influenza-Fowl Pox H5 Subtype, Live Fowl Pox Vector Vaccine (USDA: 1061.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1130
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1131
Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.10 )
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1132
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1133
Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1134
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1135
Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1136
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1137
Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1138
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1139
Avian Encephalomyelitis-Fowl Pox Live Virus Vaccine (USDA: 10M1.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1140
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1141
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1142
Avian Encephalomyelitis-Fowl Pox-Laryngotracheitis Live Virus, Live Fowl Pox Vector Vaccine (USDA: 10S1.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1128
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1129
Avian Encephalomyelitis-Chicken Anemia Virus-Fowl Pox C155Live and Modified Live C212Virus Vaccine (USDA: 10T1.40)+C433
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1414
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1415
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1416
Bursal Disease-Marek's Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1417
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1418
Bursal Disease-Marek's Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1281.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1419
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1420
Bursal Disease-Marek's Disease Variant, Serotype 3, Live Virus Vaccine (USDA: 1282.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1421
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1422
Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.42)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1423
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1424
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.43)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1425
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1426
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.44)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1427
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1428
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1288.45)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1429
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1430
Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1288.4A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1431
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1432
Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1433
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1434
Bursal Disease-Marek's Disease Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.51)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1435
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1436
Bursal Disease-Marek's Disease Variant Strain, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C2.52)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1439
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1440
Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1441
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1442
Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.42)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1443
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1444
Bursal Disease-Marek's Disease Standard & Variant, Serotype 3, Live Virus Vaccine (USDA: 12C8.43)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1445
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1446
Bursal Disease-Marek's Disease Standard & Variant, Serotypes 2 & 3, Live Virus Vaccine (USDA: 12C8.44)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1539
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1540
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1541
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1542
Bursal Disease-Reovirus Killed Virus Vaccine (USDA: 12D5.02)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1543
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1544
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.03)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1545
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1546
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1547
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1548
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1465
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1466
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1467
Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12D5.45)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1549
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1550
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.E0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1551
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1552
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1553
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1554
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.F1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1555
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1556
Bursal Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12D5.T0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1457
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1458
Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1459
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1460
Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1461
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1462
Bursal Disease-Newcastle Disease Standard & Variant, Killed Virus Vaccine (USDA: 12G5.42)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1463
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1464
Bursal Disease-Newcastle Disease Killed Virus Vaccine (USDA: 12G5.43)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1468
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1469
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1470
Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.4M)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1471
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1472
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1473
Bursal Disease-Newcastle Disease-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 12H1.67)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1474
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1475
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1476
Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1477
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1478
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1479
Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.43)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1480
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1481
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1482
Bursal Disease-Newcastle Disease-Bronchitis Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12J5.61)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1483
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1484
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1485
Bursal Disease-Newcastle Disease-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 12J5.62)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1486
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1487
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1488
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1489
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1490
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1491
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1492
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1493
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1494
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1495
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1496
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1497
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1498
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1499
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1500
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1501
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Killed Virus Vaccine (USDA: 12M5.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1502
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1503
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1504
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1505
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.41)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1506
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1507
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1508
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1509
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass & Ark Types, Killed Virus Vaccine (USDA: 12M5.42)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1510
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1511
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1512
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1513
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.43)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1514
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1515
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1516
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1517
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1518
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1519
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1520
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1521
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.90)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1522
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1523
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1524
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1525
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Mass Type, Killed Virus Vaccine (USDA: 12M5.91)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1526
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1527
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1528
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1529
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Standard & Variant, Mass Type, Killed Virus Vaccine (USDA: 12M5.E0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1530
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1531
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1532
Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.40)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1533
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1534
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1535
Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.41)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1536
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1537
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1538
Bursal Disease-Newcastle Disease-Reovirus Standard & Variant, Killed Virus Vaccine (USDA: 12P5.E0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1558
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1559
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1560
Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1657
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1658
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1659
Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1660
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1661
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1662
Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1663
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1664
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1665
Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1666
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1667
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1668
Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus Vaccine (USDA: 1331.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1669
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1670
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1671
Canine Distemper-Adenovirus Type 2-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 1331.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1605
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1606
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1607
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1608
Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Modified Live Virus Vaccine (USDA: 1341.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1685
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1686
Canine Distemper-Measles Modified Live Virus Vaccine (USDA: 1351.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1682
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1683
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1684
Canine Distemper-Hepatitis-Parainfluenza Modified Live Virus Vaccine (USDA: 1381.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1576
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1577
Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1578
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1579
Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine (USDA: 13A1.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1609
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1610
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1611
Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine (USDA: 13C1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1612
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1613
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1614
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1615
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1616
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1617
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1618
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1619
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1620
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1621
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1622
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1623
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1624
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1625
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1626
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1627
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1628
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1629
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1630
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1631
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1632
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1633
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1634
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1635
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1636
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1637
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1638
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1639
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.28)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1640
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1641
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1642
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1643
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1644
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1645
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1646
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1647
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Canarypox Vector Vaccine (USDA: 13D1.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1648
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1649
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1650
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1651
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine (USDA: 13D1.T0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1652
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1653
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1654
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1655
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1656
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13G9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1672
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1673
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1674
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1675
Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Modified Live & Killed Virus Vaccine (USDA: 13H9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1687
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1688
Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1689
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1690
Canine Distemper-Parvovirus Modified Live Virus Vaccine (USDA: 13P1.27)
A horse Encephalomyelitis-Influenza-West Nile Virus vaccine that is inactivated and manufactured by Wyeth Pharmaceuticals Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1717
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1718
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1719
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1720
Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 13W5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1715
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1716
Encephalomyelitis Eastern & Western, Killed Virus Vaccine (USDA: 1475.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1676
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1677
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1678
Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D7.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1679
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1680
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1681
Canine Distemper-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14D9.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1693
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1694
Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1695
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1696
Canine Parainfluenza-Bordetella Bronchiseptica Modified Live Virus, Avirulent Live Culture Vaccine (USDA: 14M1.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1564
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1565
Canine Coronavirus-Parvovirus Modified Live Virus Vaccine (USDA: 14R1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1566
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1567
Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1568
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1569
Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1570
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1571
Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1572
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1573
Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1574
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1575
Canine Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 14R7.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1721
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1722
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1723
Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine (USDA: 14W5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1724
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1725
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1726
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1727
Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine (USDA: 14W5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1728
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1729
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1730
Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine (USDA: 14W7.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1746
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1747
Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1748
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1749
Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1750
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1751
Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1752
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1753
Equine Rhinopneumonitis-Influenza Killed Virus Vaccine (USDA: 1515.2A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1754
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1755
Equine Rhinopneumonitis-Influenza Modified Live & Killed Virus Vaccine (USDA: 1518.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1580
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1581
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1582
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1583
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1584
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus; Canarypox Vector Vaccine (USDA: 1591.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1585
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1586
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1587
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1588
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1589
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1590
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1591
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1592
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1593
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1594
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1595
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1596
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1597
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1598
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1599
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1600
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1601
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1602
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1603
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1604
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine (USDA: 1599.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1921
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1922
Fowl Pox-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 15E2.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1909
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1910
Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1911
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1912
Fowl Laryngotracheitis-Marek's Disease Serotypes 2 & 3, Modified Live & Live Marek's Disease Vector Vaccine (USDA: 16J1.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1953
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1954
Marek's Disease-Newcastle Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16N1.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1955
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1956
Marek's Disease-Newcastle Disease Serotypes 1 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1957
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1958
Marek's Disease-Newcastle Disease Serotypes 1 & 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 16N1.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1963
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1964
Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live & Modified Live Virus Vaccine (USDA: 16T1.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1965
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1966
Marek's Disease-Tenosynovitis Serotypes 2 & 3, Live Virus Vaccine (USDA: 16T1.03)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1996
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1997
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1998
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1999
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2000
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2001
Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2002
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2003
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2004
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2005
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2006
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2007
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1761.17)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2008
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2009
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2010
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2011
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1761.19)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2012
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2013
Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1761.1A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2014
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2015
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1762.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2016
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2017
Newcastle-Bronchitis B1 Type, B1 Strain, Conn Type, Live Virus Vaccine (USDA: 1762.13)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2018
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2019
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1762.1H)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2020
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2021
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2022
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2023
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2024
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2025
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2026
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2027
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1771.17)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2028
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2029
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2030
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2031
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.19)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2032
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2033
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass Type, Live Virus Vaccine (USDA: 1771.1A)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2034
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2035
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2036
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2037
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1775.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2038
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2039
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1776.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2040
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2041
Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2042
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2043
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine (USDA: 1785.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2044
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2045
Newcastle-Bronchitis Mass & Ark Types, Killed Virus Vaccine (USDA: 1785.12)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2046
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2047
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.14)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2048
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2049
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1791.15)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2050
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2051
Newcastle-Bronchitis B1 Type, B1 Strain, Mass Type, Live Virus Vaccine (USDA: 1791.19)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2052
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2053
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2054
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2055
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 1791.1X)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2056
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2057
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1M)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2058
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2059
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A1.1N)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2060
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2061
Newcastle-Bronchitis B1 Type, B1 Strain, Mass & Ark Types, Live Virus Vaccine (USDA: 17A2.1M)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2062
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2063
Newcastle-Bronchitis B1 Type, LaSota Strain, Mass & Conn Types Vaccine (USDA: 17B1.17)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1994
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1995
Newcastle Disease-Fowl Pox Live Fowl Pox Vector Vaccine (USDA: 17C1.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1959
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1960
Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1961
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1962
Marek's Disease-Newcastle Disease Serotypes 2 & 3, Live Virus & Live Marek's Disease Vector Vaccine (USDA: 17H1.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2072
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2073
Newcastle-Paramyxovirus Type 3, Killed Virus Vaccine (USDA: 17P5.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2064
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2065
Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2066
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2067
Newcastle-Bronchitis VG/GA Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 17V1.11)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.12)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.22)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.23)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.24)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.26)
obsolete Swine Influenza H1N1 & H3N2, Killed Virus Vaccine (USDA: 19A5.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2105
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2106
Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine (USDA: 19H1.20)
obsolete Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine (USDA: 19K5.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2097
Porcine Circovirus Type 1 - Type 2 Chimera, Killed Virus Vaccine (USDA: 19K5.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1447
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1448
Bursal Disease-Marek's Disease Serotype 3, Live Virus Vaccine (USDA: 1A82.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1449
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1450
Bursal Disease-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 1A88.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1451
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1452
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1453
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1454
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus, Live Marek's Disease Vector Vaccine (USDA: 1A88.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1455
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1456
Bursal Disease-Marek's Disease Serotypes 2 & 3, Live Virus Vaccine (USDA: 1B82.50)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1923
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1924
Fowl Pox-Mycoplasma Gallisepticum Live Fowl Pox Vector Vaccine (USDA: 1D51.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1919
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1920
Fowl Pox-Laryngotracheitis Live Fowl Pox Vector Vaccine (USDA: 1F31.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2068
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2069
Newcastle-Bronchitis B1 Type, C2 Strain, Mass Type, Live Virus Vaccine (USDA: 1XB1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2070
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2071
Newcastle-Bronchitis B1 Type, C2 Strain, Mass & Conn Types, Live Virus Vaccine (USDA: 1XC1.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2150
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2151
Bovine Respiratory Syncytial Virus Killed Virus Vaccine-Haemophilus somnus Bacterin (USDA: 40A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2574
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2575
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2576
Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4629.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2571
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2572
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2573
Canine Distemper-Adenovirus Type 2 Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4629.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2696
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2697
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2698
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2699
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2700
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2701
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2702
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2703
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2704
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2705
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2706
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2707
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2708
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2709
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2710
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4637.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2671
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2672
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2673
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2674
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2675
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4637.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2711
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2712
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2713
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2714
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2715
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2716
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2717
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2718
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2719
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2720
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2676
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2677
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2678
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2679
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2680
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 4639.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2686
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2687
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2688
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2689
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2690
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2691
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2692
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2693
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2694
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2695
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 4639.28)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2721
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2722
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2723
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2724
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2725
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4639.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2667
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2668
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2669
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2670
Canine Distemper-Adenovirus Type 2-Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4659.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2589
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2590
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2591
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2592
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2593
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2594
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2595
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46B9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2569
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2570
Canine Coronavirus Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46D5.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2567
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2568
Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46E5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2559
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2560
Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2563
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2564
Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2561
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2562
Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46E5.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2565
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2566
Canine Coronavirus Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46E5.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2632
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2633
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2634
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2635
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2636
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2637
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2638
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2639
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2640
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2641
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2642
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2643
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J7.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2726
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2727
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2728
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2729
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2730
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J8.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2644
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2645
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2646
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2647
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2648
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2649
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2614
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2615
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2616
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2617
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2618
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2619
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2596
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2597
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2598
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2599
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2600
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2601
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2620
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2621
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2622
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2623
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2624
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2625
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2626
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2627
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2628
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2629
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2630
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2631
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 46J9.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2602
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2603
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2604
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2605
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2606
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2607
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 46J9.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2650
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2651
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2652
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2653
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2654
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2655
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live Virus, Live Canarypox Vector Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 46J9.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2656
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2657
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2658
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2659
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2660
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2661
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2662
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2663
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2664
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2665
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2666
Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46P9.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2799
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2800
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2801
Encephalomyelitis-Influenza-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 46W5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2551
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2552
Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47A5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2738
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2739
Canine Parvovirus Modified Live Virus Vaccine-Leptospira Canicola Icterohaemorrhagiae Bacterin (USDA: 47B1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2577
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2578
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2579
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2580
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2581
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2582
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2583
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2584
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2585
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2586
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2587
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2588
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Borrelia Burgdorferi Bacterin (USDA: 47C5.29)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2553
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2554
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2555
Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract (USDA: 47E5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2556
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2557
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2558
Canine Coronavirus Killed Virus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract (USDA: 47E5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2681
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2682
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2683
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2684
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2685
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47K1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2608
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2609
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2610
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2611
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2612
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2613
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin (USDA: 47L9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2731
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2732
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2733
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2734
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2735
Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47P9.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2768
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2769
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2770
Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2771
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2772
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2773
Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2774
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2775
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2776
Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2777
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2778
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2779
Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.45)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2780
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2781
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2782
Encephalomyelitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4835.46)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2802
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2803
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2804
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2805
Encephalomyelitis-Rhinopneumonitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4844.30)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2806
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2807
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2808
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2809
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2810
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2811
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2812
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2813
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2814
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2815
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2816
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2817
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2818
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2819
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2820
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.32)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2821
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2822
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2823
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2824
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2825
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4845.33)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2826
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2827
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2828
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2829
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2830
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2831
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2832
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2833
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2834
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2835
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2836
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2837
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2838
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2839
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2840
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2841
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2842
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2843
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2844
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2845
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2846
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2847
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2848
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2849
Encephalomyelitis-Rhinopneumonitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4847.32)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2850
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2851
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2852
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2853
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2854
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2855
Encephalomyelitis-Rhinopneumonitis-Influenza-West Nile Virus Eastern & Western, Killed Virus, Killed Flavivirus Chimera Vaccine-Tetanus Toxoid (USDA: 4855.R2)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2740
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2741
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2742
Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2743
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2744
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2745
Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2746
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2747
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2748
Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2749
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2750
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2751
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2752
Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2753
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2754
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2755
Encephalomyelitis Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2756
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2757
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2758
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2759
Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4865.27)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2760
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2761
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2762
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2763
Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2764
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2765
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2766
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2767
Encephalomyelitis Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4867.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2783
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2784
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2785
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2786
Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2787
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2788
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2789
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2790
Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2791
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2792
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2793
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2794
Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2795
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2796
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2797
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2798
Encephalomyelitis-Influenza Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 4875.A1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2911
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2912
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2913
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B5.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2914
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2915
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2916
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Mycoplasma Gallisepticum Bacterin (USDA: 48B6.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2933
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2934
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2935
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2936
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2937
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2938
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2939
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2940
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2941
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2942
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2943
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2944
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 48C5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2917
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2918
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2919
Newcastle-Bronchitis Mass Type, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D6.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2905
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2906
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2907
Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.10)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2908
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2909
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2910
Newcastle Disease-Bronchitis Mass & Ark Types, Killed Virus Vaccine-Salmonella Enteritidis Bacterin (USDA: 48D7.11)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2856
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2857
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2858
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2859
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2860
Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2861
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2862
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2863
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2864
Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2865
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2866
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2867
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2868
Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2869
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2870
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2871
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2872
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2873
Encephalomyelitis-West Nile Virus Eastern & Western & Venezuelan, Killed Virus Vaccine-Tetanus Toxoid (USDA: 48W5.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2874
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2875
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2876
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2877
Encephalomyelitis-West Nile Virus Eastern & Western, Killed Virus, Live Canarypox Vector Vaccine-Tetanus Toxoid (USDA: 48W9.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3010
Rabies Killed Virus Vaccine-Ehrlichia Risticii Bacterin (USDA: 4905.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2922
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2923
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4906.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2951
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2952
Parvovirus Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 4960.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2945
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2946
Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.01)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2947
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2948
Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2949
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2950
Parvovirus Killed Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4975.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2920
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2921
Parainfluenza 3 Modified Live Virus Vaccine-Leptospira Pomona Bacterin (USDA: 4989.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3035
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3036
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3037
Trichomonas Foetus Vaccine, Killed Protozoa-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4990.00)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3011
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3012
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3013
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3014
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae Bacterin (USDA: 4993.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3015
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3016
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3017
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3018
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3019
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3020
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3021
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3022
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3023
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3024
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3025
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3026
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin (USDA: 4994.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3027
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3028
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3029
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3030
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3031
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3032
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.25)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3033
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3034
Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 4995.26)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3003
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3004
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3005
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3006
Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49B1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2991
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2992
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2993
Porcine Rotavirus Modified Live Virus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid (USDA: 49C1.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2953
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2954
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2955
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2956
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2957
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2958
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2959
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2960
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2961
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2962
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2963
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2964
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49F6.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2965
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2966
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2967
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2968
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2969
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2970
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2971
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2972
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.23)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2973
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2974
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2975
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2976
Parvovirus-Swine Influenza H1N1 & H3N2, Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 49G6.24)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2994
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2995
Porcine Rotavirus Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49K1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2977
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2978
Porcine Circovirus Type 2, Killed Baculovirus Vector Vaccine- Mycoplasma Hyopneumoniae Bacterin (USDA: 49K5.R1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2984
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2985
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2986
Porcine Reproductive & Respiratory Syndrome-Circovirus Reproductive & Respiratory Form, Type 2, Modifed Live Virus,Killed Baculovirus Vector Vaccine-Mycoplasma Hyopneumoniae Bacterin (USDA: 49K9.R0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3007
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3008
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3009
Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Escherichia Coli Bacterin (USDA: 49P1.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2996
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2997
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2998
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2999
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3000
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3001
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3002
Porcine Rotavirus-Transmissible Gastroenteritis Modified Live Virus Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid (USDA: 49T9.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2878
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2879
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2880
Infectious Salmon Anemia Virus Killed Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin (USDA: 4A45.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2924
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2925
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2926
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2927
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2928
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2929
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.21)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2930
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2931
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2932
Parvovirus Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4BC5.22)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2987
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2988
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2989
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2990
Porcine Reproductive & Respiratory Syndrome-Parvovirus Reproductive Form, Modified Live & Killed Virus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin (USDA: 4P19.20)
avian encephalomyelitis-chicken anemia virus-fowl pox vaccine
avian encephalomyelitis-fowl pox vaccine
avian encephalomyelitis-fowl pox-laryngotracheitis vaccine
avian encephalomyelitis-fowl pox-Mycoplasma gallisepticum vaccine
Bovine Parainfluenza 3-Respiratory Syncytial Virus vaccine
bovine rhinotracheitis vaccine-haemophilus somnus-mannheimia haemolytica-pasteurella multocida bacterin-toxoid
Bovine Rhinotracheitis Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid
Bovine Rhinotracheitis Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae- Pomona Bacterin
Bovine Rhinotracheitis Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin
Bovine Rhinotracheitis Vaccine-Leptospira Hardjo-Pomona Bacterin
bovine rhinotracheitis vaccine-leptospira pomona bacterin
Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin
bovine rhinotracheitis-parainfluenza 3 vaccine
Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Haemophilus Somnus Bacterin
Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin
Bovine Rhinotracheitis-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine
Bovine Rhinotracheitis-Respiratory Syncytial Virus vaccine
Bovine Rhinotracheitis-Virus Diarrhea vaccine
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida-Salmonella Typhimurium Bacterin-Toxoid
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Hardjo-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea Vaccine-Leptospira Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Grippotyphosa-Hardjo-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Haemophilus Somnus-Mannheimia Haemolytica Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
chicken bursal disease-Newcastle disease vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona-Mannheimia Haemolytica Bacterin
Bursal Disease-Newcastle Disease-Bronchitis Vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Leptospira Hardjo Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica Toxoid
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus-Mannheimia Haemolytica-Pasteurella Multocida Vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine
Bovine Rhinotracheitis-Virus Diarrhea-Respiratory Syncytial Virus Vaccine-Leptospira Pomona Bacterin
Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid
Bovine Rotavirus-Coronavirus Vaccine-Clostridium Perfringens Types C & D-Escherichia Coli Bacterin-Toxoid
Bovine Rotavirus-Coronavirus Vaccine-Escherichia Coli Bacterin
Bovine Virus Diarrhea Vaccine-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin
Bovine Virus Diarrhea Vaccine-Haemophilus Somnus-Mannheimia Haemolytica-Pasteurella Multocida Bacterin-Toxoid
Bovine Virus Diarrhea Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Bovine Virus Diarrhea Vaccine-Leptospira Pomona Bacterin
Bursal Disease-Newcastle Disease-Bronchitis-Reovirus Vaccine
chicken Bursal Disease-Newcastle Disease-Reovirus Vaccine
Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica vaccine
Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-GrippotyphosaIcterohaemorrhagiae-Pomona Bacterial Extract
Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract
Canine Coronavirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract
Canine Coronavirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract
Canine Coronavirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract
Canine Coronavirus Vaccine-Borrelia Burgdorferi Bacterin
Canine Distemper-Adenovirus Type 2 vaccine
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine
Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract
Canine Distemper-Adenovirus Type 2 Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus vaccine-Borrelia Burgdorferi Bacterin
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Borrelia Burgdorferi Bacterin-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract
horse EEV, VEV, WEV encephalomyelitis and West Nile Virus vaccine
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Icterohaemorrhagiae-Pomona Bacterin
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract
Canine Distemper-Adenovirus Type 2-Coronavirus-Parvovirus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract
Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Vaccine
Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterial Extract
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira CanicolaGrippotyphosa-Icterohaemorrhagiae-Pomona Bacterin
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin
Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine
Canine Distemper-Adenovirus Type 2-Parvovirus-Rabies Vaccine
Canine Distemper-Hepatitis-Parainfluenza vaccine
canine parainfluenza-bordetella bronchiseptica vaccine
canine parvovirus vaccine-leptospira canicola icterohaemorrhagiae bacterin
equine EEV and WEV encephalomyelitis vaccine-tetanus toxoid
equine rhinopneumonitis-influenza vaccine
equine EEV and WEV encephalomyelitis-influenza vaccine-tetanus toxoid
equine EEV and WEV encephalomyelitis-influenza-West Nile virus vaccine-tetanus toxoid
a viral vaccine against horse EEV, WEV, and VEE viral infections
horse encephalomyelitis EEV, VEV, and WEV combination vaccine
Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin
Canine Distemper-Hepatitis-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin
Feline Immunodeficiency-Leukemia virus vaccine
equine EEV and WEV encephalomyelitis-rhinopneumonitis vaccine-tetanus toxoid
equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza vaccine-tetanus toxoid
equine EEV and WEV encephalomyelitis-rhinopneumonitis-influenza-West Nile Virus vaccine-tetanus toxoid
horse EEV, VEV, WEV encephalomyelitis-West Nile Virus Vaccine-Tetanus Toxoid
Feline Leukemia-Chlamydia Psittaci vaccine
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia Vaccine
Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine
Feline Rhinotracheitis-Calici-Chlamydia Psittaci Vaccine
Feline Rhinotracheitis-Calici-Panleukopenia Vaccine
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine
Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci-Rabies Vaccine
Feline Rhinotracheitis-Calici-Panleukopenia-Rabies Vaccine
Feline Rhinotracheitis-Calicivirus vaccine
Fowl Laryngotracheitis-Mareks Disease vaccine
Infectious Salmon Anemia Virus Vaccine-Aeromonas Salmonicida-Vibrio Anguillarum-Ordalii-Salmonicida Bacterin
Fowl Pox-Mycoplasma Gallisepticum Vaccine
fowlpox-Mycoplasma Gallisepticum vaccine
Mannheimia Haemolytica-Pasteurella Multocida vaccine
Mareks Disease-Newcastle Disease vaccine
chicken Mareks disease-tenosynovitis vaccine
Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid
Mink Distemper-Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid
Mink Enteritis Vaccine-Clostridium Botulinum Type C Bacterin-Toxoid
Mink Enteritis Vaccine-Clostridium Botulinum Type C-Pseudomonas Aeruginosa Bacterin-Toxoid
Newcastle Disease-Bronchitis Vaccine-Salmonella Enteritidis Bacterin
Newcastle-Bronchitis Vaccine-Mycoplasma Gallisepticum Bacterin
A viral vaccine that protects against infection with Hirame rhabdovirus
bovine parainfluenza 3 vaccine-Leptospira Pomona vaccine
Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-HardjoIcterohaemorrhagiae-Pomona Bacterin
Parvovirus Vaccine-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Porcine Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae vaccine
Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Bratislava-CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Parvovirus-Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Leptospira CanicolaGrippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Canine Distemper-Adenovirus Type 2-Parainfluenza-Parvovirus-Rabies Virus Vaccine
Porcine Circovirus Vaccine- Mycoplasma Hyopneumoniae Bactin
Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Bordetella Bronchiseptica-Clostridium Perfringens Type C-Erysipelothrix Rhusiopathiae-Escherichia Coli-Pasteurella Multocida Bacterin-Toxoid
Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid
Porcine Rotavirus-Transmissible Gastroenteritis Vaccine-Escherichia Coli Bacterin
Porcine Rotavirus Vaccine-Clostridium Perfringens Type C-Escherichia Coli Bacterin-Toxoid
Porcine Reproductive & Respiratory Syndrome-Circovirus Vaccine-Mycoplasma Hyopneumoniae Bacterin
Porcine Reproductive & Respiratory Syndrome-Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Porcine Rotavirus Vaccine-Escherichia Coli Bacterin
Porcine Rotavirus-Transmissible Gastroenteritis vaccine
Rabies vaccine-Ehrlichia Risticii Bacterin
Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae Bacterin
Swine Influenza Vaccine-Erysipelothrix Rhusiopathiae-Mycoplasma Hyopneumoniae Bacterin
Swine Influenza Vaccine-Mycoplasma Hyopneumoniae Bacterin
Trichomonas Foetus-Campylobacter Fetus-Leptospira vaccine
Canine Distemper-Coronavirus-Parvovirus Vaccine
A horse vaccine that protects against EEE, VEE, WEE, influenza virius infection, and West Nile virus infection.
horse Encephalomyelitis-Influenza-West Nile Virus vaccine
porcine parvovirus-erysipelothrix rhusiopathiae vaccine
Bovine Virus Diarrhea-Respiratory Syncytial Virus vaccine
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterial Extract
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Leptospira Pomona Bacterin
Bovine Respiratory Syncytial Virus Virus Vaccine-Haemophilus somnus Bacterin
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3 Vaccine-Haemophilus somnus-Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Canine Adenovirus Type 2-Parainfluenza-Bordetella Bronchiseptica Modified Live Virus & Avirulent Live Culture Vaccine (USDA: 12X1.21)
Canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Modified Live & Killed Virus Vaccine-Leptospira Icterohaemorrhagiae Bacterial Extract (USDA: 46L9.20)
Fowl Laryngotracheitis-Marek's Disease Serotype 3, Live Marek's Disease Vector Vaccine (USDA: 16J1.R3)
created according to WHO Technical Report Series, No. 927, 2005 Annex 3 Recommendations for the production and control of influenza vaccine (inactivated)
influenza vaccine (whole virion, inactivated)
influenza vaccine (split virion, inactivated)
influenza vaccine (surface antigens, inactivated)
influenza vaccine (inactivated, adjuvanted)
influenza A (H1N1) 2009 monovalent vaccine (IDB)
Vaccine that protects against Listeria monocytogenes infection.
A vaccine that protects against Mycobacterium avium.
A bacterial vaccine that protects against infection with Staphylococcus aureus.
A bacterial gene that is from Streptococcus.
A bacterial gene that is from Streptococcus equi.
Aeromonas vaccine that protects against Aeromonas hydrophila infection.
An Edwardsiella bacterial vaccine that protects against Edwardsiella tarda.
A bacterial vaccine that protects against infections by Salmonella typhimurium species.
A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Gallinarum.
A bacterial vaccine that protects against infections by Salmonella enterica subsp. enterica serovar Enteritidis.
A bacterial vaccine that protects against infections by Yersinia pseudotuberculosis.
A viral vaccine that protects against infection of human metapneumovirus.
A viral vaccine that protects against infection of Human respiratory syncytial virus.
Human respiratory syncytial virus vaccine
a malaria vaccine that protects against malaria caused by Plasmodium berghei.
a malaria vaccine that protects against malaria caused by Plasmodium yoelii.
A protozoan gene that is from Leishmania infantum.
The mutant strain, with deletion of apxIA gene, obtained in this study offered a level of cross-serovar protection against A. pleuropneumoniae infection in mice and pigs (Reference: PMID: 16930871).
apxIA from Actinobacillus pleuropneumoniae
In the intra-peritoneal mouse model, the virulence of the mutant strain decreased at least 100 fold compared with the parent strain. The mutant was evaluated as a potential vaccine using a vaccination-challenge trial. The death number and lung lesion score in the vaccinated pigs given the serovar 1 challenge were obviously lower than those in the unvaccinated pigs
apxIC from Actinobacillus pleuropneumoniae
Deletion in ureC and apxIIA genes of Actinobacillus pleuropneumoniae serotype 2 prototype provides attenuation and protection in pigs against challenge with the virulent parent strain of A. pleuropneumoniae
apxIIA from Actinobacillus pleuropneumoniae
In the present study, the gene encoding the ApxII-activating protein, apxIIC, was insertionally inactivated on the chromosome of a serovar 7 strain, HS93. Pigs vaccinated with live HS93C-Ampr via the intranasal route were protected against a cross-serovar challenge with a virulent serovar 1 strain of A. pleuropneumoniae
apxIIC from Actinobacillus pleuropneumoniae
obsolete apxIIC from Actinobacillus pleuropneumoniae
An apxIIIB mutant, in combination with an apxIIID mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain
apxIIIB from Actinobacillus pleuropneumoniae
NCBI_Nucleotide_ID: 470686; PMID: 19887737
An apxIIID mutant, in combination with an apxIIIB mutation, is highly attenuated in pigs and induces significant protection from challenge with wild type A. pleuropneumoniae. The mutant also was slightly attenuated in mice and induced protection in mice against challenge from the parent strain
apxIIID from Actinobacillus pleuropneumoniae
NCBI_Nucleotide_ID: 470687; PMID: 19887737
A precisely defined DeltaapxIICDeltaapxIVA double-deletion mutant of A. pleuropneumoniae was constructed based on HB04C(-) by transconjugation and counterselection. The results demonstrated that the DeltaapxIICDeltaapxIVA double mutant strain was less virulent than HB04C(-). Despite attenuation of virulence, the DeltaapxIICDeltaapxIVA double mutant remains immunogenic and conferred a similar level of protective immunity to pigs against challenge with a lethal dose of a heterologous fully virulent standard serovar 1 strain of A. pleuropneumoniae
apxIVA from Actinobacillus pleuropneumoniae
Deletions were introduced into the ureC and apxIIA genes of an Actinobacillus pleuropneumoniae serotype 2 strain by homologous recombination and counterselection. The double-mutant contains no foreign DNA, is highly attenuated, protects pigs from homologous challenge upon a single aerosol application
ureC from Actinobacillus pleuropneumoniae
An mntA deletion mutant, generated by allelic replacement, in Bacillus anthracis was attenuated and provided protection for guinea pigs against lethal spore dose (60 LD50) of the virulent B. anthracis Vollum strain
An actA mutant is attenuated in mice and induced significant protection from challenge with wild type L. monocytogenes
obsolete actA from Listeria monocytogenes
A plcB mutant, in combination with an actA mutant, is attenuated in mice and induces significant protection from challenge with wild type L. monocytogenes
A M. avium relA mutant is attenuated in calves and goats. This mutant also elicited an immune response in goats that limited colonization by challenge wild type M. avium
A drrC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis
An fadD26 mutant is attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis
Deletion of leuD gene was shown to be highly attenuated. Immunocompetent BALB/c mice vaccinated with the DleuD auxotroph were protected as well as BCG in terms of survival following an intravenous or aerosol challenge with virulent M. tuberculosis
A lysA mutant, in combination with a secA2 mutation, is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis
A Mce-2 mutant in Mycobacterium tuberculosis is attenuated and provides protection against challenge for mice
A mce-3 mutant in Mycobacterium tuberculosis is attenuated and provides protection against challenge for mice
A panCD mutant is attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis
obsolete panC from Mycobacterium tuberculosis
obsolete panD from Mycobacterium tuberculosis
A proC mutant is highly attenuated in mice and induces significant protection from challenge with wild type M. tuberculosis that is equal to the protection induced by the current vaccine BCG
RD1 and panCD mutants in Mycobacterium tuberculosis were attenuated and provided protection in CD4-deficient mice against an aerosol challenge with virulent M. tuberculosis
Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Gu√©rin vaccination
A viral vaccine that protects against infection with Reticuloendotheliosis virus
A sigE mutant is highly attenuated in mice and induced significant protection from challenge with wild type M. tuberculosis, more so than the existing vaccine BCG
A trpD mutant is highly attenuated in mice and induces more protection from challenge with wild type M. tuberculosis than that induced by the current vaccine BCG
An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. aureus
A vicK mutant is attenuated in mice and induced protection from challenge with wild type S. equi
An A. hydrophila aroA mutant is highly attenuated in trout, and a single immunization conferred significant protection from challenge with wild type A. hydrophila
The aroA gene was inactivated by inserting a fragment expressing kanamycin resistance within the coding sequence and challenged in fish. The LD50 for unvaccinated fish was 71. In contrast, the LD50 was 1.8 x 104 in fish vaccinated once and 3 x 105 in fish vaccinated twice
Inactivation of the aroA gene highly attenuates B. bronchiseptica, severely impairing its ability to colonize and survive in the respiratory tract of mice. Upon challenge with wild type B. bronchiseptica, the mice immunised with live attenuated B. bronchiseptica aroA mutant had rapidly reduced numbers of B. bronchiseptica in their respiratory tract
obsolete aroA from Bordetella bronchiseptica
A double mutant strain of Bordetella Bronchiseptica lacking adenylate cyclase(cyaA gene) and type III secretion(bscN gene) is attenuated and provides protection in mice against 5 x 105 CFU of RB50, the B. Bronchiseptica parent strain.
A dnt mutant in Bordetella bronchiseptica was attenuated and provides protection in guinea pigs against intranasal challenge with strain L3
A trpE mutant, in combination with an aroA mutation, is attenuated in mice and induces significant protection from challenge with wild type B. bronchiseptica
An aroA mutant is highly attenuated in mice and induces significant protection from challenge with wild type B. pertussis
A live attenuated B. pertussis vaccine strain BPZE1, developed by deleting dnt gene, protects mice upon a single intranasal administration
A flagella-less mutant of Borrelia burgdorferi (HB19Fla-) was attenuated in immunodeficient SCID mice. Mice were challenged 28 days later with virulent strain Sh. 2 and were protected from challenge
A asp24 mutation in Brucella abortus is attenuated and provides significant protection in mice
A bp26 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice
Brucella DeltaexsA mutant showed decreased survival in mice compared to the survival of parental strain S2308. This demonstrated that ExsA is critical for full bacterial virulence. The B. abortus exsA deletion mutant was used as a live vaccine candidate. Challenge experiments revealed that the exsA mutant strain induced superior protective immunity in BALB/c mice compared to the protective immunity induced by strain S19 or RB51
Unmarked rough B. abortus and B. melitensis deletion mutants of manBA (including manA and manB) were attenuated. These mutants provided protection against virulent Brucella challenge in mice
Mutants manB and manA were attenuated in Brucella melitensis and provided protection against challenge in mice's livers
A mucR mutant has a significantly reduced degree of colonization in mice and protects against wild type B. melitensis 16M
A omp25 mutant is attenuated and provides protection against challenge in mice
A omp31 mutant in Brucella melitensis was attenuated and provided protection against challenge in mice
A pgk mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus
A pgm mutant is attenuated in mice and induces significant protection from challenge with wild type B. abortus
Mice infected with delta purE201 developed only five to eight times normal spleen weight at 1 week p.i. and produced no interleukin-6 in their serum, which is much lower than the mice infected with the parental strain (16M)
A purE/purK mutant of B. melitensis 16M was attenuated in mice when given intraperitoneally. Nine weeks after immunization, mice were protected from challenge with wild type B. melitensis
A virB2 mutant is attenuated in Brucella melitensis and provides protection in mice
Deletion of gene znuA attenuates Brucella abortus and this live attenuated vaccine was challenged in mice. These mice showed significantly fewer spenic CFU
The aroC deletion in the resultant mutant, designated A2ŒîaroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. The constructed unmarked aroC mutant of B. pseudomallei is attenuated in both BALB/c and C57Bl/6 mice and is able to confer significant protection in C57Bl/6 mice
An asd mutant is highly attenuated in mice. This mutant was also able to protect against acute inhalation melioidosis caused by challenge with wild type B. pseudomallei
Mice that were challenged with a higher dose of mutant 56:65 purM were protected
Although 30:93a purN -immunized mice were challenged with a 10-fold higher dose of WT E8, mice were strongly protected and showed no signs of clinical illness until the experiment was terminated
A crp mutant is attenuated in zebrafish and catfish that were immunized intramuscularly and intracoelomically, respectively. Six weeks after immunization, both zebrafish and catfish were protected from challenge with wild type E. ictaluri
An aroC mutant is attenuated in zebra fish. The aroC mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 68.3%
An esrB mutant is highly attenuated in fish (turbot), with an LD50 of 10(8.1)cfu/fish. Vaccination with this mutant elicited significant protection from wild type E. tarda
An aroC and esrC mutant is attenuated in zebra fish. This mutant is also protective against challenge with wild type E. tarda and has a relative percent survival of 71.3%
An aroC and slyA mutant is attenuated in zebra fish. This mutant is also protective against challenge from wild type E. tarda, resulting in a relative percent survival of 80.1%
A carAB mutant is attenuated in turkeys and induces significant protection from challenge with wild type E. coli
A ler deletion mutant derived from wild-type EHEC O157:H7 86-24 was constructed by use of suicide vector pCVD442. Following challenge of 7-day-old suckling mice with O157:H7 EDL933, 75.2% born to group B mothers (immunized with F25) sur- vived, as did 83.0% born to group C mothers (immunized with F105). The surviving suckling mice consistently gained body weight. Only 16.8% of sucking mice born to control group mice survived the challenge
Deletion of waaL results in a strain that stimulates enhanced urothelial cytokine secretion, which is an enhanced innate immune response. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted >=8 weeks.
There was a deletion in gene capB of F. tularensis live vaccine strain. LVS capB, while much less virulent than LVS, induces potent protective immunity against lethal LVS i.n. challenge in mice, comparable to that induced by LVS
A clpB mutant in Francisella tularensis subspecies tularensis strain SCHU S4 was attenuated and provided protection against aerosol challenge in mice
A FTL0552 mutant in Francisella tularensis was attenuated and provided partial protection in mice against challenge with a lethal dose of the virulent SchuS4 strain when compared to naive mice
An FTT0918 mutant showed significantly reduced virulence in mice. Mice that recovered from infection with the mutant were protected 2 months later from challenge with wild type F. tularensis
A galU mutant is attenuated in mice, with only transient weight loss observed. Two months after inoculation, mice were challenge with wild type F. tularensis and were protected, once again only experiencing transient weight loss
A guaA mutant is highly attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS
A guaB mutant is attenuated in mice and induces significant protection from challenge with parent strain F. tularensis LVS
Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge
A purMCD mutant in Francisela tularensis was attenuated. A low dosage of F. tularensis LVS delta purMCD mutant provided protection against challenge in mice
Mice, which had been immunized with at least 6.95 x 103 cfu of F. tularensis U112 purF::Cm, were protected against the subsequent F. tularensis subspecies novicida challenge.
A purMCD mutant in Francisella tularensis was attenuated. A low dose of the F. tularensis LVS delta purMCD mutant provided protection against subsequent lethal challenge with the LVS parental strain
A sodC mutant in Francisella tularensis subspecies holarctica was attenuated and provided protection and cleared the infection against lethal challenge in nearly 50% of the mice infected with the delta-sodC mutant.
A wbtA mutant in Francisella tularensis was attenuated and provided protection in mice against challenge with an otherwise lethal dose of either F. tularensis LVS or a fully virulent clinical isolate of F. tularensis type B
A wbtI mutant is attenuated in mice. The mutant protected against a low dose challenge with the parental strain, but was less effective against higher doses. However, increasing the immunization dose increased the resistance to higher challenge doses
An aroA mutant is highly attenuated in mice and induced significant protection after two doses from challenge with wild type M. haemolytica
An lpd mutant is highly attenuated in chickens and induces significant protection from challenge with wild type M. gallisepticum
A metH mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis
An rfaF mutant, in combination with a siaD mutation, is attenuated in mice and induces significant protection from challenge with wild type N. meningitidis
A siaD mutant, in combination with either a metH or rfaF mutation, is attenuated in mice and induces protection from challenge with wild type N. meningitidis
obsolete siaD from Neisseria meningitidis
An aroA mutant is highly attenuated in calves and induces significant protection from challenge with wild type P. multocida
An aroA mutant is attenuated in mice and induced significant protection from challenge with wild type S. typhi Ty2
Inactivation of AroC results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908"
Inactivation of AroD results in attenuation in humans, and the deletions of both AroC and AroD provide a high level of safety against restoration of pathogenicity by recombination. An aroC/aroD-deleted derivative of S. Typhi strain Ty2 (the parent strain of Ty21a) is designated the strain "CVD 908"
An asd mutant, alone or in combination with a rfc mutation, is attenuated in mice and induces significant protection from challenge with wild type Salmonella typhimurium
An atpA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium
A cbiA mutant, in combination with a cobS mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis
A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective, and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis
A mutation in clpP (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice, and an LD50 for CS2007 could not be determined because mice did not die after inoculation with the highest dose. CS2007 also elicited protection in mice from challenge with wild type S. typhimurium
A cobS mutant, in combination with a cbiA mutation, is attenuated in chickens and induces significant protection from challenge with wild type S. Gallinarum. This mutant was also able to provide some protection against S. Enteritidis
A gyrA-cpxA-rpoB Salmonella Typhimurium mutant was attenuated and protected against challenge in pigs
A cpxR mutant, in combination with a lon mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum
A cya and crp mutant is attenuated in mice. Thirty days after immunization, mice were protected from oral challenge with wild type S. typhimurium
A crp mutant is attenuated in mice and induces significant protection from challenge with wild type S. gallinarum
A fliC mutant, in combination with a guaB mutant, is attenuated in mice and chickens and induces significant protection from challenge with wild type S. enterica
A guaBA, clpP, and fliD mutant (CVD 1923) is attenuated in mice after oral immunization. This mutant is also protective, with a vaccine efficacy of 80% in mice against wild type challenge from Salmonella Typhimurium
A gal E mutant in strain Ty2 was isolated, attenuated, and protected mice against lethal challenge
A guaBA and clpP mutant (CVD 1941) is attenuated in mice after oral immunization. This mutant is also protective in mice and had a vaccine efficacy of 76% against challenge with wild type Salmonella Enteritidis
A guaBA and clpP mutant (CVD 1921) of Salmonella Typhimurium is attenuated in mice after oral immunization. The mutant was also protective, rendering a vaccine efficacy of 86% in mice against challenge with wild type Salmonella Typhimurium
A guaB mutant, in combination with a fliC mutant, is attenuated in mice and chickens and induced significant protection from challenge with wild type S. enterica
Oral immunization with the Salmonella hfq deletion mutant efficiently protects mice against subsequent oral challenge with virulent strain of Salmonella Typhimurium
A htrA mutant in Salmonella typhimurium is attenuated and provides protection in mice against an oral challenge with virulent S. typhimurium SL1344
A lon mutant, in combination with a cpxR mutation, is highly attenuated in mice and induces significant protection from challenge with wild type S. gallinarum
An lppA mutant, in combination with an lppB/msbB mutation, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium
An lppB mutant, in combination with an msbB mutant or an msbB/lppA mutant, is attenuated in mice and induces significant protection from challenge with wild type S. Typhimurium
An msbB mutant, in combination with an lppB or lppAB mutation, is attenuated in mice and induces significant protection from challenge with S. Typhimurium
In a pig infection experiment including two oral immunizations with SalmoporcDeltaompD (OmpD, nmpC) and challenge with a multiresistant S. enterica serovar Typhimurium DT104 clinical isolate, we confirmed the protective efficacy of SalmoporcDeltaompD in pigs, showing a significant reduction of both clinical symptoms and colonization of lymph nodes and intestinal tract
A nuoG mutant is attenuated in chickens and induced significant protection from challenge with wild type S. Gallinarum
An ompR mutant is attenuated in mice after oral challenge. Twenty eight days after immunization, mice were challenged with wild type S. typhimurium and were significantly protected
Three S. typhi deletion mutants (phoP, rpoS, and rpoS-phoP double mutant) were constructed and characterized with respect to invasiveness, virulence, and protective immune response compared with wild-type Ty2. All S. typhi mutants showed an increase in the specific serum IgG levels and T-cell-mediated immunity, and showed equal protection abilities against a wild-type Ty2 challenge after two rounds of immunization in BALB/c mice
A poxA mutant is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium
A ppGpp-defective Salmonella Gallinarum, which is attained by mutating the relA and spoT genes, is attenuated in chickens and induces protection from oral challenge with wild type S. Gallinarum
An rfc mutant, in combination with an asd mutation, is attenuated in mice and induces significant protection from challenge with wild type S. typhimurium
Immunizations with Salmonella typhimurium rpoS and rpoS aroA mutants protected susceptible BALB/c mice against subsequent oral challenge with virulent S. typhimurium. When administered orally or intraperitoneally, rpoS derivatives of the mouse-virulent S. typhimurium strains, C52 and SL1344, were highly attenuated and were efficient single-dose live vaccines
A ruvB mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium
A surA mutant (BRD1115) is attenuated in BALB/c mice and induces protection from challenge with wild type S. typhimurium
A tolA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium
A trxA mutant is attenuated in mice and induced significant protection from challenge with wild type S. Typhimurium
A wecA mutant (DSM645) is attenuated in C57BL/6J mice through i.p. and oral immunization. This mutant also protects against challenge with S. typhimurium strains TML and SL1344 30 days after immunization
A znuABC mutant is attenuated in mice and induced significant protection against a challenge infection in the large intestine with wild type Salmonella typhimurium
An aroD mutant is highly attenuated in monkeys and induces significant protection from challenge with wild type S. flexneri
An envZ mutant (SC433) is greatly decreased in virulence in macaque monkeys, though some mild clinical signs were still recorded. This mutant is also highly protective against a challenge of wild type S. flexneri delivered 1 month after inoculation
A virG, senA, senB, and msbB2 mutant (WRSs3) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs3 is comparable to live attenuated vaccine strain WRSS1
A virG, senA, and senB mutant (WRSs2) is attenuated in guinea pigs and induced significant protection from challenge with wild type S. sonnei. Attenuation and protection from WRSs2 is comparable to live attenuated vaccine strain WRSS1
A hemA mutant is highly attenuated in mice and rabbits and induces protection from challenge with wild type V. cholerae in rabbits
An aroA mutant is highly attenuated in mice, and after 3 doses induces significant protection from challenge with wild type Y. enterocolitica
A htrA mutant in Yersinia enterocolitica was attenuated and provided partial protection against challenge in mice
A ompR mutant in Yersinia enterocolitica was attenuated and provided a partial protection from challenge in mice
A sodA mutant in Yersinia enterocolitica was highly attenuated and mice immunized with a single oral dose of the mutant strain were protected against a lethal oral-challenge infection with wild-type Y. enterocolitica
A guaBA mutant is attenuated in mice and induced significant protection from challenge with wild type Y. pestis
An IpxM mutant is attenuated in mice and guinea pigs. This mutant also conferred modest protection from challenge with wild type Y. pestis in Balb/c mice and significant protection in guinea pigs and outbred mice
An nlpD mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis
A pcm mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis
An smpB mutant, in combination with an ssrA mutation, is attenuated in mice and induces significant protection from challenge with wild type Y. pestis
A yopH mutant is highly attenuated in mice and induced significant protection from challenge with wild type Y. pestis
A phoP mutant in Yersinia pseudotuberculosis (Yptb) was attenuated and provided protection against oral challenge with virulent Yptb in mice
An aroA mutant is highly attenuated in rainbow trout and induces significant protection from challenge with wild type Y. ruckeri
A thymidine kinase-deficient mutant (B8-D53) showed no detectable thymidine kinase-inducing activity and was attenuated in calves. B8-D53 also induced protection from challenge with wild type BHV-1
A deletion of BHV-1 gE gene in strain A is considered as a live attenuated vaccine. After challenge, vaccinated calves were protected against disease and virus shedding was reduced
A glycoprotein G deletion in bovine respiratory syncytial virus(rBRSV) and recombinant rBRSV was attenuated and provided protection against a BRSV challenge infection in calves
glycoprotein G from Bovine Respiratory Syncytial Virus
An N269A/Q mutation in the E(rns) protein created an attenuated mutant in swine. This mutant was able to induce effective protection in swine against challenge with wild type CSFV
An N to A amino acid substitution was made in the N594 site of the E1 glycoprotein, resulting in attenuation of the virus in swine. This attenuated virus induced protection against challenge with wild type CSFV
A E2 mutant in Classical swine fever virus is attenuated and provides protection in pigs after oronasal vaccination (not intradermal vaccination) against lethal challenge dose of CSFV strain Eystrup
E2 gene from Classical swine fever virus
A glycoprotein E mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice
A glycoprotein I mutant is attenuated in mice and hamsters and induced significant protection from challenge with wild type Equid herpesvirus in mice
A thymidine kinase-deficient mutant (PR1) is attenuated in mice and induced significant protection from challenge with wild type EHV-1 5 weeks after vaccination. In foals, PR1 also showed attenuation; however, the mutant induced only partial protection from challenge with EHV-1
A thymidine kinase-deficient mutant (C7301dlTK) is attenuated in cats and induced significant protection from wild type FHV-1 4 weeks after vaccination
Feline immunodeficiency virus (FIV) made defective in the accessory gene ORF-A were previously shown to be greatly attenuated in its ability to replicate in lymphocytes but to grow normally or near normally in other cell types. 3/9 vaccinees (cats) showed no evidence of the challenge virus over a 15-month observation period. In the other vaccinees, the challenge virus was predominant for various periods of time, but pre-existing viral loads and CD4 lymphocyte counts were either unaffected or altered only marginally and transiently
ORF-A from Feline immunodeficiency virus
A vif mutant in feline immunodeficiency virus was attenuated and FIV-pPPR delta vif proviral DNA protected cats against challenge with the homologous FIV-PPR biological isolate.
A 3abc deletion mutant in Feline infectious peritonitis virus (FIPV) was attenuated and provided protection against virulent FIPV strain 79-1146 challenge in kittens
3a from Feline infectious peritonitis virus
3b from Feline infectious peritonitis virus
3c from Feline infectious peritonitis virus
A 7ab deletion mutant in Feline infectious peritonitis virus is attenuated and provides protection against virulent FIPV strain 79-1146 challenge in kittens
7a from Feline infectious peritonitis virus
7b from Feline infectious peritonitis virus
A UL0 mutant in infectious laryngotracheitis virus (ILTV) was attenuated. Chickens immunized with UL0-negative ILTV were protected from clinical disease after subsequent infection with virulent ILTV
A thymidine-kinase mutant is attenuated in chickens and induced protection from challenge with wild type GHV-1
A UL47 mutant in avian infectious laryngotracheitis virus is attenuated and provides protection in chicken against subsequent challenge infection with virulent ILTV
Researchers generated a series of woodchuck hepatitis virus (WHV) X mutants. Woodchucks inoculated with X mutants, including those with no serologic evidence of infection, were protected from later challenge with infectious Woodchuck Hepatitis Virus, suggesting previous infection with resulting protective immunity
KOS-gDA3C is attenuated with mutations in gD gene in causing skin lesions at the inoculation and zosteriform sites, yet it is as effective as rKOS-gDA3C in protecting mice against HSV-1 challenge
gD from Herpes simplex virus type 1 and 2
A gH mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1
gH from Herpes simplex virus type 1 and 2
A live-attenuated HSV-2 ICP0 virus provides significant protection against wild-type HSV-2 (MS strain) challenge in mice
iCP0 from Herpes simplex virus type 1 and 2
A thymidine kinase-deficient (TK) mutant was found to be attenuated in mice. This mutant induced complete protection from challenge with wild type HSV
TK from Herpes simplex virus type 1 and 2
A UL29 mutant is attenuated in mice and induces significant protection from challenge with wild type HSV-1
UL29 from Herpes simplex virus type 1 and 2
An HSV-1 gE (Us8) deletion strain, NS-gEnull, was used as a live attenuated vaccine. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice
US8 from Herpes simplex virus type 1 and 2
A G mutant is attenuated in African green monkeys and induces protection from challenge with wild type HMPV
An M2-2 mutant is attenuated in African green monkeys and induced protection from challenge with wild type HMPV
An M2-2 mutant of human respiratory syncytial virus A2 is attenuated in African green monkeys. When challenged with wild type RSV, two doses provided complete protection against challenge in the lower respiratory tract and a significant reduction of the challenge virus in the upper respiratory tract
M2-2 from Human Respiratory Syncytial Virus
A mutation in the non-virion protein of IHNV causes attenuated growth in rainbow trout and is able to provide significant protection from subsequent challenge with wild type IHNV
NV from Infectious Hematopoietic Necrosis Virus
Mutant influenza virus that lacks the transmembrane and cytoplasmic tail domains of M2 (M2 knockout [M2KO]) from Influenza A virus (A/Puerto Rico/8/34(H1N1)) is attenuated in both cell culture and mice. Mice intranasally vaccinated with M2KO virus developed protective immune responses and survived a lethal challenge with the wild-type virus, suggesting that the M2KO virus has potential as a live attenuated vaccine
Intranasal inoculation of mice, pigs, horses, and macaques with NS1-modified influenza virus strains induced robust humoral and cellular immune responses, and generated immune protection against challenge with wild-type virus
A mutation in the GP5 protein attenuates HP-PRRSV in piglets. This mutant (HuN4-F112) induces protection against challenge with wild type HP-PRRSV
GP5 protein from Porcine respiratory and reproductive syndrome virus
A glycoprotein E mutant, in combination with UL23 and glycoprotein G mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV
A glycoprotein G mutant, in combination with UL23 and glycoprotein E mutations, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV
A glycoprotein M, gM, deletion in pseudorabies virus was attenuated and induced protection in piglets against intranasal challenge with 108 p.f.u. of the highly virulent PrV strain NIA-3
A gp50+gp63 deletion mutant in Pseudorabies virus was attenuated and provided protection from clinical signs of Aujeszky's disease after a challenge inoculation with the virulent wild-type PRV strain NIA-3
A UL23 mutant, in combination with mutations in glycoproteins G and E, is attenuated in raccoons, with a 75% survival rate. This mutant also provides some protection from wild type PRV
A UL50 mutant is attenuated in pseudorabies virus and induces significant protection in pigs from challenge with the highly virulent NIA-3 strain of PrV
Researchers intranasally inoculated pigs, the natural host of this virus, with mutant PRV strains in which the genes encoding the protein kinase (US3) proteins were inactivated. After challenge infection with the virulent PRV strain NIA-3, no virus was excreted by wt PRV- and PK- mutant-immunized animals, indicating complete protective immunity
A glycoprotein G mutant in rabies virus is attenuated. After a one-dose intramuscular vaccination, the ERAg3m virus protected 100% of mice and hamsters from lethal challenge. In co-infections, using a lethal dose of street rabies virus mixed with ERAg3m, 100% of hamsters and 90% of mice survived and were protected against subsequent infection
A P gene mutant is attenuated in mice and induces significant protection from challenge with wild type Rabies virus
An E mutant is attenuated in hamsters and induces significant protection from challenge with wild type SARS
A SIV nef mutant is attenuated in rhesus monkeys and induces protection from challenge with wild type SIV
A virus with a mutation in protein C is attenuated in mice and induced protection from challenge with wild type TBE virus
C protein from Tick-borne Encephalitis Virus
A VEE mutant with a PE2 cleavage signal mutation and a suppressor mutation in E1 is highly attenuated in mice and provides complete protection against challenge with wild type VEE
A virus with a C protein mutation is attenuated in mice and induces significant protection from challenge with wild type West Nile virus
A PE2 mutant combined with a deletion in E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur
E1 from Western equine encephalomyelitis virus
obsolete E1 from Western equine encephalomyelitis virus
A PE2 mutant combined with a deletion in E2 (WE2102) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of this strain would occur
E2 gene from Western equine encephalomyelitis virus
obsolete E2 from Western equine encephalomyelitis virus
A PE2 mutant combined with either a deletion in E2 (WE2102) or E1 (WE2130) induced low-level viremia in chickens and protected against challenge with wild type WEE after 2 weeks. This study also found that it is unlikely that mosquito transmission of these two strains would occur
PE2 from Western equine encephalomyelitis virus
obsolete PE2 from Western equine encephalomyelitis virus
A cen1 mutant is attenuated in mice and hamsters and induces significant protection from challenge with wild type L. donovani
A Leishmania infantum deletion mutant of HSP70-II gene is attenuated and provides protection against Leishmania infection in the L. major-BALB/c infection model. Also, DeltaHSP70-II is a safe live vaccine as immunodeficient SCID mice, and hamsters, infected with mutant parasites did not develp any sign of pathology
A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage. It also conferred complete protection in mice from challenge with wild type Plasmodium
Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice
A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites
Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites
A mic2 mutant is attenuated in mice and induces protection from challenge with wild type T. gondii
An OMPDC mutant, alone or in combination with an UP mutation, is attenuated in mice and induces significant protection from challenge with wild type T. gondii
A UP mutant, in combination with an OMPDC mutation, is attenuated in mice and induces significant protection from wild type T. gondii
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3284
The mutant strain, with deletion of apxIA gene, obtained in this study offered a level of cross-serovar protection against A. pleuropneumoniae infection in mice and pigs (Reference: PMID:16930871).
Actinobacillus pleuropneumoniae apxIA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3112
Actinobacillus pleuropneumoniae ApxIC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3118
Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3120
A precisely defined DeltaapxIICDeltaapxIVA double-deletion mutant of A. pleuropneumoniae was constructed based on HB04C(-) by transconjugation and counterselection. The results demonstrated that the DeltaapxIICDeltaapxIVA double mutant strain was less virulent than HB04C(-). Despite attenuation of virulence, the DeltaapxIICDeltaapxIVA double mutant remains immunogenic and conferred a similar level of protective immunity to pigs against challenge with a lethal dose of a heterologous fully virulent standard serovar 1 strain of A. pleuropneumoniae. (Reference: PubMed: 17767980)
Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3119
Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine
obsolete Actinobacillus pleuropneumoniae apxIIIB and apxIIID double mutant vaccine
obsolete Actinobacillus pleuropneumoniae apxIIC and apxIVA double deletion mutant vaccine
obsolete Actinobacillus pleuropneumoniae ureC and apxIIA double mutant deletion vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3115
Bacillus anthracis mntA deletion mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3214
Listeria monocytogenes actA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3215
Listeria monocytogenes actA/plcB mutant vaccine
obsolete Listeria monocytogenes actA/plcB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3212
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3203
Mycobacterium tuberculosis drrC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3204
Mycobacterium tuberculosis fadD26 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3205
Mycobacterium tuberculosis leuD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3206
Mycobacterium tuberculosis lysA/secA2 mutant vaccine
Mycobacterium tuberculosis mce-2/mce-3 mutant vaccine
A viral vaccine that protects against infection with Chikungunya virus
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3208
Mycobacterium tuberculosis panCD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3281
Mycobacterium tuberculosis RD1/panCD mutant vaccine
a bacterial vaccine against Streptococcus suis infection
Vaccine against infection with Corynebacterium pseudotuberculosis.
Corynebacterium pseudotuberculosis vaccine
obsolete M. tuberculosis phoP mutant SO2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3209
Mycobacterium tuberculosis proC mutant vaccine
A protozoan vaccine against Trichinella spiralis infection
A vaccine that prevents or treats atherosclerosis disease.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3211
Mycobacterium tuberculosis sigE mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3210
Mycobacterium tuberculosis trpD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3149
Staphylococcus aureus aroA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3148
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3114
Aeromonas hydrophila aroA mutant vaccine
obsolete A. salmonicida live-attenuated vaccine encoding AroA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3122
Bordetella bronchiseptica aroA mutant vaccine (strain BBS18)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3268
Bordetella bronchiseptica aroA/trpE mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3123
Bordetella bronchiseptica bscN and cyaA double mutant vaccine
obsolete Bordetella bronchiseptica bscN and cyaA double mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3124
Bordetella bronchiseptica dnt mutant vaccine
obsolete Bordetella bronchiseptica aroA/trpE mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3134
Bordetella pertussis aroA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3176
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3267
B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=299
Brucella abortus and Brucella melitensis mutants with unmarked deletion of asp24, virB2, or manBA vaccine
A vaccine that prevents or treats diabetes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3260
A vaccine that prevents or treats a non-infectious disease.
There are mainly five types of non-infectious diseases, which are diabetes, allergies, cardiovascular diseases, cancer and genetic diseases. URL: http://www.ychlpyss.edu.hk/~bio/share/0405/f6homework/Non-infectious%20disease/noninfectiousdisease(ths).htm
obsolete B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA
obsolete B. melitensis mucR mutant vaccine
obsolete B. melitensis omp25 mutant vaccine
obsolete B. melitensis omp31 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3264
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3263
Brucella melitensis WR201 (16MΔpurEK) vaccine
obsolete B. melitensis WR201 (16M-delta-purEK)
A vaccine that prevents or treats arthritis.
live attenuated B. abortus with deletion of znuA
live attenuated Brucella abortus with deletion of znuA vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3179
The aroC deletion in the resultant mutant, designated A2 Delta aroC, was confirmed by PCR, Southern hybridization and failure of the mutant to grow in a defined medium without aromatic compounds. The constructed unmarked aroC mutant of B. pseudomallei is attenuated in both BALB/c and C57Bl/6 mice and is able to confer significant protection in C57Bl/6 mice.
Burkholderia pseudomallei aroC deletion mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3272
Burkholderia pseudomallei asd mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3257
Burkholderia pseudomallei purM mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3258
Burkholderia pseudomallei purN mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3283
Edwardsiella ictaluri crp mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3273
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3275
Edwardsiella tarda aroC/slyA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3274
Edwardsiella tarda aroC/esrC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3253
obsolete Edwardsiella tarda aroC/esrC mutant vaccine
obsolete Edwardsiella tarda aroC/slyA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3248
A vaccine that prevents or treats an autoimmune disease.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3249
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3279
Deletion of waaL results in a strain that stimulates enhanced urothelial cytokine secretion, which is an enhanced innate immune response. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted >= 8 weeks.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3232
Francisella tularensis capB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3280
Francisella tularensis clpB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3233
Francisella tularensis FTL0552 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3234
Francisella tularensis FTT0918 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3278
Francisella tularensis galU mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3235
Francisella tularensis guaA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3236
Francisella tularensis guaB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3237
Francisella tularensis IglB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3238
Francisella tularensis purMCD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3239
Mice, which had been immunized with at least 6.95x103 cfu of F. tularensis U112 purF::Cm, were protected against the subsequent F. tularensis subspecies novicida challenge.
Francisella tularensis purF mutant vaccine
obsolete Francisella tularensis purMCD mutant vaccine
A Streptococcus vaccine against Streptococcus pyogenes infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3240
A sodC mutant in Francisella tularensis subspecies holarctica was attenuated and provided protection and cleared the infection against lethal challenge in nearly 50% of the mice infected with the deletion of sodC mutant.
Francisella tularensis sodC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3241
Francisella tularensis wbtA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3242
Francisella tularensis wbtI mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3213
Mannheimia haemolytica aroA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3202
Mycoplasma gallisepticum lpd mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3200
Neisseria meningitidis metH/siaD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3201
Neisseria meningitidis rfaF/siaD mutant vaccine
obsolete Neisseria meningitidis metH/siaD mutant vaccine
obsolete Neisseria meningitidis rfaF/siaD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3199
Pasteurella multocida aroA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3156
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=249
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=252
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3157
Salmonella Typhimurium asd mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3158
Salmonella Typhimurium asd/rfc mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3159
Salmonella Typhimurium atpA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3160
Salmonella Gallinarum cbiA/cobS mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3271
Salmonella Enteritidis guaBA/clpP mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3161
Salmonella Typhimurium clpP mutant vaccine
obsolete Salmonella Typhimurium guaBA/clpP mutant vaccine (merged to VO_0002872)
obsolete Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine (merged to VO_0002872)
obsolete Salmonella Gallinarum cbiA/cobS mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3162
Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3163
Salmonella Gallinarum cpxR/Ion mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3290
Salmonella Typhimurium cya/crp mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3164
Salmonella Gallinarum crp mutant vaccine
obsolete Salmonella Typhimurium cya/crp mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3165
JZ: based on comment,VO:0002890 should be 'Salmonella enterica fliC/guaB mutant vaccine'.
Salmonella enterica fliC/guaB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3270
Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3166
obsolete Salmonella Enteritidis guaBA/clpP mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3269
Salmonella Typhimurium guaBA/clpP mutant vaccine
obsolete Salmonella Typhimurium guaBA/clpP/fliD mutant vaccine (merged to VO_0002885)
obsolete Salmonella Typhimurium guaBA/clpP mutant vaccine
obsolete Salmonella enterica fliC/guaB mutant vaccine
obsolete Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3167
Salmonella Typhimurium hfq mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3168
Salmonella Typhimurium htrA mutant vaccine
obsolete Salmonella Gallinarum cpxR/Ion mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3169
Salmonella Typhimurium IppA/IppB/msbB vaccine
obsolete Salmonella Typhimurium IppA/IppB/msbB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3170
Salmonella Typhimurium IppB/msbB mutant vaccine
obsolete Salmonella Typhimurium IppB/msbB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3291
Salmonella Typhimurium ompD/nmpC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3171
Salmonella Gallinarum nuoG mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3172
Salmonella Typhimurium ompR mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3173
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3174
Salmonella Typhimurium poxA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3175
Salmonella Gallinarum relA/spoT mutant vaccine
obsolete Salmonella Typhimurium asd/rfc mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3181
Salmonella Typhimurium rpoS mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3182
Salmonella Typhimurium ruvB mutant vaccine
obsolete Salmonella Gallinarum relA/spoT mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3183
Salmonella Typhimurium surA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3184
Salmonella Typhimurium tolA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3185
Salmonella Typhimurium trxA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3282
Salmonella Typhimurium wecA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3186
Salmonella Typhimurium znuABC mutant vaccine
obsolete Salmonella Typhimurium znuABC mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=262
Shigella flexneri 2a strain CVD 1203 vaccine
Shigella flexneri strain Sfl 124 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3151
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3152
a Brucella vaccine against infection wtih B. ovis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3153
Shigella sonnei virG/senA/senB/msbB2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3154
Shigella sonnei virG/senA/senB mutant vaccine
obsolete Shigella sonnei virG/senA/senB/msbB2 mutant vaccine
obsolete Shigella sonnei virG/senA/senB mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3142
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3135
Yersinia enterocolitica aroA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3136
Yersinia enterocolitica htrA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3137
Yersinia enterocolitica ompR mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3138
Yersinia enterocolitica sodA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3128
obsolete Yersinia pestis guaBA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3129
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3130
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3131
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3132
Yersinia pestis smpB/ssrA mutant vaccine
obsolete Yersinia pestis smpB/ssrA mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3133
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3127
Yersinia pseudotuberculosis phoP mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3126
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3266
Bovine herpesvirus 1 UL23 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3178
Bovine herpesvirus 1 US8 (gE) mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3265
Bovine respiratory syncytial virus glycoprotein G mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3254
Classical swine fever virus E(rns) mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3255
Classical swine fever virus E1 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3256
Classical swine fever virus E2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3251
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3252
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3247
Feline herpesvirus 1 UL23 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3245
Feline immunodeficiency virus ORF-A mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3246
A vif mutant in feline immunodeficiency virus was attenuated and a vif-deleted FIV provirus DNA protected cats against challenge with the homologous FIV-PPR biological isolate.
Feline immunodeficiency virus vif mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3243
Feline infectiour peritonitis virus 3abc mutant vaccine
obsolete Feline infectiour peritonitis virus 3abc mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3244
Feline infectious peritonitis virus 7ab mutant vaccine
obsolete Feline infectious peritonitis virus 7ab mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3228
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3229
Gallid herpesvirus 1 UL23 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3230
Gallid herpesvirus 1 UL47 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3227
Hepatitis B virus X protein mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3222
Herpes simplex virus 1 gD mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3223
Herpes simplex virus 1 gH mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3224
Herpes simplex virus 2 ICP0 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3225
Herpes simplex virus 1 TK mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3226
Herpes simplex virus 1 UL29 mutant vaccine
obsolete Herpes simplex virus type 1 DNA vaccine encoding GE
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3220
human metapneumovirus G protein mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3221
human metapneumovirus M2-2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3219
Human Respiratory Syncytial Virus M2-2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3218
Infectious Hematopoietic Necrosis Virus NV mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1016
influenza virus CTA1-3M2e-DD protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3217
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3194
Porcine respiratory and reproductive syndrome virus GP5 protein mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3189
Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine
obsolete Pseudorabies virus glycoprotein E/G/UL23 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3190
Psuedorabies virus glycoprotein M mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3191
Pseudorabies virus gp50/gp63 mutant vaccine
obsolete Pseudorabies virus gp50/gp63 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3192
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3193
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3187
Rabies virus glycoprotein G mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3188
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3155
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3150
Simian Immunodeficiency Virus nef mutant vaccine
ick-borne Encephalitis Virus C protein mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3143
obsolete VEE Virus PE2/E1 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3141
West Nile virus C protein mutant vaccine
obsolete WEEV DNA Vaccine encoding 6K-E1 Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3139
Western equine encephalomyelitis virus PE2/E1 mutant vaccine
obsolete WEEV Subunit E2 Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3140
Western equine encephalomyelitis virus PE2/E2 mutant virus
Western equine encephalomyelitis virus PE2/E1 or E2 mutant vaccine
obsolete Western equine encephalomyelitis virus PE2/E2 mutant virus
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3216
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3277
Leishmania infantum HSP70 II mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3195
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3196
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3197
Plasmodium yoelii p36/p52 mutant vaccine
obsolete P. yoelii p36/p52 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3198
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3144
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3145
Toxoplasma gondii OMPDC/UP mutant vaccine
obsolete Toxoplasma gondii OMPDC/UP mutant vaccine
A route of administration that located in the stomach, so that the material is taken into body through stomach directly.
An intragastric route that has a vaccine injection site located in stomach.
vaccination that occurs in the intagastric route.
vaccination process that occurs in intradermal route.
vaccination process that occurs in intranasal route
vaccination process that occurs in oral route.
vaccination process that occurs in the subcutaneous route
A vaccine prepration process that mixes vaccine lyophilized powder and diluent liquid. The process forms a vaccine that can be used for administration. This term can also be considered as a child term of OBI term 'material combination'.
WEB: http://www.thehaiticonnection.org/medical/reconstitution.pdf
A vaccine may include vaccine powder and solvent. When the two mix, we get a vaccine solution, which can be used to inject. Examples: http://www.medicines.org.uk/guides/acwy%20vax/Vaccinations%20%28all%29/ http://www.medicines.org.uk/guides/menitorix/Vaccinations%20%28all%29/ http://www.medicines.org.uk/guides/priorix/Vaccinations%20%28all%29/
Use only the specific diluent provided by the manufacturer for each type of vaccine to ensure adequate potency and safety of the resulting mixture.
a vaccine powder that is freeze-dried and lyophilized.
a role inheres in the vaccine component when it is added into vaccine's formulation, it tends to stabilizes an emulsion by increasing its kinetic stablity.
a role inheres in vaccine component when added into vaccine's formulation, it tends to inhibit the reaction between two or more other vaccine substances in the final vaccine formulation; it also helps to protect the vaccine from adverse conditions such as the freeze-drying process or heat.
a protein vaccine stablizer that is specifically human serum albumin.
it is subclass of 'serum albumin (PR:000003918)'
Gelatin is a mixture of peptides and proteins produced by partial hydrolysis of collagen extracted from the skin, boiled crushed bones, connective tissues, organs and some intestines of animals such as domesticated cattle, chicken, and pigs.(wikipedia)
a vaccine-induced gene response that represents a vaccine adverse event response associated with a host susceptibility gene.
host susceptibility gene response to vaccine adverse event
susceptibility gene response to vaccine adverse event
host immune factor-induced control of intracellular replication of live attenuated vaccine
immune factor-induced control of intracellular replication of live attenuated vaccine
a protein vaccine stablizer that is specifically bovine serum albumin.
a vaccine stabilizer that is specifically made by a sugar.
a vaccine stabilizer that is generated based on amino acids.
a vaccine stabilizer that is specifically made by a sucrose.
a vaccine stabilizer that is specifically made by a lactose.
a polysorbate 20 vaccine stabilizer that is Alkest TW20.
a polysorbate 20 vaccine stabilizer that is Tween 20.
an antibiotics vaccine residual that has the antibiotics of neomycin.
the vaccine antiegn that induces protective immune response.
A viral vaccine against infection of an Sindbis virus.
A viral vaccine against infection of a Lymphocytic choriomeningitis virus.
Lymphocytic choriomeningitis mammarenavirus vaccine
Lymphocytic choriomeningitis virus vaccine
obsolete RB51 induced protection against B.suis
A protozoan vaccine against Schistosoma mansoni
A protozoan vaccine against Schistosoma infection
when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease.
The conjugate protein is a part of a conjugate vaccine and acts as a carrier protein that is covalently attached to a vaccine antigen with poor antigenicity (e.g., a polysaccharide). A conjugate protein is able to induce T-cell-dependent immune responses and stimulate the production of immune memory.
A role inheres in a material eneitity that union itself chemically with a relative weak vaccine antigen to form a new whole that can create an effective miinuogen. The
epicutaneous (application onto the skin)
Administration of a drug by the way of absorption through the skin, usually for systemic action. The route allows sustained therapeutic plasma drug levels and avoids first pass effect. Simplicity of administration tends to result in high patient compliance.|YL
The injection of a given substance directly into the bladder via a urethral catheter instead of being injected under the skin.
A viral vaccine against infection of an infectious pancreatic necrosis virus.
Infectious pancreatic necrosis virus vaccine
A viral vaccine against infection of a viral haemorrhagic septicaemia virus.
obsolete viral haemorrhagic septicaemia virus vaccine
An vaccine-induced host response that shows augmented protection and cellular immunity after a host protein is used as adjuvant.
obsolete augmented protection and cellular immunity using host protein as adjuvant
A vaccine that protects against Mycobacterium marinum.
A viral vaccine that protects against infection with Hepatitis D virus.
viral vaccine that is used to protect against Monkeypox virus infection
viral vaccine that is used to protect against Bovine viral diarrhea virus 2 infection
A viral vaccine that protects against infection with Murine Cytomegalovirus (or called murid herpesvirus 1).
obsolete RB51 induced protection against B.abortus
obsolete RB51 induced protection against B.canis
obsolete RB51 induced protection against B.Melitensis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5576
Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5556
For active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.
obsolete RB51 induced host immune response
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5561
For active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5562
For active immunization of persons 6 months of age and older for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5563
Product Name: Quadrivalent Influenza Vaccine (Split Virion, Inactivated)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5566
For active immunization of persons 6 months of age and older for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5568
Fluzone Quadrivalent Southern Hemisphere
Fluzone Quadrivalent Southern Hemisphere is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Fluzone Quadrivalent - Southern Hemisphere Formulation
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5546
Indicated in girls and women 9 through 45 years of age for the prevention of the following diseases: - Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58. (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and 11. (1.1) And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ (AIS). (1.1) - Cervical intraepithelial neoplasia (CIN) grade 1. (1.1) - Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3. (1.1) - Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3. (1.1) - Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.1) GARDASIL 9 is indicated in boys and men 9 through 45 years of age for the prevention of the following diseases: - Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58. (1.2) - Genital warts (condyloma acuminata) caused by HPV types 6 and 11. (1.2) And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58: - Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)
obsolete RB51 induced protection against B. ovis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5578
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5577
Indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5569
VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in persons 2 through 64 years of age traveling to cholera-affected areas.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5553
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is a vaccine indicated for active immunization for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is approved for use in persons (6 months and older) at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.
Product Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted by GSK
Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
influenza A (H1N1) 2009 monovalent vaccine (GlaxoSmithKline)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5549
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5571
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5579
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5583
obsolete RB51 induced immune response without protection
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5550
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5572
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5580
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5584
This vaccine is given to provide protection against diphtheria, tetanus, and pertussis in children between 6 weeks and 7 years old.
Influenza virus vaccine is used to prevent infection caused by influenza virus types A and B.
monovalent vaccine agianst poliomyelitis for infants 6-12 weeks of age, all immunized children up to 18 years of age, and high risk adults.
A malaria vaccine that consists of hepatitis B surface antigen virus-like particles, incorporating a portion of the Plasmodium falciparum-derived circumsporozoite protein and a liposome-based adjuvant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5945
In July 2015, RTS,S/AS01 was approved by the European Medicines Agency for immunization of children aged 6 weeks to 17 months against malaria under Article 58,12.
Plasmodium falciparum RTS,S/AS01 vaccine
Revaxis is a Diphtheria, Tetanus and Poliomyelitis (inactivated) vaccine manufactured by Sanofi Pasteur. This vaccine helps boost protection against diphtheria, tetanus and poliomyelitis (polio).
3-in-1 diphtheria, polio and tetanus vaccine (Revaxis)
Revaxis is used for preventing diphtheria, tetanus and polio in children from six years of age, adolescents and adults. Revaxis is used for a booster vaccination against these diseases. It is given to teenagers at 14 years of age as part of the British childhood immunisation schedule.
a Diphthpheria-Tetanus Absorbed vaccine for children 7 years of age and adults.
A rotavirus vaccine against severe diarrheal disease.
A more attenuated measles vaccine that targets measles virus strain Moraten.
Developed sometime in 1968 therefore assumed to be discontinued
An inactIve vaccine used to prevent tetanus.
An active immunization against cholera, indicated only for individuals traveling to or residing in countries where cholera is endemic or epidemic.
A combination vaccine designed to protect against six different diseases.
a hexavalent vaccine that has been withrawn on June 2012 by the European commission
A vaccine used to help prevent rabies infection in people who either have been, or are at risk of being bitten, licked or scratched by an animal infected with rabies virus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6178
LYMErix [Lyme Disease Vaccine (Recombinant OspA)] is a noninfectious recombinant vaccine developed and manufactured by SmithKline Beecham Biologicals. The vaccine contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus.
diphtheria, tetanus and whole cell pertussis vaccine
A human diploid cell vaccine against rabies, a viral infectious disease.
This absorbed recombinant hepatitis B vaccine is indicated for active immunization against hepatitis B virus infection caused by all known subtypes in subjects of any age considered at risk of exposure to the virus.
A vaccine for indivuduals who at risk or recently exposed to rabies.
A vaccine for individuals to protect against mumps virus.
An adsorbed diphtheria, tetanus, pertussis and inactivated poliomyelitis vaccine.
A vaccine for Diphtheria, haemophilus influenzae, pertussis, and tetanus diseases.
A vaccine against flu (influenza) in adults, especially in those who run an increased risk of experiencing associated complications in case they fall ill with flu.
The vaccine targets three strains of influenza virus, and is free of chicken/egg protein.
A vaccine used to prevent diphtheria and tetanus in individuals over 6 years of age.
A combined live virus vaccine used to prevent measles, mumps, and rubella.
A vaccine used to protect against measles, mumps, and rubella for 12-15 month-old individuals.
Active immunization against Haemophilius influenzae type b in recommended routinely for children at 24 months of age and for children at 15 months of age enrolled in child care facilities.
modified vaccinia virus Ankara expressing antigen 85A
A Haemophilus influenzae type B conjugate vaccine manufactured by GSB.
A vaccine against diphtheria, tetanus, and pertussis.
A TB vaccine that uses attenuated fowlpox strain FP9 to express mycobacterial mycolyl transferase Ag85A.
Pharmacotherapeutic group (ATC code): J 07 AN 01.
Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, 2-8 x 10^5 CFU per dose.
A TB vaccine that uses BCG as vaccine vector.
A TB vaccine that recombinant BCG strain with the replacment of its urease C encoding gene with the listeriolysin encoding gene from Listeria monocytogenes.
The MRK adenovirus type 5 human immunodeficiency virus type 1 clade B gag/pol/nef vaccine is a replication-incompetent adenovirus type 5-vectored vaccine that elicits cell-mediated immunity against conserved human immunodeficiency virus proteins.
A Yellow fever virus vaccine that uses the live attenated 17D strain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6144
A Yellow fever virus vaccine that uses the live attenated 17DD strain.
Two distinct strains of live attenuated yellow fever virus vaccine, 17D and 17DD, have been widely used. They have the same origin, from a yellow fever virus isolated from a patient with non fatal yellow fever named Asibi, from Ghana, in 1927. The 17D strain, used for vaccine production, corresponds to passage level 235-240 and the 17DD to a passage level 286-287. The comparison of the nucleotide sequences of all 17D vaccines showed an overall homology of 99.2%.
A YF-17DD vaccine t hat is manufactured by Bio-Manguinhos
a licensed N. meningitidis vaccine that includes meningococcal polysaccharides from Groups A, C, Y and W-135 combined, and is manufactured by GSK.
It is live attenuated YFV vaccine strain 17D manufactured in China, France, Senegal, and the USA. In powder and solvent for suspension for injection in pre-filled syringe.
A cancer vaccine against non-small cell lung cancer (NSCLC)
A non-small cell lung cancer mRNA-derived vaccine that contains modified mRNAs encoding cancer-testis antigen NY-ESO-1, melanoma-associated antigens C1 (MAGE-C1/CT7) and C2 (MAGE-C2/CT10), survivin, and the oncofetal antigen 5T4 with potential antitumor and immunomodulatory activities.
A vaccine role that indicates a clinical trial status of a vaccine
LIPO-5 is a therapeutic HIV vaccine made up of lipopeptides, Study Names: VRI02/ANRS 149 LIGHT; NCT01492985
LIPO-5 is in Phase II development as a therapeutic HIV vaccine. (LIPO-5 is also being studied as a preventive HIV vaccine.)
A Hepatitis B virus vaccine that uses recombinant Hepatitis B surface antigen as the antigen
A Hepatitis B surface antigen viral vaccine that utilizes a cytidine-phosphate-guanosine oligodeoxynucleotide (CpGODN) 1018, as an adjuvant.
For prevention of infection caused by all known subtypes of hepatitis B virus. HEPLISAV-B is approved for use in adults 18 years of age and older
A CpG DNA vaccine adjuvant that is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.
obsolete ISS 1018 CpG ODN vaccine adjuvant
A recombinant vesicular stomatitis virus Indiana serotype (rVSV) vector vaccine taht expresses Zaire GP
Ebola Zaire vaccine, live, recombinant, 1mL dose
A human paillomavirus vaccine that has the vaccine antigen ingredient of monovalent non-infectious, L1 recombinant HPV-like particles (VLP).
An inactivated Japanese encephalitis vaccine (JVax *) for use by certain travelers to and expatriates in Asia.
A viral vaccine that protects against infection with Poliovirus administered orally.
A combination vaccine that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
DTaP-Haemophilus influenzae type b conjugate vaccine
Diphtheria-Tetanus-Acellular Pertussis-Haemophilus b vaccine
A combination vaccine with whole cell that protects against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.
Contains killed whole cells of bacterium that causes pertussis.
Diphtheria-Tetanus-Whole Cell Pertussis-Haemophilus b vaccine
A vaccine used to develop immunity to rabies.
A live virus vaccine for immunization against measles and rubella.
Diphtheria-Tetanus-Pertussis-Hepatitis B vaccine
Active immunzation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards
A vaccine used to prevent diphtheria, tetanus, pertussis, and Haemophilus type B infections.
An oral vaccine against adenovirus serotype 4.
The vaccine is in a form of white enteric-coated tablets. It is typically administered with Adenovirus type 7 vaccine.
An oral vaccine against adenovirus serotype 7.
The vaccine is in a form of peach-colored enteric-coated tablets. It is typically administered with Adenovirus type 4 vaccine.
A vaccine that contains ActHIB and protects against, Diphtheria, Tetanus, Pertussis (whooping cough), Polio, and Haemophilus influenzae type b.
Diphtheria-Tetanus-Pertussis-Poliovirus-ACT-Hib vaccine
Active immunization against tetanus, diphtheria, pertussis, and poliomyelitis for individuals between 3 months and 6 years of age.
A vaccine that protects adolescents and adults from tetanus, diphtheria, and pertussis.
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed
Tdap is different than the DTaP vaccine, which is given to infants and children in five doses, starting at 2 months of age.
A measles virus vaccine manufactured outside of the U.S.
This term was used by the USA VAERS system to indicate the source, which is foreign to USA here, of the vaccine.
A Mumps-Rubella vaccine manufactured outside of the U.S.
A Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine manufactured outside of the U.S
Diphtheria-Tetanus-Pertussis-Poliovirus-Hepatitis B vaccine foreign to USA
A Diphtheria-Tetanus-Pertussis-Poliovirus vaccine manufactured outside of the U.S.
Diphtheria-Tetanus-Pertussis-Poliovirus vaccine foreign to USA
A Haemophilis influenzae Type b capsular polysaccharide vaccine manufactured outside of the U.S.
HIB Polysaccharide vaccine foreign to USA
A Hepatitis B vaccine manufactured outside of the U.S.
A Diphtheria-Tetanus-Poliovirus vaccine manufactured outside of the U.S.
Diphtheria-Tetanus-Poliovirus vaccine foreign to USA
A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine manufactured outside of the U.S.
Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b-Hepatitis B vaccine foreign to USA
A seasonal Influenza virus vaccine manufactured outside of the U.S.
seasonal influenza virus vaccine foreign to USA
A Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine manufactured outside of the U.S
Diphtheria-Tetanus-Pertussis-Poliovirus-Haemophilus b vaccine foreign to USA
A pneumococcal vaccine manufactured outside of the U.S.
An active immunizing combination agent that is used to prevent infection caused by certain groups of meningococcal bacteria and Haemophilus influenza type b (Hib) bacteria.
Meningococcal Conjugate and Haemophilis B Vaccine
A Meningicoccal Conjugate and Haemophilis B Vaccine manufactured outside of the U.S.
Meningococcal Conjugate and Haemophilis B Vaccine foreign to USA
A tick-borne encephalitis virus vaccine used to prevent subtype Far Eastern tick-borne encephalitis virus (formerly known as Russian Spring Summer encephalitis virus).
A polysaccharide vaccine to prevent typhoid caused Salmonella typhi. Acetone is used to inactivate culture, and dried.
Acetone-Dried Typhoid Vi Polysaccharide vaccine
acellular pertussis vaccine, inactivated
A vaccine to protect individuals against infections caused by hepatitis A virus and typhoid fever bacteria.
Hepatitis A and Vi Polysaccharide typhoid vaccine foreign to USA
Hepatitis A virus-Typhoid vaccine foreign to USA
Bordetella pertussis pertactin vaccine, inactivated
Bordetella pertussis toxoid vaccine, inactivated
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated
Bordetella pertussis fimbriae 2/3 vaccine, inactivated
Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML
Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML
Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML
Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML
Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML
Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML
Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML
Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML
A monovalent vaccine used to protect against H1N1 influenza virus.
Streptococcus pneumoniae type 1 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 1 vaccine
Diphtheria Toxoid-Pertussis-Poliovirus vaccine
Diphtheria-Tetanus-Poliovirus-Haemophilus B-Hepatitis B vaccine
For the prevention of influenza caused by Influenza Virus, Types A and B. For the Southern Hemisphere 2017 season, the vaccine is indicated for use only in persons aged 5 years and over.
Streptococcus pneumoniae type 11A capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 11A vaccine
Streptococcus pneumoniae type 12F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 12F vaccine
Streptococcus pneumoniae type 14 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 14 vaccine
Streptococcus pneumoniae type 15B capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 15B vaccine
Streptococcus pneumoniae type 17F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 17F vaccine
Streptococcus pneumoniae type 18C capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 18C vaccine
Streptococcus pneumoniae type 19A capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 19A vaccine
Streptococcus pneumoniae type 19F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 19F vaccine
Streptococcus pneumoniae type 2 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 2 vaccine
Streptococcus pneumoniae type 20 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 20 vaccine
Streptococcus pneumoniae type 22F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 22F vaccine
obsolete 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [Recombivax]
obsolete Hepatitis A virus-Typhoid vaccine
hepatitis B surface antigen vaccine 0.04 MG/ML
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Heplisav-B]
Streptococcus pneumoniae type 4 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 4 vaccine
obsolete 1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection
obsolete 0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML
hepatitis B surface antigen vaccine 0.01 MG/ML [Recombivax]
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injection [Recombivax]
Recombivax HB 5 MCG per 0.5 ML Injection
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe [Recombivax]
1 ML Recombivax HB, Hepatitis B vaccine (recombinant) adult formulation Prefilled Syringe
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5575
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injection [Recombivax]
hepatitis B surface antigen vaccine Injection [Recombivax]
hepatitis B surface antigen vaccine Prefilled Syringe [Recombivax]
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe [Recombivax]
Recombivax HB 5 MCG per 0.5 ML Prefilled Syringe
Streptococcus pneumoniae type 8 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 8 vaccine
The site that is the part of the host body and the entrance point where a vaccine is administered.
it is not the natural anatomical part where the body has access toward outside, such as mouth or nose. But rather the holes on the skin made by needdles used for vaccination.
Streptococcus pneumoniae type 3 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 3 vaccine
Streptococcus pneumoniae type 33F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 33F vaccine
Streptococcus pneumoniae type 6B capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 6B vaccine
A trivalent inactive influenza virus vaccine.
Vaccine sold for 1993-1994 influenza season.
Streptococcus pneumoniae type 23F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 23F vaccine
Streptococcus pneumoniae type 7F capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 7F vaccine
Streptococcus pneumoniae type 9N capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 9N vaccine
Streptococcus pneumoniae type 5 capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 5 vaccine
hepatitis B surface antigen vaccine 0.02 MG/ML
hepatitis B surface antigen vaccine 0.005 MG/ML
hepatitis B surface antigen vaccine Prefilled Syringe [Engerix-B]
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injection
hepatitis B surface antigen vaccine 20 MCG per 1 ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML
A quadrivalent influenza vaccine against two influenza A strains and two influenza B strains.
0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injection
hepatitis B surface antigen vaccine 10 MCG per 0.5 ML Injection
hepatitis B surface antigen vaccine 0.02 MG/ML [Engerix-B]
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B]
Engerix-B 20 MCG per 1 ML Prefilled Syringe
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injection [Engerix-B]
0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injection [Engerix-B]
0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B]
Engerix-B, Hepatitis B Surface Antigen Vaccine, Adsorbed (Pediatric Dose) 0.5 ML Prefilled Syringe
A combination vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b (Hib).
pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML
hepatitis B surface antigen vaccine Injection [Heplisav-B]
A combination vaccine against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus.
0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain 19,400 PFU per 0.65 ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain
varicella-zoster virus vaccine live (Oka-Merck) strain Injection
varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML
0.5 ML varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain 1350 PFU per 0.5 ML Injection
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Product
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 20000 UNT/ML
varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML
obsolete 0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Zostavax]
varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML [Zostavax]
0.65 ML varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection [Zostavax]
Zostavax 19,400 PFU per 0.65 ML Injection
pneumococcal capsular polysaccharide vaccine
Streptococcus pneumoniae capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
L1 protein, Human papillomavirus vaccine
L1 protein, human papillomavirus type 6 vaccine
L1 protein, human papillomavirus type 11 vaccine
L1 protein, human papillomavirus type 18 vaccine
L1 protein, human papillomavirus type 16 vaccine
L1 protein, human papillomavirus type 31 vaccine
L1 protein, human papillomavirus type 33 vaccine
L1 protein, human papillomavirus type 45 vaccine
L1 protein, human papillomavirus type 52 vaccine
L1 protein, human papillomavirus type 58 vaccine
pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML
A combination vaccine against diphtheria, tetanus, acellular pertussis, and inactivated poliomyelitis for individuals ages from 16 months to 13 years of age.
A vaccine that can be given to children after the age of 2 months up to 2 years to prevent infectious diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC) bacteria.
Indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
A vaccine against tetanus, diphtheria, pertussis, and inactivated poliovirus manufactured outside of the U.S.
pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML
Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML
pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML
Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
a vaccine-induced down-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.
live attenuated vaccine-induced down-regulated gene expression compared to infection with wild type pathogen
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine
A vaccine-induced up-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.
live attenuated vaccine-induced up-regulated gene expression compared to infection with wild type pathogen
meningococcal group B vaccine Prefilled Syringe
meningococcal group B vaccine Injectable Product
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML
Salmonella typhi Ty21a live antigen Delayed Release Oral Capsule [Vivotif]
Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule [Vivotif]
Salmonella typhi Ty21a live antigen 2000000000 UNT Delayed Release Oral Capsule [Vivotif]
Vivotif Berna 2,000,000,000 UNT Delayed Release Oral Capsule
Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule [Vivotif]
meningococcal group B vaccine Prefilled Syringe [Bexsero]
Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen
Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML
Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen
Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML
Outer Membrane Vesicles (Neisseria Meningitidis Group B Nz98/254 Strain)
Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle
Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML
Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen
yellow fever virus strain 17D-204 live antigen
Yellow-Fever Virus Vaccine, 17D-204 strain
yellow fever virus strain 17D-204 live antigen 2000 UNT/ML
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML
0.5 ML yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection
yellow fever vaccine (generic for Stamaril) 0.5 ML Injection
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection
Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML
Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Product
yellow fever virus strain 17D-204 live antigen Injection [Stamaril]
Yellow-Fever Virus Vaccine, 17D-204 strain Injection [Stamaril]
0.5 ML yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection [Stamaril]
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injection [Stamaril]
yellow fever virus strain 17D-204 live antigen Injection
Yellow-Fever Virus Vaccine, 17D-204 strain Injection
0.5 ML yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection
yellow fever vaccine (generic for YF-Vax) 0.5 ML Injection
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injection
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML
Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injectable Suspension
yellow fever vaccine (generic for YF-Vax) Injectable Suspension
Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 5 UNT/ML
tetanus toxoid vaccine, inactivated 10 UNT/ML
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML
acellular pertussis vaccine, inactivated 0.116 MG/ML
acellular pertussis vaccine, inactivated 96 UNT/ML
A trivalent influenza vaccine contianing two A influenza strains and one B influenza strain.
An inactivated quadrivalent influenza vaccine against 2 influenza A strains and 2 influenza B strains for infants 6 months up to 23 months, and if needed it can be administered to children 2 to 17 years old with compromised immune systems and those considered vulnerable and high risk.
diphtheria toxoid vaccine, inactivated 30 UNT/ML
A clostridium tetani vaccine that consists of formaldehyde inactivated tetanospasmin (aka tetanus toxoid).
tetanus toxoid vaccine, inactivated Injectable Solution
tetanus toxoid vaccine, inactivated Injectable Suspension
tetanus toxoid vaccine, inactivated Injectable Product
tetanus toxoid vaccine, inactivated Prefilled Syringe
tetanus toxoid vaccine, inactivated 20 UNT/ML
0.5 ML tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
tetanus toxoid vaccine 10 UNT per 0.5 ML Prefilled Syringe
tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
tetanus toxoid vaccine 5 UNT per 0.5 ML Injectable Suspension
tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 8 UNT/ML
tetanus toxoid vaccine, inactivated 4 UNT/ML
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Product
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection
Haemophilus b conjugate vaccine (meningococcal protein conjugate) 0.5 ML Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injection [PedvaxHIB]
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection [PedvaxHIB]
PedvaxHIB, Haemophilus b conjugate vaccine (Meningococcal protein conjugate) 0.5 ML Injection
Hepatitis B Surface Antigen Vaccine Injectable Product
hepatitis B surface antigen vaccine Injectable Suspension
hepatitis B surface antigen vaccine 0.005 MG/ML Injectable Suspension
hepatitis B surface antigen vaccine 5 MCG/ML Injectable Suspension
hepatitis B surface antigen vaccine Prefilled Syringe
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 20 MCG/ML Prefilled Syringe, 1 ML
hepatitis B surface antigen vaccine Injection
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 10 MCG per 1 ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.01 MG/ML
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 5 MCG per 0.5 ML Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 10 MCG per 0.5 ML Prefilled Syringe
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injection
hepatitis B surface antigen vaccine 10 MCG per 1 ML Injection
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injection
hepatitis B surface antigen vaccine 5 MCG per 0.5 ML Injection
Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
Typhoid Vaccine Live Ty21a 2000000000 UNT [Vivotif]
diphtheria toxoid vaccine, inactivated 4 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Product
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML
hepatitis A vaccine (inactivated) strain HM175 Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML
hepatitis A vaccine (inactivated) strain HM175 Injection
0.5 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection
1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection
Salmonella typhi Ty21a live antigen 2000000000 UNT
Typhoid Vaccine Live Ty21a 2000000000 UNT
Vaccine component role inheres in a vaccine vector.
A trivalent influenza vaccine containing two strains of influenza A and one strain of influenza B for use in people 18 years to 64 years for use during the 2012-2013 season.
Meningococcal conjugate vaccine, which contains four of the most common types of meningococcal bacteria (serogroups A, C, W, and Y), is used to prevent infection caused by meningococcal bacteria.
A DTaP vaccine used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past.
Salmonella typhi Ty21a live antigen 2000000000 UNT Delayed Release Oral Capsule
typhoid vaccine live Ty21a 2,000,000,000 UNT Delayed Release Oral Capsule
Typhoid Vaccine Live Ty21a 2000000000 UNT Delayed Release Oral Capsule
Salmonella typhi Ty21a live antigen Delayed Release Oral Capsule
Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML
influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML
influenza A virus A/Christchurch/16/2010 (H1N1) antigen
diphtheria toxoid vaccine, inactivated 13.4 UNT/ML
diphtheria toxoid vaccine, inactivated 50 UNT/ML
diphtheria toxoid vaccine, inactivated 25 UNT/ML
1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection [Vaqta]
1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta]
Hepatitis A Vaccine, Inactivated 50 UNT/ML [Vaqta]
0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe [Vaqta]
Vaqta 25 UNT per 0.5 ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta]
0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection [Vaqta]
0.5 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Injection [Vaqta]
1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe [Vaqta]
1 ML Hepatitis A Vaccine, Inactivated 50 UNT/ML Prefilled Syringe [Vaqta]
Hepatitis A Vaccine, Inactivated Prefilled Syringe [Vaqta]
Hepatitis A Vaccine, Inactivated Injection [Vaqta]
Hepatitis A Vaccine, Inactivated Injection
Hepatitis A Vaccine, Inactivated Injectable Product
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML
influenza A virus A/South Australia/55/2014 (H3N2) antigen
influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Brisbane/10/2010 (H1N1) antigen
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML
influenza B virus B/Brisbane/60/2008 antigen
influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML
influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML
influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML
influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML
Vaccine that protects against Neisseriales infection.
vaccine against Neisseriales bacterial infection
influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML
influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML
influenza B virus B/Phuket/3073/2013 antigen
influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML
influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML
influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML
influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML
influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML
Vaccine that protects against Spirochaetes infection.
influenza virus vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus
human influenza A (H1N1)-like virus vaccine
human influenza A (H3N2)-like virus vaccine
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML
influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain
influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML
influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.12 MG/ML
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML
influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain
influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML
influenza virus vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.09 MG/ML
influenza virus vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain
A vaccine that is used against an infection by a pathogen under Borreliella.
influenza B virus vaccine, B-Wisconsin-1-2010-like virus
influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML
influenza B virus vaccine B/Brisbane/60/2008 antigen
influenza virus vaccine, Inactivated B-Brisbane-60-2008
influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML
influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML
influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML
influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML
influenza B virus vaccine, B-Massachusetts-2-2012-like virus
influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML
influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML
influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML
Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 UNT/ML
influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML
Vaccine that protects against Yersiniaceae infection.
A vaccine that is used against an infection by a pathogen under Corynebacterium.
A vaccine that is used against an infection by a pathogen under Bacillus.
A vaccine that is used against an infection by a pathogen under Varicellovirus.
A vaccine that is used against an infection by a pathogen under Papillomaviridae.
A vaccine that is used against an infection by a pathogen under Orthopoxvirus.
Vaccine that protects against Orthohepadnavirus infection.
A vaccine that is used against an infection by a pathogen under Reoviridae.
A vaccine that is used against an infection by a pathogen under Sedoreovirinae.
A vaccine that is used against an infection by a pathogen under Morbillivirus.
A vaccine that is used against an infection by a pathogen under Rubulavirus.
A vaccine that is used against an infection by a pathogen under Lyssavirus.
A vaccine that is used against an infection by a pathogen under Flaviviridae.
A vaccine that is used against an infection by a pathogen under Enterovirus.
A vaccine that is used against an infection by a pathogen under Hepatovirus.
A vaccine that is used against an infection by a pathogen under Rubivirus.
Vaccine that protects against Spirochaetia infection.
Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) 0.5 ML Prefilled Syringe
0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumo...
Prevnar 13 vaccine 0.5 ML Prefilled Syringe
Streptococcus pneumoniae type 9V capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 9V vaccine
pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML
Pneumovax 23 (Pneumococcal vaccine polyvalent) 0.5 ML Injection
Pneumovax 23 (Pneumococcal vaccine polyvalent) Injectable Solution
PNEUMOVAX 23 vaccine Injectable Solution
Pneumovax 23 (Pneumococcal vaccine polyvalent) 0.5 ML Prefilled Syringe
PNEUMOVAX 23 vaccine 0.5 ML Prefilled Syringe
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe [Prevnar 13]
pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML
measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
ProQuad Measles, Mumps, Rubella, and Varicella Virus Vaccine Live 0.5 ML Injection
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection [ProQuad]
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 10A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 11A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 12F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 14 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 15B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 17F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 18C vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19A vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 19F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 2 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 20 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 22F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 23F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 3 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 33F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 4 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 5 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 6B vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 7F vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 8 vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9N vaccine 0.05 MG/ML / pneumococcal capsular polysaccharide type 9V vaccine 0.05 MG/ML [Pneumovax 23]
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML [Prevnar 13]
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML [ProQuad]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone 2015-2016]
Fluzone Quadrivalent 2013-2014 Formula vaccine
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML [Fluzone 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2015-2016]
Fluzone 2015-2016 High-Dose vaccine Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2015-2016]
Fluzone 2015-2016 high-dose vaccine 0.5 ML Prefilled Syringe
Fluzone 2015-2016 45 MCG (15 MCG x 3) in 0.5 ML Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone 2015-2016]
Fluzone 2015-2016 vaccine Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2016-2017]
Fluzone 2016-2017 High-Dose vaccine Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2016-2017]
Fluzone 2016-2017 high-dose vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML [Fluzone 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2017-2018]
Fluzone 2017-2018 high-dose vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2017-2018]
Fluzone 2017-2018 high-dose vaccine 0.5 ML Prefilled Syringe
RXN STRENGTH: 0.12 MG/ML (expressed as influenza A virus A/Michigan/45/2015 (H1N1) antigen) / 0.12 MG/ML (expressed as influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen) / 0.12 MG/ML (expressed as influenza B virus B/Maryland/15/2016 antigen)
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML [Fluzone 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2018-2019]
Fluzone 2018-2019 high-dose vaccine Prefilled Syringe
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2018-2019]
Fluzone 2018-2019 high-dose vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen
influenza A virus A/Michigan/45/2015 (H1N1) antigen
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen
influenza B virus B/Maryland/15/2016 antigen
influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML
Fluzone Quadrivalent 2013-2014 Formula Injectable Product
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2013-2014 Formula]
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula]
Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula]
Fluzone Quadrivalent Pediatric Dose for 6-35 Months of Age 2013-2014 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
Fluzone Quadrivalent 2014-2015 Formula vaccine
Fluzone Quadrivalent 2014-2015 Formula Injectable Product
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula]
Fluzone Quadrivalent 2014-2015 Formula Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula]
Fluzone Quadrivalent 2014-2015 Formula 0.1 ML Prefilled Syringe
Fluzone Quadrivalent 2015-2016 Injectable Product
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine Prefilled Syringe
0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine 0.1 ML Prefilled Syringe
0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine 0.25 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
Fluzone Quadrivalent 2015-2016 vaccine 0.5 ML Prefilled Syringe
Fluzone Quadrivalent 2016-2017 Injectable Product
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 Formula Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 Formula 0.5 ML Injection
RXN STRENGTH: 0.03 MG/ML (expressed as influenza A virus A/California/7/2009 (H1N1) antigen) / 0.03 MG/ML (expressed as influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen) / 0.03 MG/ML (expressed as influenza B virus B/Brisbane/60/2008 antigen) / 0.03 MG/ML (expressed as influenza B virus B/Phuket/3073/2013 antigen)
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 vaccine Prefilled Syringe
0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 vaccine 0.1 ML Prefilled Syringe
0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 vaccine 0.25 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
Fluzone Quadrivalent 2016-2017 vaccine 0.5 ML Prefilled Syringe
Fluzone Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Fluzone Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine Injection
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Injection
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
0.25 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine 0.25 ML Prefilled Syringe
0.1 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
Fluzone Quadrivalent 2017-2018 vaccine 0.1 ML Prefilled Syringe
Fluzone Quadrivalent 2018-2019 Injectable Product
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent 2018-2019 vaccine Injection
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Injection
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent 2018-2019 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent 2018-2019 Vaccine Prefilled Syringe
0.25 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent Pediatric Dose for 6-35 Months of Age 2018-2019 Vaccine 0.25 ML Prefilled Syringe
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019]
Fluzone Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML
influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML
yellow fever virus strain 17D-204 live antigen Injection [YF-Vax]
0.5 ML yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection [YF-Vax]
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injectable Suspension [YF-Vax]
YF-Vax 4000 UNT/ML Injectable Suspension
yellow fever virus strain 17D-204 live antigen Injectable Suspension [YF-Vax]
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML [YF-Vax]
Yellow-Fever Virus Vaccine, 17D-204 strain 4000 UNT/ML [YF-Vax]
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML [PedvaxHIB]
Vaccine component that is used to deliver genetic code into the cells to produce antigen.
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluvirin 2015-2016]
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2015-2016]
Fluvirin 2015-2016 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2015-2016]
Fluvirin 2015-2016 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2015-2016]
Fluvirin 2015-2016 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2016-2017]
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2016-2017]
Fluvirin 2016-2017 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2016-2017]
Fluvirin 2016-2017 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2016-2017]
Fluvirin 2016-2017 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluvirin 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Fluvirin 2017-2018]
Fluvirin 2017-2018 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluvirin 2017-2018]
Fluvirin 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2017-2018]
Fluvirin 2017-2018 vaccine 0.5 ML Prefilled Syringe
Fluarix Quadrivalent 2015-2016 Injectable Product
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2015-2016]
Fluarix Quadrivalent 2015-2016 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2015-2016]
Fluarix Quadrivalent 2015-2016 vaccine 0.5 ML Prefilled Syringe
Fluarix Quadrivalent 2016-2017 Injectable Product
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2016-2017]
Fluarix Quadrivalent 2016-2017 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2016-2017]
Fluarix Quadrivalent 2016-2017 vaccine 0.5 ML Prefilled Syringe
Fluarix Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2017-2018]
Fluarix Quadrivalent 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2017-2018]
Fluarix Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
Fluarix Quadrivalent 2018-2019 Injectable Product
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2018-2019]
Fluarix Quadrivalent 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2018-2019]
Fluarix Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria 2015-2016]
Afluria 2015-2016 45 MCG (15 MCG x 3) in 0.5 ML Injectable Suspension
afluria 2015-2016 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2015-2016]
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2015-2016]
Afluria 2015-2016 0.5 ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Afluria 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension [Afluria 2016-2017]
Afluria 2016-2017 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2016-2017]
Afluria 2016-2017 vaccine Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2016-2017]
Afluria 2016-2017 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML [Afluria 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Injectable Suspension [Afluria 2017-2018]
Afluria 2017-2018 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2017-2018]
Afluria 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2017-2018]
Afluria 2017-2018 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Afluria 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Injectable Suspension [Afluria 2018-2019]
Afluria 2018-2019 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria 2018-2019]
Afluria 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019]
Afluria 2018-2019 vaccine 0.5 ML Prefilled Syringe
Afluria Quadrivalent 2016-2017 Formula Injectable Product
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2016-2017 Formula]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2016-2017 Formula]
Afluria Quadrivalent 2016-2017 Formula Influenza Virus Vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula]
Afluria Quadrivalent 2016-2017 Formula Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula]
Afluria Quadrivalent 2016-2017 Formula 0.5 ML Prefilled Syringe
Afluria Quadrivalent 2016-2017 Formula vaccine
Afluria Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2017-2018]
Afluria Quadrivalent 2017-2018 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2017-2018]
Afluria Quadrivalent 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2017-2018]
Afluria Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
Afluria Quadrivalent 2018-2019 Injectable Product
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2018-2019]
Afluria Quadrivalent 2018-2019 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2018-2019]
Afluria Quadrivalent 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2018-2019]
Afluria Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
Flulaval Quadrivalent 2016-2017 Injectable Product
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2016-2017]
FLULAVAL QUADRIVALENT 2016-2017 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2016-2017]
Flulaval Quadrivalent 2016-2017 vaccine Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2016-2017]
Flulaval Quadrivalent 2016-2017 vaccine 0.5 Prefilled Syringe
FluLaval Quadrivalent 2015-2016 Injectable Product
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [FluLaval Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [FluLaval Quadrivalent 2015-2016]
FluLaval Quadrivalent 2015-2016 vaccine Injectable Suspension
Flulaval Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2017-2018]
FluLaval Quadrivalent 2017-2018 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2017-2018]
Flulaval Quadrivalent 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2017-2018]
Flulaval Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
Flulaval Quadrivalent 2018-2019 Injectable Product
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2018-2019]
Flulaval Quadrivalent 2018-2019 vaccine Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2018-2019]
Flulaval Quadrivalent 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2018-2019]
Flulaval Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax 2015-2016]
Flucelvax 2015-2016 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax 2015-2016]
FLUCELVAX 2015-2016 vaccine 0.5 ML Prefilled Syringe
Flucelvax Quadrivalent 2016-2017 vaccine
Flucelvax Quadrivalent 2016-2017 Injectable Product
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2016-2017]
Flucelvax Quadrivalent 2016-2017 Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2016-2017]
FLUCELVAX QUADRIVALENT 2016-2017 0.5 ML Prefilled Syringe
influenza B virus B/Hong Kong/259/2010 antigen
influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML
Flucelvax Quadrivalent 2017-2018 vaccine
Flucelvax Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2017-2018]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2017-2018]
Flucelvax Quadrivalent 2017-2018 Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2017-2018]
Flucelvax Quadrivalent 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2017-2018]
Flucelvax Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML [Shingrix]
0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection [Shingrix]
Varicella zoster virus glycoprotein E, recombinant
varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML
influenza A virus A/Bolivia/559/2013 (H1N1) antigen
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray [Flumist 2015-2016]
FluMist Quadrivalent, 2015-2016 Formula Nasal Spray
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist 2015-2016]
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML [Flumist Quadrivalent 2016-2017]
FluMist Quadrivalent, Live Attenuated, 2016-2017 Formula Nasal Spray
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray [Flumist Quadrivalent 2016-2017]
FluMist Quadrivalent, 2016-2017 Formula Nasal Spray
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2017-2018]
FluMist Quadrivalent, Live Attenuated, 2017-2018 Formula Nasal Spray
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2017-2018]
FluMist Quadrivalent, 2017-2018 Formula Nasal Spray
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML
influenza A virus A/Slovenia/2903/2015 (H1N1) antigen
influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML
influenza B virus B/Colorado/06/2017 antigen
influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [Flumist Quadrivalent 2018-2019]
FluMist Quadrivalent, Live Attenuated, 2018-2019 Formula Nasal Spray
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2018-2019]
FluMist Quadrivalent, 2018-2019 Formula Nasal Spray
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML [Havrix]
0.5 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection [Havrix]
Havrix pediatric/adolescent vaccine 720 UNT in 0.5 ML Injection
1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection [Havrix]
Havrix adult vaccine 1440 UNT in 1 ML Injection
hepatitis A vaccine (inactivated) strain HM175 Injection [Havrix]
0.5 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe [Havrix]
Havrix, Hepatitis A Vaccine (Inactivated), (Pediatric Dose) 0.5 ML Prefilled Syringe
1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe [Havrix]
Havrix, Hepatitis A Vaccine (Inactivated), (Adult Dose) 1 ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 Prefilled Syringe [Havrix]
poliovirus vaccine inactivated, type 1 (Mahoney)
poliovirus vaccine inactivated, type 2 (MEF-1)
poliovirus vaccine inactivated, type 3 (Saukett)
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [PEDIARIX]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [PEDIARIX]
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [PEDIARIX]
PEDIARIX DTaP-HepB-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine) 0.5 ML Prefilled Syringe
PEDIARIX vaccine 0.5 ML Prefilled Syringe
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML
poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML
poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML
Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML [Ipol]
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Suspension [Ipol]
Ipol (poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML per 0.5 ML) Injectable Suspension
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML [Typhim VI]
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI]
Typhim Vi, Typhoid Vi Polysaccharide Vaccine Injectable Solution
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Prefilled Syringe [Typhim VI]
0.5 ML Typhim VI 0.05 MG/ML Prefilled Syringe
Typhim VI 25 MCG per 0.5 ML Prefilled Syringe
0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI]
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.025 MG/ML
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML [Imovax]
IMOVAX rabies vaccine 2.5 UNT in 1 ML Injection
Imovax Rabies, Wistar Rabies Virus Strain PM-1503-3M (Human) 2.5 UNT per 1 ML Injection
rabies virus vaccine flury-lep strain 2.5 UNT/ML
rabies virus vaccine flury-lep strain 2.5 UNT/ML [RabAvert]
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection [RabAvert]
Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML [Hiberix]
Hiberix (Haemophilus influenzae type b strain 20,752, capsular polysaccharide (10 MCG) inactivated tetanus toxoid (25 MCG) conjugate vaccine) per 0.5 ML Injection
Hiberix (Haemophilus influenzae type b strain 20,752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine) 35 MCG per 0.5 ML Injection
0.5 ML Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection [Hiberix]
Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML
Comvax (Haemophilus influenzae b (Ross strain) capsular polysaccharide (7.5 MCG) Meningococcal Protein (125 MCG) Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine 5 MCG) per 0.5 ML Injection
Comvax, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine Injection
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection [COMVAX]
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML [COMVAX]
Flublok 2012-2013 Formula Injectable Product
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Injectable Solution [Flublok 2012-2013 Formula]
Flublok 2012-2013 Formula Influenza Virus Vaccine Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Flublok 2012-2013 Formula]
Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Flublok 2012-2013 Formula]
Flublok 2013-2014 Formula Injectable Product
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution [Flublok 2013-2014 Formula]
Flublok 2013-2014 Formula Influenza Virus Vaccine Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2013-2014 Formula]
Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2013-2014 Formula]
Flublok 2014-2015 Formula Injectable Product
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution [Flublok 2014-2015 Formula]
Flublok 2014-2015 Formula Influenza Virus Vaccine Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2014-2015 Formula]
Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Flublok 2014-2015 Formula]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok 2015-2016]
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection [Flublok 2015-2016]
Flublok 2015-2016 vaccine 0.5 ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2016-2017]
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2016-2017]
Flublok 2016-2017 vaccine 0.5 ML Injection
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML [Flublok 2017-2018]
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2017-2018]
Flublok 2017-2018 vaccine 0.5 ML Injection
Flublok Quadrivalent 2017-2018 Injectable Product
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2017-2018]
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2017-2018]
Flublok Quadrivalent 2017-2018 vaccine 0.5 ML Prefilled Syringe
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2017-2018]
Flublok Quadrivalent 2017-2018 vaccine Prefilled Syringe
Flublok Quadrivalent 2018-2019 Injectable Product
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2018-2019]
Flublok Quadrivalent 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2018-2019]
Flublok Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML
influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML
influenza B virus B/Brisbane/9/2014 antigen
influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML
influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML [FLUAD 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [FLUAD 2015-2016]
FLUAD 2015-2016 vaccine Prefilled Syringe
FLUAD 2015-2016 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe [FLUAD 2015-2016]
FLUAD 2015-2016 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2016-2017]
Fluad 2016-2017 vaccine Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2016-2017]
Fluad 2016-2017 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML [Fluad 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2017-2018]
Fluad 2017-2018 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2017-2018]
Fluad 2017-2018 vaccine 0.5 ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Fluad 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2018-2019]
Fluad 2018-2019 vaccine Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2018-2019]
Fluad 2018-2019 vaccine 0.5 ML Prefilled Syringe
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML [Gardasil]
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Injection [Gardasil]
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection [Gardasil]
Gardasil, Human Papillomavirus Quadrivalent (Types 6,11,16,18) Vaccine, Recombinant 0.5 ML Injection
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe [Gardasil]
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe [Gardasil]
Gardasil, Human Papillomavirus Quadrivalent (Types 6,11,16,18) Vaccine, Recombinant 0.5 ML Prefilled Syringe
L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML
L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML
Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine
Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML
human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML [Cervarix]
L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Prefilled Syringe [Cervarix]
Cervarix Human Papillomavirus bivalent (types 16 and 18) vaccine, recombinant 0.5 ML Prefilled Syringe
0.5 ML human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe [Cervarix]
Japanese encephalitis virus vaccine, inactivated
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML [Ixiaro]
Japanese encephalitis virus vaccine, inactivated Prefilled Syringe [Ixiaro]
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) Prefilled Syringe
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) 0.012 MG/ML 0.5 ML Prefilled Syringe
Ixiaro 6 MCG per 0.5 ML Prefilled Syringe
0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro]
0.5 ML Ixiaro 0.012 MG/ML Prefilled Syringe
Vibrio cholerae CVD 103-HGR strain live antigen
obsolete vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML
Streptococcus pneumoniae type 10A capsular polysaccharide antigen
pneumococcal capsular polysaccharide type 10A vaccine
replication defective simian adenoviral vector expressing KH, a self-cleaving polyprotein comprising L. donovani KMP-11 and HASPB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5712
Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML Oral Suspension [Vaxchora]
Vaxchora 12000000 UNT/ML Oral Suspension
Vaxchora 1,200,000,000 UNT per 100 ML Oral Suspension
obsolete vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML [Vaxchora]
hepatitis B surface antigen vaccine Prefilled Syringe [Heplisav-B]
0.5 ML Heplisav-B 0.04 MG/ML Prefilled Syringe
HEPLISAV-B 20 MCG in 0.5 ML Prefilled Syringe
Heplisav-B 0.04 MG/ML per 0.5 ML Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B]
HEPLISAV-B 20 MCG per 0.5 ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.04 MG/ML [Heplisav-B]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Pentacel]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Pentacel]
Pentacel DTaP-IPV/Hib (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)) 0.5 ML Injection
0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel]
Pentacel DTaP-IPV/Hib (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus (mIPV) and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)) 0.5 ML Injection
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Kinrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Kinrix]
KINRIX DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) 0.5 ML Prefilled Syringe
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Kinrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Kinrix]
KINRIX DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Kinrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Daptacel]
Daptacel DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Daptacel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Adacel]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Adacel]
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Adacel]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adacel]
Adacel (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 5 MCG / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 5 MCG / Bordetella pertussis pertactin vaccine, inactivated 3 MCG / Bordetella pertussis toxoid vaccine, inactivated 2.5 MCG / Diphtheria Toxoid Vaccine 2 UNT / Tetanus Toxoid Vaccine 5 UNT) per 0.5 ML Injection
Adacel Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Adacel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Infanrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Infanrix]
Infanrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.025 MG / Bordetella pertussis pertactin vaccine, inactivated 0.008 MG / Bordetella pertussis toxoid vaccine, inactivated 0.025 MG / diphtheria toxoid vaccine, inactivated 25 UNT / tetanus toxoid vaccine, inactivated 10 UNT) per 0.5 ML Injection
Infanrix DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Infanrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix]
Infanrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 25 MCG / Bordetella pertussis pertactin vaccine, inactivated 8 MCG / Bordetella pertussis toxoid vaccine, inactivated 25 MCG / diphtheria toxoid vaccine, inactivated 25 UNT / tetanus toxoid vaccine, inactivated 10 UNT) per 0.5 ML Prefilled Syringe
Infanrix DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Infanrix]
INFANRIX vaccine 0.5 ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Boostrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
Boostrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine, inactivated 5 UNT) per 0.5 ML Injection
Boostrix Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Boostrix]
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3259
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3261
Brucella melitensis omp25 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3262
Brucella melitensis omp31 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=826
Pseudorabies recombinant vector vaccine encoding gp50 protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=91
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=787
Streptococcus pneumoniae CbpA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=789
Streptococcus pneumoniae ClpP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=795
Streptococcus pneumoniae PspA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=798
Streptococcus pneumoniae SrtA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=937
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=944
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=947
Neisseria meningitidis ExbB protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=948
Neisseria meningitidis LctP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=956
Neisseria meningitidis NspA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=957
Neisseria miningitidis TBP2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=998
influenza virus DNA vaccine encoding HA from influenza A virus (A/Hong Kong/1/68(H3N2))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=999
influenza virus DNA vaccine encoding HA from influenza A virus (A/environment/Hong Kong/156/1997(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1003
influenza virus HA protein vaccine (influenza A virus (A/Yamagata/120/1986(H1N1)))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1004
influenza virus HA protein vaccine (influenza A virus (A/Fukuoka/C29/85(H3N2)))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1005
influenza virus DNA vaccine encoding HA from influenza B virus (B/Ibaraki/2/85)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1012
influenza virus DNA vaccine encoding HA from influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1014
influenza virus DNA vaccine encoding HA from influenza A virus (A/equine/Kentucky/1/1981(H3N8))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1029
Leishmania donovani GRP-78 protein vaccine
L. donovani Beta-tubulin Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1031
Leishmania donovani Beta-tubulin protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1069
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1070
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1071
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1072
Borrelia burgdorferi DbpA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1074
Borrelia burgdorferi OspA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1075
Borrelia burgdorferi OspB protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1076
Borrelia burgdorferi OspC protein vaccine
L. monocytogenes DNA Vaccine encoding hly
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1077
Listeria monocytogenes DNA vaccine encoding hly
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1078
Listeria monocytogenes p60 Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1109
Leishmania donovani Hsp70 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1111
Francisella tularensis FopB protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3543
Mycobacterium tuberculosis DNA vaccine ESAT-6
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3576
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3577
Nontypeable H. influenzae NucA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=192
Nontypeable Haemophilus influenzae NucA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=822
Psuedorabies DNA vaccine encoding IE180 protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=829
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=830
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=835
Sarcocystis neurona SAG1 Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=877
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1006
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1009
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1013
Leishmania major DNA vaccine encoding Gp63
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1082
Staphylococcus aureus ClfA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1083
Staphylococcus aureus CNA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1084
Staphylococcus aureus FnbA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1086
Streptococcus agalactiae BPS protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1087
Streptococcus agalactiae Rib protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1088
Streptococcus agalactiae Sip protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1089
Streptococcus pyogenes Emm1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1090
Streptococcus pyogenes FbaA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1091
Streptococcus pyogenes FBP54 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1092
Streptococcus pyogenes SfbI protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1093
Streptococcus pyogenes Sib35 protein vaccine
M. tuberculosis DNA Vaccine encoding KatG
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1094
Mycobacterium tuberculosis DNA vaccine encoding KatG
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1095
Mycobacterium tuberculosis HBHA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1097
Helicobacter pylori HspA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1098
Helicobacter pylori HspB Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1099
Helicobacter pylori GltA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1100
Streptococcus pneumoniae PhpA-79 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1101
Neisseria meningitidis TbpA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1105
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1108
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1028
Leishmania donovani HASPB1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=790
Streptococcus pneumoniae GtS protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=792
Streptococcus pneumoniae 6PGD protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=793
Streptococcus pneumoniae PiaA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=794
Streptococcus pneumoniae RASV synthesizing PsaA vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=61
Ebola virus recombinant adenovirus vector vaccine ADV-GP/NP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=71
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=74
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=75
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=76
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=78
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=82
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=83
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=84
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=85
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=86
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=87
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=88
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=89
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=90
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=92
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=93
Earlier investigational version of a smallpox vaccine developed by Acambis. It was part of the development process that led to the creation of ACAM2000.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=97
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=98
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=99
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=100
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=101
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=102
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=103
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=106
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=107
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=108
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=114
inactivated Campylobacter jejuni whole-cell vaccine
MBP fused on Campylobacter FlaA (MBP-FlaA)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=124
MBP fused on Campylobacter FlaA (MBP-FlaA) vaccine
Recombinant DOBV nucleocapsid protein (rDOBV N)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=140
recombinant DOBV nucleocapsid protein (rDOBV N) vaccine
Truncated Recombinant DoBV Nucleocapsid Proteins (Dob-N rNp)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=141
Truncated Recombinant DoBV Nucleocapsid Proteins (Dob-N rNp) vaccine
VEE virus complex-specific monoclonal antibody
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=167
VEE virus complex-specific monoclonal antibody vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=168
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=172
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=174
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=175
Recombinant RNA replicons from attenuated VEE virus
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=181
recombinant RNA replicons from attenuated VEE virus vaccine
Nontypeable H. influenzae Outer Membrane Protein P1 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=182
Nontypeable Haemophilus influenzae Outer Membrane Protein P1 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=183
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=184
Venezuelan equine encephalitis, live, attenuated
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=185
Nontypeable H. influenzae outer membrane recombinant P4 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=187
Nontypeable Haemophilus influenzae outer membrane recombinant P4 vaccine
Non-typeable H. influenzae dLOS-P6 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=196
Nontypeable Haemophilus influenzae dLOS-P6 vaccine
Defective adenovirus expressing VEEV E2 glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=197
defective adenovirus expressing VEEV E2 glycoprotein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=216
Adenovirus vectors expressing Marburg virus glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=217
Adenovirus vectors expressing Marburg virus glycoprotein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=218
Chimaeric HBV core particles carrying Puumala virus nucleocapsid protein fragments
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=219
Chimaeric HBV core particles carrying Puumala virus nucleocapsid protein fragments vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=220
Avirulent Salmonella vaccine strain carrying C. jejuni cjaA gene
BCG auxotroph expressing HIV-1 clade immunogen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=224
BCG auxotroph expressing HIV-1 clade immunogen vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=225
Mycobacterium tuberculosis DNA vaccine pAK4-sod
deltaphoP/Q S. typhimurium strains expressing PEB1-ss
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=226
deltaphoP/Q Salmonella typhimurium strains expressing PEB1-ss vaccine
Recombinant VEE Replicons expressing MBGV GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=227
recombinant VEE Replicons expressing MBGV GP vaccine
Recombinant VEE Replicons expressing MBGV NP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=228
recombinant VEE Replicons expressing MBGV NP vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=229
Marburg virus glycoprotein expressed by baculovirus recombinants
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=230
Marburg virus glycoprotein expressed by baculovirus recombinants vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=237
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=238
Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=240
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=241
Chloroform-methanol residue (CMR) vaccine
P1-HspB (fusion of protein 1 and heat-shock protein B)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=242
P1-HspB (fusion of protein 1 and heat-shock protein B) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=243
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=244
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=245
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=246
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=253
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=255
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=256
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=257
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=261
Shigella flexneri 2a strain CVD 1205 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=276
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=282
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=296
Brucella ovis microparticle subunit vaccine
Live, Attenuated Rifampin-Resistant Rough Mutants of Brucella melitensis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=297
live, attenuated Rifampin-resistant rough mutants of Brucella melitensis vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=303
DNA vaccine co-expressing A85A and caspase-3
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=305
Recombinant vaccinia A27L, D8L, and B5R Proteins with adjuvant MPL-TDM
Killed Vaccinia Virus with Adjuvant NanoEmulsion
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=311
killed vaccinia virus vaccine with adjuvant NanoEmulsion
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=781
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=783
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=785
Varicella subunit vaccine encoding gI and gE glycoproteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=814
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=820
Pseduorabies Subunit Glycoprotein C vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=827
Pseudorabies recombinant vector vaccine encoding gp50 and gII protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=886
Y. pestis DNA vaccine encoding dfF1 Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=906
Yersinia pestis DNA vaccine encoding dfF1 protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=908
RASV expressing Yersinia pestis Psn vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=914
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=917
P. yoelii DNA vaccine encoding PyHEP17 Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=927
Plasmodium yoelii DNA vaccine encoding PyHEP17 protein
N. caninum DNA vaccine encoding NcSAG1 and NcSRS2, combined with recombinant NcSAG1 and NcSRS2 proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=935
Neospora caninum DNA vaccine encoding NcSAG1 and NcSRS2, combined with recombinant NcSAG1 and NcSRS2 Protein
N. caninum MIC10 and p24 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=946
Neospora caninum MIC10 and p24 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=953
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=983
Clostridium botulinum DNA vaccine pSCARSA/BHc
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=991
influenza virus DNA vaccine encoding HA of Equine influenza virus H3N8
Recombinant vesicular stomatitis virus encoding HA from Influenza A virus (A/WSN/1933(H1N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=992
recombinant vesicular stomatitis virus encoding HA from Influenza A virus (A/WSN/1933(H1N1)) vaccine
Recombinant baculovirus encoding HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=995
recombinant baculovirus encoding HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1)) vaccine
Recombinant vaccinia virus encoding HA from Influenza B virus (Strain B/England/222/82)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=996
recombinant vaccinia virus encoding HA from Influenza B virus (Strain B/England/222/82) vaccine
L. major DNA Vaccine encoding LACKp24, TSA, LmSTI1 and CPa
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1000
Leishmania major DNA vaccine encoding LACKp24, TSA, LmSTI1 and CPa
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1001
Leishmania major DNA vaccine encoding SP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1002
BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1007
BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1010
Flagellin-based HA globular head fusion vaccine using HA protein from Influenza A virus (A/Viet Nam/1203/2004(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1011
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1015
influenza virus DNA vaccine encoding M1 from influenza A virus (A/chicken/Henan/12/2004(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1021
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1030
Leishmania donovani LD31 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1032
Leishmania vaccine using recombinant L. tarentolae strain expressing A2 antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1055
Theileria annulata Tams1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1056
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1057
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1060
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1062
Salmonella DNA vaccine encoding SopB Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1063
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1068
B. burgdorferi DbpA and OspA Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1073
Borrelia burgdorferi DbpA and OspA Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1079
Pseudomonas aeruginosa DNA vaccine encoding OprF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1080
Pseudomonas aeruginosa OprI protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1081
Pseudomonas aeruginosa PcrV protein vaccine
S. aureus DNA Vaccine encoding PBP2a Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1085
Staphylococcus aureus DNA vaccine encoding PBP2a Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1096
Plasmodium falciparum LSA-3 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1102
P. falciparum CS expressed in irradiated P. berghei as Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1103
Plasmodium falciparum CS expressed in irradiated Plasmodium berghei vaccine
P. falciparum DNA Vaccine encoding EBA-175
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1104
Plasmodium falciparum DNA vaccine encoding EBA-175
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1106
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1107
VVr expressing L. infantum P37/LACK vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1110
Leishmania amazonensis CP Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1112
Streptococcus agalactiae BipA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1118
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1119
Chlamydia muridarum Tarp subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1120
Campylobacter jejuni PorA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1121
Plasmodium falciparum pfCelTos protein vaccine
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix]
Boostrix (Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine, inactivated 5 UNT) per 0.5 ML Prefilled Syringe
Boostrix Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Boostrix]
BOOSTRIX vaccine 0.5 ML Prefilled Syringe
Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML
Bacillus anthracis strain V770-NP1-R antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2074
Ovine Ecthyma live virus vaccine by Colorado Serum Company CZ Veterinaria
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2075
Ovine Ecthyma live virus vaccine by Texas Agricultural Experiment Station
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2149
West Nile Virus DNA Vaccine (USDA: 1995.D0)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2736
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2737
Canine Parainfluenza Modified Live Virus Vaccine-Leptospira Canicola-Icterohaemorrhagiae Bacterin (USDA: 47A9.20)
obsolete BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2979
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2980
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2981
Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Erysipelothrix Rhusiopathiae-Haemophilus Parasuis Bacterin (USDA: 49V9.20)
obsolete BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS 0.1 MG/ML [Biothrax]
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2982
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=2983
Porcine Reproductive & Respiratory Syndrome Respiratory Form, Modified Live Virus Vaccine-Haemophilus Parasuis Bacterin (USDA: 49Q9.20)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3038
Toxoplasma gondii DNA vaccine encoding MIC8
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3039
Staphylococcus aureus IsdB subunit vaccine (V710)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3040
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3046
B. anthracis rPA Vaccine with Rehydragel HPA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3047
Bacillus anthracis rPA vaccine with Rehydragel HPA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3048
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3050
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3051
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3053
cancer vaccine using E7 protein of human papillomavirus 16 and Algammulin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3054
cancer vaccine using E7 protein of human papillomavirus 16 and Quil-A
E. maxima oocysts with Arlacel A vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3056
Eimeria maxima oocysts with Arlacel A vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3057
Tetanus Toxoid vaccine with Calcium Phosphate
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3058
Tetanus Toxoid vaccine with Stearyl Tyrosine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3059
V3 VLPs vaccine with Gamma inulin adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3061
gp120 recominant vaccine with GMDP adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3062
gp120 recominant vaccine with MDP adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3063
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3064
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3065
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3067
gp140, Gag and Tat protein vaccine with MF59
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3068
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3069
L. donovani Recombinant Ld-Gamma-GCS in NIV system Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3070
Leishmania donovani recombinant Ld-Gamma-GCS in NIV system vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3071
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3072
Plasmodium falciparum MSP4 vaccine with AFCo1 adjuvant vaccine
Inactivated split Mem 71 Virus with SPT adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3073
Inactivated split Mem 71 Virus with SPT adjuvant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3074
Recombinant Colorectal cancer antigen GA733 Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3076
Anthrax vaccine adsorbed with Squalene adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3077
Group A streptococcal recombinant fusion peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3078
recombinant NY-ESO-1 protein vaccine adjuvanted with imiquimod
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3080
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3081
attenuated Listeria expressing cancer antigen vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3082
recombinant S gene Hepatitis B vaccine with rIFN-gamma
Y. pestis F1 antigen Vaccine with Flagellin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3083
Yersinia pestis F1 antigen vaccine with Flagellin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3084
inactivated H1N1(2009) vaccine with AF03 adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3085
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3086
recombinant PA vaccine with Poly(I:C) adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3087
C. muridarum PmpG-1, PmpE/F-2, and MOMP Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3089
Chlamydia muridarum PmpG-1, PmpE/F-2, and MOMP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3091
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3092
Hepatitis B surface antigen (HBsAg) with JVRS-1000
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3093
Hepatitis B surface antigen (HBsAg) with JVRS-1000 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3094
obsolete E. coli CS3 in PLGA microspheres
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3096
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3097
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3098
pneumococcal polysaccharide conjugate vaccine serotype 1 (PNC-1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3099
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5966
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3100
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3101
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3103
Plasmodium falciparum MSA-2 subunit vaccine
B. anthracis PA protein Vaccine with TMDP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3104
Bacillus anthracis PA protein vaccine with TMDP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3105
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3106
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3107
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3108
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3110
human apo B-100 peptide-2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3111
MDA-modified human apo B-100 peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3117
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3147
Tick-borne Encephalitis Virus C protein mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3207
Mycobacterium tuberculosis mce-2 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3285
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3286
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3287
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3288
Brucella abortus S19 vjbR mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3289
African Swine Fever Virus 9GL mutant vaccine
Recombinant B. abortus CobB protein with CFA/IFA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3292
recombinant Brucella abortus CobB protein vaccine with CFA/IFA adjuvant
Recombinant B. abortus AsnC protein with CFA/IFA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3293
recombinant Brucella abortus AsnC protein vaccine with CFA/IFA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3294
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3296
Mycobacterium tuberculosis mce-3 mutant vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3299
Bovine Respiratory Syncytial Virus recombinant vector vaccine BHVl/BRSVG encoding the G protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3301
influenza virus DNA vaccine BacPAKHA encoding EqfKY HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3303
influenza virus DNA vaccine p188 encoding H7
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3304
influenza virus DNA vaccine pCMV/Hl encoding H1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3305
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3306
influenza virus DNA vaccine pIRES/HA encoding HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3307
influenza virus DNA vaccine pIRES/NA expressing NA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3308
influenza virus DNA vaccine pIRES/HA/IL-2 expressing HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3309
influenza virus DNA vaccine pIRES/NA/IL-2 encoding NA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3310
influenza virus DNA vaccine pIRES/HA/GM-CSF encoding HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3311
influenza virus DNA vaccine pIRES/NA/GM-CSF encoding NA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3312
influenza virus DNA vaccine pIRES/HA/IL-12p35 + pIRES/NA/IL-12p40
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3316
influenza virus DNA vaccine pRSV-NP encoding the coding sequence from influenza virus A/PR/8/34.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3318
influenza virus DNA vaccine pHA/NP147-155 encoding NP147-155
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3320
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3322
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3324
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3327
influenza virus DNA vaccine d1TTFC-NP encoding NP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3330
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3331
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3332
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3333
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3338
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3342
Toxoplasma gondii DNA vaccine pSAG1-ROP2-SAG2
T. gondii DNA vaccine pcDNA3.1-SAG1-ROP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3343
Toxoplasma gondii DNA vaccine pcDNA3.1-SAG1-ROP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3344
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3349
Bovine herpesvirus 1 DNA vaccine pRSVgIV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3350
Bovine herpesvirus 1 recombinant vector vaccine BHVl/BRSVG
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3357
Bovine herpesvirus 1 DNA vaccine pMASIAtgB encoding a truncated, secreted form of gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3359
Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDFL encoding gD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3360
Bovine herpesvirus 1 recombinant vector vaccine rLaSota/gDF encoding gD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3366
Foot and mouth disease DNA vaccine pWRMHX encoding a minimal self-cleaving ribozyme
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3369
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3370
IHNV DNA vaccine pCMV4-N encoding the nucleoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3372
Murine cytomegalovirus DNA vaccine pcDNA-89 encoding pp89
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3373
Newcastle disease virus DNA vaccine pCAGF encoding the F protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3374
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3375
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3376
Lymphocytic choriomeningitis virus DNA vaccine pCMV-NP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3379
Human papillomavirus DNA vaccine VlJns-Ll encoding L1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3380
Human papillomavirus DNA vaccine Pe7(pcDNA3-Sig/sE7/LAMP) encoding E7
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3383
Human papillomavirus DNA vaccine pC16-L1 encoding L1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3384
Human papillomavirus DNA vaccine CRT/E7 DNA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3388
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3389
Human papillomavirus DNA vaccine E7SH DNA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3392
Ebola virus recombinant rAD-GP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3393
Ebola virus recombinant rAD-GP encoding GP vaccine
Ebola virus recombinant VSVΔG-GP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3394
Ebola virus recombinant VSVΔG-GP encoding GP vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3395
Ebola virus recombinant vector vaccine EBO7 encoding GP from SEBOV and ZEBOV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3396
VHSV DNA vaccine pCMV-vhsG encoding glycoprotein G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3397
VHSV DNA vaccine pCMV-vhsN encoding nucleocapsid protein N and glycoprotein G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3398
Classical swine fever virus DNA vaccine pCI-gp55
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3401
Human cytomegalovirus DNA vaccine VCL-CB01 encoding phosphoprotein 65 and gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3426
HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3430
SIV DNA vaccine pVacc4 encoding env from mac239
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3439
HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3449
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3468
SIV DNA vaccine pSIVgag and pmacIL-15 encoding SIV core protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3478
HIV recombinant vector vaccine MVA-gag encoding gag
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3481
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3485
HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3491
HIV recombinant vector vaccine MVA.HIVA encoding env and rev
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3497
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3510
Hepatitis B DNA vaccine PLGA-CTAB-DNA encoding the small envelope gene
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3516
Duck hepatitis B DNA vaccine pcDNA I-S encoding small S proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3519
Hepatitis B DNA vaccine pRc/CMV-HBs(S) encoding HBsAg
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3520
influenza virus DNA vaccine pDNA encoding M2 and NP
M. tuberculosis DNA vaccine pcDNA3.1+/Ag85A DNA encoding Ag85A
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3522
Mycobacterium tuberculosis DNA vaccine pcDNA3.1+/Ag85A DNA encoding Ag85A
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3524
Hepatitis B DNA vaccine pS encoding major envelope proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3525
Hepatitis B DNA vaccine pCMV-HBs encoding HBsAg
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3528
Hepatitis B DNA vaccine pCEA/HBsAg encoding CEA and HBsAg
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3533
Hepatitis B DNA vaccine pCMV-S2.S encoding the HBV(ayw Strain) envelope protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3538
Coxsackievirus DNA vaccine pCMV/VPl encoding VP1
M. tuberculosis DNA vaccine encoding Ag85B, MPT64 and MPT83
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3540
Mycobacterium tuberculosis DNA vaccine encoding Ag85B, MPT64 and MPT83
M. tuberculosis DNA vaccine (containing the ESAT-6, MPT-64, MPT-83, and KatG constructs)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3546
Mycobacterium tuberculosis DNA vaccine (containing the ESAT-6, MPT-64, MPT-83, and KatG constructs)
M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3547
Mycobacterium tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3548
Herpes simplex virus DNA vaccine gD-2 encoding gD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3549
Herpes simplex virus DNA vaccine Delta-gB-2 encoding gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3550
Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3551
Herpes simplex virus DNA vaccine gB-DNA encoding gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3552
Herpes simplex virus DNA vaccine gBDNA encoding gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3553
Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3555
Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3556
Rabies virus DNA vaccine encoding the ERA glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3557
T. cruzi DNA vaccine encoding TSA-1, ASP-1, ASP-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3558
Trypanosoma cruzi DNA vaccine encoding TSA-1, ASP-1, ASP-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3559
Trypanosoma cruzi DNA vaccine encoding ASP-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3560
T. cruzi DNA vaccine pTS encoding T. cruzi antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3561
Trypanosoma cruzi DNA vaccine pTS encoding Trypanosoma cruzi antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3565
Lassa fever virus recombinant vector vaccine V-LSG encoding the glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3567
Lassa fever virus recombinant vector vaccine V-LSG/N encoding the glycoprotein and the nucleoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3570
Lassa fever virus recombinant vector vaccine YFV17D/LASV-GPC encoding the glycoprotein precursor
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3574
Ebola virus recombinant vector vaccine pVSVXN2-Delta-G/ZEBOVsGP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3579
Ebola virus recombinant adenovirus vaccine AdC7-ZGP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3580
Ebola virus recombinant vector vaccine Ad-CMVZGP encoding the glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3581
Ebola virus recombinant vector vaccine Ad-CAGoptZGP encoding the envelope glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3591
Ebola virus DNA vaccine DNA/rAd5 encoding ZEBOV and SEBOV antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3593
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3594
Marburg virus DNA vaccine MARV GP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3596
Marburg virus recombinant vector vaccine CAdVax-Panfilo
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3598
Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3599
Marburg virus DNA vaccine DNA-GP encoding GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3600
Marburg virus recombinant vector vaccine MBGV GP
B. abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3605
Brucella abortus DNA vaccine pcDNA3.1-p39-L7/L12 encoding p39-L7/L12 fusion protein
B. abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3607
Brucella abortus DNA vaccine pcDNA3-SOD encoding Cu-Zn SOD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3611
Brucella melitensis DNA vaccine pCI-Omp31
B. melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3613
Brucella melitensis DNA vaccine pCIBLSOmp31 encoding BLSOmp31 (fusion protein)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3615
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3616
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3617
Lymphoma DNA vaccine V-Alpha-V-Beta-V-Beta-FrC
P. falciparum recombinant vector vaccine MVA.ME-TRAP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3628
Plasmodium falciparum recombinant vector vaccine MVA.ME-TRAP
An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3643
Glypican-3-derived peptide vaccine for human hepatocellular carcinoma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3647
EAE DNA vaccine pZZ/MBP68-85 encoding MBP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3649
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3652
Autoimmune diabetes DNA vaccine pND2-SGAD55
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3653
Autoimmune diabetes DNA vaccine pCMV-1/rGAD65 encoding GAD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3655
Autoimmune diabetes DNA vaccine pND2-GAD65-BAX encoding GAD and BAX
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3656
Insulin-dependent diabetes mellitus DNA vaccine JwGAD65 + IL-4
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3661
Adjuvant arthritis DNA vaccine pCMV3.65 encoding HSP65
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3662
Pristane-induced arthritis DNA vaccine DNA-hsp65 encoding Mycobacterium leprae 65-kDa heat shock protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3663
Adjuvant arthritis DNA vaccine CII encoding type II collagen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3664
Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3665
Herpes simplex virus DNA vaccine pSIN-gB encoding gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3666
Herpes simplex virus DNA vaccine pCI-gB encoding gB
B. burgdorferi DNA vaccine pCMV-ZS7/TPA encoding OspC from Borrelia burgdorferi sensu lato
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3669
Borrelia burgdorferi DNA vaccine pCMV-ZS7/TPA encoding OspC from Borrelia burgdorferi sensu lato
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3672
C. tetani DNA vaccine pcDNA3tetC encoding fragment C
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3673
West Nile virus DNA vaccine pCBWN encoding prM and E
B. anthracis DNA vaccine pDNA encoding PA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3677
Bacillus anthracis DNA vaccine pDNA encoding PA
B. anthracis DNA vaccine LF pDNA encoding LF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3678
Bacillus anthracis DNA vaccine LF pDNA encoding LF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3681
H. rhabdovirus DNA vaccine pHRV-G encoding HIRRV and VHSV G proteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3682
Hirame rhabdovirus DNA vaccine pHRV-G encoding HIRRV and VHSV G protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3687
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3689
VEE virus DNA vaccine VEEV IA/B parent encoding structural genes
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3690
VEE virus recombinant vector vaccine RAd/VEEV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3691
VEE virus recombinant vector vaccine RAd/VEEV#2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3692
VEE virus recombinant vector vaccine RAd/VEEV#3 encoding TC-83
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3695
Gene name: Fragment C from tetanus toxin
Cancer DNA vaccine p.DOM-AH1 encoding fragment C
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3696
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3698
B-cell lymphoma DNA vaccine VCL-1642.XXX encoding a chimeric immunoglobulin molecule onsisting of tumor-specific variable (Id) regions
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3699
Colorectal cancer DNA vaccine pCEA/HBsAg encoding carcinoembryonic antigen and hepatitis B surface antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3700
B16 melanoma DNA vaccine pSin-hTRP-1 encoding TRP-1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3701
B16 melanoma DNA vaccine pCMV-hTRP-1 encoding TRP-1
Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3705
Melanoma DNA vaccine TA2M encoding tyrosinase peptides
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3713
Melanoma DNA vaccine VR-S8/VR-IL2/AD-S8 encoding survivin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3717
Melanoma DNA vaccine pCR3.1-VS-HSP65-TP-GRP6-M2 encoding 6 tandem repeats of GRP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3718
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3719
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3720
Melanoma DNA vaccine SINCp c-muMUC18 encoding MCAM/MUC18
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3723
Lung metastasis DNA vaccine pCEP4-MUC1 encoding MUC1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3724
Melanoma DNA vaccine hugp100 encoding gp100
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3726
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3727
Melanoma DNA vaccine gp75 DNA encoding melanosomal membrane glycoproteins, gp75 Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3728
Melanoma recombinant vector vaccine rVVmTRP-1 encoding TRP-1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3729
Melanoma DNA vaccine hTRP2 encoding TRP-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3730
Melanoma DNA vaccine pUB-TRP-2 encoding a fusion protein linking murine ubiquitin (UB) to the N-terminus of the full-length mTRP-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3731
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3736
Prostate cancer DNA vaccine pcDNA3-STEAP encoding six-transmembrane epithelial antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3737
Prostate cancer DNA vaccine hPSMAt encoding PSMA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3738
Prostate cancer DNA vaccine rPSMAt encoding PSMA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3740
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3742
Prostate cancer DNA vaccine psig-3P-Fc encoding 3P(hPSM, hPAP, or hPSA)-Fc fusion protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3744
Prostate cancer DNA vaccine PSCA-HSP encoding PSCA and HSP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3745
Prostate cancer DNA vaccine encoding PSCA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3746
Prostate cancer DNA vaccine pmPSCA encoding PSCA
T. gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3754
Toxoplasma gondii DNA vaccine pMIC3i encoding the complete MIC3-ORF (RH(ERP) strain)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3755
Toxoplasma gondii DNA vaccine pVR1020-GRA1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3756
Chinese S. japonicum DNA vaccine pCMV-Sjc97 encoding paramyosin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3757
Chinese Schistosoma japonicum DNA vaccine pCMV-Sjc97 encoding paramyosin
Chinese S. japonicum DNA vaccine pVAX/SjFABP encoding FABP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3758
Chinese Schistosoma japonicum DNA vaccine pVAX/SjFABP encoding FABP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3760
Chinese Schistosoma japonicum DNA vaccine SjCTPI
Chinese S. japonicum DNA vaccine SjCTPI-Hsp70
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3761
Chinese Schistosoma japonicum DNA vaccine SjCTPI-Hsp70
Chinese S. japonicum DNA vaccine pVIVO2-IL12-Sj23 encoding Sj23 and IL-12
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3762
Chinese Schistosoma japonicum DNA vaccine pVIVO2-IL12-Sj23 encoding Sj23 and IL-12
S. mansoni DNA vaccine Sm23-pcDNA encoding Sm23
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3763
Schistosoma mansoni DNA vaccine Sm23-pcDNA encoding Sm23
S. mansoni DNA vaccine pcDNA/CTSOD encoding SOD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3764
Schistosoma mansoni DNA vaccine pcDNA/CTSOD encoding SOD
S. mansoni DNA vaccine pcDNA/GPXbb encoding glutathione-S-peroxidase, GPX
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3765
Schistosoma mansoni DNA vaccine pcDNA/GPXbb encoding glutathione-S-peroxidase, GPX
S. mansoni DNA vaccine Sm-p80-pcDNA3 encoding the large subunit of S. mansoni calpain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3767
Schistosoma mansoni DNA vaccine Sm-p80-pcDNA3 encoding the large subunit of Schistosoma mansoni calpain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3768
Melanoma DNA vaccine xenogeneic DNA encoding murine tyrosinase
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3770
Dengue virus DNA vaccine sA encoding prM and E from Dengue Virus 4
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3771
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3772
Dengue virus DNA vaccine sC encoding prM and E
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3773
Dengue virus DNA vaccine sABC encoding prM and E
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3778
Dengue virus DNA vaccine D1ME encoding prM and E
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3779
Dengue virus DNA vaccine pE1D2 encoding E from Dengue Virus 2 strain New Guinea C
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3781
Dengue virus DNA vaccine pcTPANS1 encoding NS1 fused to the tissue plasminogen activator signal sequence
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3783
Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3784
Dengue virus DNA vaccine p1012D2ME encoding prM and E from DEN 2 New Guinea C strain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3785
Human papillomavirus DNA vaccine hCRTE6E7L2 DNA encoding CRT linked to E6, E7 and L2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3792
Bacillus anthracis DNA vaccine pTPA-PA63
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3793
Bacillus anthracis DNA vaccine pLAMP1-PA63
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3795
B. anthracis DNA vaccine pIMS-120 encoding PA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3796
Bacillus anthracis DNA vaccine pIMS-120 encoding PA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3801
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3802
Bacillus anthracis DNA vaccine PA83 furin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3805
Vaccinia virus DNA vaccine A33R from strain IHD-J
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3808
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3810
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3814
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3815
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3816
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3822
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3823
WEE virus DNA vaccine pVHX-6 encoding 26S
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3829
VEE virus DNA vaccine pSTU-TRDF encoding VEEV E3-E2-6K
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3830
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3831
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3834
IPNV DNA vaccine pEGFP-N1-SegA and pEGFP-N1-VP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3836
VHSV DNA vaccine pVHS-G encoding glycoproteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3837
IHNV DNA vaccine pIHN-G encoding glycoproteins
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3838
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3839
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3840
avian influenza virus DNA vaccine pN1NA encoding N1 neuraminidase
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3841
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3842
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3844
influenza virus DNA vaccine p-Beta-actinH7HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3845
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3846
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3847
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3848
avian influenza virus DNA vaccine pCMV-HA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3849
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3852
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3853
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3854
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3857
Chinese S. japonicum DNA vaccine SjC23-Hsp70
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3860
Chinese Schistosoma japonicum DNA vaccine SjC23-Hsp70
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3861
Chinese Schistosoma japonicum DNA vaccine SjC23
B. burgdorferi DNA vaccine encoding strain B31 OspA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3863
Borrelia burgdorferi DNA vaccine encoding strain B31 OspA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3864
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3865
pCgap DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3867
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3868
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3869
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3870
Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3871
Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3872
Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3873
Herpes Simplex Virus 2 DNA Vaccine encoding gD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3874
Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3876
classicals swine fever virus DNA vaccine pcDNA/E2 with TRIF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3878
Avian pneumovirus DNA vaccine expressing the F gene
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3880
Murine cytomegalovirus DNA vaccine pgM-pgN
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3881
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3882
Toxoplasma gondii DNA vaccine pVAX-TgMIC13
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3883
Hepatitis D DNA vaccine pcDNA3p27/Ad5F35p27
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3884
Leishmania major DNA vaccine pcLACK + IL-22
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3885
Toxoplasma gondii DNA vaccine ROP8-pVAX-1
T. cruzi DNA vaccine encoding TSA-1 and Tc24
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3886
Trypanosoma cruzi DNA vaccine encoding TSA-1 and Tc24
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3887
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3888
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3889
P. multocida DNA vaccine pcDNA-OMPH + pcDNA-OMPA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3890
Pasteurella multocida DNA vaccine pcDNA-OMPH + pcDNA-OMPA
P. multocida DNA vaccine pcDNA-OMPH/OMPA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3891
Pasteurella multocida DNA vaccine pcDNA-OMPH/OMPA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3892
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3893
Erysipelothrix rhusiopathiae DNA vaccine pcD-ACSC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3894
Mycobacterium avium DNA vaccine DNA-Av35/p2AIL12
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3895
Staphylococcus aureus DNA vaccine pClfaSrtD13
S. aureus DNA vaccine encoding Efb, FnbpA, ClfA, Cna
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3896
Staphylococcus aureus DNA vaccine encoding Efb, FnbpA, ClfA, Cna
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3897
Bacillus anthracis DNA vaccine expressing PA
A. pleuropneumoniae DNA vaccine pcDNA-apxIA/pcDNA-apxIIA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3898
Actinobacillus pleuropneumoniae DNA vaccine pcDNA-apxIA/pcDNA-apxIIA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3899
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3900
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3902
Dengue virus DNA vaccine expressing prM/E protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3903
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3904
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3906
Feline immunodeficiency virus recombinant vector vaccine FIV-Delta-RT
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3907
Foot-and-Mouth Disease Virus DNA vaccine pSinCMV-Vac-MEG990
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3908
Foot-and-Mouth Disease Virus Cationic Microparticle-coated DNA vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3909
FMDV DNA vaccine encoding P1 and non-structural proteins 2A, 3C, and 3D
C. trachomatis DNA vaccine pWRG7079::MOMP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3910
Chlamydia trachomatis DNA vaccine pWRG7079::MOMP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3911
Chlamydophila pneumoniae DNA vaccine pHSP-61
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3912
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3913
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3914
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3915
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3916
Helicobacter pylori DNA vaccine pcDNA3.2-hspA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3917
Helicobacter pylori DNA vaccine pcDNA3.2-hspB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3918
Leptospira interrogans DNA vaccine ompL1-pcDNA3.1(+)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3919
Leptospira interrogans DNA vaccine pTARGET/ LigBrep
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3920
SIV recombinant vector vaccine rAd5/rLCMV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3921
Laryngotracheitis DNA vaccine encoding gB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3922
Marburg virus recombinant vector vaccine MBGV GP/MBGV NP
H. rhabdovirus DNA Vaccine encoding N and G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3923
Hirame rhabdovirus DNA vaccine encoding N and G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3924
influenza virus DNA vaccine M2-DNA/M2-Ad
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3926
P. aeruginosa DNA vaccine pGACAG-OprF/OprI
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3927
Pseudomonas aeruginosa DNA vaccine pGACAG-OprF/OprI
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3928
Pseudomonas aeruginosa DNA vaccine pGACAG-PcrV
P. aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3929
Pseudomonas aeruginosa DNA vaccine pGACAG-OprF/OprI + pGACAG-PcrV + pGACAG-PilA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3930
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3931
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3932
Duck hepatitis virus 1 DNA vaccine pSCA/VP1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3933
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3934
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3935
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3936
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3937
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3938
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3939
IBV DNA vaccine pVAX-S1 with GM-CSF adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3940
Hirame rhabdovirus DNA vaccine encoding G
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3941
Infectious Bronchitis virus DNA vaccine encoding S1, N, and M
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3942
Infectious Bursal Disease virus DNA vaccine expressing VP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3943
Japanese encephalitis virus DNA vaccine P-JEV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3944
Japanese encephalitis virus DNA vaccine pCJ-3/E encoding E
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3946
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3947
Plasmodium yoelii DNA vaccine pDIP/PyCSPlasmodium 1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3948
Plasmodium yoelii DNA vaccine encoding PySSP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3949
Plasmodium berghei DNA vaccine encoding PbCSP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3950
Plasmodium yoelii DNA vaccine pPyHsp60-VR1012
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3951
Plasmodium yoelii DNA vaccine encoding MSP1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3952
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3953
P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3954
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3955
SHIV(Ba-L) DNA vaccine encoding env and gag
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3956
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3958
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3960
rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3961
Streptococcus pneumoniae pspA-rBCG vector vaccine
T. gondii recombinant vaccine vector rBCGpMV361-TgCyP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3962
Toxoplasma gondii recombinant vaccine vector rBCGpMV361-TgCyP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3963
A dendritic cell vaccine consisting of dendritic cells (DCs) electroporated with mRNA encoding three adjuvants, CD40 ligand (CD40L), a constitutively active TLR4, and CD70 (all together termed TriMix); coelectroporated with full-length mRNA encoding MAGE-A3, MAGE-C2, Tyrosinase and gp100; and linked to DC-LAMP, with potential immunostimulating activity. Upon vaccination, the DCs may stimulate the immune system to mount an antigen-specific cytotoxic T-lymphocyte (CTL) response against the melanoma antigens. This may decrease cellular proliferation of melanoma cells expressing these antigens. Electroporation with the adjuvants CD40L and TLR4 allows for the generation of mature and active DCs; electroporation with CD70 provides a costimulatory signal to CD27+ naive T cells thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5238
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3969
SL3261 expressing Trichinella spiralis Ag30 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3970
Aeromonas hydrophila LSA34 vector vaccine WED/pUTDgap
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3972
Actinobacillus pleuropneumoniae HS93Tox-/pIG-T1K vectored vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3973
Bordetella pertussis BPZE vectored vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3987
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4001
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4019
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4025
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4044
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4054
mRNA-electroporated dendritic cells encoding gp100 and tyrosinase as melanoma vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4057
The approach focuses on the use of five primary patient derived melanoma cells (MEL-2, MEL-V, 3MM, KFM, and GLM-2). These cells display differential in vitro migratory and invasive properties as well as have the ability to form solid tumors when implanted into BALB/c nude mice. The retention of the innate phenotype of these primary patient derived cells together with the expression of a multitude repertoire of melanoma associated antigens offers a novel opportunity to target melanoma so as to avoid immune evasion
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4064
short overlapping peptides and full-length recombinant protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4079
short overlapping peptides and full-length recombinant protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4082
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4083
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4084
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4085
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4087
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4088
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4089
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4091
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4092
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4095
A2-CPA-CPB(-CTE)-recombinant L. tarentolae
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4096
A2-CPA-CPB(-CTE)-recombinant L. tarentolae vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4097
Leishmania tarentolae expressing HIV-1 Gag vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4099
AdC68- rabies virus glycoprotein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4100
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4102
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4103
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4104
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4106
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4107
rSPV-HA1 (Swine influenza virus H1N1) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4108
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4110
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4111
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4112
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4113
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4114
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4115
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4116
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4117
CAdVa-Filoviruses (EbMarburg viruses) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4118
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4119
cAdVax-based bivalent ebola virus vaccine (Sudan and Zaire species)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4120
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4121
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4122
BPZE1- FHA (H1N1/PR8 influenza A virus) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4124
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4125
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4126
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4128
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4129
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4130
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4131
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4136
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4137
An Ebola virus vaccine that uses a recombinant vesicular stomatitis virus (rVSV) vector expressing an Ebola filovirus glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4140
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4141
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4142
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4143
rMVA-GnGc (Rift Valley fever virus) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4144
rMVA-SIV-CD40L Simian immunodeficiency virus vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4145
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4146
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4149
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4150
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4151
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4152
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4153
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4154
SL3261-P. aeruginosa serogroup O11 O antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4156
SL3261-Pseudomonas aeruginosa serogroup O11 O antigen vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4157
SL3261 expressing streptococcal M protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4158
SL3261 expressing streptococcal M protein vaccine
Schmidt-Ruppin Rous sarcoma virus-H7 (H7N7)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4159
Schmidt-Ruppin Rous sarcoma virus-H7 (H7N7) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4160
RBD-rAAV-SARS-CoV prime/RBD-specific T cell peptide boost
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4161
RBD-rAAV-SARS-CoV prime/RBD-specific T cell peptide boost vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4162
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4163
rNDV-H5 ( HPAI H5N1 challenge in mule ducks)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4164
rNDV-H5 ( HPAI H5N1 challenge in mule ducks) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4165
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4167
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4168
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4169
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4172
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4173
M.S-Delta-esx-3-IKEPLUS (M. tuberculosis)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4174
M.S-Delta-esx-3-IKEPLUS Mycobacterium tuberculosis vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4175
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4176
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4177
RCN-F1-V Yersinia pestis F1 and V vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4178
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4179
RCN-IRES-tPA-YpF1 Yersinia pestis vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4180
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4181
PAV3-HA (A/Hanoi/30408/2005 H5N1) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4182
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4183
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4184
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4185
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4186
Typhi strain Ty21a-PA (Bacillus anthracis)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4187
Typhi strain Ty21a-PA Bacillus anthracis vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4188
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4189
Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4190
poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4191
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4192
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4193
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4194
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4195
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4196
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4197
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4198
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4199
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4200
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4201
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4202
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4203
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4204
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4205
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4206
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4207
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4208
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4209
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4210
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4211
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4212
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4213
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4214
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4215
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4216
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4218
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4219
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4220
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4221
ALVAC-EIV (equine influenza virus H3N8) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4222
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4223
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4224
Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4225
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4226
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4227
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4228
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4229
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4230
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4231
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4232
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4233
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4234
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4237
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4239
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4240
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4241
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4242
Ac-CMV-S1 infectious bronchitis virus vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4243
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4244
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4245
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4246
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4248
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4249
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4251
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4253
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4254
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4255
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4256
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4257
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4258
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4259
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4260
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4261
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4262
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4263
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4264
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4265
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4266
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4267
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4268
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4270
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4271
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4274
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4275
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4280
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4282
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4288
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4289
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4290
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4293
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4295
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4299
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4300
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4301
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4302
rMVA-SIV-CD40L human immunodeficiency virus vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4304
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4269
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4306
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4308
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4309
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4310
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4094
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4311
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4277
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4312
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4272
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4313
BDES-PfCSP (baculovirus dual expression system)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4314
BDES-PfCSP vaccine (baculovirus dual expression system)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4315
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4316
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4317
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4318
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4319
Mycobacterium bovis DNA vaccine pCI-Ag85B
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4320
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4321
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4322
A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Florida/4/2006; Sanofi-Pasteur
2010-2011 trivalent seasonal inactivated influenza vaccine 2010 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008)
2010-2011 trivalent seasonal inactivated influenza vaccine (A/California/7/09 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4324
2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4325
Recombinant Aeromonas hydrophila vaccine (Aera)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4326
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4327
Biothrax (anthrax vaccine adsorbed) 0.5 ML Injectable Suspension
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Biothrax]
Biothrax 0.1 MG/ML Injectable Suspension
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000000 UNT/ML
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000000 UNT/ML [Rotarix]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000000 UNT/ML Oral Suspension [Rotarix]
Rotarix, Rotavirus, live attenuated (RV1) G1P[8] Vaccine 1 ML Lyophilized Powder for Oral Suspension
Rotarix, Rotavirus, live attenuated (RV1) G1P[8] Oral Vaccine
human-bovine reassortant rotavirus strain G4 vaccine
human rotavirus A type G4P7(5) strain BRB live antigen
human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML
human-bovine reassortant rotavirus strain P1A[8] vaccine
human rotavirus A type G6P1A(8) strain WI79 live antigen
human-bovine reassortant rotavirus strain G2 vaccine
human rotavirus A type G2P7(5) strain SC2 live antigen
human-bovine reassortant rotavirus strain G3 vaccine
human rotavirus A type G3P7(5) strain WI78 live antigen
human-bovine reassortant rotavirus strain G1 vaccine
human rotavirus A type G1P7(5) strain WI79 live antigen
human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML
human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML
human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML
human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML
human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML [RotaTeq]
human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML Oral Suspension [RotaTeq]
RotaTeq, Rotavirus, live pentavalent (RV5) Oral Vaccine
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Quadracel]
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel]
Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine
Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Menveo]
0.5 ML Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection [Menveo]
Menveo Meningococcal (groups A, C, Y and W-135) oligosaccharide Diphtheria CRM197 Conjugate Vaccine 0.5 ML Injection
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML [Trumenba]
meningococcal group B vaccine Prefilled Syringe [Trumenba]
0.5 ML Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe [Trumenba]
Trumenba (meningococcal group B vaccine) 0.5 ML Prefilled Syringe
Trumenba vaccine 0.5 ML Prefilled Syringe
meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML [Bexsero]
0.5 ML meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe [Bexsero]
Bexsero Meningococcal Group B Vaccine 0.5 ML Prefilled Syringe
BEXSERO vaccine 0.5 ML Prefilled Syringe
smallpox vaccine live vaccinia virus 500000000 UNT/ML
smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML Injectable Solution [ACAM2000]
ACAM2000 smallpox (vaccinia) vaccine, live Injectable Solution
smallpox vaccine live vaccinia virus 500000000 UNT/ML [ACAM2000]
meningococcal polysaccharide vaccine group Y
meningococcal group C polysaccharide 0.01 MG/ML
meningococcal group C polysaccharide 0.1 MG/ML
meningococcal polysaccharide vaccine group Y 0.01 MG/ML
meningococcal polysaccharide vaccine group Y 0.1 MG/ML
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML [MenHibrix]
MenHibrix (meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine) 0.5 ML Injection
0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection [MenHibrix]
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML
HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578
HUMAN ADENOVIRUS B SEROTYPE 7 STRAIN 55142
Adenovirus Type 4 Vaccine Live Oral Product
Adenovirus Type 4 Vaccine Live Delayed Release Oral Tablet
Adenovirus Type 4 Vaccine Live 32000 UNT Delayed Release Oral Tablet
Adenovirus Type 4 Vaccine Live 32000 UNT
Adenovirus Type 7 Vaccine Live Oral Product
Adenovirus Type 7 Vaccine Live Delayed Release Oral Tablet
Adenovirus Type 7 Vaccine Live 32000 UNT Delayed Release Oral Tablet
Adenovirus Type 7 Vaccine Live 32000 UNT
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML [Menomune A/C/Y/W-135]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injection [Menomune A/C/Y/W-135]
0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection [Menomune A/C/Y/W-135]
Menomune A/C/Y/W-135 (meningococcal group A polysaccharide 50 MCG / meningococcal group C polysaccharide 50 MCG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 50 MCG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 50 MCG) per 0.5 ML Injection
Menomune A/C/Y/W-135 Vaccine 0.5 ML Injection
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injectable Solution [Menomune A/C/Y/W-135]
Menomune A/C/Y/W-135 Vaccine Injectable Solution
meningococcal polysaccharide vaccine group W-135
meningococcal polysaccharide vaccine group W-135 0.1 MG/ML
meningococcal group A polysaccharide 0.1 MG/ML
The gH1-Qbeta vaccine is a novel pandemic-influenza vaccine produced by covalently linking the globular head domain of haemagglutinin (gH1) from A/California/07/09 produced in E. coli to VLPs from the bacteriophage Qbeta
A recombinant uncleaved clade C HIV-1 envelope gp140 protein (CN54gp140)
Fluenz is a seasonal trivalent live attenuated influenza vaccine (LAIV) administered intranasally. The vaccine contained A/California/07/2009 (H1N1) pdm09-like strain, A/Victoria/361/2011 (H3N2)-like strain, and B/Massachusetts/2/2012-like strain.
quadrivalent seasonal inactivated influenza vaccine 2014 consisting of Influenza A virus (A/California/7/2009(H1N1)), Influenza A virus (A/Texas/50/2012(H3N2)), Influenza B virus (B/Brisbane/60/2008), Influenza B virus (B/Massachusetts/02/2012)
quadrivalent seasonal inactivated influenza vaccine 2014
F' (intended to refer to a female biological sex), 'Female', 'Woman', '0' (intended to refer to a female biological sex)
A biological sex datum that represents the biological sex of an animal (including human) as being female.
I' (intended to refer to an intersex biological sex), 'Intersex', 'Hermaphrodite', 'Pseudo-hermaphrodite', '2' (intended to refer to an intersex biological sex)
A biological sex datum that represents the biological sex of an animal (including human) as being intersex.
Recommended by WHO for Vaccines: 2011-2012 Northern Hemisphere 2010 Southern Hemisphere 2011 Southern Hemisphere 2012 Southern Hemisphere 2010-2011 Northern Hemisphere
Influenza A virus A/Perth/16/2009 (H3N2) antigen
2012-2013 trivalent seasonal inactivated influenza vaccine 2012-2013 Influenza A virus (A/California/7/2009 (H1N1)), Influenza A virus (A/Victoria/361/2011 (H3N2)), and Influenza B virus (B/Wisconsin/1/2010)
2012-2013 seasonal trivalent inactivated influenza vaccine (A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Wisconsin/1/2010)
influenza B virus B/Wisconsin/1/2010 antigen
Recommended by WHO for Vaccines: 2013 Southern Hemisphere 2014 Southern Hemisphere 2012-2013 Northern Hemisphere 2013-2014 Northern Hemisphere
influenza A virus A/Victoria/361/2011 (H3N2) antigen
Inactivated monovalent influenza A/H5N1 (3.75 mcg hemagglutinin [HA] A/Indonesia/05/2005) split-virus (SV) vaccine (Sanofi)
Influenza A virus (A/Indonesia/05/2005) antigen
MERS-CoV S protein with alum and CpG adjuvant
MERS-CoV S protein with alum and CpG adjuvant vaccine
A coronavirus vaccine against the infection of SARS-CoV-2 (cause of COVID-19)
A Plasmodium falciparum vaccine that is composed of aseptic, purified, live (metabolically active), radiation-attenuated, cryopreserved Plasmodium falciparum sporozite.
The fully infectious PfSPZ are attenuated in vivo by concomitant administration of an anti-malarial drug (chloroquine). Chloroquine kills disease-associated blood stages but does not affect pre-erythrocytic (sporozoite or liver) stages, which are exposed to the host's immune system. Sporozoites-induced protection is mediated by immunity against pre-erythrocytic stages.
Sanaria(R) PfSPZ-GA1 consists of purified, aseptic, cryopreserved Pf sporozoites (NF54 strain) genetically attenuated by removal of the b9 and slarp genes to halt development in the early liver stages.
The parasite line was generated by the Leiden University Medical Center (LUMC) and RUMC in collaboration with Sanaria. Plasmodium falciparum with deletion b9 and slarp parasites invade hepatocytes but are incapable of sustaining liver stage development, similar to radiation-attenuated PfSPZ. The potential advantages of PfSPZ-GA1 are that (1) the PfSPZ are homogenous and have a precisely characterized genetic basis for attenuation; (2) manufacturing PfSPZ-GA1 cannot result in accidental exposure of staff to infectious parasites, thereby simplifying the approach to safety of operators and lowering costs. PfSPZ-GA1 also has the potential to induce more efficient protection than the radiation-attenuated PfSPZ Vaccine due to a different pattern of developmental arrest and antigen expression. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077156/
A vaccine role that inheres in a vaccine using virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines.
A vaccine that uses virus-like particles (VLPs), multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccines.
vaccine-induced T-helper 1 type immune response that is indicated by the presence of Interferon-gamma production
vaccine specific interferon-γ immune response
vaccine-induced T-helper 1 type immune response that is indicated by the presence of interleukin-2 production
vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-4 production
vaccine-induced T-helper 2 type immune response that is indicated by the presence of interleukin-10 production
vaccine specific interleukin-10 response
vaccine-induced T-helper 1 type immune response that is indicated by the presence of IgG2a production
vaccine specific Th1 immune response indicated by IgG2a production
vaccine-induced T-helper 2 type immune response that is indicated by the presence of IgG1 production
vaccine specific Th2 immune response indicated by IgG1 production
The human age is classified into four categories as Child (0-12 years), Adolescence (13-18 years), Adult (19-59 years) and Senior Adult (60 years and above) which is discussed in the paper. Reference: https://ieeexplore.ieee.org/abstract/document/6416855.
human age 60 and above years at vaccination
human adolescence age range at vaccination
human age 12 to 23 months at vaccination
A human child age range at vaccination with the range from the birth to one month after birth at when a vaccination is taken. HepB vaccination is sometimes taken within 12 hours after birth.
human age within one month at vaccination
A SARS-CoV-2 RNA vaccine formed from a lipid nanoparticle-formulated trimerized SARS-CoV-2 receptor-binding domain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5784
For active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
Replaced term with S protein of SARS-CoV-2 Wuhan strain (PR_P0DTC2) for ontology harmonization
BBV152 (also known as Covaxin) is an inactivated COVID-19 vaccine that is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5795
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)
A recombinant coronavirus-like particle SARS-CoV-2 vaccine developed by Medicago
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5796
SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz)
SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)
A P. falciparum malaria vaccine that is formed by tull length CS-expressing replication-deficient recombinant human adenovirus 35.
This is a term requested by Randi for the HIPC/ImmPort work
A SARS-CoV-2 trimeric S protein subunit vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5797
A SARS-CoV-2 S1-RBD-protein based vaccine developed by Vaxxinity
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5798
A SARS-CoV-2 replication-defective human adenovirus type 5/35 vector based vaccine expressing the S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5800
A SARS-CoV-2-RBD-Fc fusion protein designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5834
A DNA vaccine plasmid vector that has the plasmid label pCAGGSP7. This plasmid has a polylinker containing KpnI, XhoI, ClaI, EcoRV, SmaI, Not1 and Sac1 sites inserted into the EcoRI site of pCAGGS.
A DNA vaccine plasmid vector that has the plasmid label pCAGGS/MCS. This plasmid has a chicken beta-actin promoter, contains a multiple cloning site between the EcoRI and BglII sites of the rabbit beta-globin gene, and has restriction sites for the enzymes SacI, ClaI, NsiI, Asp718, SmaI, SphI, XhoI, and NheI.
A DNA vaccine plasmid vector that has the plasmid label pWRG. This plasmid is a eukaryotic expression plasmid that contains the immediate early promoter and intron A of human cytomegalovirus.
A DNA vaccine plasmid vector that has the plasmid label pHW2000. This plasmid is derived from pHW12 and contains part of the human pol I promoter and murine terminator sequences, a CMV promoter, and the polyadenylation signal of the gene encoding bovine growth hormone.
A DNA vaccine plasmid vector that has the plasmid label pCMV/R. This plasmid is a mammalian expression vector with a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label VRC-9123.
This plasmid was prepared under Good Manufacturing Practices at 4 mg/mL in phosphate buffered saline (PBS).
A DNA vaccine plasmid vector that has the plasmid label pPJV7563. This plasmid has a human cytomegalovirus immediate early promoter.
A DNA vaccine plasmid vector that has the plasmid label p188. This plasmid is a replication-defective derivative of pP1/H7.
A DNA vaccine plasmid vector that has the plasmid label VR10551. This plasmid contains a human cytomegalovirus immediate early 1 promoter, a kanamycin resistance gene, intron A and a modified rabbit b-globin terminator.
A DNA vaccine plasmid vector that has the plasmid label VCL-1632. This plasmid contains a CMV promoter, kanamycin resistance gene, the murine Kappa constant region sequence, a translational enhancer, the murine IgG2a heavy-chain sequence, and a translation terminator. This plasmid is derived from pUC-18.
A DNA vaccine plasmid vector that has the plasmid label pSport-B-gal. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pSin-B-gal. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pLXSHD. This plasmid has a murine leukemia virus enhancer-promoter LTR.
A DNA vaccine plasmid vector that has the plasmid label WRG/BEN. This plasmid is based off of pWRG7077. It contains a CMV promoter and a kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pNGVL4a. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes.
There is an extra immunostimulatory sequence (450 bp) in pNGVL4a plasmid compared to pNGVL3
A DNA vaccine plasmid vector that has the plasmid label pNGVL3. This plasmid has a CMV promoter and kanamycin and ampicillin resistance genes.
A DNA vaccine plasmid vector that has the plasmid label SINCp B-gal. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label Synchotrope TA2M. This plasmid is 3683 base pairs in length and has two copies of the murine CpG immune stimulatory sequence AACGTT inserted.
It has been shown that plasmid half-life in human serum in vitro is 20 minutes
A DNA vaccine plasmid vector that has the plasmid label pCMV/myc/ER. This plasmid is 5066 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/2236/
A DNA vaccine plasmid vector that has the plasmid label pPA63-LAMP1.
A DNA vaccine plasmid vector that has the plasmid label pSecTag2B. This plasmid is 5163 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
Invitrogen:http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf; Sequence: http://tools.invitrogen.com/content/sfs/vectors/psectag2b_seq.txt
A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63-LAMP1.
A DNA vaccine plasmid vector that has the plasmid label pTPA-PA63.
A DNA vaccine plasmid vector that has the plasmid label VR2210. This plasmid contains a CMV promoter and kanamycin resistance gene. It was created through ligation of fragments of digested plasmid VR1012, hTPA, and B. burgdorferi B31 ospA.
A DNA vaccine plasmid vector that has the plasmid label pCMV-TPA/ZS7. This plasmid contains a CMV promoter and is generated from pCMV-ZS7 by attaching hTPA to ospC ZS7.
A DNA vaccine plasmid vector that has the plasmid label pABB-CRS2. This plasmid is a derivative of pCVD442 and contains a chloramphenicol resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pMASIA-tgD. This plasmid is based off of pMASIA and contains a CMV promoter and kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pCMVi-UB. This plasmid was built from pCMV-5 and contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pCI30. This plasmid contains a CMV promoter, ampicillin resistance gene, T7 RNA polymerase promoter, a multiple cloning region and a 6xHis tag coding sequence.
A DNA vaccine plasmid vector that has the plasmid label pCP15/60.
A DNA vaccine plasmid vector that has the plasmid label pUMVC3. This plasmid is 4030 base pairs in length and contains a CMV promoter and kanamycin resistance gene.
Aldevron: http://www.aldevron.com/products/dnas/umvc_expression/
A DNA vaccine plasmid vector that has the plasmid label pcDNA1. This plasmid is 4000 base pairs in length and contains a CMV promoter.
Addgene: https://www.addgene.org/vector-database/2089/
A DNA vaccine plasmid vector that has the plasmid label pCAT. This plasmid is 4364 base pairs in length and contains an ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/2051/
A DNA vaccine plasmid vector that has the plasmid label pGT36. This plasmid is a derivative of pcDNA3 and contains a CMV promoter and a kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label VR1040. This plasmid contains four copies of the mouse immunostimulatory sequence and is similar to VR1012.
A DNA vaccine plasmid vector that has the plasmid label pcTPA. This plasmid is based on pcDNA3 and contains the hTPA signal sequence.
A DNA vaccine plasmid vector that has the plasmid label pMV10.1. This plasmid contains a CMV promoter and a kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pET11d. This plasmid is 5674 base pairs in length and contains an ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/2628/
A DNA vaccine plasmid vector that has the plasmid label pUMVC4b. This plasmid is 4478 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes.
Aldevron: http://www.aldevron.com/products/dnas/umvc_expression/; Sequence: https://system.netsuite.com/c.606687/pUMVC4a.txt
A DNA vaccine plasmid vector that has the plasmid label pRC. This plasmid is 7400 base pairs in length and contains CMV and RSV promoters.
A DNA vaccine plasmid vector that has the plasmid label pAK-4. This plasmid is 6600 base pairs in length and contains a CMV promoter and kanamycin and ampicillin resistance genes.
A DNA vaccine plasmid vector that has the plasmid label pCMVi(-H3)Ubs. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label Auxo-GTU.
A DNA vaccine plasmid vector that has the plasmid label pCMN160. This plasmid has a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label V1Jns. This plasmid contains the human CMV promoter, enhancer and intron A as well as the polyadenylation sequences of bovine growth hormone.
A DNA vaccine plasmid vector that has the plasmid label pND-14. This plasmid contains a CMV promoter, ampicillin resistance gene, a tissue plasminogen activator leader sequence, a bovine growth hormone terminator, and constitutive transport element from simian retrovirus.
A DNA vaccine plasmid vector that has the plasmid label pSecTag2A. This plasmid is 5159 base pairs in length and contains a CMV promoter and ampicillin reisistance gene.
Invitrogen: http://tools.invitrogen.com/content/sfs/manuals/psectag2_man.pdf; Sequence: http://tools.invitrogen.com/content/sfs/vectors/psectag2a_seq.txt
A DNA vaccine plasmid vector that has the plasmid label pRc/CMV-HBs(S). This plasmid is 5618 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
Bioresearch Online: http://www.bioresearchonline.com/doc/pRcCMV-HBsS-0001
A DNA vaccine plasmid vector that has the plasmid label pcDNA.
A DNA vaccine plasmid vector that has the plasmid label proVAX. This plasmid contains a CMV promoter and a hCG-beta leader sequence.
A DNA vaccine plasmid vector that has the plasmid label p1012.
A DNA vaccine plasmid vector that has the plasmid label pUSE-. This plasmid is a mammalian expression vector derived from pCI-neo.
A DNA vaccine plasmid vector that has the plasmid label APL023.
A DNA vaccine plasmid vector that has the plasmid label pEGFP-N1. This plasmid is 4733 base pairs in length and contains a CMV promoter and kanamycin resistance gene.
Addgene: http://www.addgene.org/vector-database/2491/
A DNA vaccine plasmid vector that has the plasmid label pCDL-SRa296. This plasmid is 3700 base pairs in length and contains a SRalpha promoter.
Addgene: http://www.addgene.org/vector-database/2084/
A DNA vaccine plasmid vector that has the plasmid label pUSK.
A DNA vaccine plasmid vector that has the plasmid label pUBIQ. This plasmid is derived from pGEM3 and contains a CMV promoter and an ampicillin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/Hygro(-). This plasmid is 5596 base pairs in length and contains a CMV promoter and an ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/2105/
Differs from other pcDNA3.1 in drug resistance; +/- refers to orientation of f1 ori
A DNA vaccine plasmid vector that has the plasmid label pCMV3ISS. This plasmid is a eukaryotic expression vector.
A DNA vaccine plasmid vector that has the plasmid label pWRG7079. This plasmid contains a CMV promoter and a kanamycin resistance gene and differs from pWRG7077 by the insertion of a TPA sequence.
A DNA vaccine plasmid vector that has the plasmid label pVR1020. This plasmid contains a CMV promoter and kanamycin resistance gene.
A DNA vaccine plasmid vector that has the plasmid label nkCMVintpolyli. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1/V5-His-TOPO. This plasmid is 5523 base pairs in length and contains a CMV promoter and ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/5587/
pcDNA3.1/V5-His-TOPO DNA vaccine plasmid
A DNA vaccine plasmid vector that has the plasmid label pIRES1neo. This plasmid is 5257 base pairs in length and contains an ampicillin resistance gene.
Metalife: http://www.metalife.com/Genbank/1899169
A DNA vaccine plasmid vector that has the plasmid label pRc/RSV. This plasmid is 5224 base pairs in length and contains a RSV LTR promoter and ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/3908/
A DNA vaccine plasmid vector that has the plasmid label pCI-TPA. This plasmid contains the N-terminal signal sequence of TPA.
A DNA vaccine plasmid vector that has the plasmid label pCSIVgag.
A DNA vaccine plasmid vector that has the plasmid label pVacc4. This plasmid is a derivative of pVacc1 and contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pBC12B1. This plasmid is a eukaryotic expression vector.
A DNA vaccine plasmid vector that has the plasmid label pGFP. This plasmid is 3300 base pairs in length and contains a lac promoter and an ampicillin resistance gene.
Clontech: http://www.clontech.com/xxclt_ibcGetAttachment.jsp?cItemId=17740
A DNA vaccine plasmid vector that has the plasmid label pCMV-beta. This plasmid is 7164 base pairs in length and contains a CMV promoter and ampicllin resistance gene.
Addgene: http://www.addgene.org/vector-database/2245/
A DNA vaccine plasmid vector that has the plasmid label pSW3891. This plasmid contains a CMV promoter.
A DNA vaccine plasmid vector that has the plasmid label pJW4304. This plasmid is 5132 base pairs in length and contains a CMV promoter.
NIH AIDS Reagent Program: https://www.aidsreagent.org/reagentdetail.cfm?t=cloning_vectors&id=76
A DNA vaccine plasmid vector that has the plasmid label pGT146-mIL-12.
A DNA vaccine plasmid vector that has the plasmid label pDNAVACC.
A DNA vaccine plasmid vector that has the plasmid label VR1055. This plasmid is derived from pUC19 and contains a CMV promoter, kanamycin resistance gene, a cloning polylinker, and a transcriptional terminator region derived from the rabbit beta-globin gene.
A DNA vaccine plasmid vector that has the plasmid label pRSC.
A DNA vaccine plasmid vector that has the plasmid label pcDNA3.1(Zeo)+. This plasmid is 5015 base pairs in length and contains a zeocin selectable marker, a CMV promoter, and an ampicillin resistance gene.
Addgene: http://www.addgene.org/vector-database/2110/
A DNA vaccine plasmid vector that has the plasmid label pVF.
A SARS-CoV-2 vaccine consisting of autologous dendritic cells previously loaded ex vivo with spike protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5801
A SARS-CoV-2 vaccine that includes a protein antigen, SARS-CoV-2 Spike RBD, adsorbed to the adjuvant Alhydrogel (Alum), in combination with another approved adjuvant, CpG 1018
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5802
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax)
SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
An authorized SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5803
A SARS-CoV-2 protein subunit vaccine based on recombinant RBD subunits manufactured by the Center for Genetic Engineering and Biotechnology (CIGB).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5804
A SARS-CoV-2 inactivated virus vaccine by Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology Co.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5805
SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
A stabilised pre-fusion SARS-CoV-2 spike protein vaccine produced in a baculovirus expression system and manufactured by Sanofi Pasteur and GlaxoSmithKline
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5833
An influenza virus vector SARS-CoV-2 vaccine administered as an intranasal spray manufactured by University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5806
A SARS-CoV-2 protein subunit vaccine that relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5794
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona)
COVID-19 PS Non-US Vaccine (EpiVacCorona)
A SARS-CoV-2 plasmid DNA vaccine developed by GeneOne Life Science.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5807
A rVSV-SARS-CoV-2-S vaccine developed by the Israel Institute for Biological Research (IIBR).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5799
A SARS-CoV-2 recombinant vector vaccine by Shenzhen Geno-Immune Medical Institute
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5808
A SARS-CoV-2 subunit vaccine with recombinant SARS-CoV-2 spike (S) protein and aluminum phosphate adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5809
A SARS-CoV-2 inactivated vaccine manufactured by the Research Institute for Biological Safety Problems (Republic of Kazakhstan)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5810
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN)
COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
A SARS-CoV-2 virus-like particle vaccine that contains the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike (S) protein and is adjuvanted with aluminum.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5811
A SARS-CoV-2 protein subunit vaccine by West China Hospital
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5812
Recombinant SARS-CoV-2 vaccine (Sf9 cell)
A SARS-CoV-2 recombinant protein vaccine¬¨‚Ä†that uses the Baculovirus expression vector system.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5813
A SARS-CoV-2 subunit vaccine developed by Finlay Vaccine Institute (IFV)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5814
A SARS-CoV-2 vaccine candidate that uses a measles virus vector platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021.
A SARS-CoV-2 inactivated, Vero-cell based vaccine adjuvanted with aluminum and CpG 1018. It uses the manufacturing platform of Valneva's commercial Japanese encephalitis (JE) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5816
SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)
A SARS DNA vaccine that is made from recombinant plasmid containing nucleocapsid protein (N) sequence constructed then expressed and purified from E. coli bacteria.
A SARS DNA combination vaccine that is made from recombinant plasmids' containing membrane protein (M) and nucleocapsid protein (N) sequences constructed then expressed and purified from E. coli bacteria.
A SARS DNA vaccine that is made from recombinant plasmid containing membrane protein (M) sequence constructed then expressed and purified from E. coli bacteria.
A SARS DNA vaccine that is made from oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained CTLA4HingeSARS800 with SARS-CoV S protein.
A SARS DNA vaccine that is made from intraperitoneal recombinant spike polypeptide generated by amplififying gene encoding amino acids residues 14-667 of S protein that was cloned BamHI and KpnI sites of vector pQE-31 that was generated by Escherichia coli
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5734
Recombinant SARS spike polypeptide vaccine
A SARS DNA vaccine that is made from CTLA4HingeSARS800 DNA with SARS-CoV S protein
A SARS DNA vaccine that is made from tpa-optimize800 DNA with SARS-CoV S protein
A SARS DNA vaccine made from CTLA4HingeSARS800 DNA with SARS-CoV S protein
A SARS recombinant vector vaccine that is made from of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5729
A SARS recombinant vector vaccine that is made from recombinant MA15 virulent mouse-adapted SARS-CoV (MA15) background of E-deleted vaccine candidate (rMA15-DeltaE).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5728
A SARS recombinant vector vaccine that is made from a recombinant live-attenuated modified vaccinia virus Ankara (MVA) that had a full-length SARS-CoV envelope Spike (S) glycoprotein gene introduced into the deletion III region of the MVA genome.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5726
A MERS subunit vaccine that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5714
MERS-CoV S vaccine adjuvanted with CpG and Alum
A MERS inactivated whole virus vaccine that has a combined adjuvant that has a combined adjuvant of aluminum hydroxide and CpG oligodeoxynucleotides.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5721
Inactivated whole MERS-CoV (IV) vaccine with CpG and Alum
A SARS recombinant vector vaccine made from a recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5725
A SARS inactivated vaccine made from whole killed (inactivated by beta-propiolactone) SARS-CoV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5730
beta-propiolactone-inactivated SARS-CoV vaccine
A SARS recombinant vector vaccine made of combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein
A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the the S1 extracellular domain of S protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5720
A MERS recombinant vector vaccine made of a recombinant adenoviral vector encoding the full-length MERS-CoV S protein (Ad5.MERS-S)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5719
A MERS DNA vaccine made of plasmid that encoded S1 subunit only
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5716
MERS England1 S1 protein subunit vaccine
A MERS combination vaccine made of made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein and a DNA vaccine that is a plasmid that encoded S1 subunit
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5717
MERS England1 S DNA + England1 S protein subunit vaccine
A MERS DNA vaccine made of the VRC8400 plasmid that encodes the full-length, membrane anchore MERS spike protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5715
A MERS subunit vaccine made of neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the ribosomal binding domain (RBD) of the MERS-CoV S protein that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV.
A MERS DNA vaccine made of plasmid that encodes the first 725 amino acids of S from MERS-CoV
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5718
A MERS recombinant vector virus made from chimeric virus based on the vesicular stomatitis virus (VSV) in which the G gene was replaced by MERS-CoV S gene (VSV≈í√ÆG-MERS).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5722
A MERS subunit vaccine made of a neutralizing monoclonal antibodiesagainst MERS-CoV which bind to the N-terminal domain (NTD) of the MERS-CoV S1 subunit that was expressed by baculovirus-insect cell sf9-derived recombinant MERS-CoV.
A SARS inactivated vaccine made from inactivated whole virus by formalin and Ultraviolet radiation, hence Double Inactivated (DI) Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5742
inactivated whole (formalin and UV radiation) SARS-CoV vaccine
A recombinant SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5743
recombinant SARS DNA spike protein vaccine
A SARS VLP vaccine made from the SARS-CoV spike protein (S) and the Nucleocapsid (N), envelope (E) and membrane (M) proteins from mouse hepatitis coronavirus (MHV)
A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation and a Toll-Like Receptor Agonist Adjuvant is added to prevent eosinophilic immunopathology
UV-Inactivated SARS + TLR agonist vaccine
A SARS inactivated vaccine made from SARS-CoV inactivated by ultraviolet radiation
A MERS recombinant vector made from Venezuelan equine encephalitis replicons bearing epitopes of N protein from MERS. Crosslisted as SARS vaccine (VIOLINID:5754). Efficacy higher intranasally than subcutaneously.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5748
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5754
A SARS recombinant vector vaccine made from Venezuelan equine encephalitis replicons (VRP) encoding a SARS-CoV CD4+ T cell epitope vaccinated intranasally. Crosslisted as MERS vaccine (VIOLINID:5789). Efficacy higher intranasally than subcutaneously.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5749
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5755
A MERS DNA vaccine made of plasmid vaccines that encoded S1 subunit only
A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV spike protein (MERS-S).
A MERS recombinant vector vaccine made of live-attenuated measles virus (MV) vaccine encoding the MERS-CoV nucleocapsid protein (MERS-N).
A MERS recombinant vector made of Chimpanzee adenovirus Oxford 1 vector expressing S protein from MERS-CoV.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5751
A MERS recombinant vector made of Adenovirus type 41 used as vector for MERS-CoV S protein.
A MERS VLP vaccine made from a recombinant baculovirus co-expresssing the spike S, envelope (E), and membrane (M) proteins of MERS.
A SARS DNA vaccine made from encoding calrectulin linked to a SARS-CoV N protein
A SARS recombinant vector vaccine made from a line attenuated and recombinant SARS-CoV lacking the E gene
A MERS recombinant vector made of MVvac2 (measle virus) expressing a soluble, truncated version of spike glycoprotein of MERS-CoV in its full length cloned into the MVvac2 genome and rescued.
A SARS-CoV-2 whole virus vaccine made from a purified inactivated SARS-CoV-2 virus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5761
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)
COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)
A SARS-CoV-2 subunit vaccine composed of the SARS-CoV-2 S protein receptor-binding domain produced in Chinese hamster ovary (CHO) cells and adjuvant aluminum hydroxide.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5764
A SARS-CoV-2 RNA vaccine made of self-coding RNA encoding SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5771
A SARS-CoV-2 vaccine made from a recombinant adinvorius type-5 expressing SARS-CoV-2 S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5768
A MERS DNA Vaccine that is made of the plasmid pGX9109 expressing MERS S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5769
A SARS DNA vaccine made of a single closed plasmid DNA marcromolecule (VRC-8138) that produces a deletion mutant of the SARS Spike glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5770
A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the mesogenic Beaudette C strainexpressing SARS-CoV S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5766
A SARS-CoV recombinant vector vaccine that is made from the Newcastle disease virus from the lentogenic LaSota strain expressing SARS-CoV S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5767
A SARS DNA vaccine made from rDNA-expressed ectodomain of the S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5745
A SARS DNA vaccine made up of arecombinat vector vaccine made from recombinant measles virus expressing S protein and recombinant measles virus expressing N protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5762
A SARS-CoV recombinant vector made from a baculovirus vector expressing SARS-CoV S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5763
A MERS recombinant vector made of recombinant modified vaccinia virus Ankara (rMVA) vaccine vector carrying full MERS-CoV spike glycoprotein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5752
A SARS-CoV-2 single dose intranasal vaccine manufactured by Altimmune in collaboration with the University of Alabama-Birmingham. This vaccine was discontinued after a Phase 1 trial.
A plasmid pCI-N, encoding the full-length N gene of SARS-CoV, was constructed and expressed in Escherichia coli DH5alpha
A SARS-CoV 2 (rSARS-CoV-2) subunit vaccine made of nanoparticles composed of a trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M1 adjuvant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5791
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose
COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL
A SARS-CoV-2 RNA vaccine that has a lipid nanoparticle (LNP) platform and Spike protein antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5842
A SARS-CoV2 RNA vaccine made of lipid nanoparticle with mRNA which encodes the S-2P antigen, made of the SARS-CoV-2 glycoprotein with a transmembrane anchor and intact S1-S2 cleavage site.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5789
A SARS-CoV2 recombinat vector vaccine made of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5774
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL
COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL
A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 vector expressing S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5782
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL
COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL
A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Wuhan Institute of Biological Products.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5775
A SARS-CoV-2 mRNA vaccine made of lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 manufactured by Academy of Military Science (AMS), Walvax Biotechnology, and Suzhou Abogen Biosciences.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5783
A SARS-CoV-2 plasmid DNA vaccine that encodes the envelope protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5778
SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D)
SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)
A SARS-CoV-2 recombinant viral vector vaccine composed of Ad26 and Ad5 vectors expressing S protein that lyophilised.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5777
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V)
COVID-19 VVnr Non-US Vaccine (Sputnik V)
A SARS-CoV-2 investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5781
A SARS-CoV-2 DNA vaccine developed by AnGes, named as AG0301-COVID19.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5780
A SARS-CoV-2 inactivated whole virus vaccine that produced in Vero cells that is developed by the Beijing Institute of Biological Products.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5776
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)
COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)
A SARS-CoV-2 inactivated whole virus vaccine that is developed by the Chinese Academy of Medical Sciences .
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5785
Chinese Academy of Medical Sciences COVID-19 vaccine
A SARS-CoV-2 mRNA vaccine developed by CureVac AG and CEPI.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5786
A SARS-CoV 2 recombinant viral vector using Gorilla Adenovirus that encodes for SARS-CoV-2 Spike protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5787
A SARS-CoV-2 DNA vaccine expressing the SARS-CoV-2 S protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5788
A SARS-CoV-2 subunit vaccine that is made of a protein subunit made of the RBD domain of the S protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5792
A DNA vaccine that expresses S protein from the pGX9501 vector
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5793
A SARS-CoV-2 protein subunit vaccine developed by Adimmune Corporation. AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5873
A SARS-CoV-2 oral DNA vaccine that delivers plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5817
A SARS-CoV-2 mRNA vaccine manufactured by Chulalongkorn University
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5818
A synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine.
an adenovirus vaccine vector that uses a gorilla adenovirus.
A nanoparticle vector composed of lipids.
Vaccine vector that is a tiny particle, typically in the nanometer size range, used to deliver genetic code to specific cells within the body.
A chimpanzee adenovirus vaccine vector that patented by Oxford and derived from ChAd serotype Y25 that exchanges the native E4 orf4, orf6 and orf6/7 genes for those from HAdV-C5
chimpanzee adenovirus Oxford1 vaccine vector
A chimpanzee adenovirus vaccine vector developed by Oxford by deleting E1/E3 from ChAd68 with a modified E4 region.
chimpanzee adenovirus Oxford2 vaccine vector
A SARS-CoV-2 DNA vaccine developed by Providence Health & Services.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5820
A SARS-CoV-2 recombinant vector vaccine employing the lentiviral vector system and developed by Shenzhen Geno-Immune Medical Institute.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5821
A SARS-CoV-2 refrigerator-stable mRNA vaccine by Moderna that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5868
A prophylactic plasmid DNA Vaccine for SARS CoV-2 by Entos Pharmaceuticals
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5823
A SARS-CoV-2 live, attenuated vaccine manufactured by Codagenix, Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5824
SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC)
A SARS-CoV-2 inactivated vaccine developed by Health Institutes of Turkey
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5836
A SARS-CoV-2 human adenovirus serotype 5 (hAd5) vector vaccine with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5825
A SARS-CoV-2 subunit vaccine developed by University Hospital Tuebingen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5826
A SARS-CoV-2 recombinant vector vaccine that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein (S)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5827
A SARS-CoV-2 subunit vaccine that contains the Spike (S) protein with CpG 1018 and aluminum content as adjuvant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5828
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901)
SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)
A SARS-CoV-2 protein subunit vaccine developed by Vaxine Pty Ltd and CinnaGen Co. and adjuvanted with Advax
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5829
A SARS-CoV-2 subunit vaccine with the S1 component of the SARS-CoV-2 spike (S) protein and SWE adjuvant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5830
A SARS-CoV-2 vaccine that uses a recombinant vesicular stomatitis virus (rVSV) platform, and is made by Merck. Development of the vaccine was discontinued on January 25, 2021.
A SARS-CoV-2 adenoviral vector-based oral vaccine by Vaxart expressing a SARS-CoV-2 antigen and dsRNA adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5832
A SARS-CoV-2 protein subunit vaccine manufactured by SK Bioscience Co., Ltd., and equipped with an aluminum hydroxide adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5831
COVID-19 recombinant adenoviral vector vaccine
A saponin vaccine adjuvant comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid.
A carbohydrate vaccine adjuvant derived from delta inulin
Chemical Nature: Carbohydrate Mechanism of Action: Complement, Dendritic cells (unknown receptor), Other, Unknown Immune profile induced: mixed Th1/Th2 By routes: IM, IN, IP, SQ, inhalation, Point of Contact: Nikolai Petrovsky, Vaxine https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889 https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500 https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637 https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620 https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245 https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367 https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758 https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440 https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451 https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269 https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559 https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742 https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913 https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687 https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531 https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701 https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480 https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134 https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724 https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215 https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356 https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015 https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608 https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380 https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494 https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344 https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225 https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225 https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153 https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280 https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280 https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330 https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480 https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000 https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914 https://www.ncbi.nlm.nih.gov/pubmed/?term=12
VAC: https://vac.niaid.nih.gov/view?id=37
A SARS-CoV-2 protein subunit vaccine manufactured by the Razi Vaccine and Serum Research Institute with a Spike protein antigen
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5779
A SARS-CoV-2 recombinant adenoviral vector vaccine that is manufactured by Bharat Biotech International Ltd. and administered intranasally
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5839
A SARS-CoV-2 Chimpanzee Adenovirus serotype 6 vector vaccine manufactured by Gritstone Oncology and the National Institute of Allergy and Infectious Diseases
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5845
A SARS-CoV-2 inactivated vaccine by Shifa Pharmed
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5815
A SARS-CoV-2 plasmid DNA vaccine manufactured by Takis and Rottapharm Biotech
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5838
A SARS-CoV-2 DNA vaccine manufactured by University of Sydney, Bionet Co., and Technovalia
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5837
A SARS-CoV-2 protein subunit vaccine by EuBiologics Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5848
A SARS-CoV-2 lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5846
A SARS-CoV-2 protein subunit vaccine by SK Bioscience
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5844
A SARS-CoV-2 recombinant viral vector vaccine by Mahidol University
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5841
A SARS-CoV-2 mRNA vaccine by Providence Therapeutics
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5840
A SARS-CoV-2 protein subunit vaccine manufactured by Walter Reed Army Institute of Research
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5847
A SARS-CoV-2 virus-like particle vaccine that expresses a modified version of the SARS-CoV-2 spike (S) glycoprotein and is equipped with an aluminum phosphate adjuvant. It is manufactured by VBI Vaccines Inc. and is delivered intramuscularly.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5843
A SARS-CoV-2 inactivated vaccine developed by Organization of Defensive Innovation and Research in Iran
A SARS-CoV-2 live, attenuated vaccine manufactured by Meissa Vaccines, Inc. that expresses the spike (S) protein of SARS-CoV-2.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5851
A SARS-CoV-2 mRNA vaccine that is manufactured by Sanofi Pasteur
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5850
A SARS-CoV-2 inactivated whole virus vaccine developed by the Chumakov Centre at the Russian Academy of Sciences
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5852
A SARS-CoV-2 protein subunit vaccine manufactured by Instituto Finlay de Vacunas. It is used as a booster dose for the Soberana 02 COVID-19 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5853
A SARS-CoV-2 mRNA vaccine manufactured by Daiichi Sankyo Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5854
A SARS-CoV-2 recombinant Newcastle Disease Virus vector vaccine expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5855
A SARS-CoV-2 subunit vaccine developed by Livzon Mabpharm Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5856
A SARS-CoV-2 subunit vaccine developed by the National Vaccine and Serum Institute of China
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5857
COVID-19 subunit vaccine by National Vaccine and Serum Institute of China
A SARS-COV-2 temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5858
A SARS-CoV-2 inactivated vaccine developed by KM Biologics Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5859
A COVID-19 virus-like particle vaccine developed by the Scientific and Technological Research Council of Turkey
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5862
COVID-19 VLP vaccine by the Scientific and Technological Research Council of Turkey
A SARS-CoV-2 subunit vaccine by Jiangsu Rec-Biotechnology Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5863
A SARS-CoV-2 inactivated virus vaccine by Kocak Farma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5860
Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine
A SARS-CoV-2 recombinant adenoviral vector vaccine by Tetherex Pharmaceutical Corporation
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5864
A COVID-19 virus-like particle vaccine developed by Radboud University
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5865
A SARS-CoV-2 Lipid-Inorganic Nanoparticle (LION(TM)) formulated replicating mRNA vaccine that encodes for a full-length spike (S) protein of the SARS-CoV-2 virus
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5866
A SARS-CoV-2 inactivated virus vaccine by the Scientific and Technological Research Council of Turkey adjuvanted by aluminum hydroxide and CpG ODN
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5867
COVID-19 inactivated vaccine by the Scientific and Technological Research Council of Turkey
An MF59-adjuvanted SARS-CoV-2 subunit vaccine based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp (spike glycoprotein-clamp [sclamp])
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5861
MF59-adjuvanted SARS-CoV-2 Sclamp vaccine
A recombinant Newcastle Disease Virus vectored vaccine for SARS-CoV-2 by Laboratorio Avi-Mex
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5822
COVID-19 rNDV vector vaccine by Laboratorio Avi-Mex
A SARS-CoV-2 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5869
COVID-19 mRNA vaccine by Shanghai East Hospital and Stemirna Therapeutics
A SARS-CoV-2 subunit vaccine by OSE Immunotherapeutics
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5870
A SARS-CoV-2 recombinant viral vector vaccine by the German Center for Infection Research
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5924
A SARS-CoV-2 subunit vaccine that is orally administered and manufactured by Syneos Health
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5872
A COVID-19 vaccine that is authorized for emergent use, which is typically authorized based on an Emergency Use Authorization (EUA).
authorized COVID-19 recombinant vector vaccine
authorized COVID-19 recombinant adenoviral vector vaccine
A vaccine adjuvant that includes IV270, which is a low-molecular weight TLR7 agonist conjugated to a phospholipid and is a highly potent and stable immune activator.
Chemical Nature: Small molecule Receptor: TLR7 Mechanism of Action: Activation of innate immune pathways Immune profile induced: Th1-biased Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody affinity maturation, (6) Promotes antibody epitope spreading By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=6
Chemical Nature: Small molecule Receptor: TLR4 Mechanism of Action: Innate immune activation Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Anti-inflammatory, (3) Promotes antibody epitope spreading. By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=7
A role of a material entity that binds to TLR7 and activates the receptor for pathogen recognition and activation of innate immunity.
A SARS-CoV-2 protein subunit vaccine manufactured by the Research Institute for Biological Safety Problems in Kazakhstan
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5874
A SARS-CoV-2 self-amplifying RNA vaccine sponsored by MRC/UVRI and LSHTM Uganda Research Unit
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5875
A multivalent SARS-CoV-2 mRNA booster vaccine which combines mRNA-1273, Moderna's authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at the 50 ug dose level and lower.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5876
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. In (H115D)VHL35 peptide, histidine is substituted for an aspartic acid in position 115. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5304
Chemical Nature: Small molecule Receptor: Dendritic cells (unknown receptor) Mechanism of Action: Innate immune activation Immune profile induced: Th1-biased Other Features/Characteristics: Other. Specify: Co-adjuvant for TLR4 ligands Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=9
Chemical Nature: Small molecule Receptor: CLR (Dectin, Mincle) Mechanism of Action: None/Unknown Immune profile induced: Th17-component Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune
VAC: https://vac.niaid.nih.gov/view?id=27
Chemical Nature: Small molecule and Synthetic derivative of natural compound Receptor: Unknown and NLRP3 Mechanism of Action: Presumably the same as QS-21 in the absence of dose-limiting toxicity Immune profile induced: Th1-biased Other Features/Characteristics: None Point of Contact: Melissa Malhame, Adjuvance Technologies
VAC: https://vac.niaid.nih.gov/view?id=36
Chemical Nature: Emulsion Receptor: TLR2 and TLR4 Mechanism of Action: Activation of mucosal and systemic immunity Immune profile induced: Th1/Th17 Other Features/Characteristics: Promotes antibody affinity maturation Point of Contact: Ali Fattom, BlueWillow Biologics
VAC: https://vac.niaid.nih.gov/view?id=22
Chemical Nature: Other Receptor: TLR4 Mechanism of Action: TLR4 agonist Immune profile induced: Th1-biased Other Features/Characteristics: None/Unknown Point of Contact: Darrick Carter, PAI Life Sciences
VAC: https://vac.niaid.nih.gov/view?id=16
Chemical Nature: (1) Natural compound, (2) Carbohydrate, (3) Combination adjuvant Receptor: CLR (Dectin, Mincle) and NAIP Mechanism of Action: Activation of Dectin-2-expressing innate immune cells; dual targeting of injection site and draining lymph node. Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: Promotes antibody epitope spreading Point of Contact: Ivan Zanoni, Boston Children's Hospital
VAC: https://vac.niaid.nih.gov/view?id=14
Chemical Nature: Combination Adjuvant Receptor: TLR4 Mechanism of Action: TLR4 agonist plus potential inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None/Unknown Point of Contact: Darrick Carter, PAI Life Sciences
VAC: https://vac.niaid.nih.gov/view?id=20
Chemical Nature: Small molecule Receptor: TLR7 and TLR8 Mechanism of Action: None/Unknown Immune profile induced: Th1-biased Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune
VAC: https://vac.niaid.nih.gov/view?id=28
Chemical Nature: Small molecule Receptor: TLR4 Mechanism of Action: None/Unknown Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Kendal Ryter, U. Montana & Inimmune
VAC: https://vac.niaid.nih.gov/view?id=26
VAC: https://vac.niaid.nih.gov/view?id=29
Chemical Nature: Small molecule and Combination adjuvant Receptor: TLR4 and TLR7 Mechanism of Action: Activation of antigen presenting cells and stimulating B cell proliferation Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody epitope spreading. By routes: intramuscular and intranasal. Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=5
Chemical Nature: Emulsion Receptor: TLR4 Mechanism of Action: Squalene emulsion plus TLR4 Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Sciences
VAC: https://vac.niaid.nih.gov/view?id=17
Chemical Nature: Emulsion Receptor: Unknown Mechanism of Action: Squalene emulsion possibly triggering inflammasome or through extracellular ATP Immune profile induced: None Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Sciences
VAC: https://vac.niaid.nih.gov/view?id=18
Chemical Nature: (1) Synthetic derivative of natural compound, (2) Nucleic acid Receptor: TLR3 Mechanism of Action: TLR3, possibly RIG-I - agonist Immune profile induced: Th1-biased Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection. By routes: SQ, IM. Point of Contact: Carolina Lopez, University of Washington at St Louis
DDO (Defective viral genome-Derived Oligonucleotide)
Defective viral genome-Derived Oligonucleotide
VAC: https://vac.niaid.nih.gov/view?id=30
defective viral genome-derived oligonucleotide vaccine adjuvant
Chemical Nature: Synthetic derivative of natural compound Receptor: Unknown Mechanism of Action: (1) Antigen carrier, (2) Innate immune enhancer/activator Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection, (4) Other, (5) Promotes antibody affinity maturation, (6) High stability. By routes: IM, IN, IP, IN, ID, IVag. Specify: Safe for systemic or mucosal administration Point of Contact: Tulin Morcol, Captivate Pharma
VAC: https://vac.niaid.nih.gov/view?id=11
Chemical Nature: Small molecule, other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: Other Point of Contact: Robert Ernst, University of Maryland - Baltimore
VAC: https://vac.niaid.nih.gov/view?id=32
Chemical Nature: (1) Synthetic derivative of natural compound, (2) other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Robert Ernst, University of Maryland-Baltimore
VAC: https://vac.niaid.nih.gov/view?id=33
Chemical Nature: Small molecule, other Receptor: TLR4 Mechanism of Action: None Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Robert Ernst, University of Maryland Baltimore
VAC: https://vac.niaid.nih.gov/view?id=31
Chemical Nature: Combination adjuvant Receptor: TLR4 Mechanism of Action: TLR4 and potentially inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Services
VAC: https://vac.niaid.nih.gov/view?id=19
Chemical Nature: Combination adjuvant Receptor: TLR3 Mechanism of Action: TLR3 agonist plus potential inflammasome Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Darrick Carter, PAI Life Services
VAC: https://vac.niaid.nih.gov/view?id=21
Chemical Nature: Small molecule Receptor: (1) TLR7, (2) TLR8 Mechanism of Action: TLR7/8 dual agonist - lymph node delivery Immune profile induced: Th1-biased Other Features/Characteristics: Promotes antibody affinity maturation Point of Contact: Sunil David, Virovax
VAC: https://vac.niaid.nih.gov/view?id=12
Chemical Nature: (1) Synthetic derivative of natural compound, (2) Emulsion, (3) Combination adjuvant, (4) Other Receptor: TLR4 Mechanism of Action: Adjuplex enhances cross presentation to CD8 T cells and GLA stimulates TLR4 signaling Immune profile induced: Mixed Th1/Th17 Other Features/Characteristics: None Point of Contact: Marulasiddappa Suresh, UW Madison
VAC: https://vac.niaid.nih.gov/view?id=15
Chemical Nature: Small molecule Receptor: Dendritic cells (unknown receptor) Mechanism of Action: Innate immune activation/enhancer Immune profile induced: Mixed Th1/Th2 Other Features/Characteristics: None Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=8
A role of a material entity that binds to TLR4 and activates the receptor for pathogen recognition and activation of innate immunity.
A role of a material entity that binds to TLR3 and activates the receptor for pathogen recognition and activation of innate immunity.
A role of a material entity that binds to TLR8 and activates the receptor for pathogen recognition and activation of innate immunity.
A role of a material entity that binds to TLR2 and activates the receptor for pathogen recognition and activation of innate immunity.
Process profile that reflects a pattern of a specific immune response.
An immune profile that is characterized by mainly presence of Type 1 T helper (Th1) cells that produce interferon-gamma, interleukin (IL)-2, and tumor necrosis factor (TNF)-beta, which activate macrophages and are responsible for cell-mediated immunity and phagocyte-dependent protective responses.
An immune profile that is characterized by mainly presence of T type 2 Th (Th2) cells that produce IL-4, IL-5, IL-10, and IL-13, which are responsible for strong antibody production, eosinophil activation, and inhibition of several macrophage functions, thus providing phagocyte-independent protective responses.
An immune profile that is characterized by the presense of both Type 1 and Type 2 T helper (Th1 and Th2) cells.
An immune profile that is characterized by the presence of T helper 17 cells (Th17), a subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17). They are related to T regulatory cells and the signals that cause Th17 to differentiate and inhibit Treg differentiation.
An immune profile that is characterized by the presense of both Type 1 and Type 17 T helper (Th1 and Th17) cells.
A SARS-CoV-2 subunit vaccine by Clover Biopharmaceuticals AUS Pty Ltd that contains the S protein from the B.1.351 variant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5879
A SARS-CoV-2 subunit vaccine by Bagheiat-allah University of Medical Sciences
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5877
A SARS-CoV-2 subunit vaccine by Baiya Phytopharm Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5878
A SARS-CoV-2 recombinant vector vaccine manufactured by CyanVac LLC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5880
A SARS-CoV-2 recombinant vector vaccine by AstraZeneca and Oxford University against variant strain B.1.351
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5881
A SARS-CoV-2 subunit vaccine manufactured by Shanghai Zerun Biotechnology, Walvax Biotechnology, and CEPI
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5835
A SARS-CoV-2 protein subunit vaccine by Laboratorios HIPRA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5883
A SARS-CoV-2 DNA vaccine developed by AnGes, named as AG0302-COVID19.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5882
An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2.
Pubmed References:Chemical Nature: (1) combination adjuvant Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1 Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability By routes: SQ, IM Point of Contact: Nikolai Petrovsky, Vaxine LTD
VAC: https://vac.niaid.nih.gov/view?id=38
A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step. VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21. VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable sources.
Pubmed References: Chemical Nature: (1) Synthetic derivative of natural compound Mechanism of Action: unknown Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21 By routes: SQ Point of Contact: Pengfei Wang, University of Alabama https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001
VAC: https://vac.niaid.nih.gov/view?id=42
A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available.
Pubmed References: Chemical Nature: (1) Synthetic derivative of natural compound Mechanism of Action: unknown Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21 By routes: SQ Point of Contact: Pengfei Wang, University of Alabama https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920
VAC: https://vac.niaid.nih.gov/view?id=41
A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1.
Pubmed References: Chemical Nature: (1) Protein Mechanism of Action: unknown Immune profile induced: Th1 Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation. By routes: IM Point of Contact: Sara Lustigman, New York Blood Center
Recombinant O. volvulus activation-associated secreted protein-1
VAC: https://vac.niaid.nih.gov/view?id=43
A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A)
Chemical Nature: protein Mechanism of Action: CGM1 ganglioside, cAMP, inflammasome Immune profile induced: mixed Th1/Th17 Other Features/Characteristics: Induces mucosal immunity (IM, ID, SQ, SL, oral, , transcutaneous), Induces epitope spreading, Promotes antibody affinity maturation, Effective in newborns, promotes antibody epitope spreading By routes: IM, ID, SL, oral, SQ, IN, IP, intragastric, transcutaneous, transdermal, buccal, intrarectal Point of Contact: Elizabeth Norton, Tulane University https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994 https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349 https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197 https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082 https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793 https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827 https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241 https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122 https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825 https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621 https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536 https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379 https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125 https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441 https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067 https://www.ncbi.nlm.nih.gov/pubmed/?term=25944298 https://www.ncbi.nlm.nih.gov/pubmed/?term=6424635 https://www.ncbi.nlm.nih.gov/pubmed/?term=3916310 https://www.ncbi.nlm.nih.gov/pubmed/?term=4826740 https://www.ncbi.nlm.nih.gov/pubmed/?term=2884428 https://www.ncbi.nlm.nih.gov/pubmed/?term=30778066 https://www.ncbi.nlm.nih.gov/pubmed/?term=4893257 https://www.ncbi.nlm.nih.gov/pubmed/?term=28063704 https://www.ncbi.nlm.nih.gov/pubmed/?term=4375349 https://www.ncbi.nlm.nih.gov/pubmed/?term=28792004 https://www.ncbi.nlm.nih.gov/pubmed/?term=25765967 https://www.ncbi.nlm.nih.gov/pubmed/?term=25483682 https://www.ncbi.nlm.nih.gov/pubmed/?term=30638799 https://www.ncbi.nlm.nih.gov/pubmed/?term=21326197 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=31427449 https://www.ncbi.nlm.nih.gov/pubmed/?term=6957164 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933 https://www.ncbi.nlm.nih.gov/pubmed/?term=31641151 https://www.ncbi.nlm.nih.gov/pubmed/?term=27133878 https://www.ncbi.nlm.nih.gov/pubmed/?term=27676456 https://www.ncbi.nlm.nih.gov/pubmed/?term=27226279 https://www.ncbi.nlm.nih.gov/pubmed/?term=22406456 https://www.ncbi.nlm.nih.gov/pubmed/?term=30787109 https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527 https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527 https://www.ncbi.nlm.nih.gov/pubmed/?term=30563789 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=30473185 https://www.ncbi.nlm.nih.gov/pubmed/?term=30248001 https://www.ncbi.nlm.nih.gov/pubmed/?term=24049109 https://www.ncbi.nlm.nih.gov/pubmed/?term=30797634 https://www.ncbi.nlm.nih.gov/pubmed/?term=31482013 https://www.ncbi.nlm.nih.gov/pubmed/?term=29771685 https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774 https://www.ncbi.nlm.nih.gov/pubmed/?term=25444830 Clinical trials: https://clinicaltrials.gov/ct2/show/NCT03922061 https://clinicaltrials.gov/ct2/show/NCT04232943 https://clinicaltrials.gov/ct2/show/NCT02531685 https://clinicaltrials.gov/ct2/show/NCT02052934 https://clinicaltrials.gov/ct2/show/NCT02531802 https://clinicaltrials.gov/ct2/show/NCT01147445 https://clinicaltrials.gov/ct2/show/NCT03548064 https://clinicaltrials.gov/ct2/show/ NCT01739231 https://clinicaltrials.gov/ct2/show/NCT03404674 https://clinicaltrials.gov/ct2/show/NCT03729219 https://clinicaltrials.gov/ct2/show/NCT04826094
dmLT (double mutant of heat-labile E.coli)
VAC: https://vac.niaid.nih.gov/view?id=13
Chemical Nature: (1) other (Peptide) Mechanism of Action: C5aR1 on mononuclear phagocytes Immune profile induced: mixed Th1/Th2 Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation. By routes: SQ, IP, IV. Point of Contact: Joseph Vetro, University of Nebraska Medical Center https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/10516626/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/12538044/, https://pubmed.ncbi.nlm.nih.gov/19428909/, https://pubmed.ncbi.nlm.nih.gov/21723901/
VAC: https://vac.niaid.nih.gov/view?id=39
A recombiant vector vaccine that is has a viral vector.
A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc., named as ARCT-165.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5888
A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.351 (Beta) variant and containing the Matrix-M1 adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5885
A SARS-CoV-2 bivalent protein subunit vaccine by Novavax containing antigen for both the ancestral strain and B.1.351 (Beta) variant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5887
A SARS-CoV-2 monovalent protein subunit vaccine by Novavax immunizing against the B.1.617.2 (Delta) variant and containing the Matrix-M1 adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5886
A SARS-CoV-2 recombinant viral vector vaccine by Biocad
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5889
A vaccine adjuvant that includes UM-3005, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
Chemical Nature: (1) small molecule Mechanism of Action: TLR7/8 agonist Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, InImmune
VAC: https://vac.niaid.nih.gov/view?id=47
A SARS-CoV-2 subunit vaccine by Sinocelltech Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5890
A SARS-CoV-2 replication deficient human adenovirus vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5899
A SARS-CoV-2 DNA vaccine developed by Vaccibody AS encoding the receptor-binding domain
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5893
A SARS-CoV-2 T-Cell-based DNA vaccine developed by Vaccibody AS
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5894
A SARS-CoV-2 replication deficient chimpanzee adenovirus 68 vector vaccine expressing the spike, nucleocapsid and RNA polymerase proteins.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5900
A SARS-CoV-2 subunit vaccine by PT Bio Farma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5895
COVID-19 subunit vaccine by PT Bio Farma
A SARS-CoV-2 DNA vaccine developed by Scancell Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5891
A SARS-CoV-2 subunit vaccine by Yisheng Biopharma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5892
A SARS-CoV-2 DNA vaccine developed by University of Hong Kong and Immuno Cure 3 Limited
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5896
COVID-19 DNA vaccine by the University of Hong Kong and Immuno Cure 3 Limited
A SARS-CoV-2 RNA vaccine by Arcturus Therapeutics, Inc., named as ARCT-154.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5884
A COVID-19 virus-like particle vaccine developed by Yantai Patronus Biotech Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5901
A SARS-CoV-2 inactivated vaccine developed by the National Research Centre of Egypt
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5902
A SARS-CoV-2 subunit vaccine containing a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5898
A SARS-CoV-2 subunit vaccine by HK inno.N Corporation
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5897
A SARS-CoV-2 RNA vaccine manufactured by VLP Therapeutics Japan, LLC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5903
A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
Chemical Nature: (1) small molecule Mechanism of Action: TLR7/8 agonist Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, University of Montana
VAC: https://vac.niaid.nih.gov/view?id=46
A vaccine adjuvant that includes UM-3003, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.
VAC: https://vac.niaid.nih.gov/view?id=45
A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC). This LTA1 adjuvant is able to induce Th1, Th2, and Th17 immune responses.
Chemical Nature: (1) Protein Mechanism of Action: cAMP, inflammasome induction Immune profile induced: mixed Th1/Th2/Th17 Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces epitope spreading, (3) Promotes antibody affinity maturation, (4) Promotes antibody epitope spreading, (5) High stability Route of immunization: IM, IN, SL, ID, IP Point of Contact: Elizabeth Norton, Tulane University
VAC: https://vac.niaid.nih.gov/view?id=44
A carbohydrate vaccine adjuvant that is a glucan carbohydrate microcapsules with a beta(1-3)/beta(1-6) - linked glucan structure to allow targeting of antigens to macrophages or neutrophils through interactions with the beta-glucan receptor found uniquely on the surface of these cell types. Adjuvax- ligand complexes are formed by physically entrapping or crosslinking the ligand within the beta-glucan.
A vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide (ODN).
A combination vaccine adjuvant includes 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution.
An AS02 vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL.
A carbohydrate vaccine adjuvant that is aminoglycan consisting of beta-(1->4)-linked D-glucosamine residues and induces Th1/Th17 mixed immune profile.
A Montanide vaccine adjuvant that is a water-dispersed liquid IMS 1313 nanoparticle combined with an immuno-stimulating compound.
A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound.
A Montanide vaccine adjuvant that Mannide oleate derivative in a mineral oil solution ( Seppic SA, France).
A carbohydrate vaccine adjuvant that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose.
A carbohydrate vaccine adjuvant that polysaccharide prepared from the cell wall of Saccaromyces cerevisiae (bakers' yeast).
An emulsion vaccine adjuvant that is oil-based adjuvant (Adjuvant XtendIII®; Grand Laboratories, Larchwood, IA).
A microbial derivative vaccine adjuvant that is monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) in 2% oil (squalene)-Tween 80-water.
Monophosphoryl-lipid A + Trehalose dicorynomycolate
A muramyl dipeptide vaccine adjuvant that muramyl dipeptide derivative (threonyl-MDP) in an oil-in-water (o/w) emulsion vehicle.
A vaccine adjuvant that diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol.
A vaccine adjuvant that includes naturally occurring trivalent alcohol.
A vaccine adjuvant includes three palmitic acid groups that are bound in an ester and amide linkage to a cysteine residue.
A vaccine adjuvant that is equimolar mixture of the cationic lipid GAP-DMORIE [(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide)] and a neutral colipid DPyPE (1,2-diphytanoyl-sn-glydero-3-phosphoethanolamine).
A vaccination process that involves adding a vaccine into a host prior to disease.
A vaccination process that involves adding a vaccine into a host after a disease has occurred.
A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation.
Chemical Nature: other Mechanism of Action: TLR4; inflammasome; DC activation Immune profile induced: Th1/Th2/Th17 Receptor: TLR4, NLRP3 Storage information: -20 or -80C Point of Contact: Lisa Morici, Tulane University
VAC: https://vac.niaid.nih.gov/view?id=61
An immune profile that is characterized by the presense of Type 1, Type 2, and Th17 T helper cells.
A role of a material entity that binds to NLRP3.
Chemical Nature: Nucleic Acid Mechanism of Action: TLR/RLR-agonist Immune profile induced: Th1/Th2 Route of immunization: IM and IN Point of Contact: Xiaoliang Ren, Yisheng Bio Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02657161 https://clinicaltrials.gov/ct2/show/NCT02956421
VAC: https://vac.niaid.nih.gov/view?id=55
Chemical Nature: peptide Mechanism of Action: activation of mast cells, epithelial cells, macrophages and dendritic cells Immune profile induced: Th2-biased Route of immunization: IM and IN Point of Contact: Herman Staats, Duke University
VAC: https://vac.niaid.nih.gov/view?id=53
Chemical Nature: small molecule Mechanism of Action: mast cell activation Immune profile induced: Th2-biased Route of immunization: IN Point of Contact: Herman Staats, Duke University
VAC: https://vac.niaid.nih.gov/view?id=54
Mast cell activator small molecules vaccine adjuvant
Chemical Nature: small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital
VAC: https://vac.niaid.nih.gov/view?id=56
Precision Vaccines Program (PVP)-037 vaccine adjuvant
Chemical Nature: small molecule Mechanism of Action: TLR4 agonist Immune profile induced: Th1/Th2 Route of immunization: IM and IN Point of Contact: Robert Ernst, University of Maryland - Baltimore
VAC: https://vac.niaid.nih.gov/view?id=60
Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Helene Bazin-Lee, University of Montana
VAC: https://vac.niaid.nih.gov/view?id=48
Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1/Th17 Route of immunization: IM and IN Point of Contact: Christopher Fox, AAHI
VAC: https://vac.niaid.nih.gov/view?id=58
Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI
VAC: https://vac.niaid.nih.gov/view?id=57
Chemical Nature: small molecule Mechanism of Action: innate immune activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Clinical trials: https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT04915768 https://clinicaltrials.gov/ct2/show/NCT05197712
VAC: https://vac.niaid.nih.gov/view?id=59
Chemical Nature: (1) emulsion Mechanism of Action: unknown Immune profile induced: Th1/Th17 Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute Clinical trial: https://clinicaltrials.gov/ct2/show/NCT04702178
VAC: https://vac.niaid.nih.gov/view?id=50
Chemical Nature: (1) Emulsion (with Saponin) Mechanism of Action: unknown Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute
VAC: https://vac.niaid.nih.gov/view?id=52
Chemical Nature: (1) other (liposome with Saponin) Mechanism of Action: unknown Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Patrice Dubois, Vaccine Formulation Institute
VAC: https://vac.niaid.nih.gov/view?id=51
A SARS-CoV-2 RNA vaccine by Suzhou Abogen Biosciences Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5943
A SARS-CoV-2 protein subunit vaccine manufactured by ACM Biolabs.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5938
A SARS-CoV-2 DNA vaccine developed by Imam Abdulrahman Bin Faisal University.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5920
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5819
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
A SARS-CoV-2 protein subunit vaccine manufactured by the University of Melbourne.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5871
A SARS-CoV-2 inactivated vaccine developed by Eva Pharma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5921
A SARS-CoV-2 RNA vaccine by Gritstone Bio, Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5944
A SARS-CoV-2 RNA vaccine by the University of Melbourne.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5927
A SARS-CoV-2 inactivated vaccine developed by Osve Pharmaceutical Company.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5919
A SARS-CoV-2 protein subunit vaccine manufactured by Speransa Therapeutics.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5936
A SARS-CoV-2 RNA vaccine by Wuhan Recogen Biotechnology Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5930
A SARS-CoV-2 RNA vaccine by Walvax Biotechnology and Shanghai RNACure Biopharma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5937
A SARS-CoV-2 RNA vaccine by RVAC Medicines
A SARS-CoV-2 protein subunit vaccine manufactured by Vaxxas Pty Ltd
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5932
A SARS-CoV-2 RNA vaccine by ImmunityBio, Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5935
A SARS-CoV-2 protein subunit vaccine manufactured by Human Stem Cell Institute
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5929
A SARS-CoV-2 RNA vaccine by CanSino Biologics Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5934
COVID-19 mRNA vaccine by CanSino Biologics
A SARS-CoV-2 RNA vaccine by EyeGene Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5923
A SARS-CoV-2 mRNA vaccine by Moderna that combines the mRNA-1273 COVID-19 vaccine and the mRNA-1010 influenza vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5941
A SARS-CoV-2 mRNA vaccine by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5931
A SARS-CoV-2 inactivated vaccine developed by Airlangga University
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5922
A SARS-CoV-2 protein subunit vaccine manufactured by Livzon Pharmaceutical Group Inc.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5928
A SARS-CoV-2 mRNA vaccine by Gennova Biopharmaceuticals Limited
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5933
A SARS-CoV-2 mRNA vaccine by AIM Vaccine Co., Ltd.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5925
A SARS-CoV-2 bivalent mRNA vaccine by Moderna that contains the mRNA-1273 COVID-19 vaccine and the mRNA-1273.214 Omicron booster
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5939
A SARS-CoV-2 mRNA booster vaccine by Moderna that targets the Omicron variant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5926
A SARS-CoV-2 inactivated vaccine developed by China National Biotec Group Company Limited
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5940
Omicron COVID-19 inactivated vaccine by China National Biotec Group Company Limited
authorized COVID-19 virus-like particle vaccine
Chemical Nature: other Mechanism of Action: Activation of APCs, activation of T cells and stimulating B cell proliferation (IgG) Immune profile induced: Th1-biased Route of immunization: IM and SQ Point of Contact: Matthew Heath, Allergy Therapeutics (UK) Ltd
VAC: https://vac.niaid.nih.gov/view?id=25
MicroCrystalline Tyrosine vaccine adjuvant
Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329 https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089 https://www.ncbi.nlm.nih.gov/pubmed/?term=21816196 https://www.ncbi.nlm.nih.gov/pubmed/?term=21690242 https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869 https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184 https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184 https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649 https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649 https://www.ncbi.nlm.nih.gov/pubmed/?term=22509423 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=23904160 https://www.ncbi.nlm.nih.gov/pubmed/?term=23954378 https://www.ncbi.nlm.nih.gov/pubmed/?term=22425788 https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286 https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286 https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057 https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057 https://www.ncbi.nlm.nih.gov/pubmed/?term=23228811 https://www.ncbi.nlm.nih.gov/pubmed/?term=25024362 https://www.ncbi.nlm.nih.gov/pubmed/?term=25030053 https://www.ncbi.nlm.nih.gov/pubmed/?term=24404140 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898 https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898 https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521 https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521 https://www.ncbi.nlm.nih.gov/pubmed/?term=25367751 https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135 https://www.ncbi.nlm.nih.gov/pubmed/?term=25637347 https://www.ncbi.nlm.nih.gov/pubmed/?term=27005808 https://www.ncbi.nlm.nih.gov/pubmed/?term=26656121 https://www.ncbi.nlm.nih.gov/pubmed/?term=26874325 https://www.ncbi.nlm.nih.gov/pubmed/?term=26791076 https://www.ncbi.nlm.nih.gov/pubmed/?term=27466350 https://www.ncbi.nlm.nih.gov/pubmed/?term=27699241 https://www.ncbi.nlm.nih.gov/pubmed/?term=29176865 https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370 https://www.ncbi.nlm.nih.gov/pubmed/?term=29263879 https://www.ncbi.nlm.nih.gov/pubmed/?term=29795025 https://www.ncbi.nlm.nih.gov/pubmed/?term=29983563 https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252 https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252 https://www.ncbi.nlm.nih.gov/pubmed/?term=27895131 https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844 https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075 https://www.ncbi.nlm.nih.gov/pubmed/?term=33705411 https://www.ncbi.nlm.nih.gov/pubmed/?term=35126135 https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214 https://www.ncbi.nlm.nih.gov/pubmed/?term=26731269 https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448 https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448 https://www.ncbi.nlm.nih.gov/pubmed/?term=27456709 https://www.ncbi.nlm.nih.gov/pubmed/?term=32023469 https://www.ncbi.nlm.nih.gov/pubmed/?term=32402293 https://www.ncbi.nlm.nih.gov/pubmed/?term=32348377 https://www.ncbi.nlm.nih.gov/pubmed/?term=32697993 https://www.ncbi.nlm.nih.gov/pubmed/?term=29515589 https://www.ncbi.nlm.nih.gov/pubmed/?term=33046728 https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678 https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937 https://www.ncbi.nlm.nih.gov/pubmed/?term=30567978 https://www.ncbi.nlm.nih.gov/pubmed/?term=31362695 https://www.ncbi.nlm.nih.gov/pubmed/?term=29769270 https://www.ncbi.nlm.nih.gov/pubmed/?term=31521953 https://www.ncbi.nlm.nih.gov/pubmed/?term=28298421 Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT01484548 https://clinicaltrials.gov/ct2/show/NCT01751048 https://clinicaltrials.gov/ct2/show/NCT02071758 https://clinicaltrials.gov/ct2/show/NCT02465216 https://clinicaltrials.gov/ct2/show/NCT01927159 https://clinicaltrials.gov/ct2/show/NCT01599897 https://clinicaltrials.gov/ct2/show/NCT01154049 https://clinicaltrials.gov/ct2/show/NCT03302897 https://clinicaltrials.gov/ct2/show/NCT02465216 https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT03806686 https://clinicaltrials.gov/ct2/show/NCT01949909 https://clinicaltrials.gov/ct2/show/NCT01540474 https://clinicaltrials.gov/ct2/show/NCT02014727 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT02658253 https://clinicaltrials.gov/ct2/show/NCT01991561 https://clinicaltrials.gov/ct2/show/NCT01596725 https://clinicaltrials.gov/ct2/show/NCT01147068 https://clinicaltrials.gov/ct2/show/NCT03820414 https://clinicaltrials.gov/ct2/show/NCT03220724 https://clinicaltrials.gov/ct2/show/NCT03409276 https://clinicaltrials.gov/ct2/show/NCT01864876 https://clinicaltrials.gov/ct2/show/NCT02115815 https://clinicaltrials.gov/ct2/show/NCT01397604
VAC: https://vac.niaid.nih.gov/view?id=62
Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT03589794
VAC: https://vac.niaid.nih.gov/view?id=63
Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI
VAC: https://vac.niaid.nih.gov/view?id=64
Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: n/a Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT03820414 https://clinicaltrials.gov/ct2/show/NCT02071758
VAC: https://vac.niaid.nih.gov/view?id=65
Chemical Nature: other Mechanism of Action: TLR4; Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Christopher Fox, AAHI Ongoing clinical trial: https://clinicaltrials.gov/ct2/show/NCT02508376 https://clinicaltrials.gov/ct2/show/NCT02647489 https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT03589794
VAC: https://vac.niaid.nih.gov/view?id=66
A cancer vaccine that is used against prostate cancer.
A cancer vaccine that is used against colorectal cancer
A cancer vaccine that is used against lymphoma.
A cancer vaccine that is used against brain canceer.
A cancer vaccine that is used against liver canceer.
A cancer vaccine that is used against pancreatic canceer.
A recombinant viral vaccine vector that uses PVSRIPO, a recombinant nonpathogenic polio-rhinovirus chimera. PVSRIPO is an engineerable oncolytic virus whereas its internal ribosomal entry site element can be substituted to demolish its cytopathogenic effect. PVSRIPO has a natural inherent tropism for antigen-presenting cells (including dendritic cells and macrophages) due to the presence of the CD-155 receptor on their cellular surfaces. This enables it of inducing CD8+ T-cell mediate immune responses.
A Comirnaty COVID-19 mRNA vaccine produced by Pfizer-BioNTech,which is a bivalent vaccine that is effective against the original strain of COVID-19 as well as the Omicron BA.1 variant.A non-US vaccine product.
Authorized by WHO 10/19/2022 - Counted toward immunity in US.Ref:https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech
A Comirnaty COVID-19 mRNA vaccine utilizes Lipid Nanoparticle-Self-amplifying RNA technology, available as a bivalent boosters against the original strain of COVID-19 as well as the Omicron BA.1 variant produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL to provide enhanced protection.
EUA authorized Pfizer adult bivalent booster ages 12+ yrs, original strain + omicron BA.4/BA.5. Not Authorized by WHO. Non-US Tradename for same formulation (Comirnaty Bivalent) counted toward immunity in US. Ref:https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation
A Comirnaty COVID-19 mRNA vaccine utilizing Lipid Nanoparticle-Self-amplifying RNA technology against the original strain of COVID-19 without preservative ,which is produced by Pfizer (PF) with a dose of 30 mcg/0.3 mL.
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose
A vaccine that is made of immune globulin and used to immunize an individual against some disease(s).
licensed human anthrax immune globulin passive vaccine
cytomegalovirus immune globulin, intravenous
licensed human cytomegalovirus immune globulin passive vaccine, intravenous
Hepatitis A Immune Globulin passive vaccine is a passive vaccine that provides protection against hepatitis A through the passive transfer of an antibody. Hep A, IG provides temporary immunity to the virus for two to three months, if administered prior to exposure or within two weeks after exposure.
Stapleton, Jack T. "Passive immunization against hepatitis A." Vaccine 10 (1992): S45-S47.
licensed human hepatitis A immune globulin passive vaccine
licensed human hepatitis B immune globulin passive vaccine
licensed human immune globulin passive vaccine, intramuscular
licensed human immune globulin passive vaccine, intravenous
immune globulin, unspecified formulation
licensed human immune globulin passive vaccine
licensed human rabies immune globulin passive vaccine
respiratory syncytial virus immune globulin, intravenous
licensed human respiratory syncytial virus immune globulin passive vaccine, intravenous
licensed human Rho(D) immune globulin - IM passive vaccine
licensed human Rho(D) immune globulin- IV or IM passive vaccine
licensed human Rho(D) immune globulin passive vaccine
licensed human tetanus immune globulin passive vaccine
licensed human vaccinia immune globulin passive vaccine
licensed human varicella zoster immune globulin passive vaccine
varicella zoster immune globulin (Investigational New Drug)
licensed human varicella zoster immune globulin passive vaccine (Investigational New Drug)
Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent)
Diphtheria-Pertussis-Tetanus-Haemophilus B-Hepatitis B vaccine,(Pentavalent)
DTP-Haemophilus influenzae type b conjugate and hepatitis B vaccine
Influenza, injectable, MDCK, quadrivalent, preservative
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservative
Influenza, MDCK, quadrivalent, preservative
influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative
diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation
DTP-Haemophilus influenzae type b conjugate vaccine
A viral vaccine that protects against infection with influenza virus and with high-dose seasonal,quadrivalent,0.7ml dose,preservative free.
influenza, high-dose seasonal, quadrivalent, 0.7ml dose, preservative free
Influenza, injectable,quadrivalent, preservative free, pediatric
influenza, injectable, quadrivalent, preservative free, pediatric
influenza, intradermal, quadrivalent, preservative free
influenza, intradermal, quadrivalent, preservative free, injectable
A poliovirus vaccine that contains two types of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
Non-US bivalent oral polio vaccine (types 1 and 3)
A poliovirus vaccine that contains one type of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
Non-US monovalent oral polio vaccine, unspecified formulation
Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)
Td, adsorbed, preservative free, adult use, Lf unspecified
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified
tetanus and diphtheria toxoids, not adsorbed, for adult use
A poliovirus vaccine that contains three types of poliovirus and uses poliovirus particles that have been grown under controlled conditions and then killed to prevent disease caused from the vaccine.
trivalent poliovirus vaccine, live, oral
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine.
A vaccine adjuvant 30:70 (w/w) Water-in-Oil (W/O) emulsion that stimulates a mixed Th1/Th2 response.
Chemical Nature: emulsion Mechanism of Action: adjuvanted antigen depot at injection site Immune profile induced: Mixed Th1/Th2 Route of immunization: IM and SQ Point of Contact: Peter Blackburn, MerciaPharma Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760 https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964 https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319 https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT02500680 https://clinicaltrials.gov/ct2/show/NCT02500680 https://clinicaltrials.gov/ct2/show/NCT03624062 https://clinicaltrials.gov/ct2/show/NCT02118077
VAC: https://vac.niaid.nih.gov/view?id=68
A vaccine adjuvant that induces CD8 T cells and provides innate protection.
Chemical Nature: small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: SQ Point of Contact: Taegyan Kang, Progeneer Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335 Ongoing clinical trials: n/a
VAC: https://vac.niaid.nih.gov/view?id=34
A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response.
Chemical Nature: Liposome Mechanism of Action: n/a Immune profile induced: n/a Route of immunization: IN, IP, IM, Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772 https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684 https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03715985
VAC: https://vac.niaid.nih.gov/view?id=76
A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed.
Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326 https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT05781542 https://clinicaltrials.gov/ct2/show/NCT05471076 https://clinicaltrials.gov/ct2/show/NCT04915768 https://clinicaltrials.gov/ct2/show/NCT05781542
VAC: https://vac.niaid.nih.gov/view?id=69
A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response.
Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742 https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264
VAC: https://vac.niaid.nih.gov/view?id=71
A vaccine adjuvant is a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens.
Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728 https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202 https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388 https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783 https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712 https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT05370040
VAC: https://vac.niaid.nih.gov/view?id=70
Nanostructured Lipid Carrier (NLC) vaccine adjuvant
a malaria vaccine that protects against malaria caused by Plasmodium knowlesi.
a malaria vaccine that protects against malaria caused by Plasmodium chabaudi.
A vaccine adjuvant is an oil-in-water emulsion that induces Th1-based immune response.
Chemical Nature: Small molecule Mechanism of Action: Innate Immune Activation Immune profile induced: n/a Route of immunization: IM Point of Contact: Valerie Soza, AAHI Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577 https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225
VAC: https://vac.niaid.nih.gov/view?id=72
A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response.
Chemical Nature: Liposome system Mechanism of Action: n/a Immune profile induced: Th1/Th17 Route of immunization: IP, IM, IN, SQ, ID, SC, SL, intratracheal, endotracheal, Fish vaccination Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263 https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488 https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790 https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110 https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776 https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936 https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987 https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731 https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939 https://www.ncbi.nlm.nih.gov/pubmed/?term=33072125 https://www.ncbi.nlm.nih.gov/pubmed/?term=35585969 https://www.ncbi.nlm.nih.gov/pubmed/?term=26494626 https://www.ncbi.nlm.nih.gov/pubmed/?term=26379666 https://www.ncbi.nlm.nih.gov/pubmed/?term=35124896 https://www.ncbi.nlm.nih.gov/pubmed/?term=34358167 https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075 https://www.ncbi.nlm.nih.gov/pubmed/?term=31130946 https://www.ncbi.nlm.nih.gov/pubmed/?term=31906072 https://www.ncbi.nlm.nih.gov/pubmed/?term=32106599 https://www.ncbi.nlm.nih.gov/pubmed/?term=19492047 https://www.ncbi.nlm.nih.gov/pubmed/?term=33422991 https://www.ncbi.nlm.nih.gov/pubmed/?term=28414746 https://www.ncbi.nlm.nih.gov/pubmed/?term=33066267 https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370 https://www.ncbi.nlm.nih.gov/pubmed/?term=23308247 https://www.ncbi.nlm.nih.gov/pubmed/?term=30984200 https://www.ncbi.nlm.nih.gov/pubmed/?term=20505822 https://www.ncbi.nlm.nih.gov/pubmed/?term=27525651 https://www.ncbi.nlm.nih.gov/pubmed/?term=23873630 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT00922363 https://clinicaltrials.gov/ct2/show/NCT01009762 https://clinicaltrials.gov/ct2/show/NCT02787109 https://clinicaltrials.gov/ct2/show/NCT01141205 https://clinicaltrials.gov/ct2/show/NCT03926728
VAC: https://vac.niaid.nih.gov/view?id=75
A cancer vaccine that is developed against breast cancer.
A cancer vaccine that is developed against bladder cancer.
A cancer vaccine that is developed against lung cancer.
A cancer vaccine that is developed against leukemia.
A cancer vaccine that is developed against cervical cancer.
A cancer vaccine that is developed against colon cancer.
A cancer vaccine that is developed against gastric cancer
A cancer vaccine that is developed against mesothelioma cancer.
A cancer vaccine that is developed against myeloma cancer.
A cancer vaccine that is developed against ovarian cancer.
A cancer vaccine that is developed against renal cancer.
A cancer vaccine that is developed against sarcoma cancer.
A cancer vaccine that is developed against esophageal cancer.
A cancer vaccine that is developed against head and neck cancer.
A cancer vaccine that is developed against nasopharyngeal cancer.
A cancer vaccine that is developed against hepatocellular carcinoma.
A vaccine that prevents or reduce the transmission of a disorder within a target host or among a population by inducing or modifying specific adaptive immune responses against the antigens present in the vaccine.
Vaccine that prevents or treats specific disease.
Vaccine against an infectious disease caused by specific pathogen(s).
Note that all infectious diseases are caused by some pathogens, so 'infectious disease vaccine' and 'vaccine against pathogen infection' are basically synonyms.
Vaccine that is developed and produced by specific technology or method.
Gene expressing a protein which serves, either in whole or in part, as an antigen within a cancer vaccine.
Vaccine adjuvant that is primarily composed of protein and actives innate immune pathways to induce a mixed Th1/Th2 response.
Chemical Nature: protein Mechanism of Action: Activation of innate immune pathways Immune profile induced: Th1/Th2 Route of immunization: SC, IN, SQ Point of Contact: Marcel Wuethrich, University of Wisconsin Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=28793349 https://www.ncbi.nlm.nih.gov/pubmed/?term=31900406 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=97
Combination vaccine adjuvant contains both Bl-Eng2 and adjuplex vaccine adjuvants and is able to induce a mixed Th1/Th2 response.
Chemical Nature: Protein, Combination adjuvant Mechanism of Action: Activation of innate immune pathways Immune profile induced: Th1/Th2 Route of immunization: IN Point of Contact: Marcel Wuethrich, University of Wisconsin Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=33735218 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=98
Nucleic acid vaccine adjuvant that targets on cytokine receptor to induce a Th1-based response.
Chemical Nature: nucleic acid Mechanism of Action: Cytokine Receptor Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Romain Micol, Combined Therapeutics Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=39047117 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=100
Botryococcene oil-in-water emulsion vaccine adjuvant made by EVAX Inc., which targets to induce a mixed Th1/Th2 response.
Chemical Nature: Emulsion Mechanism of Action: Botryococcene oil-in-water emulsion Immune profile induced: Mixed Th1/Th2 Route of immunization: SQ Point of Contact: Chase Kempinski , EVAX Inc. Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=33051497 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=101
Squalene oil-in-water emulsion vaccine adjuvant made by EVAX Inc., which targets to induce a mixed Th1/Th2 response.
Chemical Nature: Emulsion Mechanism of Action: Squalene oil-in-water emulsion Immune profile induced: Mixed Th1/Th2 Route of immunization: SQ Point of Contact: Chase Kempinski , EVAX Inc. Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=33051497 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=102
Vaccine adjuvant based on VesiVax® liposome.
Chemical Nature: VesiVax® liposome Mechanism of Action: none Immune profile induced: none Route of immunization: SQ prime and IN boost, SQ, Combination sub-cheek, IN and ID, IN prime and sub-cheek boosts Point of Contact: Gary Fujii, Molecular Express Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037 https://www.ncbi.nlm.nih.gov/pubmed/?term=17981684 https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825 https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821 https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243 https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747 https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339 https://www.ncbi.nlm.nih.gov/pubmed/?term=28922045 https://www.ncbi.nlm.nih.gov/pubmed/?term=29420901 https://www.ncbi.nlm.nih.gov/pubmed/?term=3568049 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=104
ME-F-1122 is a Liposome-based vaccine adjuvant with TLR4 agonist to induce a mixed Th1/Th2 response..
Chemical Nature: Natural compound - Liposome formulation with TLR4 agonist Mechanism of Action: none Immune profile induced: Mixed Th1/Th2 Route of immunization: SQ, Combination of sub-cheek, IN and ID, IN prime with sub-cheek boosts, Point of Contact: Gary Fujii, Molecular Express Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=23313243 https://www.ncbi.nlm.nih.gov/pubmed/?term=26312747 https://www.ncbi.nlm.nih.gov/pubmed/?term=27997339 https://www.ncbi.nlm.nih.gov/pubmed/?term=35680499 https://www.ncbi.nlm.nih.gov/pubmed/?term=19835825 https://www.ncbi.nlm.nih.gov/pubmed/?term=21545821 https://www.ncbi.nlm.nih.gov/pubmed/?term=16713037 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=103
Short class B CpG-containing sequence with phosphorothioate-linked nucleotides that is able to induce a Th1-biased response.
Chemical Nature: Nucleic acid Mechanism of Action: CpG 1018 is a short class B CpG-containing sequence with phosphorothioate-linked nucleotides Immune profile induced: Th1-biased Route of immunization: IN, IM Point of Contact: Ben Wizel, Dynavax Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=24464743 https://www.ncbi.nlm.nih.gov/pubmed/?term=33649322 https://www.ncbi.nlm.nih.gov/pubmed/?term=33873199 https://www.ncbi.nlm.nih.gov/pubmed/?term=33888840 https://www.ncbi.nlm.nih.gov/pubmed/?term=38570604 https://www.ncbi.nlm.nih.gov/pubmed/?term=35927132 https://www.ncbi.nlm.nih.gov/pubmed/?term=35869085 https://www.ncbi.nlm.nih.gov/pubmed/?term=37703367 https://www.ncbi.nlm.nih.gov/pubmed/?term=39231203 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/ACTRN12624000064505 https://clinicaltrials.gov/ct2/show/NCT06334393 https://clinicaltrials.gov/ct2/show/NCT04177355 https://clinicaltrials.gov/ct2/show/NCT04672395 https://clinicaltrials.gov/ct2/show/NCT05188677 https://clinicaltrials.gov/ct2/show/NCT05011526 https://clinicaltrials.gov/ct2/show/NCT05364242 https://clinicaltrials.gov/ct2/show/NCT04956224 https://clinicaltrials.gov/ct2/show/NCT0486456 https://clinicaltrials.gov/ct2/show/ACTRN12620001177943 https://clinicaltrials.gov/ct2/show/NCT00251394 https://clinicaltrials.gov/ct2/show/NCT01282762 https://clinicaltrials.gov/ct2/show/NCT00346086 https://clinicaltrials.gov/ct2/show/NCT06569823 https://clinicaltrials.gov/ct2/show/NCT05245838 https://clinicaltrials.gov/ct2/show/NCT05506969
VAC: https://vac.niaid.nih.gov/view?id=105
Small molecule, synthetic derivative of natural compound (galactosylceramide) that induces Th1/Th2/Th17 response.
VAC: https://vac.niaid.nih.gov/view?id=67
3DSNA is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
Triphosphate RNA (3pRNA) is a RIG-I Ligand.
Vaccine adjuvant that stimulates TLR1 to enhance the immune response to vaccination.
ADP-ribosylating adjuvant is a microbial derivative vaccine adjuvant that induces Th1/Th17 mixed immune profile.
AH:CpG is a combination vaccine adjuvant that induces Th1-biased immune profile.
Aikejia is a microbial derivative vaccine adjuvant Th1-biased immune profile.
Al-BSA-Ce6 NPs is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
A substance that signals tissue and cell damage. In this context, it refers to Interleukin-33 (IL-33).
A family of anionic liposome-based adjuvants containing synthetic phospholipids, cholesterol, and monophosphoryl lipid A (MPLA).
Algel-IMDQ is a combination vaccine adjuvant that induces Th1-biased immune profile.
AlO(OH)-polymer nanoparticles is a Nano-sized vaccine carriers derived from aluminum hydroxide gel..
AlO(OH)-polymer nanoparticle vaccine adjuvant
Alum refers to Aluminium adjuvant or Alum Compounds, which are Adjuvants, Immunologic used in vaccines to enhance the immune response. IL-10 is a key cytokine that limits excessive immune responses.
A combination of aluminum-containing adjuvants (Alum) with oligodeoxynucleotides containing CpG motifs (a TLR9 agonist) adsorbed to Alum.
Alum/CpG-based formulation vaccine adjuvant
AmpB is a microbial derivative vaccine adjuvant Th1-biased immune profile.
Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein found intracellularly, membrane-bound, or secreted, existing as a monomer or heterotetramer. Monomeric ANXA2 (ANXA2m), particularly when overexpressed in low-oxygen conditions, acts as an adjuvant by inducing dendritic cell maturation through TLR2.
AP adjuvant is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
Ccarbohydrate vaccine adjuvant that induces a mixed Th1/Th2 response
An Adjuvant System consisting of a TLR4 ligand, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and a saponin, QS-21.
Carbohydrate vaccine adjuvant that induces a Th1 response
Babassu aqueous extract vaccine adjuvant
BVP22 is a fusion protein adjuvant that induces TH1 reponse.
C3 adjuvant is a molecular adjuvant that induces Th2 response.
C60(OH)22 is a synthetic vaccine adjuvant Th1-biased immune profile.
Carbonate apatite (CA) nanoparticles containing CpG oligodeoxynucleotides (ODNs).
Combination vaccine adjuvant contains CAF04 Th1-biased immune profile.
CAF05 is a combination vaccine adjuvant that induces a mixed Th1/Th17 response.
CAF06 is a synthetic vaccine adjuvant that induces mixed Th1/Th17 response.
A nanoemulsion-based adjuvant containing a synthetic CMI-inducing mycobacterial monomycoloyl glycerol (MMG) analogue.
Combination vaccine adjuvant contains CAF23 Th1-biased immune profile.
A nanoemulsion engineered from the active components of CAF09 (dimethyldioctadecylammonium bromide, a synthetic monomycoloyl glycerol analog, and polyinosinic:polycytidylic acid), with a biodegradable squalane oil phase and varied surface charge by replacing DDA with zwitterionic distearoylphosphoethanolamine.
microbial derivative vaccine adjuvant from C. albicans that induces a mixed Th1/Th17 response
Candida skin test reagent vaccine adjuvant
carbon-silica nanocomposite is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
carbon-silica nanocomposite vaccine adjuvant
caspase-1 is a cytokine vaccine adjuvant that induces Th1/Th17 mixed immune profile.
CBP-12 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
CCL19 is a cytokine vaccine adjuvant that prodices a mixed Th1/Th2 response.
CCL21 and IL1β is a combination vaccine adjuvant that induces Th1/Th17 mixed immune profile.
A Chemokine, CC and Ccl28 protein, mouse, functioning as a mucosal adjuvant when GPI-anchored.
CCL3 adjuvant is a cytokine vaccine adjuvant that induces Th1 response.
CCL34 is a cytokine vaccine adjuvant Th1-biased immune profile.
CCL5 adjuvant is a cytokine vaccine adjuvant that induces Th1 response.
A co-stimulatory molecule belonging to the immunoglobulin superfamily, which is expressed on most NK cells, T cells, monocytes, and platelets, contributing to both innate and adaptive immune responses.
A vaccine adjuvant that is the bacterial second messenger (3'-5')-cyclic-di-guanosine-monophosphate (c-di-GMP).
CGAMP is a nucleic acid vaccine adjuvant that produces a mixed Th1/Th2 response.
Carbohydrate vaccine adjuvant that induces bisaed Th2 response, but also smaller Th1/Th17 responses
CITCO is a cytokine vaccine adjuvant that induces Th1-biased immune profile.
A vaccine that targets against a microbial eukaryote caused disease.
CL429 is a synthetic vaccine adjuvant Th1-biased immune profile and stimulate TLR2 and NOD2 to enhance immune responses when used in vaccines.
CnB is a synthetic vaccine adjuvant that induces Th1 response.
CoVaccine HT™ is a emulsion vaccine adjuvant that induces Th1-biased immune profile.
CPG 7909 is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.
CpG refers to CpG-oligodeoxynucleotide (CpG-ODN), which functions as an immune adjuvant. DcMNPs are PAMAM dendrimer-coated magnetic nanoparticles.
CpG M362 is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.
CpG oligodeoxynucleotide 1826 (CAF10) vaccine adjuvant
CpG-MUC1-hydrogel is a combination vaccine adjuvant Th1-biased immune profile.
CpG-ODN and Coa-ASC16 is a combination vaccine adjuvant Th1-biased immune profile.
Insecticidal crystal proteins from Bacillus thuringiensis (Bt) bacteria, primarily used in GM crops for insect resistance.
Carbohydrate vaccine adjuvant that induces a mixed Th1/Th17 response
Cholera Toxin A (CTA) is a protein that can be used as a genetic adjuvant for DNA vaccines. It enhances the immune response by its ADP-ribosyltransferase activity.
Cholera toxin derived vaccine adjuvant that induces a Th17 response
Cholera toxin derived vaccine adjuvant that induces Th1 response
Cholera toxin subunit B (CTB) is a protein that can be used as a genetic adjuvant to enhance immune responses.
curcumin is a plant-derived vaccine adjuvant that induces Th1-biased immune profile.
CVC1302 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
cytokine vaccine adjuvant derived from CXCL10 chemokine head
CXCL11 is a cytokine vaccine adjuvant that induces a Th1 response.
CXCL11-Fc is a cytokine vaccine adjuvant.
CXCL9 is a cytokine vaccine adjuvant that induces a Th1 response.
Cyclophilin A (CyPA) is a host protein that can serve as a genetic adjuvant to enhance the immunogenicity of DNA vaccines.
A hexose sugar that can be used to improve non-viral gene therapy.
DAI is a synthetic vaccine adjuvant that induces a Th1 response.
DLinDMA is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
DOTAP and DP7-C liposomes is a liposome-based vaccine adjuvant that induces Th1-biased immune profile.
DOTAP and DP7-C liposomes vaccine adjuvant
epigallocatechin-3-gallate is a plant-derived vaccine adjuvant from catechins from green tea that induces mixed Th1/Th2 response.
epigallocatechin-3-gallate vaccine adjuvant
FimH is a microbial derivative vaccine adjuvant Th1/Th17 mixed immune profile.
A fusion protein combining flagellin (FlaB) with pneumococcal surface protein A (PspA).
Major structural protein of flagellin in salmonella that induces mixed Th1/Th2 response
Flt-3 ligand is a cytokine vaccine adjuvant that induces a Th1 response.
Fuc-Sc is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
A G2 adjuvant that upregulates gene expression and increases the surface expression of the NKG2D receptor on NK cells.
G3 is a synthetic vaccine adjuvant Th1-biased immune profile.
GC@ICG nanoparticle is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.
Gel-gffy is a particulate antigen delivery system vaccine adjuvant that induces Th1/Th2 mixed immune profile.
Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand (GITRL) is involved in modulating both innate and adaptive immune responses.
A novel, non-toxic immunoadjuvant, which is a derivative of chitosan.
GM3 is a carbohydrate vaccine adjuvant that induces Th1/Th2 mixed immune profile.
gp63 is a liposome-based vaccine adjuvant that induces a Th1 response .
particulate antigen delivery system vaccine adjuvant from mast cell that induces a mixed Th1/Th2 response
Granulysin is a microbial derivative vaccine adjuvant that induces Th1 response.
Graphene oxide is a synthetic vaccine adjuvant that induces a Th1 response.
HAV-aCNP is a synthetic vaccine adjuvant Th1-biased immune profile.
The core antigen of the Hepatitis B virus.
HBHA is a microbial derivative vaccine adjuvant that induces Th1 response.
hexosomes is a emulsion vaccine adjuvant Th1/Th2 mixed immune profile.
HIV-1 protease is a microbial derivative vaccine adjuvant that induces Th1 response.
Hexamethylene bisacetamide (HMBA), a hybrid bipolar compound developed over 30 years ago for its ability to induce terminal differentiation of transformed cells.
HMGB1 is a microbial derivative vaccine adjuvant that induces Th1 repsonse.
An immunobiotic Lactobacillus rhamnosus strain and an immunomodulatory strain Lactobacillus rhamnosus strain IBL027.
IFN-α is a cytokine vaccine adjuvant that induces Th1 repsonse.
IFNβ is a cytokine vaccine adjuvant that induces Th1-biased immune profile.
Vaccine adjuvant that stimulates TLR2 to enhance the immune response to vaccination.
IL-18 is a cytokine vaccine adjuvant that produces Th1 response.
IL-1R1 is a cytokine vaccine adjuvant that induces Th17-biased immune profile.
IL-21 is a cytokine vaccine adjuvant that induces Tfh/Th17 mixed immune profile.
IL-27 is a cytokine vaccine adjuvant that induces Treg-biased immune profile.
IL33 is a cytokine vaccine adjuvant Th2-biased immune profile.
IL-36 is a cytokine vaccine adjuvant that induces a Th1 response.
Water soluble cytokine vaccine adjuvant that induces a Th2 response.
IL-7-Fc is a cytokine vaccine adjuvant that induces Th1 response.
A LAG-3Ig fusion protein that acts as an adjuvant to induce a more robust and durable cellular antitumor immune response.
Immunopotentiator from Pantoea agglomerans 1, identified as Pantoea agglomerans LPS.
Imiquimod (TLR-7 ligand)-loaded PLGA microparticles.
iron oxide nanoparticle vaccine adjuvant
IRX-2 is a multiple cytokine vaccine adjuvant that induces Th1 response.
ISG15 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.
A second-generation TLR9 agonist, specifically a humanized CpG DNA (K3) complexed with schizophyllan (SPG), and functions as a nonagonistic Dectin-1 ligand.
The B-chain of the Korean mistletoe lectin (KML).
Kynurenine is a synthetic vaccine adjuvant that induces Treg-biased immune profile.
L-NAME is a synthetic vaccine adjuvant that induces Th1 response.
L-siRNA is a nucleic acid vaccine adjuvant Th1-biased immune profile.
A member of the TNF superfamily that acts as a costimulatory molecule, promoting the proliferation of human naïve T cells.
Listeriolysin O is a microbial derivative vaccine adjuvant Th1-biased immune profile.
LP-GMP is a synthetic vaccine adjuvant Th1-biased immune profile.
LT-IIb is a E. coli LT toxin derived vaccine adjuvant that induces mixed Th1/Th2 response.
Man-TLR7 is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
MCP-3 is a cytokine vaccine adjuvant that induces Th1 response.
MDA5 is a synthetic vaccine adjuvant that induces a Th1 response.
MDP-1 is a muramyl dipeptide vaccine adjuvant that induces Th1 response.
A plain mesoporous silica (MS) nanoparticle.
mesoporous silica nanoparticle vaccine adjuvant
MIP-2 is a cytokine vaccine adjuvant that induces a Th1 response.
MMG-1 is a microbial derivative vaccine adjuvant Th1-biased immune profile.
MSP-102, an engineered FLAGELLIN variant, demonstrated enhanced immunostimulatory effects as an adjuvant. Its efficacy was verified through co-administration with the RBD protein of the COVID-19 virus and the HA protein of the influenza virus, confirming its potential in vaccine formulations. It is a microbial derivative vaccine adjuvant that induces mixed Th1/Th2 response.
Chemical Nature: Protein Mechanism of Action: Innate Immune Activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IN Point of Contact: Kyung A Cho, Medispan, Inc. Ongoing clinical trials: none
MUC1 based adjuvant-protein-antigen is a particulate antigen delivery system vaccine adjuvant Th1/Th2 mixed immune profile.
MUC1 based adjuvant-protein-antigen vaccine adjuvant
A chimeric adjuvant that combines innate and adaptive immune signaling.
A widespread Toll-like receptor adaptor molecule that is significant in B cell responses to both infections and vaccinations.
An emerging and effective adjuvant that induces protective cellular and Th1 immune responses against Fasciola hepatica infection.
NP DNA adjuvant is a nucleic acid vaccine adjuvant that induces Th1 response.
NP-3pRNA-CpG is a combination vaccine adjuvant Th1-biased immune profile.
NP-R@M-M is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
OK-432 is a microbial derivative vaccine adjuvant Th1-biased immune profile.
OMPC – TLR2 is a combination vaccine adjuvant Th1-biased immune profile.
Ophiopogonin D is a plant-derived vaccine adjuvant Th1-biased immune profile.
OVA-csNLCs is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.
OVA-LNPs is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
A gallotannin-rich fraction from Caesalpinia spinosa.
PAA:nanoalum is a combination vaccine adjuvant Th1/Th2 mixed immune profile.
PAMK is a synthetic vaccine adjuvant Th1-biased immune profile.
PAPE is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
PEI-PPAS is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
PET Lipid A is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.
PhotothermalPhage is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.
microbial derivative vaccine adjuvant that induces Th1 response
PI-sRI is a synthetic vaccine adjuvant that induces Th1 response.
Pinaceae-derived nanoemulsions is a emulsion vaccine adjuvant Th1/Th2 mixed immune profile.
Pinaceae-derived nanoemulsions vaccine adjuvant
PLA-b-P(NAS-co-NVP is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
Vaccine adjuvant derived from plant that is added to a vaccine formulation to enhance or modulate the body’s immune response to the vaccine antigen.
Platycodin D is a plant-derived vaccine adjuvant that induces Th1/Th17 mixed immune profile.
PLGA is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
Biodegradable poly(DL-lactic-co-glycolic acid).
PNPS-0.3 is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
Poly-ϵ-caprolactone/chitosan nanoparticles (NPs) are vaccine adjuvants that enhance the immune response to hepatitis B surface antigen (HBsAg).
Poly-ϵ-caprolactone and chitosan nanoparticle
Poly-ϵ-caprolactone and chitosan nanoparticle vaccine adjuvant
Polyethyleneimine is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
PolyIC:LC is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
polysorbitol-co-PEI polymer is a synthetic vaccine adjuvant that induces Th1-biased immune profile.
A micro- and nanometer-sized particle used as a candidate for cancer vaccine adjuvants.
porous silicon microparticle vaccine adjuvant
A bacterium known for its adjuvant effects in experimental and clinical settings.
Propionibacterium acnes vaccine adjuvant
pSPreS2 is a microbial derivative vaccine adjuvant that induces Th1 resopnse.
QS-17 and18 is a saponin vaccine adjuvant Th1/Th2 mixed immune profile.
The rate-limiting enzyme in retinoic acid (RA) biosynthesis.
retinoic acid and IL-15 is a combination vaccine adjuvant that induces mixed Th1/Th17 response.
retinoic acid and IL-15 vaccine adjuvant
rHP-NAP is a microbial derivative vaccine adjuvant Th1-biased immune profile.
A 547-nt uncapped noncoding ssRNA containing polyU repeats, stabilized by a cationic carrier peptide.
rNDV-mOX40L is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.
Rotavirus VP6 is a microbial derivative vaccine adjuvant Th1-biased immune profile.
Rv3628 is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.
SAG1 and TLR-5 ligand is a combination vaccine adjuvant Th1-biased immune profile.
An antimicrobial peptide known for its anticancer properties, including tumor progression suppression.
Shrimp anti-lipopolysaccharide factor vaccine adjuvant
An anhydrous, highly dispersed vehicle containing active pharmaceutical ingredients like imiquimod in a submicron particle size distribution, carried in a suspended state.
solid-in-oil-in-water emulsion is a emulsion vaccine adjuvant that induces Th1-biased immune profile.
solid-in-oil-in-water emulsion vaccine adjuvant
sPD-1 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.
sPLA2 is a cytokine vaccine adjuvant Th2-biased immune profile.
spontaneous nanoliposome antigen particleization is a particulate antigen delivery system vaccine adjuvant Th1-biased immune profile.
spontaneous nanoliposome antigen particleization
spontaneous nanoliposome antigen particleization vaccine adjuvant
A pore-forming protein from the Caribbean Sea anemone Stichodactyla helianthus.
synthetic melanin is a synthetic vaccine adjuvant Th1-biased immune profile.
t-NanoCpG is a CpG DNA vaccine adjuvant that induces Th1-biased immune profile.
Vaccine adjuvant composed of a TLR7 agonist adsorbed to alum.
Taishan Robinia Pseudoacacia polysaccharide is a polysaccharides derived from the Robinia pseudoacacia flower.
Taishan Robinia Pseudoacacia polysaccharides
Taishan Robinia Pseudoacacia polysaccharide vaccine adjuvant
TDM is a microbial derivative vaccine adjuvant adjuvant that induces Th1 response.
Aluminum vaccine adjuvant that induces Th1/Th2 mixed immune profile.
thymosin alpha-1 is a cytokine vaccine adjuvant Th1-biased immune profile.
Vaccine adjuvant that stimulates Toll-like receptors (TLRs) to enhance the immune response to vaccination.
TLR7 agonist and NOD2 agonist is a combination vaccine adjuvant Th1-biased immune profile.
TLR7 agonist and NOD2 agonist vaccine adjuvant
oligonucleotide vaccine adjuvant that induces Th1-biased immune profile
trichosanthin is a microbial derivative vaccine adjuvant that induces Th1-biased immune profile.
TRIF is a microbial derivative vaccine adjuvant that induces Th1 response.
Tumour-derived exosome is an exosomes released by tumour cells, with potential use in cancer vaccines.
U-Omp19 and alum is a combination vaccine adjuvant that induces Th1-biased immune profile.
VISA is a synthetic vaccine adjuvant that induces Th1 response.
α-galactosylceramide is a microbial derivative vaccine adjuvant that induces Th1/Th2 mixed immune profile.
α-Galactosylceramide (α-GalCer) is a Natural Killer T Cell Ligand, and Monophosphoryl lipid A (MPL) is a TLR4 ligand.
LAB EPS is a microbial derivative vaccine adjuvant Th1-biased immune profile.
IFN-gamma vaccine adjuvant that induces Th1 response
rcIL-15 is a cytokine vaccine adjuvant that induces Th1-biased immune profile.
AAV-IL-27 is a cytokine vaccine adjuvant that induces Treg-biased immune profile.
rhIL-7 adjuvant is a cytokine vaccine adjuvant.
c-di-AMP is a nucleic acid vaccine adjuvant Th1/Th2 mixed immune profile.
VLP@Silica is a particulate antigen delivery system vaccine adjuvant that induces Th1/Th2 mixed immune profile.
DP-D is a synthetic vaccine adjuvant Th1-biased immune profile.
T7-EA is a synthetic vaccine adjuvant Th1-biased immune profile.
STING V155M is a synthetic vaccine adjuvant that induces Th1/Th2/Th17 mixed immune profile.
LCP is a particulate antigen delivery system vaccine adjuvant that induces Th1-biased immune profile.
Vaccine adjuvant that stimulates TLR3 to enhance the immune response to vaccination.
Ad-SLC is a cytokine vaccine adjuvant that induces a Th1 response.
Vaccine adjuvant that stimulates TLR4 to enhance the immune response to vaccination.
Combination vaccine adjuvant contains QS21, MPLA, and CPG7909 that induces Th1/Th2 mixed response.
AS1517499 is a synthetic vaccine adjuvant Th2-biased immune profile.
Vaccine adjuvant that stimulates TLR5 to enhance the immune response to vaccination.
Vaccine adjuvant that stimulates TLR6 to enhance the immune response to vaccination.
Vaccine adjuvant that stimulates TLR7 to enhance the immune response to vaccination.
L. polysaccharide is a carbohydrate vaccine adjuvant that induces Th1/Th2 mixed immune profile.
Vaccine adjuvant that stimulates TLR8 to enhance the immune response to vaccination.
Vaccine adjuvant that stimulates TLR9 to enhance the immune response to vaccination.
NS-TLR is a synthetic vaccine adjuvant Th1-biased immune profile.
AS02 vaccine adjuvant that induces Th1 response
Vaccine adjuvant derived from snake venom that activates the innate immune response by binding and engaging Toll-like receptor 2 (TLR2) on immune cells, which leads to the activation of dendritic cells and enhances antigen presentation.
Murabutide induces an additive effect on immunogenicity when formulated together with Advax, initiating a sequence of events starting with the recognition of murabutide by pattern recognition receptors (PRRs) like TLRs.
The Ace-DEX adjuvant triggers an immune response by sensing its presence through pattern recognition receptors (PRRs), such as TLRs.
GDQ triggers a strong immune response by initially sensing pathogens through pattern recognition receptors (PRRs), such as TLRs, which leads to the activation of innate immune cells like dendritic cells.
The slow-release synthetic oligodeoxynucleotide (ODN) adjuvant triggers an immune response by initially sensing through pattern recognition receptors (PRRs), such as TLRs, which leads to the activation of innate immune cells like dendritic cells.
The SMQ adjuvant triggers an immune response by activating the NLRP3 inflammasome, a multiprotein complex that senses cellular stress and triggers the production of pro-inflammatory cytokines, such as IL-1β.
PHAD triggers an innate immune response, activating dendritic cells through a TLR4-mediated signaling cascade.
Vaccine adjuvant activates pattern recognition receptors (PRRs) such as TLRs trigger an innate immune response and leads to the activation of dendritic cells.
MIP-1alpha acts as an adjuvant by upregulating the function of antigen-presenting cells (APCs), enhancing their ability to process and present antigens.
Levamisole initiates an immune response by stimulating strong Th1 cell activity, which is characterized by the activation of T helper 1 cells.
Microbial derivative vaccine adjuvant recognizes TLR4, and senses Hsp65, leading to the activation of innate immune cells like dendritic cells.
Particulate antigen delivery system vaccine adjuvant initiates an immune response by being sensed by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), leading to the activation of innate immune cells, including dendritic cells, which then present antigens to T cells, inducing a Th1 response and the production of interferon-gamma (IFN-γ).
Upon recognition by pattern recognition receptors (PRRs) such as TLRs, GPI-0100 initiates an immune response by activating innate immune cells like dendritic cells.
Tween 80 induces a suppressed Th1 response, characterized by decreased T cell activation and cytokine production, resulting in a reduced adaptive immune response.
The EP67 adjuvant induces an inflammatory immune response by triggering the release of Th1-type cytokines from APCs, which are activated through the C5a receptor.
The adjuvant induces rapid Th2-associated IgG1 responses by initially sensing pathogens through pattern recognition receptors (PRRs) like TLRs, leading to innate cell activation of dendritic cells, and subsequently shaping the adaptive response through T cell polarization towards Th2 cells, resulting in the production of IgG1 antibodies.
Upon sensing by Dectin-1, Curdlan triggers an innate immune response, activating dendritic cells that subsequently induce the activation of T follicular helper (TFH) cells, germinal centers (GCs), and bone marrow high-affinity plasma cells. This leads to the production of high-affinity antibodies.
The adjuvant CARP-1 initiates an immune response by stimulating the CD40 and CD86 co-receptors on antigen-presenting cells, leading to the production of pro-inflammatory cytokines such as TNF-α and IL-6. This activation of the NF-κB and MAPK signaling pathways ultimately shapes the adaptive immune response, including T cell polarization and antibody production.
Upon sensing the ASPPR adjuvant, innate immune cells express pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), which lead to the activation of antigen-processing cells (APCs) like dendritic cells.
BLP adjuvant enhances immune responses by boosting both systemic and mucosal immunity, initiating a cascade of events starting with the recognition of pathogens by pattern recognition receptors (PRRs), such as TLRs. This recognition triggers the activation of innate immune cells like dendritic cells, which subsequently polarize T cells and induce antibody production.
BX795 adjuvant interferes with antiviral signaling by inhibiting TANK-binding kinase 1 (TBK1), thereby enhancing the replication of replication-competent live viral vaccines. This inhibition of TBK1 prevents the activation of interferon (IFN) responses, creating an environment that favors viral replication.
C5a activates the NLRP3 inflammasome, initiating a cascade of events that ultimately leads to the formation of a depot for slow antigen release. This process triggers the activation of innate immune cells, including neutrophils and macrophages, which release pro-inflammatory cytokines such as IL-1β.
The adjuvant HP-β-CD temporarily releases IL-33 from alveolar epithelial type 2 cells in the lung, initiating an immune response through IL-33/ST2 signaling. This release of IL-33 subsequently activates innate immune cells, including dendritic cells, which then shape the adaptive response by presenting antigens to T cells, leading to T cell polarization and antibody production.
CYT387 interferes with antiviral signaling by inhibiting TANK-binding kinase 1 (TBK1), which enhances the replication of replication-competent live viral vaccines. This inhibition of TBK1 leads to the suppression of type I interferon (IFN) signaling, which in turn allows for the replication of viral vaccines.
CARP-2 stimulates the immune response by binding to CD40 and CD86, triggering the activation of NF-κB and MAPK pathways. This activation leads to the production of pro-inflammatory cytokines, including TNF-α and IL-6, which in turn activate dendritic cells and other innate immune cells, ultimately shaping the adaptive response. The production of TNF-α and IL-6 also promotes the activation of T cells, leading to the polarization of T cells towards Th1 and Th17 responses, while also inducing antibody production.
Vaccine adjuvant composed of peptides that is added to vaccines to enhance the body’s immune response to an antigen.
Vaccine adjuvant obtained from animals, such as from animal tissues, fluids, or byproducts and added to vaccines to enhance the body's immune response to an antigen.
Vaccine adjuvant composed of fusion proteins, which is added to vaccines to enhance and modulate the immune response to a specific antigen.
Vaccine adjuvant composed of adenovirus to stimulate and augment the immune response to an antigen.
A Inactivated vaccine that immunizes against Neospora caninum protozoa.
Neospora caninum killed protozoa vaccine
A Inactivated vaccine that immunizes against Toxoplasma gondii trypmastigote.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6065
A Live attenuated vaccine encoding a1-giardin and CWP2 that immunizes against Giardi lamblia trophozoite.
G. lamblia bivalent DNA vaccine encoding a1-giardin and CWP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5993
Giardia lamblia bivalent DNA vaccine encoding a1-giardin and CWP2
A Live attenuated vaccine encoding a-enolase that immunizes against Giardi lamblia trophozoite.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5991
Giardia lamblia vaccine encoding a-enolase
A Live attenuated vaccine encoding a1-giardin that immunizes against Giardi lamblia trophozoite.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5989
Giardia lamblia vaccine encoding a1-giardin
A Live attenuated vaccine expressing VSPH7 that immunizes against Giardi lamblia trophozoite.
G. lamblia vaccine using attenuated Salmonella vaccine expressing VSPH7
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6004
Giardia lamblia vaccine using attenuated Salmonella vaccine expressing VSPH7
A Live attenuated vaccine p52(-)/p36(-) GAP that immunizes against Plasmodium falciparum sporozoite.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5952
A Live attenuated vaccine Pb(PfCS@UIS4) that immunizes against Plasmodium falciparum sporozoite.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5988
A Live attenuated vaccine PfSPZ that immunizes against Plasmodium falciparum sporozoite.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5950
A Live attenuated vaccine RH-AMA1KO that immunizes against Toxoplasma gondii trypmastigote.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6069
A Live attenuated vaccine with GRA17 mutant that immunizes against Toxoplasma gondii trypmastigote.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6082
A Live attenuated vaccine irradiated sterilised tachyzoites that immunizes against Toxoplasma gondii trypmastigote.
T. gondii irradiated sterilised tachyzoites
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6090
Toxoplasma gondii irradiated sterilised tachyzoites vaccine
A Live attenuated vaccine with LDH1 and LDH2 mutant that immunizes against Toxoplasma gondii trypmastigote.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6087
Toxoplasma gondii LDH1 and LDH2 mutant vaccine
A Live attenuated vaccine with DSCG adjuvant that immunizes against Toxoplasma gondii trypmastigote.
UV-attenuated Toxoplasma gondii with DSCG adjuvant
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6091
UV-attenuated Toxoplasma gondii vaccine with DSCG adjuvant
adenovirus vaccine, unspecified formulation
adenovirus vaccine unspecified formulation
cholera vaccine, unspecified formulation
Haemophilus influenzae type b vaccine, conjugate unspecified formulation
Haemophilus influenzae type b vaccine conjugate unspecified formulation
Haemophilus influenzae type b vaccine, PRP-D conjugate
Haemophilus influenzae type b vaccine PRP-D conjugate
hepatitis A vaccine, pediatric dosage, unspecified formulation
Hep A, pediatric, unspecified formulation
hepatitis A vaccine pediatric dosage unspecified formulation
hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
hepatitis A vaccine pediatric/adolescent dosage 3 dose schedule
hepatitis A vaccine, unspecified formulation
hepatitis A vaccine unspecified formulation
Hepatitis B vaccine (recombinant), 3-antigen, Al(OH)3 adjuvanted
Hepatitis B vaccine (recombinant) 3-antigen Al(OH)3 adjuvanted
hepatitis B vaccine, adolescent/high risk infant dosage
hepatitis B vaccine adolescent/high risk infant dosage
hepatitis B vaccine, unspecified formulation
hepatitis B vaccine unspecified formulation
Historical record of a typhus vaccination
Human Rabies vaccine from human diploid cell culture
influenza nasal, unspecified formulation
influenza split (incl. purified surface antigen)
influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE
influenza, split (incl. purified surface antigen)
influenza virus vaccine split virus (incl. purified surface antigen)
influenza virus vaccine, unspecified formulation
influenza virus vaccine unspecified formulation
Japanese Encephalitis unspecified formulation
Japanese Encephalitis vaccine, unspecified formulation
Japanese Encephalitis, unspecified formulation
Japanese Encephalitis vaccine unspecified formulation
A viral vaccine that protects against infection with Mammarenavirus juninense.
Mycobacterium vaccine that is used to protect against leprosy infection.
meningococcal A polysaccharide vaccine (non-US)
meningococcal AC polysaccharide (non-US)
meningococcal AC polysaccharide vaccine (non-US)
meningococcal ACWY unspecified formulation
meningococcal ACWY vaccine, unspecified formulation
meningococcal ACWY, unspecified formulation
meningococcal ACWY vaccine unspecified formulation
meningococcal B, unspecified formulation
meningococcal vaccine of unknown formulation and unknown serogroups
meningococcal polysaccharide (groups A C Y W-135) TT conjugate
meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative free
meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
meningococcal polysaccharide (groups A C Y W-135) tetanus toxoid conjugate vaccine 0.5mL dose preservative free
meningococcal MCV4 unspecified formulation
Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135)
meningococcal MCV4, unspecified formulation
Meningococcal MCV4 unspecified conjugate formulation(groups A C Y and W-135)
Novel Influenza-H1N1-09 all formulations
Novel influenza-H1N1-09, all formulations
Novel Influenza-H1N1-09, live virus for nasal administration
Novel Influenza-H1N1-09 live virus for nasal administration
Novel influenza-H1N1-09 preservative-free
Novel influenza-H1N1-09, preservative-free, injectable
Novel influenza-H1N1-09, preservative-free
Novel influenza-H1N1-09 preservative-free injectable
Pneumococcal conjugate PCV15 polysaccharide CRM197 conjugate adjuvant PF
Pneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative free
Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF
Pneumococcal conjugate vaccine 15-valent (PCV15) polysaccharide CRM197 conjugate adjuvant preservative free
c conjugate PCV20 polysaccharide CRM197 conjugate adjuvant PF
Pneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative free
Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF
Pneumococcal conjugate vaccine 20-valent (PCV20) polysaccharide CRM197 conjugate adjuvant preservative free
pneumococcal conjugate vaccine, 10 valent
pneumococcal conjugate vaccine 10 valent
Pneumococcal Conjugate unspecified formulation
Pneumococcal Conjugate, unspecified formulation
rabies vaccine, for intradermal injection
rabies vaccine for intradermal injection
respiratory syncytial virus monoclonal antibody (motavizumab), intramuscular
respiratory syncytial virus monoclonal antibody (motavizumab) intramuscular
respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular
respiratory syncytial virus monoclonal antibody (palivizumab) intramuscular
Vaccine that protects against group A Streptococcus infection causing rheumatic fever.
rotavirus vaccine, unspecified formulation
rotavirus vaccine unspecified formulation
COVID-19 D614 recomb preS dTM AS03 adjuvant add PF 10mcg/0.5mL
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 10mcg/0.5mL dose
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 10mcg/0.5mL
SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 10mcg/0.5mL dose
COVID-19 D614 recomb preS dTM AS03 adjuvant add PF 5mcg/0.5mL
SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose
COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL
SARS-COV-2 (COVID-19) vaccine D614 prefusion spike recombinant protein subunit (CoV2 preS dTM) AS03 adjuvant added preservative free 5mcg/0.5mL dose
COVID-19 mRNA LNP-S bivalent booster PF 10 mcg/0.2 mL
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose
COVID-19 mRNA LNP-S bivalent booster PF 10 mcg/0.2 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 10 mcg/0.2 mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S bivalent booster PF 30 mcg/0.3 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 30 mcg/0.3 mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S bivalent booster PF 50 mcg/0.5 mL or 25mcg/0.25 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose
COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent booster preservative free 50 mcg/0.5 mL or 25 mcg/0.25 mL dose
COVID-19 mRNA LNP-S bivalent PF 3 mcg/0.2 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP bivalent preservative free 3 mcg/0.2 mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S PF 10 mcg/0.2 mL dose tris-sucrose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 10 mcg/0.2mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S PF 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 100 mcg/0.5mL dose or 50 mcg/0.25mL dose
COVID-19 mRNA LNP-S PF 3 mcg/0.2 mL dose tris-sucrose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 3 mcg/0.2mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S PF 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose
COVID-19 mRNA LNP-S PF 30 mcg/0.3 mL dose tris-sucrose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 30 mcg/0.3mL dose tris-sucrose formulation
COVID-19 mRNA LNP-S PF 50 mcg/0.5 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free 50 mcg/0.5 mL dose
COVID-19 mRNA LNP-S PF pediatric 25 mcg/0.25 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 25 mcg/0.25 mL dose
COVID-19 mRNA LNP-S PF pediatric 50 mcg/0.5 mL dose
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose
SARS-COV-2 (COVID-19) vaccine mRNA spike protein LNP preservative free pediatric 50 mcg/0.5 mL dose
SARS-COV-2 (COVID-19) vaccine UNSPECIFIED
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna
SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna
SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine (Spikevax Bivalent) Moderna
COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product Pfizer-BioNTech
COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
SARS-COV-2 COVID-19 mRNA bivalent original/Omicron BA.1 Non-US Vaccine Product (Comirnaty Bivalent) Pfizer-BioNTech
SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown
COVID-19 Non-US Vaccine, Product Unknown
SARS-COV-2 COVID-19 Non-US Vaccine Specific Product Unknown
COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention)
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro Chinese Acad of Sciences)
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences)
COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology Chinese Academy of Sciences)
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Zifivax)
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax)
SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)
SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Zifivax)
COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA) CanSino Biological Inc./Beijing Institute of Biotechnology
COVID-19 VVnr Non-US Vaccine (Sputnik Light)
SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light)
Tick-borne encephalitis vaccine (non-US)
Tick-borne encephalitis inactivated PF 0.25mL
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dose
Tick-borne encephalitis, inactivated, PF, 0.25mL
Tick-borne encephalitis vaccine inactivated preservative free 0.25mL dose
Tick-borne encephalitis inactivated PF 0.5mL
Tick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL dose
Tick-borne encephalitis, inactivated, PF, 0.5mL
Tick-borne encephalitis vaccine inactivated preservative free 0.5mL dose
Tick-borne encephalitis vaccine, unspecified
Tick-borne encephalitis vaccine unspecified
typhoid vaccine, parenteral, acetone-killed, dried (U.S. military)
typhoid, parenteral, AKD (U.S. military)
typhoid vaccine parenteral acetone-killed dried (U.S. military)
typhoid vaccine, parenteral, other than acetone-killed, dried
typhoid vaccine parenteral other than acetone-killed dried
typhoid vaccine, unspecified formulation
Vaccinia smallpox monkeypox vaccine live PF SQ or ID injection
Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection
Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection
Vaccinia smallpox monkeypox vaccine live attenuated preservative free subcutaneous or intradermal injection
Venezuelan equine encephalitis vaccine, unspecified formulation
Venezuelan equine encephalitis vaccine unspecified formulation
Venezuelan equine encephalitis, inactivated
Venezuelan equine encephalitis inactivated
A combination vaccine adjuvant that is liposome-based adjuvant of a synthetic TLR agonist and saponin induced a Th1-biased immune response.
Chemical Nature: Combination adjuvant Mechanism of Action: n/a Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Maria Lawrenz, Vaccine Formulation Institute
VAC: https://vac.niaid.nih.gov/view?id=78
A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils.
Chemical Nature: Other - Peptide Mechanism of Action: (Primary) Selectively activates C5aR1 on mononuclear phagocytes vs neutrophils Immune profile induced: Th1/Th2/Th17 Route of immunization: IP, IV Point of Contact: Joseph Vetro, University of Nebraska Medical Center
VAC: https://vac.niaid.nih.gov/view?id=40
A vaccine adjuvant with a Toll-like receptor 9 (TLR9)-active oligonucleotide that is able to induce Th1/Th2 immune responses.
Chemical Nature: Nucleic acid Mechanism of Action: TLR9 agonist Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, SQ Point of Contact: Nikolai Petrovsky, Vaxine LTD
VAC: https://vac.niaid.nih.gov/view?id=10
A combination vaccine adjuvant that includes AS01-mimic, Immune Stimulating Complex (ISCOM) with a TLR4 agonist.
Chemical Nature: Combination adjuvant Mechanism of Action: Cytokine induction in draining lymph nodes with increased lymph flow and lymph antigen accumulation Immune profile induced: Mixed Th1/Th2 Route of immunization: s.c. / i.m. / i.n. Point of Contact: Katarzyna Kaczmarek Michaels, Massachusetts Institute of Technology Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=34860581 https://www.ncbi.nlm.nih.gov/pubmed/?term=36131022 https://www.ncbi.nlm.nih.gov/pubmed/?term=34878851
saponin and MPLA nanoparticle vaccine adjuvant
VAC: https://vac.niaid.nih.gov/view?id=77
A combination vaccine adjuvant that is an AS01-mimic, liposomal adjuvant of a TLR4 agonist and saponin.
Chemical Nature: - Natural compound - Synthetic derivative of natural compound - Combination adjuvant Mechanism of Action: MPLA: TLR4 agonist QS21: Sugar-lawn likely recog. by lectins to facilitate uptake by M_, DCs, etc Immune profile induced: Mixed Th1/Th2 Route of immunization: ID, IM Point of Contact: Mangala Rao, Walter Reed Army Institute of Research Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178 https://www.ncbi.nlm.nih.gov/pubmed/?term=31827000 https://www.ncbi.nlm.nih.gov/pubmed/?term=34470866 https://www.ncbi.nlm.nih.gov/pubmed/?term=35632473 https://www.ncbi.nlm.nih.gov/pubmed/?term=36417525 https://www.ncbi.nlm.nih.gov/pubmed/?term=34914540 https://www.ncbi.nlm.nih.gov/pubmed/?term=32881968 https://www.ncbi.nlm.nih.gov/pubmed/?term=26372857 https://www.ncbi.nlm.nih.gov/pubmed/?term=36055874 https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178 https://www.ncbi.nlm.nih.gov/pubmed/?term=36679887 https://www.ncbi.nlm.nih.gov/pubmed/?term=36934088 https://www.ncbi.nlm.nih.gov/pubmed/?term=34903722 https://www.ncbi.nlm.nih.gov/pubmed/?term=31775762 https://www.ncbi.nlm.nih.gov/pubmed/?term=28596090 https://www.ncbi.nlm.nih.gov/pubmed/?term=31151801 https://www.ncbi.nlm.nih.gov/pubmed/?term=34711815 https://www.ncbi.nlm.nih.gov/pubmed/?term=34159328 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT04268420 https://clinicaltrials.gov/ct2/show/NCT04296279 https://clinicaltrials.gov/ct2/show/NCT04784767 https://clinicaltrials.gov/ct2/show/NCT05500417 https://clinicaltrials.gov/ct2/show/NCT04826094 https://clinicaltrials.gov/ct2/show/NCT04658667 https://clinicaltrials.gov/ct2/show/NCT05423418
VAC: https://vac.niaid.nih.gov/view?id=79
A vaccine adjuvant which is a small molecule TLR agonist that drives a mixed Th1/Th2 response.
Chemical Nature: Small molecule Mechanism of Action: Innate immune activation Immune profile induced: Mixed Th1/Th2 Route of immunization: IM Point of Contact: Dennis Carson, UCSD
VAC: https://vac.niaid.nih.gov/view?id=81
A vaccine adjuvant, a small molecule TLR agonist that drives a mixed Th1/Th2 response.
VAC: https://vac.niaid.nih.gov/view?id=80
A combination vaccine adjuvant of a synthetic TLR agonist and aluminum salt.
Chemical Nature: - Synthetic derivative of natural compound - Combination adjuvant - Mineral salt Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: SQ, IM Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=37454145 https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505 https://www.ncbi.nlm.nih.gov/pubmed/?term=28828575 https://www.ncbi.nlm.nih.gov/pubmed/?term=30013570 https://www.ncbi.nlm.nih.gov/pubmed/?term=24211167 https://www.ncbi.nlm.nih.gov/pubmed/?term=23933525 https://www.ncbi.nlm.nih.gov/pubmed/?term=34597297 https://www.ncbi.nlm.nih.gov/pubmed/?term=36996185 https://www.ncbi.nlm.nih.gov/pubmed/?term=28464026 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03910972 https://clinicaltrials.gov/ct2/show/NCT02126462 https://clinicaltrials.gov/ct2/show/NCT02839161 https://clinicaltrials.gov/ct2/show/NCT03110757 https://clinicaltrials.gov/ct2/show/NCT02337855 https://clinicaltrials.gov/ct2/show/NCT01717950 https://clinicaltrials.gov/ct2/show/NCT02476773 https://clinicaltrials.gov/ct2/show/NCT01261130 https://clinicaltrials.gov/ct2/show/NCT01385189 https://clinicaltrials.gov/ct2/show/NCT03172975
VAC: https://vac.niaid.nih.gov/view?id=83
A combination vaccine adjuvant of a synthetic TLR4 agonist and aluminum salt.
Chemical Nature: - Synthetic derivative of natural compound - Combination adjuvant - Mineral salt Mechanism of Action: Innate Immune Activation Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=26901122 https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577
VAC: https://vac.niaid.nih.gov/view?id=82
An emulsion vaccine adjuvant that includes squalene-based oil-in-water emulsion.
Chemical Nature: Emulsion Mechanism of Action: n/a Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, SQ Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI) Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214 https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687 https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728 https://www.ncbi.nlm.nih.gov/pubmed/?term=37495191 https://www.ncbi.nlm.nih.gov/pubmed/?term=36256646 https://www.ncbi.nlm.nih.gov/pubmed/?term=28089141 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT03330899 https://clinicaltrials.gov/ct2/show/NCT01612000 https://clinicaltrials.gov/ct2/show/NCT02464163 https://clinicaltrials.gov/ct2/show/NCT02464163
VAC: https://vac.niaid.nih.gov/view?id=84
A nucleic acid vaccine adjuvant that is primarily composed of oligonucleotide.
An emulsion vaccine adjuvant that is squalene-based adjuvant, induces T follicular helper cells and humoral immune responses via alpha-tocopherol component.
Chemical Nature: Emulsion Mechanism of Action: n/a Immune profile induced: Th1-biased Route of immunization: IM Point of Contact: Maki Hayase, Shionogi &Co., Ltd Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=36372670 https://www.ncbi.nlm.nih.gov/pubmed/?term=36891311 https://www.ncbi.nlm.nih.gov/pubmed/?term=36460696 https://www.ncbi.nlm.nih.gov/pubmed/?term=35691872 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT05212948
VAC: https://vac.niaid.nih.gov/view?id=90
An oligonucleotide vaccine adjuvant that is a TLR9-agonistic adjuant containing a CpG oligonucleotide annealed to a complementary strand with an amphiphilic chain unit, acts as a potent cancer vaccine adjuvant by targeting draining lymph nodes.
Chemical Nature: Oligonucleotide Mechanism of Action: Activation of TLR9 signaling pathway Immune profile induced: Th1-biased Route of immunization: IM, SQ Point of Contact: Maki Hayase, Shionogi &Co., Ltd Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=35003132 https://www.ncbi.nlm.nih.gov/pubmed/?term=37243234 Ongoing clinical trials: N/A
VAC: https://vac.niaid.nih.gov/view?id=91
A vaccine adjuvant which is a small molecule adjuvant that is able to induce a mixed Th1/Th2 response and active innate immunity.
Chemical Nature: Small molecule Mechanism of Action: Activation of innate immunity Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, ID Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital
It may actually be the world’s first small-molecule TLR3 agonist.
VAC: https://vac.niaid.nih.gov/view?id=86
precision vaccines program-057 vaccine adjuvant
An emulsion vaccine adjuvant that targets on TLR-agonist. It is a nucleic acid-based adjuvant for chemical nature.
Chemical Nature: Nucleic acid, Emulsion Mechanism of Action: Innate Immune Activation, preferential uptake by APCs Immune profile induced: Th1-biased Definition: TLR-agonist for target; nucleic acid-based adjuvant for chemical nature Route of immunization: SQ, IN, IM Point of Contact: Madhavan Nallani, ACM Biolabs Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=34618423 https://www.ncbi.nlm.nih.gov/pubmed/?term=36223228 Ongoing clinical trials: https://clinicaltrials.gov/ct2/show/NCT05385991
VAC: https://vac.niaid.nih.gov/view?id=92
A particulate antigen delivery system vaccine adjuvant derived from Cowpea mosaic virus that is able to induce a Th1-biased response.
Chemical Nature: Nucleoprotein complex Mechanism of Action: recognized by PRRs Immune profile induced: Th1-biased Route of immunization: Intratumoral, intraperitoneally , IV Point of Contact: Nicole Steinmetz, University of California, San Diego Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=26689376 https://www.ncbi.nlm.nih.gov/pubmed/?term=37844250 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=93
A nucleic acid vaccine adjuvant that targets on TLR3 agonist to induce a mixed Th1/Th2 response.
Chemical Nature: dsRNA Mechanism of Action: TLR3 agonist Immune profile induced: Mixed Th1/Th2 category: nucleic-acid based adjuvant (TLR-agonist) synthetic derivative of natural compound Route of immunization: IM Point of Contact: Seungbin Cha, NA Vaccine Institute Pubmed References: https://www.ncbi.nlm.nih.gov/pubmed/?term=36761735 https://www.ncbi.nlm.nih.gov/pubmed/?term=38136298 Ongoing clinical trials: none
VAC: https://vac.niaid.nih.gov/view?id=94
A vaccine adjuvant that is primarily composed of nucleic acid.
A recombinant oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cells lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus may promote a cytotoxic T cell response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48412
NCT: https://clinicaltrials.gov/ct2/show/NCT00109655
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5475
Oncolytic Adenovirus Encoding GM-CSF Vaccine
A non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the gene for interferon alpha-2b (IFN_2b) and the gene transfer enhancement agent Syn 3, with potential antineoplastic activity. Upon intravesical administration, recombinant adenovirus-interferon with Syn3 transfects both cancerous and normal bladder cells, and the adenovirus secretes interferon (IFN_2b) into the bladder. IFN exerts a direct antitumor killing effect and a bystander effect, thereby killing adjacent, non-transfected cancerous bladder cells. Syn 3 enhances the ability of the adenoviral vector to transfect cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104743
NCT: https://clinicaltrials.gov/ct2/show/NCT02773849
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5047
Recombinant Adenovirus-Interferon/Syn3 Vaccine
A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2686
NCT: https://clinicaltrials.gov/ct2/show/NCT00072137
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4994
Recombinant Fowlpox GM-CSF Vaccine Adjuvant
A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C107243
NCT: https://clinicaltrials.gov/ct2/show/NCT02864368
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5259
A cancer vaccine consisting of a human epidermal growth factor receptor variant III (EGFRvIIi)-specific peptide conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Vaccination with rindopepimut may elicit a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing EGFRvIII. EGFRvIII, a functional variant of EGFR that is not expressed in normal tissues, was originally discovered in glioblastoma multiforme (GBM) and has also been found in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head and neck cancers. EGFRvIII contains an 83 amino acid deletion in its extracellular domain and has been shown to transform NIH/3T3 mouse embryonic fibroblast cells in vitro.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C69076
NCT: https://clinicaltrials.gov/ct2/show/NCT01498328
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5032
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29786
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5192
A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient‚Äö√†√∂‚àö√òs own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116332
NCT: https://clinicaltrials.gov/ct2/show/NCT02149225
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5086
Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2
A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively-personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C116331
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5231
Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1
An orally available DNA cancer vaccine containing an attenuated strain of the bacterium Salmonella typhimurium encoding murine vascular endothelial growth factor receptor 2 (VEGFR-2) (VXM01), with potential immunomodulating, anti-angiogenic and antineoplastic activity. Upon oral administration and successful transduction, VEGFR-2 DNA vaccine VXM01 expresses VEGFR-2 in addition to inducing the expression of T-cell activation markers, such as CD25, interleukin-2, the early T-cell activation antigen CD69 and the lymphocyte function-associated antigen LFA-2. The immune response targets the fast growing VEGFR-2 expressing endothelial cells found in the tumor vasculature, thereby blocking angiogenesis which may ultimately inhibit tumor cell proliferation. VEGFR-2 is a receptor tyrosine kinase overexpressed on proliferating endothelial cells in the tumor vasculature.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99378
NCT: https://clinicaltrials.gov/ct2/show/NCT02718443
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5521
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the HER2 protein (E75 peptide) and combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activity. Upon intradermal injection, nelipepimut-S plus GM-CSF vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cell types. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types. GM-CSF potentiates the antitumor immune response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C99228
NCT: https://clinicaltrials.gov/ct2/show/NCT02636582
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5363
A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C121947
NCT: https://clinicaltrials.gov/ct2/show/NCT02427581
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5348
Personalized Synthetic Long Peptide Breast Cancer Vaccine
A plasmid DNA cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene. Upon administration and after cellular uptake by skin or muscle cells, the pNGVL3-hICD vaccine plasmid expresses the HER-2/neu protein, which, after intracellular processing, may elicit both antigen-specific cytotoxic T-lymphocyte (CTL) and humoral immune responses against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61146
NCT: https://clinicaltrials.gov/ct2/show/NCT05163223
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5040
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29785
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5530
Recombinant Adenovirus-Cre Recombinase Vaccine
An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880
NCT: https://clinicaltrials.gov/ct2/show/NCT01220128
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5297
Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine
A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49177
NCT: https://clinicaltrials.gov/ct2/show/NCT00140738
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5241
A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C102782
NCT: https://clinicaltrials.gov/ct2/show/NCT00004156
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5077
Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49087
NCT: https://clinicaltrials.gov/ct2/show/NCT00227474
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5058
Recombinant Modified Vaccinia Ankara-5T4 Vaccine
A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510
NCT: https://clinicaltrials.gov/ct2/show/NCT00071942
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5281
A vaccine containing a recombinant vaccinia virus that encodes the gene for human mucin-1, a tumor-associated antigen. Upon administration, recombinant vaccinia-MUC-1 vaccine may elicit a MUC-1-specific cytotoxic T cell response against tumor cells bearing MUC-1.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2732
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5321
A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1690
NCT: https://clinicaltrials.gov/ct2/show/NCT00003638
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5425
A vaccine comprised of a synthetic Sialyl-Tn antigen linked to the protein carrier, keyhole limpet hemocyanin (KLH), administered with immunostimulant, Detox. Vaccination with STn-KLH plus Detox may elicit an IgG-based anti-STn antibody response and ultimately a cytotoxic T-cell response against STn-expressing cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2501
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5061
A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61076
NCT: https://clinicaltrials.gov/ct2/show/NCT00304096
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5271
Synthetic Breast Cancer Peptides-Tetanus Toxoid-Montanide ISA-51 Vaccine
A vaccine containing a clustered pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH) with potential antineoplastic activity. Alpha-N-acetylgalactosamine (Tn) is a monosaccharide usually O-linked to serine or threonine residues of mucins found on most epithelial cancers with the highest expression on prostate cancer. This vaccine contains the Tn epitope cluster (c) that is synthesized by linking 3 copies of the Tn epitope on a threonine backbone to achieve the essential immunogenic structure. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition. Vaccination with Tn(c)-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing Tn antigen, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2474
NCT: https://clinicaltrials.gov/ct2/show/NCT00030823
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5025
A population of activated, immortalized, interleukin-2 (IL-2)-dependent, cytotoxic natural killer (NK) cells with potential antitumor activity. Natural killer cells ZRx101 are derived from NK-92 cells, having been modified to target tumor-associated antigens (TAAs) upregulated in certain types of cancer. The NK-92 cell line was originally isolated from a patient with large granular lymphocytic (LGL) leukemia/lymphoma. (NCIT_C85466).
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85466
NCT: https://clinicaltrials.gov/ct2/show/NCT00900809
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5026
A cancer vaccine consisting of an immunogenic peptide derived from the cancer-testis antigen (NY-ESO-1), an antigen found in normal testis and various tumors. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response to cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2657
NCT: https://clinicaltrials.gov/ct2/show/NCT05479045
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5206
A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 with potential immunostimulating and antitumor activities. Upon administration, NY-ESO-1 plasmid DNA cancer vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1 is a tumor associated antigen (TAA) found in normal testes and expressed on the surfaces of various tumor cells, including melanoma, breast, bladder, prostate, lung, ovarian, and hepatocellular tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62452
NCT: https://clinicaltrials.gov/ct2/show/NCT00199849
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5283
A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113432
NCT: https://clinicaltrials.gov/ct2/show/NCT02015416
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5445
A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68999
NCT: https://clinicaltrials.gov/ct2/show/NCT00199836
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5428
A tumor-associated antigen belonging to the family of immunogenic testicular proteins that are aberrantly expressed in human cancers in a lineage-nonspecific fashion. Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma; and restricted expression in normal tissues, with high-level mRNA expression found only in testis and ovary tissues. The gene for NY-ESO-1 maps to Xq28 and codes for an 18-kDa protein having no homology with any known protein. NY-ESO-1 elicits a strong, integrated humoral and cellular immune response in a high proportion of patients with NY-ESO-1-expressing tumors and is under investigation as a cancer immunotherapy agent.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26680
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5182
An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2830
NCT: https://clinicaltrials.gov/ct2/show/NCT00006106
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5486
A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide vaccine may elicit an HLA-A2.1-restricted cytotoxic T lymphocyte immune response against tumor cells that overexpress p53 protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1986
NCT: https://clinicaltrials.gov/ct2/show/NCT00001827
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5255
A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78820
NCT: https://clinicaltrials.gov/ct2/show/NCT00722839
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5441
A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2786
NCT: https://clinicaltrials.gov/ct2/show/NCT00001386
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5451
A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 6.1-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2787
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5443
A cancer vaccine consisting of Her2/neu peptides incorporated into microspheres of poly (lactide-co-glycolide) (PLGA), a biodegradable polymer. Poly microsphere encapsulated HER2/neu oral vaccine has been investigated for use in immunotherapy for tumors positive for HER-2/neu, a tumor associated antigen that is overexpressed in various cancers, including breast and ovarian cancer.‚Äö√†√∂‚àö¬ß
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2718
NCT: https://clinicaltrials.gov/ct2/show/NCT02795988
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5176
poly microsphere encapsulated HER2/neu oral vaccine
A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2438
NCT: https://clinicaltrials.gov/ct2/show/NCT00019006
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5320
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the stimulatory molecule transgene B7-1. Recombinant fowlpox-B7.1 (rF-B7.1) vaccine may enhance antigen presentation and activate antitumoral cytotoxic T-cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2666
NCT: https://clinicaltrials.gov/ct2/show/NCT00030693
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5424
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2620
NCT: https://clinicaltrials.gov/ct2/show/NCT00028496
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5049
recombinant Fowlpox-CEA(6D)/TRICOM vaccine
A whole, heat-killed, recombinant Saccharomyces cerevisiae yeast-based vaccine genetically altered to express the carcinoembryonic antigen (CEA) peptide 610D with potential immunostimulating and antineoplastic activities. Upon administration, recombinant Saccharomyces cerevisia-CEA(610D) vaccine GI-6207 may stimulate a host cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells, which may result in tumor cell lysis. CEA, a tumor associated antigen, is overexpressed on a wide variety of human cancer cells including colorectal, gastric, lung, breast and pancreatic cancer cells. CEA 610D encodes for 9 amino acids (605-613) in which aspartate is substituted for asparagine at position 610 (610D) in order to strengthen the induction of the CTL response against CEA-expressing tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82371
NCT: https://clinicaltrials.gov/ct2/show/NCT00924092
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5152
recombinant Saccharomyces Cerevisia-CEA(610D)-expressing vaccine GI-6207
A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; also called TRICOM). Vaccination with recombinant vaccinia-CEA(6D)-TRICOM vaccine stimulates the host immune system to mount a T-cell response against tumor cells expressing the CEA antigen. The use of TRICOM in the vaccine may elicit a greater antitumor cytotoxic T lymphocyte (CTL) immune response compared to the use of vaccinia-CEA alone.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2619
NCT: https://clinicaltrials.gov/ct2/show/NCT00217373
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5037
recombinant Vaccinia-CEA(6D)-TRICOM vaccine
An admixture of recombinant vaccinia virus encoding MUC-1 and recombinant vaccinia virus encoding the murine T-cell co-stimulatory molecule B7.1. MUC-1 is a glycosylated mucin that is overexpressed in breast, lung, pancreatic, prostate, stomach, colon, and ovarian carcinomas. Vaccination with MUC-1 in combination with B7.1 may enhance the cytotoxic T cell (CTL) immune response to tumors expressing MUC-1, compared to vaccination with MUC-1 alone.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29409
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5326
A cancer vaccine consisting of a recombinant vaccinia viral vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with recombinant vaccinia- NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48419
NCT: https://clinicaltrials.gov/ct2/show/NCT00112957
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5389
A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49082
NCT: https://clinicaltrials.gov/ct2/show/NCT00505271
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5437
retrovector encoding mutant Anti-Cyclin G1 vaccine
An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114285
NCT: https://clinicaltrials.gov/ct2/show/NCT00978913
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5180
survivin/p53/HER2 antigen-loaded autologous dendritic cell vaccine
A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95705
NCT: https://clinicaltrials.gov/ct2/show/NCT02334865
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5008
A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT-encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120118
NCT: https://clinicaltrials.gov/ct2/show/NCT02960594
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5171
A cancer vaccine consisting of E-PRA and E-PSM, two synthetic peptide analogs of PRAME (PReferential Antigen MElanoma) and PSMA (Prostate Specific Membrane Antigen), with potential immunostimulating activity. Upon direct administration into lymph nodes, synthetic peptides E-PRA and E-PSM vaccine may sitmulate a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing tumor cells. PRAME and PSMA are tumor-associated antigens upregulated and expressed on the cell surfaces of certain tumor cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67098
NCT: https://clinicaltrials.gov/ct2/show/NCT00423254
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5496
synthetic peptides E-PRA and E-PSM vaccine
A peptide-based cancer vaccine, containing amino acid residues 27 through 35 of T cell receptor gamma alternate reading frame protein (TARP), with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 27-35 peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85462
NCT: https://clinicaltrials.gov/ct2/show/NCT00972309
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5448
A peptide-based cancer vaccine, consisting of amino acid residues 29 through 37 of T cell receptor gamma alternate reading frame protein (TARP) with a leucine-to-valine substitution at position 9, with potential immunostimulatory and antineoplastic activities. Upon administration, TARP 29-37-9V peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against TARP-expressing tumor cells, which may result in decreased tumor cell proliferation. The leucine-to-valine substitution at position 9 of this peptide improves its immunogenicity. The nuclear protein TARP is commonly expressed on prostate and breast cancer cells and is highly immunogenic.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C85463
NCT: https://clinicaltrials.gov/ct2/show/NCT02362464
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5242
A cancer vaccine consisting of a recombinant vector encoding the tumor-associated carcinoembryonic antigen (CEA) that is‚Äö√†√∂‚àö¬ßcontaminated‚Äö√†√∂‚àö¬ßwith bovine viral diarrhea virus (BVDV). The carcinoembryonic antigen (CEA) is a prevalent tumor marker expressed by a number of different cancers such as colorectal, breast, lung and ovarian carcinomas; vaccination with vaccinia virus genetically engineered to express‚Äö√†√∂‚àö¬ßCEA‚Äö√†√∂‚àö¬ßmay generate antitumoral T-cell responses.‚Äö√†√∂‚àö¬ßBVDV‚Äö√†√∂‚àö¬ßis an RNA pestivirus that may contaminate vaccines due to its presence in fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29476
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5295
A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific HLA-A2-restricted epitopes (TAAs): topoisomerase II alpha, B-cell receptor-associated protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog 2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor 1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting the TAAs to the immune system for a prolonged period of time. This may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate cancer cells and play an important role in tumor cell growth and survival.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C91077
NCT: https://clinicaltrials.gov/ct2/show/NCT01095848
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5458
therapeutic Breast/Ovarian/Prostate peptide cancer vaccine DPX-0907
A cancer vaccine containing URLC10 (up-regulated lung cancer 10) epitopes with potential immunostimulatory and antineoplastic activities. Upon administration, URL peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells. Up-regulated in lung and esophageal cancers, the function of URLC10 is unknown.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74087
NCT: https://clinicaltrials.gov/ct2/show/NCT00624182
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5115
A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74088
NCT: https://clinicaltrials.gov/ct2/show/NCT00632333
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5001
URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine
A highly tumor-selective vaccinia virus (vv) with an engineered double deletion (DD) of the thymidine kinase (tk) and vaccinia growth factor genes and additions of both a cytosine deaminase (CD) gene and a somatostatin receptor (SR) gene with potential oncolytic viral activity. The tk and vaccinia growth factor gene deletions in intratumorally administered vaccinia virus (vvDD-CDSR) help to restrict its replication and cytolytic activity to tumor cells with large nucleotide pools and tumor cells with activation of the EGFR-Ras pathway. Addition of the CD gene to the viral genome allows control of oncolytic viral infection through the administration of the prodrug 5-fluorocytosine (5-FC), converted by CD to the antimetabolite 5-fluorouracil (5-FU) in cells infected with this agent. Addition of the SR gene allows anatomical localization of vaccinia virus (vvDD-CDSR) through the use of octreotide scintigraphy.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74089
NCT: https://clinicaltrials.gov/ct2/show/NCT00574977
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5296
A vaccine consisting of two plasmids encoding the human cytomegalovirus (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with immunostimulatory properties. Vaccination with VCL-CB01 may stimulate the host immune system to mount cellular and humoral immune responses against CMV positive cells, resulting in cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61327
NCT: https://clinicaltrials.gov/ct2/show/NCT00285259
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5390
A live attenuated bacteria injectable vaccine used to prevent typhoid, which is caused by Salmonella typhi.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97127
NCT: https://clinicaltrials.gov/ct2/show/NCT03294564
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5322
Vi capsular polysaccharide typhoid vaccine
A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C104738
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5430
A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61442
NCT: https://clinicaltrials.gov/ct2/show/NCT01842139
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5089
A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104734
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5029
A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5468
A cancer vaccine consisting of the DNA plasmid pNGVL4a-A encoding calreticulin (CRT) linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, this vaccine may generate a potent cytotoxic T-lymphocyte (CTL) response against E7-expressing tumor cells, resulting in tumor cell death. For E7(detox), the amino acids in E7 at positions 24 (cysteine to glycine) and 26 (glutamic acid to glycine) were substituted. CRT, a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER), may potentiate MHC class I presentation of HPV-16 E7 to E7-specific CD8-positive T cells. In addition, pNGVL4a-A contains two short immunostimulatory DNA sequences (ISS) in the noncoding region, which may elicit the production of IFN- and IL-12 in transfected keratinocytes and dermal antigen presenting cells (APCs), resulting in a potent T helper cell type 1 response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88289
NCT: https://clinicaltrials.gov/ct2/show/NCT00988559
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5011
An antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48418
NCT: https://clinicaltrials.gov/ct2/show/NCT00121173
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5069
A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) Types 6, 11, 16, and 18 with immunoprophylactic activity. The immunoprohylactic efficacy of L1 VLP vaccines, such as recombinant human papillomavirus quadrivalent vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61087
NCT: https://clinicaltrials.gov/ct2/show/NCT00411749
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5406
Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.‚Äö√†√∂‚àö¬ß
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C119664
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5342
Recombinant Human Papillomavirus Nonavalent Vaccine
A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C88326
NCT: https://clinicaltrials.gov/ct2/show/NCT01022346
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5208
Recombinant Vaccinia Viral Vector RO5217790 Vaccine
A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C111037
NCT: https://clinicaltrials.gov/ct2/show/NCT02128126
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5186
Synthetic Long E6/E7 Peptides Vaccine HPV-01
A recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from Mycobacterium bovis, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2811
NCT: https://clinicaltrials.gov/ct2/show/NCT00493545
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5542
A synthetic vaccine used for cancer immunotherapy also known as Ras(cis 12)-Vaccinia Vaccine, RASVAC-C is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29401
NCT: https://clinicaltrials.gov/ct2/show/NCT00019591
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5504
A synthetic vaccine used for cancer immunotherapy also known as Ras(val 12)-Vaccinia Vaccine, RASVAC-V is based on a mutant peptide epitope of the Ras oncoprotein at codon 12 (valine instead of glycine) that induces recognition and induction of tumor-specific, cell-mediated immune responses. Ras is an intracellular GTP-binding protein involved in signal transduction and regulation of proliferation and differentiation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29402
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5497
A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2423
NCT: https://clinicaltrials.gov/ct2/show/NCT00002960
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5470
Recombinant Adenovirus-p53 SCH-58500 Vaccine
An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166939
NCT: https://clinicaltrials.gov/ct2/show/NCT01253837
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5219
Recombinant Human Fusion Protein L19TNFalpha Vaccine
A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212
NCT: https://clinicaltrials.gov/ct2/show/NCT00681577
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5350
A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.126, with potential antitumor activity. Upon vaccination with p.DOM-WT1-126 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96738
NCT: https://clinicaltrials.gov/ct2/show/NCT01334060
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5165
A fusion DNA vaccine containing the first domain of fragment C (FrC) of tetanus toxin (TT865-1120) (p.DOM) fused to the human Wilms' Tumor gene-1 (WT1)-derived MHC class I-binding epitope WT1.37, with potential antitumor activity. Upon vaccination with p.DOM-WT1-37 DNA and subsequent electroporation, this vaccine may induce a WT1 epitope-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing cancer cells. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. The FrC of tetanus toxin contains the MHC II-binding sequence, p30, which induces T-helper cell activation for long-lasting immunity.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96737
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5471
A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2235
NCT: https://clinicaltrials.gov/ct2/show/NCT00004918
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5140
A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens (substances isolated from tumor cells). A tumor antigen vaccine may stimulate the body's immune system to find and kill cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2341
NCT: https://clinicaltrials.gov/ct2/show/NCT00100971
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5387
A leukemia cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C106257
NCT: https://clinicaltrials.gov/ct2/show/NCT01961882
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5330
An immunotherapeutic consisting of the recombinant fusion protein WT1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT1-A10/AS01B immunotherapeutic GSK2130579AWT1 may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT1 sequence; ASO1B consists of a combination of the adjuvants monophosporyl lipd A (MPL) and Q21.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78865
NCT: https://clinicaltrials.gov/ct2/show/NCT00725283
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5354
WT1-A10/AS01B Immunotherapeutic GSK2130579A Vaccine
A recombinant vaccinia virus encoding carcinoembryonic antigen (CEA). CEA is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung cancers. Attenuated vaccinia virus is a highly effective immunizing agent that evokes both humoral and cell-mediated responses. Vaccination with this agent may evoke a cytotoxic immune response to CEA-expressing cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2809
NCT: https://clinicaltrials.gov/ct2/show/NCT00081848
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5401
Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors and expanded ex vivo, with potential immunosuppressive activity. Remestemcel-L cells are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule expression, eliciting little, if any, host immune response upon intravenous infusion. Infusion of allogeneic MSCs may result in: a) increased production of anti-inflammatory cytokines, such as interleukin-10, prostaglandin E, and hepatocyte growth factor; b) decreased mononuclear phagocyte expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its pro-inflammatory metabolites; and c) modulated dendritic cell (DC)maturation and disrupted activities of natural killer (NK) cells and CD8+ and CD4+ T cells. In addition, pluripotent MSCs, upon administration, may be recruited to damaged tissue sites, differentiating along specific lineages when stimulated.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C67082
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4993
A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. OBP-301 contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C119617
NCT: https://clinicaltrials.gov/ct2/show/NCT02293850
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5072
Telomerase-specific Type 5 Adenovirus OBP-301 Vaccine
A proprietary cancer DNA vaccine that contains multiple natural and modified epitopes derived from the four tumor associated antigens, CEA, HER2/neu, p53, and MAGE 2/3. OSE 2101 also includes CAP1-6D, a heteroclitic CEA analog, and PADRE, a proprietary universal T-cell epitope that serves to enhance the immunogenicity of the epitopes. This agent has been shown to elicit cytotoxic T-lymphocyte responses against tumor cells expressing these multiple epitopes.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C26645
NCT: https://clinicaltrials.gov/ct2/show/NCT02654587
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5528
A tumor-specific peptide encoded by patient-specific mutant p53 oncogene with potential immunostimulatory properties. The peptide (LPTGQDL) contains a frame shift mutation at amino acid position 134. It was used to pulse dendritic cells, which are then used in the adoptive immunotherapy setting and may stimulate the host immune system to mount a specific cytotoxic T lymphocyte response against tumor cells expressing the p35 mutation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38121
NCT: https://clinicaltrials.gov/ct2/show/NCT00049218
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5272
An anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. Racotumomab binds to the idiotype region of P3 MoAb and functionally mimics the three-dimensional structure of N-glycolyl ceramides of mono-sialyl lactose, the antigenic target of P3. As a result, this anti-idiotype antibody may stimulate the host immune system to elicit humoral and cellular immune responses against tumor cells expressing NeuGc-GM3 gangliosides, which are expressed in a wide variety of tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95024
NCT: https://clinicaltrials.gov/ct2/show/NCT01598454
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5201
A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49289
NCT: https://clinicaltrials.gov/ct2/show/NCT00062907
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5074
A plasmid DNA encoding human L523S, an RNA-binding protein that belongs to the KOC (K homology domain containing protein overexpressed in cancer) family, with potential antineoplastic activity. Vaccination with L523S DNA may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express the L523S protein. As an oncofetal protein, L523S is normally expressed in early embryonic tissue, but is overexpressed in certain cancer cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49290
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5156
A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70674
NCT: https://clinicaltrials.gov/ct2/show/NCT00516685
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5190
Gene name: LV28_RS26095 transcriptional regulator RegF
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
An allogeneic lung cancer vaccine with potential immunostimulating and antineoplastic activities. Derived from allogeneic lung tumor cells, tergenpumatucel-L is engineered to express the murine alpha-1,3-galactosyltransferase (GalT), an enzyme humans lack. GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes in glycoproteins and in glycolipids on the cell membranes of the allogeneic lung tumor cells present in the vaccine, essentially producing a 'xenograft'. The hyperacute rejection involves pre-existing human anti-alpha-gal antibodies that bind the foreign alpha-gal epitopes expressed by the vaccine tumor cell xenograft, resulting in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous lung tumor cells with unmodified carbohydrate epitopes.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C66985
NCT: https://clinicaltrials.gov/ct2/show/NCT02460367
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5527
A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073
NCT: https://clinicaltrials.gov/ct2/show/NCT02439450
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5513
A cancer vaccine consisting of a mixture of a murine lymphoma-derived idiotype and interleukin-2 (IL-2) encapsulated in dimyristoylphosphatidylcholine liposomes. The use of a liposomal carrier confers immunogenicity to the naturally non-immunogenic idiotype.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2783
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5541
A lipid depot-based therapeutic cancer vaccine composed of survivin epitopes, a universal T Helper peptide and a polynucleotide adjuvant encapsulated in liposomes and then formulated in the hydrophobic carrier Montanide ISA51 VG, with potential immunopotentiating and antineoplastic activities. Upon injection of the maveropepimut-S, a depot is created at the injection site from which the antigens and adjuvant are released. This vaccine may elicit a long lasting cellular response against survivin-expressing cancers, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C97951
NCT: https://clinicaltrials.gov/ct2/show/NCT02323230
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5371
A vaccine consisting of lymphoma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated lymphoma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.‚Äö√†√∂‚àö¬ß
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2821
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5046
A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96042
NCT: https://clinicaltrials.gov/ct2/show/NCT01308294
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5305
NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine
A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17. A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2680
NCT: https://clinicaltrials.gov/ct2/show/NCT01307618
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5323
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL) and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114380
NCT: https://clinicaltrials.gov/ct2/show/NCT00313508
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5100
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine
A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1 peptide-pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C120129
NCT: https://clinicaltrials.gov/ct2/show/NCT00798629
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5366
NY-ESO-1/MART-1 peptide-pulsed dendritic cell vaccine
A cancer vaccine consisting of PEP-3, a synthetic peptide encompassing a tumor-specific mutated segment of the epidermal growth factor receptor type vIII (EGFRvIII), conjugated to the naturally-occurring immunoadjuvant keyhole limpet hemocyanin (KLH) with potential immunostimulating and antineoplastic activities. Upon administration, PEP-3-KLH conjugate vaccine may induce a cytotoxic immune response against tumor cells that overexpress EGFRvIII; this antitumoral immune response may involve antibody-dependent cellular cytotoxicity (ADCC).
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74070
NCT: https://clinicaltrials.gov/ct2/show/NCT00626015
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5480
A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103192
NCT: https://clinicaltrials.gov/ct2/show/NCT01690377
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5006
rime/boost vaccination proved to be of no advantage or even detrimental in therapeutic settings in B16F1 and transgenic adenocarcinoma of the mouse prostate (TRAMP) models, respectively
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4074
A melanoma vaccine comprised of a recombinant fowlpox vector construct encoding a modified epitope of the melanoma antigen glycoprotein 100 (gp100), ES-2092M(gp100), containing an endoplasmic reticulum signal sequence targeted to the endoplasmic reticulum apparatus. Vaccination with recombinant fowlpox-gp100p209 vaccine may stimulate the host immune system more efficiently to mount a cytotoxic T lymphocyte response against tumor cells expressing the gp100 antigen.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2806
NCT: https://clinicaltrials.gov/ct2/show/NCT00080353
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5274
A cancer vaccine consisting of a replication-defective recombinant fowlpox virus that encodes for the murine melanoma antigen glycoprotein 100 (mgp100) with potential antineoplastic activity. Vaccination with recombinant fowlpox-mgp100 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2805
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5499
A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2807
NCT: https://clinicaltrials.gov/ct2/show/NCT00054535
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5518
A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103830
NCT: https://clinicaltrials.gov/ct2/show/NCT01744171
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5359
recombinant human Hsp110-gp100 chaperone complex vaccine
A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. gp100p209 is a fragment epitope of gp100 in which the threonine in position 2 is replaced with methionine; this modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.‚Äö√†√∂‚àö¬ß
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29566
NCT: https://clinicaltrials.gov/ct2/show/NCT00116597
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5393
recombinant Vaccinia-gp100:209-217 vaccine
A recombinant vaccinia virus encoding a modified peptide of the gp100 melanoma-melanocyte antigen with potential use in cancer immunotherapy. gp100 human antigen is a wild type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas. This recombinant vaccinia Mgp100 encodes a fragment epitope of gp100 bearing 2 amino acids substitution; T->M at position 210 and 288 A ->V at position 210. This modification may stimulate tumor infiltrating lymphocytes (TIL) more efficiently.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C51978
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5505
A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48638
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5232
recombinant Vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine
A recombinant vaccinia virus encoding the melanocyte differentiation antigen tyrosinase-related protein-1 (TRP-1) with potential use in cancer immunotherapy.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29564
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5063
A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2430
NCT: https://clinicaltrials.gov/ct2/show/NCT01216436
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5194
Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant
A recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207-216 and tyrosinase 1-17, both of which are derived from human tyrosinase.
A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchotrope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4002
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5218
A bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity. Synchrovax SEM plasmid DNA vaccine contains a plasmid pSEM that encodes 4 epitopes: Melan-A (26-35), Melan-A (31-96), tyrosinase (1-9), and tyrosinase (369-377). Both Melan-A and tyrosinase are tumor antigens associated with melanoma. Vaccination with this plasmid DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) responses against cells expressing either or both of these antigens, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28549
NCT: https://clinicaltrials.gov/ct2/show/NCT00033228
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5506
A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48639
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5217
synthetic melanoma-associated antigens vaccine
A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C122396
NCT: https://clinicaltrials.gov/ct2/show/NCT02410733
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5114
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4004
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4075
A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815
NCT: https://clinicaltrials.gov/ct2/show/NCT00022438
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5325
A recombinant peptide consisting of amino acid residues 1 to 9 of the tyrosinase-related protein 1 (TRP1). Expressed by cells of melanocyte origin, TRP1 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP1(0RF3):1-9 may stimulate cytotoxic T cell responses to melanoma cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2816
NCT: https://clinicaltrials.gov/ct2/show/NCT00019383
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5487
A peptide vaccine containing a tyrosinase epitope conjugated with keyhole lymphocyte hemocyanin (KLH) with potential antineoplastic activity. Tyrosinase, one of the melanoma differentiation antigens, is the rate-limiting enzyme for melanin synthesis. This tyrosine epitope is conjugated with KLH, which serves as an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with tyrosinase-KLH peptide vaccine may produce anti-tyrosinase antibodies as well as elicit a cytotoxic T lymphocyte (CTL) response against cells expressing tyrosinase antigen, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2384
NCT: https://clinicaltrials.gov/ct2/show/NCT00028431
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5060
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3999
A cancer vaccine with VMCL was not associated with a statistically significant improvement in OS or RFS, with CIs not ruling out important gains from such treatment.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4007
vaccinia melanoma cell lysates (VMCL) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4023
Vaccinia melanoma oncolysates (VMO) vaccine
A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2674
NCT: https://clinicaltrials.gov/ct2/show/NCT00002817
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5508
A vaccine consisting of recombinant vaccinia virus, based on the modified vaccinia virus Ankara (MVA) that encodes the melanoma-associated antigen tyrosinase. Vaccination with vaccinia-tyrosinase may stimulate the host immune system to mount a cytotoxic T-cell response against tumor cells expressing tyrosinase. Tyrosinase is a melanoma-specific differentiation agent that catalyzes the synthesis of the melanin precursor L-3,4-dihydroxyphenylalanine (L-DOPA).
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2531
NCT: https://clinicaltrials.gov/ct2/show/NCT00019734
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5223
A plasmid DNA vaccine, encoding an epitope of mouse tyrosinase, with potential antineoplastic activity. Administered via intramuscular electroporation, vaccination with xenogeneic tyrosinase DNA vaccine may induce both humoral and cytotoxic lymphocyte (CTL) immune responses against melanoma cells that express tyrosinase, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68839
NCT: https://clinicaltrials.gov/ct2/show/NCT00471133
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5416
A recombinant replication-defective adenovirus which encodes the gene for the cytokine human interferon-beta (IFN-beta). Once inserted into and replicating in host tumor cells, recombinant adenovirus-hIFN-beta expresses human IFN-beta, which may stimulate an antiproliferative natural killer (NK) cell response against tumor cells and induce caspase-mediated tumor cell apoptosis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C28550
NCT: https://clinicaltrials.gov/ct2/show/NCT00066404
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5510
Recombinant Adenovirus-hIFN-beta Vaccine
A modified recombinant nonapeptide (LMLGEFLKL) derived from the anti-apoptosis protein survivin with potential immunopotentiating and antineoplastic activities. Upon administration, survivin Sur1M2 peptide vaccine may elicit humoral and cellular immune responses against survivin-expressing cancers, resulting in decreased tumor cell proliferation and tumor cell death. The survivin protein inhibits caspase activation and apoptosis; it is undetectable in normal adult tissues but is expressed by several human cancers including lung, colon, breast, pancreas, and prostate cancer as well as hematopoietic malignancies and skin cancers.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71741
NCT: https://clinicaltrials.gov/ct2/show/NCT00499577
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5265
A vaccine consisting of myeloma-specific immunoglobulin that is not conjugated to a carrier molecule. Vaccination with unconjugated myeloma Ig Id may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against myeloma cells, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2822
NCT: https://clinicaltrials.gov/ct2/show/NCT00001561
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5391
A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635
NCT: https://clinicaltrials.gov/ct2/show/NCT01827137
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5341
A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C102751
NCT: https://clinicaltrials.gov/ct2/show/NCT01621542
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5027
A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens. The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C103823
NCT: https://clinicaltrials.gov/ct2/show/NCT01718899
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5415
XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C113651
NCT: https://clinicaltrials.gov/ct2/show/NCT02033616
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5481
A cancer vaccine comprised of synthetic peptides corresponding to naturally-occurring peptides derived from ovarian cancer cell antigens. Ovarian cancer peptide vaccine may elicit a cytotoxic T-cell response against tumor cells expressing the related ovarian cancer cell antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48414
NCT: https://clinicaltrials.gov/ct2/show/NCT00091273
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5502
A cancer vaccine containing autologous dendritic cells (DCs) that are transfected with mRNAs extracted from amplified ovarian cancer stem cells, and mRNAs of the universal tumor antigens human telomerase reverse transcriptase (hTERT) and survivin with potential immunostimulatory and antineoplastic activities. Upon administration, ovarian cancer stem cell/hTERT/survivin mRNAs-loaded autologous DC-006 vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against ovarian cancer cells expressing hTERT, survivin, and specific ovarian cancer stem cell antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. Ovarian cancer stem cells contain a specific range of antigens that are essential for the neoplastic growth and survival of ovarian cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C96739
NCT: https://clinicaltrials.gov/ct2/show/NCT01334047
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5403
Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine
A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115105
NCT: https://clinicaltrials.gov/ct2/show/NCT02107950
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5280
Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine
A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82420
NCT: https://clinicaltrials.gov/ct2/show/NCT00844506
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5278
A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2428
NCT: https://clinicaltrials.gov/ct2/show/NCT00006216
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5245
An oncolytic thymidine kinase (TK)-deleted vaccinia poxvirus expressing human GM-CSF (hGM-CSF) with antineoplastic activity. Upon intratumoral or intravenous administration, pexastimogene devacirepvec selectively infects and lyses tumor cells. While vaccinia displays a natural tumor cell tropism, deletion of the TK gene increases the tumor selectivity of vaccinia by limiting viral replication to cells expressing high levels of TK, such as certain cancer cells. hGM-CSF expression by this agent helps recruit antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to virally infected tumor cells, thereby initiating an antitumoral immune response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C71533
NCT: https://clinicaltrials.gov/ct2/show/NCT02562755
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5078
A plasmid DNA vaccine containing mammalian expression vector pUMVC3, encoding epitopes of human insulin-like growth factor-binding protein 2 (hIGFBP-2) with potential immunostimulating and antineoplastic activities. Upon vaccination, pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against hIGFBP-2-expressing cells. The tumor associated antigen (TAA) hIGFBP-2, a member of the insulin like growth factor receptor family, is overexpressed in a number of cancer cell types and its expression has been associated with increased invasiveness.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95727
NCT: https://clinicaltrials.gov/ct2/show/NCT01322802
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5365
pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
A recombinant retrovirus containing the modified murine retroviral vector MFG-S encoding a chimeric construct, MOv18-gamma. MOv18 is a murine monoclonal antibody developed against epitope of human folate binding protein, which is overexpressed on more than 90% of non-mucinous epithelial ovarian neoplasms. The chimeric construct (MOv18-gamma) encodes the variable region of MOv18 antibody, and the gamma chain of human T-cell receptor. This virion might be used to transduce autologous T lymphocytes, and reintroduced back to the patient after expansion ex vivo to invoke specific immune response against ovarian cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29192
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5131
Retroviral Vector MFGS-MOv18-gamma Vaccine
A fowlpox vaccine containing the tumor-associated antigen mucin-1 (MUC1), found in pancreatic tumor cells, and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM), which is designed to enhance antigen presentation and activation of immune responses critical for tumor destruction. Vaccination with this agent may elicit a host immune response against MUC1-expressing tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29558
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5477
A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2445
NCT: https://clinicaltrials.gov/ct2/show/NCT00389610
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5340
Sargramostim Plasmid DNA Pancreatic Tumor Cell Vaccine
A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor 1 (VEGFR1 or Flt-1) with potential immunostimulating, antiangiogenic, and antineoplastic activities. Upon vaccination, VEGFR1-1084 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1-expressing endothelial cells of the tumor microvasculature, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR1, a receptor tyrosine kinase, may be overexpressed on endothelial cells of the tumor microvasculature and is associated with tumor cell proliferation, invasion and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenicity.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C77895
NCT: https://clinicaltrials.gov/ct2/show/NCT00655785
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5214
A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74090
NCT: https://clinicaltrials.gov/ct2/show/NCT00639925
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5419
A cancer vaccine containing HLA class I- and II-binding peptides derived from the NY-ESO-1/LAGE-1 cancer/testis antigen with potential immunostimulatory and antineoplastic activities. Upon administration, NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine may induce a cytotoxic immune response against tumor cells that over-express NY-ESO-1/LAGE-1. Rarely expressed by normal cells, the NY-ESO-1/LAGE-1 cancer/testis antigen has been shown to be preferentially expressed on the surface of some cancer cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C74066
NCT: https://clinicaltrials.gov/ct2/show/NCT00616291
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5379
An autologous dendritic cell (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C95771
NCT: https://clinicaltrials.gov/ct2/show/NCT00345293
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5205
Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine
This DNA vaccine expressed prostate-specific membrane antigen (PSMA)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3710
Prostate cancer DNA vaccine pDOM-PSMA27 encoding PSMA
A cell-based vaccine derived from prostate cancer with potential immunopotentiating and antineoplastic activities. Prostate cancer vaccine ONY-P1 is derived from three irradiated allogeneic prostate cancer cell lines that represent different stages of prostate cancer and express a broad range of prostate and prostate cancer antigens. Upon administration, this vaccine may stimulate a host immune response against prostate cancer cells; in the vaccination schedule, the first two vaccinations are co-administered with bacillus Calmette-Guerin (BCG) as an adjuvant.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C71723
NCT: https://clinicaltrials.gov/ct2/show/NCT00514072
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5351
A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the prostate tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C115106
NCT: https://clinicaltrials.gov/ct2/show/NCT02111577
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5132
Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine
A vaccinia virus carrying a copy of the human gene encoding prostate-specific antigen (PSA), contaminated with bovine viral diarrhea virus (BVDV).
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29334
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5260
A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2497
NCT: https://clinicaltrials.gov/ct2/show/NCT00015977
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5087
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2236
NCT: https://clinicaltrials.gov/ct2/show/NCT00004211
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5022
A 30-residue prostate specific antigen (PSA) oligoepitope peptide (OP) vaccine with potential antineoplastic activity. PSA-OP peptide vaccine contains the PSA-1 and PSA-3 HLA-A2 epitopes and the PSA-9 HLA-class I-A3 epitope joined by peptide linker sequences. In an animal model, vaccination with this agent has been shown to elicit a cytotoxic T-lymphocyte immune response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29337
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5234
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the prostate-specific tumor associated antigens (TAAs) prostate specific antigen (PSA) and prostate acid phosphatase (PAP), and conjugated to the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, prostate cancer antigen/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against prostate cancer cells expressing PSA and PAP, which may result in prostate cancer cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C92573
NCT: https://clinicaltrials.gov/ct2/show/NCT01171729
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5353
PSA-PAP/KLH-pulsed Autologous Dendritic Cell Vaccine
A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C114289
NCT: https://clinicaltrials.gov/ct2/show/NCT02058680
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5109
A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C123283
NCT: https://clinicaltrials.gov/ct2/show/NCT02514213
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5252
A synthetic peptide based on sequence corresponding to positions 154-163 of the amino acids of prostate-specific antigen (PSA), VISNDVCAQV. Upon administration, PSA:154-163 peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2798
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5106
A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29338
NCT: https://clinicaltrials.gov/ct2/show/NCT00109811
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5155
A peptide-based cancer vaccine containing epitopes of T cell receptor gamma-chain alternate reading frame protein (TARP) and prostate-specific membrane antigen (PSMA) in combination with a Poly IC-LC immunoadjuvant, with potential antineoplastic activity. Upon administration, PSMA/TARP peptide vaccine may stimulate a host cytotoxic T-cell (CTL) response against TARP- and PSMA-expressing tumor cells, resulting in tumor cell cytotoxicity. The nuclear protein TARP and PSMA are commonly expressed in prostate cancer cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C78819
NCT: https://clinicaltrials.gov/ct2/show/NCT00694551
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5052
A cancer vaccine containing plasmid DNA encoding human prostatic acid phosphatase (PAP) (pTVG-HP) with potential immunostimulatory and antineoplastic activities. Upon administration, pTVG-HP plasmid DNA vaccine may stimulate the host immune system to generate a cytotoxic T lymphocyte (CTL) response against PAP-expressing prostate cancer cells. PAP or prostatic specific acid phosphatase (PSAP) is a tumor associated antigen (TAA) that may be overexpressed in prostate cancer.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C82407
NCT: https://clinicaltrials.gov/ct2/show/NCT02499835
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5535
A cancer vaccine containing xenogenic DNA from rhesus macaque (Macaca mulatta) that encodes prostate specific antigen (PSA) with potential immunostimulating and antineoplastic activities. Upon repeated intradermal administration via electroporation, pVAXrcPSAv53l vaccine may induce a cytotoxic T-lymphocyte (CTL) response against PSA-expressing prostate cancer cells. Rhesus PSA is 89% homologous to human PSA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82352
NCT: https://clinicaltrials.gov/ct2/show/NCT00859729
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5092
A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2675
NCT: https://clinicaltrials.gov/ct2/show/NCT00005039
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4988
Recombinant Fowlpox-Prostate Specific Antigen Vaccine
A cancer vaccine consisting of a recombinant fowlpox virus encoding fragment of human prostate-specific antigen (PSA), PSA:154-163 (155L), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38708
NCT: https://clinicaltrials.gov/ct2/show/NCT00108732
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5434
Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding TRICOM. TRICOM is comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3) that may enhance antigen presentation and activate cytotoxic T-cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2667
NCT: https://clinicaltrials.gov/ct2/show/NCT00450619
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5253
A vaccine consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA). Vaccination with recombinant vaccinia prostate-specific antigen vaccine stimulates the host immune system to mount a cytotoxic T-cell response against tumor cells expressing PSA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2433
NCT: https://clinicaltrials.gov/ct2/show/NCT02649439
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5154
A recombinant vaccinia virus encoding prostate-specific antigen (PSA). Vaccination with recombinant vaccinia-PSA may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for PSA, which may decrease tumor growth.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29945
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5302
Recombinant Vaccinia-Prostate Specific Antigen Vaccine
A recombinant vaccinia virus encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) with potential use in cancer immunotherapy.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29563
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5307
Gene name: Prostate-specific membrane antigen
A synthetic fowlpox viral vaccine containing the tumor-associated antigens prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; TRICOM). Vaccination with this viral vaccine may enhance antigen presentation and activate cytotoxic T-cells against PSA- or PSMA-expressing tumor cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29559
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5005
A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38681
NCT: https://clinicaltrials.gov/ct2/show/NCT02772562
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5183
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1985
NCT: https://clinicaltrials.gov/ct2/show/NCT02159950
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5216
A synthetic peptide vaccine, containing 16 amino acid residues (611-626) of the human telomerase reverse transcriptase catalytic subunit (hTERT), with potential antineoplastic activity. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation. Vaccination with tertomotide may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C62756
NCT: https://clinicaltrials.gov/ct2/show/NCT02855892
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5101
A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.
NCT: https://clinicaltrials.gov/ct2/show/NCT01784913
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5478
An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116879
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5397
Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Vaccine
A multipeptide cancer vaccine targeting renal cell carcinoma with potential immunopotentiating activity. Renal cell carcinoma peptides vaccine IMA901 consists of 10 different synthetic tumor-associated peptide (TUMAP) antigens (9 HLA-class I-binding and 1 HLA class II-binding); endogenously, these TUMAPs are expressed by the majority of renal cell carcinomas. Vaccination with this agent may significantly increase host cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing these peptide antigens.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70968
NCT: https://clinicaltrials.gov/ct2/show/NCT00523159
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5013
Renal Cell Carcinoma Peptides Vaccine IMA901
A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C129522
NCT: https://clinicaltrials.gov/ct2/show/NCT02170389
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5373
Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
Peripheral blood lymphocytes (PBL) harvested from the blood of a renal cancer patient and exposed in vitro to renal tumor-associated antigens (TAA). Introducing these renal tumor-reactive autologous peripheral blood lymphocytes back to the same patient target tumor cells expressing these TAAs and could induce a cytotoxic T-cell-mediated immune response against renal cell cancer.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48816
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5196
Renal Tumor-Reactive Autologous Peripheral Blood Lymphocyte Vaccine
A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5097
A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift mutation. As a cancer vaccine, VHL-59: 116-128(FrSh116-128) peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38123
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5172
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein; the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2741
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5012
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I, is a point mutation variant of the VHL tumor suppressor protein; the mutation is in amino acid position 111. Vaccination with this agent may stimulate a cytotoxic T-cell response in patients with VHL-associated cancers that express this variant of the VHL tumor suppressor protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2740
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5333
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2824
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5490
A cancer vaccine composed of peptides derived from a tumor-associated protein encoded by a mutated Von Hippel-Lindau (VHL) oncogene. VHL peptide vaccine may stimulate a cytotoxic T cell response against tumor cells expressing the VHL tumor-associated protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2492
NCT: https://clinicaltrials.gov/ct2/show/NCT00001703
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5127
A synthetic peptide vaccine based on the sequences of a translocation mutation of 2 transcriptional factor genes, PAX3 and FKHR. PAX3/FKHR fusion proteins are frequently found in patients with rhabdomyosarcomas. Vaccination with PAX3/FKHR peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this PAX3/FKHR fusion protein.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49023
NCT: https://clinicaltrials.gov/ct2/show/NCT00001564
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5484
A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a constitutively active form of the AKT Gene. The viral vector RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29908
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5044
A recombinant retroviral virus derived from SR-A strain of Rous sarcoma virus carrying a human gene encoding the G12D mutant form of K-Ras. The viral vector, RCAS harbors a Replication Competent ALV Splice acceptor. This recombinant virus was use in animal model to study gliomagenesis.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29910
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5500
A recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT). Telomerase expression has been directly linked to tumor development; its catalytic subunit is expressed in the majority of human cancer cells, but infrequently in normal cells. Vaccination with telomerase:540-548 peptide may stimulate cytotoxic T cells to recognize and kill telomerase-expressing cells.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2640
NCT: https://clinicaltrials.gov/ct2/show/NCT00069940
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5098
A cancer vaccine that may stimulate an immune response against 4 different melanoma associated antigens. This may lead to a reduction in tumor cell proliferation of cancer cells expressing these antigens. The vaccine may contain 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a helper tetanus peptide. The peptides may include Melan-A, gp100, MAGE-3, and NA17. The vaccine can be used in combination Ontak, which may produce an immune response in patients with metastatic melanoma, and the Ontak may improve these immune responses and lead to tumor shrinkage.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91722
NCT: https://clinicaltrials.gov/study/NCT00515528
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6370
To obtain SOCS1-silenced DCs, DCs derived from mouse bone marrow cells ex vivo were induced to differentiation in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4, and then transduced with Len-SOCS1-shRNA or control Len-GFP lentiviruses. The SOCS1-silenced DCs were loaded by TRP2 peptide to prepare the DC vaccine, which was induced to mature by LPS. The DCs were analyzed by flow cytometry (FCM) for surface expressions of MHCII and CD86 and by real-time PCR for the expressions of SOCS1, IL-10 as well as IL-12p40. B16 or IL-10-silenced B16 (IL-10(-/-);) cells were inoculated into C57BL/6 mice.
1(SOCS1)-silenced dendritic cell (DC) Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4071
1(SOCS1)-silenced dendritic cell vaccine
A fragment of fibroblast growth factor-5 (FGF-5). Originally isolated from a renal cell carcinoma cell line that overexpressed FGF-5, FGF-5:117-126 peptide is recognized by tumor infiltrating cytotoxic T lymphocytes. Overexpressed by several cancer cell types, this peptide is being tested as a potential target for antineoplastic immunotherapies. (NCI04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5414
Melonoma vaccine that uses 12 class I major histocompatibility complex-restricted melanoma peptides (12MP) from cancer-testis antigens (CTAs) and melanocytic differentiation proteins (MDPs).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3978
4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12 MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6 MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6 MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4070
12MP, 12MP/Tet, 12MP/6MHP, or 6MHP vaccine
A synthetic peptide consisting of amino acids 27 through 35 of the melanoma differentiation antigen MART-1. 27-35(27L) MART-1 has a leucine substitution at amino acid position 27 to improve binding to HLA-A*0201. Vaccination with this agent may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against melanoma cells expressing MART-1.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5290
A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4986
A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity. With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5244
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5543
A cancer vaccine consisting of a recombinant adenoviral vector encoding the tumor-associated antigen (TAA) human MUC-1 (hMUC-1) linked to the extracellular domain (ecd) of the co-stimulatory molecule CD40 ligand (CD40L) and an adenovirus signal sequence that encodes a secretory signal peptide (Ad-sig) with potential immunostimulating and antineoplastic activities. Due to the presence of the secretory signal peptide expressed by Ad-sig in the vaccine construct, transfected cells may secrete a fusion protein composed of hMUC-1 and the CD40L ecd. The CD40L moiety part of the fusion protein binds to CD40 receptors on dendritic cells (DCs). Subsequently, DCs may be activated and migrate, T-cells may expand, and a cytotoxic T lymphocyte (CTL) response against tumor cells that overexpress hMUC-1 may follow. MUC-1 is a hypoglycosylated TAA overexpressed by epithelial cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5179
obsolete Ad5-yCD/mutTKSR39rep-hIL12 Vaccine
A nonreplicating adenoviral vector (adenovector) encoding the melanoma differentiation-associated 7 gene (MDA7) with potential antineoplastic activity. After intratumoral injection and adenovector-mediated gene transfer of MDA7 into tumor cells, the expressed MDA7 transgene may inhibit tumor cell proliferation and induce tumor cell apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5523
A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4999
Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201
A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5137
An adenovirus vector engineered to produce CD40 ligand. For use as a possible gene therapy agent. May induce apoptosis through the TNF pathway.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5529
Fibroblast growth factor-2-retargeted adenoviral vectors may be used to increase the transduction of GBM-derived endothelial cells, enabling a new and efficient antiangiogenesis strategy for the treatment of malignant gliomas.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5489
Adenovirus 5-Fibroblast Growth Factor 2 Vaccine
A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.
NCT: https://clinicaltrials.gov/ct2/show/NCT04111172
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5147
Adenovirus 5-Human Guanylyl Cyclase C-PADRE vaccine
A gene-viral vector complex comprised of an adenovirus vector and B7-1 gene targeting the CD80 antigen. Adenovirus B7-1 is used as a component in antineoplastic vaccines to elicit a cytotoxic T-cell response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5435
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding HER-2/neu.
NCT: https://clinicaltrials.gov/ct2/show/NCT00307229
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5388
Adenovirus Encoding Rat HER-2/neu Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5370
Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus HER2-transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers.
NCT: https://clinicaltrials.gov/ct2/show/NCT00197522
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5082
Adenovirus HER2-Transduced Autologous Dendritic Cell Vaccine
A gene viral vector complex comprised of a replication-defective adenovirus and a herpes simplex virus thymidine kinase gene that activates ganciclovir, causing inhibition of DNA synthesis and apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5122
A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5285
Gene name: Prostate-specific membrane antigen gene engineering
Adenovirus-mediated Human Interleukin-12 Vaccine
A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant adenovirus encoding p53 peptide, with potential immunomodulating activity. Intradermal vaccination with adenoviral-p53 transduced dendritic cell vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5256
Adenovirus-p53 transduced dendritic cell vaccine
A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5010
A cell-based vaccine comprised of prostate cancer cells transduced with an adenoviral vector encoding human RTVP-1 (AdRTVP-1), with potential antineoplastic and immunostimulating activities. RTVP-1, also referred to as glioma pathogenesis-related protein 1 (GLIP1), is down-regulated in prostate tumors. Regulated by tumor suppressor p53, the expression of RTVP-1 functions as a tumor suppressor, and is abundant in normal human prostate epithelial cells as well as in differentiated macrophages. Administration of this vaccine leads to an induction of apoptosis through the expression of RTVP-1 and results in a reduction in cellular proliferation in prostate cancer cells. In addition, this cancer-cell based vaccine may induce a cytotoxic T lymphocyte (CTL) response against prostate specific tumor associated antigens, resulting in an immune-mediated prostate cancer cell death. Furthermore, RTVP-1 stimulates CTL and natural killer (NK) cell activities.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5203
AdRTVP-1-Transduced Prostate Cancer Cell-Based Vaccine
A vaccine containing HER2/Neu-derived epitope (amino acids 776-790) linked to li-Key peptide (li-Key/HER2/neu hybrid peptide or AE37), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activities. Upon vaccination, AE37 may activate the immune system and stimulate T-helper cells against HER2/Neu expressing cancer cells. GM-CSF may potentiate the immune response against cancer cells expressing the HER2/Neu antigen. The Ii-Key moiety, a 4-amino acid (LRMK) epitope from the MHC class II-associated invariant chain (Ii protein), increases T-helper cell stimulation against HER2/neu antigen when compared to unmodified class II epitopes. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5436
A cancer vaccine composed of naked plasmid DNA of the gene for the tumor-associated antigen alpha-fetoprotein (AFP), a macromolecule that acts as a specific immunologic target for hepatocellular carcinoma. This agent exerts an antitumor effect by inducing cytotoxic T-lymphocytes to attack AFP-expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5275
AFP Gene Hepatocellular Carcinoma Vaccine
A cancer vaccine made of a recombinant NY-ESO-1 protein with a TLR7 agonist
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3991
A cancer vaccine containing the three frame shift peptides (FSP) AIM2(-1), HT001(-1) and TAF1B(-1), with potential immunomodulating activity. Upon administration, the AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine may induce an immune response against microsatellite instability (MSI) colorectal cancer-associated antigens. Frame shift mutations of AIM2 (absent in melanoma 2, an interferon-inducible protein), HT001 (asteroid homolog 1 or ASTE1, with an unknown function) and TAF1B (TATA box-binding protein-associated RNA polymerase I B, a transcription factor) are seen in MSI-positive colorectal cancers and may be associated with malignant transformation, tumor progression and the presence of tumor-infiltrating lymphocytes. These FSPs all have one-base deletions.
NCT: https://clinicaltrials.gov/ct2/show/NCT01461148
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5402
AIM2(-1)/HT001(-1)/TAF1B(-1) Frameshift Peptide Vaccine
A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with potential antitumor activity. Vaccination is associated with the expression of murine alpha-1,3-galactosyl (alpha-gal) carbohydrate residues on cell membrane glycoproteins and glycolipids of the vaccine pancreatic cancer cell allograft; murine alpha-gal epitopes, not present on human cells, then induce a hyperacute rejection of the vaccine pancreatic cancer cell allograft. The hyperacute rejection involves the binding of pre-existing human anti-alpha-gal antibodies (which naturally occur against gut flora) to murine alpha-gal epitopes, resulting in the rapid activation of antibody-dependent cell-mediated cytotoxicity (ADCC) towards allograft cells. The host immune system then attacks endogenous pancreatic cancer cells, resulting in ADCC towards endogenous pancreatic cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5422
A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5020
Allogeneic AML Antigen-expressing Dendritic Cell Vaccine
An allogeneic whole cell vaccine, derived from irradiated allogenic tumor cells manipulated to express human B7.1 (CD80 antigen) and human leukocyte antigen (HLA) A1, with potential antitumor activity. Vaccination with allogeneic B7.1/HLA-A1 transfected tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4998
Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine
A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5257
A cancer vaccine consisting of allogeneic, immortalized dendritic cells (DCs) loaded with tumor specific antigens and activated, with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration of the allogeneic dendritic cell vaccine COMBIG-DC, these activated DCs attract natural killer (NK) cells, induce an anti-inflammatory response leading to the induction of NK-cell-mediated tumor cell death. Upon release of tumor associated antigens (TAAs) from the lysed tumor cells, these antigens are taken up by antigen presenting cells which activate the immune system to elicit a potent cytotoxic T-cell (CTL) response against the TAAs, resulting in the death of TAAs-expressing tumor cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT01525017
NCT: https://clinicaltrials.gov/ct2/show/NCT01974661
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5446
allogeneic dendritic cell vaccine COMBIG-DC
A cell-based vaccine composed of allogeneic dendritic cells pulsed ex-vivo with an autologous myeloma idiotype with potential antineoplastic activity. Upon administration, allogeneic dendritic cell-myeloma idiotype vaccine may stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against myeloma cells, resulting in cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5102
Allogeneic Dendritic Cell-Myeloma Idiotype Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5023
Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine
An allogeneic tumor cell vaccine containing myeloma cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Upon vaccination, allogeneic GM-CSF-based myeloma cellular vaccine secretes GM-CSF, which may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against myeloma cancer cell-associated antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5327
Allogeneic GM-CSF-Based Myeloma Cell Vaccine
An allogenic vaccine consisting of irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene. Upon vaccination, the genetically modified cells secrete GM-CSF, thereby potentiating a tumor-specific T cell response against breast cancer cell-asociated antigens.A vaccine that is being studied as a way to help the body's immune system kill breast cancer cells. To make the vaccine, the GM-CSF gene is put into breast cancer cells in the laboratory. The cells are then treated with radiation to stop them from growing and injected into the same or a different patient. The GM-CSF protein made by the changed breast cancer cells may help the immune system kill breast cancer cells in the body.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5059
Allogeneic GM-CSF-Secreting Breast Cancer Vaccine
An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.
NCT: https://clinicaltrials.gov/ct2/show/NCT01088789
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5075
Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo
An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5515
Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo
A cancer vaccine, containing human-specific large multivalent immunogens (LMIs) isolated from the membrane fraction of cells from a breast cancer cell line, with potential immunostimulatory and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen breast cancer vaccine may stimulate a cytotoxic T lymphocyte (CTL) immune response against tumor cells that express the breast cancer cell-specific LMIs.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5269
Allogeneic Large Multivalent Immunogen Breast Cancer Vaccine
A cancer vaccine, containing human-specific large multivalent immunogen (LMI) isolated from plasma membrane fractions of the melanoma cell lines MSM-M1 and MSM-M2, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic large multivalent immunogen melanoma vaccine LP2307 may stimulate a CD8+ cytotoxic T lymphocyte (CTL) response against melanoma tumor cells that express melanoma-specific LMI.
NCT: https://clinicaltrials.gov/ct2/show/NCT00726739
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5423
Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307
A cancer vaccine derived from two gentically modified human melanoma cell lines with potential antineoplastic activity. Allogeneic melanoma vaccine AGI-101H consists of a 1:1 mixture of cells from two genetically modified human melanoma cell lines, designated as Mich1H6 and Mich2H6, that have been gamma-irradiated to render the cells non-proliferative. Upon administration, this vaccine may stimulate a cytotoxic immune response against melanoma tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5376
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5440
Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine
A biologic product that consists of undifferentiated stem cells, obtained from adult bone marrow or other non-embryonic tissue sources, that are expanded in vitro and deposited in master cell banks for ""off-the-shelf"" use, with potential hematopoiesis-inducing and immunomodulating activities. Allogeneic multipotent adult progenitor cells (MAPCs) are non-immunogenic due to the lack of major histocompatibility (MHC) molecule expression, and so elicit no immune response upon administration. In vivo, bone marrow-derived adult stem cells are capable of maturing into a broad range of cell types and may help restore the immune system by producing multiple therapeutic molecules in response to inflammation and tissue damage.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5054
allogeneic multipotent adult progenitor cells vaccine
A whole cell vaccine comprised of irradiated allogeneic renal cell carcinoma (RCC) with potential immunostimulating and antineoplastic activities. Allogeneic renal cell carcinoma vaccine MGN1601 contains two active ingredients: 1) genetically modified allogeneic RCC cells that are transiently transfected with four different MIDGE (Minimalistic Immunogenically Defined Gene Expression) vectors encoding IL-7, GM-CSF, CD80 and CD154 and 2) the synthetic DNA-based immunomodulator dSLIM-30L1, a TLR9 agonist.. Vaccination results in expression of IL-7, GM-CSF, CD80 and CD154, which all contribute to the activation or enhancement of immune responses. Furthermore, administration of this RCC vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5358
Allogeneic Renal Cell Carcinoma Vaccine MGN1601
A vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient to stimulate cytotoxic immune responses to a similar tumor cell type. The cells found in this type of whole-cell vaccine express many cell-surface tumor-associated antigens. This vaccine is frequently administered with an adjuvant immunostimulant.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5339
A vaccine composed of killed glioma cancer cells from another patient for use in immunotherapy
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5119
A vaccine consisting of a recombinant adenoviral vector encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5313
Alpha Fetoprotein Adenoviral Vector Vaccine
An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5349
Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine
A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with four alpha-fetoprotein (AFP) peptides, with potential immunostimulatory and antineoplastic activities. Upon administration, AFP peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against AFP-expressing cancer cells, resulting in tumor cell lysis. AFP is overexpressed in a variety of cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5315
Alpha-fetoprotein Peptide-Pulsed Autologous Dendritic Cell Vaccine
A cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with the marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) with potential immunostimulatory and antimetastatic activities. Upon administration, alpha-galactosylceramide-pulsed autologous dendritic cells may result in the activation and proliferation of a subset of endogenous natural killer T (NKT) cells, B cells, and CD4+ and CD8+ T cells, and the production of interferon-gamma and interleukin-12; these cascade events may result in a T helper-1 cell-biased proinflammatory antitumor immune response. The NKT cell ligand alpha-GalCer was originally isolated from the marine sponge Agelas mauritianusis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5288
Alpha-Galactosylceramide-Pulsed Autologous Dendritic Cell Vaccine
A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the ""gold standard"" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5198
Alpha-type-1 polarized dendritic cell vaccine
A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate. Thus, it produces a self-limiting infection which does not produce symptoms or harm the host. When carrying foreign genes it will cause transient expression of protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5334
A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus. ALVAC-B7-CEA expresses carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cells, and B7.1 (also known as CD80), the natural ligand for the T-cell antigen CD28, to augment the host immune response. This agent has been shown to stimulate a host immune response against tumor cells that express CEA. (NCI04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5444
A replication-defective recombinant canarypox virus (ALVAC) that contains the entire human carcinoembryonic antigen (CEA) gene. Vaccination with ALVAC-CEA (VCP248) may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against CEA-positive tumor cells, thereby decreasing tumor growth. (NCI04)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5003
A cancer vaccine that uses a viral vector system derived from the canarypox virus engineered to target the carcinoembryonic antigen (CEA). It causes infected cells to temporarily display CEA and activates the immune system to attack the tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5125
A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5051
A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT01982487
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5332
A vaccine comprise of a canarypox viral vector that carries the gene for human B7.1 (CD80 antigen) with potential use as an autologous therapeutic cancer vaccine. Tumor cells harvested from a patient are infected with ALVAC-hB7 1, thereby producing an autologous cell line that exhibits increased expression of HLA class I and class II, CD54 (ICAM), and CD80. Increased expression of these proteins by this autologous cell line may activate an antitumor T-cell response when the modified cells are administered to the patient.
NCT: https://clinicaltrials.gov/ct2/show/NCT00003556
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5181
A cancer vaccine containing a replication-defective recombinant canarypox virus (ALVAC), encoding an epitope of MART-1 (melanoma antigen recognized by T-cells), with potential immunostimulatory and antineoplastic activities. Upon administration, the MART-1 epitope is expressed by the ALVAC vector in ALVAC-MART-1 vaccine; a host cytotoxic T lymphocyte (CTL) response against MART-1-expressing tumor cells may follow, resulting in tumor cell lysis and decreased tumor cell proliferation
NCT: https://clinicaltrials.gov/ct2/show/NCT00612222
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5124
A cancer vaccine used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2.
NCT: https://clinicaltrials.gov/study/NCT01898039
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6260
A therapeutic cancer vaccine, based on a replication-defective recombinant canarypox virus (ALVAC) encoding multiple melanoma antigens, with potential immunostimulatory and antineoplastic activities. Vaccination with ALVAC(2) melanoma multi-antigen therapeutic vaccine may stimulate the host immune system to mount an immune response against antigen-expressing melanoma cells, resulting in inhibition of tumor growth and/or metastasis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5394
A cancer vaccine consisting of a replication-defective recombinant canarypox virus [ALVAC(2)] encoding the cancer-testis antigen NY-ESO and the TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3; also called TRICOM), with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC(2)/NY-ESO (M)/TRICOM vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells, including bladder, breast, hepatocellular, melanoma, and prostate tumor cells. TRICOM may enhance antigen presentation and activate cytotoxic T-cells. In addition, ALVAC(2) encodes the vaccinia virus (vv) E3L ad K3L genes, which may potentiate the translation of the NY-ESO and TRICOM genes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5268
A cancer vaccine consisting of autologous dendritic cells loaded with separate preparations of acute myelogenous leukemia (AML) cell lysate and AML-specific messenger RNA (mRNA) with potential immunostimulatory and antineoplastic activities. Upon administration, AML mRNA plus lysate loaded autologous dendritic cell vaccine may elicit a potent cytotoxic T-cell (CTL) response against AML cells, resulting in tumor cell death. Autologous dendritic cells doubly-loaded with AML cell lysate and AML-specific mRNA may elicit superior primary, recall, and effector lytic immune responses compared to autologous dendritic cells loaded with tumor lysate or tumor mRNA alone.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5533
AML mRNA Positive Lysate Loaded Autologous Dendritic Cell Vaccine
A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5243
A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5331
Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118
A modified vaccinia Ankara (MVA) encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3994
Recombinant MVA-gp100M and ALVAC(2)-5T4 were constructed to complement existing ALVAC(2)-gp100M and MVA-5T4 vectors. Recombinant TAA expression in chicken embryo fibroblast cells was confirmed by Western blot analysis. 5T4 expression was approximately equal for both viruses, whereas ALVAC-derived gp100 was quickly degraded, at a time point when MVA-derived gp100 was still stable and expressed at high levels
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4073
An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5199
Anti-CD19/CD3 Tetravalent Antibody AFM11 Vaccine
Autologous activated T cells that have been coated with bispecific antibodies (BiAb), with potential antineoplastic and immunomodulating activities. In vitro, T cells are activated through exposure to the anti-CD3 murine monoclonal antibody OKT3 and low-dose interleukin 2 (Il-2) for 6-14 days and then armed with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi). Upon administration, anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells (AATC) attach to CD3-expressing T cells and CD20-expressing tumor cells, selectively cross-linking T cells and tumor cells. This may result in the recruitment and activation of cytotoxic T lymphocyte (CTLs), CTL-mediated specific tumor cell lysis, and the secretion of antitumor cytokines and chemokines. CD20, a cell surface phosphoprotein, is found on normal B cells and most B-cell tumors.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5411
Anti-CD3 x Anti-CD20 Bispecific Antibody-Armed Activated T Cells Cancer Vaccine
Autologous human peripheral blood lymphocytes (PBLs), transduced with a retroviral vector encoding both the alpha and beta chains of a T cell receptor (TCR) specific for the carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, anti-CEA TCR retroviral vector-transduced autologous lymphocytes bind to tumor cells expressing CEA, which may result in cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. The tumor-associated antigen (TAA) CEA is overexpressed by a variety of cancer cell types, including those of the gastrointestinal tract, lung, and breast.
Anti-CEA TCR Retroviral Vector-Transduced Autologous Peripheral Blood Lymphocytes
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5536
anti-CEA TCR retroviral vector-transduced autologous peripheral blood lymphocyte vaccine
An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5375
anti-CTLA4 MoAb RNA-transfected autologous dendritic cell vaccine
An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. Anti-CTLA4 MoAb RNA/GITRL RNA-transfected DC vaccine is prepared by transfecting DCs with RNAs encoding humanized heavy and light chains of the anti-CTLA4 (cytotoxic T-Lymphocyte-Associated Antigen 4) monoclonal antibody and tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of anti-CTLA4 blocks the inhibitory effect of CTLA4 on the activation of T-lymphocytes, while expression of GlTRL modulates T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5149
anti-CTLA4 MoAb RNA/GITRL RNA-transfected autologous dendritic cell vaccine
A peptide vaccine derived from the synthetic peptide pyroEHWSYGLRPG, corresponding to amino acids 22-31 of mouse gonadotropin releasing hormone (GnRH), with potential immunocastration activity. PEP223 is dimerized and contains a D-lysine (k) substitution at position 6 (pyroEHWSYkLRPG) to increase its immunogenicity. Anti-GnRH vaccine PEP223 may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GnRH, neutralizing its activity. In turn, testosterone production and tumor cell growth may be inhibited in testosterone-sensitive tumors.
NCT: https://clinicaltrials.gov/ct2/show/NCT00895466
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5405
A monoclonal antibody that functionally mimics MUC-1 antigen, a tumor cell surface antigen. Administration of anti-idiotype MUC-1 monoclonal antibody may elicit an anti-idiotype antibody and corresponding T-cell response against MUC-1 expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5175
anti-idiotype MUC-1 monoclonal antibody vaccine
A synthetic antibody produced by a genetically homogenous population of hybrid cells (hybridoma) against determinant idiotypes (Id) which usually mimic human epitopes. Anti-Id vaccines may be effective in the treatment of B-cell lymphomas, resulting in tumor regression. Anti-idiotype vaccine therapy is less likely to induce autoimmunity if the target antigen is not normally expressed on normal tissues. Monoclonal antibodies have become powerful tools for tumor targeting, recognizing different protein markers on certain cancer cells and may be used alone or as delivery agents for drugs, toxins or radioactive material targeted to tumors.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5301
anti-Idiotype specified monoclonal antibody vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4015
A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that is directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating an immune response to produce Ab3 that may be used in combination with other adjuvants for treatment of melanomas.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5433
anti-idiotypic monoclonal antibody BEC2 vaccine
An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5485
anti-NY-ESO-1 Immunotherapeutic GSK-2241658A vaccine
Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5081
anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes vaccine
Human autologous peripheral blood lymphocytes (PBLs) transduced with an anti-p53 T cell receptor gene with potential antineoplastic activity. PBLs are harvested from a patient and pulsed with a retroviral vector that encodes the T-cell receptor gene specific for a mutated form of p53. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these modified PBLs express the anti-p53 T cell receptor which binds to mutant p53-overexpressing tumor cells; PBL-mediated tumor growth inhibition may follow. Many tumor cell types overexpress mutant p53 proteins, which are associated with the loss of apoptosis regulation and abnormal cell proliferation.
NCT: https://clinicaltrials.gov/ct2/show/NCT00393029
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5447
anti-p53 T-Cell Receptor-Transduced peripheral blood lymphocytes vaccine
An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.
NCT: https://clinicaltrials.gov/ct2/show/NCT01853878
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5361
anti-PRAME Immunotherapeutic GSK2302032A Vaccine
An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (""off the shelf"") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5138
antigen-targeted Personalized Breast Cancer Vaccine
A cell-based vaccine composed of previously frozen autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP.
NCT: https://clinicaltrials.gov/ct2/show/NCT01133704
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5420
A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5222
Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells Vaccine
A cancer vaccine that uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer.
NCT: https://clinicaltrials.gov/study/NCT01174082
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6261
adenovirus-transfected autologous dc vaccine plus cik cells
A vaccine comprised of autologous epithelial ovarian cells infected with ALVAC-hB7.1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5319
An autologous tumor cell vaccine containing chronic lymphocytic leukemia (CLL) B cells transduced with an adenoviral vector carrying chimeric CD154 (ad-CD154) with potential antineoplastic activity. Administration of autologous ad-CD154 transduced CLL B cells may result in increases in the numbers of leukemia-specific CD4+ T cells and high serum-levels of IL-12 and IFN-gamma. Due to ligation of CD154 to CD40 on CLL cells, this agent may induce CLL cells to express the proapoptotic molecule BID and death receptors CD95 (Fas) and DR5, rendering CLL B cells first resistant and then sensitive to Fas-mediated apoptosis. In addition, autologous ad-CD154 transduced CLL B cells may induce MHC class I-dependent cytotoxic T lymphocyte (CTL) responses against autologous leukemia cells. CD154 is a type II membrane glycoprotein and ligand for CD40; both molecules are important in cognate co-stimulatory cell-cell interactions.
NCT: https://clinicaltrials.gov/ct2/show/NCT00779883
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5053
Autologous Ad-CD154-Transduced CLL B Cells Vaccine
Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues 154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas.
NCT: https://clinicaltrials.gov/ct2/show/NCT00509496
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5507
autologous anti-gp100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes vaccine
Human autologous peripheral blood lymphocytes (PBLs) transduced with a melanoma antigen MART-1 epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector that encodes the TCR specific for an epitope of MART-1 (F5 TCR). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient, and bind to melanoma cells expressing the MART-1 antigen, which may result in specific cytotoxic T-lymphocyte (CTL) killing of MART-1-expressing melanoma cells. MART-1 (melanoma antigen recognized by T cells 1), also known as Melan-A, is a melanocyte lineage-specific transmembrane protein.
NCT: https://clinicaltrials.gov/ct2/show/NCT00509288
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5293
autologous anti-mart-1 f5 T-cell receptor gene-engineered peripheral blood lymphocytes vaccine
A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with CD133-positive autologous brain tumor stem cells (BTSCs) -derived mRNA with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous CD133-positive BTSC mRNA-pulsed autologous dendritic cell vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against the CD133-positive BTSCs from which the autologous tumor mRNA is derived. CD133, a tumor-associated antigen (TAA) and neural stem cell marker, has been found on a specific subset of glioblastoma multiforme (GBM) stem cells; its presence has been correlated with resistance to conventional chemotherapy and radiotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5463
Autologous CD133-Positive BTSC mRNA-Pulsed Autologous Dendritic Cell Vaccine
A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5174
Autologous CD40L-expressing B-CLL Vaccine
A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5150
Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine
An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma.
NCT: https://clinicaltrials.gov/ct2/show/NCT01995708
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5128
Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3967
A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.
NCT: https://clinicaltrials.gov/ct2/show/NCT02649829
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5085
Autologous Dendritic Cell Vaccine ACT2001
A cancer vaccine comprised of autologous dendritic cells (DCs) that have been transduced ex vivo with an adenoviral vector containing the CCL21 gene with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, autologous dendritic cell-adenovirus CCL21 vaccine expresses the chemokine CCL21, which may induce an antitumoral cytotoxic immune response in the tumor microenvironment. CCL21 [chemokine (C-C motif) ligand 21] has been shown to attract antigen presenting cells (APCs), like leukocytes and DCs, and natural killer (NK) cells and their T-cell effectors to induce a cytotoxic immune response.
NCT: https://clinicaltrials.gov/ct2/show/NCT03546361
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5030
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine
An autologous vaccine composed of dendritic cells (DC) that have been transduced with a p53 tumor suppressor gene-modified virus. When the autologous dendritic cell-adenovirus p53 vaccine is administered, the host cytotoxic T lymphocytes (CTL) are directed against p53-positive tumor cells, which may result in tumor cell death and decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5088
autologous dendritic cell-Adenovirus P53 vaccine
A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5495
autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
cancer vaccine consisting of autologous dendritic cells transfected with autologous tumor mRNA and the human CD40 ligand (CD40L) gene with immunostimulatory and antitumor activities. Vaccination with autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine may elicit a cytotoxic T cell response against tumor cells from which the autologous tumor mRNA was derived. When expressed by dendritic cells, tumor antigens and the co-stimulatory molecule CD40L, which binds to CD40 receptors on antigen presenting cells (APC), facilitate both humoral and cellular immune responses against tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5066
Autologous Dendritic Cell-Autologous Tumor mRNA-Human CD40L Vaccine
A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of autologous DC-based immunotherapeutic AV0113, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5284
Autologous Dendritic Cell-based Immunotherapeutic AV0113 Vaccine
A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5056
Autologous Dendritic Cell-Tumor Fusion Vaccine
A vaccine consisting of autologous cancer cells modified with the hapten, Dinitrophenyl. The treatment program consists of multiple intradermal injections of irradiated DNP-modified autologous tumor cells mixed with bacillus Calmette-Guerin.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5537
A cancer vaccine consisting of autologous ovarian cancer cell peptide antigens conjugated to the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of autologous dinitrophenyl-modified ovarian cancer vaccine may induce a cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5459
Autologous Dinitrophenyl-Modified Ovarian Cancer Vaccine
A cell-based vaccine composed of autologous tumor cells with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5118
Autologous EBV-Transformed B Lymphoblastoid-Tumor Fusion Cell Vaccine
A cell-based vaccine composed of autologous tumor cells fused with Epstein-Barr virus-transformed B-lymphoblastoid cells. Upon administration, this vaccine may stimulate a cytotoxic T cell response against tumor cells, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5225
Autologous Epstein-Barr Virus-Transformed B-Lymphoblastoid Cell Vaccine
Multipotent self-renewing adherent non-hematopoietic stromal cells harvested from a patient's bone marrow and grown in vitro. When injected back into the patient, autologous expanded mesenchymal stem cells OTI-010 may differentiate into various mesenchyme-derived cell types and, in some instances, may augment bone marrow engraftment after whole-body irradiation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5491
Autologous Expanded Mesenchymal Stem Cells OTI-010 Vaccine
An autologous tumor cell vaccine containing irradiated breast cancer cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Autologous breast cancer cells are transduced ex vivo with an adenovirus vector encoding the GM-CSF gene and irradiated and then reintroduced into the patient. Upon repeated subcutaneous administration of the vaccine, autologous GM-CSF-secreting breast cancer cells secrete GM-CSF, which may stimulate a tumor-specific cytotoxic T-lymphocyte (CTL) response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5250
Autologous GM-CSF-Secreting Breast Cancer Vaccine
A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5188
Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine
An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5240
Autologous GM-CSF-Secreting Lethally Irradiated Leukemia Cell Vaccine
A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5266
Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858
A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus.
NCT: https://clinicaltrials.gov/ct2/show/NCT02211027
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5043
autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine
A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT00458679
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5228
Autologous IL-2-expressing B-CLL Vaccine
A cancer vaccine composed of tumor-specific idiotype determinants derived from an individual's tumor cells which are conjugated to keyhole limpet hemocyanin, an immunostimulant carrier protein. When injected into the individual from whom the tumor cells were isolated, this vaccine may stimulate an antitumoral cytotoxic T-lymphocytic immune response.
NCT: https://clinicaltrials.gov/ct2/show/NCT00104819
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5057
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous lymphoma cells with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, autologous lymphoma cell lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against lymphoma cells, which may result in lymphoma cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5248
Autologous Lymphoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine
A cell-based cancer vaccine consisting of hybrid cells created by electrofusing allogeneic dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5503
Autologous Lymphoma Cell/Allogeneic Dendritic Cell Electrofusion Hybrid Vaccine
A cell-based cancer vaccine consisting of hybrid cells created by electrofusing autologous dendritic cells (DCs) and autologous lymphoma cells with potential immunostimulating and antitumor activities. Upon administration, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine may stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against specific autologous lymphoma-associated antigens, resulting in lymphoma cell apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5431
Autologous Lymphoma Cell/Autologous Dendritic Cell Electrofusion Hybrid Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5148
autologous melanoma lysate-pulsed autologous dendritic cell vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and conjugated to the immunostimulant Keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against melanoma cells, which may result in melanoma cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses and can be used to evaluate vaccine efficacy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5213
autologous melanoma Lysate/KLH-pulsed autologous dendritic cell vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5158
autologous melanoma Lysate/NY-ESO-1-pulsed autologous dendritic cell vaccine
A vaccine consisting of irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous non-small cell lung cancer (NSCLC)-derived DNA with potential immunostimulatory and antineoplastic activities. Upon administration, autologous NSCLC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses NSCLC tumor-associated antigens (TAAs) in addition to MHC class I-determinants and the co-stimulatory molecule B7.1, which may induce a cytotoxic T-lymphocyte (CTL) response against NSCLC cells. The MRC-5 cell line is a human diploid lung fibroblast cell line extablished in 1966.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5377
Autologous NSCLC DNA-Transfected Semi-Allogeneic Fibroblasts MRC-5 Vaccine
A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5311
Autologous NSCLC Peptide-specific Dendritic Cell Vaccine
A cancer vaccine consisting of autologous, mature monocyte-derived dendritic cells (DCs) transfected with oncofetal antigen immature laminin receptor protein (OFA-iLRP) RNA, with potential antineoplastic activity. Upon administration, DCs in the OFA-iLRP RNA-transfected autologous dendritic cell vaccine express, process, and present OFA-iLRP to the host immune system, which may mount a potent cytotoxic T-cell (CTL) response against OFA-iLRP-expressing tumor cells. As a highly conserved protein, OFA-iLRP is preferentially expressed in fetal tissues and in many types of cancer, including hematopoietic malignancies, but is not detectable in normal differentiated adult cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT00715832
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5368
Autologous OFA-iLRP RNA-Transfected Dendritic Cell Vaccine
A cell-based cancer vaccine composed of autologous, irradiated dendritic cells (DCs) pulsed with ovarian tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian tumor cells expressing the patients ovarian tumor cell-specific TAAs, which may result in ovarian tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5427
Autologous Ovarian Tumor Cell Lysate-Pulsed Dendritic Cell Vaccine
A specific population of autologous, pluripotent bone marrow derived cells that express high levels of the cytosolic enzyme aldehyde dehydrogenase (ALDH) with potential protective and neuro-cognition improving activity. Expression of high levels of ALDH is an indicator of the biological activity in heterogenous early stage stem cells. Upon intravenous administration, these ALDH bright cells may protect normal cells and may repair damaged cells. These cells may also protect brain cells from damage and may improve neurocognition.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5220
Autologous Pluripotent ALDHbr Stem Cells ALD-451 Vaccine
A genetically-modified autologous dendritic cell-based vaccine expressing a drug-inducible costimulatory CD40 receptor (iCD40) with potential immunomodulating and antineoplastic activities. Autologous dendritic cells (DCs) are genetically modified to express the iCD40 receptor and are pulsed with the tumor antigen prostate-specific membrane antigen (PSMA). Upon intradermal administration, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizer agent AP1903 is administered; AP1903 binds to and activates iCD40 receptors presented on DC surfaces, thus activating the DCs and stimulating a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. This delayed activation strategy optimizes DC accumulation in local draining lymph nodes prior to DC activation. iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to a drug-binding domain.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5282
Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with renal cell carcinoma (RCC) tumor cell lysate containing tumor associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, autologous renal cell carcinoma tumor lysate-dendritic cell vaccine may stimulate anti-tumoral cytotoxic T-lymphocyte (CTL) and antibody responses against RCC tumor cells expressing RCC TAAs, resulting in RCC tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5018
Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5189
Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine
A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT02362451
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5024
Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine
A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522
NCT: https://clinicaltrials.gov/study/NCT02944357
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6363
An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5108
Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine
A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5396
A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5035
autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine
An autologous therapeutic vaccine for the treatment of acute myelogenous leukemia. This vaccine is prepared from blood samples of patients following their first relapse. Tumor cells extracted from blood sample are modified with hapten, a process that makes the cells appear foreign to the patient's body and results in stimulating immune response against the cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5404
An autologous-cell vaccine for melanoma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5110
A cancer vaccine that restored priming of Anaplastic lymphoma kinase (ALK)-specific CD8+ T cells, eradicated lung tumors in combination with ALK tyrosine kinase inhibitors (TKIs) and prevented metastatic dissemination of tumors to the brain. Human ALK peptides are displayed by HLA-A*02:01 and HLA-B*07:02 molecules. The peptides are immunogenic and recognized by CD8+ T cells from individuals with non-small cell lung cancer (NSCLC).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6382
A cancer vaccine made of allogeneic pancreatic tumor cells are transfected with a GM-CSF gene to treat ocally advanced, unresectable or metastatic pancreatic adenocarcinoma. It may be in combination with Ipilimumab (an antibody that blocks negative signals to T cells).
NCT: https://clinicaltrials.gov/study/NCT00836407
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6336
allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine
A cancer vaccine that consists of an allogeneic cell line that has a high expression level of melanoma molecules (HLA A2/4-1BB Ligand), and has been genetically modified to induce a strong immune response. Stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease.
NCT: https://clinicaltrials.gov/study/NCT01861938
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6313
allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine
A cancer vaccine that uses anti-HER2/HER3 dendritic cells in combination with Pembrolizumab in patients with Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC). The dendritic cells boost the immune system, and the Pembrolizumab enhances cancer immune responses, in combination they may shrink the cancer.
NCT: https://clinicaltrials.gov/study/NCT04348747
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6263
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5230
A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis. (NCI04)A vaccine consisting of replication-defective recombinant adenovirus that encodes for Bcl-Xs with potential antineoplastic activity. Vaccination with Bcl-Xs adenovirus vaccine induces apoptosis in Bcl-2 and Bcl-XL positive cancer cells, resulting in decreased tumor growth while leaving normal cells unaffected. Bcl-Xs block the function of the protooncogenes Bcl-2 and Bcl-XL which are overexpressed in a variety of solid tumors and promote cancer cell survival by inhibiting apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5399
A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5374
A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4992
A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5439
Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine
A cell-based cancer vaccine comprised of brain tumor initiating cells (BTICs), with potential immunostimulating and antineoplastic activity. BITCs are from the glioblastoma multiforme (GBM) cell line GBM-6 and contain glioma stem-like cell-associated antigens. Upon administration, the BITC vaccine may stimulate a specific anti-tumoral cytotoxic T-lymphocyte (CTL) response against brain tumor cancer cells and brain tumor stem like cells, resulting in tumor cell lysis. BITC have unique antigenicity and have the ability to self-renew; vaccination against BITC antigens may kill these cells and may prevent tumor recurrences.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5210
A cancer vaccine consisting of recombinant modified vaccinia Ankara (rMVA) encoding the prostate specific antigen (PSA), the prostate-specific membrane antigen (PSMA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). Vaccination with PSA/PSMA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells over-expressing PSA or PSMA.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29561
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5309
A vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) that encodes the gene for human interleukin-12 (hIL-12). Produced mainly by B-cells, IL-12 is an endogenous cytokine that activates natural killer (NK) cells, promotes cytotoxic T lymphocyte (CTL) responses, induces the release of interferon-gamma (IFN-gamma), and may exhibit antitumor and anti-angiogenic effects. Vaccination with canarypox-hIL-12 melanoma vaccine may stimulate the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth and/or metastasis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5544
A cancer vaccine that uses dendritic cells pulsed with autologous tumor homogenate in combination With High Dose-IL2 and immunomodulating radiotherapy for patients with Metastatic RCC.
NCT: https://clinicaltrials.gov/study/NCT03226236
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6266
autolgous DC vaccine pulsed with autologous tumor homogenate for metastatic rcc
A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6379
A cancer vaccine that uses autologous cancer testis (CT) antigen specific dendritic cell (DC) preceded by decitabine as a demethylating chemotherapy for patients with high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma. The mature DC is pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3.
NCT: https://clinicaltrials.gov/study/NCT01241162
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6268
autologous cancer testis antigen specific dendritic cell vaccine
A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. The vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a powerful adjuvant capable of stimulating macrophage function, inducing proliferation and maturation of DCs, and is able to enhance T-lymphocyte stimulatory function. The vaccine can be used in combination with monoclonal antibodies, such as basiliximab, that can block tumor growth in different ways, as well as temozolomide, and radiation therpay. The combination of treatments may kill more tumor cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C156067
NCT: https://clinicaltrials.gov/study/NCT00626483
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6347
autologous CMV-pp65-flLAMP mRNA loaded dendritic cell vaccine
A cancer vaccine made of dendritic cells (DCs) loaded with personalized peptides (PEP) given in combination with low-dose cyclophosphamide for patients with advanced or recurrent metastatic NSCLC.
NCT: https://clinicaltrials.gov/study/NCT05195619
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6267
autologous dendritic cell vaccine loaded with personalized peptide vaccine (pep-dc vaccine)
A cancer vaccine that encodes macrophage inflammatory protein 3 alpha (MIP3a)-fused lymphoma idiotype in single chain format for patients with atients with Asymptomatic Phase Lymphoplasmacytic Lymphoma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6264
autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine
A cancer vaccine that uses autologous neuroblastoma cells, irradiated and genetically modified by adenoviral vectors to secrete interleukin-2 (IL-2) for patients with high-risk neuroblastoma. The adenoviral vector are used to transduce the cells ex-vivo, patients are not treated with the viral vector.
NCT: https://clinicaltrials.gov/study/NCT00048386
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6269
A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C122402
NCT: [https://clinicaltrials.gov/study/NCT01312376
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6330
autologous oxidized ovarian tumor cell lysate vaccine
A cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells and mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), formulated in DOTAP lipid particles, with potential immunostimulatory and antineoplastic activities. he autologous total tumor mRNA and CMV-pp65-flLAMP mRNA loaded liposome vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs). This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine is used to treat patients with Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM). The vaccine is also used for for the treatment of early melanoma recurrence following adjuvant Anti-PD-1 antibody therapy.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C178432
NCT: https://clinicaltrials.gov/study/NCT04573140
NCT: https://clinicaltrials.gov/study/NCT05264974
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6270
autologous total tumor mrna and CMV-pp65-flLAMP mRNA loaded liposome vaccine
A cancer vaccine made from the patient's cancer cells that may make the body build an immune response and kill their tumor cells. The autologous tumor cell vaccine will be given together with adjuvant interferon gamma or sargramostim (GM-CSF) in patients with advanced cancer (breast, lung, prostate, colorectal, sarcoma, renal, melanoma). The vaccine uses irradiated autologous tumor cells and tumor lysate.
NCT: https://clinicaltrials.gov/study/NCT00002505
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6364
A cancer vaccine made from the patient's own tumor tissue may stimulate an immune response against the patient's tumor cells. O-Vax nay induce a DTH response to autologous, DNP-modified ovarian cancer cells. The vaccine includes DNP-modified autologous ovarian tumor cells followed by cyclophosphamide then weekly doses of DNP-modified autologous ovarian tumor cells mixed with Bacillus of Calmette and Guérin (BCG).
NCT: https://clinicaltrials.gov/study/NCT00660101
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6334
autologous, dnp-modified ovarian cancer vaccine
A cancer vaccine containing human acute myeloid leukemic (AML) blasts that have been genetically engineered to express a B7.1/IIL-2 fusion protein. It uses B7.1 (CD80)/IL-2 immune gene therapy for high risk MDS RAEB-2 and acute myeloid leukaemia (AML) patients who are unsuitable for an allogeneic haematological stem cell transplant.
NCT: https://clinicaltrials.gov/study/NCT02493829
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6265
A cancer vaccine made with BC-819 (also known as DTA-H19), which is a double-stranded DNA plasmid, 4,560 base pairs (bp) in length, carrying the gene for the Diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter. The DT-A chain expression is triggered by the presence of H19 transcription factors that are only up-regulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis selectively in the tumor cell, enabling highly targeted cancer treatment. It is used in combination with intravenously administered gemcitabine for patients with Locally Advanced Pancreatic Adenocarcinoma. The activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C107685
NCT: https://clinicaltrials.gov/study/NCT01413087
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6273
A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system.
NCT: https://clinicaltrials.gov/study/NCT03412786
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6272
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5329
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5380
9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA.
NCT: https://clinicaltrials.gov/ct2/show/NCT00203892
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5356
Carcinoembryonic Antigen Peptide 1-6D Vaccine
A cancer vaccine, consisting of alphavirus vector-derived virus-like replicon particles expressing the 9-amino-acid carcinoembryonic antigen peptide (CAP) 1-6D, with potential antineoplastic activity. Vaccination with this agent may elicit a cytotoxic T lymphocyte (CTL) immune response against CEA-expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5129
carcinoembryonic antigen peptide 1-6D virus-like replicon particles vaccine
A cancer vaccine comprised of an epitope from the Carcinoembryonic Antigen obtained from cancer cells that can stimulate an immune response against tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5209
carcinoembryonic antigen peptide-1 vaccine
A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5041
Carcinoembryonic Antigen RNA-pulsed DC Cancer Vaccine
A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT_C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309
NCT: https://clinicaltrials.gov/study/NCT00267085
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6353
A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5193
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.
NCT: https://clinicaltrials.gov/ct2/show/NCT02049489
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5107
CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine
A vaccine comprised of CD80-transfected allogenic breast cancer cells to induce T-cell response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5476
Autologous human dendritic cells pulsed with RNA encoding the carcinoembryonic antigen (CEA) are being studied for possible use in the treatment of cancer expressing CEA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5045
CEA RNA-pulsed Autologous Human Cultured Dendritic Cells Vaccine
A plasmid vaccine encoding wild type human carcinoembryonic antigen (CEA) fused to a tetanus toxoid T helper epitope, with potential antineoplastic activity. Upon vaccination and subsequent intradermal electroporation, CEA/tetanus toxoid T helper epitope fusion protein-expressing DNA plasmid vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA, a tumor associated antigen, is overexpressed in a variety of cancer cell types. The tetanus toxoid helper peptide epitope, obtained from the bacterial Clostridium tetani toxoid, binds to class II MHC molecules and increases the helper T-cell response thereby inducing an increased and long-term immune response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5367
CEA/Tetanus Toxoid T Helper Epitope Fusion Protein-Expressing DNA Plasmid Vaccine
A complex, replication-selective, E1B and partial E3 gene deleted, adenovirus type 11p (Ad11p)/Ad3 chimeric oncolytic virus with potential antineoplastic activity. Upon intralesional injection of enadenotucirev, the adenovirus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation in host cells, which promotes viral replication. Deletion of E1B prevents replication in normal, healthy cells that express wild-type p53. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of the E3 gene, which encodes the adenovirus death protein, enhances the safety profile of the administered adenovirus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5316
Chimeric Ad11p/Ad3 Oncolytic Virus Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4985
CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine
A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5306
A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61310
NCT: https://clinicaltrials.gov/study/NCT00466726
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6274
A vaccine composed of synthetic peptides derived from beta-human chorionic gonadotropin (hCG) conjugated to diphtheria toxoid. Vaccination with this peptide may elicit the host immune response against hCG-producing cancer cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5372
A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with cyclin B1 peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, cyclin B1 peptide-pulsed autologous dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and anti-cyclin B1 antibody responses against cyclin B1-expressing cancer cells, resulting in tumor cell lysis. Cyclin B1, a key regulator of the cell cycle and cell division, is overexpressed in a variety of cancer cells.
NCT: https://clinicaltrials.gov/ct2/show/NCT01398124
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5139
Cyclin B1 Peptide-pulsed Autologous Dendritic Cell Vaccine
A preparation of autologous lymphocytes with potential immunopotentiating and antineoplastic activities. Cytokine-induced killer (CIK) cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes, generated ex-vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, interleukin (IL)-2, IL-1, and interferon gamma (IFN-gamma) and then expanded. When reintroduced back to patients after autologous stem cell transplantation, CIK cells may recognize and kill tumor cells associated with minimal residual disease (MRD). CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5070
A vaccine composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5163
Dendritic Cell Tumor Cell Lysate Vaccine
A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as dendritic cells. The dendritic cells are transduced with the gene encoding an antigen specific to the patient's cancer and then returned to the patient. In the host, the altered cells stimulate the immune system to mount a primary T cell response against lung tumor cells expressing the target antigen. Dendritic cell-autologous lung tumor vaccines have been investigated for use in cancer immunotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5161
Dendritic Cell-Autologous Lung Tumor Vaccine
A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5417
An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5067
dendritic cell-gp100-MART-1 Antigen vaccine
A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of MART-1 (melanoma antigen recognized by T-cells), an antigen expressed by melanoma cells. When the altered dendritic cells are returned to the patient, they stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5524
A vaccine comprised of autologous dendritic cells pulsed with a recombinant prostate specific membrane antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5000
Gene name: Prostate-specific membrane antigen gene engineering:
Dendritic Cell-Recombinant Prostate-Specific Membrane Antigen Vaccine
An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5493
Dendritic Cell-targeting Lentiviral Vector ID-LV305 Vaccine
A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5338
Dinitrophenyl-Modified Autologous Renal Cell Carcinoma Tumor cell Vaccine
A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of DNA plasmid encoding interleukin-12 INO-9012, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.
DNA Plasmid Encoding Interleukin-12 INO-9012 Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5016
DNA plasmid-encoding Interleukin-12 INO-9012 vaccine
A DNA-based combination immunotherapeutic, INO-3112, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.
NCT: https://clinicaltrials.gov/ct2/show/NCT03439085
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5136
DNA plasmid-encoding Interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112
A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, the DNA vaccine VB10.16 expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5207
A cancer vaccine consisting of a DNA plasmid encoding epitopes of the human preferential antigen of melanoma (PRAME) and the prostate specific membrane antigen (PSMA) with potential immunostimulating activity. Upon direct administration of this vaccine into lymph nodes, peptides expressed by DNA plasmid vector pPRA-PSM may activate the immune system, resulting in a cytotoxic T-lymphocyte (CTL) response against PRAME- and PSMA-expressing cells. PRAME and PSMA are tumor associated antigens upregulated in a number of cancer cell types. As part of the MKC1106-PP regimen exploiting the 'prime-boost strategy', this plasmid is responsible for priming the immune response and is used in conjunction with a peptide vaccine consisting of PRAME and PSMA that boosts the immune system against PRAME- and PSMA-expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5407
A cancer vaccine comprised of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), MUC-1, a transmembrane glycoprotein secreted by glandular epithelial tissues, and TRICOM, comprised of three co-stimulatory molecule transgenes (B7-1, ICAM-1 and LFA-3). This agent may enhance CEA and MUC-1 presentation to antigen-presenting cells (APC) and may activate a cytotoxic T-cell response against CEA- and MUC-1-expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5378
A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5090
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5464
HPV-6-targeting immunotherapeutic vaccine INO-3106
A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic activity. Upon vaccination, MUC-1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against MUC-1-expressing tumor cells, resulting in growth inhibition. MUC-1 antigen is a high-molecular-weight transmembrane glycoprotein that is overexpressed on the cell surfaces of many epithelial tumor cells as well as on the cell surfaces of some B-cell lymphoma cells and multiple myeloma cells. (NCIT_C2195).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5103
An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of the gp96-Ig-secreting allogeneic bladder cancer cell vaccine HS-410, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5033
gp96-secreting Allogeneic Bladder Cancer Cell Vaccine HS-410
A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an antigen found in normal testis and various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5300
A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5096
Glioma-Associated Antigen Peptide-Pulsed Autologous Dendritic Cell Vaccine
A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5073
Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5202
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5298
IDH1R132H Mutation-targeting IDH1 Peptide Vaccine
A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5461
IDH1R132H-Specific Peptide Vaccine PEPIDH1M
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5215
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5531
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5151
Fas-Chimera Transgene-expressing Endothelial Tumor Cell-targeting Adenovector VB-111 Vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5277
A multivalent vaccine againt breast cancer that comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32(aa), TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5229
Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH Conjugate Vaccine
A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5237
HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4997
A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5166
A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5036
Modified Vaccinia Ankara (Bavarian Nordic)-HER2 Vaccine
A cancer vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein. The bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine is used in combination with GM-CSF. The peptides may help the body build an effective immune response to kill cancer cells, and the GM-CSF may increase the number of immune cells found in bone marrow or peripheral blood. This combination is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. It can also be used in combination with imatinib mesylate to decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2205
NCT: https://clinicaltrials.gov/study/NCT00004052
NCT: https://clinicaltrials.gov/study/NCT00455221
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6372
A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor. (NCIT_C62801).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4987
A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide, with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine may elicit an immune response against cancer cells expressing hTERT and survivin by activating cytotoxic T-cells (CTLs), natural killer cells (NKs), and B-lymphocytes. The tumor associated antigens (TAAs) hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and play key roles in tumor cell growth and survival.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5121
hTERT mRNA/survivin peptide-double-loaded autologous dendritic cell vaccine
A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5516
hTERT multipeptide/montanide ISA-51 VG/Imiquimod vaccine GX 301
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5065
A poxvirus made non-infectious by ultraviolet light or other inactivation methods in order to reduce its pathogenicity. In cancer gene therapy, inactivated vaccinia virus may be used as a vector to express a protein that kills tumor cells or elicits specific anti-tumor immunity. In a cancer vaccine application, tumor cells taken from the host may be adsorbed with inactivated vaccinia virus and returned to the host, where the modified tumor cells may stimulate an anti-tumor immune response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5130
A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5099
A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated double-deleted Listeria monocytogenes bacteria JNJ-64041809 is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5258
live-attenuated double-deleted listeria monocytogenes bacteria JNJ-64041809 vaccine
A conjugate consisting of keyhole-limpet hemocyanin (KLH) and fluorescein isothiocyanate (FITC) with potential immunostimulating activity. Vaccination with KLH-FITC may elicit an immune response against fluorescein and the production of anti-fluorescein IgG antibodies. KLH, a natural protein isolated from the marine mollusk keyhole limpet, is an immunostimulant carrier protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5146
A cell-based vaccine targets tumors expressing the HER2/neu marker. HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers. APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient. These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5538
A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5187
mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine
A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5235
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5347
A vaccine consisting of a monoclonal antibody (MoAb) directed against an idiotype that mimics a human milk fat globule (HMFG) membrane epitope. Vaccination with monoclonal antibody 11D10 anti-idiotype vaccine induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5286
monoclonal antibody 11D10 anti-idiotype vaccine
A recombinant monoclonal antibody in which the heavy and light chain variable domains mimic a specific epitope of the tumor-associated protein carcinoembryonic antigen (CEA). This agent is used as a cancer vaccine against tumors that express CEA.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5452
monoclonal antibody 3H1 anti-idiotype vaccine
An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma, and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5308
monoclonal antibody A1G4 anti-idiotype vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5469
monoclonal antibody GD2 anti-idiotype vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5239
Montanide ISA-51/survivin peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5362
A cancer vaccine comprised of a synthetic peptide derived from the mucin 1 (MUC1) antigen with potential antineoplastic activity. Upon administration, MUC1 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in decreased tumor growth. Overexpressed on many tumor cells, MUC1 antigen, a mammary-type apomucin, is a high-molecular-weight transmembrane glycoprotein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5517
A peptide vaccine containing human mucin 2 (MUC2) protein conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. MUC2, a secretory or gel forming glycoprotein expressed predominantly in goblet cells of the gastrointestinal and respiratory tracts, is overexpressed as an aberrant or deglycosylated form in various tumors such as gastric carcinomas and some hormone-refractory prostate cancers. MUC2 protein is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. Vaccination with MUC2-KLH may result in the production of antibodies as well as elicit a cytotoxic T- lymphocyte (CTL) response against tumor cells expressing MUC2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5169
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5123
A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5251
A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity. MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen. Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5160
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5068
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5522
multi-epitope folate receptor alpha peptide vaccine
A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5064
A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5364
mutant p53 peptide pulsed dendritic cell vaccine
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5091
A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296, with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296) peptide vaccine may be capable of inducing an active specific immune response, mounting a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in a variety of cancers and is correlated with increased tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296) corresponds to the binding site of pertuzumab on the dimerization loop of domain II of HER-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5400
MVF-HER-2(597-626)/MVF-HER-2 (266-296) peptide vaccine
A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L. major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L. major capsid proteins or functional L. major capsid protein derivatives.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5449
Human Papilloma Virus L1 Virus-Like Particle V504 Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5408
liposomal HPV-16 E6/E7 multipeptide vaccine PDS0101
A cancer vaccine consisting of a humanized monoclonal antibody that mimics a tumor-associated antigen 791Tgp72 (also known as CD55). Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing CD55, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5195
monoclonal antibody 105AD7 anti-idiotype vaccine
A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5164
A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5055
A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-2 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 2 fusion protein. (NCIT_C49064).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5432
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5421
multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ICT-107
A preparation of allogeneic HLA-matched leukocytes treated with a derivative of placental protein 14 (PP14) with potential immunomodulating activity. PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes contain at least fifty-five percent early-apoptotic T cells; after infusion and when processed by recipient dendritic cells, early-apoptotic T cells may help induce a decrease in the donor effector T-cell responses against the recipient of an allogeneic hematopoietic stem cell (HSC) transplant, thereby minimizing allogeneic HSC transplant-related graft-versus-host disease (GVHD). PP14, a 162 amino acid glycosylated protein secreted by the late secretory phase endometrium, binds to T cells in a carbohydrate fashion and has been shown to induce T-cell apoptosis; maternal immune tolerance to the fetus and pregnancy-related remissions of autoimmune disease may involve PP14-induced T cell apoptosis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5093
HLA-Matched Donor Mononuclear Cell-Enriched Leukocytes Apocell vaccine
Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5168
IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051
A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5015
MiHA-loaded PD-L1/L2-silenced dendritic cell vaccine
A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5002
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the suicide gene FCU1 with potential antineoplastic activity. FCU1 is a bifunctional yeast cytosine deaminase (CD) / uracil phosphoribosyltransferase (UPRT) fusion gene. Upon intratumoral administration, MVA-FCU1TG4023 enters tumor cells where FCU1 is expressed. Subsequently, the noncytotoxic prodrug 5-fluorocytosine (5-FC) is administered systemically and is deaminated by CD in FCU1- transduced tumor cells into 5-fluorouracil (5-FU), which is then directly metabolized to 5-fluoro-uridine monophosphate (5-FUMP) by UPRT; 5-FUMP may then be further transformed to 5-fluoro-deoxyuridine monophosphate (5-FdUMP), an irreversible inhibitor of thymidylate synthase and, so, DNA synthesis through deprivation of deoxythymidine triphosphate (dTTP). 5-FU and its active metabolites may then selectively kill tumor cells, avoiding toxicity in nonmalignant cells. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5312
A synthetic HIV vaccine based on a recombinant canary pox virus vector expressing the human immunodeficiency virus (HIV) glycoprotein gp160. HIVgP160 vaccine has been used to generate in vivo primary T lymphocyte response against HIV antigens.
A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions and has a high affinity for the most common human lymphocyte antigen (HLA), HLA-A2. Immunogenic peptides from the HPV 16 E6 may be used to trigger a T-cell-mediated immune response to HPV.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5474
human papillomavirus 16 E6 (18-26) peptide vaccine
A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5184
human papillomavirus 16 E7:86-93 peptide vaccine
A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L. major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5520
A synthetic peptide vaccine consisting of amino acids 13 through 21 of the viral oncoprotein human papillomavirus (HPV) 18 E6. The HPV 18E6 peptide cross-reacts immunologically with both HPV type 16 and HPV type 18, the most common HPV types involved in cervical cancer. Vaccination with HPV-18 E6:13-21 peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV 16 and 18.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5159
human papillomavirus 18 E6:13-21 peptide vaccine
Noninfectious, synthetic, virus-like particles (VLP) containing the major viral capsid protein, L1, of the human papillomavirus type 18 with potential immunoprotective activity. Vaccination with HPV 18 L1-VLP may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) response against cells positive for HPV 18, thereby preventing cervical infection upon exposure to HPV type 18.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5247
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis.
HPV DNA plasmids therapeutic vaccine VGX-3100
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5226
human papillomavirus DNA plasmids therapeutic vaccine VGX-3100
A vaccine directed against Human Papillomavirus Type 11 that causes majority of the genital warts and anogenital cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5227
A synthetic agent derived from human papillomavirus (HPV) E7 nuclear protein which is used to produce vaccines against HPV infection and HPV-related neoplasms. HPV E7 oncogenic protein binds the retinoblastoma tumor suppressor protein, pRB, as well as a number of other cellular proteins, and serves as a transcriptional activator. This protein is important in the induction and maintenance of cellular transformation and is co-expressed in the majority of HPV-containing carcinomas. PADRE(R) is a proprietary family of molecules that enhances the immune systems response against an administered immunogen such as the HPV E7 nuclear protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5162
human papillomavirus 16 E7 peptide/padre 965.10 vaccine
A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5233
human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
A vaccinia viral based vaccine, encoding epitopes of E6 and E7 proteins from human papillomavirus (HPV) types 16 and 18, with immunostimulatory and antineoplastic activities. HPV types 16 and 18 account for approximately 70% of cervical cancers. Vaccination with this HPV-TA (tumor antigen) vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for E6 and E7 from either type 16 or 18 HPV, resulting in decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5279
human papillomavirus tumor antigen vaccine
A vaccine consisting of noninfectious, recombinant virus-like particles (VLP) containing the major viral capsid protein L1 of nine strains of human papillomavirus (HPV), with potential immunoprotective activity. Vaccination with HPV V503 may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against cells positive for any of these nine strains of HPV, thereby preventing cervical infection upon exposure to certain HPV subtypes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5167
A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type 16. HPV-16 E7 12-20 peptide vaccine may elicit a specific CD8 T-cell response to the E7 oncogene protein, thereby inhibiting the abrogation of p53 and pRb function and thus prevent tumorigenesis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5079
human papillomavirus 16 E7:12-20 peptide vaccine
A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5083
human papillomavirus E6/E7 DNA vaccine GX-188E
A vaccine consisting of a plasmid DNA encoding the human prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express this antigen, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5262
Human Prostate-Specific Membrane Antigen Plasmid DNA Vaccine
A vaccine consisting of a plasmid DNA encoding the murine prostate-specific membrane antigen (PSMA). Upon administration, expressed PSMA may stimulate a cytotoxic T cell response against tumor cells that express PSMA, resulting in tumor cell lysis
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5105
Mouse Prostate-Specific Membrane Antigen Plasmid DNA Vaccine
Early-to late-stage myeloid progenitor cells derived from adult human stem cells with potential hematopoietic activity. Upon infusion, human myeloid progenitor cells CLT-008 proliferate into mature myeloid cells, including granulocytes, macrophages, platelets, and erythrocytes. These myeloid progenitor cells die within forty-five days after a burst of hematopoiesis. This agent cannot create lymphoid cells, including T cells associated with graft-versus-host disease
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5511
Human Myeloid Progenitor Cells CLT-008 vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with corpses of apoptotic leukemic cells, with potential immunostimulatory and antineoplastic activities. Upon vaccination, autologous dendritic cells pulsed with leukemic apoptotic corpse may activate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against leukemic cells expressing leukemia-associated antigens, which may result in leukemic cell lysis and inhibition of tumor cell growth. Apoptotic tumor cell corpses contain an array of tumor associated antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5004
Leukemic Apoptotic Corpse-Pulsed Autologous Dendritic Cells Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5200
multi-peptide CMV-modified vaccinia ankara vaccine
This is an autologous lung cancer vaccine consisting of patient-specific lung cancer cells genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), an immunostimulatory cytokine (NCIT_C1979). GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5453
A cancer vaccine that is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer.
NCT: https://clinicaltrials.gov/study/NCT00911560
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6262
bivalent neuroblastoma vaccine with adjuvant OPT-821
A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5112
HLA-A*2402-Restricted VEGFR1 peptide vaccine
A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5294
HLA-A2402-restricted VEGFR1/2 multipeptide vaccine
A cancer vaccine consisting of allogeneic neuroblastoma tumor cells have been genetically modified to secrete the human cytokine interleukin-2 (IL-2) and the human chemokine lymphotactin (Lptn) with potential immunostimulating and antineoplastic activities. Upon administration, IL-2 and Lptn are secreted by the IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, potentially enhancing the cytotoxic T lymphocyte (CTL) response elicited by vaccine neuroblastoma tumor-associated antigens (TAAs) against host neuroblastoma tumor cells. Produced by activated progenitor T cells, Lptn belongs to the C chemokine subfamily and is a potent chemotactic factor for lymphocytes; IL-2 stimulates natural killer (NK) cells and may enhance a vaccine-elicited CTL immune response against tumor cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5173
IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine
An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular administration with GSK1572932A may stimulate the immune system to exert both humoral and cellular immune responses against MAGE-A3-expressing tumor cells. MAGE-A3, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, and bladder cancer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5343
GVAX cancer vaccines are autologous cell vaccines comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5211
A replication-defective adenoviral serotype 5 vector encoding a recombinant form of the human cytokine interferon-gamma (IFN-g), with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the sustained expression of IFN-g by IFN-g-expressing adenovirus vaccine ASN-002 promotes a T-helper type 1 (Th1) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in both an inhibition of tumor cell proliferation and tumor cell death. Compared to IFN-g injections, the prolonged local production of IFN-g at the tumor site allows for higher efficacy and a reduction of systemic toxicity
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5540
Interferon-gamma-expressing Adenovirus Vaccine ASN-002
A vaccine based on anti-idiotype (Id) monoclonal antibodies combined with interleukin-2 (IL-2). Anti-Id vaccines have been shown to be effective in treatment of B-cell lymphoma in animal models and in clinical trials, resulting in tumor regression; the addition of interleukin-2 (IL-2) may augment the therapeutic effect of anti-Id vaccines.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5352
A chimeric lymphoma vaccine generated by combining the recipient's Ig idiotype (Id) protein with keyhole limpet hemocyanin (KLH), an immune stimulant, with potential antineoplastic activity. Vaccination with KLH-Lymphoma Ig Vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against lymphoma cells, resulting in decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5519
obsolete Lymphoma DNA vaccine V_V_V_-FrC
A preparation of autologous peripheral blood mononuclear cells (PBMCs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PBMCs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PBMCs localized in lymphoma tissue.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5212
indium in 111-labeled autologous peripheral blood mononuclear cells vaccine
A preparation of autologous peripheral polymorphonuclear (PMNLs) radiolabeled with indium In 111 with radioisotopic activity. Autologous PMNLs are isolated, expanded ex vivo, radiolabeled with indium In 111, and then infused back into the patient. Gamma scintigraphy may then be used to image gamma ray-emitting indium In 111 PMNLs localized in lymphoma tissue.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5273
indium in 111-labeled autologous polymorphonuclear leukocytes vaccine
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated protein ESO-1 in vitro, and then transferred back to the same patient to target tumor cells expressing ESO-1. ESO-1 is a human self-antigen expressed by melanomas. The ESO-1 gene encodes several MHC class I- and MHC class II-restricted epitopes that may activate cytotoxic T-cell-mediated tumor destruction
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5178
ESO-1 reactive autologous peripheral blood lymphocyte vaccine
A recombinant fowlpox virus-based vaccine vector designed to express various tumor-associated peptide antigens. Strong CD8 cytotoxic T cell responses may be induced after prolonged immunization with fowlpox virus vaccines and have been associated with tumor regression. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5042
A cancer vaccine containing of a synthetic form of the renal cell carcinoma (RCC)-associated antigen G250 with potential antineoplastic activity. Vaccination with G250 peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the G250 antigen, resulting in decreased tumor growth. Found in the majority of renal cell carcinomas, G250 is a cell surface tumor-associated antigen (TAA) that contains an HLA-A2.1-restricted epitope that is recognized by CTLs.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5249
An autologous dendritic cell (DC) cancer vaccine with GITRL RNA-transfected that has potential immunostimulatory activity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5410
GITRL RNA-transfected autologous dendritic cell vaccine
Used C57BL/6 mice and irradiated B16 tumor cells expressing granulocyte and macrophage colony-stimulating factor (GM-CSF), interleukin-12 (IL-12) or both. Tumor was transplanted by the injection of wild-type B16 cells. Tumor growth and survival were measured to evaluate the efficacy of vaccination. Specific humoral response and immunoglobulin G (IgG) switch were evaluated measuring total IgG and IgG1 and IgG2a subtypes against tumor membrane proteins of B16 cells
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4061
GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccine
A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential antineoplastic activity. Upon administration, the oncolytic adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, GM-CSF (sargramostim) expressed by the oncolytic adenovirus enhances antigen presentation, promotes natural killer (NK) cell-mediated killing and causes a cytotoxic T cell (CTL) response against tumor cells harboring the oncolytic adenovirus, resulting in an immune-mediated tumor cell death. CGTG-102 is designed to replicate only in cells with defects in the p16/Rb/E2F pathway, attributed to a mutation common in many solid tumors. Replacement of the Ad5 capsid protein knob with a knob domain from serotype 3 causes higher transduction in cancer cells as compared to normal cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5111
GM-CSF-encoding Oncolytic Adenovirus CGTG-102 vaccine
A cancer vaccine made of peripheral blood and tumor specimen harvested from patients with metastatic adenocarcinoma of the pancreas to generate cancer stem cell (CSC)-loaded denritic cell (DC) vaccines. CSC-primed antibodies and T cells are capable of selective targeting CSCs and conferring antitumor immunity.
NCT: https://clinicaltrials.gov/study/NCT02074046
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6276
A vaccine that injected peptides of gp100, MART-1, MAGE-3
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3993
A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100 adenovirus vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5133
A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF). Vaccination with gp100 and GM-CSF DNA/gold vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive cells, resulting in decreased tumor growth. GM-CSF is thought to increase the induction and activation of antigen-presenting cells (APC), allowing for a reduction in the dose of gp100 administered.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5084
A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a valine substitution at position 184. Vaccination with this peptide may evoke a cytotoxic T lymphocyte (CTL) response against tumor cells expression the gp100 antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5482
A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5153
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic activity. The expression of gp100 may generate a cellular immune response to melanoma cells; this effect is enhanced by the co-administration of interleukin 2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5135
Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a tumor associated antigen (TAA) commonly expressed by melanoma cells, may increase melanoma-reactive cytotoxic lymphocytes (CTL) in the PBL cell population. Autologous gp100-pulsed PBL have been administered to melanoma patients in order to augment cytotoxic immune responses to melanoma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5007
gp100-Pulsed Peripheral Blood Mononuclear Cell vaccine
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the same patient to target tumor sites expressing gp100. gp100 human antigen is a wild-type self-antigen expressed by melanocytes, pigmented retinal cells and most melanomas.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4990
gp100-Reactive Autologous Peripheral Blood Lymphocyte vaccine
To understand why cancer vaccine-induced T cells often do not eradicate tumors, we studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete Freund's adjuvant (peptide/IFA), which is commonly used in clinical cancer vaccine trials (Hailemichael et al., 2013). Immunization Route: Intramuscular injection (i.m.)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4078
A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5095
A peptide consisting of amino acid residues 154 through 162 of the melanoma-melanocyte antigen gp100. Vaccination with gp100:154-162 peptide may enhance tumor-specific T-cell immunity. gp100 antigen is a self-antigen expressed by melanocytes, pigmented retinal cells, and most melanoma lesions and is recognized via class I and II HLA-restricted mechanisms.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5145
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5050
A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with gp100:280-288 peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5526
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3989
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A1-binding melanoma-associated antigen peptides MAGE-1 and MAGE-3 with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against MAGE1- and MAGE-3-expressing cancer cells, resulting in tumor cell lysis. HLA-A1 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A1 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5185
HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted melanoma-associated antigen peptides tyrosinase (TYR), MART-1(melanoma antigen recognized by T-cells) and melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activity. Upon vaccination, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount an anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against Tyr-, MART-1 and gp100-expressing cancer cells, resulting in tumor cell lysis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5034
HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5270
hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine
A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5143
A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5021
A cancer vaccine made with chimeric antigen receptor (CAR) T cells that can be used to treat solid tumors. These CAR-T cells are engineered to target carbonic anhydrase IX (CAIX) to secrete anti-PD-L1 monoclonal antibody (mAb), termed immune-restoring (IR) CAR G36-PDL1. The T cells can be used to treat clear cell renal cell carcinoma (ccRCC) with reconstituted human leukocyte antigen (HLA) partially matched human leukocytes derived from fetal CD34+ hematopoietic stem cells (HSCs) and bearing human ccRCC skrc-59 cells under the kidney capsule. The cells can restore active antitumor immunity by promoting tumor-killing cytotoxicity, reducing immunosuppressive cell components such as M2 macrophages and exhausted CD8+ T cells, and enhancing T follicular helper (Tfh)-B cell crosstalk.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6380
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4003
A vaccine consisting of recombinant adenovirus vector encoding MART-1 (melanoma antigen recognized by T-cells 1), an immunogenic protein of unknown function that is expressed by certain types of melanoma. Vaccination with MART-1 adenovirus vaccine may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against MART-1 positive melanoma cells, resulting in an antitumor effect.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5398
A synthetic cancer vaccine derived from a melanoma-associated antigen, MART-1. Antigenic peptides derived from MART-1 are recognized by CD8+ T lymphocytes and have been used to immunize patients with advanced melanomas; prolonged immunization may result in a reduction in tumor size. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5254
A cancer vaccine consisting of an attenuated recombinant vaccinia virus expressing the melanoma-associated antigen MART-1. Vaccination with this agent may stimulate cytotoxic host immune responses to melanoma cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5204
Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5028
MART-1/gp100/Tyrosinase/MAGE-A3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5141
A natural or synthetic peptide cancer vaccine consisting of amino acid residues 27 through 35 of the melanoma-associated antigen MART-1 with potential antineoplastic activity. Vaccination with MART-1:27-35 peptide may induce cytotoxic host immune responses against melanoma cells that express this peptide
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5450
A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5142
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5318
A cancer vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858
NCT: https://clinicaltrials.gov/study/NCT01094496
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6277
A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer.
NCT: https://clinicaltrials.gov/study/NCT05559177
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6278
A cancer vaccine that treats patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL) by using a fragment of Deoxyribonucleic acid (DNA) containing the sequence of their own immunoglobulin gene. The vaccine is designed to generate an immune response and shrink or slow the CLL.
NCT: https://clinicaltrials.gov/study/NCT00038415
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6279
A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC.
NCT: https://clinicaltrials.gov/study/NCT02018458
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6288
A cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. It is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. The vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis. When dendritic cells and tumor cells are brought together, the dendritic cells can stimulate immune responses against the tumor and, in some cases, cause the tumor to shrink. GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148214
NCT: https://clinicaltrials.gov/study/NCT01096602
NCT: https://clinicaltrials.gov/study/NCT03059485
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6374
A cancer vaccine made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The dendritic cells contain survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry. The vaccine is given in combination with G-CSF, T cells, and the CD34 progenitor cells.
NCT: https://clinicaltrials.gov/study/NCT02851056
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6351
A cancer vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity. This vaccine is used to treat diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). It is made with the patient's own white blood cells and peptide-pulsed dendritic cells, which may help the body build an effective immune response to kill tumor cells. It is combined with immunotherapy monoclonal antibodies, such as nivolumab and ipilimumab, which also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1987
NCT: https://clinicaltrials.gov/study/NCT05457959
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6282
A cancer vaccine onsisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480
NCT: https://clinicaltrials.gov/study/NCT02728102
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6323
obsolete Melanoma DNA vaccine TA2M(TM) encoding tyrosinase peptides
A cancer vaccine made of tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Allogeneic haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.
NCT: https://clinicaltrials.gov/study/NCT01759810
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6285
dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
A cancer vaccine from tumor cells and tumor stem cells that are isolated from a sample from a patient with glioblastoma multiforme. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. The tumor sample provides tumor specific antigens to prepare the dendritic vaccine. Cytotoxic lymphocytes are obtained from peripheral blood after dendritic vaccine administrations. Hematopoietic stem cells are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration. Autologous haploidentical hematopoietic stem cells are administered intrathecally, dendritic cells are administered subcutaneously, and cytotoxic lymphocytes are adminstered intrathecally. The combination of these treatments may control tumor cell quantity and target regulation of effector functions of tumor stem cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6286
dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
A cancer vaccine based on ex vivo genetic modifications in combination with known tumor-specific antigens may substantially enhance the activation potential of tumor-specific T cells with improved benefit to patients. This DC vaccine is based on autologous DCs pulsed with genetically modified tumor cells or related antigens such as neoantigens to induce a strong anti-tumor immunity. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg).
NCT: https://clinicaltrials.gov/study/NCT03914768
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6301
DIPG and GMB Immunomodulatory DC vaccine
A cancer vaccine made with PEG fusions generated from allogeneic dendritic cells and autologous tumor-derived cells with GM-CSF and Il-4. The vaccine is irradiated, frozen, and thawed before being administered to patients with AJCC Stage IV Renal Cell Carcinoma. The vaccine could have and effect on the immune system and cancer.
NCT: https://clinicaltrials.gov/study/NCT00625755
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6287
A synthetic allogeneic cancer vaccine. Melanoma theraccine typically consists of lysed melanoma cells obtained from several melanoma cell lines combined with an adjuvant (such as DETOX or RIBI). This agent may be combined with immunomodulatory cytokines such as interferon alpha. Melanoma theraccine may induce a rise in the level of cytotoxic T-lymphocyte precursors.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4989
A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5014
A multipeptide cancer vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5261
A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590
NCT: https://clinicaltrials.gov/study/NCT04270149
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6289
A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2 with potential immunostimulating and antineoplastic activities. Upon administration, monoclonal antibody 4B5 anti-idiotype vaccine may elicit both cellular and humoral immune responses against GD2- expressing tumor cells. GD2 is a glycosphingolipid (ceramide and oligosaccharide) that may be highly expressed by melanomas and other neuroectodermal tumors, while only minimally expressed by normal tissues.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5039
monoclonal antibody 4B5 anti-idiotype vaccine
A vaccine consisting of a plasmid DNA encoding the murine melanoma-associated antigen gp100. Upon administration, expressed gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against tumor cells that express the gp100 antigen, resulting in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5386
obsolete mRNA-Electroporated Dendritic Cells Vaccine
A cancer vaccine directed against the soluble protein idiotype of an individual follicular lymphoma with potential antineoplastic activity. The vaccine may induce an idiotype-specific cytotoxic T-lymphocyte (CTL) response against follicular lymphoma cells expressing the idiotype, resulting in tumor cell lysis. Idiotypic vaccinations have the capacity of inducing an idiotype- and tumor-specific immune response, inducing specific immune responses able to kill in vivo follicular lymphoma cells, and prolonging survival of responding patients. This vaccine may contribute to preventing relapse indefinitely in responding patients.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71036
NCT: https://clinicaltrials.gov/study/NCT00530140
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6290
follicular lymphoma, patient-specific, soluble protein idiotype vaccine
A plasmid DNA vaccine encoding the mouse tumor associated antigen tyrosinase-related protein-2 (TYRP2) with potential immunostimulating and antineoplastic activities. Upon administration, murine TYRP2 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing TYRP2; this vaccine may also induce an immune response against tyrosinase-related protein-1 (TYRP1). TYRP2 and TYRP1, melanosomal membrane glycoproteins upregulated in melanoma cells, are involved in melanin synthesis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5310
A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and LAMP.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5276
hTERT-LAMP mRNA-loaded autologous dendritic cell vaccine GRNVAC1
A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04) (NCIT_C28775).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5264
A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5473
A recombinant virus-based vaccine that contains various peptide antigens. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it does not multiply in human tissues. Strong CD8 T cell responses may be induced after prolonged immunization and have been associated with tumor regression.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5031
A peptide vaccine against the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), with potential immunomodulating and antineoplastic activities. Vaccination with indoleamine 2,3-dioxygenase peptide vaccine may activate the immune system to induce an immune response against IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and may eradicate IDO-expressing tumor cells. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression; Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5144
Indoleamine 2,3-dioxygenase Peptide vaccine
A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5317
A cancer vaccine consisting of a recombinant vaccinia virus encoding the tumor-associated gene MAGE-1 that is contaminated with bovine viral diarrhea virus (BVDV). The MAGE-1 gene is a member of the melanoma antigen-encoding gene family which is expressed in various malignant tumors such as hepatocellular carcinoma and germ cell tumors in addition to melanoma. Vaccination with vaccinia virus expressing human MAGE-1 may generate antitumoral T-cell responses. BVDV is an RNA pestivirus that may contaminate vaccines due to its presence in the fetal calf serum used as a growth supplement in the tissue culture of mammalian cells used in vaccine production.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5157
MAGE-1 Vaccinia contaminated with bovine viral diarrhea virus vaccine
A peptide cancer vaccine comprised of a peptide derived from the human melanoma antigen A3 (MAGE-A3), with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A3 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5395
An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5336
MAGE-A3-expressing Adenovirus Type 5 vaccine
A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic activities. hTERT I540/R572Y/D988Y multipeptide vaccine contains strongly antigenic peptide epitopes I540 (9-mer), R572Y (9-mer) and D988Y (10-mer). Vaccination with this agent may elicit a cytotoxic T cell (CTL) response against telomerase-expressing tumor cells. Directly linked to tumorigenesis, telomerase is expressed in the majority of human cancer cells but is infrequently expressed in normal cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5191
hTERT I540/R572Y/D988Y multipeptide vaccine
A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with tumor-derived clonal immunoglobulin (Ig) with potential immunostimulatory and antineoplastic activities. Upon administration, idiotype-pulsed autologous dendritic cell vaccine APC8020, containing idiotype (Id) protein structures that can be recognized by antibodies and by CD41 T lymphocytes and CD81 T lymphocytes, may stimulate antitumoral cytotoxic T lymphocyte (CTL) and antibody responses against Id-expressing tumor cells. The Id represents the unique antigenic determinants in the variable regions of the clonal Ig.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5344
Idiotype-pulsed autologous dendritic cell vaccine APC8020
A cancer vaccine made from tumor-specific neopeptides resulting from frameshift mutations in tumor cells, so-called Frames, present potentially potent targets for the immune system and can be utilized in therapeutic anti-cancer vaccination with the intention to synergize in their effect with immune checkpoint inhibitors. The personalized vaccine FRAME-001 based on a patient's Framome and selection of Frame peptides in advanced NSCLC cancer patients after standard first line treatment consisting of immune checkpoint inhibitor pembrolizumab as monotherapy or combined with chemotherapy (carboplatin/cisplatin and pemetrexed/paclitaxel) could help treat patients with non-small cell lung cancer.
NCT: https://clinicaltrials.gov/study/NCT04998474
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6291
A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5460
A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5314
A peptide vaccine containing amino acids residues from 340 through 349 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:340-349 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5466
A peptide vaccine containing amino acids residues from 419 through 427 of the latent membrane protein-2 (LMP-2) of the Epstein-Barr virus (EBV) with potential immunostimulating and antineoplastic activities. LMP-2, an EBV transmembrane protein, is expressed in various malignancies including nasopharyngeal cancer and EBV-positive Hodgkin's disease. Vaccination with the LMP-2:49-427 peptide may boost the immune system to mount a specific cytotoxic T-lymphocyte response against LMP-2 producing cells, resulting in cell lysis and inhibition of cancer cell proliferation.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5479
A cancer vaccine comprised of synthetic peptides derived from human melanoma antigen A1 (MAGE-A1), human melanoma antigen A3 (MAGE-A3) and cancer-testis antigen NY-ESO-1 with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-A1/MAGE-A3/NY-ESO-1 peptides vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-A1, MAGE-A3 and NY-ESO-1, resulting in tumor cell lysis. The MAGE-A1, MAGE-A3, and NY-ESO-1 tumor-associated antigens (TAAS) are overexpressed by a variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5263
MAGE-A1/MAGE-A3/NY-ESO-1 peptide vaccine
A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5532
GM2/GD2/GD3 Lactone-KLH conjugate trivalent vaccine
A cancer vaccine containing four HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from ring finger protein 43 (RNF43); translocase of outer mitochondrial membrane 34 (TOMM34); and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing RNF43, TOMM34, and VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5429
HLA-A*2404-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine
A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.
HLA-A1, A2, B35-Restricted Survivin Peptides/Montanide ISA-51 Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5120
HLA-A1, A2, B35-restricted survivin peptide/montanide ISA-51 vaccine
A dendritic cell (DC) vaccine containing ex vivo expanded autologous DCs obtained from a patient with leukemia with potential immunostimulating activity. Upon reintroduction into the host, the host dendritic cell vaccine-001 MSSM/BIIR may stimulate the immune system to mount a leukemia-specific cytotoxic T lymphocyte (CTL) response.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5246
host dendritic cell vaccine-001 MSSM/BIIR
A multi-peptide cancer vaccine with potential immunostimulating and antineoplastic activities. IMT-1012 immunotherapeutic vaccine contains twelve different synthetic peptides or tumor associated antigens (TAAs), including cyclin I (CCNI), cyclin-dependent kinase CDC2, EDDRI and TACE/ADAM17, each of which is involved in a different pathway associated with tumor growth, survival, and metastasis. Each antigen in the vaccine elicits a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing that antigen. This multi-antigen/multi-pathway targeting strategy provides broad immunotherapeutic coverage with respect to tumor complexity and heterogeneity and may result in enhanced vaccine efficacy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5048
A cancer vaccine containing four HLA-A0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein 100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor 2 (HER2). Upon administration, HLA-A0201-restricted TRp2-gp100-EphA2-HER2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5355
HLA-A0201-Restricted TRP2-gp100-EphA2-HER2 multipeptide vaccine
A cancer vaccine containing three HLA-A0201-restricted peptide epitopes with potential immunostimulatory, antiangiogenic, and antitumor activities. Vaccine peptide epitopes are derived from the tumor associated antigen (TAA) URLC (up-regulated in lung cancer 10) and vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against URLC10-expressing tumor cells and the tumor microvasculature expressing VEGFR 1 and 2 peptides; this may result in tumor cell lysis, the inhibition of tumor angiogenesis, and decreased tumor growth. HLA-A0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5017
HLA-A*0201-Restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine
A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4991
live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 vaccine ADU-623
A multivalent vaccine comprised of the epitope antigens of Globo H hexasaccharide 1 (Globo H), GM2 ganglioside, Lewis-Y, MUC1-32-mer, TF(c), and Tn(c) conjugated with keyhole limpet hemocyanin, with potential antineoplastic activity. The antigens included in this vaccine are associated various cancer cells. Vaccination with this multivalent vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing these antigens.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5104
Globo H-GM2-Lewis-y-MUC1-32-mer-TF(c)-Tn(c)-KLH conjugate vaccine
Peripheral blood lymphocytes (PBL) transfected to express MOv have been designed for possible use in autologous adoptive cellular immunotherapy of ovarian adenocarcinomas that overexpress folate-binding protein. MOv-PBLs express MOv-gamma (MOv), a chimeric receptor gene product derived from a recombinant gene encoding the variable region of murine monoclonal antibody MOv18 against folate-binding protein (FBP), often overexpressed in human ovarian cancer cells, and the human gene encoding the IgG and IgE Fc receptor gamma subunit. Autologous vaccination with these PBLs stimulates a host cytotoxic T lymphocyte response against ovarian cancer cells that overexpress FBP.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5335
An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5385
light-emitting Oncolytic Vaccinia virus GL-ONC1 vaccine
A cancer vaccine containing an HLA-A*0201-restricted vascular endothelial growth factor receptor 1 (VEGFR1) peptide (sequence: TLFWLLLTL) with potential immunostimulatory and antitumor activities. Upon administration, HLA-A*0201-restricted VEGFR1-derived peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR1, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5413
HLA-A*0201-Restricted VEGFR1 peptide vaccine
A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA) and TRICOM, a combination of three immunostimulants (i.e., B7.1, ICAM-1, and LFA-3). Administration of this agent may induce a cytotoxic T cell response against PSA-expressing tumor cells. Dendritic cells infected with TRICOM vectors greatly enhance naive T-cell activation and peptide-specific T-cell stimulation. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5038
A prostate cancer vaccine containing mRNAs encoding prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA) and six-transmembrane epithelial antigen of the prostate (STEAP), with potential antitumor activity. Upon administration, mRNA-derived prostate cancer vaccine CV9103 may stimulate the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PSCA- and STEAP-expressing prostate tumor cells. The mRNA used in this vaccine is modified and formulated to have enhanced translational potency and adjuvant activities. PSA, PSMA, PSCA and STEAP may be upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5369
mRNA-Derived Prostate Cancer Vaccine CV9103
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5126
A recombinant agent consisting of a genetically-modified adenovirus 5 vector encoding the protein cytokine tumor necrosis factor (TNF) alpha. TNF exhibits potent anti-tumor cytolytic properties; the adenovirus 5 vector efficiently infects tumor cells, delivering tumor-specific TNF.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5292
A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5465
HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine
A naturally occurring 9-residue peptide of fibroblast growth factor 5 (FGF-5). Recognized by tumor infiltrating cytotoxic T lymphocytes originally isolated from a renal cell carcinoma that overexpressed FGF-5, FGF-5:172-176/217-220 peptide activates various cytotoxic CD8 lymphocytes in an HLA-restricted manner. Overexpressed in several cancer cell lines, FGF-5 is a tumor-associated antigen that may be useful in cancer immunotherapy.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5498
A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently found in patients with Ewing's sarcoma or primitive neuroectodermal tumors (PNET). Vaccination with EF-1 peptide may stimulate the host immune response to elicit a cytotoxic T-cell response against tumor cells that express this EWS/FL1 type 1 fusion protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5509
A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5488
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5345
A peptide derived from the tumor suppressor protein Von Hippel-Lindau (VHL). This peptide, sequence: MEAGRPRPCCAR, was constructed based on a frameshift mutation of one of the VHL gene products; the more abundant protein VHLp18(MEA) (where MEA stands for three amino acids, Met-Glu-Ala). Vaccination with FrSh61(MEA)VHL33 peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5236
A cancer vaccine based on virus-like replicon particles (VRP) packaged with an alphaviral vector encoding the extracellular domain (ECD) and transmembrane (TM) regions of the human epidermal growth factor receptor 2 (EGFR2, NEU or HER2), with potential antineoplastic activity. After immunization with HER2 ECD+TM virus-like replicon particles vaccine AVX901, the VRPs infect cells and express HER2 ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. The alphaviral replicon of this vaccine is an attenuated strain of the Venezuelan equine encephalitis virus (VEEV) in which 3 of the 7 viral genes were substituted with a truncated HER2 gene to create a self-amplifying replicon RNA. HER2, a tyrosine kinase involved in several cell growth signaling pathways, is dysregulated or overexpressed in a wide variety of cancer cell types.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5442
HER2 ECD+TM virus-like replicon particles vaccine AVX901
A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5303
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5324
Ad5F35-LMP1/LMP2-Transduced autologous dendritic cell vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5534
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4995
VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5085
obsolete Autologous Dendritic Cell Vaccine ACT2001
obsolete Autologous Dendritic Cell-Tumor Fusion Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4051
autologous dendritic cells (DCs) vaccine
obsolete Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3981
autologous monocyte-derived mature DCs pulsed with p53, survivin and telomerase-derived peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4029
Bacille Calmette Guerin for melanoma of lower extremity vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4028
Bacillus Calmette-Guerin (BCG) vaccine for melanoma
Bacillus Calmette-Guerin (BCG), C. parvum vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4036
Bacillus Calmette-Guerin (BCG), Corynebacterium parvum vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4035
Bacillus Calmette-Guerin (BCG), dinitrochlorobenzene (DNCB) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4034
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4021
BCG and chemotherapy for malignant melanoma vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4022
BCG and Corynebacterium parvum for malignant melanoma vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4033
BCG treatment after surgical tumor removal vaccine
VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5399
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4017
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3984
VIOLIN: https://violinet.org/canvaxkb/vaccine_detail.php?c_vaccine_id=5476
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4072
class I HLA-A0201-restricted gp100209-2M peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5456
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3990
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4170
Recorded as licensed cancer vaccine without reference. Based on the vaccine name, it is not correct, see term:VO:0004719.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5494
dendritic cell-Idiotype-Keyhole Limpet Hemocyanin vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5346
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5116
DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4060
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3998
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4076
electroloading of mature dendritic cells with melanoma whole tumor cell lysate vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4067
ESAT-6-gpi DNA vaccine combined with B16F10-ESAT-6-gpi/IL-21 vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4081
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4018
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4047
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4008
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3974
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5438
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5062
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4010
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3992
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4053
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3986
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4058
Hsp70 chaperone-based gel composition vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3982
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3980
human leukocyte antigen class I-modified peptide vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4077
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3976
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4009
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4062
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3977
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4069
Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4037
intralesional bacile Calmette-Guerin (BCG) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4038
intralesional bacile Calmette-Guerin (BCG), DTIC, vincristine vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3975
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4045
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4012
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4050
irradiated melanoma cells plus BCG vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5472
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4000
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3968
Large Multivalent Immunogen (LMI) vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4048
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4066
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4005
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4059
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4039
MAGE-A3-genetically modified lymphocyte vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4065
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4046
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3996
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3985
Melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3979
melanoma-specific Melan-A/Mart-1 peptide + virus-like nanoparticles vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5412
modified Vaccinia virus ankara vaccine expressing p53
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4068
mouse/human gp10025-33 peptide plus CpG adjuvant; mouse/human gp100; mouse/human gp10025-33 peptide-pulsed DCs vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5224
multi-epitope folate receptor alpha-loaded dendritic cell vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4063
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4030
Oral Bacille Calmette-Guerin for malignant melanoma vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3983
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4032
procarbazine, dactinomycin, velba vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4031
Pulmonary BCG immunotherapy for malignant melanoma vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6075
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=4011
A cancer that is caused by human papillomavirus (HPV) infection. HPV infection can lead to six types of cancer including anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancer.
placeholder, will send new term requst to DOID
An infection that has as part organisms of the human papillomavirus (HPV).
Either a tumor-specific or a tumor-associated antigen.
Cancer vaccine that prevents cancer formation and development.
Cancer vaccine that aims to eliminate or control tumor cells.
A cancer vaccine that uses whole cells to deliver cancer antigen(s).
A whole cell cancer vaccine that uses whole tumor cells to deliver cancer antigen(s).
A cancer vaccine that is composed of a plasmid vaccine vector (a circular double stranded DNA molecule) containing the whole of parts of genes encoding one or more vaccine antigen proteins.
A cancer vaccine made with T cells genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned.
NCT: https://clinicaltrials.gov/study/NCT02107963
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6381
A cancer vaccine used to treat patients with small cell lung cancer by using several components (small cell lung cancer targets) that have been tested individually in patients with small cell lung cancer or other cancers (GD2, GD3, Globo H, Fucosyl GM1 and N-propionylated polysialic acid) so that the body will make antibodies to the vaccine which will also react against the cancer. Two other substances (KLH and OPT-821) are added which boost the immune system. Vaccination with the pentavalent KLH conjugate vaccine may induce production of IgG and IgM antibodies as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumors expressing any of these antigens.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C97034
NCT: https://clinicaltrials.gov/study/NCT01349647
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6275
GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid KLH conjugate vaccine
A cancer vaccine made with HLA class I-matched allogeneic human prostate carcinoma cells that are genetically engineered to secrete interleukin-2 and interferon gamma for patients with prostate carcinoma. Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer.
genetically engineered allogeneic prostate carinoma cells secreting interleukin-2 and interferon gamma
NCT: https://clinicaltrials.gov/study/NCT00002637
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6292
genetically engineered allogeneic prostate carinoma cells secreting interleukin-3 and interferon gamma vaccine
A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C52190
NCT: https://clinicaltrials.gov/study/NCT00301093
NCT: https://clinicaltrials.gov/study/NCT00361296
NCT: https://clinicaltrials.gov/study/NCT00442130
NCT: https://clinicaltrials.gov/study/NCT00809250
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6293
A cancer vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand (CD40L) genes. The vaccine may stimulate an anti-tumoral dendritic cell-mediated host immune response. Universal GM-CSF-producing and CD40L-expressing bystander cell line is used to form an autologous tumor cell-based vaccine for patients with mantle cell lymphoma in order to make the body build an effective immune response to kill cancer cells. It can be used in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, and IL-2. The vaccine can be done with bystander and autologous tumor cells for patients with malignant melanoma. It can also be combined with lenalidomide for patients with myelodysplastic syndrome (MDS).
NCT: https://clinicaltrials.gov/study/NCT00840931
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48391
NCT: https://clinicaltrials.gov/study/NCT00101101
NCT: https://clinicaltrials.gov/study/NCT00101166
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6271
A cancer vaccine using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells.
NCT: https://clinicaltrials.gov/study/NCT00683670
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6308
A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer.
NCT: https://clinicaltrials.gov/study/NCT01773395
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6385
A cancer vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Following the administration of the vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. A lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3) is a feature mutation in diffuse intrinsic pontine gliomas (DIPGs). This vaccine contains an H3.3-K27M targeted neoantigen peptide that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C132684
NCT: https://clinicaltrials.gov/study/NCT04749641
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6295
A cancer vaccine comprised of HER-2-neu and carcinoembryonic antigen synthetic (CEA) peptides, combined with the adjuvants granulocyte-macrophage colony stimulating factor (GM-CSF), and Montanide ISA-51 with potential antineoplastic activity. The vaccine may stimulate a cytotoxic T-cell response against HER-2-neu- and CEA-expressing tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells. This vaccine is compromised of HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51, and aims to cause an immune response in patients with stage IIB, III, or IV colorectal cancer.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48392
NCT: https://clinicaltrials.gov/study/NCT00091286
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6294
HER-2-neu, CEA peptides, GM-CSF, montanide ISA-51 vaccine
A cancer vaccine made from peptides that may help the body build an effective immune response to kill tumor cells. Patients with HER2 positive locally advanced breast cancer can be vaccinated with a HER2 Intracellular Domain (ICD) peptide-based vaccine administered concurrently with trastuzumab. The vaccine may lead to an immune response (HER2 specific T cell immunity and/or the development of intramolecular epitope spreading).
NCT: https://clinicaltrials.gov/study/NCT00343109
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6352
A cancer vaccine for vaccination with neoantigens that can both expand pre-existing neoantigen-specific T-cell populations and induce a broader repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in favour of enhanced tumour control. The vaccine targets up to 20 predicted personal tumour neoantigens. The vaccine induced CD4+ and CD8+ T cells responses. These T cells discriminated mutated from wild-type antigens, and in some cases directly recognized autologous tumour.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6377
A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which
NCT: https://clinicaltrials.gov/study/NCT00056134
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6283
HLA-A1, HLA-A2, and CD40-ligand pulsed dendritic cell vaccine
A cancer vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592
NCT: https://clinicaltrials.gov/study/NCT00478062
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6296
hodgkin's antigens-GM-CSF-expressing cell vaccine
A cancer vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. The vaccine induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. The vaccine may help to treat patients with a history of (pre) malignant cervical lesions.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148539
NCT: https://clinicaltrials.gov/study/NCT03141463
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6369
HPV E6/E7-encoding semliki forest virus vaccine Vvax001
A cancer vaccine composed of irradiated allogeneic breast cancer cell lines (HAB-1 and HAB-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.
NCT: https://clinicaltrials.gov/study/NCT00090480
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6297
A cancer vaccine composed of irradiated allogeneic melanoma cell lines (HAM-1, HAM-2 and HAM-3). These cell lines have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha(1,3)GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. The immune response to the foreign substance could stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.
NCT: https://clinicaltrials.gov/study/NCT00300612
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6298
A cancer vaccine composed of irradiated allogeneic prostate cancer cell lines (HAP-1 and HAP-2) that have been transduced with a recombinant Moloney murine leukemia virus (MoMLV)-based retroviral vector expressing the murine alpha (1,3) GT gene, a mouse gene that causes the production of a foreign pattern of protein-sugars on the cell surface. It is hoped that the immune response to the foreign substance will stimulate the immune system to attack the patient's own cancer cells that have similar proteins without this sugar pattern, causing the tumor to remain stable or shrink.. The expression of the murine alpha (1,3) galactosyltransferase [alpha (1,3) GT] gene results in the cell surface expression of alpha (1,3) galactosyl-epitopes (alpha-gal) on membrane glycoproteins and glycolipids.
NCT: https://clinicaltrials.gov/study/NCT00105053
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6299
A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat malignant melanoma that has metastasized.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159498
NCT: https://clinicaltrials.gov/study/NCT02077114
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6368
A cancer vaccine compromised of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy.
NCT: https://clinicaltrials.gov/study/NCT00928902
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6312
IL-2 peptide and GM-CSF-in-adjuvant melanoma vaccine
A cancer vaccine made with autologous dendritic cells that are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients.
NCT: https://clinicaltrials.gov/study/NCT01189383
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6300
A cancer vaccine that could teach T-cells to detect and kill cancer cells better. Intracel KLH is given without adjuvant subcutaneously and with Tetanus Toxoid 0.5 ml intramuscularly.
NCT: https://clinicaltrials.gov/study/NCT00000105
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6302
A cancer vaccine made with dendritic cells pulsed with KLH and tumor lysate for patients with neuroblastoma.
NCT: https://clinicaltrials.gov/study/NCT02745756
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6303
A cancer vaccine made of tumor protein taken from a cancer patient's plasma (liquid part of the blood) and KLH (a protein designed to increase the immune response of the vaccine).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6259
A cancer vaccine made with autologous dendritic cells pulsed with KLH for this vaccination, combined with radiation or a gene therapy agent, TNFerade. TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.
NCT: https://clinicaltrials.gov/study/NCT00868114
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6304
KLH-pulsed autologous dendritic cell vaccine
A cancer vaccine used alone or in combination with PD-1 inhibitor in patients with advanced solid tumors with KRAS mutation (G12C, G12D, or G12V) and HLA type HLA-A11:01 or HLA C08:02. The vaccine is a lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets the most commonly occurring KRAS mutations (G12D, G12V, and G12C). The mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162186
NCT: https://clinicaltrials.gov/study/NCT05202561
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6348
A cancer vaccine made with Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines are administered alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. It may induce EBV derived tumor antigen specific CD8+ T cell response in patients with EBV+ lymphoma in the setting of autologous stem cell transplant.
NCT: https://clinicaltrials.gov/study/NCT02115126
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6305
A cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775
NCT: https://clinicaltrials.gov/study/NCT00373217
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6306
MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
A cancer vaccine made with autologous dendritic cells (DC) are transduced with the MART-1, tyrosinase and MAGE-A6 (melanoma associated antigens, MAA) genes for melanoma patients. Some patients also receive interferon-alfa 2b (IFN) intravenously.
NCT: https://clinicaltrials.gov/study/NCT01622933
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6280
MART-1, tyrosinase and MAGE-A6 autologous DC vaccine
A cancer vaccine that may elicit a cytotoxic T-cell (CTL) response against cancer cells. Autologous dendritic cells are pulsed with melanoma tumor-specific peptides. The mature dendritic cell (mDC3/8) vaccine (primer and booster) in patients with stage III and stage IV melanoma is followed by treatment with pembrolizumab (anti-PD-1 therapy). Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C162250
NCT: https://clinicaltrials.gov/study/NCT03092453
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6307
A cancer vaccine made up of two peptides that are pieces of a bigger melanoma protein (gp100). These peptides bind to HLA-A2 which is then recognized by T cells. It could be given in combination with MDX-010 (ipilimumab, BMS-734016). MDX-010 (anti-CTLA4) antibodies are designed to keep the immune system running by blocking CTLA-4 from down-regulating T cell activation.
NCT: https://clinicaltrials.gov/study/NCT00094653
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6309
MDX-1379 (gp100) melanoma peptide vaccine
A cancer vaccine composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.
NCT: https://clinicaltrials.gov/study/NCT00028431
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6310
MDX-CTLA4 antibody/tyrosinase/gp100/MART-1 melanoma vaccine
A cancer vaccine consisting of peptides derived from melanoma-associated antigens and an adjuvant peptide derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic T-cell response against tumor cells expressing melanoma-associated antigens, resulting in tumor cell lysis. Vaccines made from peptides may make the body build an immune response to kill tumor cells. Vaccines using melanoma peptides from cytotoxic T cells and helper T cells could work in treating patients with metastatic melanoma. This vaccine contains 12 melanoma peptides restricted by Human Leukocyte Antigen (HLA)-A1, -A2, or -A3 and 6 melanoma helper peptides restricted by HLA-DR molecules emulsified with sargramostim (Granulocyte-macrophage colony-stimulating factor, GM-CSF) and Montanide ISA-51 or Montanide ISA-51 VG (ISA-51).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38700
NCT: https://clinicaltrials.gov/ct2/show/NCT00071981
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6311
A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with malignant tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C74063
NCT: https://clinicaltrials.gov/study/NCT00623831
A cancer vaccine with or without PD-1/L1 may help treat patients with advanced gastric cancer. A personalized mRNA tumor vaccine encoding neoantigen may also help treat patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma. The vaccine can also be used in combination with PD-1 for the treatment of advanced solid tumors.
NCT: https://clinicaltrials.gov/study/NCT03468244
NCT: https://clinicaltrials.gov/study/NCT05227378
NCT: https://clinicaltrials.gov/study/NCT05359354
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6328
A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses.
NCT: https://clinicaltrials.gov/study/NCT02808416
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6339
A cancer vaccine targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. Up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. The mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments. This mRNA vaccine might cause certain tumors to shrink. Immunogenic neoantigens and can predict for neoantigens binding the patient human leukocyte antigen (HLA) molecules from melanoma or epithelial cancer patients and use these epitopes for a personalized therapeutic messenger ribonucleic acid (mRNA) vaccine.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148239
NCT: https://clinicaltrials.gov/study/NCT03480152
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6324
mRNA-based personalized cancer vaccine NCI-4650
A cancer vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670
NCT: https://clinicaltrials.gov/study/NCT04741984
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6315
A cancer vaccine containing mucus 1 (MUC1) peptide and the adjuvant poly-ICLC with potential immunostimulatory and antineoplastic activities. MUC1 peptide-poly-ICLC adjuvant vaccine may induce the host immune system to mount a cytotoxic T cell response against MUC1-expressing tumor cells. MUC1 peptide-poly-ICLC adjuvant vaccine in boosting systemic immunity to MUC1 in women with stage I-III 'triple-negative' [i.e., ER(-) PR(-) HER2/neu(-)] breast cancer. MUC1 peptide-Poly-ICLC vaccine could also work in preventing lung cancer in current and former smokers at high risk for lung cancer. Vaccines made from peptides may help the body build an effective immune response to kill cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop the changes from normal to pre-cancer to cancer.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C82417
NCT: https://clinicaltrials.gov/study/NCT00986609
NCT: https://clinicaltrials.gov/study/NCT03300817
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6316
A cancer vaccine comprised of four peptides derived from the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. The four peptides may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. TPIV100 and sargramostim could work in treating patients with HER2 positive, stage II-III breast cancer.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C173525
NCT: https://clinicaltrials.gov/study/NCT04197687
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6317
multi-epitope HER2 peptide vaccine TPIV100
A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695
NCT: https://clinicaltrials.gov/study/NCT00085189
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6318
A cancer vaccine for which Advanced Renal Cell Carcinoma patients undergo total nephrectomy to harvest primary tumor for vaccine preparation. Dendritic cells are then pulsed with multiantigens or tumor cells. Some patients also receive vaccination with irradiated autologous tumor lysate. The vaccine may make the body build an immune response to kill tumor cells.
NCT: https://clinicaltrials.gov/study/NCT00004880
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6284
multiantigen liposome loaded dendritic cell vaccine
A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological malignancies without any approved treatment options.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179595
NCT: https://clinicaltrials.gov/study/NCT04688385
NCT: https://clinicaltrials.gov/study/NCT05014607
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6319
A cancer vaccine that can efficiently present T cells with antigens of HCC sensitize their antitumor properties meanwhile low dose cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Multiple signals loaded dendritic cells vaccine combined low dose of cyclophosphamide combining with radical surgery or TACE or targeted agents for patients with hepatocellular carcinoma coul prolong their survival time.
NCT: https://clinicaltrials.gov/study/NCT04317248
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6320
multiple signals loaded dendritic cells vaccine
A cancer vaccine with neopeptides designed with single amino acid mutations to enhance their immunogenicity and bind to HLA class I and II molecules. Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6383
A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059
NCT: https://clinicaltrials.gov/study/NCT04574583
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6321
A cancer vaccine of a chimeric peptide immunogen of human epidermal growth factor-2 (HER-2) with antineoplastic property. MVF-HER-2(628-647)-CRL 1005 vaccine, coated with poloxamer CRL-1005 to form microparticles, consists of a mutated HER-2 B-cell epitope, HER-2(628-647), and a promiscuous T cell epitope (amino acid sequence 288-302) of the measles virus fusion protein (MVF). The vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. MVF-HER-2(628-647)-CRL 1005 vaccine may induce anti-HER-2 antibody in patients with metastatic or recurrent cancer (Breast, Ovarian, Non-small cell lung cancer, Gastric adenocarcinoma).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2637
NCT: https://clinicaltrials.gov/study/NCT00017537
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6322
A cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Both metastatic squamous non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (SCLC) are incurable with current therapies, but due to mutations induced by cigarette smoke, typically express a large number of altered proteins that can be recognized as foreign by the immune system. Targeting the immune system against tumor specific antigens using a peptide vaccine could lead to improved response rate and prolonged overall survival with no additional toxicity when combined with Pembrolizumab (monoclonal antibodies that block PD-1/PD-L1 interactions) and standard of care chemotherapy.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129935
NCT: https://clinicaltrials.gov/study/NCT03166254
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6325
A cancer vaccine that may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody).
NCT: https://clinicaltrials.gov/study/NCT03598816
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6326
A cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. The neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Personalized neo-antigen peptide vaccine is a product combines multiple patient specific neo-antigens. Given personalized neo-antigen peptide vaccine together with Th1 polarizing adjuvant poly ICLC may induce a polyclonal, poly-epitope, cytolytic T cell immunity against the patient's tumor. Patients also receive nivolumab.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C165508
NCT: https://clinicaltrials.gov/study/NCT05098210
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6327
A cancer vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells. This vaccine is a optimized neoantigen synthetic long peptide (SLP) vaccines for pancreatic cancer patients following neoadjuvant chemotherapy. The neoantigen SLP vaccines will incorporate prioritized neoantigens and will be co-administered with poly-ICLC. It can be used in combination with chemoradiation with temozolomide for patients with newly diagnosed glioblastoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C150471
NCT: https://clinicaltrials.gov/study/NCT02510950
NCT: https://clinicaltrials.gov/study/NCT05111353
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6332
neoantigen synthetic long peptide vaccine
A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM).
NCT: https://clinicaltrials.gov/study/NCT03871205
NCT: https://clinicaltrials.gov/study/NCT04147078
NCT: https://clinicaltrials.gov/study/NCT04912765]
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C141422
NCT: https://clinicaltrials.gov/study/NCT03674073
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6281
neoantigen-loaded autologous dendritic cell vaccine
A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs).
NCT: https://clinicaltrials.gov/study/NCT02332889
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6367
NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine
A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological malignancies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127125
NCT: https://clinicaltrials.gov/study/NCT02750995
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6329
NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine
A cancer vaccine made with autologous DCs that are pulsed with HOCl-oxidized autologous tumor lysate (OCDC) and administered in prime phase, along with a personal neoantigen-sensitized DC(NeoDC) vaccine administered in the boost phase for Esophageal Squamous Cell Carcinoma.
NCT: https://clinicaltrials.gov/study/NCT05317325
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6331
A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C159540
NCT: https://clinicaltrials.gov/study/NCT03556566
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6354
A cancer vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. Cholangiocarcinoma (CCA) is a malignant neoplasm originating from the epithelial cells lining the intra- or extrahepatic biliary ducts. This immunotherapeutic formulation is made from pooled heat- and chemically-inactivated blood from donors with CCA for a pill for cholangiocarcinoma patients.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148144
NCT: https://clinicaltrials.gov/study/NCT03042182
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6333
A cancer vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. The vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. Hiltonol is used as an adjuvant to stimulate or enhance the activation of your immune system. The vaccine and adjuvant may help treat HLA-A*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C187131
NCT: https://clinicaltrials.gov/study/NCT05283109
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6362
P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS
A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine.
NCT: https://clinicaltrials.gov/study/NCT00148928
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6335
A cancer vaccine based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, which may help treat patients with pancreatic ductal adenocarcinoma. This vaccine may elicit measurable neoantigen-specific immunologic responses in patients.
NCT: https://clinicaltrials.gov/study/NCT03558945
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6341
pancreatic tumor personalized neoantigen vaccine
A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146
NCT: https://clinicaltrials.gov/study/NCT03042793
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6338
A cancer vaccine composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148154
NCT: https://clinicaltrials.gov/study/NCT03047928
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6337
A cancer vaccine designed to target the unique immunogenic mutations arising in each patient's tumor. Peptide binding to MHC is a critical gateway to both the initiation of a T-cell immune response by the antigen presenting cell (APC), and to the detection and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic T lymphocyte (CTL). The attraction of neoantigens as cancer targets for the immune system results from the structural and geographical features of the mutation. Neoantigen peptides are only found in tumor cells, so CTLs should show exquisite specificity, reducing the opportunity for autoimmune disease.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6387
A cancer vaccine co-administered with poly-ICLC, nivolumab, and rituximab (or another monoclonal antibody against CD20) to treat Follicular Lymphoma. The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D).
NCT: https://clinicaltrials.gov/study/NCT03121677
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6342
personalized follicular lymphoma vaccine
A cancer vaccine that may stimulate the immune system to react to lung cancer cells, in combination with Cyclophosphamide.
NCT: https://clinicaltrials.gov/study/NCT02419170
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6340
personalized mature dendritic cell vaccine
A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma.
NCT: https://clinicaltrials.gov/study/NCT01970358
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6375
personalized neoantigen melanoma vaccine
A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278
NCT: https://clinicaltrials.gov/study/NCT03391232
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6343
A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1633
NCT: https://clinicaltrials.gov/study/NCT00004104
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6344
A cancer vaccine made with autologous dendritic cells targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT_C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174
NCT: https://clinicaltrials.gov/study/NCT05533203
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6345
A cancer vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. The vaccine This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. This vaccine may prevent cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast cancer in which all signs and symptoms have disappeared. Vaccines made from deoxyribonucleic acid (DNA) may help the body build an effective immune response to kill tumor cells. It is given in combination with sargramostim.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C127910
NCT: https://clinicaltrials.gov/study/NCT02780401
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6346
pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine
A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C200465
NCT: https://clinicaltrials.gov/study/NCT05638698
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6356
A cancer vaccine that encodes a melanoma antigen tyrosinase-related protein 2 (TRP2) cytotoxic T-lymphocyte (CTL) epitope and a modified monoclonal antibody, a chimera of human IgG1/murine IgG2a with T cell mimotopes expressed within the complementarity-determining regions (CDR) of the antibodies, with potential immunostimulating and antineoplastic activities. The melanoma TRP2 CTL epitope vaccine SCIB1 expresses the modified antibody. Subsequently, the Fc component of the engineered antibody targets and binds to the CD64 receptor on the dendritic cells (DCs); upon processing by DCs, the cellular immune system may be activated to induce helper T-cell and CTL immune responses against tumor cells expressing the TRP2 antigen. SCIB1 can be used in combination with either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C91380
NCT: https://clinicaltrials.gov/study/NCT04079166
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6349
A cancer vaccine made with secPD-L1, a splice variant of PD-L1 (programmed death ligand-1, an immune checkpoint pathway) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte function than monomeric soluble PD-L1. Recombinant secPD-L1 can dimerize and inhibit T-cell proliferation and IFN-gamma production in vitro. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect. This could lead to improved survival for patients with numerous types of cancers, including lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6376
A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C69000
NCT: https://clinicaltrials.gov/study/NCT00470574
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6350
sialyl lewis-keyhole limpet hemocyanin conjugate vaccine
A cancer vaccine consisting of peptides derived from melanoma-associated antigens and a modified T-cell epitope derived from tetanus toxoid. Vaccination with this agent may stimulate a host cytotoxic and helper T-cell response against tumor cells expressing melanoma-associated antigens, resulting in decreased tumor growth. This vaccine is compromised of multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C2468
NCT: https://clinicaltrials.gov/study/NCT00071981
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6355
A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector.
NCT: https://clinicaltrials.gov/study/NCT00684294
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6357
TGFβ2 antisense-GMCSF gene modified autologous tumor cell vaccine
A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913
NCT: https://clinicaltrials.gov/study/NCT03396575
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6360
total tumor RNA-loaded dendritic cell vaccine
A cancer vaccine made as patient's lymphocytes are rendered transgenic for a gene coding for selected portion of telomerase an enzyme expressed in the vast majority of cancer cells. Transgenic cells are then returned to the patient to produce an immune response targeted at cancer cells expressing telomerase. The transgenic cells serve as antigen- presenting cells (APCs) with the dual function of antigen synthesis and presentation. Vaccination produces an immune response targeting cancer cells expressing telomerase.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38720
NCT: https://clinicaltrials.gov/study/NCT00061035
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6358
transgenic lymphocyte immunization vaccine
A cancer vaccine of 3 adenoviral vaccines (ETBX-011, ETBX-051 & ETBX-061). ETBX-011 uses a replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA). ETBX-051 is composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded. ETBX-061 composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded. The three of these vaccines act against tumor associated antigens and have potential immunostimulating and antineoplastic activities. The TriAd vaccine can be used in combination with Anti-PD-L1/TGF-beta trap (M7824) and Anktiva (N-803) to shrink previously untreated head and neck tumors before surgery or stop the tumors from coming back after all treatment.
NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91373
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143034
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143035
NCT: https://clinicaltrials.gov/study/NCT04247282
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6359
A cancer vaccine that can be used in combination with Neo-antigen DC vaccine and their sensitized T cells for the treatment of esophageal cancer, advanced malignant melanoma, bladder cancer and colorectal cancer.
NCT: https://clinicaltrials.gov/study/NCT05023928
NCT: https://clinicaltrials.gov/study/NCT05235607
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6361
A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor).
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1988
NCT: https://clinicaltrials.gov/study/NCT00405327
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6366
tumor lysate-pulsed dendritic cell vaccine
A cancer vaccine made from proteins from the patient's tumor cells may boost the body's immune response against the tumor. The effects of chemotherapy on the immune system can potentially make immunotherapy more effective if administered soon after completion of chemotherapy. The addition of recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7)) may make the immunotherapy more effective. Alpha cluster of differentiation 25 (CD25) and 8H9 depleted autologous lymphocytes plus tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccines plus or minus r-hIL7 (CYT107) may induce immune responses to tumor lysate in patients (with Ewing's sarcoma, rhabdomyosarcoma or neuroblastoma).
NCT: https://clinicaltrials.gov/study/NCT00923351
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6365
tumor lysate/KLH pulsed dendritic cell vaccine
A cancer vaccine made as the patient's cancer will be surgically removed to provide cells for the vaccine, then the patient will be vaccinated twice with those cells and GM-CSF. After, the patient's blood will be filtered for white cells which will then be cultured and stimulated to reach a higher (killer) activity level. Next, the activated white blood cells will be infused into the patient's bloodstream so that they will be able to attack the cancer. Lastly, the entire process starting with vaccination will be repeated, for a total of two rounds of therapy. The autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T-cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.
NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C199632
NCT: https://clinicaltrials.gov/study/NCT01081223
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6373
A cancer vaccine administered within the first 2 to 3 months after allogeneic stem cell transplantation may enhance graft-vs.-leukemia responses. Irradiated autologous cancer cells provide a source of tumor antigens at the vaccination site. Granulocyte macrophage colony-stimulating factor (GM-CSF) secreted by irradiated bystander cells stimulates the recruitment, maturation and immunostimulatory activity of dendritic cells (DCs) at the vaccination site. Autologous whole tumor cell-based vaccination may tip the balance between leukemia-specific and alloreactive T cell responses in favor of a graft-vs.-leukemia (GvL) effect.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6388
Vaccine role that indicates a vaccine has received emergency use authorization (EUA) from regulatory authorities for distribution and administration to the public.
USA licensed vaccine for veterinary uses approved by USDA.
A Cp12 protein that is part of Crptosporidium parvum
A Cp21 protein that is part of Crptosporidium parvum
A Cp15 protein that is part of Crptosporidium parvum
A CP60 protein that is part of Crptosporidium parvum
A Cp23 protein that is part of Crptosporidium parvum
A CpP2 protein that is part of Crptosporidium parvum
A 3-1E protein that is part of Eimeria acervulina
A gam56 protein that is part of Eimeria maxima
Vaccine role that is characteristic of an inactivated vaccine.
A a1-giardin protein that is part of Giardia duodenalis
A a1-giardin protein that is part of Giardia lamblia
A alpha-enolase protein that is part of Giardia lamblia
A CWP2 protein that is part of Giardia lamblia
A Acen1 protein that is part of Leishmania donovani
A Beta-tubulin protein that is part of Leishmania donovani
A FML protein that is part of Leishmania donovani
A Gp63 protein that is part of Leishmania donovani
A HASPB1 protein that is part of Leishmania donovani
A KH protein that is part of Leishmania donovani
A LdyGCS protein that is part of Leishmania donovani
A NH36 protein that is part of Leishmania donovani
A P1 protein that is part of Leishmania donovani
A A2 protein that is part of Leishmania infantum
A HSP70 II protein that is part of Leishmania infantum
A KMP-11 protein that is part of Leishmania major
A LmSTI1 protein that is part of Leishmania major
A LIPO-A protein that is part of Leishmania major
A P36 protein that is part of Leishmania major
A PEPCK protein that is part of Leishmania major
A LeIF protein that is part of Leishmania major
A MIC3 protein that is part of Neospora caninum
A GRA2 protein that is part of Neospora caninum
A GRA6 protein that is part of Neospora caninum
A SRS2 protein that is part of Neospora caninum
A MIC10 protein that is part of Neospora caninum
A p24 protein that is part of Neospora caninum
A PDI protein that is part of Neospora caninum
A SAG1 protein that is part of Neospora caninum
Vaccine role that is characteristic of a live attenuated vaccine.
A P36p protein that is part of Plasmodium berghei
A ABRA protein that is part of Plasmodium falciparum|An ABRA protein that is part of Plasmodium falciparum
A EBA-175 RII protein that is part of Plasmodium falciparum
A Hsp90 protein that is part of Plasmodium falciparum
A MSP1 protein that is part of Plasmodium falciparum
A RESA protein that is part of Plasmodium falciparum
A MSP2 protein that is part of Plasmodium falciparum
A MSP4 protein that is part of Plasmodium falciparum
A Pf ribosomal protein P0 protein that is part of Plasmodium falciparum
Plasmodium falciparum Pf ribosomal protein P0
A PfCelTOS protein that is part of Plasmodium falciparum
A PfSSP2 protein that is part of Plasmodium falciparum
A LSA1 protein that is part of Plasmodium falciparum
A Pfen protein that is part of Plasmodium falciparum
A Pfs230 protein that is part of Plasmodium falciparum
A Pfs25 protein that is part of Plasmodium falciparum
A Pfs48 protein that is part of Plasmodium falciparum
A RH5 protein that is part of Plasmodium falciparum
A TRAP protein that is part of Plasmodium falciparum
A Pfs45 protein that is part of Plasmodium falciparum
A PkCSP protein that is part of Plasmodium knowlesi
A PkSSP2 protein that is part of Plasmodium knowlesi|A SSP2 protein that is part of Plasmodium knowlesi
Plasmodium vivax Thrombospondin-related apical merozoite protein
A PkAMA1 protein that is part of Plasmodium knowlesi
A PkMSP1 protein that is part of Plasmodium knowlesi|A PkMSP1p42 protein that is part of Plasmodium knowlesi
A CelTOS protein that is part of Plasmodium vivax|A PvCelTOS protein that is part of Plasmodium vivax
A CS protein that is part of Plasmodium vivax|A PvCS protein that is part of Plasmodium vivax
A DBPII protein that is part of Plasmodium vivax|A PvDBPII protein that is part of Plasmodium vivax
A TRAP protein that is part of Plasmodium vivax
A HEP17 protein that is part of Plasmodium yoelii
A HSP60 protein that is part of Plasmodium yoelii
PMC98419 citation for occurance in all lifestages
A SSP2 protein that is part of Plasmodium yoelii
A ASP-1 protein that is part of Trypanosoma cruzi
A CRP protein that is part of Trypanosoma cruzi
A G1 protein that is part of Trypanosoma cruzi
A PAR3 protein that is part of Trypanosoma cruzi
A PFR Ag protein that is part of Trypanosoma cruzi
A rTcENO from H8 protein that is part of Trypanosoma cruzi
A Tc24 protein that is part of Trypanosoma cruzi
A Tc80 protein that is part of Trypanosoma cruzi
A TcENO protein that is part of Trypanosoma cruzi
A TcSSP4 protein that is part of Trypanosoma cruzi
A TcTASV-C protein that is part of Trypanosoma cruzi
A TCTS-154 protein that is part of Trypanosoma cruzi
A Trans-salidase protein that is part of Trypanosoma cruzi
A TSA-1 protein that is part of Trypanosoma cruzi
A TsF protein that is part of Trypanosoma cruzi
A TSSA protein that is part of Trypanosoma cruzi
A CDPK1 protein that is part of Toxoplasma gondii
A CDPK6 protein that is part of Toxoplasma gondii
A ROP18 protein that is part of Toxoplasma gondii
A CST2 protein that is part of Toxoplasma gondii
A CyP protein that is part of Toxoplasma gondii
A GRA1 protein that is part of Toxoplasma gondii
A GRA16 protein that is part of Toxoplasma gondii
A GRA17 protein that is part of Toxoplasma gondii
A GRA24 protein that is part of Toxoplasma gondii
A GRA23 protein that is part of Toxoplasma gondii
A GRA25 protein that is part of Toxoplasma gondii
A GRA41 protein that is part of Toxoplasma gondii
A GRA6 protein that is part of Toxoplasma gondii
A GRA7 protein that is part of Toxoplasma gondii
A GRA8 protein that is part of Toxoplasma gondii
A hsp70 protein that is part of Toxoplasma gondii
A ISP3 protein that is part of Toxoplasma gondii
A MIC1 protein that is part of Toxoplasma gondii
A MIC11 protein that is part of Toxoplasma gondii
A MIC13 protein that is part of Toxoplasma gondii
A MIC4 protein that is part of Toxoplasma gondii
A MIC6 protein that is part of Toxoplasma gondii
A MIC8 protein that is part of Toxoplasma gondii
A PGAM2 protein that is part of Toxoplasma gondii
A RACK1 protein that is part of Toxoplasma gondii
A ROP16 protein that is part of Toxoplasma gondii
A ROP17 protein that is part of Toxoplasma gondii
A PLP1 protein that is part of Toxoplasma gondii
A ROP38 protein that is part of Toxoplasma gondii
A ROP8 protein that is part of Toxoplasma gondii
A ROP2 protein that is part of Toxoplasma gondii
A SAG2 protein that is part of Toxoplasma gondii
A SAG5B protein that is part of Toxoplasma gondii
A SAG5C protein that is part of Toxoplasma gondii
A TgADF protein that is part of Toxoplasma gondii
A TgNTPase-II protein that is part of Toxoplasma gondii
A TgPF protein that is part of Toxoplasma gondii
A variable representing the species of the host used for a study.
obsolete Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.
influenza, live, intranasal, quadrivalent
influenza, live, intranasal, quadrivalent vaccine
A variable representing the host's participation in a disease state (i.e. healthy, or diabetic).
A variable representing the biological sex of the host
A variable representing the age of the host
A variable representing the presence of another developing organism in an animal host
influenza, seasonal vaccine, quadrivalent, adjuvanted, 0.5mL dose, preservative free
A variable representing host quality's that leads to a wore outcome to vaccination or pathogen disease state.
Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free
RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF
Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free
RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months
RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months
RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose
COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL
A variable representing the prior immungenic memory a host has against a specific pathogen
Meningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative free
Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF
Chikungunya, live attenuated vaccine, 0.5 mL, preservative free
Chikungunya live attenuated vaccine, 0.5 mL, PF
Anthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxis
An information content entity that specify no vaccine adminstered.
A record of missing knowledge indicating that vaccine or immune globulin is unknown.
record of unknown vaccine or immune globulin
SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK
COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK
hepatitis B vaccine, dialysis patient dosage
Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis
Diphtheria, Tetanus, Poliomyelitis adsorbed
diphtheria and tetanus toxoids, adsorbed for pediatric use
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)
Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed
diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens
Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated
Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine.
diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)
non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)
Haemophilus influenzae type b conjugate and Hepatitis B vaccine
Haemophilus influenzae type b vaccine, HbOC conjugate
Haemophilus influenzae type b vaccine, PRP-T conjugate
Haemophilus influenzae type b vaccine, PRP-OMP conjugate
hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule
hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US)
hepatitis B vaccine, pediatric or pediatric/adolescent dosage
Hepatitis B vaccine (recombinant), CpG adjuvanted
human papilloma virus vaccine, quadrivalent
influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile)
Influenza, high-dose, split virus, trivalent, injectable, preservative free
Influenza, split virus, trivalent, injectable, preservative free
Influenza, split virus, trivalent, injectable, contains preservative
Influenza, split virus, trivalent, preservative
seasonal influenza, intradermal, preservative free
influenza, seasonal, intradermal, preservative free
Influenza, live, quadrivalent, intranasal
Influenza, split virus, quadrivalent, injectable, preservative free
Influenza, split virus, quadrivalent, PF
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative free
Influenza, recombinant, trivalent, injectable, preservative free
Influenza, split virus, quadrivalent, injectable, contains preservative
Influenza, split virus, quadrivalent, preservative
Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013
Influenza A monovalent (H5N1), ADJUVANTED-2013
Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free
Influenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative free
Influenza, recombinant, quadrivalent, injectable, preservative free
Influenza, recombinant, quadrivalent, PF
influenza, Southern Hemisphere, unspecified formulation
Influenza, high-dose, split virus, quadrivalent, injectable, preservative free
influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free
influenza, Southern Hemisphere, pediatric, preservative free
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, no preservative
influenza, Southern Hemisphere, preservative free
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative
influenza, Southern Hemisphere, quadrivalent, with preservative
Influenza, adjuvanted, inactivated, quadrivalent, injectable, preservative free
influenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative free
influenza, Southern Hemisphere, high-dose, quadrivalent
Influenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservative
Influenza, MDCK, trivalent, preservative
Japanese Encephalitis vaccine for intramuscular administration
meningococcal polysaccharide vaccine (MPSV4)
meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P)
meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O)
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
meningococcal B vaccine, fully recombinant
meningococcal B vaccine, recombinant, OMV, adjuvanted
pneumococcal polysaccharide vaccine, 23 valent
poliovirus vaccine, unspecified formulation
Oral Polio Vaccine, Unspecified formulation
pneumococcal conjugate vaccine, 7 valent
pneumococcal conjugate vaccine, 13 valent
rabies vaccine, for intramuscular injection RETIRED CODE
Human rabies vaccine from Chicken fibroblast culture
Respiratory syncytial virus (RSV), unspecified
Respiratory syncytial virus (RSV) vaccine, unspecified
Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified
Respiratory syncytial virus (RSV) MAB, unspecified
pneumococcal vaccine, unspecified formulation
typhoid Vi capsular polysaccharide vaccine
Yellow fever vaccine live - alternative formulation for vaccine shortage
Yellow fever vaccine, unspecified formulation
An information content entity that specifies the CVX code that will not be used to avoid confusion with code 999.
tuberculin skin test; old tuberculin, multipuncture device
tuberculin skin test; purified protein derivative solution, intradermal
tuberculin skin test; purified protein derivative, multipuncture device
tuberculin skin test; unspecified formulation
A variable representing the lineage (breed, ethnicity) of the animal host
A variable representing the interval between vaccination and pathogen challenge
A variable representing the interval between the vaccination and pathogen challenge start
A variable representing the interval between the pathogen challenge start and end
A variable representing the administration route of the pathogen challenge
A variable representing the planned process used for the sacrifice
A variable representing the presence of host adverse events from the vaccination process.
A variable representing the measurement used for an assay
A variable representing the timepoint a biological sample was taken after vaccination
A variable representing the assay type (ELISA, microarray) etc.
A variable representing the programs used to analyze an assay
A variable representing the tissue or source of sample used for an assay.
A variable representing the assay platform used (Nanopore,) etc.
A variable representing the species or type of the pathogen
A variable representing the lineage of pathogen strain (incljuding presence or absence of virulence factors)
A variable representing the presence of an attenuation process (killed microbe) on a pathogen challenge
A variable representing the host vaccination frequency etc.
A variable representing the vaccination route etc.
A variable representing dose representing the vaccination
A variable represting the number of occurences a vaccination was administered
A variable representing the interval between multiple vaccinations.
A variable representing the vaccine target (pathogen, disease) etc.
A variable representing the vaccine antigen (SARS-CoV-2 protein, whole organism) etc.
A variable representing the vaccine adjuvant (silver) etc.
A variable representing the vaccine vector (DNA plasmid, viral vector) etc.
A variable representing the vaccine preservative
A study design variable that is used in a vaccine study.
A study design that is about a vaccine study.
A vaccine study design that is about the host response to a vaccine.
A vaccine study design that is about the vaccine challenge to a host.
A measurement datum that records the presence of a disease process in a host during the implementation of a vaccine study.
A biological sex datum that records the biological sex of the target of a vaccine.
A measurment datum that records the age of thost.
A measurement datum that records to involvement of the host of the pregnancy process.
A measurment datum that records the quality of the host to have a comorbidity.
A measurment datum that records the presence of a prior infection or immune memory to a pathogen.
A measurment datum that records the interval between the vaccine challenge and the sacrifice of the organism during a vaccine challenge.
A measurment datum that records the route of a pathogen challenge occurs in.
A measurment datum that records the method of sacrifice (i.e. killing).
A measurment datum that records the presence or abasence of adverse event in a host in response of some vaccine.
A measurment datum that records the measurement of an assay.
A measurment datum that records the time point between the start of a first intervention in a planned process and the measurment of a sample.
A measurment datum that records the type of assay used.
A measurment datum that records the version of an analysis tool (software) used for an assay.
A measurment datum that records the type of platform used for an assay.
A measurment datum that records the utilization of an attenaution process on a pathogen.
A measurment datum that records the number of occurences the host was vaccinated as part of the vaccination process.
A measurment datum that records the interval between vaccinations of a host.
A measurment datum that records the intended target of a vaccine.
A measurment datum that records the vaccine vector of a vaccine.
A measurment datum that records the vaccine preservative of a vaccine.
An assay that measures the survival rate of organisms exposed to a pathogen.
An assay that measures the gut adhesion of a pathogen within an organism.
An assay that measures the titer of antibodies that neturalize a pathogen within an organism.
A directive information entity that is part of a study design. It can be eithor independent variables whose values are selected to determine its relationship to an observed phenomenon (the dependent variable) or dependent variables that are studied and expected to change when the independent variable varies.
meningococcal group A polysaccharide vaccine
meningococcal group C polysaccharide vaccine
Bacillus anthracis strain V770-NP1-R antigen vaccine
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen vaccine
Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen vaccine
Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen vaccine
Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen vaccine
influenza A virus A/Brisbane/10/2010 (H1N1) antigen vaccine
Influenza A virus (H1N1) antigen vaccine
influenza A virus A/South Australia/55/2014 (H3N2) antigen vaccine
influenza A virus (H3N2) antigen vaccine
influenza B virus B/Utah/9/2014 antigen vaccine
influenza A virus A/Christchurch/16/2010 (H1N1) antigen vaccine
influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen vaccine
influenza B virus B/Brisbane/60/2008 antigen vaccine
influenza B virus B/Phuket/3073/2013 antigen vaccine
influenza A virus A/California/7/2009 (H1N1) antigen vaccine
influenza A virus A/Bolivia/559/2013 (H1N1) antigen vaccine
influenza B virus B/Brisbane/9/2014 antigen vaccine
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen vaccine
influenza B virus B/Hong Kong/259/2010 antigen vaccine
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen vaccine
Vibrio cholerae CVD 103-HGR strain live antigen vaccine
influenza A virus A/Michigan/45/2015 (H1N1) antigen vaccine
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen vaccine
influenza A virus A/Slovenia/2903/2015 (H1N1) antigen vaccine
influenza B virus B/Maryland/15/2016 antigen vaccine
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen vaccine
influenza B virus B/Colorado/06/2017 antigen vaccine
Neisseria meningitidis Group B Membrane vesicles External Omv vaccine
Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B vaccine
Bordetella Pertussis Filamentous Haemagglutinin Antigen vaccine
Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen vaccine
Haemophilus capsular oligosaccharide vaccine
influenza A virus (H5N1) antigen vaccine
hepatitis A virus strain CR 326F antigen, inactivated vaccine
Varicella zoster virus glycoprotein E vaccine
hepatitis B virus subtype ADW2 HBsAg surface protein antigen vaccine
Varicella zoster virus glycoprotein E, recombinant vaccine
influenza A virus A/Victoria/361/2011 (H3N2) antigen vaccine
A route of administration that inject the material (such as vaccines, allergens) directly into a tumor.
A route of administration that inject the material (such as vaccines, allergens) directly into a lesion or into the skin.
Antigen that is only expressed by tumor cells.
Antigen that is overexpressed by tumor cells.
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
Active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
Afluria Quadrivalent Southern Hemisphere
AFLURIA QUADRIVALENT SOUTHERN HEMISPHERE vaccine
Influenza Virus Vaccine (Trivalent, Types A and B)
Active immunization against influenza disease cause by influenza virus subtypes A and type B present in the vaccine. Afluria is approved for use in persons 6 months of age and older.
Respiratory Syncytial Virus Vaccine, Adjuvanted
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: individuals 60 years of age and older; individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV
Influenza A (H5N1) Monovalent Vaccine, Adjuvanted
AUDENZ is an inactivated vaccine indicated for active immunization for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine. AUDENZ is approved for use in persons 6 months of age and older at increased risk of exposure to the influenza A virus H5N1 subtype contained in the vaccine.
Pneumococcal 21-valent Conjugate Vaccine
CAPVAXIVE is indicated for: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A,15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B inindividuals 18 years of age and older. Active immunization for the prevention of pneumonia caused by S. pneumoniaeserotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F,23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older. The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
For post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5954
For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
ERVEBO is a vaccine indicated for For the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
For active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine
Influenza Virus Vaccine (Quadrivalent, Types A and Types B)
Fluzone High-Dose Quadrivalent: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Measles, Mumps and Rubella Vaccine, Live
Frozen Formulation - Human SerumAlbumin (HSA) - ProQuad vaccine
For the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV.
Influenza A (H1N1) 2009 Monovalent Vaccine
Active immunization of persons ages 18 years of age older against influenza disease caused by pandemic (H1N1) 2009 virus.
Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec)
Influenza Virus Vaccine, H5N1 (for National Stockpile)
For active immunization of persons 18 through 64 years of age at increased risk of exposure to the H5N1 influenza virus subtype contained in the vaccine
Smallpox and Monkeypox Vaccine, Live, Non-Replicating
For prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
MRESVIA is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
Meningococcal (Groups A, C, Y, and W-135) Vaccine
MenQuadfi is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals 2 years of age and older.MenQuadfi does not prevent N. meningitidis serogroup B disease.
Meningococcal Groups A, B, C, W and Y Vaccine
PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age.
For prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years and older.
Pneumococcal 20-valent Conjugate Vaccine
Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older. Active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age. Active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older.
Refrigerator-Stable Formulation - ProQuad vaccine
Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
For active immunization for the prevention of tetanus and diptheria for use in persons 7 years of age or older.
For active immunization to prevent tick-borne encephalitis (TBE) in individuals 1 year of age and older.
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib) in children 6 weeks through 4 years of age (prior to fifth birthday).
VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12 months of age and older.
For the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9), for use in infants 6 weeks to 24 weeks of age.
(Squeezable Tube Presentation) - ROTARIX vaccine
Fluzone High-Dose Quadrivalent Southern Hemisphere
Fluzone High-Dose Quadrivalent Southern Hemisphere is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Fluzone High-Dose Quadrivalent Southern Hemisphere vaccine
Fluzone Quadrivalent : For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is approved for use in persons 6 months of age and older.
Fluzone Quadrivalent 2022-2023 formula vaccine
Tetanus & Diphtheria Toxoids Adsorbed for Adult Use
For active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel is approved for use as a four dose series in children 6 weeks through 4 years of age (prior to 5thbirthday).
Pentacel - (inactivated poliovirus component grown in Vero cells) vaccine
Frozen Formulation - Recombinant Human Albumin (RHA) - ProQuad vaccine
Patient information for M-M-R II vaccine
Measles, Mumps, and Rubella Virus Vaccine, Live
Active immunization against diphtheria, tetanus, pertussis and poliomyelitis. A single dose of Quadracel is approved as a fifth dose in the diphtheria, tetanus, pertussis (DTaP) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (IPV) vaccination series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Pentacel, DAPTACEL, and/or VAXELIS.
Quadracel (inactivated poliovirus component grown in MRC-5 cells) vaccine
Quadracel (inactivated poliovirus component grown in Vero cells) vaccine
A vaccine that is designed to immunize against a single antigen or single strain of a pathogen.
A vaccine that is designed to immunize against multiple antigen or multiple strain of a pathogen.
A period typically associated with a higher incidence of influenza virus infections, characterized by the increased circulation of flu viruses in a population.
Flu viruses circulate year-round, but most cases are typically reported during the fall and winter months, a period known as flu season (CDC, 2022). The seasonality of flu varies globally, influenced by the distinct seasonal patterns of each hemisphere. Therefore, the flu season in the Northern Hemisphere often spans two calendar years, while in the Southern Hemisphere, it generally occurs within a single year. In temperate climate zones, peak flu activity typically occurs from October to April in the Northern Hemisphere and from April to October in the Southern Hemisphere (CDC, 2023; Kakoullis et al., 2023). In the United States, the flu season typically peaks between December and February, according to the CDC (2022).
Bacillus anthracis vaccine with license for human use.
licensed human bacillus anthracis vaccine
Bordetella pertussis vaccine with license for human use.
licensed human bordetella pertussis vaccine
Clostridium tetani vaccine with license for human use.
licensed human clostridium tetani vaccine
Haemophilus influenzae serotype b vaccine with license for human use.
licensed human haemophilus influenzae serotype b vaccine
Hepatitis A virus vaccine with license for human use.
licensed human hepatitis A virus vaccine
Hepatitis B virus vaccine with license for human use.
licensed human hepatitis B virus vaccine
Japanese encephalitis virus vaccine with license for human use.
licensed human Japanese encephalitis virus vaccine
Measles virus vaccine with license for human use.
Mumps virus vaccine with license for human use.
Mycobacterium tuberculosis vaccine with license for human use.
licensed human mycobacterium tuberculosis vaccine
Neisseria meningitidis vaccine with license for human use.
licensed human neisseria meningitidis vaccine
Corynebacterium diphtheriae vaccine with license for human use.
licensed human orynebacterium diphtheriae vaccine
human papillomavirus vaccine with license for human use.
Poliovirus vaccine with license for human use.
Rabies virus vaccine with license for human use.
Rotavirus vaccine with license for human use.
Rubella virus vaccine with license for human use.
Salmonella typhi vaccine with license for human use.
Smallpox virus vaccine with license for human use.
Streptococcus pneumoniae vaccine with license for human use.
licensed human streptococcus pneumoniae vaccine
Tick-borne Encephalitis Virus (TBEV) vaccine with license for human use.
licensed human tick-borne encephalitis virus vaccine
Vibrio cholerae vaccine with license for human use.
yellow fever virus vaccine with license for human use.
licensed human yellow fever virus vaccine
seasonal licensed human influenza virus vaccine
vaccine-induced cell-mediated immune response
An immune biomarker that indicates a humoral immune response.
An immune biomarker that indicates a cell-mediated immune response.
correlated profile of immune protection based on population coverage
Correlated profile of immune protection that reliably predicts vaccine efficacy across settings different from those studied in an efficacy trial.
correlated profile of immune protection based on statistical level
correlated profile of immune protection based on causality
Correlated profile of immune protection that is not a mechanistic causal agent of protection, but is still predictive of vaccine efficacy.
nonmechanistic correlate of immune protection
Correlated profile of immune protection that is mechanistically and causally responsible for protection.
mechanistic correlate of immune protection
diphtheria, tetanus toxoids and acellular pertussis vaccine
Diphtheria, Tetanus, and acellular Pertussis vaccine
Coxiella burnetii vaccine that is licensed for use in humans.
licensed human coxiella burnetii vaccine
Francisella tularensis vaccine that is licensed for use in humans.
licensed human francisella tularensis vaccine
Borrelia burgdorferi vaccine that is licensed for use in humans preventing Lyme disease.
Rheumatic fever vaccine that is licensed for use in humans.
Leprosy vaccine that is licensed for use in humans.
Hantavirus vaccine that is licensed for use in humans.
Human immunodeficiency virus vaccine that is licensed for use in humans.
licensed human immunodeficiency virus vaccine
Junin virus vaccine that is licensed for use in humans.
Rift Valley Fever virus vaccine that is licensed for use in humans.
licensed human Rift Valley Fever virus vaccine
Licensed human smallpox virus vaccine that uses vaccinia virus.
Leishmania vaccine is licensed for use in humans.
malaria vaccine is licensed for use in humans.
Melanoma vaccine that is licensed for use in humans.
Parainfluenza 3 virus vaccine is licensed for use in humans.
licensed human Parainfluenza 3 virus vaccine
An immune profile that is characterized by the presence of Type 1 T helper (Th1) cells that produce interferon-gamma, interleukin (IL)-2, and tumor necrosis factor (TNF)-beta, which activate macrophages and are responsible for cell-mediated immunity and phagocyte-dependent protective responses.
An immune profile that is characterized by the presence of T type 2 Th (Th2) cells that produce IL-4, IL-5, IL-10, and IL-13, which are responsible for strong antibody production, eosinophil activation, and inhibition of several macrophage functions, thus providing phagocyte-independent protective responses.
USA is a country that exists in north America.
A viral vaccine that protects against infection with Rubella virus.
A vaccine regulation for vaccine safety.
A vaccine regulatory process that is for vaccine regulatory agent to review vaccine license application from vaccine producer.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=554
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=555
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=557
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=761
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=559
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=560
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=3231
BCG vaccine (Freeze-Dried) (by Sanofi Pasteur)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=563
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=567
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=759
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=323
ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.
A Measles-Rubella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=568
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=569
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=570
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=742
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=572
For active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b. HIBERIX is approved for use in children 6 weeks through 4 years of age (prior to fifth birthday).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=573
A poliovirus vaccine that contains inactivtated Poliomyelitis to prevent disease caused from the vaccine.
A combination vaccine that protects infants from diphtheria, tetanus, pertussis (whooping cough), polio, hepatitis B and Haemophilus influenzae type b (Hib).
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=578
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=579
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=581
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=582
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=583
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=763
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=584
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=585
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=587
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=762
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=588
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=589
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=591
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=767
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=592
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=593
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=595
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=596
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=764
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=598
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=599
Meningococcal Polysaccharide Vaccine, Groups A & C, Menomune A/C
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=600
A live attenuated V. cholerae vaccine that is manufactured by Berna Biotech, Ltd. This vaccine uses the V. Cholera strain CVD 103-HGR.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=780
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=603
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=604
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=605
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=607
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=608
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=766
A polyvalent pneumococcal vaccine used to protectsagainst serious infection (e.g., meningitis, bacteria in the blood) due to Streptococcus pneumoniae, and it is manufactured by Sanofi Pasteur.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=615
Generic Name: pneumococcal vaccine polyvalent (Intramuscular route, Subcutaneous route)
A MMR vaccine that is manufactured by GlaxoSmithKline Biologicals.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6143
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=616
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=617
For active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.
A Measles-Mumps-Rubella-Vericella vaccine that is live attenuated and manufactured by GlaxoSmithKline Biologicals.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=619
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=620
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=621
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=622
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=623
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=624
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=626
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=770
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=322
RECOMBIVAX HB is indicated for vaccination against infection caused by all known subtypes of hepatitis B virus.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=343
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=627
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=771
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=632
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=633
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=778
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=637
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=638
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=639
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=321
For the prevention of disease cause by hepatitis A virus (HAV) in persons 12 months of age and older.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=640
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=641
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=643
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=644
Tick-borne Encephalitis Virus (TBEV) protein
Infectious Hematopoietic Necrosis Virus protein
Vibrio anguillarum (Listonella anguillarum) protein
Herpes simplex virus type 1 and 2 protein
Western equine encephalomyelitis virus protein
IMMUNOGENICITY: Induces antigen-specific Th1 immune response, as indicated by the specific induction of serum IgG2a, but not IgG1, antibodies and by the secretion of IFN-alpha but not IL-4, by the Cu/Zn SOD-stimulated splenocytes. Has been used for vaccine development [PubMed: 10816475][PubMed: 11953393][PubMed: 12933826]. MUTATION: An isogenic sodC mutant constructed from B abortus 2308 by gene replacement exhibited much greater susceptibility to killing by exogenous O(2)(-) than the parental 2308 strain, supporting a role for SodC in protecting this bacterium from O(2)(-) stress. The B abortus sodC mutant was much more sensitive to killing by cultured resident peritoneal macrophages from C57BL6J mice than 2308, and its attenuation in cultured murine macrophages was enhanced when these phagocytes were treated with gamma interferon. The attenuation of the B abortus sodC mutant in both resting and IFN-gamma-activated macrophages was alleviated in the presence of the NADPH oxidase inhibitor apocynin. Consistently, the B abortus sodC mutant also displayed significant attenuation in infected C57BL6J mice compared to the parental strain. These findings suggest that SodC protects B abortus 2308 from the respiratory burst of host macrophages [PubMed: 15845493].
VIOLILN Protegen ID: 3; NCBI Protein GI: 83269434; NCBI Protein Accession: YP_418725.1; NCBITaxon: 234
Protegen ID: 5; NCBI Gene GI: 1158731; NCBI Protein GI: 40646957; NCBI Protein Accession: AAR88323.1; NCBITaxon: 32630
Protegen ID: 11; NCBI Gene GI: 955194; NCBI Protein GI: 22789223; NCBI Protein Accession: NP_690580; NCBITaxon: 186539
Protegen ID: 12; NCBI Gene GI: 955193; NCBI Protein GI: 22789228; NCBI Protein Accession: NP_690586; NCBITaxon: 186539
Protegen ID: 13; NCBI Gene GI: 955192; NCBI Protein GI: 22789225; NCBI Protein Accession: NP_690582; NCBITaxon: 186539
Protegen ID: 14; NCBI Gene GI: 955196; NCBI Protein GI: 22789227; NCBI Protein Accession: NP_690585; NCBITaxon: 186539
Protegen ID: 15; NCBI Gene GI: 955189; NCBI Protein GI: 22789224; NCBI Protein Accession: NP_690581; NCBITaxon: 186539
VP35 expressed from alphavirus replicons induced a protective immune response in C57BL/6 mice when challenged with Ebola virus Zaire [PubMed: 11485406].
Protegen ID: 16; NCBI Gene GI: 911827; NCBI Protein GI: 10313992; NCBI Protein Accession: NP_066244; NCBITaxon: 186538
Recombinant Tbp1 and Tbp2 proteins were expressed from Escherichia coli and antisera were raised to the purified proteins. In a passive model of bacteraemia, infant rats were protected from challenge with Hib after transfer of anti-rTbp2 antiserum, but not after anti-rTbp1 antiserum [PubMed: 8830248].
Protegen ID: 277; NCBI Gene GI: 3430457; NCBI Protein GI: 68249580; NCBI Protein Accession: YP_248692; NCBITaxon: 281310
VP24 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406].
Protegen ID: 17; NCBI Gene GI: 911828; NCBI Protein GI: 10313998; NCBI Protein Accession: NP_066250; NCBITaxon: 186538
VP30 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406].
Protegen ID: 18; NCBI Gene GI: 911826; NCBI Protein GI: 10313997; NCBI Protein Accession: NP_066249; NCBITaxon: 186538
Vaccination of BALB/c or C57BL/6 mice with eVLPs, composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge [PubMed: 16002721]. VP40 expressed from alphavirus replicons induced a protective immune response in BALB/c mice when challenged with Ebola virus Zaire [PubMed: 11485406].
Protegen ID: 19; NCBI Gene GI: 911825; NCBI Protein GI: 10313993; NCBI Protein Accession: NP_066245; NCBITaxon: 186538
HLA-A*0201 mice immunized with either GPC(42-50) from LASVsSgp2 glycoprotein or GPC(60-68) were protected against challenge with a recombinant vaccinia virus that expressed LASV GPC [PubMed: 16912286].
Protegen ID: 20; NCBI Gene GI: 956585; NCBI Protein GI: 23343511; NCBI Protein Accession: NP_694870; NCBITaxon: 11620
Caf1 from Y. pestis biovar Microtus str. 91001
Protegen ID: 23; NCBI Gene GI: 2767670; NCBI Protein GI: 45478667; NCBI Protein Accession: NP_995523; NCBITaxon: 229193
It has previously been shown that a DNA subunit vaccine (4pox) based on four orthopoxvirus immunogens (L1R, B5R, A27L and A33R) can produce protective immunity against lethal orthopoxvirus challenges in mice and nonhuman primates. the immunogenicity of an L1R construct to which a tissue plasminogen activator signal sequence was placed in frame with the full-length L1R gene was tested. When the tPA-L1R construct was substituted for the unmodified L1R gene in the 4pox vaccine, given as a prime and single boost, animals were better protected from lethal challenge with vaccinia virus (VACV) [PubMed: 18485547].
Protegen ID: 28; NCBI Gene GI: 928938; NCBI Protein GI: 17974998; NCBI Protein Accession: NP_536512; NCBITaxon: 619591
PagA from B. anthracis str. Ames Ancestor
Protegen ID: 32; NCBI Gene GI: 2820165; NCBI Protein GI: 47566476; NCBI Protein Accession: NC_007322.2
Lef from B. anthracis str. Ames Ancestor
Protegen ID: 38; NCBI Gene GI: 2820148; NCBI Protein GI: 47566484; NCBI Protein Accession: NC_007322.2
MAb BA5 protected animals against plague, neutralized the Y. pestis type III secretion pathway and promoted opsonophagocytic clearance of bacteria in blood. LcrV residues 196-225 were necessary and sufficient for MAb BA5 binding. These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection [PubMed: 20005318].
Protegen ID: 44; NCBI Gene GI: 1172676; NCBI Protein GI: 16082719; NCBI Protein Accession: NP_395165; NCBITaxon: 214092
An LcrV variant lacking amino acid residues 271 to 300 (rV10) elicited immune responses that protected mice against a lethal challenge with Y. pestis [PubMed: 16041032].
Protegen ID: 45; NCBI Gene GI: 1149310; NCBI Protein GI: 31795491; NCBI Protein Accession: NP_857946; NCBITaxon: 187410
Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to pla [PubMed: 10085037].
Protegen ID: 48; NCBI Gene GI: 1172643; NCBI Protein GI: 16082686; NCBI Protein Accession: NP_395233; NCBITaxon: 214092
The type III secretion apparatus encoded on the low-calcium response (LCR) virulence plasmid, pCD1 in strain KIM5, of Y. pestis is a conserved virulence mechanism that is absolutely required for virulence of Y. pestis. YscF is a surface localized protein required both to secrete Yops and to translocate toxins into eukaryotic cells. YscF polymerization is possibly required for a YscF needle to puncture eukaryotic cell membranes. It is also likely that YscF and its homologs function to provide a base that a translocon complex is built upon, or that YscF builds a conduit from the bacterium to the eukaryotic membrane - this suggestion seems more likely given that other proteins such as YopB, YopD, and LcrV are also required for translocation into eukaryotic cells. YscF is thought to be a surface-expressed protein in Y. pestis and is required for virulence. YscF has been found to function as a protective antigen against experimental plague infection [PubMed: 15978133].
Protegen ID: 49; NCBI Gene GI: 1172673; NCBI Protein GI: 16082716; NCBI Protein Accession: NP_395162; NCBITaxon: 214092
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatA) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatB
Protegen ID: 422; NCBI Protein GI: 62184918; NCBITaxon: 218497
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #3, gatB) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648]. Note: Part of CP #3 also belongs to gatA
Protegen ID: 424; NCBI Protein GI: 62147986; NCBITaxon: 218497
The MOMP (omp1) DNA immunization induced a non-specific and partial protection in OF1 outbred mice fetuses against challenge with C. abortus [PubMed: 12488563].
Protegen ID: 425; NCBI Protein GI: 40601; NCBITaxon: 83555
In pregnant mice, the dnaK vaccine induced a non-specific partial protection from abortion after challenge with Chlamydophila abortus [PubMed: 12056482].
Protegen ID: 426; NCBI Protein GI: 26006347; NCBITaxon: 83555
The immunogenicity and protective effect of recombinant LcrE protein combined either with Freund's or Alum adjuvant were investigated in mice. The immunization with both protocols resulted in a significant reduction of the number of viable C. pneumoniae in the lungs after challenge. Results confirm that LcrE induces protective immunity in mice [PubMed: 19451031].
Protegen ID: 428; NCBI Gene GI: 895078; NCBI Protein GI: 15618244; NCBI Protein Accession: NP_224529; NCBITaxon: 115713
Results of this study showed that intranasal immunization of BALB/c mice with heat-aggregated CopN protein and an Escherichia coli heat-labile toxin (LT) induced a strong immune response. The immunization induced statistically significant protection against intranasal C. pneumoniae challenge, the level of which correlated with the magnitude of CopN-specific lymphocyte proliferation [PubMed: 16949182].
Protegen ID: 429; NCBI Protein GI: 33241669; NCBITaxon: 182082
Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0512 showed significant levels of protection when compared to negative control animals. At 9 days following challenge TC0512 showed a 73% reduction in the number of recoverable Chlamydia compared with vector only immunized controls [PubMed: 17239501].
Protegen ID: 430; NCBI Gene GI: 1245872; NCBI Protein GI: 15835130; NCBI Protein Accession: NP_296889; NCBITaxon: 243161
Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0757 showed significant levels of protection when compared to negative control animals [PubMed: 17239501].
Protegen ID: 431; NCBI Gene GI: 1246122; NCBI Protein GI: 15835371; NCBI Protein Accession: NP_297130; NCBITaxon: 243161
Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0439 showed significant levels of protection when compared to negative control animals [PubMed: 17239501].
Protegen ID: 432; NCBI Gene GI: 1245792; NCBI Protein GI: 15835057; NCBI Protein Accession: NP_296816; NCBITaxon: 243161
Following vaginal challenge with live Chlamydia, the groups of female BALB/c mice immunized intra-abdominally with TC0767/768 showed significant levels of protection when compared to negative control animals [PubMed: 17239501].
Protegen ID: 433; NCBI Gene GI: 1246132; NCBI Protein GI: 15835381; NCBI Protein Accession: NP_297140; NCBITaxon: 243161
Protegen ID: 434; NCBI Gene GI: 1246133; NCBI Protein GI: 15835382; NCBI Protein Accession: NP_297141; NCBITaxon: 243161
Female BALB/c mice were immunized with chlamydial major outer membrane protein (MOMP) mixed with cholera toxin and CpG oligodeoxynucleotide adjuvants by either the IN or TCI routes. Both intranasal and transcutaneous immunization protected mice against respiratory challenge with Chlamydia [PubMed: 16153755].
Protegen ID: 435; NCBI Protein GI: 1518659; NCBITaxon: 83560
Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. Overall, vaccination with DCs transfected with PmpG-1(25-500) exhibited the greatest degree of protective immunity among the four Chlamydia Ags tested [PubMed: 19155509].
Protegen ID: 436; NCBI Gene GI: 1246433; NCBI Protein GI: 15834883; NCBI Protein Accession: NP_296642; NCBITaxon: 243161
Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, RplF was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509].
Protegen ID: 437; NCBI Gene GI: 1246168; NCBI Protein GI: 15835415; NCBI Protein Accession: NP_297174; NCBITaxon: 243161
Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection. In addition, pmpE/F-2 was able to engender protective immunity against challenge with C. muridarum [PubMed: 19155509].
Protegen ID: 438; NCBI Gene GI: 1246432; NCBI Protein GI: 15834882; NCBI Protein Accession: NP_296641; NCBITaxon: 243161
IM-ID vaccination with CPn0095 (pknD) generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p0.019). This resulted in the ability of CPN0095 to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129].
Protegen ID: 439; NCBI Gene GI: 895704; NCBI Protein GI: 161353778; NCBI Protein Accession: NP_224303; NCBITaxon: 115713
M-ID vaccination with fabD generated a response that resulted in moderately, but significantly reduced total C. pneumoniae lung loads as compared to control mice vaccinated with a plasmid expressing a non-Chlamydia ORF (p 0.019). This resulted in the ability of fabD to mediate a moderate, but statistically significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129].
Protegen ID: 440; NCBI Gene GI: 894994; NCBI Protein GI: 15618217; NCBI Protein Accession: NP_224502; NCBITaxon: 115713
Mice vaccinated with candidate gene ssb showed significant reduction of spleen chlamydial loads as compared to nave, non-protected control mice (p 0.048). This resulted in the ability of ssb to mediate a modest, but significant level of protection in an inbred A/J mouse respiratory challenge model [PubMed: 16434129].
Protegen ID: 441; NCBI Gene GI: 894901; NCBI Protein GI: 15618301; NCBI Protein Accession: NP_224586; NCBITaxon: 115713
Pigs were subjected to challenge infection with a dose of 1x10(5)TCID(50) (50% tissue culture infective dose) virulent CSFV strain. At 1 week post challenge infection, all of the yE2-immunized pigs were alive and without symptoms or signs of CSF. The yeast-expressed E2 protein retains correct immunogenicity and is able to induce a protective immune response against CSFV infection [PubMed: 19625145]. In a seperate study, swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549].
Protegen ID: 442; NCBI Gene GI: 920146; NCBI Protein GI: 12657942; NCBI Protein Accession: NP_075354; NCBITaxon: 11096
Swine vaccinated with VVR expressing E0 and/or E2 resisted a lethal challenge infection with CSFV. Glycoprotein E0 represents a second determinant for the induction of protective immunity against classical swine fever [PubMed: 7666549].
Protegen ID: 443; NCBI Protein GI: 115343287; NCBITaxon: 11096
Intramuscular vaccination of pigs with immunoaffinity-purified E1 (gp55) in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV (Classical swine fever virus) strain Brescia [PubMed: 8350404].
Protegen ID: 444; NCBI Protein GI: 1763691; NCBITaxon: 11096
A single dose of ciBoNT/A1 HP provided equivalent or greater protective immunity, not only against the homologous toxin, but also against two distinct toxin subtypes with significant amino acid divergence in mice when challenged with BoNT/A subtypes /A1, /A2, and /A3 from Clostridium botulinum [PubMed: 19450643].
Protegen ID: 445; NCBI Protein GI: 241183337; NCBITaxon: 1491
Purified FHc was used to vaccinate mice and evaluate their survival against challenge with active botulinum neurotoxin serotype F (BoNT/F). Mice that received one injection of 5 microg or two injections of >or=0.04 microg of FHc were completely protected [PubMed: 18845829].
Protegen ID: 446; NCBI Protein GI: 166236883; NCBITaxon: 32630
A completely synthetic gene encoding fragment C, a approximately 50-kDa fragment, of botulinum neurotoxin serotype A was constructed from oligonucleotides. Mice given three subcutaneous vaccinations were protected against an intraperitoneal administration of 10^6 50% lethal doses (ID50) of serotype A toxin [PubMed: 7790092].
Protegen ID: 447; NCBI Protein GI: 733429; NCBITaxon: 32630
Mice and rabbits were immunized with recombinant HCR/A1 (rHCR/A1) from the classical type A-Hall strain (ATCC 3502) (BoNT/A1) and rHCR/E from BoNT serotype E Beluga (BoNT/E(B)). The protection elicited by rHCR/A1 to BoNT/A1 and BoNT/A2 and by rHCR/E(B) to BoNT/E(A) indicate that immunization with receptor binding domains elicit protection within sub-serotypes of BoNT [PubMed: 16177380].
Protegen ID: 448; NCBI Gene GI: 5398487; NCBI Protein GI: 153936924; NCBI Protein Accession: YP_001386738; NCBITaxon: 441771
The DNA replicon vaccine (pSCARSBHc) encoding the Hc domain of BoNT/B (BHc) induced better responses and protection against BoNT/B mouse challenge than conventional DNA vaccine. Recombinant SFV particle VRP-BHc protected mice from high-dose BoNT/B challenge [PubMed: 19712769].
Protegen ID: 449; NCBI Gene GI: 6030102; NCBI Protein GI: 169834607; NCBI Protein Accession: YP_001693307; NCBITaxon: 498213
Researchers constructed a replication-incompetent adenovirus encoding a synthesized codon-optimized gene for expression of the heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C). After a single dose of 2 x 10^7pfu adenoviral vectors in a mouse model, the animals were completely protected against intraperitoneal challenge with 100 x MLD(50) of active BoNT/C [PubMed: 17897756].
Protegen ID: 450; NCBI Protein GI: 217781; NCBI Protein Accession: BAA14235.1; NCBITaxon: 12336
A recombinant vaccinia virus containing most of the P1 region of hepatitis A virus (HAV) was constructed bearing epitopes from structural polypeptides VP4, -3 and -2, and the N terminus of VP. Inoculation of tamarin monkeys with the recombinant virus resulted in the development of a specific anti-HAV immune response which was protective against challenge with a virulent strain of HAV [PubMed: 1654376].
Protegen ID: 680; NCBI Gene GI: 1493919; NCBI Protein GI: 9626734; NCBI Protein Accession: NP_041008; NCBITaxon: 12092
Following two intragastric immunizations in BALB/c mice, the Yersinia vectors harboring a DNA vaccine encoding BFR (P39) induced antigen-specific serum immunoglobulin and Th1-type responses among splenocytes. The best protection was conferred by a serotype O:9 strain carrying pCIP39, confirming the importance of the P39 T-cell antigen in this mechanism [PubMed: 11895955].
Protegen ID: 681; NCBI Gene GI: 6326162; NCBI Protein GI: 189022832; NCBI Protein Accession: YP_001932573; NCBITaxon: 430066
Study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both the Brucella abortus L7/L12 protein (ribosomal protein, rplL) and Omp16 protein (outer membrane lipoprotein). This divalent DNA vaccine induced a significant level of protection against challenge with the virulent B. abortus in BALB/c mice [PubMed: 16622210].
Protegen ID: 682; NCBI Gene GI: 3788918; NCBI Protein GI: 82700077; NCBI Protein Accession: YP_414651; NCBITaxon: 359391
The fragment C of tetanus toxin was amplified from Clostridium tetani DNA by PCR. Immunization of mice with rTTC resulted in the production of antibodies that were able to protect mice against a challenge with tetanus toxin furthermore, rTTC in vivo appeared to be able to undergo retrograde axonal transport [PubMed: 12075415].
Protegen ID: 451; NCBI Protein GI: 157829735; NCBITaxon: 1513
Cynomolgus macaques were immunized with DNA/rAd5 vaccines expressing ZEBOV (GP) and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV [PubMed: 20502688].
Protegen ID: 452; NCBI Gene GI: 911829; NCBI Protein GI: 10313995; NCBI Protein Accession: NP_066246; NCBITaxon: 186538
Protegen ID: 453; NCBI Gene GI: 3160774; NCBI Protein GI: 55770812; NCBI Protein Accession: YP_138523; NCBITaxon: 186540
Guinea pigs infected with a single intranasal inoculation of HPIV3/EboGP-NP showed no apparent signs of disease yet developed a strong humoral response specific to the EV proteins. When these animals were challenged with an intraperitoneal injection of 10(3) PFU of EV, there were no outward signs of disease, no viremia or detectable EV antigen in the blood, and no evidence of infection in the spleen, liver, and lungs. In contrast, all of the control animals died or developed severe EV disease following challenge [PubMed: 16474134].
Protegen ID: 454; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538
Ten mice were inoculated subcutaneously, administered booster injections after one month, and challenged with 130 LD(50) of wild type Y. pestis CO92. The vaccinated animals produced high levels of specific antibodies against YscF as determined by Western blot. The data were statistically significant (P = 0.053 by two-tailed Fisher's test), suggesting that the YscF protein can provide a protective immune response against lethal plague challenge during subcutaneous plague infection [PubMed: 15939303].
Protegen ID: 54; NCBI Gene GI: 1172700; NCBI Protein GI: 16082743; NCBI Protein Accession: NP_395189; NCBITaxon: 214092
The P4 protein is an integral outer membrane protein that has a role in acquiring hemin and nucleosides [PubMed: 1715322 ].
Recombinant P6 (pal) was capable of eliciting a protective antibody response against live H. influenzae type b challenge in a modified infant rat model of bacteremia [PubMed: 9261944].
Protegen ID: 101; NCBI Gene GI: 3429820; NCBI Protein GI: 68248984; NCBI Protein Accession: YP_248096; NCBITaxon: 281310
When mice immunized intranasally with recombinant protein corresponding to the C-terminal region of Hap(S) from H. influenzae strains N187, P860295, and TN106 plus mutant cholera toxin CT-E29H were challenged with strain TN106, they were protected against nasopharyngeal colonization [PubMed: 15557618].
Protegen ID: 103; Protegen ID: 102; NCBI Protein GI: 21686508; NCBITaxon: 727
OMP26 was used to immunize rats via intestinal Peyer's patches, followed by an intratracheal boost. Immunization was found to significantly enhance bacterial clearance following pulmonary challenge with both the homologous NTHI strain and a different NTHI strain [PubMed: 9573117].
Protegen ID: 276; NCBI Nucleotide GI: 4574245; NCBI Protein GI: 4574246; NCBI Protein Accession: AAD23967.1; NCBITaxon: 727
The heterologous prime-boost strategy of live Salmonella vaccine expressing Mycobacterium tuberculosis fusion antigen Age5B-ESAT6 (esxA) from the chromosome followed by a systemic boost of antigen and adjuvant reduced the levels of M. tuberculosis bacteria in the lungs and spleen to the same extent as BCG. Additionally, this vaccination regimen was observed to be statistically equivalent in terms of protection to immunisation with BCG [PubMed: 19755145].
Protegen ID: 104; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773
Protegen ID: 138; NCBI Gene GI: 814170; NCBI Protein GI: 124513464; NCBI Protein Accession: XP_001350088; NCBITaxon: 36329
LolC was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the LolC protein domain afforded significant protection against a subsequent challenge with B. pseudomallei. LolC provided a greater level of protection when it was administered with immune-stimulating complexes complexed with CpG oligodeoxynucleotide 10103. Immunization with LolC also protected against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the potential utility of this protein as a vaccine antigen for melioidosis [PubMed: 17517877].
Protegen ID: 768; NCBI Gene GI: 3093214; NCBI Protein GI: 53719887; NCBI Protein Accession: YP_108873; NCBITaxon: 272560
PotF was evaluated as an antigen for a vaccine candidate against B. pseudomallei infection. Nonmembrane regions of the B. pseudomallei protein was expressed and purified from Escherichia coli and then evaluated as a vaccine candidate in an established mouse model of B. pseudomallei infection. When delivered with the monophosphoryl lipid A-trehalose dicorynomycolate adjuvant, the protein stimulated antigen-specific humoral and cellular immune responses. Immunization with the PotF protein domain afforded significant protection against a subsequent challenge with B. pseudomallei [PubMed: 17517877].
Protegen ID: 769; NCBI Gene GI: 3095748; NCBI Protein GI: 53721504; NCBI Protein Accession: YP_110489; NCBITaxon: 272560
Protegen ID: 139; NCBI Gene GI: 810891; NCBI Protein GI: 124804478; NCBI Protein Accession: XP_001348015; NCBITaxon: 36329
The ompA codon was adapted to the codon usage in birds, resulting in pcDNA1/MOMP(opt). Researchers examined the capacity of nebulised or intramuscularly (IM) administered brPEI-pcDNA1/MOMP(opt) to induce a significant protective immune response in SPF turkeys experimentally infected with 10^8 TCID(50) of a virulent Cp. psittaci strain. Vaccinated groups were significantly protected against Cp. psittaci challenge [PubMed: 20199760].
Protegen ID: 766; NCBI Protein GI: 94467392; NCBITaxon: 83554
Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce protective immunity against Cp. psittaci challenge in budgerigars. DNA immunisation significantly reduced clinical signs, macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies, as compared to the placebo-vaccinated controls [PubMed: 19640395].
Protegen ID: 767; NCBI Nucleotide GI: 144544; NCBI Protein GI: 144545; NCBI Protein Accession: AAA17396.1; NCBITaxon: 83554
This gene was originally isolated from a lambda gt11 expression library probed with sera from Brucella-infected sheep. Sequence analysis of the cloned gene revealed the presence of an open reading frame of 158 amino acids encoding a protein of 17.3 kDa [PubMed: 7664168 ]. It was later identified as a cytoplasmic protein lumazine synthase [PubMed: 10482294 ]. This gene can be used for diagnosis [PubMed: 7664168 ] [PubMed: 10482294 ] and vaccine development [PubMed: 11953389 ].
Protegen ID: 113; NCBI Nucleotide GI: 599653; NCBI Protein GI: 599654; NCBI Protein Accession: CAA86936.1; NCBITaxon: 235
Protegen ID: 114; NCBI Protein GI: 304271
Guinea pigs were vaccinated with recombinant VEE replicons (packaged into VEE-like particles), inoculated with MBGV, and evaluated for viremia and survival after challenge with typical MGBV disease. Results indicated that VP35 afforded incomplete protection [PubMed: 9813200 ].
Protegen ID: 167; NCBI Gene GI: 920948; NCBI Protein GI: 13489277; NCBI Protein Accession: NP_042026.1; NCBITaxon: 11269
The purified recombinant proteins, P1, HspB, and P1-HspB, and whole-cell antigen (WCA) of C. burnetii were used to immunize BALB/c mice. Protective immunity against Q fever was induced with a recombinant P1 antigen fused with HspB after Coxiella burnetii challenge [PubMed: 16481504 ].
Protegen ID: 171; NCBI Protein GI: 30025845; NCBITaxon: 777
Protegen ID: 172; NCBI Gene GI: 911830; NCBI Protein GI: 10314000; NCBI Protein Accession: NP_066243; NCBITaxon: 186538
Protegen ID: 173; NCBI Protein GI: 21702651; NCBITaxon: 186538
Protegen ID: 174; NCBI Protein GI: 91177744; NCBITaxon: 378809
Protegen ID: 175; NCBI Protein GI: 197253489; NCBITaxon: 777
Mice were immunized with recombinant H3L protein to examine H3L-specific antibody responses in greater detail. H3L-immunized mice developed high-titer vaccinia virus-neutralizing antibodies (mean PRNT50 = 1:3,760). Importantly, H3L-immunized mice were subsequently protected against lethal intranasal challenges with 1 or 5 50% lethal doses (LD50) of pathogenic vaccinia virus strain WR, demonstrating the in vivo value of an anti-H3L response. To formally demonstrate that neutralizing anti-H3L antibodies are protective in vivo, we performed anti-H3L serum passive-transfer experiments. Mice receiving H3L-neutralizing antiserum were protected from a lethal challenge with 3 LD50 of vaccinia virus strain WR (5/10 versus 0/10; P < 0.02) [PubMed: 16140750].
Protegen ID: 62; NCBI Gene GI: 3707557; NCBI Protein GI: 66275898; NCBI Protein Accession: YP_232983; NCBITaxon: 10245
Protegen ID: 225; NCBI Gene GI: 1262010; NCBI Protein GI: 9632507; NCBI Protein Accession: NP_049501; NCBITaxon: 10730
Protegen ID: 231; NCBI Gene GI: 3788834; NCBI Protein GI: 82700421; NCBI Protein Accession: YP_414995; NCBITaxon: 359391
Protegen ID: 199; NCBI Gene GI: 960860; NCBI Protein GI: 15804222; NCBI Protein Accession: NP_290261.1; NCBITaxon: 562
ETEC also expresses a range of colonisation factor antigens (CFAs), which allow adherence to the mucosal surface and therefore colonisation of the intestine. Some CFAs are sub-divided into coli surface (CS) antigens [PubMed: 17566016].
Protegen ID: 79; NCBI Gene GI: 4188469; NCBI Protein GI: 110643341; NCBI Protein Accession: YP_671071; NCBITaxon: 362663
Protegen ID: 87; NCBI Gene GI: 905631; NCBI Protein GI: 15792662; NCBI Protein Accession: NP_282485.1; NCBITaxon: 197
LT is a hetero-oligomeric AB5 type enterotoxin composed of a 27 kDa A subunit with toxic ADP ribosyl transferase activity and a stable noncovalent-linked pentamer of 11.6 kDa B subunits. ETEC infection and colonization of the small intestine, and the production of LT, causes acute diarrhea that can be fatal without intervention [PubMed: 17188785].
Protegen ID: 92; NCBI Protein GI: 157021162; NCBITaxon: 562
EHEC strains produce intimin, an outer membrane adhesin encoded by the eae gene located in a chromosomal pathogenicity island termed the locus of enterocyte effacement [PubMed: 17258324].
Protegen ID: 93; NCBI Gene GI: 960862; NCBI Protein GI: 15804220; NCBI Protein Accession: NP_290259; NCBITaxon: 155864
FimH is a protective antigen [PubMed: 9110982]
Protegen ID: 263; NCBI Gene GI: 3992235; NCBI Protein GI: 91213965; NCBI Protein Accession: YP_543951; NCBITaxon: 364106
Protegen ID: 264; NCBI Gene GI: 903357; NCBI Protein GI: 15677945; NCBI Protein Accession: NP_275117; NCBITaxon: 122586
Protegen ID: 265; NCBI Gene GI: 904124; NCBI Protein GI: 15677829; NCBI Protein Accession: NP_274993; NCBITaxon: 122586
Protegen ID: 110; NCBI Protein GI: 122892474; NCBI Protein Accession: ABM67295
A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV [PubMed: 11522184].
Protegen ID: 98; NCBI Gene GI: 956108; NCBITaxon: 159122
Vaccination of mice and guinea pigs with a secA2 mutant significantly increased resistance to M. tuberculosis challenge compared with standard M. bovis bacille Calmette-Gurin vaccination [PubMed: 17671656].
Protegen ID: 117; NCBI Gene GI: 885594; NCBI Protein GI: 15608958; NCBI Protein Accession: NP_216337; NCBITaxon: 83332
The 10-kDa culture filtrate protein (CFP-10, esxB) and 6-kDa early secretory antigen of T cells (ESAT-6) are secreted in abundance by Mycobacterium tuberculosis. Study demonstrated that protective immunity is induced by CFP-10 DNA vaccination in C3H mice as measured by a CFU reduction in the lung and spleen 4 and 8 weeks after challenge with M. tuberculosis [PubMed: 18332205].
Protegen ID: 121; NCBI Gene GI: 886194; NCBI Protein GI: 15611010; NCBI Protein Accession: NP_218391; NCBITaxon: 83332
Researchers have developed DNA vaccines expressing M. tuberculosis antigen 85A (Ag85A, fbpA) and cytokine granulocyte macrophage colony stimulating factor (GM-CSF). The immune strategy of BCG-prime and DNA vaccine boost induced mice to generate efficient immune protection against M. tuberculosis challenge [PubMed: 19450898].
Protegen ID: 122; NCBI Gene GI: 886132; NCBI Protein GI: 15610940; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773
Protegen ID: 123; NCBI Gene GI: 886924; NCBI Protein GI: 15607267; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773
Protegen ID: 124; NCBI Gene GI: 886073; NCBI Protein GI: 57116841; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773
Protegen ID: 133; NCBI Gene GI: 3231573; NCBI Protein GI: 57237809; NCBI Protein Accession: YP_179057.1; NCBITaxon: 197
A total of 840 Light Sussex chickens were used to evaluate a Salmonella enterica serovar Typhimurium DeltaaroA vaccine expressing the C. jejuni amino acid binding protein CjaA. Chickens were given the vaccine at 1-day-old and two weeks later by oral gavage, then challenged after a further two weeks with C. jejuni. Across six biological replicates, statistically significant reductions in caecal C. jejuni of c. 1.4log(10) colony-forming units/g were observed at three and four weeks post-challenge relative to age-matched unvaccinated birds. Protection was associated with the induction of CjaA-specific serum IgY and biliary IgA [PubMed: 19853682].
Protegen ID: 134; NCBI Protein GI: 1813949; NCBITaxon: 197
Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum. Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection [PubMed: 8529111].
Protegen ID: 143; NCBI Protein GI: 94420988; NCBITaxon: 5833
Study compared the immunogenicity and protective efficacy of recombinant DOBV nucleocapsid protein (rDOBV N, S) given with Alum or Freund's as adjuvant, or PBS, in C57/BL6 mice. Mice receiving rDOBV N with Freund's adjuvant were protected from challenge (75% protected) [PubMed: 15364453].
S nucleocapsid protein from Dobrava-Belgrade virus
Protegen ID: 146; NCBI Gene GI: 2656266; NCBI Protein GI: 38505524; NCBI Protein Accession: NP_942553; NCBITaxon: 12506
Study developed replication-competent vaccines against EBOV and MARV based on attenuated recombinant vesicular stomatitis virus vectors expressing either the EBOV glycoprotein or MARV glycoprotein from Lake Victoria marburgvirus - Musoke. A single intramuscular injection of the EBOV or MARV vaccine elicited completely protective immune responses in nonhuman primates against lethal EBOV or MARV challenges [PubMed: 15937495].
Protegen ID: 150; NCBI Protein GI: 77543430; NCBITaxon: 33727
This is a protective antigen [PubMed: 17239499].
Protegen ID: 232; NCBI Gene GI: 1196247; NCBI Protein GI: 17986819; NCBI Protein Accession: NP_539453; NCBITaxon: 224914
Protegen ID: 236; NCBI Gene GI: 1196463; NCBI Protein GI: 161511151; NCBI Protein Accession: NP_539669; NCBITaxon: 224914
Protegen ID: 240; NCBI Gene GI: 5616654; NCBI Protein GI: 157418230; NCBI Protein Accession: YP_001481302; NCBITaxon: 405955
Protegen ID: 247; NCBI Gene GI: 4492541; NCBI Protein GI: 117624167; NCBI Protein Accession: YP_853080; NCBITaxon: 405955
Brucella Omp25 is a protective antigen [PubMed: 17049676].
Protegen ID: 253; NCBI Gene GI: 1196960; NCBI Protein GI: 17987532; NCBI Protein Accession: NP_540166; NCBITaxon: 224914
Brucella IalB is a protective antigen [PubMed: 17049676].
Protegen ID: 254; NCBI Gene GI: 1197295; NCBI Protein GI: 17987867; NCBI Protein Accession: NP_540501; NCBITaxon: 224914
Brucella bacterioferritin is a protective antigen [PubMed: 11447155 ]
Bfr from B. melitensis biovar Abortus 2308
Protegen ID: 255; NCBI Gene GI: 3828133; NCBI Protein GI: 83269559; NCBI Protein Accession: YP_418850; NCBITaxon: 359391
Protegen ID: 256; NCBI Gene GI: 1196780; NCBI Protein GI: 17987352; NCBI Protein Accession: NP_539986; NCBITaxon: 224914
Brucella DnaK is a protective antigen [PubMed: 17686554].
Protegen ID: 257; NCBI Gene GI: 3341115; NCBI Protein GI: 62290965; NCBI Protein Accession: YP_222758; NCBITaxon: 262698
Brucella SurA is a protective antigen [PubMed: 17686554].
Protegen ID: 258; NCBI Gene GI: 3787419; NCBI Protein GI: 82699574; NCBI Protein Accession: YP_414148; NCBITaxon: 359391
Brucella Omp19 is a protective antigen [PubMed: 18981242].
Protegen ID: 259; NCBI Gene GI: 3788831; NCBI Protein GI: 82700695; NCBI Protein Accession: YP_415269; NCBITaxon: 359391
Brucella Omp16 is a protective antigen [PubMed: 18981242].
Protegen ID: 260; NCBI Gene GI: 3788229; NCBI Protein GI: 82700483; NCBI Protein Accession: YP_415057; NCBITaxon: 359391
Protegen ID: 266; NCBI Gene GI: 904205; NCBI Protein GI: 15677776; NCBI Protein Accession: NP_274940; NCBITaxon: 122586
Protegen ID: 267; NCBI Gene GI: 903642; NCBI Protein GI: 15677093; NCBI Protein Accession: NP_274245; NCBITaxon: 122586
Protegen ID: 268; NCBI Gene GI: 903582; NCBI Protein GI: 15677037; NCBI Protein Accession: NP_274189; NCBITaxon: 122586
Protegen ID: 269; NCBI Gene GI: 903112; NCBI Protein GI: 15676883; NCBI Protein Accession: NP_274028; NCBITaxon: 122586
Protegen ID: 270; NCBI Gene GI: 902136; NCBI Protein GI: 15675973; NCBI Protein Accession: NP_273099; NCBITaxon: 122586
Protegen ID: 271; NCBI Gene GI: 902774; NCBI Protein GI: 15676561; NCBI Protein Accession: NP_273705; NCBITaxon: 122586
Protective antigen [PubMed: 16825336][PubMed: 12045242] with GeneID: 902509. However, according to sequence analysis, this nadA is not the same NadA that was found to be protective antigen [PubMed: 16825336][PubMed: 12045242].
Protegen ID: 272; NCBI Gene GI: 904134; NCBI Protein GI: 15677822; NCBI Protein Accession: NP_274986; NCBITaxon: 122586
Protegen ID: 273; NCBI Gene GI: 904318; NCBI Protein GI: 15677705; NCBI Protein Accession: NP_274866; NCBITaxon: 122586
Protective antigen as shown in some assays [PubMed: 16825336]
Protegen ID: 274; NCBI Gene GI: 903958; NCBI Protein GI: 15677911; NCBI Protein Accession: NP_275079; NCBITaxon: 122586
Protegen ID: 275; NCBI Gene GI: 903167; NCBI Protein GI: 15676917; NCBI Protein Accession: NP_274064; NCBITaxon: 122586
A vaccine made by Hma from E. coli strain CFT073 and 536 induced protection to the infection of virulent strain CFT073 and 536, respectively, in the bladder in the CBA/J mice. [PubMed: 19806177].
Protegen ID: 278; NCBI Gene GI: 1037732; NCBI Protein GI: 26248334; NCBI Protein Accession: NP_754374; NCBITaxon: 199310
Immunization with IreA protects against urinary tract colinization by E.coli CFT073 and reduces colinization by E.coli 536 in the bladder of CBA/J mice [PubMed: 19806177].
Protegen ID: 279; NCBI Gene GI: 1037614; NCBI Protein GI: 26250982; NCBI Protein Accession: NP_757022; NCBITaxon: 199310
Immunization with IutA protects against urinary tract colinization by E.coli CFT073 in the bladders of CBA/J mice [PubMed: 19806177].
Protegen ID: 280; NCBI Gene GI: 1039578; NCBI Protein GI: 26249458; NCBI Protein Accession: NP_755498; NCBITaxon: 199310
Antibodies directed at the putative binding region of FimH (anti- s-FimH1-25) significantly reduced E. coli bladder infections in the experimental mouse model of urinary tract infections [PubMed: 9276729].
Protegen ID: 281; NCBI Gene GI: 948847; NCBI Protein GI: 16132141; NCBI Protein Accession: NP_418740; NCBITaxon: 511145
Active immunization of BALB/c mice with IroN antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948 ].
Protegen ID: 282; NCBI Gene GI: 7379404; NCBI Protein GI: 222104801; NCBI Protein Accession: YP_002539290; NCBITaxon: 562
Active immunization of BALB/c mice with C0393 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948].
Protegen ID: 283; NCBI Gene GI: 1034958; NCBI Protein GI: 26246291; NCBI Protein Accession: NP_752330; NCBITaxon: 199310
Active immunization of BALB/c mice with C4424 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948].
Protegen ID: 284; NCBI Gene GI: 1038067; NCBI Protein GI: 26250246; NCBI Protein Accession: NP_756286; NCBITaxon: 199310
Active immunization of BALB/c mice with recombinant E. coli protein C3389 antigen in Freund's adjuvant protects mice from lethal challenge with ExPEC strain S26 [PubMed: 17145948].
Protegen ID: 285; NCBI Gene GI: 1039252; NCBI Protein GI: 26249224; NCBI Protein Accession: NP_755264; NCBITaxon: 199310
S. flexneri M90T is a colonisation-defective mutant with a transposon in fnr, which encodes a regulator of anaerobic metabolism. To establish whether FNR-mediated repression of spa32 and spa33 contributes to increased Shigella entry into cells in an anaerobic cabinet, recombinant M90T strains were constructed which contain spa32 and spa33 under the control of either their native promoters (M90Tp32/33) or promoters with disrupted FNR boxes (M90Tp#32/#33).The presence in M90T of spa32 and spa33 alleles that are not repressed by FNR led to IpaB secretion during anaerobic growth, and loss of the increased entry of Shigella into cells in an anaerobic cabinet [PubMed: 20436458].
Protegen ID: 288; NCBI Gene GI: 876502; NCBI Protein GI: 13449098; NCBI Protein Accession: NP_085314; NCBITaxon: 424718
Oral immunization of FaeG-expressing L. lactis exhibits a protective response against ETEC infection in mice [PubMed: 19277476].
Protegen ID: 289; NCBI Gene GI: 7003192; NCBI Protein GI: 209921909; NCBI Protein Accession: YP_002295988; NCBITaxon: 409438
The invasiveness and virulence of Shigella spp. are largely due to the expression of plasmid-encoded virulence factors, among which are the invasion plasmid antigens (IpaB, IpaC, and IpaD). Recent observations have indicated that the Ipa proteins (IpaB, IpaC, and possibly IpaD) form a multiprotein complex capable of inducing the phagocytic event which internalizes the bacterium. Researchers isolated a complex of invasins and LPS from water-extractable antigens of virulent shigellae. Western blot analysis of the complex indicates that all of the major virulence antigens of Shigella, including IpaB, IpaC, and IpaD, and LPS are components of this macromolecular complex. Guinea pigs (keratoconjunctivitis model) or mice (lethal lung model) immunized intranasally with purivied invasin complex (invaplex) on days 0, 14, and 28 and challenged 3 weeks later with virulent shigellae were protected from disease (P<0.01 for both animal models) [PubMed: 11083774].
Protegen ID: 307; NCBI Protein GI: 22036246; NCBITaxon: 42897
Protegen ID: 308; NCBI Protein GI: 47056; NCBITaxon: 42897
Protegen ID: 309; NCBI Protein GI: 22036352; NCBITaxon: 42897
Thirty-day-old chickens were immunized intramuscularly with purified IroN from Salmonella Typhimurium mixed with Freund's incomplete adjuvant; the chickens were then challenged intravenously with Salmonella Enteritidis. The mortality rate of immunized chickens was 10%. On the other hand, that of control chickens was 80% [PubMed: 20095157].
Protegen ID: 318; NCBI Protein GI: 259475459; NCBITaxon: 90371
Researchers evaluated the immunogenicity and protective efficacy of GroEL of Salmonella enterica serovar Typhi against lethal infection by S. typhi Ty2 in mice with or without adjuvants. Immunization of mice with GroEL-alone, GroEL + alum, and GroEL + CFA provided 70, 50 and 80% protection, respectively, against lethal challenge by S. typhi in mice. The present study shows that GroEL forms an ideal candidate molecule to develop a recombinant protein based vaccine against human typhoid [PubMed: 19851830].
Protegen ID: 320; NCBI Gene GI: 1068458; NCBI Protein GI: 29144631; NCBI Protein Accession: NP_807973; NCBITaxon: 209261
The entire SopB and SifB genes were cloned into DNA vaccine vectors and were administered along with live attenuated Salmonella. It was found that SopB vaccination reduced the bacterial burden of organs by about 5-fold on day 4 and day 8 after challenge with virulent Salmonella and proved to be a more efficient vaccination strategy than live attenuated bacteria alone [PubMed: 19428891].
Protegen ID: 321; NCBI Protein GI: 54036439; NCBITaxon: 90371
Oral immunization of mice with ZJ111/pcDNA3-SAG1 elicited specific humoral responses and stimulated proliferation of splenocytes (P<0.05). Mice immunized with ZJ111/pcDNA3-SAG1 displayed significant protection against an intraperitoneally challenge with 500 tachyzoite forms of T. gondii RH strain. Vaccination at 10(7) and 10(8)CFU per mice provided a 20% and 10% survival rate comparing 100% mortality of the non-immunized mice, exhibiting longer living time and better survival rate [PubMed: 18590785].
Protegen ID: 326; NCBI Gene GI: 7900172; NCBI Protein GI: 237839159; NCBI Protein Accession: XP_002368877; NCBITaxon: 508771
Modified YscF antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562].
Protegen ID: 338; NCBI Gene GI: 1149286; NCBI Protein GI: 31795470; NCBI Protein Accession: NP_857922; NCBITaxon: 187410
Modified yopD antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562].
Protegen ID: 339; NCBI Gene GI: 1149313; NCBI Protein GI: 31795494; NCBI Protein Accession: NP_857949; NCBITaxon: 187410
Modified yopO antigens were able to partially protect immunized mice at various levels against lethal challenge with Y. pestis KIM 1001 strain [PubMed: 18291562].
Protegen ID: 340; NCBI Gene GI: 5798322; NCBI Protein GI: 162417777; NCBI Protein Accession: YP_001604502; NCBITaxon: 349746
Intranasal immunization with flagellin and the F1 antigen was protective against intranasal challenge with virulent Y. pestis CO92, with 93 to 100% survival of immunized mice. Lastly, vaccination of cynomolgus monkeys with flagellin and a fusion of the F1 and V antigens of Y. pestis induced a robust antigen-specific IgG antibody response [PubMed: 16428759].
Protegen ID: 341; NCBI Gene GI: 1172839; NCBI Protein GI: 16082876; NCBI Protein Accession: NP_395430; NCBITaxon: 214092
Using a mouse model, YPO0606 (yapF) partially protected mice from infection with Y. pestis at a high challenge dosage (200x LD(50)) [PubMed: 19651863].
Protegen ID: 342; NCBI Gene GI: 1173449; NCBI Protein GI: 218927800; NCBI Protein Accession: YP_002345675; NCBITaxon: 214092
Using a mouse plague model, YPO1914 (irp7) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 343; NCBI Gene GI: 1174753; NCBI Protein GI: 218929030; NCBI Protein Accession: YP_002346905; NCBITaxon: 214092
Using a mouse plague model, YPO0612 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 344; NCBI Gene GI: 1173455; NCBI Protein GI: 218927806; NCBI Protein Accession: YP_002345681; NCBITaxon: 214092
Using a mouse plague model, YPO3119 (htpG) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 345; NCBI Gene GI: 1175934; NCBI Protein GI: 218930152; NCBI Protein Accession: YP_002348027; NCBITaxon: 214092
Using a mouse plague model, YPO3047 (ydeN) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 346; NCBI Gene GI: 1175868; NCBI Protein GI: 218930092; NCBI Protein Accession: YP_002347967; NCBITaxon: 214092
Using a mouse plague model, YPO1377 (lolA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 347; NCBI Gene GI: 1174218; NCBI Protein GI: 218928525; NCBI Protein Accession: YP_002346400; NCBITaxon: 214092
Using a mouse plague model, YPCD1.05c (yerA) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 348; NCBI Gene GI: 1172650; NCBI Protein GI: 16082696; NCBI Protein Accession: NP_395142; NCBITaxon: 214092
Using a mouse plague model, YPO0420 may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 349; NCBI Gene GI: 1173265; NCBI Protein GI: 218927621; NCBI Protein Accession: YP_002345496; NCBITaxon: 214092
Using a mouse plague model, YPO3720 (hpmB) may provide partial protection against challenge with a low dose (20 times the 50% lethal dose [20x LD(50)]) of Y. pestis [PubMed: 19651863].
Protegen ID: 350; NCBI Gene GI: 1176539; NCBI Protein GI: 218930726; NCBI Protein Accession: YP_002348601; NCBITaxon: 214092
Study tested the efficacy of 2 proteins, Psn and a portion of LcrV in protecting mice against virulent Yersinia pestis challenge. Results show that the truncated LcrV protein delivered by RASV is sufficient to afford a full protective immune response in a mouse model of bubonic plague and the Psn protein afforded partial protection in a non-optimized system [PubMed: 17966435].
Protegen ID: 351; NCBI Gene GI: 1147351; NCBI Protein GI: 22126288; NCBI Protein Accession: NP_669711; NCBITaxon: 187410
Study evaluated the humoral immune response of mice that survived lethal Y. pestis aerosol challenge after antibiotic treatment. Results indicated that one of the predominant antibody response of mice surviving pneumonic plague after treatment with antibiotics was to yopH [PubMed: 10085037].
Protegen ID: 352; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092
Complexes of YopB (pYV0055), YopD, and YopE (BDE) secreted by Yersinia pseudotuberculosis were purified by affinity chromatography and used as immunogens to determine if antibodies to the translocon could provide protection against Y. pestis in mice. The YopB protein or a complex of YopB and YopD (BD) was purified and determined by vaccination to be immunogenic in mice. Mice actively vaccinated with BD or passively vaccinated with anti-BD serum were protected against lethal challenge with F1(-) Y. pestis [PubMed: 18765742].
Protegen ID: 354; NCBI Gene GI: 2952948; NCBI Protein GI: 51593897; NCBI Protein Accession: YP_068464; NCBITaxon: 273123
Vaccination of mice with deF1 DNA conferred protection against subcutaneous infection with the virulent Y. pestis Kimberley53 strain, even at challenge amounts as high as 4,000 50% lethal doses [PubMed: 12496187 ].
Protegen ID: 355; NCBI Protein GI: 48621; NCBITaxon: 632
Following passive immunization, antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. As assessed by immunoblotting, pooled adult human sera contained antibodies reactive with P145. Following passive immunization, these antisera partially protected infant rats from bacteremia resulting from intraperitoneal challenge with bacteria. Antibody to P145 may contribute to protection against Brazilian purpuric fever [PubMed: 1937817].
The ApxI antigen is an important factor in the protection against Actinobacillus pleuropneumoniae serotype 5 infection; therefore, the protective immunity in mice following oral immunization with Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) was compared with that in two control groups (group A and B). The immunogenicity of the rApxIA antigen derived from the yeast was confirmed by a high survival rate and an ApxIA-specific IgG antibody response (p < 0.01) [PubMed: 17993753].
Protegen ID: 358; NCBI Protein GI: 312899; NCBITaxon: 715
The levels of local and systemic antibodies specific to the Apx antigens were investigated in mice orally immunized with Apx antigen-expressing yeast. Specific IgA responses to ApxIA or ApxIIA in the intestines and lungs from mice immunized with yeast expressing Apx antigens were significantly higher than those in the control groups after the second and third immunizations, respectively (p < 0.05). All mice were monitored for up to 72 h after challenge with the MLD of an A. pleuropneumoniae field isolate. Overall, the final survival rates of the vaccinated groups were higher than those of the control groups at each time point [PubMed: 17993753].
Protegen ID: 360; NCBI Protein GI: 52630374; NCBITaxon: 715
Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP (cps5C), LPS, and HP was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686].
Following a booster vaccination, a significant (P < 0.05) IgG antibody response to the CP, LPS, and HP (APP7_1016) was detected in the vaccinated pigs. The pigs vaccinated with the CP-HP and LPS-HP conjugates exhibited significantly less mortality (P < 0.05) and significantly greater weight gain (P < 0.001) than unvaccinated pigs. Vaccinated pigs exhibited significantly fewer and less extensive gross pulmonary lesions (P < 0.001) when compared with unvaccinated pigs [PubMed: 1455686].
Protegen ID: 362; NCBI Gene GI: 6398034; NCBI Protein GI: 190150285; NCBI Protein Accession: YP_001968810; NCBITaxon: 537457
The aroA gene of A. salmonicida was cloned in Escherichia coli, and the nucleotide sequence was determined. Vaccination of brown trout with 10(7) CFU of A. salmonicida 644Rb aroA by intraperitoneal injection resulted in a 253-fold increase in the 50% lethal dose (LD50) compared with unvaccinated controls challenged with a virulent clinical isolate 9 weeks later [PubMed: 8478107].
Protegen ID: 366; NCBI Protein GI: 512545; NCBITaxon: 645
Passive immunisation of Atlantic salmon with rainbow trout or rabbit anti-AsaP1 antisera conferred significant protection against challenge with a virulent A. salmonicida [Ref1011:Gudmundsdottir et al., 1997]
Protegen ID: 367; NCBI Gene GI: 4998702; NCBITaxon: 382245
RAP-1 (21B4) is a candidate for inclusion in a B. bovis vaccine based on its ability to induce partial protection in vaccinates, defined as a significant reduction in parasitemia upon challenge [PubMed: 1441189].
Protegen ID: 368; NCBI Gene GI: 5479143; NCBI Protein GI: 156087004; NCBI Protein Accession: XP_001610909; NCBITaxon: 484906
Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. Two of these, GST-12D3 and GST-11C5, when used in combination were almost as protective as has been previously shown for the commercially available live attenuated vaccine [PubMed: 1441189].
Protegen ID: 371; NCBI Gene GI: 5478971; NCBI Protein GI: 156086656; NCBI Protein Accession: XP_001610737; NCBITaxon: 484906
Crude extracts of Babesia bovis parasites were systematically fractionated and tested in numerous sequential vaccination/challenge experiments in adult cattle. A short fragment of the third antigen (21B4) has been shown to be protective [PubMed: 1441189].
Protegen ID: 373; NCBI Protein GI: 1246924; NCBITaxon: 5865
Study described the construction and evaluation of an adenovirus vaccine expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4. Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular injection, which were further increased upon boosting. Furthermore, two doses of Ad.D4 4 weeks apart were sufficient to protect 67% of mice from toxin challenge [PubMed: 16428747].
Protegen ID: 374; NCBI Protein GI: 9280533; NCBITaxon: 1392
A combination of the 69-kDa outer membrane protein and filamentous hemagglutinin (fhaB), both isolated from lymphocytosis promoting factor (LPF; pertussis toxin) minus mutants of Bordetella pertussis, is protective in the mouse intracerebral challenge potency (Kendrick) test [PubMed: 2056199].
Protegen ID: 375; NCBI Protein GI: 3980256; NCBITaxon: 520
A study demonstrated that passive immunization with specific anti-B. pertussis adenylate cyclase antibodies or active immunization with purified B. pertussis secreted adenylate cyclase (cyaA) protect mice against a lethal respiratory challenge with B. pertussis or B. parapertussis. Results suggest that adenylate cyclase might be the primary cytotoxin responsible for mouse pulmonary lesions during respiratory tract infection with B. pertussis or with the related species B. parapertussis and is a protective antigen of B. pertussis [PubMed: 2622329].
Protegen ID: 376; NCBI Protein GI: 580668; NCBITaxon: 520
BALB/c mice were immunized with PTx vaccine on day 6 of life and then challenged with B. pertussis using the aerosol challenge model. These primed mice were significantly better protected against leukocytosis, weight loss, and proliferation of B. pertussis in the lungs following aerosol challenge than the nonprimed group. This protection correlated with levels of anti-PT antibody in serum present on the day of aerosol challenge [PubMed: 12117973].
Protegen ID: 377; NCBI Protein GI: 225311181; NCBITaxon: 520
Researchers constructed isogenic mutants of B. pertussis Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B. pertussis strains regardless of the allele expression pattern, the strain expressing ptxA1 and prn2 displayed a survival advantage over the other strains [PubMed: 20357056].
Protegen ID: 378; NCBI Gene GI: 2664290; NCBI Protein GI: 33592195; NCBI Protein Accession: NP_879839; NCBITaxon: 257313
Protegen ID: 379; NCBI Gene GI: 2665068; NCBI Protein GI: 33594638; NCBI Protein Accession: NP_882282; NCBITaxon: 257313
A soluble fraction obtained from Bordetella pertussis was evaluated as adjuvant for the pertussis component of the Diphtheria-Pertussis-Tetanus (DPT) vaccine. High levels of antibodies were induced, and a 78% protection rate of mice challenged with live B. pertussis was observed. Two proteins were identified as the 73 kDa N-terminal alpha-domain of BrkA autotransporter protein and the Cpn60/60 kDa chaperonin. Both stimulated antibodies against pertussis and induced a 42% protection rate against the challenge [PubMed: 17011680].
Protegen ID: 382; NCBI Protein GI: 968920; NCBITaxon: 520
Protegen ID: 383; NCBI Protein GI: 562026; NCBITaxon: 520
Protegen ID: 384; NCBI Protein GI: 225311180; NCBITaxon: 520
Protegen ID: 385; NCBI Protein GI: 225311183; NCBITaxon: 520
Protegen ID: 386; NCBI Protein GI: 225311182; NCBITaxon: 520
Protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22 (UL49), as shown by significant reductions in viral excretion [PubMed: 15650221].
Protegen ID: 389; NCBI Gene GI: 1487397; NCBI Protein GI: 9629826; NCBI Protein Accession: NP_045310; NCBITaxon: 10320
Calves were injected intranasally with either AdCMVgC or AdCMVgD (US6) or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD (US6) followed by the live vaccine and to a lower extent with the combination of the two recombinants. Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization [PubMed: 11818166].
Protegen ID: 390; NCBI Gene GI: 1487406; NCBI Protein GI: 9629886; NCBI Protein Accession: NP_045370; NCBITaxon: 10320
Immunization of calves with truncated gpI (US7) protein induced gpI-specific nasal IgA, IgG1, serum neutralizing antibodies and gpI-specific peripheral lymphocyte proliferation. All immunized calves were protected from clinical disease after BHV-1 challenge. Further, nine of ten immunized calves had no intranasal viral shedding [PubMed: 8147097].
Protegen ID: 392; NCBI Gene GI: 4783432; NCBI Protein GI: 9629887; NCBI Protein Accession: NP_045371; NCBITaxon: 10320
A DNA vaccine expressing glycoprotein C (gC, UL44) of bovine herpesvirus-1 (BHV-1) was evaluated for inducing immunity in bovines. Results indicate that DNA immunization with gC could induce neutralizing antibody and lymphoproliferative responses with BHV-1 responsive memory B cells in bovines. However, the immunity developed sufficient for only partial protection against BHV-1 challenge [PubMed: 11182496].
Protegen ID: 393; NCBI Gene GI: 4783424; NCBI Protein GI: 9629830; NCBI Protein Accession: NP_045314; NCBITaxon: 10320
Chitosan-DNA vaccines were prepared by embedding pcDNA3.1(+)-cadF and pcDNA3.1(+)-peblA with chitosan respectively. The mice immunized with chitosan-DNA vaccines have generated high levels of IgA and IgG from the sera and IgA from the intestinal secretions and the P/N value went up to 20.58, 30.13 and 6.87 respectively. The chitosan-DNA vaccines induced strongest level of protection in BALB/c mice against challenge with C. jejuni HS:19 strain and the protective efficacies was 93.70 [PubMed: 18206008].
Protegen ID: 396; NCBI Protein GI: 4704601; NCBITaxon: 197
Protegen ID: 397; NCBI Protein GI: 112360246; NCBITaxon: 192222
Mice were immunized intranasally with two doses of 3 to 50 microgram of MBP-FlaA. The protective efficacies of a 50 microgram of MBP-FlaA plus LT(R192G) dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 microgram of MBP-FlaA plus LT(R192G) intranasally were challenged orally with 8 x 10(10), 8 x 10(9), or 8 x 10(8) cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively [PubMed: 10531231].
Protegen ID: 398; NCBI Gene GI: 4682159; NCBI Protein GI: 121612545; NCBI Protein Accession: YP_001000997; NCBITaxon: 354242
Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176 [PubMed: 18426878].
Protegen ID: 399; NCBI Protein GI: 116292649; NCBITaxon: 197
Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. All three proteins were immunogenic, FlaC provided an 18% protection against disease from C. jejuni 81-176 [PubMed: 18426878].
Protegen ID: 400; NCBI Gene GI: 4682885; NCBI Protein GI: 121612344; NCBI Protein Accession: YP_001000416; NCBITaxon: 354242
Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486 [PubMed: 18426878].
Protegen ID: 409; NCBI Protein GI: 116292677; NCBITaxon: 197
A DNA vaccination trial was performed on sheep to determine whether vaccination with bovine leukemia virus (BLV) transactivator Tax DNA is effective against BLV infection. Results showed higher levels of virus titers in control sheep than those in Tax-vaccinated sheep. Higher levels of IFN-gamma mRNA expression have been demonstrated in vaccinated sheep after the challenge. These results suggested that Th1 type immune response induced by Tax DNA vaccine inhibited BLV propagation in vaccinated sheep at the early phase of infection [PubMed: 14665749].
Protegen ID: 410; NCBI Gene GI: 2760848; NCBI Protein GI: 9626228; NCBI Protein Accession: NP_056895; NCBITaxon: 11901
The bovine leukemia virus (BLV) envelope gene encoding extracellular glycoprotein gp51 (encoded by env gene) and transmembrane glycoprotein gp30 was cloned into a vehicle expression vector under the human cytomegalovirus (CMV) intermediate early promoter. The intramuscular injection of this plasmid vector generated a cellular immune response. Seven out of ten cows vaccinated with the DNA construct resisted a drastic challenge [PubMed: 10824867].
Protegen ID: 411; NCBI Gene GI: 2760849; NCBI Protein GI: 9626230; NCBI Protein Accession: NP_056898; NCBITaxon: 11901
Young mink kits (n=8) were vaccinated with DNA plasmids encoding the viral haemagglutinin protein (H) of a vaccine strain of Canine distemper virus (CDV). The mink were protected against viraemia, lymphopenia, clinical disease and changes in the percentage of IFN-gamma producing peripheral blood leucocytes after challenge inoculation with a recent wild type strain of CDV. Essentially, these results demonstrate that early life DNA vaccination with the H gene of a CDV vaccine strain induced robust protective immunity against a recent wild type CDV [PubMed: 19596418].
Protegen ID: 412; NCBI Gene GI: 1489792; NCBI Protein GI: 9630651; NCBI Protein Accession: NP_047206; NCBITaxon: 11232
Study reports the engineering and the characterization of two replication-competent canine adenovirus type 2 (CAV2)-based vaccines expressing, respectively, the CDV hemagglutinin (HA) and fusion (F) antigens (CDVgp5). We first demonstrated that the intranasal vaccination with a mixture of both recombinant CAV2s provides an excellent level of protection in seronegative puppies, confirming the value of replication-competent adenovirus-based vectors for mucosal vaccination [PubMed: 12297394].
Protegen ID: 413; NCBI Gene GI: 1489793; NCBI Protein GI: 9630650; NCBI Protein Accession: NP_047205; NCBITaxon: 11232
A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). Results show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. [PubMed: 11395200].
Protegen ID: 414; NCBI Gene GI: 1489588; NCBITaxon: 10788
This study shows that a plasmid DNA (pGT36VP1) encoding the full length VP1 region of canine parvovirus (CPV) induces immunity that protects dogs against challenge with virulent virus [PubMed: 9569471].
Protegen ID: 415; NCBI Gene GI: 1489587; NCBITaxon: 10788
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. DNA pol III Gamma and Tau (CP #1, dnaX) was found to be protective. CP #1 (dnaX) was more protective than the live-vaccine, positive control. [PubMed: 15811648].
Protegen ID: 416; NCBI Protein GI: 62148024; NCBITaxon: 218497
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Glu-tRNA Gln Amidotransferase (CP #2, gatC) was found to be protective. Three of the clones (CP #1) elicited protection that was statistically higher than the unvaccinated control, which has high variance [PubMed: 15811648].
Protegen ID: 417; NCBI Protein GI: 62184917; NCBITaxon: 218497
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Protective clone CP #4 (OMP90A, pomp90A) was diluted 1/2000 in a non-protective sublibrary pool of clones. This CP #4-spiked sublibrary conferred protection. Five clones were significantly more protective than the genes encoding fewer than 50 amino acids (CP #1 and 7, p-value of less than 0.05 when comparing lung weights). [PubMed: 15811648].
Protegen ID: 418; NCBI Protein GI: 187438939; NCBITaxon: 83555
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #5 (Transglycolase/transpeptidase, CAB049 putative penicillin-binding protein) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648].
CAB049 putative penicillin-binding protein
Protegen ID: 419; NCBI Protein GI: 62184696; NCBITaxon: 218497
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. CP #7 (omlA) was significantly more protective than the genes encoding fewer than 50 amino acids (p-value of less than 0.05 when comparing lung weights). The chlamydial loads generally tracked with protection and the most protective genes were significantly lower than in unvaccinated controls (p < 0.05 in the Mannhitney U-test for genes CP #1, 2, 4, 9, 10) [PubMed: 15811648].
Protegen ID: 420; NCBI Protein GI: 62184824; NCBITaxon: 218497
Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Of the 14 individually tested clones, CP #1 through CP #9 had positive relative protection scores. CP #8 (CAB613, Oligopeptidase) was found to confer protection [PubMed: 15811648].
Protegen ID: 421; NCBI Protein GI: 62185225; NCBITaxon: 218497
Animals vaccinated with Gam82 and challenged with E. maxima showed lower oocyst shedding and reduced intestinal pathology compared with non-vaccinated and parasite-challenged animals. Gam82 vaccination also stimulated the production of antigen-specific serum antibodies and induced greater levels of IL-2 and IL-15 mRNAs compared with non-vaccinated controls. These results demonstrate that the Gam82 recombinant protein protects against E. maxima and augments humoral and cell-mediated immunity [PubMed: 20178868].
Protegen ID: 457; NCBI Protein GI: 38565038; NCBITaxon: 5804
Birds vaccinated with Eimeria tenella microneme recombinant gene (EtMIC2) and encoded protein developed protective immunity against infection by E. tenella as assessed by significantly increased body weight gain and decreased fecal oocyst shedding compared with non-vaccinated controls. Vaccination with the EtMIC2 gene also led to protective immunity against infection by E. acervulina, but not E. maxima [PubMed: 15882535].
Protegen ID: 459; NCBI Protein GI: 225579627; NCBITaxon: 5802
Two recombinant Mycobacterium bovis BCG (rBCG) strains carrying the Eimeria tenella rhomboid gene (Rho) delivered by extrachromosomal vector pMV261 and integrative vector pMV361 were evaluated for their ability to protect chickens against E. tenella challenge. Chickens were immunized intranasal with BCG, rBCG pMV261-Rho, or rBCG pMV361-Rho twice at a 2-week interval. All the recombinant BCG immunized chickens developed specific immune responses, and there was a significant increases of the percentages of CD4(+) and CD8(+) cells compared to the control (P<0.05). Challenge experiments demonstrated that the two rBCG strains could provide significant protection against E. tenella challenge [PubMed: 19117681].
Protegen ID: 460; NCBI Protein GI: 84043169; NCBITaxon: 5802
The immunization procedure of DNA vaccine pcDNA-TA4-IL-2 of Eimeria tenella, including route, dose, time of immunization and age of primary immunization of chicken, was optimized. results illustrated that 25 microg was the optimal dose and intramuscular injection was the most effective route to induce protective immunity in Chinese Yellow chickens [PubMed: 19019543].
Protegen ID: 461; NCBI Protein GI: 84783094; NCBITaxon: 5802
The Eimeria tenella antigen gene (3-1E) and chicken interferon gamma gene (ChIFN-gamma) were subcloned into the mammalian expression vector proVAX forming the plasmids proE and prol. After challenge the proIE-vaccinated chickens showed protective immunity as demonstrated by significantly reduced oocyst shedding [PubMed: 17274297].
Protegen ID: 463; NCBI Protein GI: 126362934; NCBITaxon: 5802
A cDNA clone derived from sporulated oocysts of Eimeria tenella and encoding the expression product GX3262 was identified using a monoclonal antibody raised against Eimeria acervulina sporozoites. After challenge with an experimental E. tenella infection, the greatest degree of protection in immunized broiler chickens was seen after only a single immunization of 2-day-old birds with a live recombinant E. coli preparation [PubMed: 2659532].
Protegen ID: 464; NCBI Protein GI: 102304; NCBITaxon: 5802
Study describes experiments which demonstrate that the vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796].
Protegen ID: 465; NCBI Gene GI: 1491868; NCBI Protein GI: 9630709; NCBI Protein Accession: NP_047256; NCBITaxon: 11768
The vaccine, (EURIFEL FeLV; Merial) that expresses the FeLV env and gag protective genes, is effective against any oronasal FeLV challenge. The protection was shown to be solid against an oronasal challenge one year after the initial vaccination, and was effective against a very severe 'in-contact' challenge [PubMed: 12934796].
Protegen ID: 466; NCBI Protein GI: 323916; NCBITaxon: 11768
Intranasal immunization of HLA-DR4 tg mice with the single antigen FopB from F. tularensis subsp. novicida conferred significant protection against lethal pulmonary challenge with an F. tularensis subsp. holarctica live vaccine strain.
Protegen ID: 468; NCBI Gene GI: 4547777; NCBI Protein GI: 118496734; NCBI Protein Accession: YP_897784; NCBITaxon: 401614
Intranasal vaccination with KKF235 (F. tularensis subsp. novicida mutant (DeltaiglB) ) protected mice from subsequent homotypic challenge with U112 as well as heterotypic challenge with F. tularensis subsp. holarctica (LVS). Most significantly, oral immunization with KKF235 protected mice from a highly lethal subsp. tularensis (SCHU S4) pulmonary challenge [PubMed: 20016043].
Protegen ID: 469; NCBI Gene GI: 4548125; NCBI Protein GI: 118497903; NCBI Protein Accession: YP_898953; NCBITaxon: 401614
Mice immunized with rLm/iglC were protected against lethal challenge with F. tularensis LVS administered by the intranasal route, a route chosen to mimic airborne infection, and, most importantly, against aerosol challenge with the highly virulent Type A F. tularensis SchuS4 strain [PubMed: 19126421].
Protegen ID: 470; NCBI Gene GI: 3191591; NCBI Protein GI: 56708413; NCBI Protein Accession: YP_170309; NCBITaxon: 177416
Protegen ID: 471; NCBI Gene GI: 3191814; NCBI Protein GI: 56708721; NCBI Protein Accession: YP_170617; NCBITaxon: 177416
Immunization with WbtI(G191V) protected mice against a relatively low-dose intraperitoneal challenge with LVS (F. tularensis subspecies holarctica live vaccine strain), but was less protective against a high-dose challenge [PubMed: 17768257].
Protegen ID: 472; NCBI Gene GI: 5522688; NCBI Protein GI: 156502002; NCBI Protein Accession: YP_001428067; NCBITaxon: 458234
Researchers have shown that mice that had been immunized with purified heat shock protein 60 (Hsp60, groEL) isolated from Francisella tularensis were protected against a subsequent challenge with some strains of the bacterium [PubMed: 15213156].
Protegen ID: 473; NCBI Protein GI: 282159959; NCBITaxon: 510831
A 17-kDa lipoprotein, TUL4, of the facultative intracellular bacterium Francisella tularensis is one of several membrane proteins that induce an in vitro response in T cells from F. tularensis-primed humans. When mice were immunized with S. typhimurium chi 4072(pTUL4-15), some animals showed an antibody response and a T-cell response to TUL4. The present study demonstrated that the 17-kDa lipoprotein TUL4 of F. tularensis is involved in a protective immunity to tularemia [PubMed: 1612751].
Protegen ID: 474; NCBI Protein GI: 148688; NCBITaxon: 263
C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. SodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice [PubMed: 18692537].
Protegen ID: 475; NCBI Gene GI: 3190713; NCBI Protein GI: 56707247; NCBI Protein Accession: YP_169143; NCBITaxon: 177416
Anti-FopA MAbs protected 90% of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered prophylactically as well as therapeutically [PubMed: 19176692].
Protegen ID: 476; NCBI Gene GI: 4306351; NCBI Protein GI: 115315051; NCBI Protein Accession: YP_763774; NCBITaxon: 393011
Anti-lpnA MAbs conferred significant, although not complete, protection of nave C3H/HeN mice from lethal challenge with F. tularensis LVS when administered therapeutically [PubMed: 19176692].
Protegen ID: 477; NCBI Gene GI: 3191792; NCBI Protein GI: 56708002; NCBI Protein Accession: YP_169898; NCBITaxon: 177416
The gene encoding the full length cyst wall protein-2 (CWP2) from Giardia lamblia was subcloned into the pCDNA3 mammalian expression vector and stably introduced into S. typhimurium STM1. Challenge infection with live Giardia muris cysts revealed that mice receiving the CWP2-encoding DNA vaccine were able to reduce cyst shedding by approximately 60% compared to control mice [PubMed: 17996337].
Protegen ID: 479; NCBI Gene GI: 5703171; NCBI Protein GI: 159120052; NCBI Protein Accession: XP_001710242; NCBITaxon: 50803
Rats vaccinated with PD (hpd) cleared NT H. influenzae better after middle ear and pulmonary bacterial challenge, and chinchillas vaccinated with PD showed significant protection against NT H. influenzae-dependent acute otitis media. In a clinical trial involving children, PD was used as an antigenically active carrier protein in an 11-valent pneumococcal conjugate investigational vaccine; significant protection was achieved against acute otitis media not only caused by pneumococci but also caused by NT H. influenzae [PubMed: 18230042].
Protegen ID: 480; NCBI Protein GI: 148971; NCBITaxon: 727
In a chinchilla model of otitis media, initial screening of P5-fimbrin, delivered singly or in combination with either Freund's adjuvant or alum, indicated that augmented bacterial clearance from the nasopharynx, the middle ears, or both anatomical sites could be induced by parenteral immunization with P5-fimbrin combined with lipoprotein D, lipoprotein D alone, or the synthetic chimeric peptide LB1 (derived from P5-fimbrin), respectively [PubMed: 10338477].
Protegen ID: 482; NCBI Gene GI: 3430592; NCBI Protein GI: 68249712; NCBI Protein Accession: YP_248824; NCBITaxon: 281310
Purified rD15 was found to be highly immunogenic in mice, guinea pigs, and rabbits, and passive transfer of anti-rD15 antibodies protected infant rats from challenge with H. influenzae type b or type a in infant rat models of bacteremia [PubMed: 9284140].
Protegen ID: 483; NCBI Gene GI: 3430379; NCBI Protein GI: 68249503; NCBI Protein Accession: YP_248615; NCBITaxon: 281310
Rabbit antibody prepared against P2 from one strain was cross-reactive with P2 isolated from the other two heterologous strains by Western blot. This antibody passively protected infant rats against type b Haemophilus infection caused by the homologous organism, but not against challenge by a strain with the heterologous 36,500 mol wt P2 protein [PubMed: 6603479].
Protegen ID: 485; NCBI Gene GI: 3429565; NCBI Protein GI: 68248747; NCBI Protein Accession: YP_247859; NCBITaxon: 281310
Seoul virus (SEOV) is one of the four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). A replication-competent recombinant canine adenovirus type 2 expressing the Gc protein of SEOV (rCAV-2-Gc) in BALB/c mice induced complete protection against a intensive infectious challenge with ~1,000 50% infective doses (ID50) for SEOV strain CC-2 [PubMed: 20181748].
Protegen ID: 486; NCBI Protein GI: 284157806; NCBITaxon: 11608
Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene also was protective [PubMed: 12075094].
Protegen ID: 487; NCBI Protein GI: 1113859; NCBITaxon: 37705
Study used a deer mouse infection model to test the protective efficacy of genetic vaccine candidates for Sin Nombre (SN) virus that were known to provoke immunological responses in BALB/c mice. Protective epitopes were localized in each of four overlapping cDNA fragments that encoded portions of the SN virus G1 glycoprotein antigen; the nucleocapsid gene (SNVsSgp1) also was protective [PubMed: 12075094].
Protegen ID: 489; NCBI Gene GI: 2943142; NCBI Protein GI: 38371726; NCBI Protein Accession: NP_941975; NCBITaxon: 37705
To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV (PUUVsSgp1) and TOPV rN were completely protected [PubMed: 12050380].
Protegen ID: 490; NCBI Gene GI: 2943083; NCBI Protein GI: 38371721; NCBI Protein Accession: NP_941984; NCBITaxon: 11604
To investigate the ability of recombinant N (rN, nucleocapsid proteins) from different hantaviruses to elicit cross-protection, we immunized bank voles with rN from Puumala (PUUV), Topografov (TOPV), Andes (ANDV), and Dobrava (DOBV) viruses and subsequently challenged them with PUUV. All animals immunized with PUUV and TOPV rN were completely protected [PubMed: 12050380].
Protegen ID: 491; NCBI Protein GI: 4757106; NCBITaxon: 83192
Researchers vaccinated hamsters with a vaccinia virus-vectored vaccine expressing the M and the S segments of Hantaan (HTN) virus and challenged them with HTN, Seoul (SEO), or Puumala (PUU) virus. Study found that vaccinated hamsters, challenged with HTN or SEO virus, were neither viremic nor had evidence of virus in their lungs or kidneys [PubMed: 7666542].
Protegen ID: 492; NCBI Protein GI: 1389703; NCBITaxon: 11599
Passive transfer of spleen cells from mice immunized with rNP (HTNVsSgp1) conferred partial protection or prolongation of time to death from fatal Hantaan virus infection in suckling mice which were challenged with Hantaan virus at 40 LD50 (survival rate: 43%) or 4 LD50 (survival rate: 43%) [PubMed: 8517793].
Protegen ID: 493; NCBI Gene GI: 2943078; NCBI Protein GI: 38371711; NCBI Protein Accession: NP_941977; NCBITaxon: 11599
Nonreplicating adenovirus (Ad) vectors that express Andes hantavirus (ANDV) nucleocapsid protein (AdN, ANDVsSgp1) or glycoproteins (AdG(N) and AdG(C)) were constructed . When administered once, all three Ad vectors, individually or in combination, elicited a robust immune response that protected Syrian hamsters from a lethal ANDV infection that mimics the pulmonary disease seen in humans. No vaccinated animal died, and there were no obvious clinical signs of disease [PubMed: 19403663].
Protegen ID: 494; NCBI Gene GI: 991232; NCBI Protein GI: 19744950; NCBI Protein Accession: NP_604471; NCBITaxon: 46607
Study compared a current HBV vaccine that contains recombinant hepatitis B surface antigen HBsAg) adsorbed to alum in chimpanzees, with two novel vaccine strategies that have proven superior to the current vaccine in mice. All animals receiving either control or CpG-containing subunit vaccines at 0 and 4 weeks attained titers of HBsAg-specific antibody (anti-HBs) considered protective (> or =10 mIU/ml) and were indeed protected from challenge at 8 weeks with 10(3.5) 50% chimp infectious doses (CID(50)) of intravenous HBV [PubMed: 16428890].
Protegen ID: 495; NCBI Protein GI: 128168861; NCBITaxon: 10407
The immunological protection of pVAX-PS, a DNA vaccine, was assessed in the tree shrews model. pVAX-PS was constructed by inserting the gene encoding the middle (pre-S2 plus S) envelope protein of HBV into a plasmid vector pVAX1. Results indicated that pVAX-PS immunization could induce remarkable humoral immune response and prevent the experimental tree shrews from infection of HBV [PubMed: 12932306].
Protegen ID: 496; NCBI Protein GI: 113207330; NCBITaxon: 10407
Immunisation with a plasmid encoding the DHBV large (L) envelope protein (HBVgp2 pre-S1/pre-S2/S) induced a strong, specific, highly neutralising and long-lasting anti-preS humoral response in uninfected ducks. Importantly, maternal antibodies elicited by such DNA immunisation were vertically transmitted and protected progeny against viral challenge [PubMed: 12531335].
Protegen ID: 497; NCBI Gene GI: 944569; NCBI Protein GI: 77680739; NCBI Protein Accession: YP_355333; NCBITaxon: 10407
The herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome. Expression of gD2 in cells infected with the recombinant Oka strain VZV (ROka-gD2) was confirmed by antibody staining of fixed cells and by immunoblot analysis. Forty days after the third inoculation, guinea pigs were challenged intravaginally with HSV-2. Inoculation of guinea pigs with ROka-gD2 significantly reduced the severity of primary HSV-2 infection (P < 0.001) [PubMed: 7494331].
US6 from Herpes simplex virus type 1 and 2
Protegen ID: 499; NCBI Gene GI: 1487358; NCBI Protein GI: 9629336; NCBI Protein Accession: NP_044536; NCBITaxon: 10310
The present study evaluated the modulatory functions of salbutamol co-administered with DNA vaccine expressing gB (UL27) of herpes simplex virus (HSV) via intranasal (i.n.) route. The enhanced immune responses caused by co-administration of salbutamol provided effective and rapid responses to HSV mucosal challenge, thereby conferring prolonged survival and reduced inflammation against viral infection [PubMed: 19641376].
Protegen ID: 500; NCBI Protein GI: 1869850; NCBITaxon: 10310
BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 [PubMed: 19174474].
Protegen ID: 501; NCBI Gene GI: 2703406; NCBI Protein GI: 9629447; NCBI Protein Accession: NP_044668; NCBITaxon: 10298
Study demonstrated that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB, UL27)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection in mice [PubMed: 17404252].
Protegen ID: 502; NCBI Gene GI: 2703455; NCBI Protein GI: 9629408; NCBI Protein Accession: NP_044629; NCBITaxon: 10298
Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN-gamma and TNF-alpha production in Balb/c mice. When the DNA vaccine was supplemented with as little as 50ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality [PubMed: 16621198].
Protegen ID: 503; NCBI Protein GI: 124181; NCBITaxon: 10315
Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge with HSV [PubMed: 15569635].
Protegen ID: 504; NCBI Protein GI: 75812153; NCBITaxon: 10298
In two experiments, mice immunised with phage displaying a single epitope of gG2 (US4) were protected against challenge with a lethal dose of whole HSV-2 [PubMed: 10725197].
Protegen ID: 505; NCBI Gene GI: 1487356; NCBI Protein GI: 9629334; NCBI Protein Accession: NP_044534; NCBITaxon: 10310
Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527].
UL44 from Herpes simplex virus type 1 and 2
Protegen ID: 506; NCBI Gene GI: 2703410; NCBI Protein GI: 9629425; NCBI Protein Accession: NP_044646; NCBITaxon: 10298
Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10(4) pfu) with gC or gE (US8) plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge [PubMed: 9728527].
Protegen ID: 507; NCBI Gene GI: 2703448; NCBI Protein GI: 9629449; NCBI Protein Accession: NP_044670; NCBITaxon: 10298
Researchers combined the HPV16 E7 peptide(38-61) with a murine IgG heavy chain constant region to construct a chimeric protein compound. The chimeric vaccine candidate was able to effectively protect mice against the challenge of HPV16-positive tumor cells, and to eradicate HPV16-expressing tumors in mice [PubMed: 15661238].
Protegen ID: 509; NCBI Gene GI: 1489079; NCBI Protein GI: 9627105; NCBI Protein Accession: NP_041326; NCBITaxon: 333760
Antibody responses of mice (n = 120) and rabbits (n = 23) to vaccination with HPV-16 amino-terminal L2 polypeptides or multitype L2 fusion proteins were compared. 11-200 x 3 formulated in GPI-0100 adjuvant or alum with 1018 ISS protected mice against HPV-16 challenge (reduction in HPV-16 infection vs phosphate-buffered saline control, P < .001) 4 months after vaccination as well as HPV-16 L1 VLPs [PubMed: 19470949].
Protegen ID: 510; NCBI Gene GI: 1489081; NCBI Protein GI: 9627107; NCBI Protein Accession: NP_041331; NCBITaxon: 333760
C57BL/6 mice vaccinated with pNGVL4a-E6/opt are able to generate potent protective and therapeutic antitumor effects against challenge with E6-expressing tumor cell line, TC-1 of HPV [PubMed: 16649071].
Protegen ID: 511; NCBI Gene GI: 1489078; NCBI Protein GI: 9627104; NCBI Protein Accession: NP_041325; NCBITaxon: 333760
rAAV5, -8 and -9 vectors expressing an HPV16 L1/E7 fusion gene were generated and applied intranasally for combined prophylactic and therapeutic vaccination of mice. Vaccination with the rAAV vectors led to a significant protection of animals against a challenge with different HPV tumour cell lines [PubMed: 20032542].
Protegen ID: 512; NCBI Gene GI: 1489082; NCBI Protein GI: 9627108; NCBI Protein Accession: NP_041332; NCBITaxon: 333760
The DNA vaccine pIHNw-G encodes the glycoprotein of the fish rhabdovirus infectious hematopoietic necrosis virus (IHNV). Vaccine performance in rainbow trout was measured 3, 6, 13, 24, and 25 months after vaccination. At three months all fish vaccinated with 0.1 microg pIHNw-G had detectable neutralizing antibody (NAb) and they were completely protected from lethal IHNV challenge with a relative percent survival (RPS) of 100% compared to control fish [PubMed: 16154239].
G glycoprotein from Infectious Hematopoietic Necrosis Virus
Protegen ID: 513; NCBI Gene GI: 1489848; NCBI Protein GI: 9628086; NCBI Protein Accession: NP_042679; NCBITaxon: 11290
BALB/c mice were immunized intranasally with an adjuvant (cholera toxin B subunit containing 0.2% of the whole toxin)-combined with A or B virus recombinant NP. The NP-immune mice, when challenged intranasally with a sublethal dose of the virus 3 wk after immunization, had accelerated virus clearance from the nasal site in both an influenza type-specific and a nonspecific manner, as shown by the protection from high morbidity from the second day after challenge [PubMed: 8621928].
Protegen ID: 514; NCBI Gene GI: 956539; NCBI Protein GI: 8486155; NCBI Protein Accession: NP_056661; NCBITaxon: 11520
Protegen ID: 515; NCBI Protein GI: 3722159; NCBITaxon: 41857
Skin and mucosal vaccination provided complete protection from clinical signs of infection with ponies subjected to a challenge infection of Equine influenza virus, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592].
Protegen ID: 516; NCBI Protein GI: 404517; NCBITaxon: 31660
A nonpathogenic vector of the cytoplasmic domain of the VSV G protein and expressing influenza virus HA (derived from Influenza A virus (A/WSN/1933(H1N1))) provides complete protection from lethal influenza virus challenge after intranasal administration. A second vector with VSV G deleted and expressing HA (DeltaG-HA) is also protective and nonpathogenic and has the advantage of not inducing neutralizing antibodies to the vector itself [PubMed: 10196265].
HA from Influenza A virus (A/WSN/1933(H1N1))
Protegen ID: 518; NCBI Protein GI: 324200; NCBITaxon: 382835
A recombinant baculovirus expressing the hemagglutinin gene of the influenza virus, A/PR/8/34 (H1N1), under the control of the chicken beta-actin promoter, was constructed. Protection from a lethal challenge of the influenza virus was achieved by intranasal immunization of the recombinant baculovirus [PubMed: 12874198].
HA from Influenza A virus (A/Puerto Rico/8/1934(H1N1))
Protegen ID: 519; NCBI Protein GI: 126599271; NCBITaxon: 211044
Two cyclic peptide analogues corresponding to residues 139-146 (site A) of influenza A virus haemagglutinin (strain X31) were synthesized. When OF1 mice were immunized with cyclic peptides, approximately 80% of the animals were protected against an intranasal challenge with influenza virus [PubMed: 2396470].
HA from Influenza A virus (A/Aichi/2/1968(H3N2)), (X31)
Protegen ID: 520; NCBI Protein GI: 324132; NCBITaxon: 387139
Mice and ferrets were immunised with two doses of the split virus vaccine (12-24 microg haemagglutinin derived from Influenza A virus (A/chicken/Italy/13474/99(H7N1))) with or without aluminium hydroxide adjuvant and challenged 3 weeks after second dose with the highly pathogenic A/chicken/Italy/13474/99 (H7N1) virus. The vaccine induced significant protection from disease after challenge with the wild-type virus. In the murine lethal challenge model, vaccination effectively prevented death and, furthermore, formulation with adjuvant reduced excessive weight loss and viral shedding [PubMed: 19453487].
HA from Influenza A virus (A/chicken/Italy/13474/99(H7N1))
Protegen ID: 521; NCBI Protein GI: 32261025; NCBITaxon: 199442
Immunization and challenge experiments in mice indicated that even though vaccination with the recombinant HA vaccinia viruses derived from Influenza B virus (Strain B/England/222/82) induced different levels of cross-reactive neutralizing antibodies, mice vaccinated with either recombinant vaccinia virus were protected from infection with either subpopulation of influenza virus [PubMed: 3318092].
HA from Influenza B virus (Strain B/England/222/82)
Protegen ID: 522; NCBI Protein GI: 122955; NCBITaxon: 11527
Mice vaccinated with a recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates (Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1))) with pandemic potential were protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was homologous or heterologous to the vaccine [PubMed: 18231588].
HA from Influenza A virus (A/duck/Badung-Bali/05/2005(H5N1))
Protegen ID: 523; NCBI Protein GI: 190344179; NCBITaxon: 389226
A targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope derived from Influenza A virus (A/Puerto Rico/8/34(H1N1)), CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity [PubMed: 18243429].
M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1))
Protegen ID: 524; NCBI Gene GI: 956528; NCBI Protein GI: 56583270; NCBI Protein Accession: NP_040979; NCBITaxon: 211044
Vaccination with HA-VRP derived from Influenza A virus (A/Hong Kong/1/68(H3N2)) did not strongly stimulate either neutralizing or IgG1 antibodies but did induce IgG2a antibodies. Expression of IgG2a antibodies in this context correlated with clearance of virus and increased protection against lethal influenza challenge [PubMed: 16960108].
HA from Influenza A virus (A/Hong Kong/1/68(H3N2))
Protegen ID: 525; NCBI Protein GI: 16960108; NCBITaxon: 10090
Researchers report that a DNA vaccine encoding hemagglutinin from the index human influenza isolate A/HK/156/97 provides immunity against H5N1 infection of mice [PubMed: 9971791].
HA from Influenza A virus (A/environment/Hong Kong/156/1997(H5N1))
Protegen ID: 527; NCBI Protein GI: 269826115; NCBITaxon: 680785
A simian adenovirus 24 (AdC7) vector expressing the influenza A/Puerto Rico/8/34 NP was tested for its efficacy in protecting BALB/c mice against two H5N1 strains. When tested in a mouse challenge model, there was a significantly improved survival rate following challenge with the Vietnam/1203/04 strain of H5N1 that has caused human outbreaks [PubMed: 17728024].
NP from Influenza A virus (A/Puerto Rico/8/34(H1N1))
Protegen ID: 528; NCBI Gene GI: 956531; NCBI Protein GI: 8486130; NCBI Protein Accession: NP_040982; NCBITaxon: 211044
The protective effect of neuraminidase (NA) was studied in a mouse protection test using isolated neuraminidase of A2/Aichi/68(H3N2) virus and the complete recombinant virus A/eq(Heq-1)-HK(N2) as antigens. Immunized mice were protected against A2/Aichi(H3N2) challenge virus; however, the protection rate was low in comparison to animals immunized with comparable amounts of the complete A2/68(H3N2) virus9 [PubMed: 1126575].
NA from Influenza A virus (A/Aichi/2/1968(H3N2))
Protegen ID: 530; NCBI Protein GI: 46401580; NCBITaxon: 387139
In mouse models of influenza infection, the vaccines derived from Influenza A virus (A/Solomon Islands/3/2006(H1N1)) hemagglutinin elicit robust antibody responses that mitigate disease and protect mice from lethal challenge [PubMed: 18493310].
HA from Influenza A virus (A/Solomon Islands/3/2006(H1N1))
Protegen ID: 531; NCBI Protein GI: 156123416; NCBITaxon: 464623
Results indicated that two doses of 10 microg of pCAGGoptiHA derived from Influenza A virus (A/Goose/Guangdong/1/96(H5N1)) could induce complete protection in chickens against H5 lethal virus challenge [PubMed: 17451817].
HA from Influenza A virus (A/Goose/Guangdong/1/96(H5N1))
Protegen ID: 532; NCBI Gene GI: 3654620; NCBI Protein GI: 73852955; NCBI Protein Accession: YP_308669; NCBITaxon: 93838
The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice [PubMed: 2781859].
HA from Influenza A virus (A/Yamagata/120/1986(H1N1))
Protegen ID: 533; NCBI Protein GI: 221344; NCBITaxon: 379740
HA from Influenza A virus (A/Fukuoka/C29/85(H3N2))
Protegen ID: 534; NCBI Protein GI: 221306; NCBITaxon: 62549
Protection against a lethal influenza B virus infection was examined in BALB/c mice immunized with plasmid DNAs encoding hemagglutinin (HA), neuraminidase (NA and NB) and nucleoprotein (NP) from the B/Ibaraki/2/85 virus. Both HA and NA DNAs conferred complete protection against the lethal challenge in all the tested mouse strains [PubMed: 11163667].
HA from Influenza B virus (B/Ibaraki/2/85)
Protegen ID: 535; NCBI Protein GI: 122959; NCBITaxon: 107411
NA from Influenza B virus (B/Ibaraki/2/85)
Protegen ID: 536; NCBI Protein GI: 53829726; NCBITaxon: 107411
Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC669/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572].
HA from Influenza A virus (A/Indonesia/CDC669/2006(H5N1))
Protegen ID: 537; NCBI Protein GI: 113497156; NCBITaxon: 400828
Viral challenge studies showed that live BacHA derived from Influenza A virus (A/Indonesia/CDC594/2006(H5N1)) was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1 [PubMed: 20071572].
HA from Influenza A virus (A/Indonesia/CDC594/2006(H5N1))
Protegen ID: 538; NCBI Protein GI: 113495780; NCBITaxon: 400810
A DNA vaccine encoding HA (from Influenza A virus (A/Hawaii/01/1991(H3N2))), NP and M1 (from a 1989 strain) protected ferrets better against challenge with the antigenic drift variant A/Georgia/03/93 than did the inactivated vaccine from the 1992-93 influenza season. Researchers report that the same DNA vaccine protected ferrets against a second, further divergent, drift variant (A/Johannesburg/33/94) [PubMed: 9234535].
HA from Influenza A virus (A/Hawaii/01/1991(H3N2))
Protegen ID: 539; NCBI Protein GI: 110313990; NCBITaxon: 387158
Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with HA plasmid once and the NA plasmid twice survived 100% [PubMed: 19067149].
HA from Influenza A virus (A/chicken/Henan/12/2004(H5N1))
Protegen ID: 540; NCBI Protein GI: 61698018; NCBITaxon: 319102
Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with NP plasmid showed 60-80% survival rate with at least three immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149].
NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1))
Protegen ID: 541; NCBI Protein GI: 61698066; NCBITaxon: 319102
NA from Influenza A virus (A/chicken/Henan/12/2004(H5N1))
Protegen ID: 542; NCBI Protein GI: 61698053; NCBITaxon: 319102
Plasmids carrying the HA, NA, NP, M1, and M2 genes, respectively, of the avian influenza virus (AIV) A/Chicken/Henan/12/2004(H5N1) strain were administered to mice, and the mice were challenged with the homologous virus later. The mice immunized with M1 plasmid survived 25% with five immunizations. The mixture of M1 and NP plasmids protected 95% of the mice against the homologous virus, and 80% of the mice against a challenge with heterologous H1N1 (PR8) virus [PubMed: 19067149].
M1 from Influenza A virus (A/chicken/Henan/12/2004(H5N1))
Protegen ID: 543; NCBI Protein GI: 61698034; NCBITaxon: 319102
Vaccination with ptPAs/NP derived from Influenza A virus (A/chicken/Hubei/489/2004(H5N1)) efficiently cleared the homologous H5N1 influenza virus in the infected lungs and induced partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice [PubMed: 18789973].
NP from Influenza A virus (A/chicken/Hubei/489/2004(H5N1))
Protegen ID: 544; NCBI Protein GI: 55233233; NCBITaxon: 298603
Researchers evaluated the immunogenicity and efficacy of a panel of flagellin-based hemagglutinin (HA) globular head fusion vaccines in inbred mice. The HA globular head of these vaccines was derived from the A/Vietnam/1203/04 (VN04; H5N1) HA molecule. Results show that replacement of domain D3 of flagellin with the VN04 HA globular head creates a highly effective vaccine that elicits protective HAI titers which protect mice against disease and death in a lethal challenge model with H5 VN virus [PubMed: 19654064].
HA from Influenza A virus (A/Viet Nam/1203/2004(H5N1))
Protegen ID: 545; NCBI Protein GI: 159144921; NCBITaxon: 284218
Using reverse genetics, we constructed a recombinant NDV expressing an H9 AIV hemagglutinin (HA) from an H9N2 field isolate, A/Chicken/ Shandong/2/2007. When tested, 90% of chickens were protected from clinical disease, mortality, and virus shedding against challenge with homologous H9N2 AIV [PubMed: 20521648].
HA from Influenza A virus (A/chicken/Guangdong/02/2007(H9N2))
Protegen ID: 546; NCBI Protein GI: 206812650; NCBITaxon: 563925
Immunization with DNA/rAd5 vaccines encoding HA derived from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) conferred protection in ferrets against a stringent virus challenge [PubMed: 20352112].
HA from Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1))
Protegen ID: 547; NCBI Nucleotide GI: 46578137; NCBI Protein GI: 46578138; NCBI Protein Accession: AAS65615.2; NCBITaxon: 266827
All specific-pathogen-free chickens immunized with (vFP89) expressing the native hemagglutinin (HA) gene from H5N8 A/turkey/ Ireland/1378/83 were clinically protected from HPAI challenge [PubMed: 20521642].
HA from Influenza A virus (A/turkey/Ireland/1378/1983(H5N8))
Protegen ID: 549; NCBI Protein GI: 115279333; NCBITaxon: 380285
All specific-pathogen-free chickens immunized with (vFP2211) expressing a modified synthetic HA gene from H5N1 A/chicken/Indonesia/7/2003 were clinically protected from HPAI challenge [PubMed: 20521642].
HA from Influenza A virus (A/chicken/Indonesia/7/2003(H5N1))
Protegen ID: 550; NCBI Protein GI: 129282887; NCBITaxon: 430432
A neutralizing monoclonal antibody (mAb) 9F4 against the hemagglutinin (HA) of the influenza A/chicken/hatay/2004 H5N1 virus was generated. MAb 9F4 was found to be protective, both prophylactically and therapeutically, against lethal viral challenge of mice [PubMed: 20519402].
HA from Influenza A virus (A/Hatay/2004/(H5N1))
Protegen ID: 551; NCBI Protein GI: 56311402; NCBITaxon: 303316
Chickens immunized with attenuated Salmonella strains expressing the hemagglutinin (HA1) gene from a highly pathogenic avian influenza (HPAI) H5N1 (A/whooper swan/Mongolia/3/2005) demonstrated a statistically significant increase in survival compared to control groups [PubMed: 20406663].
HA from Influenza A virus (A/whooper swan/Mongolia/3/05(H5N1))
Protegen ID: 553; NCBI Protein GI: 81687119; NCBITaxon: 344596
Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine [PubMed: 19006097].
Protegen ID: 554; NCBI Protein GI: 16445023; NCBITaxon: 11072
Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA [PubMed: 12634382].
Protegen ID: 555; NCBI Protein GI: 90019439; NCBITaxon: 11072
Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV [PubMed: 15121294].
Protegen ID: 556; NCBI Protein GI: 18418672; NCBITaxon: 11072
Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model. Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus [PubMed: 12922097].
Protegen ID: 557; NCBI Protein GI: 27696332; NCBITaxon: 11072
Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus [PubMed: 12922097].
Protegen ID: 558; NCBI Protein GI: 158702649; NCBITaxon: 11072
A cDNA clone representing the genome of structural proteins of Japanese encephalitis virus (JEV) was inserted into the thymidine kinase gene of vaccinia virus strains LC16mO and WR. Inoculation of rabbits with the infectious recombinant vaccinia virus resulted in rapid production of antiserum specific for the PreM and E glycoproteins of JEV. Mice vaccinated with the recombinant produced JEV-neutralizing antibodies and were resistant to challenge with JEV [PubMed: 2159544].
Protegen ID: 559; NCBI Protein GI: 14600066; NCBITaxon: 11072
Vaccine efficacy trials in guinea pigs indicated that the nucleoprotein is capable of eliciting a protective immune response against a lethal dose of Lassa virus. Ninety-four percent of the animals vaccinated with V-LSN survived a Lassa virus challenge in which only 14% of unvaccinated animals and 39% of animals vaccinated with the New York Board of Health (NYBH) strain of vaccinia virus survived [PubMed: 2741340].
Protegen ID: 560; NCBI Gene GI: 956584; NCBI Protein GI: 23343510; NCBI Protein Accession: NP_694869; NCBITaxon: 11620
BALB/c mice were immunized with a vaccine expressing the 78kDa (GRP-78) antigen of Leishmania donovani. Challenge infection was given intracardially after 2 weeks of second booster. A significant decrease in parasite burden was seen in vaccinees over the infected controls on all post challenge days and was found that maximum protection was provided by 78kDa+rIL-12 vaccine. It was highly immunogenic as depicted by the reduction in parasite load (71-94.8%) [PubMed: 20093205].
Protegen ID: 561; NCBI Protein GI: 16797868; NCBITaxon: 5661
Study results show that a single intraperitoneal administration of the A2-recombinant L. tarentolae strain expressing the Leishmania donovani A2 antigen protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-gamma production prior and after challenge [PubMed: 19818721].
Protegen ID: 563; NCBI Protein GI: 30385439; NCBITaxon: 5671
Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD31 (ATP synthase alpha chain) reduced parasite burden by 74%-77% [PubMed: 19503834].
Protegen ID: 564; NCBI Protein GI: 722242; NCBITaxon: 5661
Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD51 (beta-tubulin) reduced parasite burden by 72%-75% [PubMed: 19503834].
Protegen ID: 565; NCBI Protein GI: 262233287; NCBITaxon: 5661
Study compared the vaccine efficacy of various L. donovani antigens encapsulated in cationic liposomes in BALB/c mice against challenge infection with L. donovani. Results demonstrated that liposomal LD72 (Hsp70) reduced parasite burden by 65%-67% [PubMed: 19503834].
Protegen ID: 566; NCBI Protein GI: 281426606; NCBITaxon: 5661
KMP-11 DNA vaccination alone in an experimental BALB/c mice model showed significant potential in terms of resolution of splenic and hepatic parasite burden against virulent LD challenge. KMP-11 DNA immunization significantly protects against L. donovani infection [PubMed: 19162111].
Protegen ID: 567; NCBI Protein GI: 7579896; NCBITaxon: 5661
Study showed that cationic distearoyl phosphatidylcholine (DSPC) liposomes, when used as vaccine adjuvant with the immunodominant 63-kDa glycoprotein (gp63, mspC) of Leishmania donovani promastigotes, induced significant protection against progressive visceral leishmaniasis in susceptible BALB/c mice. gp63 used without adjuvant elicited partial protection but in association with liposomes exhibited marked resistance in both the livers and spleens of the mice challenged 10 days after the last vaccination [PubMed: 18195029].
Protegen ID: 568; NCBI Protein GI: 21954466; NCBITaxon: 5661
An expression plasmid encoding both p35 and p40 subunits of IL-12 when co-administered with a recombinant open-reading frame (rORFF) gene from the LD1 locus of Leishmania donovani induces significant protection with around 82% protection in both liver and spleen of BALB/c mice when challenged with L. donovani [PubMed: 16413950].
Protegen ID: 569; NCBI Protein GI: 703122; NCBITaxon: 5661
Immunization of mice with recombinant BT1 proteins (a biopterin transporter) from multigenic LD1 locus on chromosome 35 of L. donovani conferred partial protection against challenge with Leishmania donovani in a BALB/c mice [PubMed: 15357215].
Protegen ID: 570; NCBI Protein GI: 703123; NCBITaxon: 5661
Experimental infection of immunized BALB/c mice demonstrated that the VR1012-NH36 DNA vaccine derived from the nucleoside hydrolase gene (NH) of L. donovani induced an 88% reduction in L. chagasi parasite load and a 65% reduction in L. mexicana lesion size [PubMed: 15664920].
Protegen ID: 571; NCBI Protein GI: 19697561; NCBITaxon: 5661
Study demonstrated for the first time that a recombinant stage-specific hydrophilic surface protein of Leishmania donovani, recombinant hydrophilic acylated surface protein B1 (HASPB1), is able to confer protection against experimental challenge with L. donovani in BALB/c mice [PubMed: 11120835].
Protegen ID: 572; NCBI Protein GI: 51847753; NCBITaxon: 5661
Nonhuman primates (cynomolgus macaques) were inoculated with VEE replicons expressing MBGV GP and/or NP and challenged with MGBV. MBGV NP afforded incomplete (partial) protection, sufficient to prevent death but not disease in two of three macaques [PubMed: 9813200 ].
Protegen ID: 573; NCBI Protein GI: 332181; NCBITaxon: 11269
Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gB1 expressing MDV040 conferred 42% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881].
Protegen ID: 574; NCBI Gene GI: 4811501; NCBI Protein GI: 125745079; NCBI Protein Accession: YP_001033956; NCBITaxon: 10390
Recombinant fowl poxviruses (rFPVs) were constructed to express genes from serotype 1 Marek's disease virus (MDV, Gallid herpesvirus 2). rFPV/gI expressing MDV095 conferred 43% protection in maternal antibody-positive chickens when challenged with highly virulent MDV isolates [PubMed: 14562881].
Protegen ID: 575; NCBI Gene GI: 4811454; NCBI Protein GI: 125745128; NCBI Protein Accession: YP_001034012; NCBITaxon: 10390
Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles were used to express the hemagglutinin (H) and fusion (F) proteins of measles virus (MV). When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia [PubMed: 20130066].
Protegen ID: 577; NCBI Gene GI: 1489801; NCBI Protein GI: 9626951; NCBI Protein Accession: NP_056923; NCBITaxon: 11234
Mice vaccinated with a vaccinia virus recombinant encoding the fusion protein of Measles virus developed measles neutralizing antibodies. The mice also resisted a normally lethal intracerebral inoculation of a cell-associated measles virus subacute sclerosing panencephalitis strain [PubMed: 3422488].
Protegen ID: 578; NCBI Gene GI: 1489800; NCBI Protein GI: 9626950; NCBI Protein Accession: NP_056922; NCBITaxon: 11234
Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVN (Nucleocapsid Protein) -immunized rats survived a MV challenge infection [PubMed: 1833505].
Protegen ID: 579; NCBI Gene GI: 1489804; NCBI Protein GI: 9626946; NCBI Protein Accession: NP_056918; NCBITaxon: 11234
Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge [PubMed: 1833505].
Protegen ID: 580; NCBI Gene GI: 1489805; NCBI Protein GI: 9626947; NCBI Protein Accession: NP_056919; NCBITaxon: 11234
Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge [PubMed: 1833505].
Protegen ID: 581; NCBI Gene GI: 1489803; NCBI Protein GI: 9626949; NCBI Protein Accession: NP_056921; NCBITaxon: 11234
A novel mumps vaccine with good immunity and safety was developed by selecting an antigen (HN) component of the mumps virus. The clinical and pathological observations after challenge of vaccinated rhesus monkeys indicated further that the immune response induced by this vaccine provided complete protection from wild-type virus infection [PubMed: 18597904].
Protegen ID: 582; NCBI Gene GI: 1489765; NCBI Protein GI: 9695422; NCBI Protein Accession: NP_054713; NCBITaxon: 11161
Immunization with DNA encoding Ag85B (fbpB), a candidate vaccine antigen of Mycobacterium tuberculosis, elicited in mice a low but protective CD4(+) T cell-mediated IFN-gamma response [PubMed: 20544034].
Protegen ID: 583; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NP_216402; NCBITaxon: 83332
Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32(C)-Mtb39-Mtb32(N). All forms of Mtb72F immunization tested resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis [PubMed: 15187142].
Protegen ID: 584; NCBI Protein GI: 283801990; NCBITaxon: 32630
Protective experiments of DNA vaccine pcDNA3-MIC3 (pMIC3i) in Kumming mice showed that the vaccine could significantly prolong the survival time of the mice challenged by virulent RH strains of T. gondii [PubMed: 19800170].
Protegen ID: 587; NCBI Gene GI: 7901253; NCBI Protein GI: 237841071; NCBI Protein Accession: XP_002369833; NCBITaxon: 508771
We show that the 50- to 55-kDa Apa protein, specified by the Rv1860 gene of M. tuberculosis, can elicit both lymphoproliferative response and gamma interferon (IFN-gamma) production. A poxvirus recombinant expressing the Apa protein conferred a significant level of protective immunity in guinea pigs against a challenge dose of virulent M. tuberculosis [PubMed: 12654810].
Protegen ID: 588; NCBI Gene GI: 885896; NCBI Protein GI: 57116926; NCBI Protein Accession: YP_177849; NCBITaxon: 83332
MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis, is immunoreactive in antibody assays in humans and animals and provides protection as a combined DNA vaccine in mice [PubMed: 19281533].
Protegen ID: 589; NCBI Gene GI: 885334; NCBI Protein GI: 15609063; NCBI Protein Accession: NP_216442; NCBITaxon: 83332
The immunogenicity and protective efficacy of a recombinant subunit West Nile virus (WNV) vaccine was evaluated in rhesus macaques (Macaca mulatta). The vaccine consisted of a recombinant envelope (E) protein truncated at the C-terminal end, resulting in a polypeptide containing 80% of the N-terminal amino acids of the native WNV protein (WN-80E), mixed with an adjuvant (GPI-0100). Groups of monkeys were immunized with the WN-80E/GPI-0100 vaccine or an adjuvant-only control formulation. Animals were then challenged by inoculation of wild-type WNV, and the level of viremia in each animal was monitored daily for 10 days. The results showed that whereas all animals in the control group had detectable viremia for at least 3 days after challenge, all of the vaccinated animals were negative on all days after challenge. Thus, the WN-80E vaccine was 100% efficacious in protecting monkeys against infection with WNV [PubMed: 19641099].
Protegen ID: 590; NCBI Protein GI: 111145461; NCBITaxon: 11082
An antiserum raised in chicken against the TM-1 polypeptide, which was produced by recombinant Escherichia coli cells and purified by column chromatography, inhibited growth of M.g. cells in vitro. Moreover, chickens immunized with this 29 kDa polypeptide (TM-1) were partially protected from a challenge with virulent M.g [PubMed: 8212828].
Protegen ID: 591; NCBI Protein GI: 7249262; NCBITaxon: 2096
Starting with a previously designed eukaryotic expression vector, a recombinant plasmid (pCBWN) that expressed the WN virus prM and E proteins was constructed. A single intramuscular injection of pCBWN DNA induced protective immunity, preventing WN virus infection in mice and horses when subjected to challenge with the NY99-6480 strain of WNV [PubMed: 11287553].
Protegen ID: 592; NCBI Gene GI: 5714902; NCBI Protein GI: 158516888; NCBI Protein Accession: YP_001527877; NCBITaxon: 11082
Seventeen monoclonal antibodies to one of three main cell surface antigens of Neisseria meningitidis group B were tested for protective efficacy in the infant rat using as challenge seven strains of different class 2/3 protein serotypes. Survival of the animals was regularly obtained with antibodies to the P1 protein and to LPS [PubMed: 2510417].
Protegen ID: 594; NCBI Gene GI: 902192; NCBI Protein GI: 15676020; NCBI Protein Accession: NP_273150; NCBITaxon: 122586
Sera of the challenge group immunized with CCPS-P64kR showed a three-fold higher bactericidal response than the sera of the group immunized with the plain CCPS and they were able to protect against challenge with Neisseria meningococci in the infant rat protection model [PubMed: 15039094].
Protegen ID: 596; NCBI Protein GI: 1017430; NCBITaxon: 487
Mice immunized with purified Tbp2 survived a lethal challenge to a similar degree as animals immunized with the Tbp1-Tbp2 complex, demonstrating that Tbp2 played an important role in the protective activity observed with the complex, eliciting antibodies that are not only bactericidal but also inhibitory for meningococcal growth [PubMed: 7868259].
Protegen ID: 597; NCBI Protein GI: 1017433; NCBITaxon: 487
Immunization with recombinant forms of a sporozoite surface antigen (r-p67), derived from either bacterial or insect cells, induces high levels of sporozoite neutralizing antibodies in cattle.In vivo immunization studies have shown that approximately 30% of immunized cattle are nonreactors to a needle LD70 sporozoite challenge, 40% experience a mild disease reaction from which they recover, and the remaining 30% suffer severe disease and are clinically indistinguishable from controls. Transient parasitosis and mild clinical reactions are also observed in challenge of cattle immunized by infection and treatment and such responses constitute immunity to ECF. Hence, p67 is able to routinely induce immunity at a level of about 70% [PubMed: 11193661].
Protegen ID: 598; NCBI Protein GI: 4106806; NCBITaxon: 5875
NspA-containing outer membrane vesicles conferred protection against otherwise lethal intraperitoneal challenge of mice with N. meningitidis serogroup B, and sera raised against them mediated opsonophagocytosis of meningococcal strains expressing this antigen [PubMed: 15501782].
Protegen ID: 599; NCBI Protein GI: 5825543; NCBITaxon: 487
A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; the lactate permease (LctP) elicited protective immunity [PubMed: 15964482].
Protegen ID: 600; NCBI Protein GI: 254667969; NCBITaxon: 662598
A total of 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect mice against live bacterial challenge against N. meningitidis; ExbB, which is required for iron acquisition, elicited protective immunity [PubMed: 15964482].
Protegen ID: 601; NCBI Gene GI: 903370; NCBI Protein GI: 15677575; NCBI Protein Accession: NP_274732; NCBITaxon: 122586
The trial vaccination of cattle against T. annulata using recombinant sporozoite antigens (SPAG-1 and p67) and/or merozoite antigens (TAMS 1-1 and 1-2). The aim of these trials was to try and enhance the levels of protection induced compared with previous trials. Different approaches were tried. SPAG-1 was expressed as a fusion protein with a His6 tag and then either incorporated into ISCOMs, with or without TAMS 1-1 and 1-2, or administered with RWL, a proprietary saponin-based adjuvant. Cross-protection studies were also performed by immunizing cattle with the T. parva sporozoite antigen, p67, and then challenging with a T. annulata sporozoite stabilate.All the data collected from these two trials indicate that SPAG-1 administered with RWL is better at inducing an effective immune response than SPAG-1 incorporated into ISCOMs, with or without the presence of merozoite antigens [PubMed: 9668470].
Protegen ID: 602; NCBI Protein GI: 161885; NCBITaxon: 5874
To test the potential of subunit vaccines against T. annulata infection, we immunized four groups of three calves with either recombinant (re-) (Tams1-1 and Tams1-2) proteins or naked DNA encoding these antigens. All calves vaccinated with ISCOMs proved to be protected from T. annulata infection and had generated antibodies against both re-(Tams1-1 and Tams1-2) at the time of challenge [PubMed: 9364686].
TA17050 merozoite-piroplasm surface antigen Tams1
Protegen ID: 603; NCBI Gene GI: 3864438; NCBI Protein GI: 84997996; NCBI Protein Accession: XP_953719; NCBITaxon: 353154
Intraperitoneal application of NcMAG1 suspended in saponin adjuvants lead to protection against disease in 50% of animals vaccinated in a C57Bl/6 mouse cerebral infection model [PubMed: 19835644].
Protegen ID: 604; NCBI Protein GI: 147886433; NCBITaxon: 29176
Vaccination with an RASV synthesizing full-length PsaA induced high titers of anti-PsaA antibodies in both systemic (IgG in serum) and mucosal (IgA in vaginal washes, nasal washes, and lung homogenates) sites. BALB/c (haplotype H2(d)) or C57BL/6 (haplotype H2(b)) mice vaccinated either orally or intranasally exhibited a significant reduction in colonization of nasopharyngeal tissues after intranasal challenge with S. pneumoniae strains compared to controls, although protection was not observed with all challenge strains. None of the vaccine constructs provided protection against intraperitoneal challenge with S. pneumoniae strain WU2 (serotype 3) [PubMed: 20479086].
Protegen ID: 605; NCBI Protein GI: 209867628; NCBITaxon: 1313
A 90% protection rate was achieved following intra-nasal vaccination with recNcPDI emulsified in cholera toxin employing the C57Bl/6 mouse cerebral infection model when challenged with Neospora caninum tachyzoites [PubMed: 19835644].
Protegen ID: 606; NCBI Protein GI: 82568727; NCBITaxon: 29176
The protective effects a pneumolysin mutant (DeltaA146 Ply) against pneumococcal infections in mice was evaluated. Vaccinated mice were challenged with pneumococcal strain D39 at 1,500 times the LD50 (1.5 x 105 CFU) and the vaccinated mice survived significantly longer than control mice after challenge [PubMed: 20038538].
Protegen ID: 607; NCBI Gene GI: 4441611; NCBI Protein GI: 116515376; NCBI Protein Accession: YP_817150; NCBITaxon: 373153
The protective effects of ATP-dependent caseinolytic protease (ClpP) was evaluated. Vaccinated mice were intraperitoneally and/or intranasally challenged with different pneumococcal strains. In intraperitoneal challenge models with pneumococcal strain D39 (serotype 2), clpP elicited some protection in mice [PubMed: 20038538].
Protegen ID: 608; NCBI Gene GI: 4441476; NCBI Protein GI: 116516216; NCBI Protein Accession: YP_816144; NCBITaxon: 373153
The production of a recombinant vaccine was achieved following PCR amplification of putative lipoate protein ligase (Lpl), with subsequent cloning and expression of the genes in E. coli. The putative lipoate protein ligase (Lpl) , resulted in a reduced CFU titre and a trend towards reduced mortality in an animal sepsis model [PubMed: 18034862].
Protegen ID: 609; NCBI Gene GI: 934072; NCBI Protein GI: 15903091; NCBI Protein Accession: NP_358641; NCBITaxon: 171101
NcSAG1 and NcSRS2, the two major immunodominant tachyzoite surface antigens of the apicomplexan parasite Neospora caninum, were investigated for their potential as vaccine candidates in mice. Results suggest that a combined DNA/recombinant antigen-vaccine, based on NcSAG1 and NcSRS2, respectively, exhibited a highly significant protective effect against experimentally induced cerebral neosporosis in mice [PubMed: 12741509].
Protegen ID: 610; NCBI Protein GI: 5579384; NCBITaxon: 29176
Protegen ID: 611; NCBI Protein GI: 4583447; NCBITaxon: 29176
Mice immunized with recombinant (r)PsrP(BR) had significantly less bacteria in their blood and improved survival versus controls following intranasal challenge [PubMed: 19627498].
Protegen ID: 613; NCBI Gene GI: 7329552; NCBI Protein GI: 221232510; NCBI Protein Accession: YP_002511663; NCBITaxon: 561276
This study used an immunisation/challenge model of transplacental transmission, based on the Qs mouse with an Nc-Liverpool challenge to investigate the vaccine potential of a number of formulations based on four recombinant proteins of N. caninum. A mixture of MIC10 and p24B produced partial protection against transplacental transmission of N. caninum in this mouse model [PubMed: 18789996]. Note: MIC10 must be used in conjunction with p24B in order to confer protection against N. caninum.
Protegen ID: 614; NCBI Protein GI: 11141617; NCBITaxon: 29176
Intraperitoneal immunization with recombinant SrtA was found to have conferred to mice protection against S. pneumoniae intraperitoneal challenge and the passive transfer of immune serum before intraperitoneal challenge was also protective. Moreover, by using the intranasal challenge model, significant reduction of bacteremia when mice were intraperitoneally immunized with SrtA was observed, while a moderate decrease of lung infection was achieved by intranasal immunization, even though no influence on nasopharynx colonization was seen [PubMed: 19433540].
Protegen ID: 615; NCBI Gene GI: 4442999; NCBI Protein GI: 116515518; NCBI Protein Accession: YP_816547; NCBITaxon: 373153
Study assessed the potential protectivity of NcMIC1-based vaccination against experimental N. caninum infection in mice. Quantitative real-time PCR revealed that the infection intensity was significantly reduced in the group vaccinated with recNcMIC1 antigen. Serological analysis showed that only recNcMIC1-immunized animals generated detectable antibody levels recognizing native NcMIC1. Thus, of all protocols applied, only recNcMIC1 vaccination appears to be suited to reduce cerebral infection in mice challenged with N. caninum tachyzoites [PubMed: 16108562].
Protegen ID: 616; NCBI Protein GI: 17226315; NCBITaxon: 29176
Glutamyl tRNA synthetase (GtS) has been found to be among the Streptococcus pneumoniae cell wall-derived proteins that have age-dependent immunogenicity in children. Here, GtS was cloned, expressed, and purified and then was used to immunize 7-week-old BALB/c OlaHsd mice. Thirty-nine percent of rGtS-immunized mice survived a lethal bacterial challenge, whereas no control mice survived [PubMed: 17703427].
Protegen ID: 617; NCBI Gene GI: 931970; NCBI Protein GI: 15901888; NCBI Protein Accession: NP_346492; NCBITaxon: 170187
Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. The highest protection efficacy was observed for combined vaccination with NcSRS2 and NcDG1 (67.5% survival) compared to control (17.4% survival). Vaccination with NcDG1 alone elicited 62.5% survival in the challenge model [PubMed: 15793355].
Protegen ID: 618; NCBI Protein GI: 2149142; NCBITaxon: 29176
Mice were actively immunized with a fragment of choline binding protein A (CbpA; also known as PspC, Hic, and SpsA). CbpA was able to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39 [PubMed: 11553536].
Protegen ID: 619; NCBI Gene GI: 4441159; NCBI Protein GI: 116515359; NCBI Protein Accession: YP_817402; NCBITaxon: 373153
Groups of BALB/c mice immunized with choline binding protein PspA were challenged with either D39 or WCH16. PspA elicited protection by using moderate challenge doses of S. pneumoniae [PubMed: 17088353].
Protegen ID: 620; NCBI Gene GI: 4441373; NCBI Protein GI: 116515876; NCBI Protein Accession: YP_815641; NCBITaxon: 373153
Separate groups of gerbils were immunized with purified recombinant proteins singly or in combinations and animals were then challenged with N. caninum. The protective efficacy of each vaccination was determined by assessing animal survival rate. All experimental groups showed protective effects. Vaccination with NcDG2 alone elicited 50% survival rate compared to a control survival rate of 17.4% [PubMed: 15793355].
Protegen ID: 621; NCBI Protein GI: 3237325; NCBITaxon: 29176
BALB/c mice were immunized with recombinant 6-Phosphogluconate dehydrogenase (r6PGD) and boosted after 3 weeks. Immunized mice were challenged intranasally with a lethal dose of S. pneumoniae. Immunization of mice with r6PGD protected 60% (P < 0.001) of mice for 5 days and 40% (P < 0.05) of the mice for 21 days following intranasal lethal challenge [PubMed: 16634799].
Protegen ID: 622; NCBI Gene GI: 4441177; NCBI Protein GI: 116515453; NCBI Protein Accession: YP_815856; NCBITaxon: 373153
Mice immunized with recombinant PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae [PubMed: 11598041].
Protegen ID: 623; NCBI Gene GI: 4442863; NCBI Protein GI: 116515816; NCBI Protein Accession: YP_815744; NCBITaxon: 373153
A recombinant fowlpox virus expressing the fusion protein of Newcastle disease virus strain F48E8 protected chickens against virulent NDV challenge. The protective rate was 96.7% [PubMed: 11191764].
F fusion protein from Newcastle disease virus
Protegen ID: 624; NCBI Gene GI: 912271; NCBI Protein GI: 11545723; NCBI Protein Accession: NP_071469; NCBITaxon: 11176
Recombinant baculoviruses containing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic velogenic (vv) Newcastle disease virus (NDV) isolate, Kr-005/00, and a lentogenic La Sota strain of the NDV were constructed. A single dose of rNDHN(V) had a protective effect against mortality (p <0.01) in chickens [PubMed: 18716451].
Protegen ID: 625; NCBI Gene GI: 912270; NCBI Protein GI: 11545724; NCBI Protein Accession: NP_071470; NCBITaxon: 11176
Researchers constructed a new recombinant molecule of SERA5, namely SE36. Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge [PubMed: 20493274].
Protegen ID: 626; NCBI Protein GI: 238629807; NCBITaxon: 5833
Vaccination of mice with EAG (2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) as a single antigen with EtxB (as an adjuvant) induced protection in mice against bacterial challenge, but was less protective than at affording protection than immunization with FNZ, SFS, EAG, and EtxB [PubMed: 15155624].
Protegen ID: 627; NCBI Gene GI: 7696154; NCBI Protein GI: 225870123; NCBI Protein Accession: YP_002746070; NCBITaxon: 553482
Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain [PubMed: 8363656].
Protegen ID: 628; NCBI Gene GI: 3791597; NCBI Protein GI: 82596427; NCBI Protein Accession: XP_726257; NCBITaxon: 352914
Mice were immunised i.n. with collagen-binding protein (CNE) and were subsequently subjected to infection with S. equi subsp. equi. A control group of mice was given only adjuvant. The CNE vaccinated group had a delayed onset of infection compared to the control group. Immunization with CNE led to significant protection from infection [PubMed: 16580099].
collagen binding, ancillary pilus subunit Cne
Protegen ID: 629; NCBI Gene GI: 7695900; NCBI Protein GI: 225870316; NCBI Protein Accession: YP_002746263; NCBITaxon: 553482
Parts of the three recombinant proteins (FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein)) were used to immunize mice, either subcutaneously or intranasally, prior to nasal challenge with S. equi subsp. equi. The adjuvant used was EtxB, a recombinant form of the B subunit of Escherichia coli heat-labile enterotoxin. It was shown that nasal colonization of S. equi subsp. equi and weight loss due to infection were significantly reduced after vaccination compared with a mock-vaccinated control group. This effect was more pronounced after intranasal vaccination than after subcutaneous vaccination; nearly complete eradication of nasal colonization was obtained after intranasal vaccination (P < 0.001) [PubMed: 15155624].
Protegen ID: 630; NCBI Gene GI: 7695217; NCBI Protein GI: 225869227; NCBI Protein Accession: YP_002745175; NCBITaxon: 40041
Protegen ID: 631; NCBI Gene GI: 7696331; NCBI Protein GI: 225869898; NCBI Protein Accession: YP_002745845; NCBITaxon: 553482
The fibrinogen-binding protein (FgBP) reacted with serum taken from horses recovering from strangles and protected mice against lethal challenge from S. equi subsp. equi [PubMed: 9579073].
Protegen ID: 632; NCBI Gene GI: 7697172; NCBI Protein GI: 225871286; NCBI Protein Accession: YP_002747233; NCBITaxon: 553482
Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared. [PubMed: 19915055].
Protegen ID: 633; NCBI Gene GI: 3428738; NCBI Protein GI: 68076353; NCBI Protein Accession: XP_680096; NCBITaxon: 5823
A P. berghei parasite line was used to expresses a heterologous circumsporozoite protein (CSP) from P. falciparum. A sterile immunity was obtained by vaccination with the radiation-attenuated P. berghei parasite [PubMed: 18159254].
Protegen ID: 634; NCBI Protein GI: 552191; NCBITaxon: 5833
Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites [PubMed: 19890387].
Protegen ID: 635; NCBI Gene GI: 3830374; NCBI Protein GI: 83317409; NCBI Protein Accession: XP_731149; NCBITaxon: 352914
Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection [PubMed: 19073223].
Protegen ID: 636; NCBI Protein GI: 113207288; NCBITaxon: 5833
Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection [PubMed: 18097046].
Protegen ID: 637; NCBI Protein GI: 58197887; NCBITaxon: 5861
Intranasal or oral delivery of the chimeric rotavirus VP6 protein MBP::VP6 to mice elicited >90% reductions in fecal rotavirus shedding after murine rotavirus challenge [PubMed: 17629371].
Protegen ID: 638; NCBI Protein GI: 268080815; NCBITaxon: 28327
Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii [PubMed: 17785475].
Protegen ID: 639; NCBI Gene GI: 810313; NCBI Protein GI: 124802328; NCBI Protein Accession: XP_001347440; NCBITaxon: 36329
Mice immunized with recombinant PbAMA-1 were partially protected from the challenge of P. berghei [PubMed: 17639690].
Protegen ID: 640; NCBI Protein GI: 1438889; NCBITaxon: 5821
Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P < 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P < 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P < 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P < 0.01) [PubMed: 17568385].
Protegen ID: 641; NCBI Protein GI: 1762646; NCBITaxon: 5821
Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Neonates of animals immunized with virus-like particles composed of VP7 assembled on VP6 spherical particles were protected against challenge with the homotypic virus and significantly protected from a heterotypic challenge. Unassembled VP7 protein provided partial protection against challenge [PubMed: 8382422].
Protegen ID: 642; NCBI Protein GI: 195661008; NCBITaxon: 10927
Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP4 protein on assembled particles or in cell lysates showed protection against challenge with both homologous (bovine C486) and heterologous (SA-11) strains of rotavirus [PubMed: 8382422].
Protegen ID: 643; NCBI Protein GI: 172054621; NCBITaxon: 10927
Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge [PubMed: 17303242].
Protegen ID: 644; NCBI Protein GI: 1399353; NCBITaxon: 5861
Immunized animals were challenged in vivo with various parasite strains or clones of malaria. Immunization with the PfEMP1-DBL1 alpha domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heterologous parasite strains was also confirmed by direct or indirect challenge in the rat model [PubMed: 17074852].
Protegen ID: 645; NCBI Protein GI: 2961468; NCBITaxon: 5833
Immunization of BALB/c mice and Aotus monkeys with PvMSP-1 induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages [PubMed: 16291762].
Protegen ID: 646; NCBI Protein GI: 26985160; NCBITaxon: 5855
A DNA vaccine based on lysosome-targeted glycoprotein of the rabies virus was evaluated in BALB/c mice. It imparted partial protection (60%) against challenge with 20 LD(50) of the challenge virus standard (CVS) strain of rabies virus [PubMed: 19741168].
Protegen ID: 647; NCBI Protein GI: 56384945; NCBITaxon: 11292
Mice vaccinated intraperitoneally (i.p.) with 10^7 p.f.u. of a vaccinia virus recombinant expressing either the glycoprotein (rVac-G) or nucleoprotein (rVac-N) of rabies virus 3 weeks before challenge were protected against peripheral lethal infection [PubMed: 8207400].
Protegen ID: 648; NCBI Gene GI: 1489853; NCBI Protein GI: 9627198; NCBI Protein Accession: NP_056793; NCBITaxon: 11292
Two large fragments of PfKbeta representing the N- and C-terminal halves were expressed in E. coli. The recombinant proteins were highly immunogenic in mice, and also found to be the target for immune response in natural infections of Plasmodium spp. Immunization with recombinant PfKbeta fragments was partially protective against a heterologous challenge infection in mice [PubMed: 15987343].
Protegen ID: 649; NCBI Gene GI: 813054; NCBI Protein GI: 124506397; NCBI Protein Accession: XP_001351796; NCBITaxon: 36329
Immunization with one of the constructs of M. vaccae expressing OmpA in combination with booster immunization with the homologous recombinant protein protected a significant portion of mice from lethal challenge [PubMed: 11738766].
Protegen ID: 650; NCBI Protein GI: 112710; NCBITaxon: 783
R. rickettsii OmpB contain B and T lymphocyte epitopes. Immunizations with each of two fragments from OmpB (rompB1550-2738 and rompB2459-4123) conferred protection against challenge with a lethal dose of R. conorii. Protection appeared to be better achieved among the groups that received both DNA and recombinant protein immunizations, although recombinant protein immunizations alone provided some protection [PubMed: 11693887].
Protegen ID: 651; NCBI Protein GI: 6685726; NCBITaxon: 783
Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection [PubMed: 15385527].
Protegen ID: 652; NCBI Protein GI: 49798469; NCBITaxon: 73239
Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami [PubMed: 10861076].
Protegen ID: 653; NCBI Protein GI: 1469500; NCBITaxon: 5825
Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route [PubMed: 19116444].
Protegen ID: 654; NCBI Protein GI: 4138504; NCBITaxon: 10345
A trial vaccine containing pseudorabies virus (PRV) glycoprotein gC as the main component showed excellent protection against virulent virus infection in pigs [PubMed: 9300361].
Protegen ID: 655; NCBI Gene GI: 2952505; NCBI Protein GI: 51557513; NCBI Protein Accession: YP_068347; NCBITaxon: 10345
The pseudorabies virus (PrV) DNA vaccine carrying the glycoprotein D (gD) gene delivered by E. coli was able to induce protective immune responses in mice against a lethal PrV challenge [PubMed: 11312026]. Immunization of mice with affinity-purified gD of Aujeszky's disease virus (ADV, Suid herpesvirus 1) induced a strong humoral immune response and protected mice against lethal ADV challenge [PubMed: 17601050].
Protegen ID: 656; NCBI Gene GI: 2952521; NCBI Protein GI: 51557553; NCBI Protein Accession: YP_068387; NCBITaxon: 10345
A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported. Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites. Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys [PubMed: 8303938].
Protegen ID: 657; NCBI Protein GI: 1093612; NCBITaxon: 5833
To examine the response by IE180 more closely, a vaccine trial in mice with a vector DNA construct that contains the gene encoding for IE180, designated pcDNAIE180 was conducted. Seven months after immunization with pcDNAIE180, an overall 25% of BALB/c, C3H/HeJ, and C57BL/6 mice receiving a lethal PrV challenge were protected [PubMed: 9586695].
Protegen ID: 658; NCBI Gene GI: 2952540; NCBI Protein GI: 51557548; NCBI Protein Accession: YP_068382; NCBITaxon: 10345
An open reading frame 2 plasmid (pORF2) and the capsid protein (Cap) of PCV2 were used as DNA and subunit vaccines, respectively. In FCM analysis, although pORF2 and Cap alone showed comparable efficacy in eliciting lymphoproliferative responses and Cap-specific CD4(+) T cells, pORF2 was superior to the Cap protein in triggering CD8(+) T cells. Following virus challenge, real-time PCR and histopathological analysis confirmed that only low viral DNA loads and mild microscopic lesions appeared in pORF2-immunized mice [PubMed: 18632956].
Protegen ID: 659; NCBI Protein GI: 78217439; NCBITaxon: 85708
To examine the mechanism of immunity in vivo, researchers used poliovirus receptor-transgenic mice on a BALB/c (H-2d) background. Mice immunized with the vaccine strain were protected against a subsequent challenge with wild-type virus. Protection was observed when mice received primed B cells in the presence of a VP4-specific Th1 clone. Findings demonstrate that CD4+ T cells, specific for the internal poliovirus capsid protein, VP4, can provide effective help for a protective antibody response directed against surface capsid proteins [PubMed: 7699320].
Protegen ID: 660; NCBI Protein GI: 68532656; NCBITaxon: 12080
Series of plasmid constructs encoding different forms of the envelope glycoprotein E of the flavivirus tick-borne encephalitis virus were constructed. These included a secreted recombinant subviral particle, a secreted carboxyl-terminally truncated soluble homodimer, a nonsecreted full-length form, and an inefficiently secreted truncated form. Mice were immunized using both i.m. injection and Gene Gun-mediated application of plasmids. The functional immune response was evaluated by determining specific neutralizing and hemagglutination-inhibiting Ab activities and by challenging the mice with a lethal dose of the virus.The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge [PubMed: 10586074].
Protegen ID: 661; NCBI Gene GI: 1489719; NCBI Protein GI: 9628432; NCBI Protein Accession: NP_043135; NCBITaxon: 11084
Monoclonal antibodies to gE neutralize VZV in vitro in a complement- dependent manner [PubMed: 9125048]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709].
Protegen ID: 662; NCBI Gene GI: 1487709; NCBI Protein GI: 9625942; NCBI Protein Accession: NP_040190; NCBITaxon: 10335
Monoclonal antibodies to gI neutralize VZV in vitro in a complement- dependent manner [PubMed: 3021804]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [PubMed: 9697709].
Protegen ID: 663; NCBI Gene GI: 1487689; NCBI Protein GI: 9625941; NCBI Protein Accession: NP_040189; NCBITaxon: 10335
A NYVAC vaccinia vector containing genes for pseudorables virus glycoproteins gII and gp50 was administered to pigs to determine if it would have a greater protective effect than a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs similarly from virulent pseudorabies virus challenge [PubMed: 8904669].
Protegen ID: 664; NCBI Protein GI: 2440155; NCBITaxon: 10345
Protegen ID: 665; NCBI Protein GI: 1335775; NCBITaxon: 10345
Mice immunized with either gII, gIII, gVI antigen or a mixture of them were challenged intraperitoneally with 8.5 x 10(3) plaque forming units of PRV. All the mice immunized with 1.5 and 4.5 micrograms of the mixture and 4.5 micrograms of the gIII antigen survived [PubMed: 1322712].
Protegen ID: 667; NCBI Protein GI: 334050; NCBITaxon: 10345
Vaccination of mice with fusion proteins containing the N terminus of gI from Suid herpesvirus 1 are able to confer protection to mice against a lethal challenge of PRV [PubMed: 1693164].
Protegen ID: 668; NCBI Protein GI: 255957222; NCBITaxon: 10345
A recombinant, vP869, expressing prM and E induced high titers of neutralizing and hemagglutination inhibiting antibodies in mice and was protective against intracranial challenge with the French neurotropic strain of YFV [PubMed: 1736531].
Protegen ID: 669; NCBI Protein GI: 262283879; NCBITaxon: 11089
Horses were vaccinated with adjuvanted recombinant SnSAG1 (rSnSAG1)and 5 control (sham vaccinated) horses were vaccinated with adjuvant only. The effect of vaccination with rSnSAG1 on in vivo infection by S. neurona was evaluated by challenging all the horses with S. neurona merozoites. The study showed that vaccination with rSnSAG-1 produced antibodies in horses that neutralized merozoites when tested by in vitro culture and significantly reduced clinical signs demonstrated by in vivo challenge [PubMed: 19794889].
Protegen ID: 672; NCBI Protein GI: 295682690; NCBITaxon: 42890
Both inbred BALB/c and outbred CD-1 mice were immunized with rotavirus VP2/6-rVLPs (2/6-VLPs) combined with CT-E29H, orally or intranasally (i.n.), and the comparative efficacy of different formulations was then determined. Two immunizations with 2-6VLPs and CT-E29H were sufficient to protect BALB/c mice, regardless of the route of administration [PubMed: 11270595].
Protegen ID: 673; NCBI Protein GI: 431460; NCBITaxon: 10970
Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP4 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117].
Protegen ID: 675; NCBI Protein GI: 475695; NCBITaxon: 28327
Plasmid DNA vaccines encoding for murine rotaviral proteins VP4, VP6, and VP7 were tested in adult BALB/c mice for their ability to induce immune responses and provide protection against rotavirus challenge. Vaccines encoding VP7 were effective in protecting mice against infection after rotavirus (100 ID50) challenge [PubMed: 9015117].
Protegen ID: 676; NCBI Protein GI: 475697; NCBITaxon: 28327
VP6 derived from Group A rotavirus conferred in vivo partial protection against rotavirus challenge in a neonatal mouse model [PubMed: 18632867].
Protegen ID: 677; NCBI Gene GI: 7011372; NCBI Protein GI: 210136699; NCBI Protein Accession: YP_002302229; NCBITaxon: 28875
Rotavirus structural proteins VP4, VP6 and VP7 from Bovine Rotavirus Strain C486 were cloned and expressed in a baculovirus expression system. Challenge of neonates born to animals immunized with VP6 protein showed partial protection [PubMed: 8382422].
Protegen ID: 678; NCBI Protein GI: 195661002; NCBITaxon: 10927
Protection from lethal viral infection has been achieved with passively administered monoclonal antibody specific for flavivirus glycoprotein NS1 [PubMed: 1736531]. Immunization of monkeys with yellow fever virus-specified nonstructural protein NS1 resulted in protection against fatal hepatitis as well as marked reduction in the magnitude of viremia after subcutaneous challenge with yellow fever virus [PubMed: 3783816].
Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge. A truncated portion of the LACK antigen (LACKp24) was able to induce the highest protective effect compared to other constructs. The DNA vaccine encoding LACK was able to induce partial protection in mice [PubMed: 18951941].
Protegen ID: 734; NCBI Nucleotide GI: 1276476; NCBI Protein GI: 1276477; NCBI Protein Accession: AAA97577.1; NCBITaxon: 5664
Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 108 plaque forming units of vv-nef, whereas the intact protein was less protective [PubMed: 19193636].
Protegen ID: 707; NCBI Gene GI: 156110; NCBI Protein GI: 28872818; NCBI Protein Accession: NP_057857; NCBITaxon: 11676
HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice [PubMed: 17707956].
Protegen ID: 711; NCBI Gene GI: 155871; NCBI Protein GI: 9629358; NCBI Protein Accession: NP_057853; NCBITaxon: 11676
Protegen ID: 713; NCBI Gene GI: 155030; NCBI Protein GI: 9629360; NCBI Protein Accession: NP_057850; NCBITaxon: 11676
Mice immunized with Recombinant-derived nucleoprotein (rNP) from S. typhimurium expressing the cloned NP gene from A/NT/60/68 (Jones & Brownlee, 1985) were protected against a lethal challenge with Influenza A/Puerto Rico/8/34 (A/PR8) virus but showed considerable morbidity before recovery [PubMed: 2172156].
NP from Influenza A virus (A/nt/60/1968(H3N2))
Protegen ID: 718; NCBI Protein GI: 324704; NCBITaxon: 384505
Since the E2 amino-terminal sequence for all VEE subtype viruses is conserved, we tested the protective capacity in mice of passively transferred mAb 1A2B-10 and found it to protect from both epizootic and enzootic VEE virus challenge. Since horses are an important natural host for VEE virus, pep1-19 was used to immunize horses and was found to be immunogenic and to elicit virus-reactive antibody [PubMed: 7543231].
Protegen ID: 725; NCBI Protein GI: 25140296; NCBITaxon: 11036
Study demonstrated that a recombinant construction of heat-shock protein (hslU) with lypopolysaccharide (rcHSP-LPS) administered 24 hours before inoculation induced resistance to S. typhimurium infection. Protection formed after 3 injections of rcHSP-LPS with 10 mcg in each or single injection with 100 mcg/mouse. Forty to eighty percent of immunized mice survived after challenge while 90% of control animals died. Destruction of the HSP by boiling of the construction led to loss of protective effect [PubMed: 19621817].
Protegen ID: 726; NCBI Protein GI: 9650897; NCBITaxon: 90371
The monoclonal antibody against E1 glycoprotein protect outbred albino mice from lethal infection caused by the virulent strain Trd of the VEE virus [PubMed: 7529989].
Protegen ID: 727; NCBI Protein GI: 798795; NCBITaxon: 11036
Immunisation of mice with DnaJ derived from Salmonella enterica subsp. enterica serovar Typhi str. CT18 was found to provide 70% protection against lethal challenge by S. Typhimurium indicating the possible use of DnaJ as vaccine candidate against typhoid [PubMed: 16887241].
Protegen ID: 728; NCBI Gene GI: 1246524; NCBI Protein GI: 16759006; NCBI Protein Accession: NP_454623; NCBITaxon: 220341
The viaB (tviB) gene coding for the Vi antigen of Salmonella typhi Ty2 was subcloned into expression vector pYA248. The recombinant plasmid was termed SMM202 and transformed into Salmonella typhimurium 4072, an attenuated crp mutant. Immunization of mice with Vi4072 afforded complete protection against fatal infection with virulent S. typhi Ty2 [PubMed: 1612747].
Protegen ID: 729; NCBI Gene GI: 1067316; NCBI Protein GI: 29144603; NCBI Protein Accession: NP_807945; NCBITaxon: 209261
The immune sera elicited by CTB DNA vaccine were functional and protective against V. cholerae O1 infection in mice [PubMed: 19443090].
Protegen ID: 731; NCBI Protein GI: 110264635; NCBITaxon: 127906
Antibodies against TCP were able to protect baby mice against challenge with V. cholerae O1 of the classical but not of the El Tor biotype [PubMed: 7911787].
Protegen ID: 732; NCBI Protein GI: 21616882; NCBITaxon: 127906
Antibodies generated against TcpF are protective against experimental V. cholerae infection in the infant mouse cholera model [PubMed: 16040956].
Protegen ID: 733; NCBI Gene GI: 2614504; NCBI Protein GI: 15640854; NCBI Protein Accession: NP_230485; NCBITaxon: 243277
Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-TSA developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941].
Protegen ID: 735; NCBI Nucleotide GI: 3411093; NCBI Protein GI: 3411094; NCBI Protein Accession: AAC31146.1; NCBITaxon: 5664
Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-LmSTI1 developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941].
Protegen ID: 736; NCBI Nucleotide GI: 1698879; NCBI Protein GI: 1698880; NCBI Protein Accession: AAB37318.1; NCBITaxon: 5664
Researchers evaluated the potency of different DNA vaccine candidates in BALB/c mice using high dose footpad parasite challenge with L. major. Mice inoculated pCMV3ISS-CPa developed significantly smaller lesions in their footpads after challenge with the parasite. The vaccine was able to induce a partially protective effect [PubMed: 18951941].
Protegen ID: 737; NCBI Nucleotide GI: 71084305; NCBI Protein GI: 71084306; NCBI Protein Accession: AAZ23598.1; NCBITaxon: 5664
The potential protection of Lmjsp (Leishmania major signal peptidase) was evaluated in three different vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein), against L. major infection. We demonstrated that vaccination with SPase through all three mentioned strategies induced a parasite specific Th1 response and conferred partial protection against parasite challenge. However, our results indicated that DNA/DNA strategy developed more effective protective responses than the other two approaches and induced 81% reduction in L. major parasite load [PubMed: 16481076].
Protegen ID: 738; NCBI Protein GI: 23168331; NCBITaxon: 5664
Researchers tested the ability of the entire H2B protein of L. major, its divergent or conserved regions to provide protection against virulent L. major challenge. The divergent amino-terminal region of H2B is able to confer potent protection against a virulent challenge in BALB/c mice [PubMed: 16417957].
Protegen ID: 739; NCBI Protein GI: 13384083; NCBITaxon: 5664
Cell-mediated immunity to Leishmania major (L. major) was induced by injecting BALB/c mice intradermally with plasmid DNA expressing the conserved L. major cell surface glycoprotein gp63 (gp63-pcDNA-3). Challenge studies revealed that gp63-pcDNA-3 vaccination protected 30% of susceptible mice (21 of 70) from Leishmania infection [PubMed: 9741428].
Protegen ID: 741; NCBI Protein GI: 259011719; NCBITaxon: 5664
Intraperitoneal vaccination of C3H/He mice with PSA-2 with Corynebacterium parvum as an adjuvant resulted in complete protection from lesion development after challenge infection with virulent L. major. Significant protection was also obtained in the genetically susceptible BALB/cH-2k and BALB/c mice [PubMed: 7591056].
Protegen ID: 742; NCBI Protein GI: 1129058; NCBITaxon: 5664
In a murine model of experimental cutaneous leishmaniasis, researchers investigated the protection elicited by injection of histone H1 (SW3.1) isolated from parasites by perchloric extraction, of a H1 recombinant protein produced in E. coli, and of H1 long and short synthetic peptides, against infection by L. major. Partial protection was achieved in most of the animals as shown by reduction in lesion size, upon immunization with histone H1 or its peptides, provided that the region 1-60 was present in the molecule [PubMed: 10580198].
Protegen ID: 743; NCBI Protein GI: 4008565; NCBITaxon: 5664
Together with poloxamer 407 as adjuvant the recombinant type I (rCPB) cysteine proteinase of Leishmania major was screened as a potential vaccines against L. major in a mouse model. Using the footpad thickness increase to monitor the clinical outcome/cutaneous lesion at site of L. major delivery, it was possible to document that rCPB allowed BALB/c mice to mount a partial protective response [PubMed: 12057598].
Protegen ID: 744; NCBI Protein GI: 54287314; NCBITaxon: 5664
Upon challenge with L. infantum, C57BL/6 mice immunized with SMT formulated in MPL-SE adjuvant showed significantly lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone [PubMed: 17804125].
Protegen ID: 745; NCBI Protein GI: 146104463; NCBITaxon: 435258
Study examined the immunogenic properties of the Leishmania infantum acidic ribosomal protein P0 (LiP0) in the BALB/c mouse model. When mice were immunized with pcDNA3-LiP0, noticeable protection against L. major infection was achieved [PubMed: 14573678].
Protegen ID: 746; NCBI Protein GI: 730579; NCBITaxon: 5671
BALB/c mice immunized with a DNA vector expressing p36/LACK of Leishmania infantum followed by a booster with VVp36/LACK induced significant protection against Leishmania major infection [PubMed: 11489418].
Protegen ID: 747; NCBI Protein GI: 134085114; NCBITaxon: 5671
Following infection with L. infantum promastigotes, five out of eight beagle dogs immunized with H1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that H1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026].
Protegen ID: 748; NCBI Nucleotide GI: 78146499; NCBI Protein GI: 78146500; NCBI Protein Accession: ABB22792.1; NCBITaxon: 5671
Following infection with L. infantum promastigotes, four out of eight beagle dogs immunized with HASPB1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that HASPB1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions [PubMed: 17576026].
Protegen ID: 749; NCBI Nucleotide GI: 3724133; NCBI Protein GI: 3724134; NCBI Protein Accession: CAA09789.1; NCBITaxon: 5661
In 1923, it was discovered that treatment with formalin eliminated the toxicity of diphtheria toxin (DT) without destroying its immunogenicity. Formalinreated DT, now called diphtheria toxoid, rapidly became the preferred vaccine against diphtheria, and diphtheria toxoid (usually in combined vaccines, such as diphtheriaetanus toxoidsertussis vaccine [DTP] or diphtheriaetanus toxoidscellular pertussis vaccine [DTaP] for children and tetanusiphtheria toxoids vaccine for adults [Td]) is still used throughout the world for active immunization against diphtheria [PubMed: 10657208].
Protegen ID: 750; NCBI Protein GI: 38199106; NCBITaxon: 1717
Susceptible BALB/c mice were immunized with the DNA encoding P4 alone, P4/IL-12, or P4/HSP70 prior to challenge with L. amazonensis promastigotes. Mice immunized with P4 alone had a delayed onset of lesion development and significantly smaller lesions than the infection control group at 11 weeks postinfection (P < 0.05). P4/IL-12 immunized animals showed no sign of lesion development in three independent experiments (P < 0.01). Our results indicate that different vaccine combinations, including DNA encoding P4, HSP70, or IL-12, can provide significant protection against both Old World and New World cutaneous leishmaniasis [PubMed: 14573646].
Protegen ID: 751; NCBI Nucleotide GI: 29165286; NCBI Protein GI: 29165287; NCBI Protein Accession: AAO65599.1; NCBITaxon: 5659
To examine the efficacy of a new mode of recombinant viral vaccine, a vaccine was constructed of two non-transmissible Sendai viruses (rSeV/dF) encoding the full-length parasite antigen amastigote surface protein-2 (ASP2) or ASP2 fused with a mono-ubiquitin on its N-terminus (UASP2). C57BL/6 mice immunized intranasally with rSeV/dF expressing either ASP2 or UASP2 showed significantly suppressed parasitemia and could be protected from lethal T. cruzi challenge [PubMed: 19712768].
Protegen ID: 752; NCBI Protein GI: 284180153; NCBITaxon: 5693
DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens [PubMed: 15039343].
Protegen ID: 753; NCBI Nucleotide GI: 38455440; NCBI Protein GI: 38455441; NCBI Protein Accession: AAR20840.1; NCBITaxon: 5659
Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) [PubMed: 3182080].
Protegen ID: 754; NCBI Nucleotide GI: 2828562; NCBI Protein GI: 2828563; NCBI Protein Accession: AAC08302.1; NCBITaxon: 5659
cDNAs encoding L. m. amazonensis gp46 antigen were subcloned into the VR1012 plasmid, and susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA. Mice were challenged by the injection of 4 x 10^6 L. m. mexicana parasites in the foot pad to evaluate protection. Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection [PubMed: 11713811].
Protegen ID: 755; NCBI Nucleotide GI: 159320; NCBI Protein GI: 159321; NCBI Protein Accession: AAA29234.1; NCBITaxon: 5659
To study the protective effects in vivo of cruzipain-specific Th1 responses against systemic T. cruzi challenges, mice were immunized with recombinant cruzipain plus interleukin 12 (IL-12) and a neutralizing anti-IL-4 MAb. These immunized mice developed potent cruzipain-specific memory Th1 cell responses and were significantly protected against normally lethal systemic T. cruzi challenges. To study whether cruzipain could induce mucosal immune responses relevant for vaccine development, recombinant attenuated Salmonella enterica serovar Typhimurium vaccines expressing cruzipain were prepared. BALB/c mice immunized with salmonella expressing cruzipain were significantly protected against T. cruzi mucosal infection [PubMed: 12183554].
Protegen ID: 756; NCBI Protein GI: 1136308; NCBITaxon: 5693
To develop a vaccine strategy taking advantage of activated CD8(+)T cells,a DNA vaccine, designated pGFP-TSA1, encoding a fusion protein linking GFP to a single CTL epitope of TSA1(TS), a leading candidate for vaccine against T. cruzi was constructed. C57BL/6 mice vaccinated with this plasmid showed suppressed parasitemia and prolonged survival. Vaccination with pGFP-TSA1 enhanced epitope-specific cytotoxicity and IFN-gamma secretion by CD8(+)T cells [PubMed: 18321749].
Protegen ID: 757; NCBI Protein GI: 258547365; NCBITaxon: 5693
A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24. Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice [PubMed: 19735658].
Protegen ID: 758; NCBI Nucleotide GI: 30142041; NCBI Protein GI: 30142042; NCBI Protein Accession: AAN34826.1; NCBITaxon: 5659
Following the intramuscular immunization of H-2(b) and H-2(d) mice with a plasmid DNA encoding an N-terminally truncated TSA-1 lacking or containing the C-terminal nonapeptide tandem repeats, the antibody level, CTL response, and protection against challenge with T. cruzi were assessed. In H-2(b) mice, antiparasite antibodies were induced only by immunization with the DNA construct encoding TSA-1 containing the C-terminal repeats. However, both DNA constructs were efficient in eliciting long-lasting CTL responses against the protective H-2Kb-restricted TSA-1515-522 epitope. In H-2(d) mice, inoculation with either of the two TSA-1-expressing vectors effectively generated antiparasite antibodies and primed CTLs that lysed T. cruzi-infected cells in an antigen-specific, MHC class I-restricted, and CD8(+)-T-cell-dependent manner. When TSA-1 DNA-vaccinated animals were challenged with T. cruzi, 14 of 22 (64%) H-2(b) and 16 of 18 (89%) H-2(d) mice survived the infection [PubMed: 9784506].
Protegen ID: 759; NCBI Protein GI: 162315; NCBITaxon: 5693
A complement regulatory protein (CRP) of Trypanosoma cruzi was evaluated as a vaccine candidate in a murine model of experimental T. cruzi infection. Recombinant CRP derived from an Escherichia coli expression system and a plasmid encoding the full-length crp structural gene under the control of a eukaryotic promoter were used to immunize BALB/c mice. Immunization with both protein and DNA vaccines resulted in a Th1-type T-cell response, comparable antibody titers, and similar immunoglobulin G isotype profiles. Only mice immunized with the crp DNA plasmid produced antibodies capable of lysing the parasites in the presence of complement and were protected against a lethal challenge with T. cruzi trypomastigotes [PubMed: 10948115].
Protegen ID: 760; NCBI Protein GI: 1389837; NCBITaxon: 5693
The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G4-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 90% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728].
Protegen ID: 761; NCBI Protein GI: 52424038; NCBITaxon: 5693
The vaccine efficacy of a putative candidate antigen against T. cruzi infection and disease in a mouse model. C57BL/6 mice vaccinated with a T. cruzi G2-encoding plasmid and cytokine (interleukin-12 and granulocyte-macrophage colony-stimulating factor) expression plasmids elicited a strong Th1-type antibody response dominated by immunoglobulin G2b (IgG2b)/IgG1 isotypes. The dominant IgG2b/IgG1 antibody response was maintained after a challenge infection and was associated with 50% control of the acute-phase tissue parasite burden and an almost undetectable level of tissue parasites during the chronic phase, as determined by a sensitive T. cruzi 18S rRNA gene-specific real-time PCR approach [PubMed: 18550728].
Protegen ID: 762; NCBI Protein GI: 205278890; NCBITaxon: 5693
C57BL/6 mice were immunized s.c. with recombinant PFR-2 (PAR2) protein co-adsorbed to alum with rIL-12. rPFR-2 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650].
Protegen ID: 763; NCBI Gene GI: 3532027; NCBI Protein GI: 71398801; NCBI Protein Accession: XP_802646; NCBITaxon: 353153
C57BL/6 mice were immunized s.c. with recombinant PFR-1 (PAR1) protein co-adsorbed to alum with rIL-12. rPFR-1 immunized animals were able to successfully resolve parasitemia by day 30 p.i., with the peak parasitemia occurring between days 17 and 21 p.i. [PubMed: 12798650].
Protegen ID: 764; NCBI Protein GI: 2209137; NCBITaxon: 5693
Skin and mucosal vaccination of ponies with HA from influenza virus A/equine/Ky/1/81 provided complete protection from clinical signs of infection after challenge, while skin vaccination provided partial protection; DNA vaccination provided partial protection from viral shedding [PubMed: 10403592].
HA from Influenza A virus (A/equine/Kentucky/1/1981(H3N8))
Protegen ID: 765; NCBI Nucleotide GI: 166079523; NCBI Protein GI: 166079524; NCBI Protein Accession: ABY81481.1; NCBITaxon: 475467
Flagellin encoding plasmid DNA was injected into Balb/c mice intramuscularly and this elicited both a humoral and a cellular immune response. Subsequent intravenous challenge of the vaccinated Balb/c mice with 10^5CFU of B. pseudomallei resulted in the number of bacterial cells detected in liver and/or spleen being significantly reduced in the flagellin plasmid DNA vaccinated mice. At 7 days subsequent to infection of B. pseudomallei, 5/6 (83%) of flagellin plasmid DNA vaccinated mice had survived [PubMed: 16169637].
Protegen ID: 770; NCBI Protein GI: 1929918; NCBITaxon: 28450
Transgenic rice immunization expressing the Chlamydophila psittaci (Cp. psittaci) antigen (MOMP) fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) induced partial protection (53.3%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain in a BALB/c mouse model [PubMed: 19146896].
Protegen ID: 771; NCBI Nucleotide GI: 40568; NCBI Protein GI: 40569; NCBI Protein Accession: CAA40300.1; NCBITaxon: 331636
This report describes the successful cloning of the E2 gene of WEEV and expression in Escherichia coli as inclusion bodies. The immunogenicity of the refolded rE2 protein was demonstrated by strong humoral and cell mediated immune (CMI) responses in rE2-immunized BALB/c mice. The current study also demonstrated that rE2-immunized mice could be partially protected from lethal challenge of WEEV [PubMed: 17499379].
E2 from Western equine encephalomyelitis virus
Protegen ID: 773; NCBI Protein GI: 29611992; NCBITaxon: 11039
DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The E1 glycoprotein is part of the 6K-E1 structural protein
Protegen ID: 774; NCBI Nucleotide GI: 17148716; NCBI Protein GI: 17148717; NCBI Protein Accession: AAL35792.1; NCBITaxon: 11039
DNA vaccines encoding different portions of the structural proteins of western equine encephalitis virus were tested for the efficacy of their protection in a 100% lethal mouse model of the virus. The 6K-E1 structural protein encoded by the DNA vaccine conferred complete protection against challenge with the homologous strain and limited protection against challenge with a heterologous strain [PubMed: 19923571]. Note: The 6K protein is part of the 6K-E1 structural protein
Protegen ID: 775; NCBI Protein GI: 29611993; NCBITaxon: 11039
In this study, Cp23 antigen was investigated as a vaccine candidate using the DNA vaccine model in adult interleukin-12 (IL-12) knockout (KO) mice, which are susceptible to C. parvum infection. Cp23-DNA vaccination induced a 50-60% reduction in oocysts shedding, indicating a partial protection against C. parvum infection in IL-12 KO mice [PubMed: 17487508].
Protegen ID: 776; NCBI Protein GI: 88659549; NCBITaxon: 5807
Preparturient cows were immunized three times over a six-week period with recombinant plasmid DNA encoding the Cryptosporidium parvum CP15/60 antigen by injecting the DNA in the mammary gland. Colostrum from these cows contained Ab specific for C. parvum sporozoites and oocysts as indicated by immunofluorescence Ab (IFA) staining. Mice receiving immune colostrum showed partial protection (about 50% reduction) against intestinal C. parvum development compared to mice receiving control colostrum. This protection was evident at a challenge dose of 10^3 C. parvum oocysts per mouse [PubMed: 10392628].
Protegen ID: 777; NCBI Nucleotide GI: 170676501; NCBI Protein GI: 170676502; NCBI Protein Accession: ACB30404.1; NCBITaxon: 5807
A subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein G from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Upon oronasal challenge with NiV (50,000TCID50), all vaccinated cats were protected from disease although virus was detected on day 21 post-challenge in one animal [PubMed: 18556094].
Protegen ID: 779; NCBI Gene GI: 1446471; NCBI Protein GI: 29468607; NCBI Protein Accession: NP_047112; NCBITaxon: 63330
A recombinant baculovirus encoding a dengue (DEN)-2 virus envelope glycoprotein truncated of 102 amino acids (aa) at its C-terminus (D2EA102) was constructed. Both intracellular and extracellular D2EA102 induced neutralizing antibodies in mice and were thus immunogenic. Sixty eight percent (P < 0.001) of mice vaccinated with 5 gg of extracellular D2EA102 protein were protected against lethal challenge [PubMed: 7826210].
Protegen ID: 780; NCBI Protein GI: 202078796; NCBITaxon: 11060
The protective efficacy and immune responses of mice intramuscularly injected with plasmid encoding DEN-2 non-structural protein 1 (NS1) was evaluated. Intravenously challenged by lethal DEN-2, mice vaccinated with NS1-DNA exhibited a delay onset of paralysis, a marked decrease of morbidity, and a significant enhancement of survival [PubMed: 12922127].
Protegen ID: 781; NCBI Protein GI: 288848; NCBITaxon: 11060
Hamsters were immunized subcutaneously with either 107 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.G-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115].
Protegen ID: 782; NCBI Gene GI: 920955; NCBI Protein GI: 13559814; NCBI Protein Accession: NP_112027; NCBITaxon: 121791
Hamsters were immunized subcutaneously with either 10^7 PFU of VV-NiV.G or VV-NiV.F expressing the G and F glycoproteins, respectively, or with the two combined. When the VV-NiV.F-vaccinated animals were challenged with Nipah virus 3 months after the last immunization (1,000 PFU/animal intraperitoneally), there was complete protection against mortality [PubMed: 14694115].
Protegen ID: 783; NCBI Nucleotide GI: 8164021; NCBI Protein GI: 8164022; NCBI Protein Accession: AAF73956.1; NCBITaxon: 121791
A recombinant vaccinia virus that expressed the pre-M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792].
Protegen ID: 784; NCBI Protein GI: 18308086; NCBITaxon: 11070
A recombinant vaccinia virus that expressed the M protein of Dengue 4 virus was constructed. Mice immunized with the recombinant virus were protected against subsequent dengue 4 encephalitis challenge [PubMed: 1926792].
Protegen ID: 785; NCBI Protein GI: 73671170; NCBITaxon: 11070
Guinea pigs immunized with different doses of the SPA appear to be protected against challenge with live organisms as compared with nonimmunized controls [PubMed: 2122457].
Protegen ID: 786; NCBI Protein GI: 152498; NCBITaxon: 782
The glycoprotein (GP) and nucleocapsid (NC) genes of Rift Valley fever virus (RVFV) were expressed in different expression systems and were evaluated for their ability to protect mice from virulent challenge using a prime-boost regime. Mice vaccinated with a lumpy skin disease virus-vectored recombinant vaccine (rLSDV-RVFV) expressing the two RVFV glycoproteins (G1 and G2, expressed by the RVFV M Segment) developed neutralising antibodies and were fully protected when challenged, as were those vaccinated with a crude extract of truncated G2 glycoprotein (tG2) [PubMed: 16870311].
Protegen ID: 787; NCBI Gene GI: 956559; NCBI Protein GI: 27881464; NCBI Protein Accession: NP_777376; NCBITaxon: 11588
Immunisation of mice with cDNA encoding the nucleocapsid protein induced strong humoral and lymphocyte proliferative immune responses. Even though complete protection was not achieved by genetic immunisation, four out of eight mice vaccinated with cDNA encoding the nucleocapsid protein displayed no clinical signs of infection after challenge. In contrast, all fourteen control animals displayed clinical manifestations of Rift Valley Fever after challenge [PubMed: 19149901].
Protegen ID: 788; NCBI Gene GI: 956562; NCBI Protein GI: 9632367; NCBI Protein Accession: NP_049344; NCBITaxon: 11588
The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. A previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. The immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost were assessed. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone [PubMed: 18289745].
Protegen ID: 789; NCBI Gene GI: 1489668; NCBI Protein GI: 29836496; NCBI Protein Accession: NP_828851; NCBITaxon: 694009
Mice actively immunized using a recombinant V antigen (rVagHis, encoded by lcrV gene) of Y. enterocolitica were completely protected against challenge with both, Y. enterocolitica 0:8 and Y. pseudotuberculosis serotype III [PubMed: 10089162].
Protegen ID: 790; NCBI Gene GI: 1449458; NCBI Protein GI: 32470278; NCBI Protein Accession: NP_863514; NCBITaxon: 630
80% of C3H/HeJ mice immunized with Eh29 administered in combination with a subclinical dose of whole cholera toxin, but not as an Eh29-CTxB fusion, showed no evidence of infection in tissue sections harvested following intracecal challenge with virulent E. histolytica trophozoites. These results suggest that Eh29 is capable of inducing protective anti-amoebic immune responses in mice following oral immunization and could be used in the development of oral vaccines against amoebiasis [PubMed: 20303954].
Protegen ID: 791; NCBI Nucleotide GI: 399673; NCBI Protein GI: 399674; NCBI Protein Accession: CAA50324.1; NCBITaxon: 5759
Study tested if vaccination with the E. histolytica Gal/GalNAc lectin could prevent cecal infection in a C3H mouse model of amebic colitis. Vaccination prevented intestinal infection with efficacies of 84 and 100% in the two native lectin trials and 91 and 34% in the two LecA trials. Results show for the first time that immunization with the Gal/GalNAc lectin can prevent intestinal amebiasis in mice [PubMed: 14741152].
Protegen ID: 792; NCBI Gene GI: 3404842; NCBI Protein GI: 67469085; NCBI Protein Accession: XP_650534; NCBITaxon: 294381
Report describes a recombinant fusion protein containing the serine-rich Entamoeba histolytica protein (SREHP), a protective antigen derived from virulent amebae, and a bacterially derived maltose-binding protein (MBP) from an attenuated strain of Salmonella typhimurium. Gerbils vaccinated with S typhimurium SREHP-MBP were protected against amebic liver abscess after challenge with E. histolytica, the most common extraintestinal complication of amebiasis [PubMed: 8613356].
Protegen ID: 793; NCBI Gene GI: 3402462; NCBI Protein GI: 67463194; NCBI Protein Accession: XP_648254; NCBITaxon: 294381
Groups of C57BL/6 mice (20 per group) vaccinated with rPep1 (1 mug per dose) plus adjuvant and challenged with an intranasal inoculum began to die at about 14 to 16 days but then showed significantly greater survival than the control mice [PubMed: 16369008].
Protegen ID: 794; NCBI Protein GI: 73915320; NCBITaxon: 199306
Researcherse tested the ability of the galactose-specific adherence lectin of E. histolytica to elicit a protective immune response in conjunction with Freund's incomplete and complete adjuvants. Four independent trials demonstrated complete protection from amebic liver abscess formation in 67% of lectin-immunized gerbils. The gerbil antilectin antibodies were shown by Western immunoblotting to be directed to the heavy subunit (CEL-170/4) but not the light subunit of the lectin [PubMed: 1987067].
Protegen ID: 795; NCBI Protein GI: 401088; NCBITaxon: 5759
C57BL/6 mice immunized with rPlb showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008].
Protegen ID: 796; NCBI Protein GI: 74486661; NCBITaxon: 199306
C57BL/6 mice immunized with rAMN1 showed a significant reduction of the fungal burden in their lungs at 90 days postchallenge compared to the control mice at 15 days [PubMed: 16369008].
Protegen ID: 797; NCBI Protein GI: 76786276; NCBITaxon: 199306
ELI-Antigen 1 (ELI-Ag1) was tested for its protective capacity in BALB/c mice against intraperitoneal challenge with 2500 arthroconidia of this dimorphic fungus and was found to be highly protective [PubMed: 14505918].
Protegen ID: 798; NCBI Protein GI: 37779128; NCBITaxon: 5501
The GEL1 mRNA of C. posadasii was detected at the highest level during the endosporulation stage of the parasitic cycle, and the mature protein was immunolocalized to the surface of endospores. BALB/c or C57BL/6 mice were immunized subcutaneously with the bacterium-expressed recombinant protein (rGel1p) to evaluate its protective efficacy against a lethal challenge of C. posadasii by either the intraperitoneal or intranasal route. In both cases, rGel1p-immune mice infected with the pathogen showed a significant reduction in fungal burden and increased survival compared to nonimmune mice [PubMed: 12761077].
Protegen ID: 799; NCBI Protein GI: 14582416; NCBITaxon: 199306
Recombinant urease (rURE) of C. immitis was expressed in Escherichia coli and tested asa vaccine candidate in BALB/c mice. BALB/c mice immunized subcutaneously with rURE and subsequently challenged by the intraperitoneal (i.p.) route with a lethal inoculum of C. immitis arthroconidia demonstrated a significant reduction in the level of C. immitis infection compared to control animals [PubMed: 11292702].
Protegen ID: 800; NCBI Protein GI: 73808050; NCBITaxon: 5501
Recombinant Pmp1 was reactive with serum from individuals with both acute and protracted disease, and evoked protection in two murine models of infection with C. posadasii [PubMed: 16495561].
Protegen ID: 801; NCBI Protein GI: 78364922; NCBITaxon: 199306
C57BL6 mice were immunized with syngeneic, bone marrow-derived DCs (JAWS II cells) transfected with a cDNA encoding the protective Coccidioides-Ag2/proline-rich Ag (pra). The immunized mice were lethally challenged with C. posadasii through either an i.p. or intranasal route. Upon necropsy after 10 days of infection, fungal burden in lung and spleen of immunized mice was significantly reduced as compared with the control animals. The lung tissue homogenates of immunized animals showed higher levels of IFN-gamma. Histologically, lung tissues of immunized mice were in better condition than the control mice [PubMed: 16148136].
Protegen ID: 802; NCBI Protein GI: 42742528; NCBITaxon: 5501
The microtubule-associate protein (MAP p15) was tested as a vaccine in mice, and tests showed that p15 (native or recombinant) generated up to 100% protection from an otherwise lethal challenge of a heterologous strain of Trypanosoma brucei [PubMed: 15161078].
Protegen ID: 803; NCBI Protein GI: 777767; NCBITaxon: 5691
Vaccination with poliovirus vector containing the gene for the B subunit of H. pylori urease provides significant prophylactic and strong therapeutic protection against H. pylori in mice [PubMed: 15603891].
Protegen ID: 804; NCBI Protein GI: 40737733; NCBITaxon: 210
Researchers prepared an oral liposome-encapsulated recombinant Helicobacter pylori (Hp) heat shock protein 60 (Hsp60) vaccine and investigate its effect against Hp infection in mice. rHsp60 plus CT (choleratoxin), liposome-encapsulated rHsp60 and liposome-encapsulated rHsp60 plus CT had protective rates against Hp infection of 73.3%, 66.7% and 86.7%, respectively [PubMed: 15897126].
Protegen ID: 805; NCBI Protein GI: 397869; NCBITaxon: 210
A study shows that vaccination of mice with HP-NAP (H. pylori NAP) induces protection against H. pylori challenge, and that the majority of infected patients produce antibodies specific for HP-NAP, suggesting an important role of this factor in immunity [PubMed: 10790422].
Protegen ID: 806; NCBI Protein GI: 8777456; NCBITaxon: 210
BALB-c mice immunized intramuscularly with a single dose (100 microg) of a plasmid DNA encoding the 5'-terminal region of the trans-sialidase (nTSA) gene of T. brucei brucei are able to produce IgG antibodies that bind to the bloodstream form of T. brucei-protein extract and recognize the recombinant nTSA protein, expressed in Escherichia coli. Furthermore, this DNA vaccination process was able to protect 60% of mice submitted to a challenge assay with the infective form of T. brucei brucei parasites [PubMed: 19582478].
Protegen ID: 807; NCBI Protein GI: 62175539; NCBITaxon: 5691
Recombinant H. pylori catalase plus CT was used for immunization, and groups of mice were challenged with the Sydney strain of H. pylori. Immunization with recombinant catalase protected a significant proportion (9 of 10) of the mice from H. pylori challenge, indicating that this enzyme should be considered as a candidate for a future vaccine [PubMed: 9353048].
Protegen ID: 808; NCBI Protein GI: 3128145; NCBITaxon: 210
A study to examine the immunostimulatory properties of Leishmania infantum Hsp83 (83) to elicit humoral and cellular response against the Toxoplasma gondii Rop2 protein in an adjuvant-free vaccination system was conducted. Mice immunized with fusion Rop2-83 elicited a stronger humoral and cellular response in comparison to mice immunized with Rop2 alone, or a mix of LiHsp83 and Rop2. The fusion protein induced a Th1 type response, with predominance of specific IgG2a/IgG2c isotype and IFN-gamma secretions, whereas Rop2 alone or mixed with LiHsp83 produced a Th1/Th2 mixed response. Vaccination with fusion protein conferred a remarkable resistance against oral infection with ME49 cysts in C57BL/6 and C3H mice, in comparison to mice immunized with Rop2 alone or the protein mixture. Following lethal challenge, a significant survival rate was observed in Rop2-83 immunized Balb/c and C57BL/6 mice in comparison to control groups [PubMed: 16545504].
Protegen ID: 809; NCBI Protein GI: 115299638; NCBITaxon: 5811
Treatment of the Helicobacter pylori vacuolating cytotoxin with very low concentrations of formaldehyde resulted in abrogation of toxic activity in both a HeLa cell vacuolation assay and an in vivo assay of gastric epithelial damage. Detoxification had only a minimal effect on the integrity of the oligomeric or monomeric structure. The toxoid retained the ability to bind to target cells and to induce high-titer neutralizing antibodies after immunization of rabbits. Furthermore, oral immunization of mice with the toxoid resulted in protection against infective challenge with mouse-adapted strains of H. pylori [PubMed: 9353041].
Protegen ID: 810; NCBI Protein GI: 50313203; NCBITaxon: 210
The immunogenicity of a 48-kDa T-cell-reactive protein (TCRP) was investigated. Immunization of BALB/c and C3H/HeN mice with the rTCRP affords a modest but significant level of protection against an intraperitoneal challenge with C. immitis. It is suggested that the rTCRP may be able to contribute to a multicomponent vaccine designed to stimulate CMI response against the parasitic cycle of C. immitis.
Protegen ID: 811; NCBI Protein GI: 13508695; NCBITaxon: 5501
Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens [PubMed: 15049780].
Protegen ID: 812; NCBI Gene GI: 810501; NCBI Protein GI: 124802897; NCBI Protein Accession: XP_001347628; NCBITaxon: 36329
Asian seabass vaccinated with the OMP38 (OmpU) DNA vaccine was challenged with pathogenic V. anguillarum by intramuscular injection. A relative percent survival (RPS) rate of 55.6% was recorded [PubMed: 17337208].
Protegen ID: 813; NCBI Protein GI: 26513901; NCBITaxon: 55601
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1067
Japanese encephalitis virus DNA vaccine encoding PrM
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=439
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=438
L. amazonensis DNA vaccine encoding WD protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1041
Leishmania amazonensis DNA vaccine encoding WD protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1042
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1043
Leishmania infantum HASPB2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1036
Japanese encephalitis virus DNA vaccine pUJENS5
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1037
Japanese encephalitis virus DNA vaccine encoding E protein
L. amazonensis DNA vaccine encoding GP46
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1038
Leishmania amazonensis DNA vaccine encoding GP47
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1039
Leishmania amazonensis M3 protein vaccine
A. pleuropneumoniae ApxIA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=782
Actinobacillus pleuropneumoniae ApxIA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=797
Bordetella pertussis Cpn60 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=799
Bordetella pertussis CyaA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=800
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=801
Bordetella pertussis PTx protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1050
Cryptosporidium. parvum DNA vaccine encoding CP24
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1051
Cancer Her-2/neu Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1052
cancer DNA vaccine MIDGE/hNIS encoding hNIS protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1053
cancer DNA vaccine pSURV encoding Survivin
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1047
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1048
cancer DNA vaccine encoding Endoglin Boosted with recombinant Endoglin Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1049
Cancer recombinant vector vaccine encoding H-2Kb
An xenogenic DNA vaccine encoding human TEM8 carried by attenuated Salmonella typhimurium to help reduce tumor growth and suppress angiogenesis in the tumors.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1046
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1064
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1066
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1058
cancer retroviral vector vaccine encoding Cd40lg
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1059
Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1054
Phleum pratense allergy Phl p 12 subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=791
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=796
Bordetella pertussis BrkA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=825
Bovine leukemia virus DNA vaccine encoding Env
Bovine leukemia virus DNA vaccine encoding Tax
B. abortus DNA vaccine encoding RplL and Omp16
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=831
Brucella abortus DNA vaccine encoding RplL and Omp16
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=821
Bovine herpesvirus 1 DNA vaccine AdCMVgD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=823
Bovine herpesvirus 1 DNA vaccine AdCMVgC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=824
Bovine herpesvirus 1 GPI protein vaccine
A. pleuropneumoniae ApxIa and ApxIIa protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=784
Actinobacillus pleuropneumoniae ApxIa and ApxIIa protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=786
Actinobacillus pleuropneumoniae HS93C-Ampr
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=788
A. salmonicida live-attenuated vaccine encoding AroA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=443
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1044
Rickettsia rickettsii vaccine using M. vaccae expressing R. rickettsii OmpA Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1045
Rickettsia DNA vaccine encoding OmpB Protein boosted with recombinant OmpB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=808
Bordetella pertussis DNA vaccine encoding Prn
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=993
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=994
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=997
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=986
P. falciparum Hsp90 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=987
Plasmodium falciparum Hsp90 protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=988
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=989
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=990
Rift Valley Fever Virus DNA Vaccine encoding N Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=949
Puumala virus PUUVsSgp1 (NP) protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=950
Sin Nombre virus DNA vaccine encoding G1
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=951
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=952
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=968
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=969
Herpes simplex virus type 2 DNA vaccine encoding ICP27
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=970
Herpes simplex virus type 2 DNA vaccine encoding GB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=971
NIpah Virus G and F Proteins subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=972
Herpes simplex virus type 1 DNA vaccine encoding GC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=963
M. tuberculosis DNA Vaccine encoding Ag85B Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=964
Mycobacterium tuberculosis DNA vaccine encoding Ag85B protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=965
Hepatitis B virus DNA vaccine encoding HBVgp2 pre-S1/pre-S2/S
M. tuberculosis Mtb72F protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=967
Mycobacterium tuberculosis Mtb72F protein subunit vaccine
Bordetella pertussis DNA vaccine encoding TcfA
E. histolytica CEL-170/4 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=918
Entamoeba histolytica CEL-170/4 protein vaccine
P. falciparum Subunit SE36 Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=919
Plasmodium falciparum subunit SE36 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=920
Entamoeba histolytica SREHP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=921
P. falciparum Pfen Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=922
Plasmodium falciparum Pfen protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=973
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=974
Herpes simplex virus type 2 vaccine using phage displaying GG protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=975
Herpes simplex virus type 1 DNA vaccine encoding GD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=976
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=977
Herpes simplex virus type 1 DNA vaccine encoding GE
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=887
Chlamydophila pneumoniae DNA vaccine encoding PknD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=888
Chlamydophila pneumoniae DNA vaccine encoding Ssb
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=889
Chlamydophila psittaci DNA vaccine pcDNA2/MOMP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=890
Classical swine fever virus vaccine VAC-E0
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=878
Chlamydophila abortus DNA vaccine encoding GatC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=879
Chlamydophila abortus DNA vaccine encoding OmlA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=880
Chlamydophila abortus DNA vaccine encoding MOMP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=881
Chlamydophila abortus DNA vaccine Pomp90A
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=882
Chlamydophila pneumoniae CopN protein vaccine
prostate cancer DNA vaccine encoding prostatic acid phosphatase (PAP)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=884
Chlamydophila pneumoniae DNA vaccine encoding FabD
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=885
Chlamydophila pneumoniae LcrE protein vaccine
B. pseudomallei Subunit LolC Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=860
Burkholderia pseudomallei subunit LolC protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=861
Chlamydia muridarum RplF protein vaccine
B. pseudomallei Subunit PotF Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=862
Burkholderia pseudomallei subunit PotF protein vaccine
P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=984
Plasmodium yoelii MSP1 and MSP4/5 proteins subunit vaccine
P. falciparum MSP3 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=985
Plasmodium falciparum MSP3 protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1035
Lassa Virus Nucleoprotein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=923
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=924
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=925
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=926
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=928
Francisella tularensis GroEL protein vaccine
obsolete Francisella tularensis DNA vaccine rLm/iglC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=912
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=913
Eimeria tenella DNA vaccine pcDNA-TA4-IL-2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=915
Entamoeba histolytica Eh29 protein vaccine
E. histolytica Gal/GalNAc lectin protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=916
Entamoeba histolytica Gal/GalNAc lectin protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=853
Dengue vaccine using Vaccinia virus expressing prM protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=854
Chlamydia muridarum MOMP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=855
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=856
Dengue vaccine using Vaccinia virus expressing M protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=857
Chlamydia muridarum PmpE/F-2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=858
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=859
Chlamydia muridarum PmpG-1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=847
Canine distemper virus DNA vaccine encoding HA
a Coccidioides vaccine that contains C. posadasii PMP1 protein
C. posadasii subunit PMP1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=848
Coccidioides posadasii subunit PMP1 protein vaccine
a Coccidioides vaccine that contains C. posadasii DNA vaccine encoding PRA protein
C. posadasii DNA Vaccine encoding PRA protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=849
Coccidioides posadasii DNA vaccine encoding PRA protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=850
a Coccidioides vaccine that contains C. immitis subunit URE protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=851
Coccidioides immitis subunit URE protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=852
Canine parvovirus CPMV-PARVO1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=901
Ebola virus DNA vaccine encoding ZEBOV GP and SEBOV GP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=902
Shigella flexneri Invaplex 24 subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=903
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=904
Shigella flexneri Invaplex 50 subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=905
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=907
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=909
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=910
Eimeria tenella DNA vaccine rBCG pMV261-Rho
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=397
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=398
Newcastle disease virus vaccine by Dow AgroSciences
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=427
Theileria parva vaccine by Centre for Ticks and Tickborne Disease, Malawi
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=428
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=960
Helicobacter pylori DNA vaccine encoding UreB
M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=961
Mycobacterium tuberculosis DNA vaccine APADNA priming and APAMVA boosting
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=962
Helicobacter pylori VacA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=981
Human papillomavirus DNA vaccine pNGVL4a-E6/opt
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=982
A multivalent vaccine against tetanus, diphtheria, and poliomyelitis.
Tetanus and Diphtheria Toxoids Adsorbed and Inactivated Poliomyelitis Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=628
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=629
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=630
WEB: https://www.vaccineshoppecanada.com/document.cfm?file=td_polio_adsorbed_e.pdf
This term is obsolete since there is another term with the same name.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=841
Campylobacter jejuni FspA1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=842
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=843
Campylobacter jejuni FspA2 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=844
Campylobacter jejuni DNA vaccine pcDNA3.1(+)-peblA
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=845
Canine distemper virus DNA vaccine encoding F and HA
a Coccidioides vaccine that contains C. posadasii subunit GEL1 protein
C. posadasii subunit GEL1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=846
Coccidioides posadasii subunit GEL1 protein vaccine
T. brucei DNA Vaccine encoding TSA protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=836
Trypanosoma brucei DNA vaccine encoding TSA protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=837
Trypanosoma brucei subunit p15 Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=838
Campylobacter jejuni MBP-FlaA protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=839
Theileria parva Subunit p67 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=840
Campylobacter jejuni FlaC protein vaccine
B. pertussis FhaB and 69 kDa OMP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=805
Bordetella pertussis FhaB and 69 kDa OMP protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=936
Haemophilus influenzae Hap protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1033
Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1034
Japanese encephalitis virus DNA vaccine pUJENS3
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=900
Cryptosporidium. parvum DNA vaccine encoding CP15/61
Y. enterocolititica Subunit V Antigen Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=896
Yersinia enterocolititica Subunit V Antigen Protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=897
Clostridium botulinum FHc protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=898
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=899
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=891
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=892
Classical swine fever virus vaccine VAC-E2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=893
Classical swine fever virus E1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=894
Clostridium botulinum DNA vaccine pSCARSBHc
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=954
Dobrava-Belgrade virus S nucleocapsid protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=955
Helicobacter pylori catalase protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=958
M. gallisepticum TM-1 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=959
Mycoplasma gallisepticum TM-1 protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1027
Japanese encephalitis virus vaccine BV-G-E
T. annulata Subunit SPAG-1 Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=873
Theileria annulata Subunit SPAG-1 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=874
Chlamydophila abortus DNA vaccine encoding DnaK
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=875
Chlamydophila abortus DNA vaccine encoding DnaX
C. abortus DNA vaccine encoding GatA/GatB
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=876
Chlamydophila abortus DNA vaccine encoding GatA/GatB
T. gondii Subunit Rop2-Hsp83 Fusion Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=866
Toxoplasma gondii Subunit Rop2-Hsp83 fusion protein vaccine
C. muridarum DNA vaccine encoding TC0757
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=867
Chlamydia muridarum DNA vaccine encoding TC0757
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=868
Toxoplasma gondii DNA vaccine pcDNA3-MIC3
C. muridarum DNA vaccine encoding TC0767/768
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=869
Chlamydia muridarum DNA vaccine encoding TC0767/768
T. gondii DNA Vaccine encoding SAG1 Protein
Toxoplasma gondii DNA vaccine encoding SAG1 protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=871
Chlamydophila abortus DNA vaccine encoding CAB049
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=872
Chlamydophila abortus DNA vaccine encoding CAB613
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1023
infleunza virus DNA vaccine encoding NP from Influenza A virus (A/chicken/Henan/12/2004(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1024
influenza virus DNA vaccine encoding NP from influenza A virus (A/chicken/Hubei/489/2004(H5N1))
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1025
Leishmania donovani DNA vaccine encoding KMP-11
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1026
influenza virus NP protein vaccine (influenza A virus (A/nt/60/1968(H3N2)))
L. donovani gp63 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1022
Leishmania donovani gp63 protein subunit vaccine
C. muridarum DNA vaccine encoding TC0439
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=864
Chlamydia muridarum DNA vaccine encoding TC0439
C. muridarum DNA vaccine encoding TC0512
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=865
Chlamydia muridarum DNA vaccine encoding TC0512
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=978
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=979
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=980
B. pseudomallei DNA vaccine encoding Flagellin Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=863
Burkholderia pseudomallei DNA vaccine encoding Flagellin protein
L. donovani ORFF Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1017
Leishmania donovani ORFF protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1018
influenza virus DNA vaccine encoding NA from influenza B virus (B/Ibaraki/2/85)
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1019
influenza virus DNA vaccine encoding NA from influenza A virus (A/chicken/Henan/12/2004(H5N1))
L. donovani DNA Vaccine encoding NH36 Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=1020
Leishmania donovani DNA vaccine encoding NH36 Protein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=945
Sin Nombre virus DNA vaccine encoding SNVsSgp1 (NP)
S. equi Subunit EAG, FNZ and SFS Protein Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=832
Streptococcus equi Subunit EAG, FNZ and SFS protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=833
Campylobacter jejuni DNA vaccine pcDNA3.1(+)-cadF
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=834
Streptococcus equi Subunit CNE protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=930
Francisella tularensis DNA vaccine pTUL4-15
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=931
Plasmodium berghei CS protein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=932
Giardia duodenalis DNA vaccine encoding CWP2
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=933
Haemophilus influenzae D15 protein vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=934
Newcastle Disease Virus HN glycoprotein subunit vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=816
Rabies DNA vaccine encoding Rabies virus Glycoprotein
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=817
Bovine herpesvirus 1 DNA vaccine tgD-VP22
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=818
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=645
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=815
Bovine herpesvirus 1 DNA vaccine pRSV-gC
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=741
For the prevention of disease caused by Japanese encephalitis virus in persons 2 months of age and older.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=740
Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human papillomavirus (HPV) types 16 and 18, in females9 through 25 years of age.
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=943
Andes virus vaccine using adenovirus viral vector expressing ANDV NP
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=938
Haemophilus influenzae Omp26 protein vaccine
N. caninum NcMIC1 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=939
Neospora caninum NcMIC1 protein subunit vaccine
N. caninum NcMAG1 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=941
Neospora caninum NcMAG1 protein subunit vaccine
N. caninum NcDG2 Protein Subunit Vaccine
VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=942
Neospora caninum NcDG2 protein subunit vaccine
A vaccine that protects against Leishmania amazonensis.
A vaccine that protects against Leishmania infantum.
A vaccine that protects against Cryptosporidium parvum.
A vaccine that protects against Bovine Leukemia virus.
A vaccine that protects against Marek's disease virus.
A vaccine that protects against Marburg Virus.
A vaccine that protects against Infectious Hematopoietic Necrosis Virus.
Infectious Hematopoietic Necrosis Virus vaccine
A vaccine that protects against Rift Valley Fever virus.
Viral vaccine that protects against Hantavirus.
A vaccine that protects against Herpes simplex virus type 1 and 2.
Herpes simplex virus type 1 and 2 vaccine
A vaccine that protects against Nipah virus.
A vaccine that protects against Hendra virus.
A vaccine that protects against Entamoeba histolytica.
A Chlamydia vaccine that protects against Chlamydophila pneumoniae.
A Chlamydia bacterial vaccine against Chlamydophila psittaci infection
A vaccine that protects against Burkholderia pseudomallei.
A Chlamydia vaccine that protects against Chlamydia muridarum.
A vaccine that protects against Lassa Fever Virus.
A vaccine that protects against Canine distemper virus.
A vaccine that protects against Coccidioides spp.
A vaccine that protects against Canine parvovirus.
Vaccine that protects against Helicobacter pylori infection.
A Campylobacter vaccine that protects against Campylobacter jejuni.
A vaccine that protects against SARS-CoV.
A vaccine that protects against Trypanosoma brucei.
A vaccine that protects against Haemophilus influenzae.
A vaccine that protects against Yersinia enterocolitica.
A vaccine that protects against Clostridium botulinum .
A vaccine that protects against Western equine encephalomyelitis virus.
Western equine encephalomyelitis virus vaccine
A vaccine that protects against Tick-borne Encephalitis Virus (TBEV).
Tick-borne Encephalitis Virus (TBEV) vaccine
A vaccine preparation that results in the generation of a Cancer vaccine
A vaccine preparation that results in the generation of a Allergy vaccine
YopH from Y. pestis strain: CO92, biovar: Orientalis
Protegen ID: 51; NCBI Gene GI: 1172712; NCBI Protein GI: 16082755; NCBI Protein Accession: NP_395201; NCBITaxon: 214092
The oprF gene was cloned into plasmid vector pVR1020, and the plasmid vaccines were delivered to mice by biolistic (gene gun) intradermal inoculation. Following the initial immunization and two consecutive boosts, each at 2-week intervals, protection was demonstrated in a mouse model of chronic pulmonary infection by P. aeruginosa. Eight days postchallenge, both lungs were removed and examined. A significant reduction in the presence of severe macroscopic lesions, as well as in the number of bacteria present in the lungs, was seen [PubMed: 11292786].
Protegen ID: 843; NCBI Gene GI: 878442; NCBI Protein GI: 15596974; NCBI Protein Accession: NP_250468; NCBITaxon: 208964
Burned Pseudomonas aeruginosa-infected mice immunized against PcrV, a type III virulence system translocating protein, showed significantly enhanced survival compared to controls [PubMed: 11500471].
Protegen ID: 844; NCBI Gene GI: 882997; NCBI Protein GI: 15596903; NCBI Protein Accession: NP_250397; NCBITaxon: 208964
Recombinant OprI protein was used to immunize mice, and was found to be protective against a challenge with a four- to fivefold 50% lethal dose of P. aeruginosa [PubMed: 2114360].
Protegen ID: 845; NCBI Gene GI: 879851; NCBI Protein GI: 15598049; NCBI Protein Accession: NP_251543; NCBITaxon: 208964
Protegen ID: 68; NCBI Nucleotide GI: 29692106
In mice, a primary vaccination with Ag85B-encoding plasmid DNA (DNA-85B) was protective against Mycobacterium tuberculosis (MTB) infection and associated with Ag85B-specific CD4+ T cells producing IFN-gamma and controlling intramacrophagic MTB growth [PubMed: 17250590].
Protegen ID: 118; NCBI Gene GI: 885785; NCBI Protein GI: 15609023; NCBI Protein Accession: NC_000962.2; NCBITaxon: 1773
Protegen ID: 228; NCBI Gene GI: 3341411; NCBI Protein GI: 62317941; NCBI Protein Accession: YP_223794; NCBITaxon: 262698
Intravenous vaccination with recombinant bacteria carrying expression plasmid for MPB/MPT51 in BALB/c mice elicited significant protective responses, comparable to those evoked by a live Mycobacterium bovis BCG vaccine [PubMed: 15039321].
Protegen ID: 814; NCBI Gene GI: 7562680; NCBI Protein GI: 224992215; NCBI Protein Accession: YP_002646905; NCBITaxon: 561275
DNA vaccines encoding secreted proteins Ag85B and MPT64 protect mice from the tuberculosis H37Rv strain [PubMed: 15498274]. *Note* MPT64 in combination with Ag85B was protective, DNA vaccine of just MPT64 was mildly protective in mice.
Protegen ID: 815; NCBI Gene GI: 885925; NCBI Protein GI: 15609117; NCBI Protein Accession: NP_216496; NCBITaxon: 83332
In a prophylactic vaccine model, immunization with the Mycobacterium tuberculosis protein ESAT-6 with LANAC adjuvant elicited significant protective immunity against aerosol challenge with virulent M. tuberculosis [PubMed: 16751377].
Protegen ID: 816; NCBI Gene GI: 886209; NCBI Protein GI: 57117165; NCBI Protein Accession: YP_178023; NCBITaxon: 83332
DNA vaccines encoding KatG antigen fused to TPA signal sequences evoked a significant protective response in mice aerogenically challenged with low doses of Mycobacterium tuberculosis Erdman 17 to 21 days after the final immunization [PubMed: 10456931].
Protegen ID: 817; NCBI Gene GI: 885638; NCBI Protein GI: 15609045; NCBI Protein Accession: NP_216424; NCBITaxon: 83332
Mice vaccinated with PstS-3 DNA demonstrated significant and sustained reduction in bacterial CFU numbers in spleen and lungs for 3 mo after M. tuberculosis challenge, as compared with CFU counts in mice vaccinated with control DNA [PubMed: 9916741].
Protegen ID: 818; NCBI Gene GI: 885366; NCBI Protein GI: 57116798; NCBI Protein Accession: YP_177768; NCBITaxon: 83332
A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs [PubMed: 16520093].
Protegen ID: 819; NCBI Gene GI: 885537; NCBI Protein GI: 57116919; NCBI Protein Accession: YP_177843; NCBITaxon: 83332
Protegen ID: 820; NCBI Gene GI: 885072; NCBI Protein GI: 57116920; NCBI Protein Accession: YP_177653; NCBITaxon: 83332
Purified preparations of HBHA were emulsified in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the ability to reduce M. tuberculosis infection in the mouse aerosol challenge model for tuberculosis. The HBHA-containing vaccine gave a approximately 0.7-log reduction in CFU in both mouse lungs and spleens compared to adjuvant controls 28 days following challenge [PubMed: 15557600].
Protegen ID: 821; NCBI Gene GI: 5211814; NCBI Protein GI: 148660242; NCBI Protein Accession: YP_001281765; NCBITaxon: 25177
immunization with the soluble recombinant rMTB41 protein plus adjuvant, a regimen known to generate primarily CD4+ T cells, resulted in induction of protection comparable to BCG in two well-established animal models of tuberculosis (mice and guinea pigs) [PubMed: 15917115].
Protegen ID: 822; NCBI Gene GI: 885069; NCBI Protein GI: 57116795; NCBI Protein Accession: YP_177765; NCBITaxon: 83332
GAPDH (Gap) associated with murine IL-12 gene in a DNA vaccine formulation partially protected mice against experimental infection [PubMed: 12171297].
Protegen ID: 823; NCBI Gene GI: 3340207; NCBI Protein GI: 62290600; NCBI Protein Accession: YP_222393; NCBITaxon: 262698
rHtrA was found to be very immunogenic and partially protective in both the passive infant rat model of bacteremia and the active chinchilla model of otitis media [PubMed: 9488373].
Protegen ID: 824; NCBI Protein GI: 2935168; NCBITaxon: 727
Orogastric immunization of mice with recombinant H. pylori HspA proteins protected 80% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021].
Protegen ID: 825; NCBI Protein GI: 712830; NCBITaxon: 210
Orogastric immunization of mice with recombinant H. pylori HspB proteins protected 70% of animals from a challenge dose of 10^4 Helicobacter felis bacteria [PubMed: 7604021].
Protegen ID: 826; NCBI Protein GI: 712831; NCBITaxon: 210
Mice were immunised with the citrate synthase protein by intra-Peyer's patch immunisation. Pre-immunisation with the citrate synthase protein led to a 84-91% reduction in H. pylori infection compared to unimmunised controls [PubMed: 10378424].
Protegen ID: 827; NCBI Protein GI: 2493711; NCBITaxon: 210
Recombinant TbpA protein was used in a mouse intraperitoneal-infection model to determine their ability to protect against meningococcal infection and to induce cross-reactive and bactericidal antibodies. TbpA was found to afford protection against meningococcal challenge when administered as the sole immunogen [PubMed: 11179327].
Protegen ID: 833; NCBI Protein GI: 8926211; NCBITaxon: 487
In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites [PubMed: 11062538].
Protegen ID: 834; NCBI Gene GI: 812783; NCBI Protein GI: 124801463; NCBI Protein Accession: XP_001349701; NCBITaxon: 36329
1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes [PubMed: 11471569].
Protegen ID: 835; NCBI Gene GI: 2654998; NCBI Protein GI: 296004911; NCBI Protein Accession: XP_001349207; NCBITaxon: 36329
Immunization with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) or a mutant cholera toxin, CT-E29H (for intranasal immunization), protected CBA/N mice against death and bacteremia, as well as reduced nasopharyngeal colonization, following intranasal challenge with a heterologous pneumococcal strain [PubMed: 11349048].
Protegen ID: 836; NCBI Protein GI: 13447096; NCBITaxon: 32630
Mice immunized with recombinant OspA protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958].
Protegen ID: 838; NCBI Gene GI: 1194357; NCBI Protein GI: 11496927; NCBI Protein Accession: NP_045688; NCBITaxon: 224326
Mice immunized with recombinant OspB protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958].
Protegen ID: 839; NCBI Gene GI: 1194340; NCBI Protein GI: 11496910; NCBI Protein Accession: NP_045689; NCBITaxon: 224326
Mice immunized with recombinant OspC protein were protected from challenge with Borrelia burgdorferi [PubMed: 8168958].
Protegen ID: 840; NCBI Gene GI: 1194415; NCBI Protein GI: 11497024; NCBI Protein Accession: NP_047005; NCBITaxon: 224326
Mice immunized with recombinant DbpA protein are protected against challenge with Borrelia burgdorferi [PubMed: 11035759].
Protegen ID: 841; NCBI Gene GI: 8319341; NCBI Protein GI: 256041910; NCBI Protein Accession: YP_003110629; NCBITaxon: 521009
In an attempt to generate a subunit vaccine in this experimental disease model, eukaryotic plasmid DNA expression vectors containing genes encoding either the wild-type or modified forms of recombinant listeriolysin O (hly) were generated and used for genetic vaccination of naive mice. Results of these studies indicate that the intramuscular immunization of mice with specifically designed plasmid DNA constructs encoding recombinant forms of listeriolysin O (hly) stimulates peptide-specific CD8+ immune T cells that exhibit in vitro cytotoxic activity. More importantly, such immunization can provide protective immunity against a subsequent challenge with viable L. monocytogenes [PubMed: 10384131].
Protegen ID: 842; NCBI Gene GI: 987033; NCBI Protein GI: 16802248; NCBI Protein Accession: NP_463733; NCBITaxon: 169963
Mice were immunized with a recombinant fragment of CNA protein, and were then challenged with the S. aureus clinical isolate strain Phillips. At 14 d after inoculation, mortality in the collagen adhesin-vaccinated group was only 13%, compared with 87% in the control antigen immunized group [PubMed: 9637697].
Protegen ID: 846; NCBI Nucleotide GI: 387879; NCBI Protein GI: 387880; NCBI Protein Accession: AAA20874.1; NCBITaxon: 1280
Mice immunized with recombinant ClfA and challenged with S. aureus developed less-severe arthritis than did mice immunized with a control antigen [PubMed: 11740733].
Protegen ID: 847; NCBI Gene GI: 5330438; NCBI Protein GI: 151220968; NCBI Protein Accession: YP_001331790; NCBITaxon: 426430
An internal region from the transpeptidase domain from the PBP2a (encoded by mecA) was cloned into a mammalian expression vector, to be used as DNA vaccine in a Murine model. After three sets of DNA vaccination, the immune response represented by antibodies against a fragment of PBP2a was evaluated by enzyme linked immunosorbent assay (ELISA), showing a significant antibody response. The antibacterial effect of the DNA vaccine was evaluated by intraperitoneal immunization and challenge with a sublethal dose of MRSA for 7 days in mice. After the challenge, the number of bacteria from kidneys from immunized and non-immunized mice were determined. Kidneys from immunized mice had 1000 times less on bacteria than the positive controls (non-immunized mice) [PubMed: 12744903].
Protegen ID: 848; NCBI Gene GI: 2861157; NCBI Protein GI: 49482291; NCBI Protein Accession: YP_039515; NCBITaxon: 282458
Mice were immunized with fusion proteins encompassing the fibronectin-binding domain of a staphylococcal fibronectin-binding protein (FnBP-A). Vaccination of mice with recombinant FnBP resulted in significant protection against challenge with S. aureus [PubMed: 7975852].
Protegen ID: 849; NCBI Protein GI: 120457; NCBITaxon: 93061
Immunization of mice with recombinant BPS protein by the subcutaneous route produced an efficient antigen-specific response, and immunized animals survived challenge with a lethal dose of a virulent strain [PubMed: 11796614].
Protegen ID: 850; NCBI Protein GI: 5327234; NCBITaxon: 1311
Intranasal immunization of mice with either SfbI alone or coupled to cholera toxin B subunit (CTB) triggered efficient SfbI-specific humoral (mainly IgG) and lung mucosal (14% of total IgA) responses. SfbI-vaccinated animals showed 80% and 90% protection against homologous and heterologous challenge, respectively [PubMed: 10068585].
Protegen ID: 851; NCBI Nucleotide GI: 511149; NCBI Protein GI: 511150; NCBI Protein Accession: CAA48133.1; NCBITaxon: 1314
Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice [PubMed: 11159987].
Protegen ID: 852; NCBI Nucleotide GI: 496254; NCBITaxon: 1314
Mice immunized with FbpA were protected from challenge with group A streptococcus [PubMed: 19254483].
Protegen ID: 853; NCBI Protein GI: 14915682; NCBITaxon: 1314
Mice were intranasally immunized with diphtheria toxoid (DT) conjugated polypeptides encompassing a conformational-constrained B cell epitope of the M1 protein (J8). Vaccinated mice were challenged 10 days after the last boost by the intranasal route. Animals had 60% protection against challenge [PubMed: 16828529].
Protegen ID: 854; NCBI Nucleotide GI: 311757; NCBI Protein GI: 311758; NCBI Protein Accession: CAA44062.1; NCBITaxon: 1314
Immunization with Sib 35 enhanced survival rates in mice challenged with a GAS strain, while exhibiting no toxicity in hosts [PubMed: 15990202].
Protegen ID: 855; NCBI Protein GI: 90567992; NCBITaxon: 342023
Immunization with the recombinant GlpQ significantly protected rabbits from subsequent T. pallidum challenge, altering lesion development at the sites of challenge [PubMed: 9826352].
Protegen ID: 856; NCBI Gene GI: 2611763; NCBI Protein GI: 15639249; NCBI Protein Accession: NP_218698; NCBITaxon: 243276
Treponema pallidum-susceptible guinea pigs of strain C4D were immunized with recombinant T. pallidum antigen TmpB. Guinea pigs receiving TmpB antigen demonstrated protection expressed by the development of significantly (P less than 0.01) smaller, atypical lesions of significantly (P less than 0.01) shorter duration and devoid of or containing fewer T. pallidum organisms than lesions in the remaining immunized and control animals [PubMed: 1937794].
Protegen ID: 857; NCBI Gene GI: 2611387; NCBI Protein GI: 15639756; NCBI Protein Accession: NP_219206; NCBITaxon: 243276
Immunization with recombinant Tp92 partially protected rabbits from subsequent T. pallidum challenge [PubMed: 10762571].
Protegen ID: 858; NCBI Protein GI: 159158965; NCBITaxon: 243276
Immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI [PubMed: 10992461].
Protegen ID: 859; NCBI Gene GI: 3685788; NCBI Protein GI: 76788047; NCBI Protein Accession: YP_328758; NCBITaxon: 205921
Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II, and vaccination with the alpha protein protected against one strain of type II and one strain of type Ib [PubMed: 8751893].
Protegen ID: 860; NCBI Protein GI: 1620648; NCBITaxon: 1311
Mice immunized with p60 encapsulated in liposomes launched a strong CTL response and were protected against a subsequent challenge with L. monocytogenes [PubMed: 18433404].
Protegen ID: 862; NCBI Protein GI: 215422507; NCBITaxon: 1639
Mouse antiserum directed against the recombinant NucA protein was reactive on Western immunoblots and whole-cell ELISA with all H. influenzae strains tested including Eagan and was bactericidal for two heterologous strains tested. The antiserum also resulted in a log reduction in bacteremia, in an infant-rat protection study with H. influenzae type b as the challenge strain [PubMed: 10768940].
Protegen ID: 863; NCBI Protein GI: 4929317; NCBITaxon: 727
When chinchillas were immunized with recombinant P1 (rP1) obtained from one of these isolates (BCH-3), all animals developed antibodies specific for rP1. Immunized animals were protected against disease when challenged with BCH-3, but not with an ompP1 mutant of BCH-3 or a strain (BCH-2) possessing a heterologous P1 (91% identity). We conclude that (i) while P1 induces protection against NTHI-mediated otitis media, development of a polyvalent vaccine reflecting the variability of P1 would be necessary to construct an efficacious vaccine [PubMed: 10899849].
Protegen ID: 864; NCBI Protein GI: 9716645; NCBITaxon: 727
Vaccination with the recombinant PstS-1 antigen and cholera toxin significantly protected against the challenge given 10 days later, but only marginally after 12 weeks [PubMed: 10869767].
Protegen ID: 865; NCBI Gene GI: 885724; NCBI Protein GI: 57116801; NCBI Protein Accession: YP_177770; NCBITaxon: 83332
In an ex vivo transfection approach with a retroviral vector a single antigen (hsp70) could evoke strong protection in mice [PubMed: 9234527].
Protegen ID: 866; NCBI Gene GI: 885946; NCBI Protein GI: 15607491; NCBI Protein Accession: NP_214864; NCBITaxon: 83332
A single DNA vaccine encoding the MPT-83 tuberculosis antigens evoked partial protection against an aerogenic challenge with M. tuberculosis Erdman in the mouse model of pulmonary tuberculosis [PubMed: 10715531].
Protegen ID: 867; NCBI Gene GI: 887155; NCBI Protein GI: 15610010; NCBI Protein Accession: NP_217389; NCBITaxon: 83332
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML [Twinrix]
1 ML hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Twinrix]
Twinrix Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine 1 ML Prefilled Syringe
1 ML hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Injection [Twinrix]
Twinrix Hepatitis A inactivated and Hepatitis B (recombinant) Vaccine 1 ML Injection
hepatitis A vaccine (inactivated) strain HM175 / hepatitis B surface antigen vaccine Injection [Twinrix]
hepatitis A vaccine (inactivated) strain HM175 / hepatitis B surface antigen vaccine Prefilled Syringe [Twinrix]
0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection [ActHIB]
ActHIB (purified capsular polysaccharide 10 MCG conjugated to inactivated tetanus toxoid 24 MCG) per 0.5 ML Injection
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML [ActHIB]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection [ActHIB]
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection
purified capsular polysaccharide 10 MCG conjugated to inactivated tetanus toxoid 24 MCG per 0.5 ML Injection
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Product
hepatitis B surface antigen vaccine Injection [Engerix-B]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Tenivac]
Tenivac (Diphtheria Toxoid Vaccine 2 UNT / Tetanus Toxoid Vaccine 5 UNT) per 0.5 ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Tenivac]
Tenivac (Diphtheria and Tetanus Toxoid Vaccines) 0.5 ML Prefilled Syringe
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Tenivac]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tenivac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Tenivac]
varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML [Varivax]
0.5 ML varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax]
varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML
0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Injection [Gardasil 9]
Gardasil 9, Human Papillomavirus 9-valent (Types 6,11,16,18,31,33,45,52,58) Vaccine, Recombinant 0.5 ML Injection
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML [Gardasil 9]
0.5 ML L1 protein, Human papillomavirus type 11 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 16 Vaccine 0.12 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.08 MG/ML / L1 protein, Human papillomavirus type 31 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 33 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 45 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 52 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 58 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 6 Vaccine 0.06 MG/ML Prefilled Syringe [Gardasil 9]
Gardasil 9, human Papillomavirus 9-valent (types 6,11,16,18,31,33,45,52,58) vaccine, recombinant 0.5 ML Prefilled Syringe
L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 31 Vaccine / L1 protein, Human papillomavirus type 33 Vaccine / L1 protein, Human papillomavirus type 45 Vaccine / L1 protein, Human papillomavirus type 52 Vaccine / L1 protein, Human papillomavirus type 58 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injection [Gardasil 9]
L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 31 Vaccine / L1 protein, Human papillomavirus type 33 Vaccine / L1 protein, Human papillomavirus type 45 Vaccine / L1 protein, Human papillomavirus type 52 Vaccine / L1 protein, Human papillomavirus type 58 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe [Gardasil 9]
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML
L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML
L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML
L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML [M-M-R II]
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection [M-M-R II]
M-M-R II, Measles, Mumps, and Rubella Virus Vaccine Live 0.5 ML Injection
measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [M-M-R II]
measles virus vaccine live, Enders' attenuated Edmonston strain
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML
rubella virus vaccine live (Wistar RA 27-3 strain)
rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML
mumps virus vaccine live, Jeryl Lynn strain
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML
Mumps Virus Vaccine Live, Jeryl Lynn Strain Injectable Product
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML Injectable Solution
Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 UNT/ML
A material entity of a drug based on their general physical form and how they are administered.
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML
An information content entity that specifies a family of drug products containing a specific active ingredient.
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1 by Stada
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1 by Novartis
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1
obsolete 0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Aca Mueller
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Axicorp
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Cc
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Emra-Med
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Gerke
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Kohlpharma
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Orifarm Leverkus
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1 by Kohlpharma
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Sanofi
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution
0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim]
0.5 ML Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim] by Sanofi
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Aca Mueller
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Cc
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Emra-Med
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Eurim-Pharm
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by European
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Gerke
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Haematogmbh
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Kohlpharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mevita
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mtk
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by MZG
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Orifarm Leverkus
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Veron
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Cc
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Emra-Med
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Eurim-Pharm
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Gerke
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Kohlpharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Mevita
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by MZG
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Orifarm Leverkus
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Veron
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10 by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20 by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50 by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 20
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 50
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1 by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1
obsolete 1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Axicorp
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1 by Mtk
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Aca Mueller
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Axicorp
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10 by Haematogmbh
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Merck
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1 by Sanofi
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Merck
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10 by Sanofi
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Emra-Med
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Eurim-Pharm
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Kohlpharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Merck
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1 by Sanofi
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Merck
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10 by Sanofi
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 10
1 ML Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection
1 ML Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection [Vivaxim]
Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [Hepatyrix]
hepatitis A vaccine (inactivated) strain HM175 / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM]
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML [Havrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe [Havrix] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1.44 UNT/ML Prefilled Syringe Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe [Vaqta] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 100 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML [Epaxal]
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML [Havpur]
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal]
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Epaxal] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur]
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe [Havpur] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1000 UNT/ML Prefilled Syringe Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML [Hepatyrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML [Hepatyrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 20
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension [Hepatyrix] Box of 50
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 20
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 CELLS/ML Injectable Suspension Box of 50
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension [Havrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Injectable Suspension Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe [Havrix] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML Prefilled Syringe Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution [Vaqta] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 25000 UNT/ML Injectable Solution Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML [Epaxal]
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal]
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe [Epaxal] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 48 UNT/ML Prefilled Syringe Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution [Vaqta] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Injectable Solution Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta]
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe [Vaqta] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 50 UNT/ML Prefilled Syringe Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution [Hav Sorbat Ssw]
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Solution [Vaqta]
hepatitis A vaccine (inactivated) strain HM175 Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Hav Sorbat Ssw]
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Havrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 Injectable Suspension [Hepatyrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Epaxal]
Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Havpur]
Hepatitis A Vaccine (Inactivated) Strain HM175 Prefilled Syringe [Vaqta]
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM]
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution [Vivaxim]
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe
Hepatitis A Vaccine, Inactivated / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe [ViATIM]
Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML
Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Vivaxim]
Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution
Hepatitis A Vaccine, Inactivated 320 UNT/ML / Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Vivaxim]
Hepatitis A Virus / Salmonella Typhi Inactivated Antigen Injection
Hepatitis A Virus / Salmonella Typhi Inactivated Antigen Injection [Vivaxim]
hepatitis A virus / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension
hepatitis A virus / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Suspension [ViATIM]
Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML
Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML [Vivaxim]
Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection
Hepatitis A Virus 160 UNT/ML / Salmonella Typhi Inactivated Antigen 0.025 MG/ML Injection [Vivaxim]
Neisseria meningitidis Group B Membrane vesicles External Omv
0.5 ML hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.0005 % Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Prefilled Syringe
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe
Neisseria meningitidis Recombinant Fusion Protein Fhbp Group B
hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.01 MG/ML Injection
hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Solution
hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension
hepatitis B surface antigen vaccine 0.02 MG/ML Injection
hepatitis B surface antigen vaccine 0.02 MG/ML Injection [Engerix-B]
hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B]
hepatitis B surface antigen vaccine 0.04 MG/ML Injection
hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine Injectable Solution
hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML [Hevac B]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [Gen Vax]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [H-B-Vax II]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Engerix B]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Gemvites]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Hepasorbat]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Lt Grk]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Fendrix]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Gen Vax]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [H-B-Vax II]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [VACCIN GENHEVAC B]
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML [Engerix B]
Hepatitis B Surface Antigen Vaccine Intramuscular Solution [Recombivax]
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN Injectable Suspension [Engerix B]
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML
Hepatitis B Surface Antigen Vaccine Intramuscular Solution
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN Injectable Suspension
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution [Recombivax]
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B]
Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injectable Solution [Procomvax]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Bimmugen]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Engerix B]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Fendrix]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Gemvites]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Gen Vax]
Hepatitis B Surface Antigen Vaccine Injectable Solution [H B Vax]
Hepatitis B Surface Antigen Vaccine Injectable Solution [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Hepasorbat]
Hepatitis B Surface Antigen Vaccine Injectable Solution [Heptavax]
Hepatitis B Surface Antigen Vaccine Injectable Suspension [Engerix B]
Hepatitis B Surface Antigen Vaccine Injectable Suspension [Engerix-B]
Hepatitis B Surface Antigen Vaccine Injectable Suspension [Fendrix]
Hepatitis B Surface Antigen Vaccine Injectable Suspension [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine Injectable Suspension [VACCIN GENHEVAC B]
Hepatitis B Surface Antigen Vaccine Injection [H-B-Vax II]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Engerix B]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Fendrix]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Gen Vax]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [H B Vax]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Hepasorbat]
hepatitis B surface antigen vaccine Prefilled Syringe [Heptavax]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Hevac B]
Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Lt Grk]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension
Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injectable Solution
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B]
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B]
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B]
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [H-B-Vax II]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix]
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO]
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 3
HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 50
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Intramuscular Solution [Recombivax] by Merck
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B]
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix]
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax]
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B]
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk]
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax]
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO]
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injection [H-B-Vax II]
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO]
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO]
10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO]
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 3
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 50
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 10
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe
10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 10
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 25
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 50
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 25
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 50
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 10
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 25
Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 2
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 25
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 3
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 50
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 25
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 3
Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 50
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 100
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 250
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 50
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 10
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1
Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Merck
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Organon
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by GSK
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] by GSK
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] by Glaxosmithkline
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Glaxosmithkline
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Glaxosmithkline
0.5 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 50 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by MSD
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] by Organon
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] by Waymade
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by GSK
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] by MSD
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] by Sanofi
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline
1 ML HEPATITIS B VIRUS SUBTYPE ADW2 HBSAG SURFACE PROTEIN ANTIGEN 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Glaxosmithkline
Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection [H-B-Vax II] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 50
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 10
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 2
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injection Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 100
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 250
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 25
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension Box of 1
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1
10 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 25 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 50 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 50 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 50 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Mtk
0.5 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Organon
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 20 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 25 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 50 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 50 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Europharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Europharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by GSK
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mevita
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mevita
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 50 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mevita
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Axicorp
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Cc
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mevita
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Aca Mueller
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Eurim-Pharm
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Gerke
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Emra-Med
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Kohlpharma
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Mtk
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 50 by Orifarm Leverkus
0.5 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Fendrix] Box of 10 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 1 by GSK
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [Fendrix] Box of 10 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [VACCIN GENHEVAC B] Box of 1 by Sanofi
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Fendrix] Box of 10 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.005 MG/ML Prefilled Syringe [Hevac B] Box of 1 by Merieux
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 10 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 2 by Boehringer Ingelheim
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 20 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Boehringer Ingelheim
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [Gen Vax] Box of 3 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 10 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution [HBvaxPRO] Box of 20 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 10 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Solution Box of 20 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by MSD
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Organon
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Merck
1 ML hepatitis B surface antigen vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Organon
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Injectable Suspension [HBvaxPRO] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 10 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 20 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [Gen Vax] Box of 3 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 20 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [H B Vax] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 10 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe [HBvaxPRO] Box of 20 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.01 MG/ML Prefilled Syringe Box of 20 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 1 by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 10 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Engerix B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Gemvites] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [H B Vax] Box of 1 by Boehringer Ingelheim
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution [Hepasorbat] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 1 by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 10 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by GSK
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Mtk
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 1 by Waymade
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 10 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Emra-Med
1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Engerix-B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Engerix-B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Haematogmbh
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by HVD
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 1 by Waymade
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Haematogmbh
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 10 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Glaxosmithkline
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix B] Box of 3 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Haematogmbh
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Haematogmbh
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 10 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 25 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Mevita
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] Box of 3 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Lt Grk] Box of 25 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1 by European
1 ML Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 3 by European
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1 by Boehringer Ingelheim
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [Gen Vax] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by HVD
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution [HBvaxPRO] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Aca Mueller
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Eurim-Pharm
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Europharma
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by HVD
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Kohlpharma
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Mtk
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Orifarm Leverkus
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Solution Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Axicorp
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Cc
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Emra-Med
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Gerke
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by HVD
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Merck
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by MSD
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Sanofi
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Injectable Suspension [HBvaxPRO] Box of 1 by Veron
1 ML Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Sanofi
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe [HBvaxPRO] Box of 1 by Orifarm Leverkus
10 ML Hepatitis B Surface Antigen Vaccine 0.001 MG/ML Prefilled Syringe Box of 1 by Orifarm Leverkus
hepatitis A vaccine (inactivated) strain HM175 / hepatitis B surface antigen vaccine Injection
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Injection
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 / hepatitis B surface antigen vaccine Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Injection [Twinrix]
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Twinrix]
1 ML hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Injection
hepatitis A inactivated and hepatitis B (recombinant) vaccine per 1 ML Injection
1 ML hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 720 UNT / hepatitis B surface antigen vaccine 20 MCG per 1 ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML [Twinrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix Adult]
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML [Twinrix Paediatric]
Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension [Twinrix Adult]
Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension [Twinrix Paediatric]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Ambirix]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Twinrix Adult]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution [Twinrix Paediatric]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Ambirix]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix Adult]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix Paediatric]
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Twinrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Solution
Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Injectable Suspension
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Injectable Solution
Hepatitis A Vaccine, Inactivated / Hepatitis B Surface Antigen Vaccine Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult]
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric]
Hepatitis A Vaccine (Inactivated) Strain HM175 / Hepatitis B Surface Antigen Vaccine Prefilled Syringe [Ambirix]
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric]
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix]
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix]
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Solution Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Paediatric] Box of 1 by Glaxosmithkline
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injectable Suspension [Twinrix Adult] Box of 1 by Glaxosmithkline
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection [Twinrix] Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Injection Box of 10
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe Box of 10
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 1440 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.04 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Aca Mueller
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by A+S Unicare
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Cc
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Emra-Med
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Eurim-Pharm
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Gerke
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Veron
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by A+S Unicare
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Aca Mueller
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Emra-Med
0.5 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Eurim-Pharm
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by A+S Unicare
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Aca Mueller
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by ADL
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Axicorp
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Bb Farma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Europharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Gerke
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by HVD
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Kohlpharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Medicopharm
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Mevita
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Milinda Am
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Mtk
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Opti
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Orifarm Leverkus
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Tisida
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 1 by Veron
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by A+S Unicare
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Abacus Medicine
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by ADL
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Cc
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Europharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Gerke
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Kohlpharma
1 ML Hepatitis A Vaccine (Inactivated) Strain HM175 720 UNT/ML / Hepatitis B Surface Antigen Vaccine 0.02 MG/ML Prefilled Syringe [Twinrix] Box of 10 by Orifarm Leverkus
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Boostrix]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Covaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Diphtherie-Adsorbat-Impfstoff Behring]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Repevax]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Revaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated 4 UNT/ML [Td-Pur]
diphtheria toxoid vaccine, inactivated 60 LFU/ML [Tetravac]
diphtheria toxoid vaccine, inactivated 60 UNT/ML [Infanrix]
diphtheria toxoid vaccine, inactivated 60 UNT/ML [Pediacel]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Boostrix]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Covaxis]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Dipht Toxoid Asid]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Infanrix]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Pediacel]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Repevax]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Revaxis]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Td-Pur]
diphtheria toxoid vaccine, inactivated Injectable Suspension [Tetravac]
diphtheria toxoid vaccine, inactivated 0.2 LFU/ML
diphtheria toxoid vaccine, inactivated 0.5 UNT/ML
diphtheria toxoid vaccine, inactivated 10 UNT/ML
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML
diphtheria toxoid vaccine, inactivated 150 UNT/ML
diphtheria toxoid vaccine, inactivated 2 UNT
diphtheria toxoid vaccine, inactivated 2 UNT/ML
diphtheria toxoid vaccine, inactivated 20 UNT
diphtheria toxoid vaccine, inactivated 30 LFU/ML
diphtheria toxoid vaccine, inactivated 30 UNT
diphtheria toxoid vaccine, inactivated 40 UNT/ML
diphtheria toxoid vaccine, inactivated 5 LFU/ML
diphtheria toxoid vaccine, inactivated 50 LFU/ML
diphtheria toxoid vaccine, inactivated 60 LFU/ML
diphtheria toxoid vaccine, inactivated 60 UNT/ML
diphtheria toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur]
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac]
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix]
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel]
diphtheria toxoid vaccine, inactivated Injectable Solution [Dipht Toxoid Asid]
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur]
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac]
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix]
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel]
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20
diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 50 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 2
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 25
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 50
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 10
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 25
diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 50
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 10
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 20
diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 2
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 50
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension Box of 50
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 20
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension Box of 25
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution
10 ML diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution Box of 5
diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution Box of 1
diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1
diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10
diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1
diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution Box of 5
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1
diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Diphtherie-Adsorbat-Impfstoff Behring] Box of 10 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 20 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Repevax] Box of 5 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Revaxis] Box of 20 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 10 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Td-Pur] Box of 2 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 1 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 20 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 5 by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 25 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 60 LFU/ML Injectable Suspension [Tetravac] Box of 50 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 60 UNT/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi
diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution by Connaught
diphtheria toxoid vaccine, inactivated 50 LFU/ML Injectable Solution by Aventis
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10
10 ML diphtheria toxoid vaccine, inactivated 0.5 UNT/ML Injectable Solution Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1 by Boehringer Ingelheim
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10 by Boehringer Ingelheim
0.5 ML diphtheria toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 10 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1 by Boehringer Ingelheim
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1 by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10 by Novartis
diphtheria toxoid vaccine, inactivated 0.2 LFU/ML Injectable Solution Box of 5 by Aventis
diphtheria toxoid vaccine, inactivated 4 LFU/ML Injectable Solution Box of 5 by Aventis
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel]
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel] Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis]
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix]
0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix] Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection
0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel]
0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel] Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline
0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
0.5 ML acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] by GSK
0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac]
0.5 ML acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac] by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by GSK
0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Tripacel]
0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
0.5 ML Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Adacel]
0.5 ML Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution by Aventis
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut
0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10 by Massbiologics
0.5 ML diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection by Massbiologics
0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster]
0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster] Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Vaccine]
0.5 ML diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im]
0.5 ML diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im] by Lederle Products
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5 by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Iaf Biovac
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension by Lederle Products
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10 by Massbiologics
0.5 ML diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection by Massbiologics
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] by Novartis
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Glaxosmithkline
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Sanofi
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster] Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Vaccine]
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution by Aventis
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution by Aventis
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix]
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix] by Glaxosmithkline
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection
0.5 ML Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB]
0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension
0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C]
0.5 ML meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C] by Pfizer
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed]
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed] by Aventis
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun]
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1 by Baxter
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10 by Baxter
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv]
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv] Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol]
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno]
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10 by Baxter
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] by Baxter
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol]
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50 by Boehringer Ingelheim
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac]
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun]
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun]
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur]
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5 by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension by Statens Serum Institut
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1 by Ribosepharm
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 80
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 80
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10 by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] by Glaxosmithkline
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 2
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 25
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 50
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol]
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20 by Novartis
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10 by Sanofi
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 100
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20
0.5 ML tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20 by Sanofi
1 ML tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution
1 ML tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution by SK Chemical
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin]
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1 by Baxter
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] by Baxter
1 ML tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution Box of 1
10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution
10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol]
10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol] Box of 1
10 ML tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution Box of 1
50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution
50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol]
50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol] Box of 1
50 ML tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution Box of 1
7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol]
7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol] Box of 1
7.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1
7.5 ML tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution
7.5 ML tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution Box of 1
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Covaxis]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adacel]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tripacel]
acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection [Boostrix]
acellular pertussis vaccine, inactivated / Bordetella Pertussis Filamentous Haemagglutinin Antigen / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / tetanus toxoid vaccine, inactivated Injection [Infanrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [HEXYON]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Solution
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix Hexa]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdt]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Anrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Hepatitis B Surface Antigen Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Eurim Pharm]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Tetravac]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Tetravac]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Covaxis]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Triaxis]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Covaxis]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Triaxis]
acellular pertussis vaccine, inactivated 0.0055 MG / Bordetella pertussis 0.01 MG / diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 20 UNT Injection
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adacel]
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel]
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adacel] Box of 5
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Covaxis]
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis]
acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT [Infanrix]
acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution
acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution [Infanrix]
acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injectable Solution [Infanrix] by Glaxosmithkline
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Boostrix]
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix]
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Boostrix] Box of 10
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 10
acellular pertussis vaccine, inactivated 0.0105 MG / Bordetella pertussis 0.008 MG / diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 20 UNT Injection
acellular pertussis vaccine, inactivated 0.013 MG / Bordetella pertussis 0.01 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT Injection
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Tripacel]
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel]
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Tripacel] Box of 5
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5
acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix]
acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix]
acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetravac]
acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetravac]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / pertactin adsorbed / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix]
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Adacel]
Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Tripacel]
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Tripacel]
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Tripacel]
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Adacel]
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension [Adacel]
Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix]
Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
Candida albicans extract / diphtheria toxoid vaccine, inactivated / Glycerin / Proteus mirabilis / Purified Protein Derivative of Tuberculin / tetanus toxin Injectable Solution
Candida albicans extract / diphtheria toxoid vaccine, inactivated / Glycerin / Proteus mirabilis / Purified Protein Derivative of Tuberculin / tetanus toxin Injectable Solution [Multitest Cmi]
Diphtheria Antitoxin / diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension
Diphtheria Antitoxin / diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix]
diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdt]
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Act-HIB DTP]
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix-Hib]
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Act-HIB DTP]
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix-Hib]
diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution
diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated / Human poliovirus / tetanus toxoid vaccine, inactivated Injectable Suspension [Revaxis]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Act-HIB DTP]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection [Act-HIB DTP]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injection [Infanrix]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Pediacel]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Suspension [Pediacel]
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe
diphtheria toxoid vaccine, inactivated / influenza B virus antigen, Hong Kong 330-2001 / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Pediacel]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Quatro Virelon No]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Acel Imune]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Di Te Tuss Asid]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Dpt Merieux]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Dpt Vaccinol]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hib Dpt Merieux]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Hibdpt Vaccinol]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Infanrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Solution [Tri-Immunol Im]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Dtp Rix]
diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / tetanus toxoid vaccine, inactivated Prefilled Syringe [Infanrix]
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxin Injectable Suspension
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxin Injectable Suspension [Revaxis]
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [Revaxis]
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe
diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Revaxis]
diphtheria toxoid vaccine, inactivated / tetanus toxin Injectable Solution
diphtheria toxoid vaccine, inactivated / tetanus toxin Injectable Suspension
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Boostrix]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Di Tetasorbat]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Diftavax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Impfstoff]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Vaccinol]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Dt Wellcovax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Repevax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution [Td Impfstoff]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Diftavax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Pur]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adt Booster]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Adt Vaccine]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Boostrix]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Diftavax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Dt Rix]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Repevax]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.05 MG/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 12.5 LFU/ML / tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection
diphtheria toxoid vaccine, inactivated 2 LFU/ML / tetanus toxoid vaccine, inactivated 2 LFU/ML Injection Box of 10
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adt Booster]
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Adt Vaccine]
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster]
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Booster] Box of 5
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Adt Vaccine]
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection Box of 5
diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML [Tri-Immunol Im]
diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution [Tri-Immunol Im]
diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxin 10 LFU/ML Injectable Suspension Box of 5
diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection
diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 4 LFU/ML Injection Box of 10
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Revaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Adt Booster]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Adt Vaccine]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Pur]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Booster] Box of 5
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection [Adt Vaccine]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML Injection Box of 5
diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 50 LFU/ML / Pertussis Vaccine 24 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 50 LFU/ML / tetanus toxin 10 LFU/ML Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide Injectable Solution [Menitorix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Solution [PedvaxHIB]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Suspension
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.015 MG / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG [PedvaxHIB]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.015 MG / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML [Hiberix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.02 MG/ML Injection [Hiberix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML [ActHIB]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.08 MG/ML Injection [ActHIB]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution [Hiberix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injectable Solution [HibTITER]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated Injectable Solution
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated Injectable Solution [Nimenrix]
meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated Injectable Suspension
meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated Injectable Suspension [Neisvac C]
meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML [Neisvac C]
meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension
meningococcal group C polysaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.04 MG/ML Injectable Suspension [Neisvac C]
Neisseria meningitidis polysaccharide group Y tetanus toxoid conjugate
Neisseria meningitidis polysaccharide group Y tetanus toxoid conjugate 0.01 MG/ML
poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution
poliovirus vaccine inactivated, type 1 (Mahoney) / tetanus toxoid vaccine, inactivated Injectable Solution [T Polio Adsorbed]
poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [T Polio Adsorbed]
poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
poliovirus vaccine inactivated, type 1 (Mahoney) 160 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [T Polio Adsorbed]
tetanus toxoid vaccine, inactivated 0.04 MG/ML
tetanus toxoid vaccine, inactivated 0.088 MG/ML
tetanus toxoid vaccine, inactivated 1.5 UNT/ML
tetanus toxoid vaccine, inactivated 1.5 UNT/ML [Tetanol]
tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 1.5 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 10 UNT/ML [Tetanol]
tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 12.5 LFU/ML
tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 20
tetanus toxoid vaccine, inactivated 12.5 LFU/ML Injectable Suspension Box of 5
tetanus toxoid vaccine, inactivated 150 UNT/ML [T Immun]
tetanus toxoid vaccine, inactivated 150 UNT/ML [Tet Aktiv]
tetanus toxoid vaccine, inactivated 150 UNT/ML [Tetanol]
tetanus toxoid vaccine, inactivated 150 UNT/ML [T-Immun Immuno]
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun]
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 1
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [T Immun] Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv]
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tet Aktiv] Box of 100
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 100
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 2
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 20
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution [Tetanol] Box of 50
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 100
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 2
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 20
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution Box of 50
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno]
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension [T-Immun Immuno] Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol]
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 100
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 20
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe [Tetanol] Box of 50
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 1
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 10
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 100
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 20
tetanus toxoid vaccine, inactivated 150 UNT/ML Prefilled Syringe Box of 50
tetanus toxoid vaccine, inactivated 2 LFU/ML
tetanus toxoid vaccine, inactivated 20 LFU/ML
tetanus toxoid vaccine, inactivated 20 LFU/ML [Tetravac]
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac]
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 10
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 25
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension [Tetravac] Box of 50
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 25
tetanus toxoid vaccine, inactivated 20 LFU/ML Injectable Suspension Box of 50
tetanus toxoid vaccine, inactivated 2000 IU/ML
tetanus toxoid vaccine, inactivated 2000 IU/ML Injectable Solution
tetanus toxoid vaccine, inactivated 250 UNT/ML
tetanus toxoid vaccine, inactivated 250 UNT/ML [Tetabulin]
tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin]
tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution [Tetabulin] Box of 1
tetanus toxoid vaccine, inactivated 250 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 4 LFU/ML
tetanus toxoid vaccine, inactivated 4 UNT/ML [Tetamun]
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun]
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 1
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution [Tetamun] Box of 10
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution Box of 10
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun]
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension [Tetamun] Box of 10
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML
tetanus toxoid vaccine, inactivated 40 UNT/ML [Boostrix]
tetanus toxoid vaccine, inactivated 40 UNT/ML [Covaxis]
tetanus toxoid vaccine, inactivated 40 UNT/ML [Repevax]
tetanus toxoid vaccine, inactivated 40 UNT/ML [Revaxis]
tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated 40 UNT/ML [Td-Pur]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 20
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 25
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Boostrix] Box of 50
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Covaxis] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 20
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Repevax] Box of 5
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Revaxis] Box of 20
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Impfstoff Merieux] Box of 20
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur]
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension [Td-Pur] Box of 2
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 2
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 20
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 25
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 5
tetanus toxoid vaccine, inactivated 40 UNT/ML Injectable Suspension Box of 50
tetanus toxoid vaccine, inactivated 5.33 UNT/ML
tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 5.33 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 8 UNT/ML [Tetanol]
tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 8 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML [Infanrix]
tetanus toxoid vaccine, inactivated 80 UNT/ML [Pediacel]
tetanus toxoid vaccine, inactivated 80 UNT/ML [T Wellcovax]
tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetanol]
tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetanus-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated 80 UNT/ML [Tetasorbat]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [T Wellcovax] Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 2
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution [Tetanol] Box of 80
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 100
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 2
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 50
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution Box of 80
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Infanrix] Box of 25
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Pediacel] Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 2
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanol] Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetanus-Impfstoff Merieux] Box of 50
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat]
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension [Tetasorbat] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 2
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 25
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Suspension Box of 50
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol]
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe [Tetanol] Box of 20
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 1
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 10
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 100
tetanus toxoid vaccine, inactivated 80 UNT/ML Prefilled Syringe Box of 20
tetanus toxoid vaccine, inactivated Injectable Solution [Clostet]
tetanus toxoid vaccine, inactivated Injectable Solution [T Immun]
tetanus toxoid vaccine, inactivated Injectable Solution [T Medevax]
tetanus toxoid vaccine, inactivated Injectable Solution [T Vaccinol]
tetanus toxoid vaccine, inactivated Injectable Solution [T Wellcovax]
tetanus toxoid vaccine, inactivated Injectable Solution [Tet Aktiv]
tetanus toxoid vaccine, inactivated Injectable Solution [Tetabulin]
tetanus toxoid vaccine, inactivated Injectable Solution [Tetamun]
tetanus toxoid vaccine, inactivated Injectable Solution [Tetanol]
tetanus toxoid vaccine, inactivated Injectable Solution [Tetasorbat]
tetanus toxoid vaccine, inactivated Injectable Solution [Tetatoxoid]
tetanus toxoid vaccine, inactivated Injectable Suspension [Boostrix]
tetanus toxoid vaccine, inactivated Injectable Suspension [Clostet]
tetanus toxoid vaccine, inactivated Injectable Suspension [Covaxis]
tetanus toxoid vaccine, inactivated Injectable Suspension [Infanrix]
tetanus toxoid vaccine, inactivated Injectable Suspension [Pediacel]
tetanus toxoid vaccine, inactivated Injectable Suspension [Repevax]
tetanus toxoid vaccine, inactivated Injectable Suspension [Revaxis]
tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated Injectable Suspension [Td-Pur]
tetanus toxoid vaccine, inactivated Injectable Suspension [Tetamun]
tetanus toxoid vaccine, inactivated Injectable Suspension [Tetanol]
tetanus toxoid vaccine, inactivated Injectable Suspension [Tetanus-Impfstoff Merieux]
tetanus toxoid vaccine, inactivated Injectable Suspension [Tetasorbat]
tetanus toxoid vaccine, inactivated Injectable Suspension [Tetravac]
tetanus toxoid vaccine, inactivated Injectable Suspension [T-Immun Immuno]
tetanus toxoid vaccine, inactivated Prefilled Syringe [Clostet]
tetanus toxoid vaccine, inactivated Prefilled Syringe [Tetanol]
Diphtheria-Tetanus-Poliovirus-Influenza B vaccine
Diphtheria-Tetanus-Haemophilus b vaccine
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection
hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML
Meningococcal-Haemophilis B-Tetanus Vaccine
poliovirus vaccine inactivated, type 1 (Mahoney) and tetanus toxoid conjugate vaccine
hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML
tetanus toxoid vaccine, inactivated 150 UNT/ML Injectable Solution
hepatitis B virus subtype ADW2 HBsAg surface protein antigen
tetanus toxoid vaccine, inactivated 4 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 80 UNT/ML
tetanus toxoid vaccine, inactivated 80 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 150 UNT/ML
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis]
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel]
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax]
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5 by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] by Sanofi
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 10
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 20
0.5 ML acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 5
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix]
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25 by Glaxosmithkline
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] by Glaxosmithkline
0.5 ML acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension Box of 25
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix]
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10 by Glaxosmithkline
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20 by Glaxosmithkline
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25 by Glaxosmithkline
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50 by Glaxosmithkline
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] by Glaxosmithkline
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 10
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 20
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 25
0.5 ML Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 50
0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension
0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P]
0.5 ML Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P] by Lederle Products
2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution
2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin]
2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin] Box of 1
2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 1
2 ML acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 5
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injection
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Haemophilus B Conjugate Vaccine / Hepatitis B Surface Antigen Vaccine Injection [Infanrix Hexa]
acellular pertussis vaccine, inactivated 0.006 MG/ML [Covaxis]
acellular pertussis vaccine, inactivated 0.006 MG/ML [Pediacel]
acellular pertussis vaccine, inactivated 0.006 MG/ML [Repevax]
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis]
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Covaxis] Box of 10
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel]
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 10
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Pediacel] Box of 20
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax]
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 10
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 20
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension [Repevax] Box of 5
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 10
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 20
acellular pertussis vaccine, inactivated 0.006 MG/ML Injectable Suspension Box of 5
acellular pertussis vaccine, inactivated 0.008 MG
acellular pertussis vaccine, inactivated 0.016 MG/ML [Infanrix]
acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix]
acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension [Infanrix] Box of 25
acellular pertussis vaccine, inactivated 0.016 MG/ML Injectable Suspension Box of 25
acellular pertussis vaccine, inactivated 160 MG/ML
acellular pertussis vaccine, inactivated 160 MG/ML [Tussoglobin]
acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution
acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin]
acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution [Tussoglobin] Box of 1
acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 1
acellular pertussis vaccine, inactivated 160 MG/ML Injectable Solution Box of 5
acellular pertussis vaccine, inactivated Injectable Solution [Acel P Lederle]
acellular pertussis vaccine, inactivated Injectable Solution [Pac Merieux]
acellular pertussis vaccine, inactivated Injectable Solution [Tussoglobin]
acellular pertussis vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated Injectable Suspension [Covaxis]
acellular pertussis vaccine, inactivated Injectable Suspension [Infanrix]
acellular pertussis vaccine, inactivated Injectable Suspension [Pediacel]
acellular pertussis vaccine, inactivated Injectable Suspension [Repevax]
Bordetella Pertussis Filamentous Haemagglutinin Antigen
Bordetella Pertussis Fimbriae Serotype 2 And 3 Antigen
Pertussis Vaccine 0.016 MG/ML [Boostrix]
Pertussis Vaccine 0.016 MG/ML Injectable Suspension
Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix]
Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 10
Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 20
Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 25
Pertussis Vaccine 0.016 MG/ML Injectable Suspension [Boostrix] Box of 50
Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 10
Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 20
Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 25
Pertussis Vaccine 0.016 MG/ML Injectable Suspension Box of 50
Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension
Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension Box of 5
Pertussis Vaccine 15000000000 UNT/ML Injectable Suspension Box of 5 by Aventis
Pertussis Vaccine 600 UNT/ML Injectable Suspension
Pertussis Vaccine 600 UNT/ML Injectable Suspension [Acel-P]
Pertussis Vaccine Injectable Solution [Pa Vaccinol]
Pertussis Vaccine Injectable Solution [Pertuvac]
Pertussis Vaccine Injectable Suspension [Acel-P]
Pertussis Vaccine Injectable Suspension [Boostrix]
acellular pertussis vaccine, inactivated 0.006 MG/ML
acellular pertussis vaccine, inactivated 0.016 MG/ML
Diphtheria Toxoid-Pertussis-Haemophilus B-Hepatitis B vaccine
acellular pertussis vaccine, inactivated Injectable Solution
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide
influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y
Meningococcal Polysaccharide Vaccine, Groups A & C
Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y / tetanus toxoid vaccine, inactivated
meningococcal group C polysaccharide / tetanus toxoid vaccine, inactivated
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injectable Solution
meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injectable Solution
meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injection
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution
Haemophilus capsular oligosaccharide 0.015 MG/ML
diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Meningitec]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Menjugate]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML [ActHIB]
meningococcal group A polysaccharide 0.008 MG/ML / meningococcal group C polysaccharide 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML [Menactra]
meningococcal group B vaccine 0.3 MG/ML [Bexsero]
meningococcal group B vaccine 0.3 MG/ML [Boostrix]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Meningitec]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML [Menjugate]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [ActHIB]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Begrivac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Enzira]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Imuvac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Invivac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe [Mastaflu]
influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injectable Solution [Menitorix]
influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injection [Menitorix]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Intramuscular Solution [Menactra]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Prefilled Syringe [Mencevax Acwy]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection [AC Vax]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection [Mengivac A + C]
meningococcal group B vaccine Injectable Solution [Bexsero]
meningococcal group B vaccine Injectable Suspension [Bexsero]
meningococcal group B vaccine Injectable Suspension [Boostrix]
meningococcal group B vaccine Injectable Suspension [Trumenba]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Meningitec]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Menjugate]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Meningitec]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML
meningococcal group A polysaccharide 0.008 MG/ML
meningococcal group A polysaccharide 0.5 MG
meningococcal group A polysaccharide 2.5 MG
meningococcal group C polysaccharide 0.008 MG/ML
meningococcal group C polysaccharide 0.5 MG
meningococcal group C polysaccharide 2.5 MG
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG
MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.25 MG/ML
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG/ML
Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.004 MG/ML
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.005 MG
Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.05 MG
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Prefilled Syringe
influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injectable Solution
influenza B virus antigen, Hong Kong 330-2001 / meningococcal group C polysaccharide Injection
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Intramuscular Solution
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Prefilled Syringe
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injection
meningococcal group B vaccine Injectable Solution
meningococcal group B vaccine Injectable Suspension
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injectable Suspension
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection
Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB]
meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero]
meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate]
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec]
diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Meningitec]
diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Menjugate]
Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide Injectable Solution [Menitorix]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Begrivac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Enzira]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Imuvac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Invivac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine Injectable Solution [Mastaflu]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [ACWY Vax]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Menactra]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Mencevax Acwy]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injectable Solution [Menquadfi]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Menveo]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injectable Solution [Nimenrix]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [ACWY Vax]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [Menveo]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y Injection [Nimenrix]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [AC Vax]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Mengivac A + C]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Mengivac]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe
meningococcal group A polysaccharide 0.008 MG/ML / meningococcal group C polysaccharide 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.008 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.008 MG/ML Intramuscular Solution
meningococcal group B vaccine 0.3 MG/ML Injectable Suspension
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.01 MG Injection
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection
diphtheria toxoid vaccine, inactivated / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine Injectable Suspension
Haemophilus B Conjugate Vaccine / meningococcal group C polysaccharide Injectable Solution
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB]
0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero]
0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix]
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec]
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec]
0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate]
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe
0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection
0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate]
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 10
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec] Box of 10
diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG Injectable Solution
meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG Injectable Solution
meningococcal group A polysaccharide 2.5 MG / meningococcal group C polysaccharide 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG Injectable Solution
Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 10
Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection Box of 10
0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Bexsero] by GSK
0.5 ML meningococcal group B vaccine 0.3 MG/ML Injectable Suspension [Boostrix] by GSK
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 10
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection [Meningitec] Box of 10
0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec]
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate]
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe Box of 1
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 10
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injection Box of 10
0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension
0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.1 MG/ML / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.1 MG/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] by Nuron Biotech
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] by Glaxosmithkline
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine 0.02 MG/ML Prefilled Syringe [ActHIB] Box of 1 by Sanofi
0.5 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Meningitec] Box of 1 by Nuron Biotech
0.6 ML Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML Injectable Suspension [Menjugate] Box of 1 by Glaxosmithkline
meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 0.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 0.5 MG Injectable Solution by Sanofi
meningococcal group A polysaccharide 0.5 MG / meningococcal group C polysaccharide 0.5 MG Injectable Solution by Aventis
meningococcal group A polysaccharide 2.5 MG / meningococcal group C polysaccharide 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP W-135 2.5 MG / MENINGOCOCCAL POLYSACCHARIDE VACCINE GROUP Y 2.5 MG Injectable Solution by Aventis
0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution
0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi]
0.5 ML poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi] by Statens Serum Institut
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension [Polio Sabin-S]
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol]
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol] Box of 10
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution Box of 10
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10 by Saudi
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection by Saudi
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5 by Sanofi
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / Pertussis Vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Adacel]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Boostrix]
acellular pertussis vaccine, inactivated / Bordetella pertussis / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) Injection [Quadracel]
Poliomyelitis Virus Type 1 (Sabin Strain (Ls-C, 2ab)) Live Attenuated Oral Vaccine
Poliomyelitis Virus Type 1 (Sabin Strain (Ls-C, 2ab)) Live Attenuated Oral Vaccine 1000000 UNT
poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Solution
poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Solution [Poliovaccine Ssi]
poliomyelitis virus type 1 brunhilde 80 UNT/ML
poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML [Poliovaccine Ssi]
poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution
poliomyelitis virus type 1 brunhilde 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution [Poliovaccine Ssi]
Poliomyelitis Virus Type 2 (Sabin Strain (P712, Ch, 2ab)) Live Attenuated Oral Vaccine
Poliomyelitis Virus Type 2 (Sabin Strain (P712, Ch, 2ab)) Live Attenuated Oral Vaccine 100000 UNT
Poliomyelitis Virus Type 3 (Sabin Strain (Leon 12a1b)) Live Attenuated Oral Vaccine
Poliomyelitis Virus Type 3 (Sabin Strain (Leon 12a1b)) Live Attenuated Oral Vaccine 600000 UNT
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injection
poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS
poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS [Polio Sabin-Rit Multi]
poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS Injectable Suspension
poliovirus vaccine inactivated, type 1 (Mahoney) 1000000 CELLS / poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS / poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS Injectable Suspension [Polio Sabin-Rit Multi]
poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML
poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML [Polio Sabin-S]
poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension
poliovirus vaccine inactivated, type 1 (Mahoney) 2000000 CELLS/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML / poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML Injectable Suspension [Polio Sabin-S]
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML [Ipol]
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol]
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution [Ipol] Box of 10
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injectable Solution Box of 10
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML Injection Box of 10
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Solution Box of 5
poliovirus vaccine inactivated, type 2 (MEF-1) 100000 CELLS
poliovirus vaccine inactivated, type 2 (MEF-1) 200000 CELLS/ML
poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML
poliovirus vaccine inactivated, type 3 (Saukett) 300000 CELLS
poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML
poliovirus vaccine inactivated, type 3 (Saukett) 600000 CELLS/ML
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett)
poliomyelitis virus type 1 brunhilde / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett)
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Priorix-Tetra]
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension Box of 1
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix]
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra]
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 10
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 100
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 20
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 25
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 40
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 50
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1 by Sanofi
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix]
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20 by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] by Glaxosmithkline
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 10
0.5 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 20
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix]
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1 by Glaxosmithkline
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe Box of 1
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix]
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1 by Glaxosmithkline
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe Box of 1
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10 by Merck
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix]
0.5 ML MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix] by Glaxosmithkline
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix]
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100 by Glaxosmithkline
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] by Glaxosmithkline
1 ML Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution Box of 100
Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution
Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix]
Measles Vaccine / Mumps Vaccine / Rubella virus vaccine / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [ProQuad]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [M-M-R II]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [M-M-RVAXPRO]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injectable Solution [Priorix]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [M-M-R II]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [M-M-RVAXPRO]
Measles Vaccine / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella virus vaccine Injection [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Vaccine / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Vaccine / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [M-M-R II]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [M-M-RVAXPRO]
measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension [M-M-RVAXPRO]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML [Priorix-Tetra]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Priorix-Tetra]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Injectable Suspension Box of 1
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML [Mmr Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML [Priorix-Tetra]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 10
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 100
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 20
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 25
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Mmr Priorix] Box of 40
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 10
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 100
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 20
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution [Priorix-Tetra] Box of 50
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 10
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 100
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 20
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 25
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 40
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML Injectable Solution Box of 50
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Injectable Suspension Box of 1
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 10
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution [Priorix] Box of 20
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 10
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 TCID/ML Injectable Solution Box of 20
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 6 CELLS/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution [Priorix] Box of 100
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 700 PFU/ML Injectable Solution Box of 100
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution
measles virus vaccine live, Enders' attenuated Edmonston strain Injectable Solution [Attenuvax]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Mmr Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain Injectable Solution [Priorix-Tetra]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection [M-M-R II]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus Injection [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine / Varicella Virus Vaccine Live (Oka-Merck) strain Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine / Varicella Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Solution [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Suspension
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Injectable Suspension [M.M.R. VaxPro]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Prefilled Syringe
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps virus / Rubella virus vaccine Prefilled Syringe [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Priorix-Tetra]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Prefilled Syringe
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Mumps Virus Vaccine Live, Jeryl Lynn Strain / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Prefilled Syringe [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID [M-M-R II]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID Injection [M-M-R II]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT [M.M.R. VaxPro]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension [M.M.R. VaxPro]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT Injectable Suspension [M.M.R. VaxPro] by MSD
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT [Priorix-Tetra]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution [Priorix-Tetra]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT Injectable Solution [Priorix-Tetra] by GSK
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT Injectable Solution [Priorix] by GSK
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT Injection
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT Injection [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe [Priorix] Box of 1
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML Prefilled Syringe Box of 1
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe [Priorix] Box of 1
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML Prefilled Syringe Box of 1
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution Box of 10
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML [Priorix]
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution [Priorix]
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Vaccine 35000 PFU/ML / Rubella virus 1400 PFU/ML / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 17500 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML
Measles Virus Vaccine Live, Enders' attenuated Edmonston strain 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 25000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 TCID / Mumps virus 12500 TCID / Rubella virus 1000 TCID
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 12500 UNT / Rubella virus vaccine 1000 UNT
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus 1000 UNT / Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT / Varicella Virus Vaccine Live (Oka-Merck) strain 1000 UNT
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 25100 UNT / Rubella virus vaccine 1000 UNT
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1000 UNT / Mumps virus 5000 UNT / Rubella virus 1000 UNT
MEASLES VIRUS VACCINE,LIVE ATTENUATED 1400 PFU/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 7000 PFU/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1400 PFU/ML
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 /ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 /ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 /ML
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML
MEASLES VIRUS VACCINE,LIVE ATTENUATED 2000 UNT/ML / Mumps Virus Vaccine Live, Jeryl Lynn Strain 20000 UNT/ML / Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML
rabies virus vaccine flury-lep strain 2.5 UNT [RabAvert]
rabies virus vaccine flury-lep strain 2.5 UNT/ML [Rabipur]
rabies virus vaccine flury-lep strain 2.5 UNT/ML [Rabivac]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT [Imovax]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [Tollwut-Impfstoff]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML [VACCIN RABIQUE INACTIVE MERIEUX]
rabies virus vaccine flury-lep strain Injectable Solution [Rabipur]
rabies virus vaccine flury-lep strain Injectable Solution [Rabivac]
rabies virus vaccine flury-lep strain Injectable Solution [Verorab]
rabies virus vaccine flury-lep strain Injectable Suspension [Rabipur]
rabies virus vaccine flury-lep strain Prefilled Syringe [Rabipur]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Suspension [Tollwut-Impfstoff]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX]
rabies virus vaccine flury-lep strain 2.5 UNT
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT
rabies virus vaccine flury-lep strain Injectable Solution
rabies virus vaccine flury-lep strain Injectable Suspension
rabies virus vaccine flury-lep strain Prefilled Syringe
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Solution
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Injectable Suspension
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated Prefilled Syringe
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur]
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac]
rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX]
rabies virus vaccine flury-lep strain Injection [Rabipur]
rabies virus vaccine flury-lep strain Injection [Verorab]
rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution
rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injectable Solution
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Solution
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur]
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac]
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur]
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff]
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX]
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe
rabies virus vaccine flury-lep strain 2.5 UNT Injection [RabAvert]
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection [Imovax]
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5
rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1
rabies virus vaccine flury-lep strain 2.5 UNT Injection
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection
rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution Box of 1
rabies virus vaccine flury-lep strain 2.5 UNT Injectable Solution Box of 5
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 5
rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] by Novartis
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] by Novartis
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Suspension [Tollwut-Impfstoff] by Sanofi
1 ML rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Prefilled Syringe [VACCIN RABIQUE INACTIVE MERIEUX] by Sanofi
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT/ML Injectable Solution by Aventis
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 5
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe Box of 1
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Boehringer Ingelheim
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Emra-Med
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Eurim-Pharm
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Kohlpharma
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Novartis
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 1 by Orifarm Leverkus
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabipur] Box of 5 by Boehringer Ingelheim
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1 by Boehringer Ingelheim
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 1 by Novartis
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution [Rabivac] Box of 5 by Boehringer Ingelheim
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injectable Solution Box of 1 by Sanofi
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Prefilled Syringe [Rabipur] Box of 1 by Glaxosmithkline
rabies virus vaccine flury-lep strain 2.5 UNT Injection [RabAvert] by Glaxosmithkline
rabies virus vaccine wistar strain PM-1503-3M (Human), Inactivated 2.5 UNT Injection [Imovax] by Sanofi
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML
Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG/ML
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0022 MG/ML
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML [Pneumovax 23]
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML [Pnu-Imune]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumopur]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumovax 23]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumopur]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumovax 23]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Pnu-Imune]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Prevnar]
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution [Synflorix]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Moniarix]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumopur]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumorix]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Pnu-Imune]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Prevnar]
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe [Synflorix]
pneumococcal capsular polysaccharide type 1 vaccine 0.001 MG
pneumococcal capsular polysaccharide type 1 vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML
pneumococcal capsular polysaccharide type 14 vaccine 0.001 MG
pneumococcal capsular polysaccharide type 14 vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 18C vaccine 0.004 MG
pneumococcal capsular polysaccharide type 18C vaccine 0.006 MG/ML
pneumococcal capsular polysaccharide type 19F vaccine 0.004 MG
pneumococcal capsular polysaccharide type 19F vaccine 0.006 MG/ML
pneumococcal capsular polysaccharide type 23F vaccine 0.001 MG
pneumococcal capsular polysaccharide type 23F vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 4 vaccine 0.004 MG
pneumococcal capsular polysaccharide type 4 vaccine 0.006 MG/ML
pneumococcal capsular polysaccharide type 5 vaccine 0.001 MG
pneumococcal capsular polysaccharide type 5 vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 6B vaccine 0.001 MG
pneumococcal capsular polysaccharide type 6B vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 7F vaccine 0.001 MG
pneumococcal capsular polysaccharide type 7F vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 9V vaccine 0.001 MG
pneumococcal capsular polysaccharide type 9V vaccine 0.002 MG/ML
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23]
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur]
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II]
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 20
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 20
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pneumovax 23] by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution [Pnu-Imune] by Lederle Products
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumopur] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumopur] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Axicorp
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Cc
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Eurim-Pharm
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Gerke
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Kohlpharma
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 1 by Orifarm Leverkus
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Abacus Medicine
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Axicorp
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Cc
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Gerke
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 10 by Kohlpharma
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Cc
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Gerke
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax 23] Box of 20 by Kohlpharma
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Novartis
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 1 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Eurim-Pharm
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Orifarm Leverkus
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 10 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Axicorp
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Eurim-Pharm
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Orifarm Leverkus
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution [Pneumovax II] Box of 20 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 1 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 10 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Merck
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe [Pneumovax II] Box of 20 by Sanofi
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 0.05 MG/ML Injectable Solution
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 1
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 10
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 20
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1 by European
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10 by European
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by Emra-Med
0.5 ML pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20 by European
pneumococcal capsular polysaccharide type 1 vaccine Injectable Solution
pneumococcal capsular polysaccharide type 1 vaccine Prefilled Syringe
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Injectable Solution Box of 20
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 1
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 10
pneumococcal capsular polysaccharide type 1 vaccine 1.15 MG/ML Prefilled Syringe Box of 20
pneumococcal capsular polysaccharide type 1 vaccine Injectable Product
0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension
0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax]
0.5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax] by Emergent Sales And Marketing
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro]
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1 by Valneva
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] by Valneva
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension Box of 1
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection
0.5 ML Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection [Jespect]
0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension
0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro]
0.5 ML Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro] by Eco.Pharma.Supply
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix]
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 10
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 20
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 10
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 20
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix]
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1 by Glaxosmithkline
0.5 ML L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension Box of 1
0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution
0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax]
0.5 ML Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax] by Merck
0.5 ML Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution
0.5 ML Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 2000 UNT/ML Injectable Solution by Aventis
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI]
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution Box of 1
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix]
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix] Box of 10
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI]
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI] Box of 10
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection Box of 10
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix]
0.5 ML Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix] by GSK
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril]
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1 by Sanofi
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10 by Sanofi
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 1
0.5 ML Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 10
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix]
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension Box of 1
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix]
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline
1.5 ML Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension Box of 1
5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension
5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax]
5 ML Anthrax Vaccine Adsorbed 0.1 MG/ML Injectable Suspension [Biothrax] by Emergent Sales And Marketing
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.0075 MG/ML
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.00752 MG/ML
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.015 MG/ML
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML
Bacillus anthracis Injectable Suspension
Bacillus anthracis Injectable Suspension [Biothrax]
Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 2210000 UNT
Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 770000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G1 Vaccine 772000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 2840000 UNT
Human-Bovine Reassortant Rotavirus Strain G2 Vaccine 980000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 2220000 UNT
Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 770000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G3 Vaccine 772000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 2040000 UNT
Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 698000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain G4 Vaccine 700000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 2290000 UNT
Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 805000 PFU/ML
Human-Bovine Reassortant Rotavirus Strain P1A[8] Vaccine 807000 PFU/ML
Japanese encephalitis virus Injectable Solution
Japanese encephalitis virus Injectable Suspension
Japanese encephalitis virus Injectable Suspension [Ixiaro]
Japanese encephalitis virus Injection [Imojev]
Japanese encephalitis virus Injection [Ixiaro]
Japanese encephalitis virus Prefilled Syringe
Japanese encephalitis virus Prefilled Syringe [Ixiaro]
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML [Jespect]
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro]
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension [Ixiaro] Box of 1
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injectable Suspension Box of 1
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML Injection [Jespect]
Japanese encephalitis virus vaccine, inactivated 1 UNT
Japanese encephalitis virus vaccine, inactivated 1 UNT [Je-Vax]
Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension
Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension [Je-Vax]
Japanese encephalitis virus vaccine, inactivated 1 UNT Injectable Suspension [Je-Vax] by The Res.Found.For Microb.Dis.Osaka University
Japanese encephalitis virus vaccine, inactivated 12 BAU/ML
Japanese encephalitis virus vaccine, inactivated 12 BAU/ML [Ixiaro]
Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension
Japanese encephalitis virus vaccine, inactivated 12 BAU/ML Injectable Suspension [Ixiaro]
Japanese encephalitis virus vaccine, inactivated Injectable Solution
Japanese encephalitis virus vaccine, inactivated Injectable Solution [Ixiaro]
Japanese encephalitis virus vaccine, inactivated Injectable Solution [Japanese encephalitis GCVC]
Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Ixiaro]
Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Japanese encephalitis GCVC]
Japanese encephalitis virus vaccine, inactivated Injection
Japanese encephalitis virus vaccine, inactivated Injection [Jespect]
Japanese encephalitis virus vaccine, inactivated Injection [Je-Vax]
Japanese encephalitis virus vaccine, inactivated Prefilled Syringe [Japanese encephalitis GCVC]
L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injectable Suspension
L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Injectable Suspension [Gardasil]
L1 protein, Human papillomavirus type 11 Vaccine / L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine / L1 protein, Human papillomavirus type 6 Vaccine Prefilled Syringe [Silgard]
L1 protein, Human papillomavirus type 11 Vaccine 0.04 MG/ML
L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Injection
L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Injection [Cervarix]
L1 protein, Human papillomavirus type 16 Vaccine / L1 protein, Human papillomavirus type 18 Vaccine Prefilled Syringe [Cervarix Grk]
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML [Cervarix]
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix]
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 10
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection [Cervarix] Box of 20
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 10
L1 protein, Human papillomavirus type 16 Vaccine 0.02 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML Injection Box of 20
L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix] Box of 1
L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension Box of 1
L1 protein, Human papillomavirus type 18 Vaccine 0.02 MG/ML
L1 protein, Human papillomavirus type 6 Vaccine 0.02 MG/ML
Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML
Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML [Mumpsvax]
Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution
Mumps Virus Vaccine Live, Jeryl Lynn Strain 10000 UNT/ML Injectable Solution [Mumpsvax]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG [Rotarix]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension [Rotarix]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000 MG Oral Suspension [Rotarix] by Glaxosmithkline
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix] Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 1000000 Powder for Oral Suspension Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension [Rotarix] Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 467000 PFU/ML Oral Suspension Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension [Rotarix] Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 667000 /ML Oral Suspension Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix]
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix] Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension [Rotarix] Box of 1 by Glaxosmithkline
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain 700000 PFU Powder for Oral Suspension Box of 1
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain Powder for Oral Suspension
Rotavirus Vaccine, Live Attenuated, G1P[8] Human 89-12 strain Powder for Oral Suspension [Rotarix]
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID [RUDIVAX]
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX]
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX] Box of 1
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension [RUDIVAX] Box of 1 by Sanofi
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 TCID Injectable Suspension Box of 1
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT Injectable Solution
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) 1000 UNT Injectable Solution by Iaf Biovac
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution [Ervevax]
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Suspension [RUDIVAX]
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection
Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injection [Ervevax]
Salmonella Typhi Inactivated Antigen 0.025 MG/ML
Salmonella Typhi Inactivated Antigen 0.05 MG/ML
Salmonella Typhi Inactivated Antigen 0.05 MG/ML [Typherix]
Salmonella Typhi Inactivated Antigen 0.05 MG/ML [Typhim VI]
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI]
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injectable Solution Box of 1
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix]
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typherix] Box of 10
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI]
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection [Typhim VI] Box of 10
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Injection Box of 10
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution
Salmonella Typhi Inactivated Antigen 0.05 MG/ML Intramuscular Solution [Typherix]
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS [Vivotif Berna]
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna]
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna] Box of 3
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule [Vivotif Berna] Box of 3 by Paxvax Berna
Salmonella Typhi Inactivated Antigen 2000000000 ORGANISMS Delayed Release Oral Capsule Box of 3
Salmonella Typhi Inactivated Antigen 8 X
Salmonella Typhi Inactivated Antigen 8 X Oral Tablet
Salmonella Typhi Inactivated Antigen 8 X Oral Tablet Box of 1
Salmonella Typhi Inactivated Antigen 8 X Oral Tablet Box of 1 by Staufen
Salmonella Typhi Inactivated Antigen Delayed Release Oral Capsule
Salmonella Typhi Inactivated Antigen Delayed Release Oral Capsule [Vivotif Berna]
Salmonella Typhi Inactivated Antigen Injectable Solution
Salmonella Typhi Inactivated Antigen Injectable Solution [Typhim VI]
Salmonella Typhi Inactivated Antigen Injection
Salmonella Typhi Inactivated Antigen Injection [Typherix]
Salmonella Typhi Inactivated Antigen Injection [Typhim VI]
Salmonella Typhi Inactivated Antigen Intramuscular Solution
Salmonella Typhi Inactivated Antigen Intramuscular Solution [Typherix]
Salmonella Typhi Inactivated Antigen Oral Tablet
Tick-borne encephalitis virus inactivated
Tick-borne encephalitis virus inactivated Injectable Suspension
Tick-borne encephalitis virus inactivated Injectable Suspension [Fsme Immun]
Tick-borne encephalitis virus inactivated Injectable Suspension [Ticovac]
Vaccine, Typh.-Paratyph.A & B Injectable Solution
Vaccine, Typh.-Paratyph.A & B Injectable Solution [Tab Impfstoff]
yellow fever virus strain 17D-204 live antigen Injectable Suspension [Arilvax]
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril]
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 1
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension [Stamaril] Box of 10
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 1
Yellow-Fever Virus Vaccine, 17D-204 strain 2000 UNT/ML Injectable Suspension Box of 10
Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Suspension [Stamaril]
A/Hong Kong/4801/2014 (H3n2) - Like Virus
A/Hong Kong/4801/2014 (H3n2) - Like Virus vaccine
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML
acellular pertussis vaccine, inactivated 0.006 MG/ML / Bordetella pertussis 0.025 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
acellular pertussis vaccine, inactivated 0.008 MG / Bordetella pertussis 0.05 MG / diphtheria toxoid vaccine, inactivated 30 UNT / tetanus toxoid vaccine, inactivated 40 UNT
acellular pertussis vaccine, inactivated 0.01 MG/ML / Bordetella pertussis 0.008 MG/ML / diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML
acellular pertussis vaccine, inactivated 0.013 MG/ML / Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
acellular pertussis vaccine, inactivated 0.016 MG/ML / Bordetella pertussis 0.1 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML
acellular pertussis vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
acellular pertussis vaccine, inactivated 0.0936 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 60 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 80 UNT/ML
Haemophilus capsular oligosaccharide 0.03 MG/ML
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 30 LFU/ML / Pertussis Vaccine 0.0468 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML
Bordetella pertussis 0.01 MG/ML / diphtheria toxoid vaccine, inactivated 4 LFU/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML
Bordetella pertussis 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / pertactin adsorbed 0.005 MG/ML / Pertussis Vaccine 0.016 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Solution
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe
diphtheria toxoid vaccine, inactivated 0.03 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML
diphtheria toxoid vaccine, inactivated 2 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML
diphtheria toxoid vaccine, inactivated 25 LFU/ML / Pertussis Vaccine 8 UNT/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Human poliovirus 160 BAU/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
diphtheria toxoid vaccine, inactivated 4 UNT/ML / Pertussis Vaccine 0.021 MG/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 40 UNT/ML
diphtheria toxoid vaccine, inactivated Injectable Solution
Human Papillomavirus 16/18 L1 virus vaccine
Human Papillomavirus 6/11/16/18 L1 virus vaccine
Japanese encephalitis virus vaccine, inactivated 0.012 MG/ML
Japanese encephalitis virus vaccine, inactivated Injectable Suspension
Japanese encephalitis virus vaccine, inactivated Prefilled Syringe
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe
L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Prefilled Syringe
L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension
L1 protein, Human papillomavirus type 16 Vaccine 0.04 MG/ML / L1 protein, Human papillomavirus type 18 Vaccine 0.04 MG/ML Injectable Suspension [Cervarix]
rabies virus vaccine flury-lep strain Injection
rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution
yellow fever virus strain 17D-204 live antigen Injectable Suspension
Yellow-Fever Virus Vaccine, 17D-204 strain Injectable Suspension
influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML
yellow fever virus strain 17D-204 live antigen 2000 UNT/ML [Stamaril]
influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML
influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML
influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML
influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML
influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML
influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML
influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML
hepatitis A virus strain CR 326F antigen, inactivated
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML [Vaqta]
influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML
influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML
influenza A virus (H3N2) antigen 0.03 MG/ML
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML
influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML
influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML
influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML
influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML
influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML
influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML
influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML
influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML
influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML
influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML
influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML
influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML
influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML
hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML [Prehevbrio]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML
influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML
influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML
influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML
influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML
influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML
influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML
influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML
influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML
influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML
influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML
influenza A virus A/Brisbane/02/2018 (H1N1) antigen
influenza A virus A/Darwin/6/2021 (H3N2) antigen
influenza A virus A/Darwin/9/2021 (H3N2) antigen
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen
influenza A virus A/Kansas/14/2017 (H3N2) antigen
influenza A virus A/Sydney/5/2021 (H1N1) antigen
influenza A virus A/Tasmania/503/2020 (H3N2) antigen
influenza A virus A/Victoria/2570/2019 (H1N1) antigen
influenza B virus B/Austria/1359417/2021 antigen
influenza B virus B/Michigan/01/2021 antigen
influenza B virus B/Washington/02/2019 antigen
0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2016-2017 (quadrivalent - California/Hong Kong/Brisbane/Phuket) 0.1 ML Prefilled Syringe
0.1 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
0.1 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (quadrivalent - Hong Kong/Michigan/Brisbane/Phuket) 0.1 ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2014-2015 trivalent intradermal 0.1 ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula]
Fluzone Intradermal 2013-2014 Formula Influenza Virus Vaccine 0.1 ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula]
Fluzone Intradermal 2014-2015 Formula Influenza Virus Vaccine 0.1 ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.09 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML 0.1 ML Prefilled Syringe
0.1 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula]
Fluzone Intradermal 2012-2013 Formula Influenza Virus Vaccine 0.1 ML Prefilled Syringe
0.1 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe
0.1 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
Fluzone Intradermal 2011-2012 Formula Influenza Virus Vaccine 0.1 ML Prefilled Syringe
0.25 ML influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 (quadrivalent - Brisbane/Kansas/Maryland/Phuket) 0.25 mL Prefilled Syringe
0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2019-2020 vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020]
0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020]
Afluria Quadrivalent 2019-2020 vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere]
Fluzone Quadrivalent 2020 Southern Hemisphere vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere]
Fluzone Quadrivalent 2016 Southern Hemisphere vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2021-2022 (quadrivalent Cambodia/Victoria/Phuket/Victoria) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
0.25 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022]
Afluria Quadrivalent 2021-2022 vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2020-2021 (quadrivalent - Guangdong-Maonan/Hong Kong/Phuket/Washington) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
Fluzone Quadrivalent 2020-2021 vaccine 0.25 ML Prefilled Syringe
influenza virus vaccine 2020-2021 (quadrivalent - Hong Kong/Victoria/Phuket/Victoria) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
afluria Quadrivalent 2020-2021 vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021]
0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2021 (quadrivalent - Hong Kong/Victoria/Phuket/Washington) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere]
Fluzone Quadrivalent 2021 Southern Hemisphere vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (quadrivalent - Hong Kong/Michigan/Brisbane/Phuket) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (quadrivalent - Michigan/Singapore/Maryland/Phuket) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
Fluzone Quadrivalent 2021-2022 vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2021-2022 (quadrivalent - Phuket/Tasmania/Victoria/Washington) 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2014-2015 pediatric quadrivalent 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2013-2014 trivalent 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula]
Fluzone 2013-2014 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula]
Fluzone Quadrivalent Pediatric 2014-2015 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML 0.25 ML Prefilled Syringe
0.25 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula]
Fluzone Pediatric 2012-2013 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe
0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula]
Fluzone 2010-2011 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
0.25 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
Fluzone Pediatric 2011-2012 Formula Influenza Virus Vaccine 0.25 ML Prefilled Syringe
acellular pertussis vaccine 0.058 MG / diphtheria toxoid vaccine 25 UNT / hepatitis B surface antigen vaccine 0.01 MG / poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT / tetanus toxoid vaccine 10 UNT per 0.5 ML Prefilled Syringe
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
acellular pertussis vaccine 0.058 MG / diphtheria toxoid vaccine 25 UNT / poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT / tetanus toxoid vaccine 10 UNT per 0.5 ML Prefilled Syringe
0.5 ML acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus (mIPV) and Haemophilus influenzae type b conjugate vaccine (DTaP-IPV/Hib) 0.5 ML Injection
0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
DTaP-IPV/Hib (diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus (vIPV) and Haemophilus b conjugate (tetanus toxoid conjugate)) 0.5 ML Injection
0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
Pentacel DTaP-IPV/Hib (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus (vIPV) and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)) 0.5 ML Injection
0.5 ML acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel]
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (generic for Adacel) 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 5 MCG / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 5 MCG / Bordetella pertussis pertactin vaccine, inactivated 3 MCG / Bordetella pertussis toxoid vaccine, inactivated 2.5 MCG / diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 5 UNT per 0.5 ML Prefilled Syringe
Tdap (tetanus toxoid vaccine, inactivated 5 UNT / diphtheria toxoid vaccine, inactivated 2 UNT / acellular pertussis vaccine, inactivated 15.5 MCG) per 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP generic for Daptacel) 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
DTaP (diphtheria toxoid vaccine, inactivated 15 UNT / tetanus toxoid vaccine, inactivated 5 UNT / acellular pertussis vaccine, inactivated 23 MCG) per 0.5 ML Injection
Tdap (tetanus toxoid vaccine, inactivated 5 UNT / diphtheria toxoid vaccine, inactivated 2.5 UNT / acellular pertussis vaccine, inactivated 18.5 MCG) per 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Tdap (tetanus toxoid vaccine, inactivated 5 UNT / diphtheria toxoid vaccine, inactivated 2.5 UNT / acellular pertussis vaccine, inactivated 18.5 MCG) per 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 8 MCG / Bordetella pertussis pertactin vaccine, inactivated 2.5 MCG / Bordetella pertussis toxoid vaccine, inactivated 8 MCG / diphtheria toxoid vaccine, inactivated 2.5 UNT / tetanus toxoid vaccine 5 UNT per 0.5 ML Injection
diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus (mIPV) vaccine (DTaP-IPV generic for Quadracel) 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Vaxelis]
Vaxelis (Diphtheria and Tetanus Toxoids and Acelluar Pertussis Absorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine) 0.5 ML Injection
DTap-IPV-Hib-HepB 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Vaxelis]
diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus (vIPV) vaccine (DTaP-IPV generic for Quadracel) 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Quadracel (with vIPV) vaccine 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel]
diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus (vIPV) vaccine (DTaP-IPV generic for Quadracel) 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Quadracel (with vIPV) vaccine 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Quadracel]
diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine (DTaP-IPV generic for Kinrix) 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP generic for Infanrix) 0.5 ML Prefilled Syringe
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
DTaP (diphtheria toxoid vaccine, inactivated 25 UNT / tetanus toxoid vaccine, inactivated 10 UNT / acellular pertussis vaccine, inactivated 58 MCG) per 0.5 ML Injection
0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 2 UNT / tetanus toxoid vaccine, inactivated 5 UNT per 0.5 ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
diphtheria toxoid vaccine 2 UNT / tetanus toxoid vaccine 5 UNT per 0.5 ML Prefilled Syringe
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Decavac]
Decavac, Tetanus and Diphtheria Toxoids Adsorbed Prefilled Syringe
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection
tetanus toxoid vaccine, inactivated 2 UNT / diphtheria toxoid vaccine, inactivated 2 UNT per 0.5 ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection [Tdvax]
Tdvax (tetanus toxoid vaccine, inactivated 2 UNT / diphtheria toxoid vaccine, inactivated 2 UNT) per 0.5 ML Injection
0.5 ML diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
diphtheria toxoid vaccine 25 UNT/ML / tetanus toxoid vaccine 5 UNT per 0.5 ML Injection
0.5 ML Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection
Haemophilus influenzae type b conjugate (meningococcal protein conjugate) 7.5 MCG vaccine / hepatitis B surface antigen recombinant vaccine 5 MCG per 0.5 ML Injection
0.5 ML Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection
meningococcal groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine 0.5 ML Injection
0.5 ML Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection
Haemophilus influenzae type b strain 20,752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 35 MCG per 0.5 ML Injection
0.5 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 720 UNT per 0.5 ML Prefilled Syringe
0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection
hepatitis A virus strain CR 326F antigen, inactivated 25 UNT per 0.5 ML Injection
0.5 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe
hepatitis A virus strain CR 326F antigen, inactivated 25 UNT per 0.5 ML Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe [Recombivax]
Recombivax HB, hepatitis B vaccine (recombinant) 0.5 ML Prefilled Syringe
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection
hepatitis B vaccine (recombinant) pediatric/adolescent 20 MCG in 0.5 ML Injection
0.5 ML human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.02 MG / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.02 MG per 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2019-2020]
Fluzone Quadrivalent 2019-2020 vaccine 0.5 ML Injection
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 (quadrivalent - Brisbane/Kansas/Maryland/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2019-2020]
Fluarix Quadrivalent 2019-2020 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020]
Fluzone Quadrivalent 2019-2020 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2019-2020]
Flulaval Quadrivalent 2019-2020 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020]
Afluria Quadrivalent 2019-2020 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 (generic for Fluad- Brisbane/Kansas/Maryland) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2019-2020]
Fluad 2019-2020 vaccine 0.5 mL Injection
influenza virus vaccine 2020 (quadrivalent - Brisbane/South Australia/Phuket/Washington) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2020 Southern Hemisphere vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere]
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 (quadrivalent generic for Flublok - Brisbane/Kansas/Maryland/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2019-2020]
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 high-dose (trivalent - Brisbane/Kansas/Maryland) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2019-2020]
Fluzone 2019-2020 high-dose vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2016-2017 (quadrivalent - Brisbane/Hong Kong/Utah/Hong Kong) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe
influenza virus vaccine 2015-2016 (trivalent - California/Switzerland/Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2016-2017 (quadrivalent - California/Hong Kong/Brisbane/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere]
Fluzone Quadrivalent 2016 Southern Hemisphere vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza virus vaccine 2016-2017 (quadrivalent - California/Hong Kong/Brisbane/Phuket) 0.5 ML Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2015-2016 (trivalent - California/South Australia/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [FluLaval Quadrivalent 2015-2016]
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection
influenza virus vaccine 2016-2017 (trivalent - California/Hong Kong/Brisbane) 0.5 ML Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe
influenza virus vaccine 2016-2017 high-dose (trivalent - California/Hong Kong/Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe
Fluad Quadrivalent 2021-2022 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent Cambodia/Victoria/Phuket/Victoria) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
Afluria Quadrivalent 2021-2022 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022]
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2015-2016 (trivalent - Christchurch/Hong Kong/Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Delaware/Singapore INFTT-16-0610/Singapore WUH4618) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe
Flucevax Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2022-2023]
Flucelvax Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
influenza virus vaccine 2022-2023 (quadrivalent - Austria/Darwin-6/Phuket/Victoria) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
Fluarix Quadrivalent 2022-2023 vaccine 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2022-2023]
Fluad Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2022-2023]
Afluria Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2022-2023]
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Wisconsin/Austria/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
Flublok Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2022-2023]
influenza virus vaccine 2023 (quadrivalent - Darwin/Sydney/Michigan/Phuket) 0.5 ML Prefilled Syringe, southern hemisphere
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2023 Southern Hemisphere vaccine 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza virus vaccine 2022-2023 (quadrivalent - Austria/Darwin-9/Phuket/Victoria) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
Flulaval Quadrivalent 2022-2023 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2022-2023]
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Michigan/Phuket) 0.5 ML Injection
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine 0.5 ML Injection
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2022-2023]
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Michigan/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere]
Fluzone Quadrivalent 2022 Southern Hemisphere vaccine 0.5 ML Prefilled Syringe
Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023]
influenza virus vaccine 2020-2021 (quadrivalent - Delaware/Nebraska/Darwin/Singapore) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
Flucelvax Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent - Guangdong-Maonan/Hong Kong/Phuket/Washington) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
Fluarix Quadrivalent 2020-2021 vaccine 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2020-2021]
Flulaval Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent - Guangdong-Maonan/Hong Kong/Phuket/Washington) 0.5 mL Injection
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection
Fluzone Quadrivalent 2020-2021 vaccine 0.5 mL Injection
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2020-2021]
Fluzone Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent generic for Flublok - Hawaii/Minnesota/Phuket/Washington) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe
Flublok Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent - Hong Kong/Victoria/Phuket/Victoria) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
Afluria Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021]
FLUAD Quadrivalent 2020-2021 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2020-2021]
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2020-2021 (Hong Kong/Victoria/Victoria) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2020-2021]
Fluad 2020-2021 vaccine 0.5 ML Prefilled Syringe
Fluzone Quadrivalent 2021 Southern Hemisphere vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere]
influenza virus vaccine 2021 (quadrivalent - Hong Kong/Victoria/Phuket/Washington) 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (trivalent generic for Afluria - Hong Kong, Singapore, Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (quadrivalent generic for Fluarix, Flulaval - Hong Kong/Singapore/Brisbane/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (trivalent generic for Fluad, Fluvirin - Hong Kong, Singapore, Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (quadrivalent generic for Flublok - Hong Kong/Michigan/Brisbane/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection
influenza virus vaccine 2017-2018 (trivalent - Hong Kong/Michigan/Brisbane) 0.5 ML Injection
0.5 ML influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 high-dose (trivalent - Michigan/Hong Kong/Brisbane) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2019-2020 (quadrivalent - Idaho/Indiana/Iowa/Singapore) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2019-2020]
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (quadrivalent generic for Flublok - Michigan/Singapore/Maryland/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (trivalent - Michigan/Singapore/Maryland) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2018-2019]
Flucelvax Quadrivalent 2018-2019 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (quadrivalent - Singapore/North Carolina/Iowa/Singapore) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2017-2018 (quadrivalent - Singapore/Singapore/Hong Kong/Utah) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (quadrivalent - Singapore/Singapore/Maryland/Phuket) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2018-2019 (trivalent - Singapore/Singapore/Maryland) 0.5 ML Prefilled Syringe
influenza virus vaccine 2021-2022 (quadrivalent - Tasmania/Victoria/Phuket/Washington) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
Flulaval Quadrivalent 2021-2022 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2021-2022]
Fluarix Quadrivalent 2021-2022 vaccine 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2021-2022]
Fluzone Quadrivalent 2021-2022 vaccine 0.5 ML Injection
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2021-2022]
Fluzone Quadrivalent 2021-2022 vaccine 0.5 Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent - Phuket/Tasmania/Victoria/Washington) 0.5 mL Injection
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection
Flucelvax Quadrivalent 2021-2022 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent Tasmania/Washington/Darwin/Singapore) 0.5 mL Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
Flublok Quadrivalent 2021-2022 vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent generic for Flublok - Phuket/Tasmania/Washington/Wisconsin) 0.5 ML Prefilled Syringe
0.5 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix Quad 2014-2015 Formula]
0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval Quad 2014-2015 Formula]
0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
Influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / Influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), Inactivated 0.03 MG/ML / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval 2014-2015 Formula]
Flulaval 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Brisbane-60-2008-like virus 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula]
Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula]
Fluzone Quadrivalent 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2013-2014 Formula]
Afluria 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2014-2015 Formula]
Afluria 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2013-2014 Formula]
Fluarix 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2014-2015 Formula]
Fluarix 2014-2015 Formula 45 mcg (15 mcg x 3) per 0.5 ML Prefilled
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2013-2014 Formula]
Flucelvax 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2014-2015 Formula]
Flucelvax 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2013-2014 Formula]
Fluvirin 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2014-2015 Formula]
Fluvirin 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula]
Fluzone 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula]
Fluzone 2014-2015 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.03 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2012-2013 Formula]
Afluria 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Agriflu 2012-2013 Formula]
Agriflu 2012-2013 Formula 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2012-2013 Formula]
Fluarix 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2012-2013 Formula]
Flucelvax 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2012-2013 Formula]
Fluvirin 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula]
Fluzone 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe
influenza virus vaccine 2014-2015 trivalent, high-dose 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula]
Fluzone High-Dose 2013-2014 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula]
Fluzone High-Dose 2014-2015 Formula 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe
influenza A virus vaccine, A-California-7-2009 (H1N1)-like virus 0.12 MG/ML / influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML 0.5 ML Prefilled Syringe
0.5 ML influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula]
Fluzone High-Dose 2012-2013 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula]
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2010-2011 Formula]
Fluarix 2010-2011 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2010-2011 Formula]
Fluvirin 2010-2011 Formula 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2010-2011 Formula]
Afluria 2010-2011 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Agriflu 2010-2011 Formula]
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
Fluzone 2011-2012 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2011-2012 Formula]
Fluarix 2011-2012 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2011-2012 Formula]
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2011-2012 Formula]
Fluvirin 2011-2012 Formula Influenza Virus Vaccine 0.5 ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula]
0.5 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
0.5 ML Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 6 MCG per 0.5 ML Prefilled Syringe
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection
human papillomavirus quadrivalent (types 6,11,16,18) vaccine, recombinant 0.5 ML Injection
human papillomavirus quadrivalent (types 6,11,16,18) vaccine, recombinant 0.5 ML Prefilled Syringe
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe
human papillomavirus 9-valent (types 6,11,16,18,31,33,45,52,58) vaccine, recombinant 0.5 mL Injection
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection
human papillomavirus 9-valent (types 6,11,16,18,31,33,45,52,58) vaccine, recombinant 0.5 ML Prefilled Syringe
0.5 ML L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection
measles, mumps, and rubella virus vaccine live (generic for M-M-R II) 0.5 ML Injection
measles, mumps, rubella and varicella virus vaccine live 0.5 ML Injection
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection
0.5 ML measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection [Attenuvax]
0.5 ML meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection
meningococcal group A polysaccharide 50 MCG / meningococcal group C polysaccharide 50 MCG / meningococcal polysaccharide vaccine group W-135 50 MCG / meningococcal polysaccharide vaccine group Y 50 MCG per 0.5 ML Injection
meningococcal group B vaccine 50 MCG / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 50 MCG / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 50 MCG / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 25 MCG per 0.5 ML Prefilled Syringe
0.5 ML meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe
meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV4 generic for Menactra) 0.5 ML Injection
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection
Menactra Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 ML Injection
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.052 MG / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.052 MG / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.052 MG / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.052 MG per 0.5 ML Prefilled Syringe
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe
Menactra Meningococcal (Groups A,C,Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Prefilled Syringe
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe [Menactra]
meningococcal (groups A, C, Y and W-135) polysaccharide tetanus toxoid conjugate vaccine 0.5 ML Injection
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection
0.5 ML Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection [Menquadfi]
meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine 0.5 ML Injection
0.5 ML Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection
0.5 ML Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 60 MCG / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 60 MCG per 0.5 ML Prefilled Syringe
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML 0.5 ML Prefilled Syringe
0.5 ML poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe [Ipol]
Ipol (poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML) 0.5 ML Prefilled Syringe
pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 Protein) 0.5 ML Prefilled Syringe
0.5 ML Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0088 MG/ML / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.0044 MG/ML Prefilled Syringe
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.002 MG per 0.5 ML Prefilled Syringe
0.5 ML Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe
pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) 0.5 ML Prefilled Syringe
0.5 ML Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe [Prevnar]
Prevnar (Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria CRM197 Protein)) 0.5 ML Prefilled Syringe
0.5 ML tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
tetanus toxoid vaccine 5 UNT per 0.5 ML Prefilled Syringe
0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 25 MCG per 0.5 ML Prefilled Syringe
0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection
0.5 ML zoster vaccine, recombinant 0.1 MG/ML
influenza virus vaccine 2023 southern hemisphere (quadrivalent - Darwin/Michigan/Phuket/Sydney) 0.7 mL Prefilled Syringe
0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2023 Southern Hemisphere vaccine 0.7 mL Prefilled Syringe
0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza virus vaccine 2022-2023 high-dose (quadrivalent - Darwin/Michigan/Phuket/Victoria) 0.7 mL Prefilled Syringe
0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2022-2023 high dose vaccine 0.7 ML Prefilled Syringe
0.7 ML influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023]
influenza virus vaccine 2020-2021 high-dose (quadrivalent - Guangdong-Maonan/Hong Kong/Phuket/Washington) 0.7 ML Prefilled Syringe
0.7 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2020-2021 high-dose vaccine 0.7 ML Prefilled Syringe
0.7 ML influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
Fluzone Quadrivalent 2021-2022 high dose vaccine 0.7 ML Prefilled Syringe
0.7 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension [Pediarix]
0.7 ML influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe
influenza virus vaccine 2021-2022 high-dose (quadrivalent - Phuket/Tasmania/Victoria/Washington) 0.7 ML Prefilled Syringe
1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.025 MG/ML Prefilled Syringe
1 ML hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 1440 UNT per 1 ML Prefilled Syringe
1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection
1 ML hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT per 1 ML Prefilled Syringe
1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection
1 ML hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection [Prehevbrio]
1 ML hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe
1 ML hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe [Recombivax]
1 ML Recombivax HB 0.0025 MG/ML Prefilled Syringe
1 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection
hepatitis B surface antigen vaccine 40 MCG in 1 ML Injection
1 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Recombivax]
Recombivax HB, Hepatitis B vaccine (recombinant) Dialysis Formulation 40 MCG per 1 ML Injection
1 ML rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection
rabies virus vaccine flury-lep strain 2.5 UNT per 1 ML Injection
1 ML rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT per 1 ML Injection
1 ML rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection [Imovax]
1.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe
1.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B]
Engerix-B, Hepatitis B Surface Antigen Vaccine, Adsorbed (Pediatric Dose) 1.5 ML Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Vaxelis]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Vaxelis]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injectable Suspension
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injectable Suspension [PEDIARIX]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / hepatitis B surface antigen vaccine / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Injection [Quadracel]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) / tetanus toxoid vaccine, inactivated Prefilled Syringe [Quadracel]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [ACEL-IMUNE]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Certiva]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injectable Suspension [Tripedia]
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection
acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Daptacel]
acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 15 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Solution
acellular pertussis vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension
DTaP-HepB-IPV (diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined) Injectable Suspension
acellular pertussis vaccine, inactivated 0.936 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 0.936 UNT/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
DTaP (Diphtheria Toxoid Vaccine 6.7 UNT / Tetanus Toxoid Vaccine 5 UNT / Acellular Pertussis Vaccine 46.8 MCG) per 0.5 ML Injectable Suspension
acellular pertussis vaccine, inactivated 600 UNT/ML
acellular pertussis vaccine, inactivated 600 UNT/ML Injectable Solution
acellular pertussis vaccine, inactivated 8 UNT/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 8 UNT/ML / diphtheria toxoid vaccine, inactivated 25 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML [Pentacel]
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML [Biothrax]
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension
Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension
Bacillus anthracis strain V770-NP1-R antigens Injectable Suspension [Biothrax]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Vaxelis]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Quadracel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Tripedia]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
DTaP (diphtheria toxoid vaccine, inactivated 13.4 UNT / tetanus toxoid vaccine, inactivated 5 UNT / acellular pertussis vaccine, inactivated 46.8 MCG) per 0.5 ML Injectable Suspension
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.0468 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0468 MG/ML / diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension [Tripedia]
Tripedia DTaP (diphtheria toxoid vaccine, inactivated 6.7 UNT / tetanus toxoid vaccine, inactivated 5 UNT / acellular pertussis vaccine, inactivated 46.8 MCG) per 0.5 ML Injectable Suspension
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [ACEL-IMUNE]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.069 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.0016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.0032 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.0064 MG/ML / diphtheria toxoid vaccine, inactivated 18 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension [ACEL-IMUNE]
Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML [Certiva]
Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension
Bordetella pertussis toxoid vaccine, inactivated 0.08 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 12 UNT/ML Injectable Suspension [Certiva]
Certiva (Bordetella pertussis toxoid vaccine, inactivated 40 MCG / diphtheria toxoid vaccine, inactivated 15 UNT / tetanus toxoid vaccine, inactivated 6 UNT) per 0.5 ML Injectable Suspension
diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Solution
diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Solution [Prohibit]
diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Suspension
diphtheria toxoid vaccine, inactivated / Haemophilus capsular oligosaccharide Injectable Suspension [HibTITER]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Decavac]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Prefilled Syringe [Decavac]
diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML [Prohibit]
diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 0.036 MG/ML / Haemophilus capsular oligosaccharide 0.05 MG/ML Injectable Solution [Prohibit]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML [HibTITER]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / Haemophilus capsular oligosaccharide 0.02 MG/ML Injectable Suspension [HibTITER]
HibTITER Diphtheria Toxoid Vaccine Injectable Suspension
diphtheria toxoid vaccine, inactivated 0.2 UNT/ML
diphtheria toxoid vaccine, inactivated 0.2 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 13.2 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
diphtheria toxoid vaccine 6.6 UNT / tetanus toxoid vaccine 5 UNT per 0.5 ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 13.4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 6.7 UNT / tetanus toxoid vaccine, inactivated 5 UNT per 0.5 ML vaccine Injectable Suspension
diphtheria toxoid vaccine, inactivated 15 UNT/ML
diphtheria toxoid vaccine, inactivated 18 UNT/ML
diphtheria toxoid vaccine, inactivated 20 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 20 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
diphtheria toxoid vaccine 10 UNT / tetanus toxoid vaccine 5 UNT per 0.5 ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 25 LFU/ML
diphtheria toxoid vaccine, inactivated 25 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 25 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injectable Suspension
diphtheria toxoid vaccine 12.5 UNT / tetanus toxoid vaccine 5 UNT per 0.5 ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 LFU/ML
diphtheria toxoid vaccine, inactivated 4 LFU/ML / tetanus toxoid vaccine, inactivated 10 LFU/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML [Decavac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Decavac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Tenivac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Decavac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Tenivac]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML [Tdvax]
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 4 UNT/ML Injection [Tdvax]
diphtheria toxoid vaccine, inactivated 5 MG/ML / tetanus toxoid vaccine, inactivated 10 MG/ML Injectable Suspension
diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
diphtheria toxoid vaccine, inactivated 50 UNT/ML Injectable Solution
Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Solution
Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Suspension
Haemophilus capsular oligosaccharide / Neisseria meningitidis Injectable Suspension [Liquid PedvaxHIB]
Haemophilus capsular oligosaccharide / tetanus toxoid vaccine, inactivated Injectable Solution
Haemophilus capsular oligosaccharide / tetanus toxoid vaccine, inactivated Injectable Solution [OmniHIB]
Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML [Liquid PedvaxHIB]
Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Solution
Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Suspension
Haemophilus capsular oligosaccharide 0.015 MG/ML / Neisseria meningitidis 0.25 MG/ML Injectable Suspension [Liquid PedvaxHIB]
Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML [OmniHIB]
Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML Injectable Solution
Haemophilus capsular oligosaccharide 0.02 MG/ML / tetanus toxoid vaccine, inactivated 0.048 MG/ML Injectable Solution [OmniHIB]
Haemophilus capsular oligosaccharide 0.03 MG/ML / Neisseria meningitidis 0.5 MG/ML Injectable Solution
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine / hepatitis B surface antigen vaccine Injection [COMVAX]
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.015 MG/ML
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.015 MG/ML Injectable Solution
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML / hepatitis B surface antigen vaccine 0.01 MG/ML Injection [COMVAX]
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection
Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.265 MG/ML Injection [PedvaxHIB]
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.005 MG/ML / meningococcal group C polysaccharide 0.01 MG/ML / meningococcal polysaccharide vaccine group Y 0.01 MG/ML Injection [MenHibrix]
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection
Haemophilus influenzae type b strain 1482, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.068 MG/ML Injection [ActHIB]
Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection
Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 0.07 MG/ML Injection [Hiberix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group Y Injection
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group Y Injection [MenHibrix]
Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine Injection [Hiberix]
hepatitis A vaccine (inactivated) strain HM175 / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML / typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.025 MG/ML Prefilled Syringe
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Injection [Havrix]
hepatitis A vaccine (inactivated) strain HM175 1440 UNT/ML Prefilled Syringe [Havrix]
hepatitis A vaccine (inactivated) strain HM175 720 UNT/ML Injectable Suspension
obsolete hepatitis A vaccine (inactivated) strain HM175 Injectable Suspension
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Injection [Vaqta]
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe
hepatitis A virus strain CR 326F antigen, inactivated 50 UNT/ML Prefilled Syringe [Vaqta]
hepatitis A virus strain CR 326F antigen, inactivated Injection
hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
hepatitis A virus strain CR 326F antigen, inactivated Prefilled Syringe
hepatitis A virus strain CR 326F antigen, inactivated Prefilled Syringe [Vaqta]
hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection
hepatitis B surface antigen (isoform L), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform M), recombinant 0.01 MG/ML / hepatitis B surface antigen (isoform S), recombinant 0.01 MG/ML Injection [Prehevbrio]
hepatitis B surface antigen vaccine 0.0025 MG/ML
hepatitis B surface antigen vaccine 0.0025 MG/ML [Recombivax]
hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe
hepatitis B surface antigen vaccine 0.0025 MG/ML Prefilled Syringe [Recombivax]
hepatitis B surface antigen vaccine 0.003 MG/ML
hepatitis B surface antigen vaccine 0.003 MG/ML Injectable Solution
hepatitis B surface antigen vaccine 0.005 MG/ML [Recombivax]
hepatitis B surface antigen vaccine 0.005 MG/ML Injectable Suspension [Recombivax]
Recombivax HB, Hepatitis B Vaccine (Recombinant) Pediatric/Adolescent Formulation Injectable Suspension
hepatitis B surface antigen vaccine 0.005 MG/ML Prefilled Syringe [Recombivax]
hepatitis B surface antigen vaccine 0.01 MG/ML Injection [Recombivax]
hepatitis B surface antigen vaccine 0.01 MG/ML Prefilled Syringe [Recombivax]
hepatitis B surface antigen vaccine 0.02 MG/ML [HB-VAX]
hepatitis B surface antigen vaccine 0.02 MG/ML Injectable Suspension [HB-VAX]
obsolete hepatitis B surface antigen vaccine 0.04 MG/ML
hepatitis B surface antigen vaccine 0.04 MG/ML [Recombivax]
hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Heplisav-B]
hepatitis B surface antigen vaccine 0.04 MG/ML Injection [Recombivax]
hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B]
hepatitis B surface antigen vaccine Injectable Suspension [HB-VAX]
hepatitis B surface antigen vaccine Injectable Suspension [Recombivax]
hepatitis B surface antigen vaccine Injection [Prehevbrio]
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.02 MG / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.02 MG per 0.5 ML Injectable Suspension
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Injectable Suspension [Cervarix]
Cervarix (Human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.02 MG / Human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.02 MG) per 0.5 ML Injectable Suspension
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe
human papillomavirus type 16, L1 capsid protein (residues 2-471) vaccine 0.04 MG/ML / human papillomavirus type 18, L1 capsid protein (residues 2-472) vaccine 0.04 MG/ML Prefilled Syringe [Cervarix]
human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension
human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
rotavirus, live pentavalent (RV5) Oral Vaccine
human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML Oral Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2016-2017 Formula]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Afluria Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flucelvax Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [FluLaval Quadrivalent 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Flulaval Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluvirin 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2016 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2021 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2022 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injectable Suspension [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Flublok 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2016-2017]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2017-2018]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [Flumist Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Nasal Spray [FluMist Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Afluria Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluad Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluarix Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flublok Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2018-2019]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flucelvax Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [FluLaval Quadrivalent 2015-2016]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Flulaval Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2019-2020]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2022-2023]
influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus (H3N2) antigen 0.03 MG/ML / influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus (H5N1) antigen Injectable Suspension
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray
influenza virus vaccine, live attenuated, 2016-2017 Quadrivalent Nasal Spray
influenza A virus A/Bolivia/559/2013 (H1N1) antigen 50000000 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 50000000 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 50000000 MG/ML Nasal Spray
influenza virus vaccine 2015-2016 Quadrivalent Nasal Spray
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML [Fluad 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2019-2020]
influenza virus vaccine 2019-2020 (quadrivalent - Brisbane/Kansas/Maryland/Phuket) Injectable Suspension
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2019-2020]
Fluzone Quadrivalent 2019-2020 vaccine Injectable Suspension
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Flulaval Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2019-2020]
Afluria Quadrivalent 2019-2020 vaccine Injectable Suspension
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza virus vaccine 2020 (quadrivalent - Brisbane/South Australia/Phuket/Washington) Injectable Suspension, southern hemisphere
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/34/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020 Southern Hemisphere]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML [Fluzone 2019-2020]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2019-2020]
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2016-2017]
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Brisbane/10/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.015 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.015 MG/ML / influenza B virus B/Brisbane/9/2014 antigen 0.015 MG/ML Prefilled Syringe [FLUAD 2015-2016]
FLUAD 2015-2016 Formula Influenza Virus Vaccine ML Prefilled Syringe
Bordetella pertussis as vaccine component
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2016 Southern Hemisphere]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2016 Southern Hemisphere]
Fluzone Quadrivalent 2016 Southern Hemisphere Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016 Southern Hemisphere]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2016-2017 Formula]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2016-2017 (trivalent - California/Hong Kong/Brisbane) Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2015-2016 (trivalent - California/South Australia/Phuket) Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/South Australia/55/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [FluLaval Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2015-2016 (trivalent - California/Switzerland/Phuket) Injectable Suspension
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection
influenza A virus A/California/7/2009 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Injection [Flublok 2015-2016]
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2016-2017]
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe
influenza A virus A/California/7/2009 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2015-2016]
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Afluria Quadrivalent 2021-2022]
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad Quadrivalent 2021-2022]
afluria Quadrivalent 2021-2022 vaccine Injectable Suspension
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent Cambodia/Victoria/Phuket/Victoria) Injectable Suspension
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2016-2017]
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2016-2017 (trivalent - Christchurch/Hong Kong/Brisbane) Injectable Suspension
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2016-2017]
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2015-2016]
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Christchurch/16/2010 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Switzerland/9715293/2013 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2015-2016]
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2022-2023]
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Delaware/Singapore INFTT-16-0610/Singapore WUH4618) Injectable Suspension
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Injectable Suspension
FLUCELVAX Quadrivalent 2022-2023 vaccine Injectable Suspension
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Afluria Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluad Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluarix Quadrivalent 2022-2023]
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Austria/Phuket) Injectable Suspension
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
Afluria Quadrivalent 2022-2023 vaccine Injectable Suspension
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML [Flublok Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza virus vaccine 2023 (quadrivalent - Darwin/Sydney/Michigan/Phuket) Injectable Suspension, southern hemisphere
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
Fluzone Quadrivalent 2023 Southern Hemisphere vaccine Injectable Suspension
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere]
Fluzone Quadrivalent 2023 Southern Hemisphere vaccine Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Flulaval Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2022 Southern Hemisphere]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML [Fluzone Quadrivalent 2022-2023]
influenza virus vaccine 2020-2021 (quadrivalent - Delaware/Nebraska/Darwin/Singapore) Injectable Suspension
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Michigan/Phuket) Injectable Suspension
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2022 Southern Hemisphere]
Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine Injectable Suspension
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Michigan/Phuket) Injection
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022 Southern Hemisphere]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Sydney/5/2021 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2023 Southern Hemisphere]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2022-2023]
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2020-2021]
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension
Flucelvax Quadrivalent 2020-2021 vaccine Injectable Suspension
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluarix Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Flulaval Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent - Guangdong-Maonan/Hong Kong/Phuket/Washington) Injectable Suspension
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2020-2021]
Fluzone Quadrivalent 2020-2021 vaccine Injectable Suspension
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2020-2021]
FluMist Quadrivalent, 2020-2021 Formula Nasal Spray
influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray [Flumist Quadrivalent 2020-2021]
influenza virus vaccine, 2020-2021 Quadrivalent Nasal Spray
influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray
influenza A virus A/Hawaii/66/2019 (H1N1) antigen 158000000 UNT/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML [Flumist Quadrivalent 2020-2021]
influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML [Flublok Quadrivalent 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Afluria Quadrivalent 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad Quadrivalent 2020-2021]
influenza virus vaccine 2020-2021 (quadrivalent - Hong Kong/Victoria/Phuket/Victoria) Injectable Suspension
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension
Afluria Quadrivalent 2020-2021 vaccine Injectable Suspension
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Injectable Suspension [Afluria Quadrivalent 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML [Fluad 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2021 Southern Hemisphere]
Fluzone Quadrivalent 2021 Southern Hemisphere vaccine Injectable Suspension
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2021 Southern Hemisphere]
influenza virus vaccine 2021 (quadrivalent - Hong Kong/Victoria/Phuket/Washington) Injectable Suspension
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2017-2018 (quadrivalent - Hong Kong/Michigan/Brisbane/Phuket) Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2017-2018 (quadrivalent generic for Afluria - Hong Kong/Singapore/Brisbane/Phuket) Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2017-2018 (trivalent generic for Afluria - Hong Kong/Singapore/Brisbane) Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/46/2015 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2017-2018 (trivalent generic for Fluvirin - Hong Kong/Singapore/Brisbane) Injectable Suspension
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe [Fluvirin 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.09 MG/ML Injection [Flublok 2017-2018]
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.12 MG/ML / influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2017-2018]
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2019-2020]
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2019-2020]
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Idaho/07/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Indiana/08/2018 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2019-2020]
influenza A virus A/Indonesia/05/2005 (H5N1) antigen 0.0075 MG/ML Injectable Suspension
influenza A (H5N1) virus vaccine (monovalent - Indonesia/05/2005) Injectable Suspension
influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray
influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [FluMist Quadrivalent 2019-2020]
influenza A virus A/Kansas/14/2017 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Switzerland/3330/2017 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2019-2020]
FluMist Quadrivalent, 2019-2020 Formula Nasal Spray
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2018-2019]
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2018-2019]
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2018-2019]
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe
influenza A virus A/Michigan/45/2015 (H1N1) antigen 0.12 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.12 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.12 MG/ML Prefilled Syringe [Fluzone 2018-2019]
influenza A virus A/New Caledonia/71/2014 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray
influenza virus vaccine, live attenuated, 2017-2018 Quadrivalent Nasal Spray
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2018-2019]
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2018-2019]
Flucelvax Quadrivalent 2018-2019 vaccine Injectable Suspension
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2018-2019]
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/North Carolina/04/2016 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Iowa/06/2017 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2018-2019 (quadrivalent - Singapore/North Carolina/Iowa/Singapore) Injectable Suspension
influenza virus vaccine 2022-2023 Quadrivalent Nasal Spray
influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray
influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML [FluMist Quadrivalent 2022-2023]
FluMist Quadrivalent, 2022-2023 Formula Nasal Spray
influenza A virus A/Norway/16606/2021 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Austria/1359417/2021 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2022-2023]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2017-2018 (quadrivalent - Singapore/Singapore/Hong Kong/Utah) Injectable Suspension
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/GP2050/2015 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Hong Kong/259/2010 antigen 0.03 MG/ML / influenza B virus B/Utah/9/2014 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2017-2018]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML [Afluria 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2018-2019 (quadrivalent - Singapore/Singapore/Maryland/Phuket) Injectable Suspension
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2018-2019 (trivalent - Singapore/Singapore/Maryland) Injectable Suspension
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Afluria 2018-2019]
influenza A virus A/Singapore/GP1908/2015 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML Prefilled Syringe [Fluad 2018-2019]
influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Slovenia/2903/2015 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Colorado/06/2017 antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML Nasal Spray
influenza virus vaccine, live attenuated, 2018-2019 Quadrivalent Nasal Spray
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluarix Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Flulaval Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML [Fluzone Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent - Phuket/Tasmania/Victoria/Washington) Injectable Suspension
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension
Fluzone Quadrivalent 2021-2022 vaccine Injectable Suspension
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2021-2022]
influenza virus vaccine 2021-2022 (quadrivalent Tasmania/Washington/Darwin/Singapore) 0.5 ML Injectable Suspension
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension
Flucelvax Quadrivalent 2021-2022 vaccine Injectable Suspension
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Injectable Suspension [Flucelvax Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML [Flucelvax Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML [Fluzone Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML [Flublok Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML [FluMist Quadrivalent 2021-2022]
Flumist Quadrivalent, 2021-2022 Formula Nasal Spray
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 158000000 UNT/ML / influenza A virus A/Victoria/1/2020 (H1N1) antigen 158000000 UNT/ML / influenza B virus B/Phuket/3073/2013 antigen 158000000 UNT/ML / influenza B virus B/Washington/02/2019 antigen 158000000 UNT/ML Nasal Spray [FluMist Quadrivalent 2021-2022]
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix Quad 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix Quad 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix Quad 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval Quad 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval Quad 2014-2015 Formula]
Flulaval Quad 2014-2015 Formula Influenza Virus Injectable Suspension
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval Quad 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval 2014-2015 Formula]
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2014-2015 Formula]
Flulaval 2014-2015 Formula Influenza Virus Vaccine Injectable Suspension
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Texas-50-2012 X-223A (H3N2), inactivated 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flulaval 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone Quadrivalent 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval Quad 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval Quad 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Nasal Spray
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Nasal Spray [Flumist 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flulaval Quad 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution [Flublok 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Solution [Flublok 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Afluria 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Afluria 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Flulaval 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluvirin 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluvirin 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Injectable Suspension [Fluzone 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Afluria 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Afluria 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluarix 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flucelvax 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flucelvax 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Flulaval 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluvirin 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluvirin 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Massachusetts-2-2012-like virus Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Solution [Flublok 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Afluria 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Flulaval 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Fluvirin 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Injectable Suspension [Fluzone 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Nasal Spray
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Nasal Spray [Flumist 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Afluria 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Agriflu 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluarix 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Flucelvax 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluvirin 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine, B-Wisconsin-1-2010-like virus Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2013-2014 Formula]
Fluzone Quadrivalent 2013-2014 Formula Influenza Virus Vaccine Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval Quad 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval Quad 2013-2014 Formula]
Flulaval Quad 2013-2014 Formula Influenza Virus Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Afluria 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Afluria 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluarix 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flucelvax 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flucelvax 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Flulaval 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluvirin 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluvirin 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML [Fluzone 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension
influenza virus vaccine 2013-2014 trivalent Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Afluria 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Afluria 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Afluria 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Agriflu 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluarix 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Flucelvax 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Flulaval 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluvirin 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML [Fluzone 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Afluria 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Flulaval 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Fluvirin 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Injectable Suspension [Fluzone 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Afluria 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Agriflu 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluarix 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Flucelvax 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluvirin 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML Prefilled Syringe [Fluzone 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Intradermal 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML [Fluzone Intradermal 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Injectable Solution
influenza virus vaccine 2014-2015 trivalent recombinant Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML [Fluzone Intradermal 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Injectable Solution
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.09 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.09 MG/ML Prefilled Syringe [Fluzone Intradermal 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML [Fluzone High-Dose 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML [Fluzone High-Dose 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2013-2014 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML [Fluzone High-Dose 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.12 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML Prefilled Syringe [Fluzone High-Dose 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML [Flumist 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML Nasal Spray
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 158000000 UNT/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML Nasal Spray [Flumist 2012-2013 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML Nasal Spray
influenza virus vaccine 2014-2015 quadrivalent Nasal Spray
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML [Flumist 2014-2015 Formula]
influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 50000000 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML / influenza B virus vaccine, B-Massachusetts-2-2012-like virus 50000000 MG/ML Nasal Spray [Flumist 2014-2015 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Afluria 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Afluria 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [FluLaval 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Flulaval 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluvirin 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluvirin 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injectable Suspension [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Afluria 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Afluria 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Agriflu 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluarix 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluarix 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluvirin 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluvirin 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Prefilled Syringe [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray [FluMist 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus vaccine B/Brisbane/60/2008 antigen / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain Nasal Spray [Flumist 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Afluria 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Afluria 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Agriflu 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluarix 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluarix 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [FluLaval 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Flulaval 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluvirin 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluvirin 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluzone 2010-2011 Formula]
Fluzone 2010-2011 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [FluLaval 2010-2011 Formula]
FluLaval 2010-2011 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluvirin 2010-2011 Formula]
Fluvirin 2010-2011 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Afluria 2010-2011 Formula]
Afluria 2010-2011 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Flulaval 2011-2012 Formula]
Flulaval 2011-2012 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Afluria 2011-2012 Formula]
Afluria 2011-2012 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Injectable Suspension [Fluvirin 2011-2012 Formula]
Fluvirin 2011-2012 Formula Influenza Virus Vaccine Injectable Suspension
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Agriflu 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluarix 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Afluria 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluvirin 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.03 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.03 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.09 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.09 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.09 MG/ML Prefilled Syringe
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.12 MG/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML / influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML Prefilled Syringe [Fluzone 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML [FluMist 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML [Flumist 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray
influenza virus vaccine, live attenuated, trivalent, 2011-2012 formula Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray [FluMist 2010-2011 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML / influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML / influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML Nasal Spray [Flumist 2011-2012 Formula]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 158000000 UNT/ML Nasal Spray
influenza-A (H1N1) virus vaccine, monvalent, live attentuated, 2009 Formula Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 MG/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine Nasal Spray
influenza B virus vaccine B/Brisbane/60/2008 antigen 0.12 MG/ML
influenza B virus vaccine B/Brisbane/60/2008 antigen 158000000 UNT/ML
influenza B virus vaccine B/Brisbane/60/2008 antigen 50000000 MG/ML
influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.03 MG/ML
influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.12 MG/ML
influenza B virus vaccine, B-Wisconsin-1-2010-like virus 158000000 UNT/ML
influenza virus vaccine, inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.12 MG/ML
influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain
influenza virus vaccine, live attenuated, A-Perth-16-2009 (H3N2) strain 158000000 UNT/ML
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML [Je-Vax]
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML Injectable Suspension
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.0000000385 MG/ML Injectable Suspension [Je-Vax]
Je-Vax Japanese Encephalitis Virus vaccine, inactivated Injectable Suspension
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe
Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated 0.012 MG/ML Prefilled Syringe [Ixiaro]
Japanese encephalitis virus vaccine, inactivated Injectable Suspension [Je-Vax]
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 31 vaccine / L1 protein, human papillomavirus type 33 vaccine / L1 protein, human papillomavirus type 45 vaccine / L1 protein, human papillomavirus type 52 vaccine / L1 protein, human papillomavirus type 58 vaccine / L1 protein, human papillomavirus type 6 vaccine Prefilled Syringe
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 31 vaccine / L1 protein, human papillomavirus type 33 vaccine / L1 protein, human papillomavirus type 45 vaccine / L1 protein, human papillomavirus type 52 vaccine / L1 protein, human papillomavirus type 58 vaccine / L1 protein, human papillomavirus type 6 vaccine Injection
L1 protein, human papillomavirus type 11 vaccine / L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine / L1 protein, human papillomavirus type 6 vaccine Injection
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Injection [Gardasil]
L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Injectable Suspension
L1 protein, human papillomavirus type 16 vaccine / L1 protein, human papillomavirus type 18 vaccine Injectable Suspension [Cervarix]
measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection
measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML [Attenuvax]
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 25000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injection [M-M-R II]
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML Injection [Attenuvax]
measles virus vaccine live, Enders' attenuated Edmonston strain Injection
measles virus vaccine live, Enders' attenuated Edmonston strain Injection [Attenuvax]
meningococcal group A polysaccharide / meningococcal group C polysaccharide / meningococcal polysaccharide vaccine group W-135 / meningococcal polysaccharide vaccine group Y Injectable Solution [Menomune A/C/Y/W-135]
meningococcal group A polysaccharide / meningococcal group C polysaccharide Injectable Solution [Meningovax-AC]
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML [Meningovax-AC]
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injectable Solution
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML / meningococcal polysaccharide vaccine group W-135 0.1 MG/ML / meningococcal polysaccharide vaccine group Y 0.1 MG/ML Injection [Menomune A/C/Y/W-135]
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML Injectable Solution
meningococcal group A polysaccharide 0.1 MG/ML / meningococcal group C polysaccharide 0.1 MG/ML Injectable Solution [Meningovax-AC]
meningococcal group A polysaccharide 0.1 MG/ML Injectable Solution
meningococcal group A polysaccharide Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Biavax II]
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML [Mumpsvax]
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML [Biavax II]
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution [Biavax II]
Biavax II, Rubella and Mumps Virus Vaccine Live Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML Injectable Solution [Mumpsvax]
Mumpsvax, Mumps Virus Vaccine Live, (Jeryl Lynn Strain) Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain Injectable Solution
mumps virus vaccine live, Jeryl Lynn strain Injectable Solution [Mumpsvax]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Prefilled Syringe
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Prefilled Syringe [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine Injection [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine Injection
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine Injection [Menquadfi]
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML [Menquadfi]
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine Injection [Menveo]
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen 0.12 MG/ML / Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen 0.12 MG/ML Prefilled Syringe [Trumenba]
Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine
Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML
Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine
Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML
Brucella melitensis as vaccine component
Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine
Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML
pertussis vaccine 0.0468 MG/ML Injectable Solution
pertussis vaccine 600 UNT/ML Injectable Solution
pertussis vaccine 8 UNT/ML Injectable Solution
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension [Ipol]
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Prefilled Syringe
poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Prefilled Syringe [Ipol]
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Suspension
poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML per 0.5 ML Injectable Suspension
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe
poliovirus vaccine inactivated Prefilled Syringe
poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Prefilled Syringe [Ipol]
Ipol (poliovirus vaccine inactivated) Prefilled Syringe
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection
rabies virus vaccine flury-lep strain 2.5 UNT/ML Injection [RabAvert]
rabies virus vaccine flury-lep strain Injection [RabAvert]
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated 2.5 UNT/ML Injection [Imovax]
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection
rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection [Imovax]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 1000000 UNT/ML Oral Suspension
rotavirus, live attenuated (RV1) G1P[8] Oral Vaccine 1 ML Lyophilized Powder for Oral Suspension
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML [Rotarix]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML Oral Suspension
rotavirus, live attenuated (RV1) G1P[8] Oral Vaccine 1.5 ML Oral Suspension
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain 667000 UNT/ML Oral Suspension [Rotarix]
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension
rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML [Meruvax II]
rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution
rubella virus vaccine live (Wistar RA 27-3 Strain) 1000 UNT per 0.5 ML Injectable Solution
rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML Injectable Solution [Meruvax II]
Meruvax II, Rubella Virus Vaccine Live (Wistar RA 27-3 Strain) Injectable Solution
rubella virus vaccine live (Wistar RA 27-3 strain) Injectable Solution [Meruvax II]
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension [Comirnaty]
SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein Injectable Suspension [Spikevax]
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.025 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.025 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.025 MG/ML Injectable Suspension
SARS-CoV-2 vaccine, mRNA-1273 bivalent original & OMICRON (BA.4/.5) Injectable Suspension, 6m through 5y (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.05 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.05 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.05 MG/ML Injectable Suspension
SARS-CoV-2 vaccine, mRNA 1273 bivalent original & OMICRON (BA.4/.5) Injectable Suspension, 6y+ (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.1 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.1 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 25 MCG/0.25 ML Injectable Suspension, 6m through 5y
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML [Spikevax]
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 100 MCG/0.5 ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension [Spikevax]
Spikevax 0.2 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.025 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (BA.4/BA.5) 0.05 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.0075 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.0075 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.0075 MG/ML Injectable Suspension
SARS-CoV-2 vaccine, mRNA-BNT162b2 bivalent original & OMICRON (BA.4/.5) Injectable Suspension, 6m through 4y (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.015 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.015 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 3 MCG/0.2 ML Injectable Suspension, 6m through 4y (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.025 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.025 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.025 MG/ML Injectable Suspension
SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) Injectable Suspension, 5y through 11y (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML / SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.05 MG/ML Injectable Suspension
SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) Injectable Suspension, 12y+ (EUA)
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 10 MCG/0.2 ML Injectable Suspension, 5y through 11y
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML [Comirnaty]
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 30 MCG/0.3 ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension [Comirnaty]
Comirnaty 30 MCG/0.3 ML Injectable Suspension
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.0075 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.025 MG/ML
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (BA.4/BA.5) 0.05 MG/ML
SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML
SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension
SARS-COV-2 (COVID-19) vaccine, vector - Ad26 0.5 ML Injectable Suspension (EUA)
SARS-COV-2 (COVID-19) vaccine, vector non-replicating
SARS-COV-2 (COVID-19) vaccine, vector non-replicating Injectable Suspension
smallpox vaccine live, New York City Board of Health vaccinia strain
smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML
smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML [Dryvax]
smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML Injectable Suspension
smallpox vaccine live, New York City Board of Health vaccinia strain 100000000 UNT/ML Injectable Suspension [Dryvax]
Dryvax, Dried Smallpox Vaccine Injectable Suspension
smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML
smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML [ACAM2000]
smallpox vaccine live, New York City Board of Health vaccinia strain 500000000 UNT/ML Injectable Solution
smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution
smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Suspension
smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Suspension [Dryvax]
Streptococcus pneumoniae serotype 1 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 3 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 7F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Injectable Suspension
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Injectable Suspension [Prevnar]
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine Prefilled Syringe [Prevnar]
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Injectable Suspension
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML [Prevnar]
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Injectable Suspension [Prevnar]
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe
Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML / Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML / Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML Prefilled Syringe [Prevnar]
Streptococcus pneumoniae serotype 18C capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 23F capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 4 capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine 0.008 MG/ML
Streptococcus pneumoniae serotype 9V capsular antigen diphtheria CRM197 protein conjugate vaccine 0.004 MG/ML
tetanus toxoid vaccine, inactivated 0.048 MG/ML
tetanus toxoid vaccine, inactivated 0.5 ML
tetanus toxoid vaccine, inactivated 0.5 ML Injectable Solution
tetanus toxoid vaccine, inactivated 10 LFU/ML
tetanus toxoid vaccine, inactivated 10 MG/ML
tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
tetanus toxoid vaccine, inactivated 1000 UNT
tetanus toxoid vaccine, inactivated 1000 UNT Injectable Suspension
tetanus toxoid vaccine, inactivated 2 UNT/ML
tetanus toxoid vaccine, inactivated 2 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 20 UNT/ML [TE Anatoxal Berna]
tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 20 UNT/ML Injectable Solution [TE Anatoxal Berna]
TE Anatoxal Berna 20 UNT/ML Injectable Solution
tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
tetanus toxoid vaccine, inactivated 5 LFU
tetanus toxoid vaccine, inactivated 5 LFU Injectable Solution
tetanus toxoid vaccine, inactivated Injectable Solution [TE Anatoxal Berna]
obsolete typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution
obsolete typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe
obsolete typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI]
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Solution
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Injectable Solution [Typhim VI]
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain Prefilled Syringe
varicella zoster virus glycoprotein E Injection
varicella zoster virus glycoprotein E Injection [Shingrix]
varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection
varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Injection [Shingrix]
varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax]
varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection
varicella-zoster virus vaccine live (Oka-Merck) strain 29800 UNT/ML Injection [Zostavax]
Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML
Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML [Vaxchora]
Vibrio cholerae CVD 103-HGR strain live antigen 12000000 UNT/ML Oral Suspension
Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension
Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection
yellow fever virus strain 17D-204 live antigen 2000 UNT/ML Injection [Stamaril]
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection
yellow fever virus strain 17D-204 live antigen 4000 UNT/ML Injection [YF-Vax]
Flucelvax Quadrivalent 2018-2019 vaccine
Flucelvax Quadrivalent 2019-2020 vaccine
Flucelvax Quadrivalent 2020-2021 vaccine
Flucelvax Quadrivalent 2021-2022 vaccine
Flucelvax Quadrivalent 2022-2023 vaccine
Typhoid Vaccine Live Ty21a 10000000000 UNT [Vivotif]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML [Hepatyrix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typherix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML [Typhim V]
Typhoid Vaccine Live Ty21a Extended Release Oral Capsule [Vivotif]
Typhoid Vaccine Live Ty21a Oral Capsule [Typhoral L]
Typhoid Vaccine Live Ty21a Oral Capsule [Vivotif Berna]
Typhoid Vaccine Live Ty21a Oral Capsule [Vivotif]
Typhoid Vaccine Live Ty21a Oral Powder [Vivotif]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension [Hepatyrix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution [Typhim V]
Typhoid Vaccine Live Ty21a 10000000000 UNT
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML
Typhoid Vaccine Live Ty21a Extended Release Oral Capsule
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Suspension
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Intramuscular Solution
Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder [Vivotif]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V]
Typhoid Vaccine Live Ty21a Delayed Release Oral Capsule [Vivotif Berna]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Injectable Solution [Typherix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain Prefilled Syringe [Typherix]
Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML Injectable Suspension
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V]
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix]
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension
Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule [Vivotif]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix]
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50
Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 10
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 20
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 50
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Intramuscular Solution [Typhim V] by Sanofi
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] by Glaxosmithkline
Typhoid Vaccine Live Ty21a 10000000000 UNT Oral Powder [Vivotif] by Berna Biotech
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 1000000000 UNT/ML Injectable Suspension by Aventis
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix]
obsolete 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI]
0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI]
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix]
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 10
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 20
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension Box of 50
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50
obsolete Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
obsolete Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 1
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 10
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 100
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 50
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] by Glaxosmithkline
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Sanofi
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Waymade
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] by Waymade
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 10 by Glaxosmithkline
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 20 by Glaxosmithkline
1 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.025 MG/ML Injectable Suspension [Hepatyrix] Box of 50 by Glaxosmithkline
Typhoid Vaccine Live Ty21a 10000000000 UNT Delayed Release Oral Capsule [Vivotif] by Paxvax Berna
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 10
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 100
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution Box of 50
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe Box of 1
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 1 by Glaxosmithkline
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 10 by Glaxosmithkline
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 100 by Glaxosmithkline
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typherix] Box of 50 by Glaxosmithkline
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Sanofi
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Waymade
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 1 by Waymade
obsolete 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Sanofi
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Sanofi
obsolete 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Waymade
0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution [Typhim VI] Box of 10 by Waymade
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typherix] Box of 1 by Glaxosmithkline
0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI] Box of 1 by Sanofi
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Injectable Solution
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 25 MCG per 0.5 ML Injectable Solution
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI]
typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe
obsolete 0.5 ML Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe
Fluzone High-Dose 2013-2014 Formula vaccine
Fluzone High-Dose 2014-2015 Formula vaccine
Fluzone Intradermal 2013-2014 Formula vaccine
Fluzone Intradermal 2014-2015 Formula vaccine
Fluzone Quadrivalent 2016 Southern Hemisphere vaccine
Fluzone Quadrivalent 2020 Southern Hemisphere vaccine
Fluzone Quadrivalent 2021 Southern Hemisphere vaccine
Fluzone Quadrivalent 2022 Southern Hemisphere vaccine
Fluzone Quadrivalent 2023 Southern Hemisphere vaccine
SARS-CoV-2 (COVID-19) vaccine, mRNA-1273
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2
Haemophilus influenzae as vaccine component
Japanese encephalitis virus as vaccine component
Neisseria meningitidis as vaccine component
Rickettsia prowazekii as vaccine component
Haemophilus influenzae type b as vaccine component
0.1 ML BCG, Live, Connaught Strain 1 MG/ML Injectable Solution
0.1 ML BCG, Live, Connaught Strain 1 MG/ML Injectable Solution by Sanofi
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent]
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent] by Astrazeneca
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist]
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5 by Astrazeneca
0.2 ML influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray Box of 5
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC]
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10 by Mylan
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] by Mylan
0.25 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10
0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension
0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC]
0.5 ML A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension Box of 1
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER]
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5 by Praxis Biologics
0.5 ML diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10 by bioCSL
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] by bioCSL
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10 by Novartis
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] by Novartis
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10 by Novartis
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] by Novartis
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10 by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20 by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10 by bioCSL
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] by bioCSL
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10 by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10 by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10 by Crucell
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] by Crucell
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10 by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20 by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] by Glaxosmithkline
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10 by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10 by Baxter
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] by Baxter
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10 by Sanofi
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20 by Sanofi
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50 by Sanofi
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] by Sanofi
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10 by Crucell
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] by Crucell
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu]
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10 by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] by Mylan
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10 by Evans Vaccines
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10 by Sanofi
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20 by Evans Vaccines
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50 by Evans Vaccines
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension by Evans Vaccines
0.5 ML influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension by Sanofi
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injectable Solution
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax] by Merck
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injection [Varivax] by Sanofi
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix]
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Cc
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Emra-Med
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Eurim-Pharm
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Kohlpharma
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1 by Orifarm Leverkus
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Cc
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Emra-Med
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Eurim-Pharm
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Glaxosmithkline
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Kohlpharma
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10 by Orifarm Leverkus
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] by Glaxosmithkline
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 1
0.5 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 10
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax]
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax] by Merck
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax]
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Merck
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1 by Sanofi
0.65 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe Box of 1
1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution
1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10
1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10 by AJ Vaccines
1 ML BCG, live, Connaught strain 20000 UNT/ML Injectable Solution by AJ Vaccines
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix]
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1 by European
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10 by European
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 1
1 ML Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 10
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst]
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3 by Sanofi
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5 by Sanofi
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6 by Sanofi
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] by Sanofi
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 3
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 5
50 ML BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 6
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac]
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1 by Lamepro
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] by Lamepro
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension Box of 1
50 ML BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension by Lamepro
A/Hong Kong/4801/2014 (H3n2) - Like Virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension
A/Hong Kong/4801/2014 (H3n2) - Like Virus / influenza A-California-7-2009-(H1N1)v-like virus vaccine / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [INFLUVAC]
A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension
A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [IMMUGRIP]
A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [VAXIGRIP]
A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension
A/Hong Kong/4801/2014 (H3n2) - Like Virus / Influenza Virus Vaccine, Inactivated A-Christchurch-16-2010 NIB-74 (H1N1) (A-California-7-2009) strain / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain Injectable Suspension [Fluarix]
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [INFLUVAC]
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC]
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 1
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / influenza A-California-7-2009-(H1N1)v-like virus vaccine 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension Box of 1
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [IMMUGRIP]
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML [VAXIGRIP]
A/Hong Kong/4801/2014 (H3n2) - Like Virus 0.03 MG/ML / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain 0.03 MG/ML / Influenza Virus Vaccine, Inactivated B-Brisbane-60-2008 strain 0.03 MG/ML Injectable Suspension
Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution
Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Injectable Solution [Metavirulent]
Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution
Aconitum napellus extract / ferrous cation / Gelsemium Sempervirens Preparation / Gentiana lutea root extract / Influenza A virus / Lactate / Luffa operculata whole extract / VERATRUM ALBUM Preparation Oral Solution [Metavirulent]
Antigens Surface Of Virus Influenza, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88
Antigens Surface Of Virus Influenza, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88 0.03 MG/ML
Antigens Surface Of Virus Influenza, strain B / Brisbane / 9/2014 Wild Type
Antigens Surface Of Virus Influenza, strain B / Brisbane / 9/2014 Wild Type 0.03 MG/ML
BCG, Live, Connaught Strain 1 MG/ML Injectable Solution
BCG, Live, Connaught Strain 1.62 MG/ML [ImmuCyst]
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst]
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 3
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 5
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution [ImmuCyst] Box of 6
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 3
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 5
BCG, Live, Connaught Strain 1.62 MG/ML Injectable Solution Box of 6
BCG, Live, Connaught Strain 1920000000 CFU
BCG, Live, Connaught Strain 1920000000 CFU [ImmuCyst]
BCG, Live, Connaught Strain 1920000000 CFU Injection
BCG, Live, Connaught Strain 1920000000 CFU Injection [ImmuCyst]
BCG, live, Connaught strain 20000 UNT/ML
BCG, live, Connaught strain 20000 UNT/ML Injectable Solution
BCG, live, Connaught strain 20000 UNT/ML Injectable Solution Box of 10
BCG, Live, Connaught Strain 660000000 CFU
BCG, Live, Connaught Strain 660000000 CFU [ImmuCyst]
BCG, Live, Connaught Strain 660000000 CFU Injection
BCG, Live, Connaught Strain 660000000 CFU Injection [ImmuCyst]
BCG, Live, Connaught Strain 81 MG [ImmuCyst]
BCG, Live, Connaught Strain 81 MG Injectable Solution
BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst]
BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] Box of 1
BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] Box of 1 by Alliance
BCG, Live, Connaught Strain 81 MG Injectable Solution [ImmuCyst] by Alliance
BCG, Live, Connaught Strain 81 MG Injectable Solution Box of 1
BCG, Live, Connaught Strain 81 MG Injectable Suspension
BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst]
BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] Box of 1
BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] Box of 1 by Sanofi
BCG, Live, Connaught Strain 81 MG Injectable Suspension [ImmuCyst] by Sanofi
BCG, Live, Connaught Strain 81 MG Injectable Suspension Box of 1
BCG, Live, Connaught Strain Injectable Solution
BCG, Live, Connaught Strain Injectable Solution [ImmuCyst]
BCG, Live, Connaught Strain Injectable Suspension
BCG, Live, Connaught Strain Injectable Suspension [ImmuCyst]
BCG, live, Connaught strain Injectable Suspension [InterVax]
BCG, Live, Connaught Strain Injection [ImmuCyst]
BCG, Live, Montreal Strain 120 MG [Pacis]
BCG, Live, Montreal Strain 120 MG Injectable Solution
BCG, Live, Montreal Strain 120 MG Injectable Solution [Pacis]
BCG, Live, Montreal Strain 120 MG Injectable Solution [Pacis] by ID bio
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML [Bcg Medac]
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac]
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension [Bcg Medac] Box of 1
BCG, Live, Montreal Strain 4000000 ORGANISMS/ML Injectable Suspension Box of 1
BCG, Live, Montreal Strain Injectable Solution
BCG, Live, Montreal Strain Injectable Solution [Pacis]
BCG, Live, Montreal Strain Injectable Suspension
BCG, Live, Montreal Strain Injectable Suspension [Bcg Medac]
BCG, Live, Tice Strain 12.5 MG [OncoTICE]
BCG, Live, Tice Strain 12.5 MG Injectable Solution
BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE]
BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] Box of 1
BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] Box of 1 by Merck
BCG, Live, Tice Strain 12.5 MG Injectable Solution [OncoTICE] by Merck
BCG, Live, Tice Strain 12.5 MG Injectable Solution Box of 1
BCG, Live, Tice Strain 12.5 MG Injectable Suspension
BCG, Live, Tice Strain 12.5 MG Injectable Suspension [OncoTICE]
BCG, live, Tice strain 12.5 MG Injection
BCG, live, Tice strain 12.5 MG Injection [OncoTICE]
BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by MSD
BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by Organon
BCG, live, Tice strain 12.5 MG Injection [OncoTICE] by Schering-Plough
BCG, Live, Tice Strain 200000000 CELLS [OncoTICE]
BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension
BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE]
BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE] Box of 1
BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension [OncoTICE] Box of 1 by MSD
BCG, Live, Tice Strain 200000000 CELLS Injectable Suspension Box of 1
BCG, Live, Tice Strain 200000000 ORGANISMS
BCG, Live, Tice Strain 200000000 ORGANISMS [OncoTICE]
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE]
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] Box of 1
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] Box of 1 by MSD
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension [OncoTICE] by MSD
BCG, Live, Tice Strain 200000000 ORGANISMS Injectable Suspension Box of 1
BCG, Live, Tice Strain 500000000 CFU [Oncotice Bcg]
BCG, Live, Tice Strain 500000000 CFU Injection
BCG, Live, Tice Strain 500000000 CFU Injection [Oncotice Bcg]
BCG, Live, Tice Strain 500000000 CFU Injection [Oncotice Bcg] Box of 3
BCG, Live, Tice Strain 500000000 CFU Injection Box of 3
BCG, Live, Tice Strain 800000000 CELLS [OncoTICE]
BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension
BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension [OncoTICE]
BCG, Live, Tice Strain 800000000 CELLS Injectable Suspension [OncoTICE] by Organon
BCG, Live, Tice Strain 800000000 UNT [OncoTICE]
BCG, Live, Tice Strain 800000000 UNT Injectable Solution
BCG, Live, Tice Strain 800000000 UNT Injectable Solution [OncoTICE]
BCG, Live, Tice Strain 800000000 UNT Injectable Solution [OncoTICE] by Merck
BCG, Live, Tice Strain Injectable Solution
BCG, Live, Tice Strain Injectable Solution [OncoTICE]
BCG, Live, Tice Strain Injectable Suspension
BCG, Live, Tice Strain Injectable Suspension [OncoTICE]
BCG, Live, Tice Strain Injection [Oncotice Bcg]
BCG, live, Tice strain Injection [OncoTICE]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [PEDIARIX]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Kinrix]
acellular pertussis vaccine, inactivated 0.116 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel]
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Pentacel]
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
acellular pertussis vaccine, inactivated 96 UNT/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine 68 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
diphtheria toxoid vaccine, inactivated / influenza B virus antigen Injectable Solution
diphtheria toxoid vaccine, inactivated / influenza B virus antigen Injectable Solution [HibTITER]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Daptacel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Adacel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Adacel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.005 MG/ML / diphtheria toxoid vaccine, inactivated 4 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML [HibTITER]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER]
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution [HibTITER] Box of 5
diphtheria toxoid vaccine, inactivated 0.05 MG/ML / influenza B virus antigen 0.02 MG/ML Injectable Solution Box of 5
Haemophilus influenzae 0.01 MG Injection
Haemophilus influenzae type b 0.035 MG Injectable Solution
Haemophilus influenzae type b 0.04 MG Injectable Solution
Haemophilus influenzae type b 0.05 MG Injectable Solution
Haemophilus influenzae type b Injectable Solution
influenza A virus (H1N1) antigen 0.03 MG/ML [Afluria]
influenza A virus (H1N1) antigen 0.03 MG/ML [Begripal]
influenza A virus (H1N1) antigen 0.03 MG/ML [Fluad]
influenza A virus (H1N1) antigen 0.03 MG/ML [Fluarix]
influenza A virus (H1N1) antigen 0.03 MG/ML [Grippe-Impfstoff Csl]
influenza A virus (H1N1) antigen 0.03 MG/ML [Grippe-Impfstoff Stada]
influenza A virus (H1N1) antigen 0.03 MG/ML [Grippeimpfstoff Ratiopharm]
influenza A virus (H1N1) antigen 0.03 MG/ML [Inflexal]
influenza A virus (H1N1) antigen 0.03 MG/ML [Influsplit]
influenza A virus (H1N1) antigen 0.03 MG/ML [INFLUVAC]
influenza A virus (H1N1) antigen 0.03 MG/ML [Preflucel]
influenza A virus (H1N1) antigen 0.03 MG/ML [VAXIGRIP]
influenza A virus (H1N1) antigen 0.03 MG/ML [Viroflu]
influenza A virus (H1N1) antigen 0.03 MG/ML [Xanaflu]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Afluria] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Begripal] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluad] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Fluarix] Box of 20
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Csl] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippe-Impfstoff Stada] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Grippeimpfstoff Ratiopharm] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Inflexal] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Influsplit] Box of 20
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [INFLUVAC] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Preflucel] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 20
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [VAXIGRIP] Box of 50
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Viroflu] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu]
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension [Xanaflu] Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 10
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 20
influenza A virus (H1N1) antigen 0.03 MG/ML Injectable Suspension Box of 50
influenza A virus (H1N1) antigen Injectable Suspension
influenza A virus (H1N1) antigen Injectable Suspension [Afluria]
influenza A virus (H1N1) antigen Injectable Suspension [Begripal]
influenza A virus (H1N1) antigen Injectable Suspension [Fluad]
influenza A virus (H1N1) antigen Injectable Suspension [Fluarix]
influenza A virus (H1N1) antigen Injectable Suspension [Grippe-Impfstoff Csl]
influenza A virus (H1N1) antigen Injectable Suspension [Grippe-Impfstoff Stada]
influenza A virus (H1N1) antigen Injectable Suspension [Grippeimpfstoff Ratiopharm]
influenza A virus (H1N1) antigen Injectable Suspension [Inflexal]
influenza A virus (H1N1) antigen Injectable Suspension [Influsplit]
influenza A virus (H1N1) antigen Injectable Suspension [INFLUVAC]
influenza A virus (H1N1) antigen Injectable Suspension [Pandemrix]
influenza A virus (H1N1) antigen Injectable Suspension [Preflucel]
influenza A virus (H1N1) antigen Injectable Suspension [VAXIGRIP]
influenza A virus (H1N1) antigen Injectable Suspension [Viroflu]
influenza A virus (H1N1) antigen Injectable Suspension [Xanaflu]
Influenza A virus / Influenza B virus Injectable Suspension
Influenza A virus / Influenza B virus Injectable Suspension [Alpha RIX Tetra]
Influenza A virus / Influenza B virus Injectable Suspension [INFLUVAC]
Influenza A virus / Influenza B virus Injectable Suspension [VAXIGRIP]
Influenza A virus Injectable Suspension [Alpha RIX Tetra]
Influenza A virus Injectable Suspension [INFLUVAC]
Influenza A virus Injectable Suspension [VAXIGRIP]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain Injectable Suspension
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-179A (H1N1) strain Injectable Suspension [Intanza]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Agrippal]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluarix]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluvax]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [INFLUVAC]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Intanza]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Vaxigrip Junior]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [VAXIGRIP]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Live Attenuated, A-California-7-2009 (H1N1) strain Nasal Spray
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus / Influenza B virus vaccine, B-Massachusetts-2-2012-like virus / Influenza Virus Vaccine, Live Attenuated, A-California-7-2009 (H1N1) strain Nasal Spray [Fluenz]
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.0075 MG/ML
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.00752 MG/ML
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.009 MG/ML
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.015 MG/ML
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 0.09 MG/ML
Influenza A virus vaccine, A-Texas-50-2012 (H3N2)-like virus 50000000 UNT/ML
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Agrippal]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluarix]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Fluvax]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [INFLUVAC]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Intanza]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [Vaxigrip Junior]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus / Influenza B virus vaccine, B-Wisconsin-1-2010-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain Injection [VAXIGRIP]
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.0075 MG/ML
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.00752 MG/ML
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.009 MG/ML
Influenza A virus vaccine, A-Victoria-361-2011 (H3N2)-like virus 0.015 MG/ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray [FluMist Quadrivalent]
influenza A-California-7-2009-(H1N1)v-like virus vaccine / influenza B virus antigen Nasal Spray [Flumist]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML [FluMist Quadrivalent]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine 160000000 /ML / influenza B virus antigen 160000000 /ML Nasal Spray [FluMist Quadrivalent]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML [Flumist]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist]
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray [Flumist] Box of 5
influenza A-California-7-2009-(H1N1)v-like virus vaccine 50000000 /ML / influenza B virus antigen 50000000 /ML Nasal Spray Box of 5
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Boostrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Boostrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inactivated 5 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Influenza B virus vaccine, B-Brisbane-60-2008-like virus / Influenza Virus Vaccine, Inactivated A-California-07-2009 X-181 (H1N1) strain / Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain Injection
Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.0075 MG/ML
Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.00752 MG/ML
Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.009 MG/ML
Influenza B virus vaccine, B-Massachusetts-2-2012-like virus 0.015 MG/ML
Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.0075 MG/ML
Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.00752 MG/ML
Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.009 MG/ML
Influenza B virus vaccine, B-Wisconsin-1-2010-like virus 0.015 MG/ML
Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Ivr-175
Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Ivr-175 0.03 MG/ML
Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88
Influenza Virus Fragmented, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / Switzerland / 9715293/2013, Nib-88 0.03 MG/ML
Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013
Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.0075 MG/ML
Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.00752 MG/ML
Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.015 MG/ML
Influenza Virus Fragmented, Inactivated, Strain B / Phuket / 3073/2013 0.03 MG/ML
Influenza Virus Surface Antigen, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Type Wild
Influenza Virus Surface Antigen, Inactivated, Strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain A / South Australia / 55/2014 Type Wild 0.03 MG/ML
Influenza Virus Surface Antigen, Inactivated, Strain B / Phuket / 3073/2013 & ndash; Analogue strain B / Utah / 9/2014, Wild Type
Influenza Virus Surface Antigen, Inactivated, Strain B / Phuket / 3073/2013 & ndash; Analogue strain B / Utah / 9/2014, Wild Type 0.03 MG/ML
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.0075 MG/ML
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.00752 MG/ML
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.009 MG/ML
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.015 MG/ML
Influenza Virus Surface Antigen, strain A / Victoria / 361/2011 H3N2 - Derived Strain Used Ivr-165 0.03 MG/ML
Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88
Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.0075 MG/ML
Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.00752 MG/ML
Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.015 MG/ML
Influenza Virus Surface Antigens, strain A / Switzerland / 9715293/2013 H3N2 - Analogue Strain Nib-88 0.03 MG/ML
Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.0075 MG/ML
Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.00752 MG/ML
Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.009 MG/ML
Influenza Virus Vaccine, Inactivated A-Victoria-210-2009 X-187 (H3N2) (A-Perth-16-2009) strain 0.015 MG/ML
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU [Varivax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU Injection
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 PFU Injection [Varivax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT [Varivax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injectable Solution
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection [Varivax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 1350 UNT Injection [Varivax] by Merck
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU Injection
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 19400 PFU Injection [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution [Varilrix] Box of 10
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 200 UNT/ML Injectable Solution Box of 10
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2000 PFU Injection [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 2700 UNT/ML Injectable Solution
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 PFU/ML Injectable Suspension [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe [Zostavax] Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 29800 UNT/ML Prefilled Syringe Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution [Varilrix] Box of 10
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 1
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain 4000 UNT/ML Injectable Solution Box of 10
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Varivax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Solution [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Suspension
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injectable Suspension [Zostavax]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Injection [Varilrix]
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Prefilled Syringe
Varicella-Zoster Virus Vaccine Live (Oka-Merck) strain Prefilled Syringe [Zostavax]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Vaxelis]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Quadracel]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe [Vaxelis]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine 0.006 MG/ML / hepatitis B surface antigen vaccine 0.02 MG/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Infanrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection [Kinrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe [Infanrix]
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Prefilled Syringe
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.05 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.05 MG/ML / diphtheria toxoid vaccine, inactivated 50 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML / tetanus toxoid vaccine, inactivated 20 UNT/ML Injection
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2022-2023]
Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine Injection
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
Fluzone Quadrivalent 2022-2023 Northern Hemisphere vaccine Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023]
influenza A virus A/Brisbane/02/2018 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Kansas/14/2017 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Maryland/15/2016 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2019-2020]
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2021-2022]
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2021-2022]
influenza A virus A/Cambodia/e0826360/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2022-2023]
influenza A virus A/Darwin/11/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Delaware/55/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML / influenza B virus B/Singapore/WUH4618/2021 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2022-2023]
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2022-2023]
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML Prefilled Syringe
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2020-2021]
influenza A virus A/Delaware/39/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Nebraska/14/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2020-2021]
influenza A virus A/Guangdong-Maonan/SWL1536/2019 (H1N1) antigen 0.0857 MG/ML / influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe
influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2020-2021]
influenza A virus A/Hawaii/70/2019 (H1N1) antigen 0.09 MG/ML / influenza A virus A/Minnesota/41/2019 (H3N2) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Afluria Quadrivalent 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe [Fluad Quadrivalent 2020-2021]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2454/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Victoria/705/2018 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021 Southern Hemisphere]
influenza A virus A/Hong Kong/2671/2019 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection [Fluzone Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Injection
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Flulaval Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluarix Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe [Flucelvax Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Washington/19/2020 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Darwin/7/2019 antigen 0.03 MG/ML / influenza B virus B/Singapore/INFTT-16-0610/2016 antigen 0.03 MG/ML Prefilled Syringe
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe [Fluzone Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.0857 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.0857 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.0857 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.0857 MG/ML Prefilled Syringe
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe [Flublok Quadrivalent 2021-2022]
influenza A virus A/Tasmania/503/2020 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML / influenza B virus B/Washington/02/2019 antigen 0.09 MG/ML Prefilled Syringe
0.5 ML influenza A virus A/California/7/2009 (H1N1) antigen 0.03 MG/ML / influenza A virus A/Hong Kong/4801/2014 (H3N2) antigen 0.03 MG/ML / influenza B virus B/Brisbane/60/2008 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2016-2017 (trivalent - California/Hong Kong/Brisbane) 0.5 ML Prefilled Syringe
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2022-2023 (quadrivalent - Austria/Darwin/Phuket/Victoria) Prefilled Syringe
influenza A virus A/Darwin/9/2021 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Victoria/2570/2019 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.03 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.03 MG/ML Prefilled Syringe
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Victoria/Austria/Phuket) Prefilled Syringe
influenza A virus A/Darwin/6/2021 (H3N2) antigen 0.09 MG/ML / influenza A virus A/Wisconsin/588/2019 (H1N1) antigen 0.09 MG/ML / influenza B virus B/Austria/1359417/2021 antigen 0.09 MG/ML / influenza B virus B/Phuket/3073/2013 antigen 0.09 MG/ML Prefilled Syringe
influenza virus vaccine 2022-2023 (quadrivalent - Darwin/Wisconsin/Austria/Phuket) Prefilled Syringe
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe [Gardasil]
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.04 MG/ML Prefilled Syringe
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe [Gardasil 9]
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection [Gardasil 9]
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Injection
L1 protein, human papillomavirus type 11 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 16 vaccine 0.12 MG/ML / L1 protein, human papillomavirus type 18 vaccine 0.08 MG/ML / L1 protein, human papillomavirus type 31 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 33 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 45 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 52 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 58 vaccine 0.04 MG/ML / L1 protein, human papillomavirus type 6 vaccine 0.06 MG/ML Prefilled Syringe
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection [ProQuad]
measles virus vaccine live, Enders' attenuated Edmonston strain 2000 UNT/ML / mumps virus vaccine live, Jeryl Lynn strain 40000 UNT/ML / rubella virus vaccine live (Wistar RA 27-3 strain) 2000 UNT/ML / varicella-zoster virus vaccine live (Oka-Merck) strain 20000 UNT/ML Injection
meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe [Bexsero]
meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML Prefilled Syringe
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection [Menactra]
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Injection
Neisseria meningitidis serogroup A capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide diphtheria toxoid protein conjugate vaccine 0.104 MG/ML Prefilled Syringe
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection [Menquadfi]
Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup W-135 capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine 0.02 MG/ML Injection
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection [Menveo]
Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML Injection
Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.04 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.04 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / poliovirus vaccine inactivated, type 1 (Mahoney) 58 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 14 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 52 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Quadracel]
A varicella-zoster virus live vaccine designed to prevent shingles (herpes zoster).
A varicella-zoster virus vaccine, also known as the chickenpox vaccine, that protects against the varicella-zoster virus (VZV) causes chickenpox.
A DTP-Haemophilus influenzae type b conjugate and hepatitis B vaccine that is used outside USA.
DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine (non-US)
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.0333 MG/ML Injection
SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.01 MG/ML Injectable Suspension
0.25 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Injection
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe [Comirnaty 2023-2024]
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Injection [Comirnaty 2023-2024]
0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML
0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection
0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe
0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Injection [Spikevax 2023-2024]
0.5 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe [Spikevax 2023-2024]
example to be eventually removed
failed exploratory term
The term was initially used in an attempt to structure part of the ontology, but in retrospect failed to do a good job.
Terms created as placeholders with the expectation of being permanent should instead be deprecated using the "placeholder removed" (obo:IAO_0000226) justification.
metadata complete
Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete.
organizational term
The term was created to ease viewing/sorting terms for development purposes, but will not be included in a release.
ready for release
Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release."
metadata incomplete
Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors.
uncurated
Nothing done yet beyond assigning a unique class ID and proposing a preferred term.
pending final vetting
All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor.
Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes.
obsolete_core
placeholder removed
The term was created to temporarily stand in for a semantic purpose, but is no longer needed, typically due to another permanent term being defined.
This reason is appropriate for a temporary term even if no permanent term is defined; for example if the need for the term no longer exists. If a permanent (replacement) term is defined, the deprecated term should reference the replacement with IAO:0100001. If no replacement is defined, it may be appropriate to reference alternative terms with oboInOwl:consider.
terms merged
The term has been combined with one or more other terms to create a more encompassing (merged) term.
The deprecated term should reference the merged term with obo:IAO_0100001. The replacement term should reference the original terms as sources using obo:RO_0001000 (derives_from). An editor note should explain what were the merged terms and the reason for the merge.
term imported
The term has been replaced by a term imported from another ontology.
This is to be used when the original term has been replaced by a term imported from an other ontology. The deprecated term should reference the imported term with obo:IAO_0100001.
term split
The term has been split into two or more new terms.
This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split. The deprecated term should reference the replacement terms with obo:IAO_0100001.
universal
Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents.
A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf
defined class
A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal
"definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal.
named class expression
A named class expression is a logical expression that is given a name. The name can be used in place of the expression.
named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions
to be replaced with external ontology term
Terms with this status should eventually replaced with a term from another ontology.
requires discussion
A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues.
The term was added to the ontology on the assumption it was in scope, but it turned out later that it was not.
This obsolesence reason should be used conservatively. Typical valid examples in disease ontologies are: unnecessary class grouping; mistaked creation of a disease associated to a phenotype.
The term was added to the ontology on the assumption it was a valid domain entity, but it turns out the entity does not exist in reality.
This obsolesence reason should be used conservatively. For example: Obsoleting class that describes a breed of cow based on a record in an existing database, that was later retracted as faulty (breed does not exist). Do not use this term to obsolete a historic concept (that was once valid, but not anymore).
Intervet has merged with Schering-Plough Animal Health and become Intervet/Schering-Plough Animal Health™ (YL.)
A British multinational pharmaceutical company headquartered in Brentford, England
GSK
Massachusetts Public Health Biologic Lab
Merck Sharp & Dohme Corp.
100 Rodolphe Street Building 1300 Durham, NC 27712
Research Foundation for Microbial Diseases of Osaka University
Aqua Health
Centre for Ticks and Tickborne Disease, Malawi
United States Department of Agriculture
Intervet has merged with Schering-Plough Animal Health and become Intervet/Schering-Plough Animal Health‚Ñ¢ (YL.)
International Duck Research Cooperative, Inc.
Vaccicel, Inc. has a location in Belton, TX. Active officers include Andre Menchu, Andres Menchu, Kathryn M Baker, Katheryn Becker and Andres Menches. Vaccicel, Inc. filed as a Domestic For-Profit Corporation on Tuesday, August 22, 1995 in the state of Texas and is currently active. Andres Menchu serves as the registered agent for this organization.The company's line of business includes Mfg Research & Development Veterinary Bacterial Vaccines. (http://www.corporationwiki.com/Texas/Belton/vaccicel-inc/34296230.aspx)
GSK Acquires Influenza Vaccine Manufacturer ID Biomedical Corporation http://www.medicalnewstoday.com/releases/34803.php GlaxoSmithKline plc (NYSE:GSK) announced the completion of the acquisition of ID Biomedical. This follows regulatory clearances of the transaction and adoption of the acquisition agreement by ID Biomedical's shareholders (which occurred on the 16th of November). ID Biomedical becomes a wholly-owned subsidiary of GSK. ...
An Israeli research and development laboratory
Israel Institute for Biological Research
Max Planck Institute for Infection Biology
French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
A company trhat is located at Berkeley, CA, USA. Its website is: http://www.dynavax.com.
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Located in Swiftwater, Pennsylvania, this company is now known as Sanofi Pasteur Limited.
ADVENT SRL VIA CRESCENZIO 9 ROMA, ROMA, 00193 Italy +39-0691093692 Company Type: Corporation Subsidiary http://www.hoovers.com/company-information/cs/company-profile.advent_srl.aebb99e74ae57b09.html?aka_re=1
A pharmaceutical company that was founded in 1953 by Paul Janssen, is headquartered in Beerse, Belgium, and owned by Johnson & Johnson.
康希诺生物
A German biotechnology company that is dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.
An American multinational pharmaceutical corporation headquartered in New York City.
A British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Sodertalje, Sweden. AstraZeneca makes products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.
Beijing Institute of Biological Products
Sinopharm
Sinopharm Group
国药控股股份有限公司
A biopharmaceutical company headquartered in Beijing, China
Sinovac
An American biotech company focused on the discovery, development and commercialization of therapeutics for rare diseases with focus on RNA
FBRI SRC VB VECTOR
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology
Vector Institute
State Research Center of Virology and Biotechnology VECTOR
An American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
A manufacturer of immunobiological drugs including vaccines in India
A China-based company principally engaged in the research, development, production and distribution of vaccines, monoclonal antibodies and blood products
A Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications
The teaching hospital of the University of Hamburg and one of the largest hospitals in Hamburg, Germany
University Medical Center Hamburg-Eppendorf
A public research university in Chengdu, Sichuan, China
四川大学
A French non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines
Pasteur Institute
A public research university located primarily in Brisbane, Queensland, Australia
An American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France.
Research Institute for Biological Safety Problems
University of Munich (Ludwig-Maximilians)
Center for Genetic Engineering and Biotechnology
Vaccine and Infectious Disease Organization
An NIAID compendium repository that stores vaccine adjuvants derived from their research studies.
VAC
A company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer.
A company offers pharmaceutical and specialized products to healthcare providers located in United States.
Emergent BioDefense Operations Lansing LLC
A company located in Gaithersburg, Maryland.
Emergent Product Development Gaithersburg, Inc.
A company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum.
Emergent Product Development Gaithersburg Inc.
Adt Vaccine
Fluzone Quadrivalent 2016 Southern Hemisphere
Fluzone Quadrivalent 2020 Southern Hemisphere
Fluzone Quadrivalent 2021 Southern Hemisphere
Fluzone Quadrivalent 2022 Southern Hemisphere
Fluzone Quadrivalent 2023 Southern Hemisphere